# Patent

## Title
Rationale, methods, and assays for identifying human and non-human primate taste specific genes and use thereof in taste modulator and therapeutic screening assays

## Abstract

This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures.

## Background
RELATED AND PRIORITY PATENT APPLICATIONS
This application is a divisional of U.S. application Ser. No. 14/162,313 filed Jan. 23, 2014, which is a divisional of U.S. application Ser. No. 13/090,335, filed Apr. 20, 2011 (now U.S. Pat. No. 8,669,066), which is a divisional of U.S. application Ser. No. 12/134,302 filed Jun. 6, 2008 (now U.S. Pat. No. 7,932,058), which claims priority to earlier filed provisional applications by the present Assignee Senomyx Inc relating to a novel rationale for identifying primate taste specific genes and in particular for identification of the primate salt receptor gene or genes. These provisional applications are U.S. Application Ser. No. 60/929,017 filed Jun. 8, 2007; U.S. Application Ser. No. 60/929,007, filed Jun. 8, 2007; U.S. Application Ser. No. 60/947,052, filed Jun. 29, 2007; U.S. Application Ser. No. 60/935,297, filed Aug. 3, 2007; U.S. Application Ser. No. 60/987,611, filed Nov. 13, 2007; U.S. Application Ser. No. 60/988,938, filed Nov. 19, 2007; U.S. 60/991,274, filed Nov. 30, 2007; U.S. Application Ser. No. 60/991,289, filed Nov. 30, 2007; U.S. Application Ser. No. 60/992,502, filed Dec. 5, 2007; U.S. Application Ser. No. 60/992,517, filed Dec. 5, 2007; U.S. Application Ser. No. 61/017,244, filed Dec. 28, 2007; U.S. Application Ser. No. 61/021,437, filed Jan. 16, 2008; U.S. Application Ser. No. 61/043,257, filed Apr. 8, 2008; U.S. Application Ser. No. 61/053,310, filed May 15, 2008. In addition, this application relates to, and claims priority to U.S. Ser. No. 11/808,356, filed Jun. 8, 2007 and U.S. Ser. No. 12/134,390 filed on Jun. 6, 2008 and claiming priority to the same applications as this application. All of the afore-mentioned provisional and non-provisional applications are incorporated by reference in their entireties herein.


SEQUENCE LISTING
The sequence listing in the filed named “43268o2908.txt” having a size of 581,051 bytes that was created Aug. 11, 2015 is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
This application generally relates to novel protocols for identifying and functionalizing taste specific genes, especially taste specific genes of primates and non-human primates, which based on their structure, tissue specific expression, cells, where they are expressed in specific tissues and cells therein, and level of expression are predicted to elicit or be involved in one or more taste cell specific functions. As described and shown infra these methods have identified taste specific GPCRs, ion channels, and other transmembrane proteins likely to regulate taste specific cellular activities. In fact, as disclosed in a related application filed on even date claiming benefit of priority to the same provisional and utility applications as the subject application, these methods have already successfully identified a gene which encodes a salty taste receptor in primates including humans, rodents, and likely other vertebrates.
More specifically, the invention relates to novel rationales for identifying and functionalizing human and primate taste specific genes, the taste specific genes identified using these rationale, and specific novel taste cell subsets which express these taste specific genes and the functional characterization of these genes, gene products and novel taste cell subsets and their use as potential taste receptor or therapeutic targets, e.g., salt receptor targets. The genes and gene products identified using these protocols are useful targets in high-throughput screening efforts to identify human salty taste enhancers. These targets are initially identified using a combination of two different techniques, gene chips and a polymerase chain reaction (PCR) screen, resulting in a set of genes which are taste specific and potential taste, e.g., salt or fat taste receptor target genes. First, Affymetrix gene chips containing most all known macaque genes are used to determine which genes are specifically expressed in primate circumvallate at the back of the tongue and fungiform papilla taste cells at the front of the tongue and not lingual epithelial cells isolated by laser capture microdissection. Second, PCR is used to determine which ion channels, from channels we have cataloged in the human/macaque genomes, are specifically expressed in macaque fungiform and/or circumvallate (CV) papilla taste cells but not lingual epithelial cells isolated by laser capture microdissection. Taste-specific expression of genes identified by either approach, are confirmed using an independent histological method such as in situ hybridization or immunohistochemistry, to determine which genes are expressed in taste cells. Using double labeling histological methods, it is determined what novel taste-specific genes are expressed in sweet, bitter, and umami cells that express the taste-specific ion channel TRPM5, sour cells that express the taste-specific ion channel PKD2L1/PKD1L3, or a unique cell type that does not express TRPM5 or PKD2L1/PKD1L3. A taste-specific gene, preferably an ion channel, that is conductive or activated by sodium and is expressed in a TRPM5- and PKD2L1/PKD1L3-negative cell population is a probable candidate for screening efforts to identify the gene(s) that encode mammalian salty taste receptors, as well as specific cell types wherein these salty taste receptor genes are expressed such as in the oral cavity and urinary tract, and also for use in high throughput assays designed to identify enhancers of saltiness in humans. The invention further provides infra in vitro and in vivo strategies for functionalizing the identified taste specific genes, especially those genes identified in unique taste cell subsets also described infra. As described infra and in more detail in the related application cited above, these strategies have already successfully identified a human and non-human primate salty taste receptor and therefore should be effective for functionalizing other taste specific genes such as fat and metallic taste receptors or other taste specific genes involved in ancillary taste cell functions enumerated infra.
In addition, as further described infra, improvements of these methods are also provided which use the combination of real time polymerase chain reaction detection of gene expression and immunochemical assays using taste buds from human post-mortem samples and other methods have been utilized to successfully isolate and identify other unique human taste cell subsets and lineages which in all likelihood are involved in detecting other taste modalities or other taste cell functions.
More specifically, the improved method identifies human taste specific genes by quantitative polymerase chain reaction (PCR). Particularly, the inventors demonstrate taste specific gene expression in humans and primates and have validated the observed specificity of expression by a quantitative method (qPCR or “TaqMan”) The identified human taste specific genes (Table 8 infra) (most of which have known primate and other species counterparts) encode multi-span transmembrane proteins and therefore are predicted to include receptors involved in different taste modalities and other functions. (One of the identified human ion channels genes disclosed therein has been confirmed to encode a salty taste receptor.)
Also, in a related aspect this application identifies taste specific genes expressed in humans based on the identification of their counterparts (orthologs) in non-human primates using the disclosed rationales. The inventors predicted that as primates and humans are closely evolutionarily related that gene expression patterns seen in primate taste tissues would correlate to those observed for these genes in human taste tissues. Based on this assumption, taste specific genes shown to be taste specific in primates (including those recited in Tables 1-5 infra) were selected to be validated in human taste buds using non-microarray analysis (TaqMan qPCR).
In another related aspect the invention detects human taste specific genes in human LCM cDNA using LCM from post-mortem LC human tissues and a single cDNA amplification step, establishing that human postmortem LCM human tissue can be used to quantify the expression of taste specific genes sung qPCR.
In yet another related aspect the invention establishes that human taste specific genes can be measured by quantitative qPCR (taqMan) and that gene expression profiles of human taste specific genes can be directly measured by TaqMan and the results used to validate previous gene expression data obtained from microarrays and/or in situ hybridization (ISH) from non-human, e.g., macaque taste cell samples.
In an additional aspect the invention provides an improved method for the identification of a set of human and non-human primate taste specific genes which should identify all potential taste receptor and taste modulator genes based on a selection protocol which compares the expression of taste specific genes in cells in the top versus the bottom of the taste bud.
In another related aspect the invention identifies novel human taste-bud specific genes using the successive approaches of gene expression via microarray in primate LCM tongue tissue; top specific gene expression within the taste bud (akin to known taste receptors) and TaqMan quantification of gene expression in human postmortem tissues and have identified new human taste specific genes not described previously as being taste specific.
In another related aspect the invention identifies human taste specific genes expressed in human post-mortem tissues and provides methods for the functionalization of these genes and cells which express these genes or a combination thereof.
In another related aspect the invention provides a method for identifying and categorizing human taste specific genes which are involved in different functions of the taste buds based on measuring their expression by quantitative qPCR or based on where they are expressed in human taste buds.
In another related aspect the invention provides the specific primate and human taste specific genes identified using these methods which are involved in different taste cell functions including taste sensation, taste bud growth and development, control of the lifespan of mature taste bud cells, and the maintenance differentiation and proliferation of taste-bud committed taste stem cells.
Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products as biomarkers of taste-bud committed stem cells.
Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products as biomarkers of different mature taste cell subsets.
Also, the invention provides the specific primate and human taste specific genes identified using these methods and the corresponding gene products in methods which purify, enrich or ablate specific taste cell subsets and taste-bud committed stem cells.
More specifically, this application identifies novel categories of taste specific genes which are tabulated and enumerated infra derived from primates and human taste cell specific sources (See tables 1-8). These genes are expressed in chemosensory or taste cells, e.g. human and non-human primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as other non-human primates. These genes are referred to by the inventors as “taste-specific” genes because they are strongly expressed in taste cells. These taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as including genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.
Relating to the foregoing the present invention provides novel sets of genes that are expressed specifically in human and non-human primate (macaque) chemosensory, e.g., macaque fungiform or circumvallate papilla taste cells that are not expressed or are expressed at significantly lower levels in lingual epithelial cells that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that directly or indirectly modulate different taste modalities, e.g., salty, sweet, umami, bitter, sour, fatty, or metallic.
While the identified taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction they also include genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.
With particular respect to fat or lipid taste detection the present invention further identifies a subgenus of taste specific genes which are predicted to be involved in detecting fats or lipids based on the presence of characteristic lipid or fat binding motifs or based on the classification of these genes. These genes potentially may be used to screen for compounds that enhance or mimic or block fatty taste detection by the taste buds and potentially detection, binding or absorption by gastrointestinal tissues since it is likely that taste receptors which sense fats or lipids may be expressed in the gastrointestinal tissues as has been observed with other types of taste receptors (sweet, umami and bitter). These genes are referred to herein as “fat taste-specific” genes because they are expressed specifically in taste cells and because based on their structure or prior fictionalization as binding to fatty acids or lipids they are predicted to be involved in fat taste detection in human and non-human primates and likely other mammals. Also, these putative fat taste-specific genes include genes that may also play an ancillary role in other taste modalities and the detection or isolation of taste cells involved in other taste modalities such as, e.g., salty, umami, sweet, sour, metallic, or bitter taste transduction. In addition based on their structural characteristics such as characteristic motifs or prior functional characterization as fatty acid or lipid receptors these genes are predicted to possess other non-taste biological functions involving lipid transport and fat metabolism such as gastric motility and gastric peptide secretion.
Further relating to the foregoing the present invention identifies taste specific human and non-human primate (macaque) genes and the corresponding gene products or cells that express same that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that are useful e.g., as therapeutics in the treatment of digestive system disorders such as cancers and autoimmune disorders, for modulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration, for affecting the regulation of immunity in the oral cavity, and the regulation of metabolism, e.g., in the treatment of diabetes, obesity, eating disorders, and other metabolic disorders.
Also relating to the foregoing the invention provides a novel set of human and primate (macaque) and human genes which are useful in the identification and/or isolation and/or enrichment of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as cells that aid in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.
Further, the invention relates to the use of these isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system, particularly the regulation of the immune homeostasis in the oral cavity, regulation of taste cell apoptosis, turnover or taste cell regeneration and proliferation, regulation of hormones or enzymes involved in digestion and other taste cell functions, treatment of digestive system disorders such as oral or digestive system cancers, autoimmune or inflammatory digestive disorders, treatment of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.
Further relating to the foregoing the present invention provides a novel set of human and primate (macaque) genes and the corresponding gene products or cells that express same that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that are useful e.g., as therapeutics in the treatment or prevention of digestive system disorders involving aberrant lipid and fat metabolism and the co morbidities associated with aberrant fat and lipid intake and metabolism such as obesity, hepatic steatosis, liver cirrhosis, atherosclerosis, hyperglycemia, insulin resistance and hepatic insulin resistance, type 1 and type 2 diabetes, abdominal obesity, cancers that are obesity or diet related, and the like.
Also, the invention relates to the use of such putative taste receptor genes and the corresponding polypeptides and cells which express same such as cancers and autoimmune disorders, in identifying compounds for modulating taste cell apoptosis or taste cell turnover, particularly compounds that modulate or inhibit fat taste cell regeneration and adipocyte differentiation, e.g., for affecting the regulation of metabolism, e.g., in the treatment of diabetes, obesity, fat accumulation, eating disorders, and other metabolic disorders.
Also relating to the foregoing the invention provides a novel set of human and primate (macaque) genes which are useful in identifying, isolating and/or enriching fat taste receptor expressing cells or cell lineages that upon maturation give rise to fat taste receptor cells using the subject genes or probes specific thereto such as nucleic acids or antibodies.
Also, the invention relates to the use of isolated chemosensory, e.g., taste or gastrointestinal, e.g., enteroendocrine cells which express one or more of the genes reported herein the identification and/or isolation and/or enrichment or ablation of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as cells that aid in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.
Further, the invention relates to the use of these isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system, regulation of taste cell apoptosis, turnover or taste cell regeneration and proliferation, regulation of hormones or enzymes involved in digestion and other taste cell functions, treatment of digestive system disorders such as digestive system cancers, of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.
The present invention further provides methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.
Also the invention relates to the use of markers e.g., antibodies or oligonucleotides, that are specific to one or more of the subject taste specific genes provided herein in mapping regions of the tongue and oral cavity which are involved in specific taste and non-taste specific functions, mapping of cell comprised on specific regions of the gastrointestinal tract and associated organs such as the intestinal epithelium or urinary tract that express specific taste specific genes and which therefore are involved in one or more of the taste cell specific functions disclosed herein, and/or the use of the subject genes and markers specific thereto in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.
In yet another aspect, this invention relates to assays for identifying a compound having potential in vivo application for modulating human salty or other specific taste. This method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8
In a preferred mode, the assay of step (ii) is an electrophysiological assay which uses a sodium sensitive dye, and preferred dyes include membrane potential dyes selected from the group consisting of Molecular Devices Membrane Potential Kit (Cat#R8034), Di-4-ANEPPS (pyridinium, 4-(2-(6-(dibutylamino)-2-naphthalen-yl)ethenyl)-1-(3-sulfopropyl)hydroxide, inner salt, DiSBACC4(2) (bis-(1,2-dibabituric acid)-triethine oxanol), Cc-2-DMPE (Pacific Blue 1,2-dietradecanoyl-sn-glycerol-3phosphoethanolamine, triethylammonium salt) and SBFI-AM (1,3-benzenedicarboxylic acid, 4,4-[1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diylbis(5-methoxy-6,1,2-benzofurandiyl)}bis-tetrakis{(acetyloxy)methyl}ester (Molecular Probes), more preferably, the sodium sensitive dye is sodium green tetraacetate (Molecular Probes) or Na-sensitive Dye Kit (Molecular Devices). In another preferred mode, the assay of step (ii) is a two electrode voltage clamping assay in Xenopus oocytes, or the assay is a patch clamp assay in mammalian cells. Preferably, the assay measures activity by an ion flux assay, including using atomic absorption spectroscopy to detect ion flux.
Alternatively, the assay may use a fluorescence plate reader (FLIPR), or a voltage imaging plate reader (VIPR), which is used to increase ion channel-dependent sodium or fluid absorption. In a preferred embodiment of this method, the activity of the putative salty taste affecting gene is assayed in a frog oocyte electrophysiologically by patch clamping or two electrode voltage clamping, preferably using an automatic imaging instrument, which may be a fluorescence plate reader (FLIPR) or a voltage imaging plate reader (VIPR).
In yet another mode, this invention relates to assays for identifying a compound having potential in vivo application for modulating human sweet, bitter, umami, or sour taste. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-8 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential enhancer or blocker for sweet, bitter or umami taste based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.
In a more specific embodiment the present invention relates to assays that screen for activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides or insulin metabolism is desirably controlled or reduced.
In another specific embodiment the present invention relates to assays using endogenous taste cells, e.g., gastrointestinal cells such as gastro-endocrine or gastro-epithelial cells or cells on the tongue or oral cavity, that screen for compounds which act as activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors, preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which activators may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides such as GLP-1 (glucagon-like peptide 1) is desirably controlled or reduced.
This invention in a more specific embodiment relates to specific taste specific genes identified infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human and primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.
Also, the invention relates to enriched, isolated or purified taste cell subsets which expresses at least one of FAM26A, MCTP1, TMEM30B, and/or TUSC3 and which further express at least one T1R or T2R or TRPM5 gene and/or which express T1R2/T1R3 or T1R1/T1R3 or T1R3 only. Particularly, the invention provides isolated taste cells that express GPR113 and/or TMEM16G and which isolated taste cells which further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R gene and/or TRPM5.
Also, the invention relates specifically to a method of using a probe specific to a gene or gene product corresponding to the genes to identify and/or isolate and or enrich taste specific cells from non-taste cells in a sample. For example, these methods include a method herein the gene is FAM26A, MCTP1, TMEM30B, and/or TUSC3 and the identified, isolated or enriched cell further expresses T1R1/T1R3, T1R2/T1R3, T1R3 only, a T2R, and/or TRPM5. Also, the invention includes methods wherein the gene is GPR113 and/or TMEM16G and the isolated, identified or enriched cell further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R or TRPM5 and/or wherein said taste cells are human or macaque taste cells. and wherein said isolated taste cells do not express PKD2L1, PKD1L3, or TRPM5 and/or wherein said cells do not express a T1R or a T2R and/or said taste cells express transducin or gustducin.
Also, the invention relates to the use of these identified taste specific genes or an ortholog or variant thereof encoding a protein at least 90% identical thereto in a cell isolation, purification, enrichment, or marking technique that isolates, purifies, enriches and/or marks at least one desired taste cell subtype or lineage contained in a mixed cell population or cell suspension comprising a desired taste cell type or lineage based on the expression or absence of expression of at least one gene contained in Tables 1-8 or an ortholog thereof, or a gene encoding a protein that is at least 90% identical to said gene or an ortholog thereof. Particularly, the invention includes methods wherein the taste cell subtype or taste cell lineage is isolated, purified, enriched, or marked by a method that includes the use of a fluorescence activated cell sorter (FACS) or by the use of labeled magnetic beads and wherein the cell suspension containing the cells may be produced by enzymatic digestion and/or tissue disaggregation of tissues containing taste cells. and methods wherein the desired taste cell subtype or taste cell lineage is isolated, purified, enriched or marked by a method that includes a negative cell selection technique that eliminates at least one non-target taste cell subtype or lineage based on the expression or absence of expression of at least one other taste cell specific gene identified herein. These methods may e.g., use cytotoxic antibodies to specifically kill at least one non-target cell type or lineage. These isolation methods may e.g., result in isolates containing sweet taste cells, umami taste cells, sour, salty, or fat taste cell subtype or lineages, taste stem cells taste cell neurons, or taste immune cells.
Also, the invention relates to methods of using a cell isolated, purified, enriched or marked according to these methods in screens for taste modulatory compounds, or in a method that screens for compounds that induce the differentiation of said enriched, isolated, purified or marked taste stem cells into one or more taste cell lineages or subtypes or taste buds or in a method wherein said taste cell lineages or subtypes are identified based on the expression or absence of expression of at least one the identified taste specific gene identified above. These cells may be used to screen for compounds that modulate at least one of sweet, umami, bitter, sour, fat, salty or metallic taste wherein the gene is GPR113 or TMEM16G or TMEM44 or to screen for compounds that modulate taste cell differentiation or turnover.
Also, the invention relates to these cells or the gene or gene product encoded thereby in assays that screen for compounds that modulate or treat the diseases and conditions involving taste cells previously identified. This in particular relates to GPR113 or the corresponding gene product or cells which express same or an ortholog or variant thereof in assays to identify compounds that modulate taste cell differentiation or taste cell turnover.
Also, the invention relates to isolated immature taste cells and/or taste stem cells that express TMEM44 or GPR113 and the use in an assay for identifying taste modulators, in particular which screens for sweet, umami, bitter, fat, salty, metallic and/or astringent taste modulators. Also, the invention relates to a recombinant cell engineered to co-express T1R3 and GPR113 and optionally TRPM5. Also, the invention embraces an assay for identifying compounds which modulate taste cell differentiation and/or maturation based on whether said compound specifically binds and/or modulates the activity of GPR113.
Also, the invention relates to the use of these cells in assays that screen for compounds that modulate the differentiation and/or maturation of sweet or umami taste cells. Also, the invention provides a method of using GPR113 as a marker to identify, enrich and/or isolate or ablate unique taste cells which express GPR113, TRPM5 and T1R3 wherein said taste cells do not express T1R1, T1R2 and/or a T2R or are immature, e.g., by FACS or magnetic bead cell separation or by use of cytotoxins.
In addition the invention relates to the discovery that TMEM44 and MFSD4 are expressed in unique taste cell type and that these gene are expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells which further expresses another taste-specific gene disclosed herein. Also, the present invention relates to the discovery that expression of TMEM44 and MFSD4 are markers for a unique taste cell type that may correspond to a fat receptor. Further, the invention relates to the discovery that ATP8A1, FAM26B and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.
This invention in a more specific embodiment identifies genes infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human or primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.
Also, the present invention relates to the discovery that MFSD4 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.
Also, the invention reveals that the expression pattern of MFSD4 is very similar to TMEM44, indicating that both genes are expressed in the same taste cell type and may be comprised in a heteromeric taste receptor.
Also, the invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5.
Also, the invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.
Also, the invention relates to the discovery based on in situ hybridization results that that TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B all are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.
Also, the present invention relates to the discovery that MFSD4 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells. Moreover, the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Based on the foregoing, the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor. Also, MFSD4 may be a marker of immature taste cells or developing taste cells.
Related thereto, the present invention also relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
Also, the present invention relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell type. Also, the present invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for a different taste than sweet, umami, sour or bitter, likely salt or fat. and may be used in screening assays.
Also, the present invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. and may regulate taste perception or other taste cell function. Moreover, the present invention reveals that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.
In another embodiment the invention relates to the discovery that ASCL1 also known as MASH is a transcription factor that defines and is a useful marker of sour taste cells as it is selectively expressed in sour taste cells that express PKD1L3 but not in other taste cell types, i.e., it is not expressed in sweet, bitter, or umami cells which express TRPM5. Therefore, the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the invention provides the use thereof in screening the genome for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
In another embodiment the invention establishes ASCL1 to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, the invention reveals that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.
In another embodiment the invention relates to the discovery that other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors related thereto that define those cell types. Therefore, the invention provides assays detecting the expression of all transcription factors in the genome in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.
In another embodiment the invention relaters to the discovery that the ASCL1 transcription factor binds to promoter elements in genes involved in sour taste perception. Thus, the invention encompasses such sequences found in the genome that comprise ASCL1 motifs and the use thereof to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
In another embodiment the invention relates to the discovery that ASCL1 (aka MASH1) is a marker useful for identifying, purifying, and/or isolating or ablating sour taste cells in a mixed cell sample, e.g., derived from the tongue or gastrointestinal or urinary tract.
In a related embodiment the invention provides the use of ASCL1 as a marker of Type III taste cells that correspond to sour taste receptor cells
In another embodiment the invention establishes that because ASCL1 defines the sour taste cell lineage it may also control sour taste cell development.
In another embodiment the invention provides the use of ASCL1 transcription factor DNA binding sequences as a probe to identify sour cell genes and sour taste receptor genes that possess related structure such as ASCL1 motifs.
Also, the invention provides the use of these and other taste cell specific transcription factors to define, mark, and/or label taste cell types because each taste cell will express one or more transcription factors that define that taste modality.
The invention further provides the use of these transcription factors that define taste modalities in cell ablation studies to specifically eliminate a specific taste cell or taste modality.
Also, the invention provides ASCL1 or other taste transcriptional gene knockouts which result in transgenic animals possessing altered taste perception and other phenotypic effects, e.g., elimination of sour taste perception or altered urinary or digestive function since ASCL1 may be involved in the metabolic response to pH changes such as excess acidity.
Also, the invention provides the use of these transcription factors that define new taste cell types which can be used in cell ablation studies and in vitro assays to determine what taste modality is lacking as a result of this ablation (i.e. what taste modality is eliminated).
In another embodiment this invention identifies taste-specific genes NALCN, TRPML3 and NKAIN3 which when expressed separately or in combination are predicted to comprise a taste receptor, putatively a salty taste receptor, as these 3 genes are expressed in primate taste cells, are enriched in the top fraction of taste bud cells, and are known to encode sodium channels. In addition the invention relates to the discovery that NALCN is expressed in a unique taste cell subset and is predicted to encode a taste related function. (As noted, TRPML3 has been shown to encode a salty taste receptor).
In a related embodiment the present invention relates to the use of these taste specific ion channel genes as markers which can be used to enrich, identify or isolate salt receptor expressing cells.
In another embodiment the invention relates to assays that identify compounds that modulate the function of the use of NALCN, TRPML3 and/or NKAIN3 and the use of the identified compounds to modulate salty taste perception.
In another embodiment the invention relates to other taste specific genes, i.e., KIT, IKBKAP, LOC285965, and SV2B that are expressed in specific subsets of taste specific cells.
In another embodiment, this invention relates to the discovery that KIT is specifically expressed in TRPM5 and T1R3 taste cells and T1R1 taste cells indicating that the gene can be used as a marker to identify umami taste cells in a mixed cell population and/or may modulate the expression and activity of the umami taste receptor.
In another embodiment, this invention relates to the discovery that IKBKAP and SV2B are specifically expressed in PKD1L3 sour taste receptor cells indicating that these genes can be used as markers to identify sour taste cells and/or modulate taste, especially sour taste.
Also, in another embodiment this invention relates to the discovery that LOC285965 is specifically expressed in TRPM5 and T1R3 taste cell subsets and T1R3 cells lacking T1R1 and T1R2 suggesting that this gene can be used as a marker of these taste cell subsets and/or may associate with or modulate the T1R3 gene and/or encode a taste receptor distant from T1R1/T1R3 or T1R2/T1R3.
Further, in another embodiment the invention relates to the discovery that SV2B is specifically expressed in PKD1L3 cells indicating that this gene can be used as a marker of these specific cell subsets and/or may encode a polypeptide that modulates the activity or expression of the PKD1L3 sour taste receptor.
In addition, in another embodiment the invention relates to the discovery that MFSD4 is expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells and that this gene is expressed in a similar taste cell population as TMEM44.
Also, in another embodiment the invention relates to primate taste specific genes identified in Table 4 found by gene chip analysis which encode transmembrane proteins for ion channels that can conduct sodium, ion transporters, G-protein coupled receptors, or may encode novel multi-transmembrane proteins with no known function which are candidate salty taste receptors.
In another embodiment, the invention relates to the use of compounds that enhance or inhibit IKBKAP and SV2B gene products to selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.
In another embodiment, since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) the invention related to the discovery that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.
In another embodiment since Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the invention relates to the use of BoTox and derivatives to selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.
In another embodiment since KIT is expressed in umami taste cells the invention relates to the use thereof as a marker of this taste cell type.
In another embodiment the invention relates to the use of KIT and compounds that enhance or inhibit this gene product to selectively modulate taste cell function and responses to umami tastants.
In another embodiment the invention relates to the use of Gleevec (Imatinib), an inhibitor of the KIT tyrosine kinase activity, and other KIT tyrosine kinase inhibitors for selectively inhibiting umami taste.
In another embodiment the invention relates to the discovery that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.
In another embodiment since LOC285965 is expressed in T1R3 only taste cells similar to GPR113 the invention relates to the use as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.
In another embodiment the invention relates to the discovery that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113, which is also expressed in T1R3 only cells.
In another embodiment the invention relates to the discovery that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.
In another aspect the invention relates to the discovery that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.
In another embodiment the invention relates to the discovery that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.
In another embodiment the invention relates to the discovery that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).
In another embodiment the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants.
In another embodiment the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor.
In another embodiment the invention relates to the discovery that MFSD4 may correspond to a marker of immature taste cells or developing taste cells or support cells.
In another embodiment the invention relates to the use of MFSD4 and compounds that enhance or inhibit this gene product to selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
In another embodiment the invention relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell population.
In another embodiment the invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for salt or fat.
In another embodiment the invention relates to the use of the genes listed in Tables 1-8 in assays for candidate salt or fat taste receptors.
BACKGROUND OF THE INVENTION
This invention and the specific rationales for identifying and functionalizing taste specific genes were developed with their initial objective being the identification and functionalization of a gene encoding a salty taste receptor. With respect thereto, epithelial sodium channels (ENaC) are members of the ENaC/degenerin family of ion channels that includes acid-sensing ion channels (ASIC) in mammals, mechanosensitive degenerin channels in worms, and FMRF-amide peptide-gated channels in mollusks (Kellenger, S. and Schild, L. (2002) Physiol. Rev. 82:735-767). ENaC mediates amiloride-sensitive apical membrane Na+ transport across high resistance epithelia in numerous tissues including kidney, colon, and lung and have been well studied and predicted to be involved in salty taste in primates and other species.
ENaC is known to be a heterotrimeric channel comprised of alpha, beta, and gamma subunits or delta, beta, and gamma subunits. Particularly, this heterotrimeric channel has been hypothesized to be involved in human salty taste perception. Previously, assays have been developed by the present assignee using ENaC sequences to identify compounds that modulate the delta beta gamma and alpha beta gamma human ENaC to examine if these compounds will potentially modulate human salty taste perception. Also, these compounds potentially may be used to treat human pathologies involving aberrant ENaC function.
Unlike other mammals, amiloride only slightly reduces the intensity of sodium chloride taste, i.e., by about 15-20% when used at concentrations that specifically modulate ENaC function (Halpern, B. P. (1998) Neuroscience and Behavioral Reviews. 23: 5-47). Experiments conducted by the inventors have shown that amiloride, or the more potent amiloride derivative phenamil did not elicit a significant effect on perceived human salt intensity when tested at levels 300-fold (for amiloride) and 3000-fold (for benzamil) above IC50 values for alpha beta gamma ENaC (equivalent to 10-fold for amiloride and 100-fold for benzamil over IC50 values for delta beta gamma ENaC). Thus, additional non-ENaC genes are likely involved in human salty taste.
In addition, it has been recently reported that taste receptors may be expressed in non-oral tissues, e.g., in the digestive system and potentially other organs such as the kidney. Particularly it has been reported that sweet, umami and bitter taste receptors are expressed in cells other than in the oral cavity such as gastrointestinal cells. (See, e.g., Sternini et al., Amer J Physiol. Gastrointestinal and Liver Physiology, 292:G457-G461, 2007; Mace, O. J. et al, J. Physiology. 10.1113/jphysiol.2007.130906. Published online May 10, 2007). Also, it has been reported by various groups (Margolskee et al., Bezencon et al., Rozengurt et al, and Sternini et al. (2007) (Id)) that bitter and umami taste receptors and other taste signaling molecules such as TRPM5 and gustducin are expressed in specialized cells in the gastrointestinal tract. (See e.g., Margolskee et al., Genes Brain Behavior 2007 (epub March 21); Rozengurt et al., Amer. J. Physiol. Gastroent. Liver Physiol. 291(2):G171-7 (2006); Bezencon et al., Chem Senses 32(1):41-47 (2007)). Margolskee et al. (Id) further reports that the loss of T1R3 or gustducin in rodents resulted in changes in insulin metabolism and the release of satiety peptides such as GLP-1 (glucagon-like peptide 1).
Based on the foregoing, it has been suggested that salty receptors may be expressed in the urinary tract. Taste receptors are purported to be involved in functions not directly related to taste such as digestive functions such as gastric motility, absorption, food detection, metabolism, and immune regulation of the oral or digestive tract and may also affect functions relating to sodium absorption, excretion and transport such as blood pressure and fluid retention.
Therefore, the identification of taste cell specific genes and identifying what specific cells these genes are specifically expressed (including unique taste cell subsets) should facilitate a better understanding of taste and non-taste functions of these taste receptors and should also facilitate the use of these genes, gene products and cells which express same in assays for identifying novel taste modulators and therapeutics, e.g., for treating digestive diseases such as autoimmune, inflammatory and cancers, metabolism, diabetes, eating disorders, obesity, taste cell turnover, hypertension, fluid retention, and immune regulation of the digestive system.
BRIEF DESCRIPTION AND OBJECTS OF THE INVENTION
The invention obviates the problems of the prior art in that it provides novel rationales for identifying and functionalizing primate and human taste specific genes and unique taste cell subsets and further provides novel uses of these taste specific genes, gene products, and modulators of these taste specific genes and cells containing.
This invention in one embodiment relates to the identification of genes that are expressed specifically in chemosensory or taste cells, particularly human and non-human primate (macaque) fungiform or circumvallate papilla cells, and in taste cells (fungiform, circumvallate, foliate, and palate) of other mammals such as humans and other non-human primates. These genes include genes which are directly or indirectly involved in detecting specific taste modalities such as salty, sweet, bitter, umami, sour, fatty and metallic taste and/or in modulating taste intensity and duration.
This invention in another embodiment relates to the identification of genes that are expressed specifically in chemosensory or taste cells, particularly primate (macaque) circumvallate cells and likely in other chemosensory or taste cells and similar cells derived from other mammals such as humans and non-human primates that are involved in other taste cell functions including by way of example taste cell apoptosis or taste cell turnover, taste cell regeneration, digestion, regulation of the immune system in the oral cavity, regulation of carbohydrate or other metabolic functions relating to digestion, food detection, taste cell trafficking, and the like.
The invention in another embodiment further relates to the identification of specific genes or gene products expressed specifically in human and primate (macaque) or other mammalian taste cells that can be used as markers for the identification, isolation, or enrichment of specific taste cell subtypes or taste cell lineages including by way of example sweet, umami, sour, bitter, salty, fatty and metallic taste cells and for isolating taste cells that are involved in non-taste functions such as regulation of immunity, e.g., in the oral cavity, regulation of digestion or metabolism, regulation of taste cell apoptosis, turnover, or taste cell differentiation and proliferation, and regulation of sodium excretion, transport and absorption.
The invention in another embodiment further relates to the use of these taste cell specific genes or gene products or said isolated or enriched taste cell lineages or taste cell types expressing said taste cell specific genes for use in screening assays, e.g. for identifying compounds that elicit of modulate sweet, sour, umami, salty, bitter, fatty or metallic taste as well as the use of these genes, gene products, or isolated or enriched taste cells for the identification of potential therapeutic compounds, e.g., therapeutics for treatment of various digestive system disorders such as ulcerative colitis, Crohn's disease, celiac disease, dyspepsia, cancers of the digestive system, compounds for modulating taste cell turnover or apoptosis or for regulating taste cell differentiation and regeneration e.g., in geriatric subjects or individuals with cancer, or undergoing chemotherapy, or radiation, compounds for modulating or enhancing the immune system of the oral cavity, compounds for the regulation of digestion and metabolism, e.g., compounds that affect the production of digestive fluids, hormones or enzymes such as saliva, stomach and intestinal fluids, GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), secretin, amylase et al., compounds that affect digestive motility, compounds for treating diabetes, for modulating food detection, and compounds for treating obesity or eating disorders, cachexia, and the like.
This invention in its more specific embodiments relates to novel rationales and methods, and results to date using these rationale and methods for identification and characterization of novel taste-specific genes that based on various parameters constitute salt or other taste modality receptor targets. The targets using these protocols are useful targets in high-throughput screening efforts to identify human salty taste enhancers. These targets are initially identified using two different techniques, gene chips and a polymerase chain reaction (PCR) screen, to identify novel salt receptor target genes. First, Affymetrix gene chips containing most all known macaque genes are used to determine which genes are specifically expressed in primate circumvallate at the back of the tongue and fungiform papilla taste cells at the front of the tongue and not lingual epithelial cells isolated by laser capture microdissection. Second, PCR is used to determine which ion channels, from channels we have cataloged in the human/macaque genomes, are specifically expressed in macaque fungiform and/or circumvallate (CV) papilla taste cells but not lingual epithelial cells isolated by laser capture microdissection. Taste-specific expression of genes identified by either approach, are confirmed using an independent histological method such as in situ hybridization or immunohistochemistry, to determine which genes are expressed in taste cells. Using double labeling histological methods, it is determined what novel taste-specific genes are expressed in sweet, bitter, and umami cells that express the taste-specific ion channel TRPM5, sour cells that express the taste-specific ion channel PKD2L1/PKD1L3, or a unique cell type that does not express TRPM5 or PKD2L1/PKD1L3. A taste-specific gene, preferably an ion channel, that is conductive or activated by sodium and is expressed in a TRPM5- and PKD2L1/PKD1L3-negative cell population is a probable candidate for screening efforts to identify the gene(s) that encode mammalian salty taste receptors, as well as specific cell types wherein these salty taste receptor genes are expressed such as in the oral cavity and urinary tract, and also for use in high throughput assays designed to identify enhancers of saltiness in humans.
In another aspect we describe an improvement of the afore-described methods in the subject application by a method wherein genes expressed in primate taste buds are identified and functionalized using a specific protocol which hinges on where they are expressed and their level of expression in the taste bud. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud (and likely human taste specific genes given the conservation of structure between primate (macaque) and human genes) for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.
The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively (see FIG. 38 and examples infra).
In a related embodiment the invention relates to these categorized taste specific genes. As disclosed infra, gene expression data obtained was queried to obtain three sets of genes. (Appendices 1-3 of this patent application). The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. The third set of genes is expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium samples. These additional taste bud-specific genes are listed in Appendix 3.
Also, in another embodiment this invention describes rationales which are useful for and which have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods include methods which identify human taste specific genes by quantitative polymerase chain reaction (PCR) using taste buds from human postmortem samples. It is an improvement over the primate gene assays since this method provides direct results concerning human taste specific genes which may be functionalized using the described methods.
Also, in another embodiment this invention identifies taste specific genes which should be involved in specific taste cell functions based on where the gene is expressed and levels of expression in the taste bud. These methods are able to classify genes into one of several functional classes that include taste receptor genes. It is an improvement since it provides accurate predictions regarding the taste specific genes which may be functionalized using the described methods.
In another embodiment the invention provides the use of the afore-mentioned improved rationale to demonstrate taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”). These methods identify the genes contained in the Table 8 infra which all encode multi-span transmembrane proteins, and are predicted to include yet unidentified taste receptors as well as other genes involved in taste modulation including the fat and salt receptor and genes involved in ancillary functions afore-mentioned.
Also, in yet another embodiment the invention identifies unique taste cell subsets which themselves can be used in screens for taste modulatory and therapeutic compounds as described infra, and also further exploits the elucidation of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.
In another embodiment the invention relates to the use of these identified taste specific genes in assays designed to identify therapeutics for the treatment of digestive system disorders such as digestive cancers, autoimmune and inflammatory digestive disorders such as ulcerative colitis, dyspepsia, Crohn's disease, celiac disease, inflammatory bowel syndrome, diverticulitis, et al., for regulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration e.g. in geriatrics, cancer patients or individuals undergoing chemotherapy or radiation, for modulating the immune system of the oral cavity, for regulation of digestive mucous and fluids, enzymes or hormones such as GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), amylase, saliva, stomach acids, intestinal fluids, pepsin, secretin, and the like; for treatment of diabetes, eating disorders, cachexia, and other metabolic disorders involving these genes and/or isolated or enriched taste cells.
In another embodiment the invention relates to the use taste-associated genes and polypeptides in assays to ascertain their role in taste cell development and apoptosis, taste cell regeneration, modulation of transcription factors that modulate taste cell receptor expression, e.g., bitter taste receptors, taste receptor trafficking to and from the apical membrane/taste pore region, regulation of taste cell action potential firing frequency/membrane potential to control the intensity of and/or to modulate specific tastes, neurotransmitter release to afferent nerves that regulate taste intensity or specific tastes, and taste cell signaling to nerve fibers.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to identify compounds that specifically bind to or which modulate the activity of these genes which compounds may be used to treat or prevent pathological conditions involving digestive function. These conditions include by way of example functional dyspepsia (bad digestion) and other dyspepsias which may or may not be ulcer derived or related and may involve different areas of the digestive tract such as the upper abdominal tract, the mid-abdominal tract or the lower abdominal tract.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to identify compounds that may be used to treat or prevent pathological conditions involving gastrointestinal fluids, mucous, enzymes or hormones involved with digestion or hunger such as gastrin, secretin, pepsin, cholecystokinin, glucose-dependent insulinotrophic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), amylase, ghrelin, leptin and the like. Also these compounds may enhance the production of saliva or other digestive mucous secretions and fluids. These compounds potentially may be used to suppress or induce hunger and/or to modulate digestion in subjects in need thereof.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and to the use of these genes, gene products, or cells that express same such as but not restricted to taste cells, e.g., gastrointestinal or oral cavity derived cells, in screening assays to identify compounds that bind to or modulate the activity or amount of these genes or gene products compounds which potentially may be used to treat or prevent pathological or chronic inflammatory or autoimmune gastrointestinal conditions such as Crohn's disease, inflammatory bowel syndrome (IBD), celiac disease, ulcerative colitis, diverticulitis, gastritis, reflux esophagitis, and the like. These compounds potentially may be used to treat or prevent autoimmune or inflammatory diseases affecting the digestive system.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes or gene products which compounds potentially may be used to modulate gastric reflux and diseases or conditions associated therewith such as gastroesophageal reflux disease, heartburn, Barrett's esophagus, and esophagitis.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of these genes or gene products and which therefore potentially may be used to treat or prevent cancers or malignancies associated with the digestive system such as by way of example cancers of the tongue, and oral cavity such as cancers of the taste buds and salivary gland cancers, stomach, esophagus, small or large intestine, anus or rectum, pancreas, gall bladder, liver, colorectal or colon.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of genes or gene products which compounds potentially my be use to treat or prevent appetite dysfunction and conditions associated therewith such as obesity, anorexia, bulimia, and cachexia associated therewith.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides for the isolation or enrichment of specific taste cell lineages or subtypes particularly taste cells derived e.g., from the tongue, oral cavity, or gastrointestinal system, which express one or several of these taste-cell associated genes.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in assays to identify compounds that bind to or which modulate the activity of these genes or gene products which may be used to treat or prevent pathological conditions involving digestive function. These conditions include by way of example functional dyspepsia (bad digestion) and other dyspepsias which may or may not be ulcer derived or related and may involve different areas of the digestive tract such as the upper abdominal tract, the mid-abdominal tract or the lower abdominal tract.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that may be used to treat or prevent pathological conditions involving gastrointestinal hormones, enzymes or fluids involved with digestion or hunger such as saliva, digestive fluids, gastrin, secretin, cholecystokinin, glucose-dependent insulinotrophic polypeptide, glucagon-like peptide 1, amylase, or ghrelin, leptin and the like. These compounds potentially may be used to suppress or induce hunger or to modulate digestion in subjects in need thereof.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes or gene products which compounds potentially may be used to treat or prevent pathological or chronic inflammatory or autoimmune gastrointestinal conditions such as Crohn's disease, inflammatory bowel syndrome (IBD), celiac disease, ulcerative colitis, diverticulitis, gastritis, reflux esophagitis, and the like. These compounds potentially may be used to treat or prevent autoimmune or inflammatory diseases affecting the digestive system.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or modulate the activity of these genes which compounds that potentially may be used to modulate gastric reflux and diseases or conditions associated therewith such as gastroesophageal reflux disease, heartburn, Barrett's esophagus, and esophagitis.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to identify compounds that bind to or which modulate the activity of these genes and which compounds therefore potentially may be used to treat or prevent cancers or malignancies associated with the digestive system such as by way of example cancers of the salivary glands and taste buds, tongue, oral cavity, stomach, esophagus, small or large intestine, anus, pancreas, gall bladder, liver, colorectal, or colon.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that regulate ion transport or ion flux, particularly sodium ions in order to identify therapeutic compounds that may be e.g., used to modulate blood pressure and fluid retention and conditions and diseases involving aberrant sodium absorption, excretion and transport.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that regulate selective apoptosis of taste cells, modulation of transcription factors that control taste receptor expression, autocrine/paracrine modulation of taste cell development, taste bud lifetime, screens using genes that result in supertaster phenotypes, compounds that activate taste stem cells, compounds that affect trafficking of taste cell receptors e.g., from the apical membrane/taste pore region, compounds that affect taste intensity by modulating regulation of taste cell action via potential firing frequency/membrane potential, compounds that regulate neurotransmitter release to afferent nerves that control general or specific taste intensity, and autocrine/paracrine modulation of taste receptor function.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays for identifying compounds that affect regeneration of taste cells or taste buds, e.g., in diseased or geriatric individuals or after injury or surgery, subjects undergoing chemotherapy or after injury, compounds for modulating drug-induced dysgeusia, ageusia, taste bud loss, dry mouth or xerostomia as for example found in Sjogren's syndrome, compounds that are useful in maintaining oral hygiene, treating or preventing halitosis, noxious oral microbia such as viruses and bacteria, and the like.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example, desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.
In another embodiment the invention relates to, as described in detail infra, a rationale and criteria for a candidate salty taste gene, preferably an ion channel which are:
a) Specific expression in primate (macaque) taste cells, particularly fungiform and/or circumvallate papilla derived taste cells, but also foliate and palate taste cells, and not lingual epithelial cells OR expression at higher levels in taste cells than lingual cells
b) Expression in a taste cell by histological methods. Specifically, expression in a unique taste cell type that does not express the sweet, bitter, and umami cell marker TRPM5 or the sour cell marker PKD2L1/PKD1L3. This unique cell type could be a dedicated salt sensing cell.
c) Functional expression as a sodium channel or a sodium-activated receptor with basal, constitutive function (i.e. a fraction of the channel population is open and passing sodium at rest) in heterologous expression systems (such as Xenopus oocytes and mammalian cells) or primary neurons (such as dorsal root ganglia neurons).
Genes fulfilling these criteria will be advanced into high-throughput screening efforts to identify compounds that enhance human salt perception. In addition the taste-specific genes reported herein, e.g., in Tables 1, 2, and 3 supra will be useful in the therapeutic screening assays as afore-mentioned.
Therefore in this patent application we describe screening assays to identify genes putatively involved in salty taste perception as well as taste and other taste-cell mediated activities in general.
In another embodiment the invention relates to a specific rationale that identifies taste-specific genes encoding membrane proteins expressed specifically in taste cells and not lingual cells at higher levels in taste cells than lingual epithelial cells using gene chip and/or PCR methodologies and use same as salt receptor targets in assays to identify salty taste modulators as well as compounds that affect other taste modalities and taste perception and taste-cell related biological and cellular functions and taste cell related phenotypes in general.
In another embodiment the invention relates to a rationale that determines which taste-specific genes are expressed in taste cells and especially in sweet, bitter, and/or umami cells (TRPM5 positive), sour cells (PKD2L1/PKD1L3 positive) or a unique cell type (TRPM5 negative). These unique cell types will likely comprise cells dedicated to salty taste perception.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to identify modulators (enhancers) of taste-specific ion channels or taste-specific genes as these compounds may modulate human salty taste perception.
In another embodiment the invention relates to a rationale wherein the inventors describe and are able to assign herein gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, this invention classifies genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities. (The rational for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively.)
In another embodiment the invention relates to novel methods for functional characterization of taste bud specific genes based on certain expression criteria. The invention provides three sets of genes which are contained in the Appendices 1-3 to this application identified using this rationale. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. (Accordingly, these lists contain top enriched and bottom enriched mRNAs). The third set of genes was identified as expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium. This set of taste bud-specific genes was obtained by the identification of taste bud-specific genes by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples. These additional taste bud-specific genes are listed in Appendix 3.
In another embodiment the invention relates to the discovery that taste-associated genes and polypeptides are expressed predominantly at the top of the taste buds. In contrast to prior knowledge, our new data clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect other yet to be identified taste receptor genes to be represented in the top-enriched gene list.
In another embodiment the invention relates to the functional characterization of particular “target” taste bud specific genes based on where they are expressed in the taste bud cells. The inventors have discovered based on gene expression profiles of the top and bottom fractions of the taste bud suggest that there are distinct functions for cells in each compartment. Functional classes of genes expressed in the top cells indicate these are mature sensory cells whereas those expressed in the bottom cells indicate these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional classes include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include extracellular matrix components, growth factors and cell cycle-associated proteins.
In another embodiment the invention relates to a comprehensive listing of taste specific genes in the Tables and Appendices of this application. By fractionating the taste bud into top and bottom compartments the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of approximately two and has identified virtually all taste bud specific genes.
In another embodiment the invention relates to a method for identifying genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to genes identified using the above method where genes involved in taste sensation would be over-expressed in the top part of the taste bud.
In another embodiment the invention relates to the set of genes identified using the above method where genes involved in modulation of taste sensation would be over-expressed in the top part of the taste bud.
In another embodiment the invention relates to a set of genes identified using the above method where genes involves in taste bud growth and development are over-expressed in the bottom part of the taste bud.
In another embodiment the invention relates to the genes identified using the above methods where the genes are involved in control of the lifespan of mature taste bud cells are over-expressed in the top part of the taste bud.
In another embodiment the invention relates to the genes identified using the above methods where genes involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells will be over-expressed at the bottom of the taste bud.
In another embodiment the invention relates to the genes identified using the methods, where the genes represent biomarkers of taste-bud committed stem cells will be over-expressed at the bottom of the taste bud.
In another embodiment the invention relates to the genes identified using the above methods where genes representing biomarkers of different mature taste cell subsets will be over-expressed in the top of the taste bud.
In another embodiment the invention provides a set of genes identified as described above and the use thereof in order to purify, enrich, isolate or label specific taste cell subsets.
In another embodiment the invention provides electrophysiological assays that measure conductance of putative taste ion channels identified herein in the presence and absence of putative enhancers.
In another embodiment the invention identifies enhancers of the subject putative salty taste related ion channels and other taste affecting genes in an oocyte expression system.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in patch clamping or two electrode voltage clamping assays using oocytes that express a putative salty taste receptor ion channel for identifying compounds that modulate the activity of this channel and therefore modulate salty taste. These and other objects of the present invention are met by one or more of the embodiments described below.
In another embodiment the invention relates to methods of isolating, purifying and marking desired taste cell types and taste cell lineages including e.g., umami, sweet, salty, bitter, fat, sour, metallic as well as taste stem cells and other immature and mature taste cell lineages including cells that differentiate into taste bud cells, taste cell neurons, taste immune cells et al. based on the expression or absence of expression of one or more of the taste specific genes provided herein. These isolation and purification methods include both positive and negative cell separation methods. For example desired taste cell lineages or types may be isolated by positive cell selection methods e.g., by the use of fluorescence activated cell sorting (FACS), magnetic bead cell selection e.g., by visual identification of desired cells such as individual transfected cells by electrophysiology using antibody coated beads. Alternatively, desired taste cell lineages or types may be recovered or purified by negative cell purification and isolation methods wherein the desired cell types are enriched or purified from a mixed cell population by the removal of one or several undesired cell lineages e.g., by contacting a mixed cell suspension containing the desired taste cells and undesired cells e.g., derived from the tongue, oral cavity or gastrointestinal tract and associated organs with cytotoxic antibodies specific to a target gene or genes expressed on the undesired taste cell type(s) which are to be removed.
In another embodiment the invention relates to the use of these taste-associated genes and polypeptides in assays to ascertain their role in and in screening assays to methods of using these genes and gene products as markers e.g., using probes specific thereto such as antibodies or oligonucleotides, i.e., that are specific to one or more of the subject taste specific genes provided herein in mapping regions of the tongue and oral cavity which are involved in specific taste and non-taste specific functions, mapping of cell comprised on specific regions of the gastrointestinal tract and associated organs such as the intestinal epithelium or urinary tract that express specific taste specific genes and which therefore are involved in one or more of the taste cell specific functions disclosed herein, and/or the use of the subject genes and markers specific thereto in taste cell differentiation studies, e.g. for identifying compounds that induce the differentiation or dedifferentiation of taste cells e.g., adult or embryonic stem cells and other pluripotent or immature cell types into desired taste cell lineages and taste cell types.
In another specific embodiment the present invention relates to assays using endogenous taste cells, e.g., gastrointestinal cells such as gastro-endocrine or gastro-epithelial cells or cells on the tongue or oral cavity, that screen for compounds which act as activators of TRPM5 or umami (T1R1/T1R3) and/or sweet (T1R2/T1R3) taste receptors, preferably those which modulate insulin metabolism and/or the release of a satiety peptide such as GLP-1 (glucagon-like peptide 1), which activators may be used in treating or preventing metabolic and eating disorders such as in the treatment of one of obesity, diabetes, weight management, fat metabolism, glucose metabolism, insulin metabolism, satiety or other conditions wherein the release of satiety peptides such as GLP-1 (glucagon-like peptide 1) is desirably controlled or reduced.
This invention in a more specific embodiment relates to specific taste specific genes identified infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human and primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.
Also, the invention in another embodiment relates to enriched, isolated or purified taste cell subsets which expresses at least one of FAM26A, MCTP1, TMEM30B, and/or TUSC3 and which further express at least one T1R or T2R or TRPM5 gene and/or which express T1R2/T1R3 or T1R1/T1R3 or T1R3 only. Particularly, the invention provides isolated taste cells that express GPR113 and/or TMEM16G and which isolated taste cells which further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R gene and/or TRPM5.
Also, the invention in another embodiment relates specifically to a method of using a probe specific to a gene or gene product corresponding to the genes to identify and/or isolate and or enrich taste specific cells from non-taste cells in a sample. For example, these methods include a method herein the gene is FAM26A, MCTP1, TMEM30B, and/or TUSC3 and the identified, isolated or enriched cell further expresses T1R1/T1R3, T1R2/T1R3, T1R3 only, a T2R, and/or TRPM5. Also, the invention includes methods wherein the gene is GPR113 and/or TMEM16G and the isolated, identified or enriched cell further expresses at least one of T1R2/T1R3, T1R1/T1R3, T1R3 only, a T2R or TRPM5 and/or wherein said taste cells are human or macaque taste cells. and wherein said isolated taste cells do not express PKD2L1, PKD1L3, or TRPM5 and/or wherein said cells do not express a T1R or a T2R and/or said taste cells express transducin or gustducin.
Also, the invention relates to the use of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B as a biomarker of specific taste cells and the isolated cells which express same as all of these genes are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.
Also, the invention in another embodiment relates to the use of these identified taste specific genes or an ortholog or variant thereof encoding a protein at least 90% identical thereto in a cell isolation, purification, enrichment, or marking technique that isolates, purifies, enriches and/or marks at least one desired taste cell subtype or lineage contained in a mixed cell population or cell suspension comprising a desired taste cell type or lineage based on the expression or absence of expression of at least one gene contained in Tables 1-8 or an ortholog thereof, or a gene encoding a protein that is at least 90% identical to said gene or an ortholog thereof. Particularly, the invention includes methods wherein the taste cell subtype or taste cell lineage is isolated, purified, enriched, or marked by a method that includes the use of a fluorescence activated cell sorter (FACS) or by the use of labeled magnetic beads and wherein the cell suspension containing the cells may be produced by enzymatic digestion and/or tissue disaggregation of tissues containing taste cells. and methods wherein the desired taste cell subtype or taste cell lineage is isolated, purified, enriched or marked by a method that includes a negative cell selection technique that eliminates at least one non-target taste cell subtype or lineage based on the expression or absence of expression of at least one other taste cell specific gene identified herein. These methods may e.g., use cytotoxic antibodies to specifically kill at least one non-target cell type or lineage. These isolation methods may e.g., result in isolates containing sweet taste cells, umami taste cells, sour, salty, or fat taste cell subtype or lineages, taste stem cells taste cell neurons, or taste immune cells.
Also, the invention in another embodiment relates to methods of using a cell isolated, purified, enriched or marked according to these methods in screens for taste modulatory compounds, or in a method that screens for compounds that induce the differentiation of said enriched, isolated, purified or marked taste stem cells into one or more taste cell lineages or subtypes or taste buds or in a method wherein said taste cell lineages or subtypes are identified based on the expression or absence of expression of at least one the identified taste specific gene identified above. These cells may be used to screen for compounds that modulate at least one of sweet, umami, bitter, sour, fat, salty or metallic taste wherein the gene is GPR113 or TMEM16G or TMEM44 or to screen for compounds that modulate taste cell differentiation or turnover.
Also, the invention in another embodiment relates to these cells or the gene or gene product encoded thereby in assays that screen for compounds that modulate or treat the diseases and conditions involving taste cells previously identified. This in particular relates to GPR113 or the corresponding gene product or cells which express same or an ortholog or variant thereof in assays to identify compounds that modulate taste cell differentiation or taste cell turnover.
Also, the invention in another embodiment relates to isolated immature taste cells and/or taste stem cells that express TMEM44 or GPR113 and the use in an assay for identifying taste modulators, in particular which screens for sweet, umami, bitter, fat, salty, metallic and/or astringent taste modulators. Also, the invention relates to a recombinant cell engineered to co-express T1R3 and GPR113 and optionally TRPM5. Also, the invention embraces an assay for identifying compounds which modulate taste cell differentiation and/or maturation based on whether said compound specifically binds and/or modulates the activity of GPR113.
Also, the invention in another embodiment relates to the use of these cells in assays that screen for compounds that modulate the differentiation and/or maturation of sweet or umami taste cells. Also, the invention provides a method of using GPR113 as a marker to identify, enrich and/or isolate or ablate unique taste cells which express GPR113, TRPM5 and T1R3 wherein said taste cells do not express T1R1, T1R2 and/or a T2R or are immature, e.g., by FACS or magnetic bead cell separation or by use of cytotoxins.
In addition the invention in another embodiment relates to the discovery that TMEM44 and MFSD4 are expressed in unique taste cell type and that these gene are expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells which further expresses another taste-specific gene disclosed herein. Also, the present invention relates to the discovery that expression of TMEM44 and MFSD4 are markers for a unique taste cell type that may correspond to a fat receptor. Further, the invention relates to the discovery that ATP8A1, FAM26B and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.
This invention in a more specific embodiment identifies genes infra, e.g., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, and TUSC3 that are expressed in chemosensory or more specifically taste cells, e.g., human or primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. and isolated taste cells expressing including cells wherein these genes are expressed as novel taste cells (do not correspond to prior taste modality) and that do not express TRPM5 or PKD2L1/PKD1L3.
Also, the present invention in another embodiment relates to the discovery that MFSD4 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) indicating that the expression of this gene is a marker for a unique taste cell type e.g., a salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.
Also, the invention in another embodiment reveals that the expression pattern of MFSD4 is very similar to TMEM44, indicating that both genes are expressed in the same taste cell type and may be comprised in a heteromeric taste receptor.
Also, the invention in another embodiment relates to the discovery that ATP8A1, FAM26B, and SLC4A11 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5.
Also, the invention in another embodiment relates to the discovery that ATP8A1, FAM26B, and SLC4A11 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.
Also, the present invention in another embodiment relates to the discovery that MFSD4 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells. Moreover, the invention relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Based on the foregoing, the invention relates to the discovery that MFSD4 may correspond to the salt receptor or fat receptor. Also, MFSD4 may be a marker of immature taste cells or developing taste cells.
Related thereto, in another embodiment the present invention also relates to the discovery that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
Also, the present invention in another embodiment relates to the discovery that MFSD4 and TMEM44 are expressed in the same unique taste cell type. Also, the present invention relates to the discovery that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor for a different taste than sweet, umami, sour or bitter, likely salt or fat. and may be used in screening assays.
Also, in another embodiment the present invention relates to the discovery that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. and may regulate taste perception or other taste cell function. Moreover, the present invention reveals that ATP8A1, FAM26B, and SLC4A11 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells.
In another embodiment the invention relates to the discovery that ASCL1 also known as MASH is a transcription factor that defines and is a useful marker of sour taste cells as it is selectively expressed in sour taste cells that express PKD1L3 but not in other taste cell types, i.e., it is not expressed in sweet, bitter, or umami cells which express TRPM5. Therefore, the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the invention provides the use thereof in screening the genome for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
In another embodiment the invention establishes ASCL1 to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, the invention reveals that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.
In another embodiment the invention relates to the discovery that other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors related thereto that define those cell types. Therefore, the invention provides assays detecting the expression of all transcription factors in the genome in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.
In another embodiment the invention relaters to the discovery that the ASCL1 transcription factor binds to promoter elements in genes involved in sour taste perception. Thus, the invention encompasses such sequences found in the genome that comprise ASCL1 motifs and the use thereof to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
In another embodiment the invention relates to the discovery that ASCL1 (aka MASH1) is a marker useful for identifying, purifying, and/or isolating or ablating sour taste cells in a mixed cell sample, e.g., derived from the tongue or gastrointestinal or urinary tract.
In a related embodiment the invention provides the use of ASCL1 as a marker of Type III taste cells that correspond to sour taste receptor cells
In another embodiment the invention establishes that because ASCL1 defines the sour taste cell lineage it may also control sour taste cell development.
In another embodiment the invention provides the use of ASCL1 transcription factor DNA binding sequences as a probe to identify sour cell genes and sour taste receptor genes that possess related structure such as ASCL1 motifs.
Also, in another embodiment the invention provides the use of these and other taste cell specific transcription factors to define, mark, and/or label taste cell types because each taste cell will express one or more transcription factors that define that taste modality.
The invention further provides in another embodiment the use of these transcription factors that define taste modalities in cell ablation studies to specifically eliminate a specific taste cell or taste modality.
Also, in another embodiment the invention provides ASCL1 or other taste transcriptional gene knockouts which result in transgenic animals possessing altered taste perception and other phenotypic effects, e.g., elimination of sour taste perception or altered urinary or digestive function since ASCL1 may be involved in the metabolic response to pH changes such as excess acidity.
Also, t in another embodiment the invention provides the use of these transcription factors that define new taste cell types which can be used in cell ablation studies and in vitro assays to determine what taste modality is lacking as a result of this ablation (i.e. what taste modality is eliminated).
In another embodiment this invention identifies taste-specific genes NALCN, TRPML3 and NKAIN3 which when expressed separately or in combination are predicted to comprise a taste receptor, putatively a salty taste receptor, as these 3 genes are expressed in primate taste cells, are enriched in the top fraction of taste bud cells, and are known to encode sodium channels. In addition the invention relates to the discovery that NALCN is expressed in a unique taste cell subset and is predicted to encode a taste related function. (As noted, TRPML3 has been shown to encode a salty taste receptor).
In a related embodiment the present invention relates to the use of these taste specific ion channel genes as markers which can be used to enrich, identify or isolate salt receptor expressing cells.
In another embodiment the invention relates to assays that identify compounds that modulate the function of the use of NALCN, TRPML3 and/or NKAIN3 and the use of the identified compounds to modulate salty taste perception.
In another embodiment the invention relates to other taste specific genes, i.e., KIT, IKBKAP, LOC285965, and SV2B that are expressed in specific subsets of taste specific cells.
In another embodiment, this invention relates to the discovery that KIT is specifically expressed in TRPM5 and T1R3 taste cells and T1R1 taste cells indicating that the gene can be used as a marker to identify umami taste cells in a mixed cell population and/or may modulate the expression and activity of the umami taste receptor.
In another embodiment, this invention relates to the discovery that IKBKAP and SV2B are specifically expressed in PKD1L3 sour taste receptor cells indicating that these genes can be used as markers to identify sour taste cells and/or modulate taste, especially sour taste.
Also, in another embodiment this invention relates to the discovery that LOC285965 is specifically expressed in TRPM5 and T1R3 taste cell subsets and T1R3 cells lacking T1R1 and T1R2 suggesting that this gene can be used as a marker of these taste cell subsets and/or may associate with or modulate the T1R3 gene and/or encode a taste receptor distant from T1R1/T1R3 or T1R2/T1R3.
Further, in another embodiment the invention relates to the discovery that SV2B is specifically expressed in PKD1L3 cells indicating that this gene can be used as a marker of these specific cell subsets and/or may encode a polypeptide that modulates the activity or expression of the PKD1L3 sour taste receptor.
In addition, in another embodiment the invention relates to the discovery that MFSD4 is expressed in sensory taste cells that are not sweet, bitter, umami, or sour cells and that this gene is expressed in a similar taste cell population as TMEM44.
In another embodiment, the invention relates to the use of compounds that enhance or inhibit IKBKAP and SV2B gene products to selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.
In another embodiment, since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) the invention relates to the discovery that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.
In another embodiment since Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the invention in another embodiment relates to the use of BoTox and derivatives to selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.
In another embodiment since KIT is expressed in umami taste cells the invention relates to the use thereof as a marker of this taste cell type.
In another embodiment the invention relates to the use of KIT and compounds that enhance or inhibit this gene product to selectively modulate taste cell function and responses to umami tastants.
In another embodiment the invention relates to the use of Gleevec (Imatinib), an inhibitor of the KIT tyrosine kinase activity, and other KIT tyrosine kinase inhibitors for selectively inhibiting umami taste.
In another embodiment the invention relates to the discovery that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.
In another embodiment since LOC285965 is expressed in T1R3 only taste cells similar to GPR113 the invention relates to the use as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.
In another embodiment the invention relates to the discovery that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113, which is also expressed in T1R3 only cells.
Also, the invention relates to the discovery that TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B may be used as biomarkers of specific taste cells and the isolated cells which express same as all of these genes are expressed by unique taste cell subsets comprised in primate taste buds and therefore can be used as biomarkers to isolate, enrich, mark or ablate these cells and thereby determine the taste related function of these taste bud cells.
In another embodiment the invention relates to the discovery that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.
In another aspect the invention relates to the discovery that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.
In another embodiment the invention relates to the discovery that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.
In another embodiment the invention relates to the discovery that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).
Moreover, in a related embodiment this invention identifies a novel set of genes, i.e., FAM26A, GPR113, MCTP1, TMEM16G, TMEM30B, TMEM44, TUSC3, ATP8A1, FAM26B, SLC4A11, ASCL1 and MFSD4 and the afore-mentioned genes that are expressed in chemosensory or more specifically taste cells, e.g., primate fungiform or circumvallate macaque taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates. In some embodiments these genes are expressed in novel taste cells that do not express TRPM5 or PKD2L1/PKD1L3. These genes are referred to herein as “taste-specific” genes because they are strongly expressed in taste cells, preferably a previously unidentified taste cell type that may be involved in fat or salty taste perception. These taste-specific genes include genes which are directly or indirectly involved in taste detection and modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as including genes which are involved in biological functions not directly related to taste detection such as the modulation of digestion, taste cell turnover, regulation of the immune system, particularly of the oral cavity, and the regulation of metabolism e.g., carbohydrate metabolism, diabetes, obesity, cachexia, detection of food during digestion, et al.
In another embodiment the invention relates to the discovery that taste cells in the bottom half of the taste bud are immature.
In another embodiment the invention reveals that taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors.
In another embodiment the invention reveals SHH to be a marker of immature and developing taste cells at the bottom of the taste bud.
In another embodiment the invention reveals TMEM44 and MFSD4 to be markers of immature and developing taste cells at the bottom of the taste bud.
In another embodiment the invention reveals a subpopulation of TMEM44 cells may be mature salty taste cells.
In another embodiment the invention suggests that a salt receptor will be expressed in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells.
In a related embodiment the invention suggests that a salty taste cell will be present in the top half of the taste bud since all other known professional, mature taste cells are expressed in the top of the taste bud.
In a specific embodiment this invention reveals TMEM44 cells, which comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud, and have identified that other genes are expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH) (a cytokine involved in immature cell differentiation). Based thereon, this invention predicts that cells expressing TMEM44 represent an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human and while immature, they may comprise a subset of mature cells that may be responsible for salt sensation.
Also in a specific embodiment this invention reveals that GPR113 cells which represent about 10% of the taste bud cell population, are distinct from sweet, bitter, and umami taste cells, are located in the top of the taste bud, and express T1R3 and TRPM5 but not the G protein alpha subunit gustducin (GNAT3), suggesting that these cells represent a novel taste cell population that detects a novel taste modality such as fat.
Also in a specific embodiment this invention reveals the existence of another cell subset which express TRPM5 and T1R3 and which include sweet cells (which also express TIR2) as well as umami cells (which also express T1R1).
Also in a specific embodiment this invention reveals that bitter (T2R expressing taste cells) express TRPM5 but not T1R3.
Also in a specific embodiment this invention reveals that sweet, bitter, and umami cells express GNAT3 indicating that this gene can be used as a marker of these types of taste cells.
Also in a specific embodiment this invention reveals that PKD2L1 and PKD1L3 cells: (which cells have been previously described to be responsible for sour taste sensation) comprise about 10% of the taste bud cell population located in the top of the taste bud, and are heterogeneous, i.e. there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population suggesting that one of these subsets may represent a salt sensing cell.
Also in a specific embodiment this invention reveals the existence of another subset of taste cells ( ̃8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3 which in addition or alternatively may represent a salt sensing cells.
More specifically, in a specific embodiment this invention provides a TMEM44 cell ablated non-human animal, e.g., a rodent.
Also, in a specific embodiment the invention provides taste cell suspensions consisting essentially of TMEM44 expressing taste cells.
Also, in a specific embodiment this invention provides a method of using the TMEM44 taste cell ablated animal (rodent) or the TMEM cell suspension for identifying the function of TMEM expressing cells in a taste modality, preferably salt or fat.
Also, in a specific embodiment the invention provides a GPR113 taste cell ablated animal, e.g., a rodent.
Also in a specific embodiment the invention provides taste cell suspensions consisting essentially of GPR113 expressing taste cells.
Also in a specific embodiment the invention provides a method of using the GPR113 taste cell ablated rodent or the GPR113 cell suspension for identifying the function of GPR113 expressing cells in a taste modality, preferably salt or fat.
Also, in a specific embodiment, the invention provides for PKD2L1 and/or PKD1L3 taste cell ablated animals, e.g., rodents.
Also, in a specific embodiment, the invention provides for taste cell suspensions consisting essentially of PKD2L1 and/or PKD1L3 expressing cells.
Also in a specific embodiment the invention reveals that the cells in the bottom half of taste buds are immature whereas taste cells in the top half of the taste bud are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to that of SHH. Thus, TMEM44 cells (which also express MFSD4) are immature and comprise, in part, developing taste cells. Supporting this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter, and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are, therefore, maturing into professional taste cells. By contrast, cells in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the salty taste cell and the salty taste receptor should also be present in the top half of the taste bud. Therefore, the invention demonstrates that taste cells in the bottom half of the taste bud are immature.
Also in a specific embodiment the invention demonstrates that taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors.
Also in a specific embodiment the invention demonstrates TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.
Also the invention reveals a subpopulation of TMEM44 cells may comprise a mature salty taste cell.
SUMMARY OF THE INVENTION
This invention relates in general to novel and improved rationales for identifying (systematically and comprehensively) sets of primate genes which should encompass virtually all primate and human taste specific genes. Thereby, the invention provides a library of genes which will contain all primate and human taste receptors as well as taste specific genes involved in ancillary functions such as those relating to digestion, excretion and sodium ion related functions. These genes and gene products and cells expressing same are useful in screening assays for identifying taste modulators and therapeutics. A further advantage of the invention is that the invention provides methods for categorizing these genes into specific categories which should correlate to function thereby facilitating the number of genes to be functionalized by methods also provided in this application. More specifically, the invention has identified a subgenus of human and primate genes which will contain all taste receptors and taste modulators including those not yet identified. For example, this subgenus contained the salty taste receptor and in all likelihood other taste receptors involved in fat, metallic, CO2, astringent and the like.
Therefore, this invention in its more broad embodiments identifies genes that are expressed in chemosensory, e.g., human and non-human primate (macaque) fungiform and/or circumvallate papilla taste cells, and taste (e.g., fungiform, circumvallate, foliate, or palate) cells derived from other mammals such as humans and non-human primates (“taste specific”). These genes include genes which are directly or indirectly involved in taste detection and taste modulation, e.g., salty, umami, sweet, sour, fatty, metallic, or bitter taste transduction as well as functions not directly related to taste detection and taste modulation such as genes that are involved in the modulation of digestion and the production and composition of digestive fluids, mucous, enzymes and hormones such as saliva, stomach and intestinal fluids, GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotrophic polypeptide), secretin, pepsin, and the like; genes that are involved in regulation of blood pressure and fluid retention, genes that are involved in taste receptor trafficking, taste cell turnover and taste cell regeneration, genes that are involved in the regulation of the immune system of the oral cavity and gastrointestinal system, genes that are involved in the prevention or onset of gastrointestinal related diseases such as cancers, inflammatory and autoimmune diseases affecting the oral cavity and digestive system, genes that are involved in the regulation of metabolism e.g., carbohydrate metabolism, obesity, eating disorders, genes that are involved in the detection of food during digestion, et al.
Relating to the foregoing the present invention provides genes that are expressed in human and non-human primate (macaque) chemosensory, e.g., primate (macaque) circumvallate and/or fungiform papilla taste cells that are not expressed or are expressed at significantly lower levels in lingual epithelial cells that are useful in screening assays, preferably high throughput screening assays, for identifying compounds that directly or indirectly modulate different taste modalities, e.g., salty, sweet, umami, bitter, sour, fatty, or metallic.
Further relating to the foregoing the present invention provides genes that are useful in screening assays, preferably high throughput screening assays for identifying compounds that are useful as therapeutics in the treatment of digestive system disorders, for modulating taste cell apoptosis or taste cell turnover, for inducing taste cell regeneration, for effecting the regulation of immunity in the oral cavity or digestive system, and the treatment of diabetes, obesity, eating disorders, and other metabolic disorders.
Also relating to the foregoing the invention provides a novel set of genes which are useful in the identification and/or isolation and/or enrichment of specific types or lineages of taste or chemosensory cells, e.g., taste or chemosensory cells that are involved in specific taste modalities, immune system regulation in the oral cavity, taste cell apoptosis or taste cell turnover, taste cell regeneration, digestive system regulation, and the regulation of metabolism such as by aiding in food detection, the secretion of hormones or enzymes involved in hunger and digestion, and the like.
Further, the invention relates to the use of the isolated chemosensory or taste cells in screening assays for identifying compounds that modulate taste, as well as in the identification of therapeutics for modulating the immune system regulation of the oral cavity, taste cell apoptosis turnover, taste cell regeneration, regulation of hormones or enzymes or fluids and mucous involved in digestion and other taste cell functions, treatment of digestive system disorders, treatment of diabetes, obesity, eating disorders, or other metabolic disorders, and the like.
This invention more specifically relates to novel rationale, methods, and assays including electrophysiological assays that identify and characterize novel taste-specific genes, including those that function as salty taste receptors.
It was hypothesized by the inventors (in part based on properties of known taste receptors) that human salty taste may be mediated, in part, by a sodium or other ion channels as well as transporters and GPCRs expressed specifically in taste-cells. Based on this assumption and other criteria provided infra, the invention provides methods for identifying taste-specific genes, including genes that may regulate salty taste, as well as other taste modalities taste cell mediated functions and phenotypes using gene chip and PCR methodologies. The compounds identified and their derivatives that modulate the activity of these target genes potentially can be used as modulators of human salty taste in foods, beverages and medicinals for human consumption. Also, such compounds and their derivatives potentially may be used to treat diseases involving abet-rant ion channel function. Further the compounds identified using the genes identified herein and cells which express same are useful in therapeutic screening assays as discussed herein for identifying potential therapeutics that modulate other taste-cell related functions and phenotypes.
In one mode this invention identifies genes expressed in primate taste cells and use of these genes for screening for taste modulators and for identifying and isolating specific taste cell lineages and subtypes. These genes are identified based on their selective expression in primate fungiform papilla taste cells found at the front of the tongue and circumvallate papilla taste cells found at the back of the tongue using gene-chips microarrays from taste receptor cells as compared to non-taste lingual epithelial cells isolated by laser capture microdissection (LCM). Since salt perception is most prevalent at the front of the tongue, a salt receptor gene is likely contained within this set of identified genes.
In another mode, this invention provides a method for identifying a gene encoding a polypeptide involved in taste, preferably salty taste in a mammal. One embodiment of this method comprises the steps of (i) identifying a set of genes including genes which are expressed in macaque taste (fungiform and circumvallate papilla taste cells) but which are not expressed in lingual epithelial cells and/or genes which are expressed in taste cells at substantially higher levels than in lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are selected based on criteria which suggest that they are likely salt receptor candidates, i.e., putative ion channels and/or encode multidomain transmembrane proteins. These genes are then examined to determine whether these genes are expressed or not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) functionally expressing one or more genes in the subset identified according to (ii) and determining which of these genes function as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. Typically, the taste tissues for this method are derived from human, primate, or rodent sources. In one preferred embodiment of the method, the genes in step (iii) function as sodium responsive ion channels, and more preferably, when the genes are expressed, a fraction of the channel population is open and passing sodium at rest.
In a preferred embodiment, step (i) comprises the use of laser capture microdissection (LCM) to dissect and purify taste tissues from non-taste tissues. In one mode of this embodiment, step (i) comprises RNA amplification of genes from taste cells and lingual cells and the amplified genes are screened against a gene chip containing a sample of genes specific to the particular mammal from which the taste and lingual tissues are obtained, and preferably, the gene chips include a set of annotated human genes. In an alternative mode of this embodiment, step (i) comprises high throughput PCR using primers for each ion channel in a mammalian genome.
In another preferred embodiment, step (ii) is effected by in situ hybridization using antisense RNA probes specific for the set of genes identified in step (i) to determine level of expression in taste versus lingual cells. In an alternative preferred embodiment, step (ii) is effected by use of immunochemical detection using a labeled antibody specific to the protein encoded by gene or genes identified in step (i).
In another embodiment of the method for identifying a gene encoding a polypeptide involved in salty taste perception in a mammal, the method of this invention comprises the steps of (i) identifying a set of macaque genes including genes which are expressed in taste cells but which are not expressed in lingual cells and/or genes which are expressed in taste cells at substantially higher levels than in macaque lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) determining, in a primary neuron which expresses one or more genes in the subset identified according to (ii), which of said genes functions as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. In one mode of this embodiment, step (iii) comprises contacting the neuron with an antibody which specifically binds the gene and inhibits its function.
Genes identified according to either of the methods described above may be characteristic of cells which do not express TRPM5 and PKD2L1/PKD1L3. In another mode, this invention provides a method to assist in selecting cells which do not express TRPM5 and PKD2L1/PKD1L3 by determining whether a cell expresses a gene identified according to the methods above. Preferably, the gene used in the method of this paragraph is one of the genes listed in Tables 1-3, listing taste-specific genes encoding transmembrane proteins in taste cells. Efforts were focused on transmembrane genes since all known taste receptor genes for sweet, bitter, umami, and sour taste encode transmembrane proteins.
In another aspect this application provides an improvement of the afore-described methods in which genes expressed in primate taste buds are identified and functionalized using the disclosed methods. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.
The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38.
In order to get more information on gene expression in both the top and bottom fractions of the taste bud the inventors isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). This technique is described supra and briefly involves excision of specific groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, the inventors are able to readily identify these structures in sections of primate tongue. As exemplified in the supporting experimental example infra, tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. The inventors reasoned that only this type of section would reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.
The gene expression data obtained was queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes are listed in Appendix 1 and bottom specific genes are listed in Appendix 2. Accordingly, these lists contain top enriched and bottom enriched mRNAs. The third set of genes was identified as expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium. This set of taste bud-specific genes applications describing the identification of taste bud-specific genes by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples. These additional taste bud-specific genes are listed in Appendix 3.
This methodology achieves various advantages and makes certain discoveries including the following:
First, the inventors have found that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to prior knowledge, the data obtained using these methods clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect yet to be identified taste receptor genes are represented in the genes which are enriched at the top of the taste bud.
Second, the inventive top-versus-bottom gene classification methods allow for the functional classification of genes based on their expression in the cells in the top versus the bottom of the taste bud. Gene expression profiles at the top and bottom fractions of the taste bud suggest distinct functions for cell in each compartment. Functional classes of genes expressed in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate that these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional clauses include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include matrix components, growth factors, and cell-cycle-associated proteins.
Third, this methodology allows for the identification of additional taste bud-specific genes. It has been found that by fractionating the taste bud into top and bottom compartments that the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of about 2. This facilitates the identification of other taste specific genes not identified by the prior-described methods. These genes are contained in the Appendices to this patent application.
Therefore, these methods can be used to identify genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud, e.g., where genes over-expressed in the top part of the taste bud. are predicted to be involved in one or more taste sensation, modulation of taste sensation, control of the lifespan of mature taste bud cells or they may be used as biomarkers of different mature taste cell subsets.
By contrast using the inventive rationale genes over-expressed at the bottom of the taste bud are predicted e.g., to be involved in one or more of the maintenance, differentiation and proliferation of taste-bud committed stem cells; or they will represent biomarkers of taste-bud committed stem cells.
In addition, genes expressed specifically in the top or bottom can be using to purify these functionally distinct taste bud cell subsets.
Also, in another aspect this invention describes rationales which are useful and have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods identify human taste specific genes by quantitative polymerase chain reaction (PCR). This also is an improvement of the afore-described methods for identifying taste specific genes, i.e., taste genes expressed in primate taste buds. and more optimally the previous described methods wherein the inventors assign gene expression patterns within the primate taste bud for all taste bud-specific genes; specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud. and thereby are e able to classify genes into one of several functional classes that include taste receptor genes.
By contrast, the third method demonstrates taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”). These methods have been used to identify genes contained in the Table 8 infra which all encode multi-span transmembrane proteins, and are predicted to include yet unidentified receptors and other genes involved in taste modulation including the fat and salt receptor and other taste receptors whose function has yet to be defined.
The previous methods which identify primate taste specific genes are useful as primates and humans are closely evolutionary related it is likely that gene expression pattern will also be closely related. Based on this reasonable assumption, taste specific genes identified by these methods (See Tables 1-4) were selected by the subject improved method to be validated in human taste buds using a technology distinct from microarray analysis—TaqMan qPCR.
As disclosed infra, these methods require a source of human taste buds. Human taste buds can be isolated by laser capture microdissection (LCM). This technique has been described supra and involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, these structures can be readily identified in sections of human tongue. In an exemplary embodiment (example 46 infra) tissue collection was limited to taste buds (TB) in circumvallate papillae and, as a control, cells from the adjacent lingual epithelium (LE). FIG. 47 which shows an example of sections used in sample collection, described in more detail in example 46). Essentially, multiple LCM preparations from different human donors are pooled ( ̃4500 cells per sample), RNA extracted and amplified (e.g., by WT-Ovation Pico RNA Amplification System) (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.
Thereafter, the expression of the taste-specific genes is quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. Exemplary results using this methodology are contained in Table 8 infra. More specifically, gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable.
As can be seen from the data in Table 8, for the majority of genes which were identified as being human taste specific genes when assayed using this methodology, expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35). This is significant outcome as this group of human taste specific genes has not been described before as taste-specific in human tissue.
In contrast to the afore described gene chip and microarray methods, this technique provides yet additional benefits. and discoveries including the following:
Firstly, these methods allow for human taste specific genes to be detected in human LCM cDNA which were not previously known to be taste specific. Particularly, this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, the data obtained to date clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR.
Secondly, this methodology allows for the expression of human taste specific genes to be reliably and accurately measured by quantitative PCR (TaqMan) providing for the gene expression profiles of taste specific genes as measured by TaqMan. This methodology further validated gene expression data obtained from the previously described methods which used microarrays and/or in situ hybridization (ISH).
Thirdly, these methods have shown to indeed identify human taste bud specific genes which are functional. Particularly, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; Top-specific gene expression within the taste bud (akin to known taste receptors) and now TaqMan quantification of gene expression in human postmortem tastes tissues, the inventors we identified new human taste specific genes that had not been described previously. (Table 8)
Therefore, these methods allow for identification of human taste specific genes in postmortem tissues, and the identifying of human genes involved in different functions of the taste bud based on measuring their expression by quantitative PCR.
It is anticipated that these human taste specific genes, based on the manner that they were identified, expressed, and categorized are involved in one or more of (i) taste sensation, modulation of taste sensation, regulation of taste bud growth and development, control of the lifespan of mature taste bud cells, and/or are involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells. In addition, genes identified using these methods are biomarkers of taste-bud committed stem cells. or represent biomarkers of different mature taste cell subsets. Therefore, these genes and gene products can be used as a basis in methods which enrich or purify these cell subsets.
In addition, as well as its more generic embodiments this invention further describes certain information and characterization of taste specific genes identified by the rationales described in detail infra. These discoveries are enumerated as follows:
Particularly, the invention describes with respect to the genes infra which are expressed in primate and human taste cell subsets and also describe specific uses of these genes, cells and gene products in taste biology. These genes which are selectively expressed in primate fungiform papilla taste cells at the front of the tongue and circumvallate papilla taste cells at the back of the tongue were identified were identified using the afore-described gene chips/microarray methods by comparing expression in taste receptor cells compared to non-taste lingual epithelial cells isolated by laser capture micro-dissection (LCM). Since salty taste perception is most prevalent at the front of the tongue, taste receptor genes including the salty taste and other taste receptor should be present within this gene set. The genes in Table 6 are expressed in different subsets of primate taste cells and were identified by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis.
The results obtained contained in the examples reveal that FAM26A, MCTP1, TMEM30B, and TUSC3 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. Also, the results show that GPR113 and TMEM16G are expressed in a subset of TRPM5 cells, suggesting that these genes could be selectively expressed in sweet, umami, or bitter taste cells (or a combination thereof).
Also, these results show that TMEM44 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) or PKD1L3 (sour), indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.
Based on the foregoing, the application teaches that FAM26A, MCTP1, TMEM30B, and TUSC3 can be used as markers for sweet, bitter, and umami taste cells or cells expressing TRPM5. In addition, FAM26A, MCTP1, TMEM30B, and TUSC3 and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.
In addition, these results indicate that GPR113 and TMEM16G can be used as a marker for sweet, bitter, or umami taste cells or subsets of TRPM5 cells. Also, the results indicate that GPR113 and TMEM16G and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, or umami.
Still further and based thereon this application teaches the use of these that TMEM44 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells and that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants.
Still further and based thereon this application teaches the use of these that TMEM44 may correspond to a salt receptor or fat receptor, or a marker of immature taste cells or stem cells. Also, TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
Still further and based thereon this application teaches the use of these gene products and compounds that enhance or inhibit gene products can affect: selective apoptosis of taste cells responding to aversive taste modalities such as bitter and sour cells; modulation of transcription factors that control taste receptor expression; modulation of specific bitter receptor expression to minimize off-tastes of vegetables, children's medicine, and coffee; autocrine/paracrine modulation of taste cell development; prolongation of taste bud lifetime; development of supertasters (rodent model systems) to screen for chemical and biological toxins (terrorism), rancid/spoiled/contaminated food and beverage products; and activation of stem cells to differentiate into defined taste cell types.
Still further this application teaches the use of these gene products as ancillary taste receptors or primary taste receptors including receptors for salt, fat, and other taste modalities including metallic.
Still further this application teaches the use of these gene products and compounds that enhance or inhibit gene products, can modulate the function of any cell expressing a taste receptor, including but not limited to cells in the gastrointestinal tract such as enteroendocrine cells that regulate gastric motility and peptide secretion (e.g. GLP-1: glucagon-like peptide 1; GIP: gastric inhibitory peptide) as well as the other therapeutic applications of taste specific genes and modulators afore-mentioned. These applications include trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes; regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes; regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific tastes; and autocrine/paracrine modulation of taste receptor function; regeneration of taste cells as well as prophylaxis/prevention of taste cell loss following injury, chemotherapy for cancer, radiation therapy for cancer, drug-induced dysgeusia, ageusia, and taste bud loss in the geriatric population; oral hygiene, halitosis, detoxification of noxious substances in oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth; saliva composition and treatment of dry mouth in conditions of xerostomia and autoimmune disease (Sjogren's syndrome).
Also, this application teaches using double label in situ hybridization histology what specific TRPM5 cell type that GPR113 is expressed in. As disclosed infra in the examples and supporting figure we identify that GPR113 is not expressed in T1R1 umami cells, T1R2 sweet cells, or T2R bitter cells. GPR113 is expressed in a subset of T1R3 cells that do not express T1R1 or T1R2. Thus, GPR113 cells define a new taste cell type of T1R3 only cells.
Therefore, this application teaches the use of GPR113 as a marker for this unique taste cell type that because it is in a unique cell population, is a GPCR (many taste receptors are known to be GPCRs) likely corresponds to a specific taste modality or modulates a specific taste modality such as CO2 sensation, salt, fat, metallic or astringent. Also, GPR113 may associate with T1R3 to form a novel taste receptor for sweet, umami, or other tastants.
Further based on the foregoing, this application teaches the use of GPR113 as a marker to identify and isolate this unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells. and used to identify taste modulators and the aforementioned therapeutic applications of compounds modulating taste specific genes.
Also, the inseminators further identified using the same rationales (gene chip, in situ hybridization analysis) that the genes KIT, IKBKAP, LOC285965, and SV2B are taste specific taste cells and are expressed in the specific primate taste cell subsets (see Table 7 infra). In addition, we show infra that another gene, MFDS4, is expressed in sensory taste cells that are not sweet, umami, bitter or sour cells, suggesting that this gene is expressed in a similar taste cell subset as TMEM44.
Also, in Table 4 the application provides a listing of other primate taste-specific genes also identified by the same rationales. This listing of genes include genes encoding transmembrane proteins such as ion channels (sodium), GPCRs, ion transporters, as well as multi-transmembrane proteins with no function yet assigned. These genes and gene products are also useful in the same therapeutic and taste modulatory screening assays.
Based on the foregoing observations and the information in Table 7, the invention further teaches that since IKBKAP and SV2B are expressed in many PKD1L3 cells, that these genes are likely expressed in sour taste cells, since PKD1L3 is a marker of sour taste cells.
Also, based on the finding that KIT is expressed in cells that express the umami taste receptor component T1R1, the application teaches that KIT is likely expressed in cells responsible for umami taste perception.
Also, based on the finding (as determined by in situ hybridization of primate taste bud cells) that all of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B are expressed by specific taste cell subsets that these genes may be used as biomarkers and that the genes and gene products may be used isolate, mark or ablate these cells and thereby determine the taste related function of these taste bud cells. Based on this same finding the invention further relates to these isolated cells and assays using these cells and genes to identify taste modulators.
Also, based on the finding that LOC285965 is expressed in cells that express TRPM5 and T1R3 but not in cells that express the umami taste receptor component T1R1, or the sweet taste receptor component T1R2; the application teaches that LOC285965 is expressed in the ‘T1R3 only’ population of taste cells (similar to GPR113).
Also, based on the experimental findings that IKBKAP and SV2B are expressed in PKD1L3 sour taste cells the application teaches that they can be used as markers of this taste cell population.
Also, based on these same experimental findings, the application further teaches that that IKBKAP and SV2B and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population.
Also, based on these same findings and the fact that IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia), this application teaches that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance.
Also, based on these same findings and the fact that Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; the application also teaches that BoTox may selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population.
Also, based on the findings that KIT is expressed in umami taste cells, this application teaches its use as a marker of this taste cell type.
Also, based on these same findings, the application teaches that KIT and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to umami tastants.
Also, based on these findings and the fact that Gleevec (Imatinib), is an inhibitor of the KIT tyrosine kinase activity, this application teaches that this and other KIT tyrosine kinase inhibitors may selectively inhibit umami taste. Also, these findings suggest that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception.
Also, based on the findings that LOC285965 is expressed in T1R3 only taste cells similar to GPR113, this application teaches that this gene can be used as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.
Also, based on these findings, the application also teaches that LOC285965 may correspond to the salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113.
Also, based on these findings the application teaches that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.
Still further, based on these findings the application teaches that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants.
Also, based on these findings the application teaches that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells.
Also, based on these findings the application teaches that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells).
Also, based on experimental findings the application teaches suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants.
Also, based on experimental findings this application teaches that MFSD4 may correspond to the salt receptor or fat receptor. or may be used as a marker of immature taste cells or developing taste cells or support cells. Still further, these findings suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
Also, based on experimental findings that reveal that MFSD4 and TMEM44 are expressed in the same taste cell population the application teaches that this cell may respond to specific tastants and also that MFSD4 and TMEM44 may form a complex (heterodimer) to generate a taste receptor (such as fat, CO2, salt, metallic, or other taste modality).
Also, we describe experimental findings have demonstrated (see results infra in the examples) that the ASCL1 (aka MASH1) transcription factor defines sour taste cells. ASCL1 is expressed in sour taste cells expressing the sour taste receptor gene PKD1L3; ASCL1 is not expressed in sweet, bitter, and umami taste cells expressing TRPM5. ASCL1 was previously reported to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, these results demonstrate that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.
This application describes that an application of this finding is that the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the genome could be screened for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
Analogously, other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors that define those cell types. Therefore, this application teaches that the expression of all transcription factors in the genome can be analyzed in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.
The application further describes various other practical applications of these discoveries. For example, the ASCL1 (aka MASH1) can be used as a marker of sour taste cells and further identify and allow for the isolation of Type III taste cells which correspond to sour taste receptor cells.
Moreover, it has been determined that ASCL1 defines the sour taste cell lineage and may control sour taste cell development. Therefore, the invention teaches that ASCL1 transcription factor DNA binding sequences can be used to identify sour cell genes and sour taste receptor genes. Also, such transcription factors can be used to define, mark, and/or label taste cell types. With respect thereto, each taste cell will express one or more transcription factors that define that taste modality.
Also, the application teaches the use of the identified transcription factors that define taste modalities such as ASCL1 in cell ablation studies to specifically eliminate a specific taste. Moreover, the application teaches the use of transcription factors that define new taste cell types in cell studies to determine what taste modality is lacking (i.e. what taste can an animal no longer perceive).
Also, as described and supported by data infra, the invention has determined that taste cells expressing the PKD2L1 and PKD1L3 genes, previously implicated in sour taste are heterogeneous and comprise multiple cell populations. In the front of the tongue, in fungiform (FG) papilla there are cells expressing PKD2L1 only, PKD1L3 only, and both PKD2L1 plus PKD1L3. In the back of the tongue, in circumvallate papilla (CV), most cells coexpress PKD2L1 plus PKD1L3, but in addition to this population there is a distinct group of taste cells that express PKD1L3 only and a smaller set of cells that express PKD2L1 only. Previous literature has suggested that cells expressing PKD2L1 (encompassing PKD2L1 and cells coexpressing PKD2L1 plus PKD1L3) responded to sour taste (Huang et al, Nature 2006 Aug. 24; 442(7105):934-8. However, PKD1L3 cells were not previously known and no function has yet been ascribed. Based thereon, the application teaches the use of PKD1L3 cells as candidate basic or salty taste responding cells and that PKD1L3 is involved in a different taste modality, e.g., basic taste perception since the related sour receptor, PKD2L1, responds to acidic taste.
In addition the invention provides experimental findings that the FAM26C gene is expressed in TRPM5 cells (see results infra) and teaches its use as a marker of sweet bitter and umami cells.
Also, based on the experimental findings herein the application teaches that PKD1L3 only taste cells are candidate taste cells, e.g., which modulate basic taste sensation or other taste modalities, and that PKD1L3 is a candidate taste receptor, e.g., basic taste sensation. Also, the application teaches that PKD1L3 may complex with one of the gene products identified herein to form a taste receptor.
Also, based on the experimental findings that FAM26C is expressed in TRPM5 cells, including sweet, bitter, and umami taste cells, the application describes its use as a marker of this taste cell population and FAM26C and use of compounds that enhance or inhibit FAM26C to selectively modulate taste cell function and responses to sweet, bitter, and umami tastants as well as other functions of the TRPM5 taste cell population, including functions of the GPR113 expressing taste cells that are candidate salty taste cells and that coexpress T1R3.
Also, This application provides data shown infra, indicating that taste cells in the bottom of the taste buds are immature whereas cells in the top half are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to SHH. Therefore, this application teaches that TMEM44 cells, (which also express MFSD4) are immature and comprise, in part, developing taste cells. Further supportive of this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are Therefore maturing into professional taste cells. By contrast, cells in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the salty taste cell and the salty taste receptor should be found in the top half of the taste bud as well.
Also, this application teaches methods for identifying and assaying the expression of taste specific genes and identifying specific taste receptors and taste cell subsets which have shown that the taste cells in the bottom half of the taste bud are immature, that the taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors, that SHH is a marker of immature and developing taste cells at the bottom of the taste bud. and that TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.
The application predicts based on these results that a subpopulation of TMEM44 cells may be mature salty taste cells. and that a salt receptor and a salty taste cell will be expressed or comprised in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells. This is a reasonable assumption based on the results obtained by the inventors herein, especially since all other known professional, mature taste cells are expressed in the top of the taste bud.
Also, based on experimental findings herein, and further relating to the foregoing, the inventors have gleaned the following information relating to several subsets of taste bud cells we have identified discussed above, including:
With respect to TMEM44 cells, they have found that these cells comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud. Also, we have identified other genes expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH). The latter is a cytokine involved in immature cell differentiation. For this reason, they predict that TMEM44 represents an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human. While these cells are immature, they may still contain a subset of mature cells that may be responsible for taste such as salt sensation.
Also, with respect to GPR113 cells, they have discovered that these cells represent about 10° A of the taste bud cell population, and are distinct from sweet, bitter, and umami taste cells, and are located in the top of the taste bud. They express T1R3 and TRPM5 but not the G protein alpha subunit gustudin (GNAT3), suggesting that they represent a novel taste cell population that detects a new taste modality such as fat. Other cells that express TRPM5 and T1R3 include sweet cells (also express TIR2) as well as umami cells (also express T1R1). Bitter cells (also express T2Rs) express TRPM5 but not T1R3. In contrast to GPR113 cells, sweet, bitter, and umami cells all express GNAT3.
Also, with respect to PKD2L1 and PKD1L3 cells, reportedly responsible for sour taste sensation, they are found to constitute about 10% of the taste bud cell population and are located in the top of the taste bud. As discussed below, we have observed that these cells are heterogeneous and that there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population. This heterogeneity suggests that one of these subsets could represent a salt sensing cell.
Also, the experimental findings herein suggest that there is another subset of taste cells ( ̃8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3, which may represent another taste e.g., CO2 or salt sensing cells. As disclosed a primary focus of this invention was the elucidation of the salty taste receptor. These results were successful as TRPML3 gene has been shown to be a salty taste receptor.
The invention further exploits the elucidation of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.
The application provides different methods. For example, one way to identify the salt cell or other taste cell modality population is to use cell ablation. This technique employs diphtheria toxin under the control of a promoter of a gene expressed in one of the taste cell subsets described above to selectively eliminate this taste cell population, while leaving all other taste cell populations intact. Cell ablation has been used successfully in other laboratories to selectively eliminate sweet (T1R2) and sour (PKD2L1) taste cell populations (work of Charles Zuker). Therefore, ablation of the afore-identified taste cell subsets described above and then use nerve recoding and licking/behavior tests will enable evaluating whether the resulting mice still sense a particular type of tastant, e.g., salt, sour, basic, metallic et al. Based thereon, the inventors have made various predictions which will be confirmed or ruled out by the subject functional assays enumerated below:
(1) Assuming that TMEM44 ablated mice do not sense salt but still sense sweet, bitter, umami, and sour, this result would point this population, or a subset of cells within this population, as the salt sensing cell. Alternatively, the resulting mice may lack taste buds and the ability to detect all 5 taste qualities because TMEM44 is expressed in immature cells or may elicit no effect.
(2) Assuming that GPR113 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to GPR113 expressing cells as the salt sensing cells. (As noted TRPML3 cells have been shown to sense salt, therefore this outcome is not probable. More likely, another taste modality would be affected.)
(3) Assuming that PKD2L1 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD2L1 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)
(4) Assuming that PKD1L3 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour. This result would point to PKD1L3 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)
(5) If none of these mice are deficient in salt perception, this suggests that the putative population of taste cells (8%) that do not express any of the aforementioned markers could be the salt sensing cell, or that all or multiple mature taste cell populations are capable of sensing salt.
Another means taught herein in order to identify the salt sensing cell involves generating a single cell suspension from taste buds and then performing single cell analyses with electrophysiology (patch clamping) or calcium imaging coupled with single cell PCR to identify which population(s) responds to sodium.
With respect to the foregoing assays, there are two main models to account for salt sensation in taste buds:
The first model is the labeled line model. In this model, a single cell type is responsible for sensing a given taste quality. This is true for sweet, bitter, umami and sour. In this model, there is a dedicated cell type responsible for salt sensation. As discussed above, and in the related utility application filed on even date, the inventors have narrowed down the list of candidate salt sensing cells and described techniques that have identified TRPML3 as a salt receptor and that TRPML3 expressing cells sense salty taste.
The second model is the across fibre model where there is not a single cell type responsible for salt sensation. Instead, all or multiple cell types sense salt. In this model, a cell surface molecule, such as a receptor or ion channel, expressed in all or multiple mature taste cells would constitute the salt sensor.
The way to distinguish between these two models is to perform cell ablation experiments such as are described above. Ablation experiments in Varitint mice depleted of TRPML3 taste cells indicate that these mice are deficient in their ability to taste salt. These results suggest TRPML3 expressing cells as being responsible for salty taste.
In yet another related aspect of the invention, the inventors teach three primate taste specific genes, TRPML3, NKAIN3 and NALCN, expressed in primate taste cells that were identified as taste specific genes by gene chip analysis, and shown to function as sodium channels in the literature. These genes were identified as being enriched in the top fraction of taste buds along with all other known taste receptor genes. Therefore, these genes were identified as probable candidates for encoding a salty taste receptor. As described in detail, and substantiated by extensive functional data in a related patent application filed on even date as this application, one of these genes, TRPML3 has been shown in functional assays and transgenic animals to be necessary for salty taste perception and to correspond to a salty taste receptor. These ion channel genes, are expressed as follows in the top versus the bottom of taste buds and in taste versus lingual epithelium tissues: NALCN, (aka VGCNL1), top vs. bottom ratio of 7.2, and TB vs. LE ratio of 11.2; TRPML3 (aka MCOLN3) top vs. bottom ratio of 1.6, and TB vs. LE ratio of 10.2; and NKAIN3 (aka FAM77D) which has a top vs. bottom ratio of 1.5, and TB vs. LE ratio of 3.3.
As reported in Cell. 2007 Apr. 20; 129(2):371-83, the neuronal channel NALCN contributes resting sodium permeability and is required for normal respiratory rhythm. Also, Lu et al. describe that NALCN as a sodium leak channel. Further, with respect to TRPML3, J. Biol. Chem. 2007 Oct. 25; [Epub ahead of print] teach that a gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. Also, Kim et al., describes TRPML3 as a channel permeable to sodium after exposure of the channel to no/low sodium (as in saliva), consistent with a salt receptor. Also, with respect to the NKAIN 3 gene, in Gorokhova et al., Human Mol. Genet. 2007 Oct. 15; 16(20):3394-410. Epub 2007 Jul. 2, this gene is reported as a member of a novel family of transmembrane proteins interacting with {beta} subunits of the Na,K-ATPase. Also, Gorokhova et al., describes a Drosophila homologue of NKAIN3 as an amiloride-insensitive sodium channel, consistent with a salt receptor. Again, the TRPML3 gene and its functional properties and that it encodes a salty taste receptor and its therapeutic applications are discussed extensively in the utility and PCT patent applications filed on the same date as this application, incorporated by reference in their entireties herein
Based on these observations and the experimental data therein and in this application, it was predicted and later confirmed that these 3 genes would include an ion channel that is involved in salty taste (TRPML3) Also, based thereon, this application teaches that NALCN, and NKAIN3 may constitute other salty taste receptors expressed in taste bud cells or may modulate the function of TRPML3 and/or may associate with TRPML3 to produce a functional taste receptor. Based on the foregoing, the application teaches the use of NALCN, and NKAIN3 as markers to identify salty taste receptor cells.
In addition, the application provides additional information in the examples concerning the NALCN taste-specific gene. Particularly, as described in the examples infra, the inventors demonstrated that NALCN is a taste-specific gene by end-point PCR using purified taste buds and lingual epithelial cells isolated by laser capture microdissection. They also found that NALCN is expressed in a novel, unique taste cell type distinct from sweet, bitter, umami, and sour taste cells by immunohistochemistry with a NALCN antibody.
Therefore, since NALCN is a taste-specific gene, is expressed in a novel taste cell type, and has been reported to function as a sodium-channel, the application teaches that NALCN is a candidate salty taste receptor and/or a marker of the salty taste cell population. Since NALCN and TRPML3 are both expressed in novel taste cell types, the application teaches that NALCN and TRPML3 may be co expressed in the same taste cell population. Accordingly, NALCN and TRPML3 may function together in a complex; or NALCN may function independently of TRPML3 as another salty taste receptor. For example, the application teaches that NALCN may function downstream of TRPML3 akin to how TRPM5 functions downstream of sweet, bitter, and umami receptors. In this manner, NALCN would be involved in the signal transduction pathway for salty taste but not constitute the primary salty taste sensory receptor.
This can be determined in mice. Rodents have 3 distinct taste cell types:
Type III cells correspond to sour cells (PKD2L1 positive, SNAP-25 positive);
Type II cells correspond to sweet, bitter, and umami cells (TRPM5-positive, IP3R3 positive); and
Type I cells have no defined function.
As shown in the examples infra, the inventors have demonstrated that NALCN is not expressed in IP3R3 cells (Type II) or SNAP-25 cells (Type III) in rodent. Thus, NALCN expression is implicated in Type I cells, and Type I cells are candidate salty taste cells.
However, alternatively, the application teaches that Type I cells may correspond to immature taste cells and if so, would likely be coexpressed with TMEM44/MFSD4 in an immature taste cell population.
Based on the foregoing discoveries, the invention further teaches NALCN as an additional salty (or other taste such as metallic or fat) taste receptor candidate gene or accessory molecule and based thereon the use thereof as a marker to identify these taste cells.
In addition, since NALCN is a sodium ion channel, and is expressed in the top half of taste buds in cells that have an indeterminate taste function, the application teaches that NALCN may control the resting membrane potential and excitability of the taste cells it is expressed in. Related thereto, compounds that enhance or inhibit function of the NALCN channel may regulate the excitability of salty taste cells, i.e., TRPML3 cells.
Based on this modulatory property, the application teaches that compounds that enhance or inhibit function of the NALCN channel may increase and decrease salt perception respectively, e.g., alone or in combination with TRPML3.
In addition, this application teaches that NALCN may associate with TRPML3 to form a salty taste receptor. (Again, as shown in the related applications filed on even date the ablation of TRPML3 expressing taste cells in Varitint mice results in inhibition of salty taste perception in these rodents and in vitro electrophysiological assays using this ion channel have confirmed that it is a functional sodium channels and may be used to identify TRPML3 blockers and enhancers which should modulate salty taste).
Moreover, based on the experimental findings the application teaches that NALCN can be used as a marker of type I taste cells, which likely include salty taste cells. Alternatively, as type I taste cells may function as precursor cells for sweet, bitter, umami and sour taste cells, modulation of NALCN function may control taste cell differentiation and development into mature taste cell types.
In addition, because the application teaches that TMEM44 and MFSD4 are markers of immature taste cells, the application also teaches that NALCN may be expressed in the subset of immature taste cells expressing TMEM44/MFSD4.
Further, because type I taste cells may also function as glial (support) cells, the application teaches that modulation of NALCN function may indirectly control the activity of sweet, bitter, umami, and sour cells and, as a result, sweet, bitter, umami, and sour taste.
Also, the application teaches based on the experimental findings that compounds that enhance or inhibit function of NALCN may increase and decrease salt perception respectively.
In yet another aspect, this invention describes an assay for identifying a compound having potential in vivo application for modulating human salty taste. This method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8.
In a preferred mode, the assay of step (ii) is an electrophysiological assay which uses a sodium sensitive dye, and preferred dyes include membrane potential dyes selected from the group consisting of Molecular Devices Membrane Potential Kit (Cat#R8034), Di-4-ANEPPS (pyridinium, 4-(2-(6-(dibutylamino)-2-naphthalen-yl)ethenyl)-1-(3-sulfopropyl)hydroxide, inner salt, DiSBACC4(2) (bis-(1,2-dibabituric acid)-triethine oxanol), Cc-2-DMPE (Pacific Blue 1,2-dietradecanoyl-sn-glycerol-3phosphoethanolamine, triethylammonium salt) and SBFI-AM (1,3-benzenedicarboxylic acid, 4,4-[1,4,10-trioxa-7,13-diazacyclopentadecane-7,13-diylbis(5-methoxy-6,1,2-benzofurandiyl)}bis-tetrakis{(acetyloxy)methyl}ester (Molecular Probes), more preferably, the sodium sensitive dye is sodium green tetraacetate (Molecular Probes) or Na-sensitive Dye Kit (Molecular Devices). In another preferred mode, the assay of step (ii) is a two electrode voltage clamping assay in Xenopus oocytes, or the assay is a patch clamp assay in mammalian cells. Preferably, the assay measures activity by an ion flux assay, including using atomic absorption spectroscopy to detect ion flux.
Alternatively, the assay may use a fluorescence plate reader (FLIPR), or a voltage imaging plate reader (VIPR), which is used to increase ion channel-dependent sodium or fluid absorption. In a preferred embodiment of this method, the activity of the putative salty taste affecting gene is assayed in a frog oocyte electrophysiologically by patch clamping or two electrode voltage clamping, preferably using an automatic imaging instrument, which may be a fluorescence plate reader (FLIPR) or a voltage imaging plate reader (VIPR).
In yet another mode, this invention describes an assay for identifying a compound having potential in vivo application for modulating human sweet, bitter, umami, or sour taste. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-8 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential enhancer or blocker for sweet, bitter or umami taste based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.
In yet another mode, this invention describes an assay for identifying a compound having potential in vivo application for as a potential therapeutic. This method comprises the steps of (i) contacting a cell that expresses a gene in Tables 1-3 with at least one putative enhancer or blocker compound; (ii) assaying sodium conductance, receptor activity or taste gene product function in the presence and absence of said putative enhancer or blocker; and (iii) identifying the compound as a potential therapeutic that may be used to modulate a taste cell related function or phenotype that does not directly involve taste such a digestive disorder or disease, taste cell or taste bud turnover or regeneration, immune regulation of the oral or digestive system, or treatment of a metabolic disorder such as diabetes, obesity, eating disorder et al., based on whether it modulates sodium conductance, the activity of said receptor or taste gene product function.
In yet another mode the present invention describes using the genes identified herein as markers to identify and/or purify specific taste cells including sweet, bitter, umami, sour, and other cells including stem cells. These methods include positive and negative cell isolation and selection methods and selection and are based on the expression or absence of expression of one or several of the genes contained in Tables 1-3, or an allelic variant or ortholog or gene that hybridizes thereto under stringent hybridization conditions and/or a gene encoding a polypeptide that is at least 80% identical to the polypeptides or orthologs thereof encoded by the genes contained in Table 1-3, moiré preferably at least 90% identical and still more preferably at least 95% identical. In one embodiment, antibodies directed against the proteins encoded by these genes produced by methods well known to those skilled in the art can be used to label cells in a suspension of taste bud cells produced by enzymatic digestion and tissue disaggregation (Herness, M. An exemplary dissociation procedure for mammalian taste buds. is reported in Neuroscience Letters. 106: 60-64, 1989). The separation can be achieved by using a fluorescence activated cell sorter (See e.g., Beavis, A. J. and K. J. Pennline. Biotechniques. 21: 498-503, 1996) or by magnetic beads (See e.g., Jurman, M. E., L. M. Boland, Y. Liu, and G. Yellen. Visual identification of individual transfected cells for electrophysiology using antibody coated beads. Biotechniques. 17: 876-881, 1994). Alternatively, cells belonging to a specific subset can also be purified by negative selection methods, e.g., by eliminating taste bud cells representing other subsets using cytotoxic antibodies against their specific markers produced using methods well known to those skilled in the art) from a cell suspension of taste bud cells.



DESCRIPTION OF THE FIGURES
FIG. 1 contains an example of laser capture microdissection (LCM) on primate fungiform (FG) taste tissue (top row) and lingual epithelium (LE) non-taste tissue (bottom row) Top row: Left image shows FG tissue before LCM with a single FG taste bud. Middle image shows FG tissue after LCM where single FG taste bud has been removed. Right image shows collected and isolated FG taste bud used for molecular biology experiments to discover taste-specific genes. Bottom row: Left image shows tissue before LCM with LE from anterior tongue surface. Middle image shows tissue after LCM where a region of LE has been removed. Right image shows collected and isolated LE region used for molecular biology experiments to discover taste-specific genes.
FIG. 2 contains an example of PCR quality control of primate taste and lingual cells collected by LCM. Taste bud cells (TB), but not lingual epithelial cells (LE), specifically express the known taste-specific genes T1R2 (a component of the sweet receptor), PLCbeta2 (an enzyme involved in sweet, bitter, and umami taste detection), and GNAT3 (i.e. gustducin, a G-protein alpha subunit involved in sweet, bitter, and umami taste detection). By contrast, both taste and lingual cells express the ubiquitous housekeeping genes GAPDH and beta-actin, indicating that taste and lingual cell RNA is intact and of high quality. ‘+’ indicates reverse transcription and ‘−’ indicates no reverse transcription was performed.
FIG. 3 contains an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate circumvallate (CV) taste tissue. TRPM5 (top; green) is not detectable in cells expressing PKD1L3 (middle; red). Overlay of TRPM5 and PKD1L3 signals is depicted in the bottom image. Note that TRPM5 and PKD1L3 signals are present in different taste cells. TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.
FIG. 4 contains an example of double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate circumvallate (CV) taste tissue. PKD2L1 (top; green) is coexpressed in cells expressing PKD1L3 (middle; red). Overlay of PKD2L1 and PKD1L3 signals is depicted in the bottom image in yellow. Note that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.
FIG. 5 contains an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate fungiform (FG) taste tissue. TRPM5 (left; purple stain) is not detectable in cells expressing PKD1L3 (middle; red). Overlay of TRPM5 and PKD1L3 signals is depicted in the left image. Note that TRPM5 and PKD1L3 signals are present in different taste cells. TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste tissue.
FIG. 6 contains an example of double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate fungiform (FG) taste tissue. PKD2L1 (left; purple stain) is coexpressed in cells expressing PKD1L3 (middle; red). Overlay of PKD2L1 and PKD1L3 signals is depicted in the right image. Note that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.
FIG. 7 contains an example of a double labeling hybridization experiment using primate circumvallate papilla. The results in FIG. 7 reveal that FAM26A (purple color; left image) colocalizes with TRPM5 (red; middle image). The results contained in the figure also show that FAM26A cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
FIG. 8 contains another double label in situ hybridization experiment. This hybridization experiment which again used primate circumvallate papilla revealed that the taste cell specific gene GPR113 (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can be seen from the figure that that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express GPR113 (merged image on the right), but that all GPR113 cells express TRPM5. Two taste buds are shown.
FIG. 9 contains another double hybridization experiment using primate circumvallate papilla cells. The results contained in the Figure reveal that MCTP1 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can be further seen that MCTP1 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the Figure.
FIG. 10 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results in FIG. 10 show that TMEM16G (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can also be seen that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express TMEM16G (merged image on the right), but that all TMEM16G cells express TRPM5.
FIG. 11 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results contained in FIG. 11 show that TMEM44 (purple color; left image), a taste cell specific gene, does not colocalize with TRPM5 (red; middle image). It can be seen from the results in the figure that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the figure.
FIG. 12 contains another double label in situ hybridization experiment of primate circumvallate papilla cells. The results contained therein reveal that TMEM44 (purple color; left image) does not colocalize with PKD1L3 (red; middle image). It can also be seen therein that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the right). Two taste buds are shown.
FIG. 13 contains another double label in situ hybridization experiment using primate circumvallate papilla cells. The results which are contained in FIG. 13 show that TUSC3 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can also be seen that TUSC3 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
FIG. 14 shows that GPR113 is not expressed in T1R1 umami cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R1 (red; middle image). Note that GPR113 and T1R1, a marker of umami cells, are in different taste cells (merged image on the right).
FIG. 15 shows that GPR113 is not expressed in T1R2 sweet cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R2 (red; middle image). Note that GPR113 and T1R2, a marker of sweet cells, are in different taste cells (merged image on the right).
FIG. 16 shows that GPR113 is expressed in a subset of T1R3 cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does colocalize with a subset of T1R3 cells (red; middle image). Note that GPR113 is always expressed in cells with T1R3, but that there are T1R3 cells that do not express GPR113 (merged image on the right). These T1R3 cells that do not express GPR113 likely coexpress either T1R1 or T1R2. The T1R3 only cells are a new population of taste cells that coexpress GPR113.
FIG. 17 shows that GPR113 is not expressed in T2R bitter cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T2R (red; middle image). Note that GPR113 and T2R, a marker of bitter cells, are in different taste cells (merged image on the right).
FIG. 18 shows that TMEM44 is not expressed in TRPM5 or PKD1L3 cells in fungiform taste buds. Double label in situ hybridization of primate fungiform papilla from the front of the tongue showing that TMEM44 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) or PKD1L3 (red; middle bottom image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, or PKD1L3, a marker of sour cells, in the merged images on the right.
FIG. 19 shows that TMEM44 is not expressed in TRPM5 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with TRPM5 (red cells; middle image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the bottom).
FIG. 20 shows that TMEM44 is not expressed in PKD1L3 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with PKD1L3 (red cells; middle image). Note that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the bottom).
FIG. 21 shows that TMEM44 cells extend processes to the taste pore. Double label histology experiment of primate circumvallate papilla at the back of the tongue. Cytokeratin 19 protein (green; left image) is present in cells expressing TMEM44 RNA (red; middle image). Note that TMEM44 cells extend processes to the taste pore facing the saliva. Asterisk denotes a TMEM44 cell nucleus and white arrows denote the apical process of this same cell extending to the taste pore (merged image on the right). Thus, TMEM44 cells are sensory taste cells that can sample the saliva for tastants. Cytokeratin 19 is a marker of all taste cells.
FIG. 22 shows that FAM26B is expressed in TRPM5 cells Double label in situ hybridization of primate circumvallate papilla showing that FAM26B (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26B cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
FIG. 23 shows that SLC4A11 is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that SLC4A11 (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that SLC4A11 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
FIG. 24 reveals that MFSD4 is not expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with TRPM5 (red; middle image). Note that MFSD4 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown.
FIG. 25 shows that MFSD4 and TMEM44 are expressed in the same taste cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. TMEM44 (top blue/purple color) and MFSD4 (bottom blue/purple color) do not colocalize with TRPM5 (red color top and bottom images) and are expressed in taste cells in the bottom halves of taste buds. The equivalent localization, abundance, and morphology of TMEM44 and MFSD4 taste cells indicates that these cells are identical and that both TMEM44 and MFSD4 genes are expressed in the same taste cell type.
FIG. 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.
FIG. 27 shows that KIT is expressed in T1R1 umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that KIT (blue/purple color; left images) colocalizes with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2nd row), does colocalize with T1R3 (red; middle image 3rdrow), and does not colocalize with T2Rs (red; middle image bottom row). Note that KIT cells express T1R1 and T1R3, markers of umami taste cells, but not T1R2 or T2Rs, markers of sweet and bitter cells respectively, in the merged images on the right.
FIG. 28 shows that IKBKAP is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that IKBKAP (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that IKBKAP cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).
FIG. 29 shows that LOC285965 is expressed in T1R3 only taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that LOC285965 (blue/purple color; left images) does not colocalize with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2nd row), does colocalize with T1R3 (red; middle image 3rd row), and does not colocalize with T2Rs (red; middle image bottom row). Note that LOC285965 cells express T1R3, but not T1R1, T1R2 or T2Rs, markers of umami, sweet and bitter cells respectively, in the merged images on the right.
FIG. 30 shows that SV2B is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SV2B (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that SV2B cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).
FIG. 31 shows that MFSD4 is expressed in a unique taste cell type. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with PKD1L3 or TRPM5 (red; middle images) but is expressed in a unique taste cell type. Note that MFSD4 cells do not express PKD1L3, a marker of sour taste cells or TRPM5, a marker of sweet, umami, and bitter taste cells (merged images on the right). Two taste buds each are shown for PKD1L3 & TRPM5 double labels.
FIG. 32 shows that MFSD4 and TMEM44 are expressed in the same taste cell population. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. MFSD4 (left; green) and TMEM44 (middle; red) signals are present in the same taste cells (right; merged image).
FIG. 33 contains an experiment showing that SHH is expressed in immature taste cells in the bottom of the taste bud. Double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SHH (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) or PKD1L3 (red; middle image bottom). Note that SHH cells do not express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image top) or PKD1L3 (merge; right image bottom). Both TRPM5 and PKD1L3 genes are expressed in professional taste cells.
FIG. 34 contains an experiment showing that TMEM44 and SHH are expressed in immature taste cells at the bottom of the taste bud. In situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (blue/purple color; top 3 images) is expressed in cells towards the base of the taste bud. A similar expression pattern was observed with SHH (blue/purple color; bottom 3 images). Since SHH is marker of immature, developing taste cells, these data indicate that TMEM44 is expressed in and is a marker of immature taste cells
FIG. 35 contains a schematic model of taste cell development. In situ hybridization of primate circumvallate papilla at the back of the tongue showing SHH (blue/purple color) expression at the base of the taste bud and PKD1L3 (red color) expression towards the top of the taste bud. This model indicates a gradient of SHH expression from high levels at the base of the taste bud (immature cells) to low levels at the top of the taste bud (mature cells). As SHH expression levels decrease, expression of taste receptor genes such as TRPM5 and PKD1L3 increase. Thus, an opposite gradient of taste cell maturation exists where taste cells progressively mature and express taste receptor genes as they differentiate from the bottom to the top of the taste bud.
FIG. 36 shows that a small fraction of TMEM44 cells express TRPM5 or PKD1L3 as they differentiate into mature taste cells. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and TMEM44 riboprobes (left pie chart) or PKD1L3 and TMEM44 riboprobes (right pie chart). Taste cells expressing TRPM5 (blue graph region; left pie chart), TMEM44 (magenta graph region; left pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; left pie chart) genes were counted and graphed in pie charts. Taste cells expressing PKD1L3 (blue graph region; right pie chart), TMEM44 (magenta graph region; right pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; right pie chart) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses. A small fraction of TMEM44 cells also express TRPM5 or PKD1L3, indicating that these cells are differentiating from an immature state (TMEM44 only) to a mature state (TRPM5 or PKD1L3 only). Inset shows example of CV taste bud labeled with TMEM44 (green) and TRPM5 (red). Note cell indicated with arrow that coexpresses both TMEM44 and TRPM5 (yellow).
FIG. 37 contains an experiment showing that mature taste cells do not coexpress markers for distinct taste modalities. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and PKD1L3. Taste cells expressing TRPM5 (blue graph region), PKD1L3 (magenta graph region), or TRPM5 plus PKD1L3 (labeled ‘both’ and yellow graph region which is too small to see any yellow segment due to the near absence of cells within this category) genes were counted and graphed in the pie chart. Total number of counted cells is listed below the pie chart in parentheses.
FIG. 38 contains an experiment showing that levels of gene expression define two compartments in primate taste buds. To create this overlay image sagittal sections of primate taste buds were initially stained with DAPI (4′,6-diamidino-2-phenylindole) to visualize cell nuclei; blue color. Double label in situ hybridization images of the same sections for TMEM44; green color and TRPM5+PKD1L3; pink color were then added. The overlay image shows that TMEM44 expression is restricted to the bottom third of each of the four taste buds shown and that TRPM5+PKD1L3 expression occurs predominantly in the upper regions of each of the taste buds.
FIG. 39 shows an exemplary experiment showing laser capture microdissection of top and bottom regions of primate taste buds. Panel) contains a methyl blue stained section A of macaque circumvallate taste buds. Panel B shows Section A following excision of bottom fraction of taste buds. Panel C contains the bottom fraction of taste buds. Panel D shows Section A following excision of bottom and top fractions of taste buds. Panel E shows the Top fraction of taste buds. Note, top and bottom fractions were only collected from taste buds exhibiting optimal morphology in section. In the example shown, the taste bud labeled with an arrow was excluded due to suboptimum sectioning or morphology.
FIG. 40 contains the results of an experiment establishing that distinct cell populations PKD2L1, PKD1L3 and PKD2L1 plus PKD1L3. Double label in situ hybridization of primate fungiform (FG; left) and circumvallate (CV; right) was performed using PKD2L1 and PKD1L3 riboprobes. Taste cells expressing PKD2L1 (blue graph regions), PKD1L3 (magenta graph regions), or PKD2L1 plus PKD1L3 (labeled ‘both’ and yellow graph regions) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses.
FIG. 41 The experiment in FIG. 41 shows that FAM26C is expressed in TRPM5 taste cells. Therein double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that FAM26C (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26C cells express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image).
FIG. 42 The experiment in FIG. 42 shows that NALCN is a taste-specific gene. The figure shows end-point PCR experiments on circumvallate taste buds (taste) and lingual epithelial cells (lingual) of non-human primate (left) and mouse (right) isolated by laser-capture microdissection demonstrating that NALCN is a taste-specific gene. NALCN is only expressed in taste cells and is not detectable in lingual cells, similar to the known taste-specific genes gustducin, T1R2, and TRPM5. □-actin is detectable in both taste and lingual samples, indicating that high-quality RNA was present in both samples. ‘+’ indicates that reverse transcription was performed and ‘−’ indicates that no reverse transcription was performed. PCR bands were only observed with reverse transcriptase indicating that PCR products are derived from mRNA and not genomic DNA. PCR products were cloned and sequenced to verify that the bands corresponded to the expected gene products.
FIG. 43 The experiment in FIG. 43 shows that NALCN is expressed in a unique taste cell type effected at low magnification. Therein is shown a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. Numerous taste buds are shown.
FIG. 44 The experiment in FIG. 44 also shows that NALCN is expressed in a unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.
FIG. 45 The experiment in FIG. 45 shows that NALCN is not expressed in TRPM5 cells. The figure contains a double label immunochemistry of circumvallate papilla from the back of the tongue showing that NALCN (red color, middle images( ) does not colocalize with TRPM5 in non-human primate (green, left image top row) or IP3R3 in rat (green; left image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since TRPM5 and IP3R3 mark sweet, bitter, and umami cells, equivalent to type II cells, NALCN is not expressed in type II cells in non-human primate and rat.
FIG. 46 The experiment in FIG. 46 shows that NALCN is expressed in a subset of fungiform taste cells. Therein single label immunochemistry of fungiform papilla from the front of the tongue of non-human primate showing that NALCN (red color) is expressed in a subset of taste cells. Top of the taste bud, facing saliva, if oriented towards the top in the image is shown (see arrow). unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.
FIG. 47 shows the laser capture microdissection of human taste buds. Panel A shows methyl blue stained section of human circumvallate human taste buds. Panel B shows Section A following excision of taste buds. Panel C contains the captured taste buds.



DETAILS OF THE INVENTION
The invention relates to the identification of genes expressed in taste tissues of human and macaque, particularly fungiform and/or circumvallate papilla derived taste cells which are putatively involved in salty taste or other taste modalities or taste in general; or which are involved in taste cell related functions and phenotypes that do not directly involve taste such as taste cell or taste bud regeneration and turnover, immunoregulation of the oral cavity or digestive system, regulation of digestion or metabolism, onset or prevention of digestive system disorders such a cancers, autoimmune diseases, and inflammatory conditions such as IBD, ulcerative colitis, Sjogren's syndrome, celiac disease, Crohn's disease, and the like and the use thereof in screening assays to identify compounds that modulate salty taste perception or other taste modalities or taste in general or for identifying potential therapeutics for use in humans. In particular the invention includes use of the following methodologies, to identify novel taste-specific genes:
1) Laser Capture Microdissection (LCM) and RNA Amplification:
In laser capture microdissection, a fine laser beam is used to dissect and purify taste cells from histological sections. This method isolates taste cells, devoid of contaminating lingual epithelial cells and connective tissue, and allows one to perform molecular biology experiments on a highly enriched taste cell population. In parallel, lingual epithelial cells are isolated by LCM and used as a negative control devoid of taste cells. LCM is advantageous to manual or enzymatic dissection of taste papilla because these crude techniques yield a heterogeneous mixture of taste and lingual cells in which taste cells comprise 1-20% of collected material. RNA amplification amplifies total RNAs from taste cells and lingual cells isolated by LCM up to 1 million-fold in a non-biased fashion to generate sufficient genetic material to perform molecular biology studies (gene chips or PCR). We have found that 5,000 taste cells are sufficient for gene chip experiments with macaque taste tissue and greater than 10,000 taste cells are sufficient for PCR experiments with macaque taste tissue.
2) Gene Chips:
Gene chips contain most all annotated genes on a small chip. Hybridizing RNA, isolated and amplified from taste and lingual cells, to gene chips can be used to determine which specific genes are expressed in taste cells and not lingual cells and which specific genes are expressed at higher levels in taste cells compared to lingual cells. Gene chips experiments were conducted using paired macaque fungiform (FG) and circumvallate (CV) taste and lingual samples using Affymetrix rhesus macaque genome arrays and analyzed using GeneSpring GX v7.3 software (Agilent Technologies). 5000 fungiform and CV taste and lingual cells were separately isolated by LCM and total RNA was purified for each sample. RNA was then amplified and hybridized to gene chips. Data analyses are performed using two separate algorithms: Affymetrix Microarray Suite 5 (MAS5) which takes into account both perfect match and mismatch probes on gene chips, and robust multi-chip algorithm (RMA) which only takes into account perfect match probes on gene chips. Taste-specific genes encoding transmembrane proteins are identified in this analysis.
3) PCR:
High-throughput PCR is performed in 96 well plates using primers specific for ion channels in the human/macaque genome and amplified RNA from human/macaque taste and lingual cells isolated by LCM. Detection of products of the appropriate size in taste cells but not lingual cells and DNA sequencing of PCR products (to confirm gene identity) indicates the ion channel of interest is a taste-specific gene. Prior to high-throughput PCR using primers against ion channels identified in the macaque genome, quality-control PCR reactions are first performed on up to 4 known taste-specific genes and 2 housekeeping genes to ensure that taste and lingual RNAs are of high quality. Four taste-specific genes which may be examined are the G alpha protein gustducin (GNAT3), the sweet receptor components, the ion channel TRPM5 and the enzyme phospholipase beta 2; the two housekeeping genes examined are beta-actin and GAPDH. Specific expression of the taste genes by taste cells but not lingual cells plus expression of the ubiquitous housekeeping genes by both taste and lingual cells indicates high quality RNA material.
PCR products are analyzed on agarose gels to determine if bands of the appropriate size are present in taste cells but not lingual cells. Genes with this expression pattern are putative taste-specific genes. All taste-specific genes were cloned and sequenced to confirm the gene identities.
4) In Situ Hybridization:
Antisense RNA probes specific for an individual gene(s) (identified by gene chips or PCR) are hybridized to tissue sections containing taste cells to determine if the mRNA transcript for the gene of interest is expressed in taste cells, specifically in sour, sweet, bitter, and/or umami cells or in a unique cell type that may be involved in salty taste detection. In double labeling in situ hybridization, two different RNA probes are generated to label two different genes, specifically two different taste-specific genes identified by gene chip and/or PCR approaches. Alternatively, one probe can be generated to label a single gene to determine if the gene is expressed in taste cells. For double labeling studies, the first gene is labeled with a FITC probe that generates one color in a fluorescent microscope while the second gene is labeled with a digoxygenin (DIG) probe that generates a different color in a fluorescent microscope. Superimposition of probe 1 and probe 2 reveals if genes are expressed in the same or in different cell types. For example, if a unique ion channel identified by gene chip or PCR approaches colocalizes to cells expressing TRPM5, that unique ion channel is expressed in cells responsible for sweet, bitter, and/or umami taste. By contrast, if a unique ion channel identified by gene chip or PCR approaches does not colocalize to cells expressing TRPM5, that unique ion channel is expressed in a different cell type that may be responsible for salty taste (or another taste modality) and that unique ion channel may be directly involved in sodium detection.
5) Immunohistochemistry:
Antibodies specific for an individual protein (whose gene was identified by gene chips or PCR) are applied to tissue sections containing taste cells to determine if the protein of interest is expressed in taste cells, specifically in sour, sweet, bitter, and/or umami cells or in a unique cell type that may be involved in salty taste detection. In double labeling immunohistochemistry, two different antibody probes are used to label two different proteins, specifically two different taste-specific proteins whose genes were identified by gene chip and/or PCR approaches. Alternatively, one antibody probe can be used to label a single protein to determine if the protein is expressed in taste cells. For double labeling studies, the first protein is labeled with an antibody at a very dilute concentration that can only be detected with a sensitive detection method termed tyramide signal amplification (TSA). The second protein is then labeled with another antibody and detected using a non-TSA method. The dilute first antibody cannot be detected by the standard non-TSA method; therefore, two different antibodies from the same species (e.g. rabbit polyclonal antibodies) will not cross-react and, therefore, can be used in double labeling experiments. Superimposition of protein label 1 and protein label 2 reveals if proteins are expressed in the same or in different cell types. For example, if a unique ion channel identified by gene chip or PCR approaches colocalizes to cells expressing TRPM5, that unique ion channel is expressed in cells responsible for sweet, bitter, and/or umami taste. By contrast, if a unique ion channel identified by gene chip or PCR approaches does not colocalize to cells expressing TRPM5, that unique ion channel is expressed in a different cell type that may be responsible for salty taste (or another taste modality) and that unique ion channel may be directly involved in sodium detection.
In particular the present invention preferably uses the following rationale to select potential salty taste receptor or ion channel candidates. It is again emphasized that while this rationale is focused on isolating and functionalizing salty taste receptors because of its inclusive criteria discussed below it likely will identify non-salty taste receptors as well such as fat or metallic taste receptors and genes that encode other functions of taste cells such as discussed above.
First taste buds are isolated using LCM as described above from human or macaque (Macaca fascicularis). Macaque genes are on average 90-95% identical to human genes and the macaque is an excellent experimental model for study of human biology including taste. Thus taste genes identified in the macaque will be highly similar to their human orthologs and carry out similar functions to those seen in humans. Using LCM a fine laser beam is used to dissect and purify taste cells from histological sections. This method isolates taste cells devoid of contaminating lingual epithelial cells and connective tissue and allows molecular biology experiments to be effected on a highly enriched taste cell population. In parallel, lingual epithelial cells are isolated by LCM and used as a negative control devoid of taste cells. LCM is advantageous to manual or enzymatic dissection of taste papilla because these crude techniques tend to yield a heterogeneous mixture of taste and lingual cells in which taste cells only comprise about 1-20% of the collected material.
Secondly, RNA isolated from taste and non-taste cells is analyzed using gene chips/microarrays. Gene chips contain most all annotated genes on a small chip. Hybridizing RNA, isolated from taste and lingual cells, to gene chips can be used to determine which specific genes are expressed in taste cells and not lingual cells as well as which specific genes are expressed at higher levels in taste cells compared to lingual cells. In order to identify genes for which probe sets are not functional on gene chips, gene chips were performed on 21 macaque non-taste tissues. Probe sets for genes not yielding data above background levels include both probe sets that do not hybridize efficiently to gene targets as well as probe sets not represented within the panel of 21 macaque tissues. These genes, representing genes not covered by the gene chip approach, are analyzed separately by PCR and/or histology to identify genes, specifically genes encoding transmembrane proteins, which are expressed in taste cells and not lingual cells as well as genes expressed at higher levels in taste cells compared to lingual cells isolated by LCM.
Third, taste-specific genes identified by gene chips and/or PCR are examined by histology using double labeling approaches, With in situ hybridization antisense probes specific for individual genes are hybridized to tissue sections containing taste cells to determine if the mRNA transcript for the gene of interest is expressed in taste cells, specifically in sweet bitter, sour and/or umami taste cells or in a unique cell type that may be involved in salt or other taste modality, e.g., fat taste detection. Using immunohistochemistry antibodies specific for an individual protein (which gene was identified by gene chips) these antibodies are applied to tissue sections containing taste cells to determine if the protein of interest is expressed in taste cells, specifically in sweet, bitter, sour and/or umami cells or in a unique cell type that may be involved in salt or fat taste detection. Genes expressed in taste cells expressing TRPM5, a marker for sweet, bitter, and umami cells, would encode proteins that may modulate sweet, bitter and/or umami taste. Genes expressed in taste cells expressing PKD2L1 or PKD1L3, markers for sour cells, would encode proteins that may modulate sour taste. Genes expressed in taste cells expressing neither TRPM5 nor PKD2L1 or PKD1L3 would encode proteins expressed in a unique cell type that may correspond to a salt or fat cell. Therefore, genes expressed in a unique taste cell type may correspond to a salty taste receptor or a fat taste receptor and may modulate salty or fat taste detection.
Fourth, taste-specific genes expressed in a unique cell type are analyzed by use of functional assays including electrophysiology to determine of gene products expressed in heterologous systems such as HEK293 cells or Xenopus oocytes generate sodium-responsive receptors or sodium-conducting ion channels. A salt receptor target should respond to sodium ions at concentrations relevant for human taste (between 20-140 mM sodium).
Fifthly, to ultimately validate the role of a gene as a salt receptor, genes meeting the criteria set forth above are advanced into high-throughput screens to identify enhancers and blockers and these compounds are tested in salty taste tests to determine if they augment or repress salty taste perception. In parallel, mouse knockouts are generated lacking the gene of interest and physiological (nerve recordings) and behavioral (2-bottle preference tests and gustometer tests) experiments are performed to determine if the animals are deficient in or lack salty taste perception.
Therefore, salt receptor candidates will comprise the following criteria: 1) Genes expressed specifically in taste cells or at higher levels in taste cells than lingual cells in gene chip and/or PCR experiments (these are defined as taste-specific genes); 2) Genes expressed in a unique cell type, that does not correspond to sweet, bitter, sour, and/or umami cells by histology; 3) Gene products that generate sodium responsive receptors or sodium channels in electrophysiology or functional experiments; and 4) Enhancers or blockers of gene products modulate salty taste perception and/or mouse knockouts of genes of interest are deficient in or lack salty taste responsiveness.
In a preferred embodiment, step (i) comprises the use of laser capture microdissection (LCM) to dissect and purify taste tissues from non-taste tissues. In one mode of this embodiment, step (i) comprises RNA amplification of genes from taste cells and lingual cells and the amplified genes are screened against a gene chip containing a sample of genes specific to the particular mammal from which the taste and lingual tissues are obtained, and preferably, the gene chips include a set of annotated human genes. In an alternative mode of this embodiment, step (i) comprises high throughput PCR using primers for each ion channel in a mammalian genome.
In another preferred embodiment, step (ii) is effected by in situ hybridization using antisense RNA probes specific for the set of genes identified in step (i) to determine level of expression in taste versus lingual cells. In an alternative preferred embodiment, step (ii) is effected by use of immunochemical detection using a labeled antibody specific to the protein encoded by gene or genes identified in step (i).
In another embodiment of the method for identifying a gene encoding a polypeptide involved in salty taste perception in a mammal, the method of this invention comprises the steps of (i) identifying a set of macaque genes including genes which are expressed in taste cells but which are not expressed in lingual cells and/or genes which are expressed in taste cells at substantially higher levels than in macaque lingual cells; (ii) identifying a subset of genes within the set of genes identified in (i) which are not expressed in taste cells which express umami, sweet or bitter taste receptors (T1Rs or T2Rs) or sour taste receptors (PKD2L1/PKD1L3); and (iii) determining, in a primary neuron which expresses one or more genes in the subset identified according to (ii), which of said genes functions as a sodium responsive ion channel or sodium responsive receptor or transporter and thereby identifying this gene or genes as a putative gene that modulates salty taste. In one mode of this embodiment, step (iii) comprises contacting the neuron with an antibody which specifically binds the gene and inhibits its function.
Genes identified according to either of the methods described above may be characteristic of cells which do not express TRPM5 and PKD2L1/PKD1L3. In another mode, this invention provides a method to assist in selecting cells which do not express TRPM5 and PKD2L1/PKD1L3 by determining whether a cell expresses a gene identified according to the methods above. Preferably, the gene used in the method of this paragraph is one of the genes listed in Tables 1-3, listing taste-specific genes encoding transmembrane proteins in taste cells. Efforts were focused on transmembrane genes since all known taste receptor genes for sweet, bitter, umami, and sour taste encode transmembrane proteins.
In another aspect this application provides an improvement of the afore-described methods in which genes expressed in primate (e.g., macaque) taste buds are identified and functionalized using the disclosed methods. The inventors have developed a rationale wherein they are able to assign gene expression patterns within the primate taste bud for all taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the human or primate taste bud, the inventors have found that they are able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode all taste receptors and should include those for salty taste and other yet to be defined taste specificities.
The rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38, described in the examples infra.
In order to get more information on gene expression in both the top and bottom fractions of the taste bud the inventors isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). This technique is described supra and briefly involves excision of specific groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, the inventors are able to readily identify these structures in sections of primate tongue. As exemplified in the supporting experimental example infra, tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. The inventors reasoned that only this type of section would reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.
The gene expression data obtained is then queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. A third set of genes is identified by comparing gene expression between whole (top+bottom) taste bud and lingual epithelium LCM samples.
This methodology achieves various advantages including the following:
Firstly, the inventors have found that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to prior knowledge, the data obtained using these methods clearly indicate that known taste receptor genes are expressed at a higher level in the top fraction of taste buds. It is reasonable to expect yet to be identified taste receptor genes are represented in the genes which are enriched at the top of the taste bud.
Secondly, the inventive top-versus-bottom gene classification methods allow for the functional classification of genes based on their expression in the cells in the top versus the bottom of the taste bud. Gene expression profiles at the top and bottom fractions of the taste bud suggest distinct functions for cell in each compartment. Functional classes of genes expressed in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate that these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top-specific functional clauses include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include matrix components, growth factors, and cell-cycle-associated proteins.
Thirdly, this methodology allows for the identification of additional taste bud-specific genes. It has been found that by fractionating the taste bud into top and bottom compartments that the inventors have increased the sensitivity of mRNA detection in each compartment by a factor of about 2. This facilitates the identification of other taste specific genes not identified by the prior-described methods.
Therefore, these methods can be used to identify genes involved in different functions of the taste bud based on measuring their expression in the top versus bottom of the taste bud, e.g., where genes over-expressed in the top part of the taste bud. are predicted to be involved in one or more taste sensation, modulation of taste sensation, control of the lifespan of mature taste bud cells or they may be used as biomarkers of different mature taste cell subsets.
By contrast using the inventive rationale genes over-expressed at the bottom of the taste bud are predicted e.g., to be involved in one or more of the maintenance, differentiation and proliferation of taste-bud committed stem cells; or they will represent biomarkers of taste-bud committed stem cells. In addition, genes expressed specifically in the top or bottom can be using to purify these functionally distinct taste bud cell subsets.
Also, in another aspect this invention describes rationales which are useful and have successfully identified human genes which are taste specific and which are predicted to be involved in one or more of the afore-described taste bud related functions. Specifically, these methods identify human taste specific genes (also identified by the afore-described macaque taste gene selection method) by quantitative polymerase chain reaction (PCR). This is an improvement of the afore-described methods for identifying primate taste specific genes, i.e., taste genes specifically expressed in primate taste buds and may be combined with these method and the previous described method wherein the inventors assign gene expression patterns for genes expressed within the primate taste bud for all taste bud-specific genes; specifically, by comparing taste specific gene expression between the top and bottom sections of the primate taste bud and thereby are able to classify genes into one of several functional classes that include taste receptor genes.
This third method is advantageous as it validates the results of the prior methods (since the identified human taste specific genes are present in those identified as taste specific in the macaque) and also demonstrates similar pattern of taste specific gene expression in humans (in addition to primate) and validates the specificity of expression by a quantitative method (qPCR or “TaqMan”).
However, it should be emphasized that the subject methods which identify primate taste specific genes are still very predictive as primates and humans are closely evolutionary related. Therefore, gene expression patterns should also be closely related. Based on this reasonable assumption, taste specific genes identified in the macaque are selected to be validated as being taste specific by assaying the expression thereof in human taste buds using a technology distinct from microarray analysis—TaqMan qPCR.
These methods similarly require a source of isolated (human) taste buds. Human taste buds can be isolated by laser capture microdissection (LCM). This technique has been described supra and involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of human taste buds, these structures similarly can be readily identified in sections of human tongue. Essentially, multiple LCM preparations from different human donors are pooled ( ̃4500 cells per sample), RNA extracted and amplified (e.g., by WT-Ovation Pico RNA Amplification System) (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.
Thereafter, the expression of the taste-specific genes is quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. More specifically, gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable.
For the majority of genes which are identified as being human taste specific genes when assayed using this methodology, expression is not detected in LE samples (CT>40) but is readily detectable in TB samples (CT<35). This is significant outcome as this group of human taste specific genes has not been described before as taste-specific in human tissue.
In contrast to the afore described gene chip and microarray methods, this technique provides yet additional benefits. and discoveries including the following:
Firstly, these methods allow for human taste specific genes to be detected in human LCM cDNA which were not previously known to be taste specific. Particularly, this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, the data obtained to date clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR.
Secondly, this methodology allows for the expression of human taste specific genes to be reliably and accurately measured by quantitative PCR (TaqMan) providing for the gene expression profiles of taste specific genes as measured by TaqMan. This methodology further validates gene expression data obtained from the previously described methods which used microarrays and/or in situ hybridization (ISH).
Thirdly, these methods have shown to indeed identify human taste bud specific genes which are functional. Particularly, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; Top-specific gene expression within the taste bud (akin to known taste receptors) and now TaqMan quantification of gene expression in human postmortem tastes tissues, the techniques identify human taste specific genes that had not been described previously.
Therefore, these methods allow for identification of human taste specific genes in postmortem tissues, and the identifying of human genes involved in different functions of the taste bud based on measuring their expression by quantitative PCR.
It is anticipated that these human taste specific genes, based on the manner that they were identified, expressed, and categorized are involved in one or more of (i) taste sensation, modulation of taste sensation, regulation of taste bud growth and development, control of the lifespan of mature taste bud cells, and/or are involved in the maintenance, differentiation and proliferation of taste-bud committed stem cells. In addition, genes identified using these methods are biomarkers of taste-bud committed stem cells. or represent biomarkers of different mature taste cell subsets. Therefore, these genes and gene products can be used as a basis in methods which enrich or purify these cell subsets.
Using these rationales, or a combination thereof, the genes contained in Tables 1-8 infra were identified. These Tables are briefly described as follows.
Table 1:
This table summarizes primate taste-bud expressed genes that were identified as multi plasma membrane proteins with little or no functional characterization. The set is consistent with this gene set including taste receptors and more particularly including salty taste receptors as the identified genes includes genes identified as sodium channels. This Table comprises the most probable candidates for salty receptor genes and genes responsible for other characterized and uncharacterized taste receptors and polypeptides that modulate taste intensity as well as genes encoding transmembrane proteins involved in other taste cell functions.
Table 2:
This table summarizes primate taste-bud expressed genes that were identified as multi plasma membrane proteins with have been functionally characterized but which are potential candidates for salty taste and other taste receptors. In addition this gene set includes genes encoding transmembrane polypeptides involved in other taste cell related functions.
Table 3:
This Table contains other fungiform expressed genes and potential taste receptor candidates. This Table of genes was derived after compiling a list of ion channel genes permeable to sodium that were systematically tested for expression in laser capture micro-dissected primate tongue tissue from lingual epithelium and taste buds by end point PCR. Genes that were expressed in fungiform taste buds but not circumvallate taste buds or lingual epithelium were included in this list. Moreover, this list of genes includes other genes which were selected that are likely to encode multi-domain transmembrane proteins included on the macaque oligo array that did not satisfy the inclusion criteria of the systematic array and are not included in the Gene Lists contained in Tables 1 and 2.
Table 4:
This table contains additional new taste-specific genes identified in macaque fungiform and/or circumvallate taste-buds by gene chip analysis. These genes all encode transmembrane proteins with no described function or that function as ion channels, ion transporters, or G-protein coupled receptors. Accession numbers, ratios of gene expression in taste cells (TB) to non-taste lingual epithelial cells (LE), and the p values calculated using a two-tailed Student's t-test are listed.
Table 5:
This table contains additional primate genes previously described as fatty acid receptors or which contain amino acid motifs that are associated with lipid binding. This list of genes includes genes that do not encode multi-transmembrane proteins but which are reported to participate in lipid transport or binding at close to the plasma membrane.
Table 6:
This table contains 11 taste-specific genes shown to be expressed in different subsets of primate taste cells. These genes were identified as taste-specific genes by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis as described in the experimental examples and Figures.
Table 7:
This table lists 4 other primate taste specific genes identified by the inventive rationales and provides information as to the specific cell types in which these genes are expressed.
Table 8:
This table contains a listing of the human taste-specific genes which were quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. As noted in Example 46, gene expression was measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample was determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold is reached early in the PCR run and the CT value is relatively low (<35) while genes with very low or no expression do not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable. For the majority of genes listed in Table 8 expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35).
Therefore, based on the foregoing, the subject invention provides methods for identifying human and other primate taste specific genes, including genes involved in salty taste perception or other taste perception modalities or modulation of taste modalities such as fat, metallic, CO2, sweet, bitter, sour, etc. and the use in screening assays for identifying human salty or other taste enhancers and other taste modulatory compounds and for identifying potential therapeutics that modulate other taste cell related functions and phenotypes including diseases and conditions not directly related to taste transduction.
Particularly, the present invention includes the use of cell-based assays to identify salty taste modulators (enhancers). These compounds have potential application in modulating human salty taste perception. Compounds identified for example in electrophysiological assays and their biologically acceptable derivatives are to be tested in human taste tests using human volunteers to confirm their effect on human salty taste perception. In addition compounds identified as potential therapeutics will be evaluated in appropriate in vitro and in vivo models depending on the nature of the intended application. For example compounds identified as potential therapeutics for diabetes may be evaluated in well known diabetic animal models such the NOD mouse model or BB rat model. Similarly, compounds identified as potential therapeutics for IBD or Crohn's disease may be tested in rodent animal models for IBD or Crohn's disease.
As discussed further infra, the cell-based assays used to identify taste, e.g., salty taste modulatory or therapeutic compounds will preferably comprise high throughput screening platforms to identify compounds that modulate (enhance) the activity of genes involved in salty taste perception using cells that express the genes disclosed herein or combinations thereof. Additionally, these sequences may be modified to introduce silent mutations or mutations having a functional effect such as defined mutations that affect ion (sodium) influx. As noted above, the assays will preferably comprise electrophysiological assays effected in amphibian oocytes or assays using mammalian cells that express a an ion channel according to the invention using fluorescent ion sensitive dyes or membrane potential dyes, e.g., sodium-sensitive dyes. Preferably, compounds that modulate such ion channels are identified by screening using electrophysiological assays effected with oocytes that express an ion channel identified herein (e.g., patch clamping or two electrode voltage clamping).
Still alternatively, compounds that modulate the subject ion channels putatively involved in salty taste may be detected by ion flux assays, e.g., radiolabeled-ion flux assays or atomic absorption spectroscopic coupled ion flux assays. As disclosed supra, these compounds have potential application in modulating human salty taste perception or for modulating other biological processes involving aberrant or normal ion channel function.
The subject cell-based assays use mutant nucleic acid sequences which are expressed in desired cells, preferably oocytes or human cells such as HEK-293 cells, or other human or mammalian cells conventionally used in screens for identifying ion channel or GPCR modulatory compounds. These cells may further be engineered to express other sequences, e.g., other taste GPCRs, i.e., T1Rs or T2Rs such as are described in other patent applications by the present Assignee Senomyx as well as appropriate G proteins. The oocyte system is advantageous as it allows for direct injection of multiple mRNA species, provides for high protein expression and can accommodate the deleterious effects inherent in the overexpression of ion channels. The drawbacks are however that electrophysiological screening using amphibian oocytes is not as amenable to high throughput screening of large numbers of compounds and is not a mammalian system. As noted, the present invention embraces assays using mammalian cells, preferably high throughput assays.
Some ion channels putatively involved in salty taste (ENaC) proteins are known to form heteromeric channels comprised of three subunits, an alpha, beta, and a gamma or delta subunit. The sequences of these respective ENaC subunits are disclosed in an earlier patent application by the present Assignee, U.S. Ser. No. 10/133,573 which is incorporated by reference in its entirety herein. Upon co-expression in a suitable cell these subunits result in a heterotrimeric channel having cation ion channel activity; in particular it responds to sodium and should similarly respond to lithium ions in cell-based assays such as those which are disclosed herein and in Senomyx's prior application referenced above.
The Senomyx application incorporated by reference provides high throughput screening assays using mammalian cells transfected or seeded into wells or culture plates wherein functional expression in the presence of test compounds is allowed to proceed.
The invention specifically provides methods of screening for modulators, e.g., activators, inhibitors, stimulators, enhancers, etc., of human salty taste or other taste modalities and potential therapeutics that target other taste cell functions or phenotypes using the nucleic acids and proteins, sequences provided herein. Such modulators can affect salty taste or other taste modalities or taste cell related functions and phenotypes, e.g., by modulating transcription, translation, mRNA or protein stability; by altering the interaction of the ion channel with the plasma membrane, or other molecules; or by affecting ion channel protein activity. Compounds are screened, e.g., using high throughput screening (HTS), to identify those compounds that can bind to and/or modulate the activity of a taste receptor or taste ion channel polypeptide or transporter or fragment thereof. In the present invention, proteins are recombinantly expressed in cells, e.g., human cells, or frog oocytes and the modulation of activity is assayed by using any measure of ion channel, receptor or transporter function, such as measurement of the membrane potential, or measures of changes in intracellular sodium or lithium levels. Methods of assaying ion, e.g., cation, channel function include, for example, patch clamp techniques, two electrode voltage clamping, measurement of whole cell currents, and fluorescent imaging techniques that use ion sensitive fluorescent dyes and ion flux assays, e.g., radiolabeled-ion flux assays or ion flux assays.
An enhancer of a gene identified as set forth in the current application can be used for a number of different purposes. For example, it can be included as a flavoring agent to modulate the salty taste of foods, beverages, soups, medicines, and other products for human consumption. Additionally, the invention provides kits for carrying out the herein-disclosed assays.
Definitions
“Putative taste receptor or ion channel gene” refers to a gene expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R, T2R, TRPM5, or PKD2L1/PKD1L3 gene.
“Putative salty taste receptor or ion channel gene” refers to a gene specifically expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R or T2R gene. Preferably this gene will also be an ion channel or a G protein coupled receptor.
“Putative fat or lipid taste receptor or ion channel gene” refers to a gene specifically expressed in taste cells that is not expressed in lingual cells or is expressed substantially less in lingual cells that moreover preferably is not expressed in taste cells that express a T1R or T2R gene. Preferably this gene will also comprise specific motifs characteristic of fatty acid or lipid binding or be predicted to be a fat or lipid associated taste receptor based on its prior identification as encoding a fatty acid binding protein or to possess a structure or homology to another fatty acid binding protein.
“Taste Cell” refers to a cell that when mature expresses at least one receptor, transporter, or ion channel that directly or indirectly regulates or modulates a specific taste modality such as sweet, sour, umami, salty, bitter, fatty, metallic or other taste perception or general taste perception such as taste intensity or the duration of a taste response. Taste cells express mRNA and/or a protein for the gene C6orf15 (chromosome reading frame 15)—also known as STG. This gene has been described as a taste-specific gene (M. Neira et al. Mammalian Genome 12: 60-66, 2001) and is among the macaque taste specific genes reported herein. In addition a mature taste receptor cell typically will express mRNA and/or protein for alpha ENaC. We have data (not shown herein) that reveals that alpha ENaC is expressed in at least sweet, bitter, umami, sour and most likely salty taste cells. Further, a mature taste receptor cell will typically express mRNA and/or protein for cytokeratin 19. This protein is only expressed in mature taste cells and is not found in basal or stem cells. (L. Wong et al. Chemical Senses 19(3): 251-264, 1994). Furthermore, taste cells can be identified by those skilled in the art base on their characteristic morphology. In particular mature taste receptor taste cells are elongated and spindle-shaped. Also, a mature taste receptor cell has the apex of the cell (apical membrane) penetrating into the taste pore thereby gaining access or exposure to saliva. By contrast, an immature taste cell, e.g., a basal cell or stem cell is rounded and is not exposed to the taste pore and saliva. Also, unlike mature taste cells, basal and stem cells tend to be localized towards the base of taste buds.
“Chemosensory cells” are cells that are involved in sensing of chemical stimulants such as tastants and other chemical sensory stimuli such as odorants. Chemosensory cells herein include in particular taste receptor cells and cells comprised in the digestive or urinary tract or other organs that when mature express one or more taste receptors. For example, gastrointestinal chemosensory cells are known which express T1Rs or T2Rs and which cells are likely involved in food sensing, metabolism, digestion, diabetes, food absorption, gastric motility, et al. In addition, cells found in the urinary tract likely express salty taste receptors and are involved in sodium transport, excretion and functions associated therewith such as blood pressure and fluid retention. Further, in the digestive system chemosensory cells that express taste receptors may also express chromogranin A, which is a marker of secretory granules. (C. Sternini, “Taste Receptors in the Gastrointestinal Tract. IV. Functional Implications of Bitter Taste Receptors in Gastrointestinal Chemosensing”. American Journal of Physiology, Gastrointestinal and Liver Physiology.”, 292:G457-G461, 2007).
“Taste-cell associated gene” or “taste specific gene” herein refers to a gene expressed by a taste cell that is not expressed by lingual cell that is involved in a taste or non-taste related taste cell function or phenotype. Taste cells include cells in the oral cavity that express taste receptors such as the tongue and taste cells in other areas of the body that express taste receptors such as the digestive system and urinary tract. Such genes are contained in Tables 1, 2, 3, 4, 5, 6, 7, and 8. With respect to putative taste receptor or taste modulatory genes, preferably, these genes are expressed more in cells comprised in the top half relative to the bottom half of the taste bud. These genes include genes involved in taste and non-taste related functions such a taste cell turnover, diseases affecting the digestive system or oral cavity, immunoregulation of the oral cavity and/or digestive system, digestive and metabolic functions involving taste cells such a diabetes, obesity, blood pressure, fluid retention et al. In referring to the particular taste specific genes identified herein these genes include the nucleic acid sequences corresponding the Accession Numbers contained in Tables 1, 2, 3, 4, 5, 6, 7, and 8 and contained in the Sequence Listing preceding the claims as well as orthologs thereof and chimeras and variants including allelic variants thereof. In particular such variants include sequences encoding polypeptides that are at least 80% identical, more preferably at least 90% or 95, 96, 97, 98 or 99% identical to the polypeptides encoded by the genes corresponding to the recited Accession numbers or to orthologs thereof, especially human and non-human primate orthologs. In addition, the genes include nucleic acid sequences that hybridize under stringent hybridization conditions to a nucleic acid sequence corresponding to one of the gene sequences corresponding to the gene Accession numbers recited in the Tables and sequence listing herein.
“Cation channels” are a diverse group of proteins that regulate the flow of cations across cellular membranes. The ability of a specific cation channel to transport particular cations typically varies with the valency of the cations, as well as the specificity of the given channel for a particular cation.
“Homomeric channel” refers to a cation channel composed of identical alpha subunits, whereas “heteromeric channel” refers to a cation channel composed of two or more different types of alpha subunits. Both homomeric and heteromeric channels can include auxiliary beta subunits.
A “beta subunit” is a polypeptide monomer that is an auxiliary subunit of a cation channel composed of alpha subunits; however, beta subunits alone cannot form a channel (see, e.g., U.S. Pat. No. 5,776,734). Beta subunits are known, for example, to increase the number of channels by helping the alpha subunits reach the cell surface, change activation kinetics, and change the sensitivity of natural ligands binding to the channels. Beta subunits can be outside of the pore region and associated with alpha subunits.
The term “authentic” or wild-type” or “native” nucleic acid sequences refer to the wild-type nucleic acid sequences contained in the Tables and sequence listing herein as well as splice variants and other nucleic acid sequences generally known in the art.
The term “authentic” or “wild-type” or “native” polypeptides refers to the polypeptide encoded by the genes and nucleic acid sequence contained in the Tables and Sequence Listing.
The term “modified enhance receptor nuclear acid sequence” or “optimized nucleic acid sequence” refers to a nucleic acid sequence which contains one or more mutations, particularly those that affect (inhibit or enhance) gene activity in recombinant host cells, and most especially oocytes or human cells such as HEK-293 cells. Particularly, these mutations include those that affect gating by the resultant ion channel containing the mutated subunit sequence. The ion channel may comprise such mutations in one or several of the three subunits that constitute the particular ion channel. The modified nucleic acid sequence for example may contain substitution mutations in one subunit that affect (impair) gating function or defective surface expression. The invention embraces the use of other mutated gene sequences, i.e., splice variants, those containing deletions or additions, chimeras of the subject sequences and the like. Further, the invention may use sequences which may be modified to introduce host cell preferred codons, particularly amphibian or human host cell preferred codons.
The term receptor or ion channel protein or transporter or fragment thereof, or a nucleic acid encoding a particular taste receptor or ion channel or transporter or a fragment thereof according to the invention refers to nucleic acids and polypeptide polymorphic variants, alleles, mutants, and interspecies homologs that: (1) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino acid sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acids, to an amino acid sequence encoded by the wild-type nucleic acid or amino acid sequence of the taste protein, e.g., proteins encoded by the gene nucleic acid sequences contained in the Tables and Sequence Listing herein as well as fragments thereof, and conservatively modified variants thereof; (3) polypeptides encoded by nucleic acid sequences which specifically hybridize under stringent hybridization conditions to an anti-sense strand corresponding to a nucleic acid sequence encoding a gene encoded by one of said genes, and conservatively modified variants thereof; (4) have a nucleic acid sequence that has greater than about 60% sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, or higher nucleotide sequence identity, preferably over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleic acid, e.g., those disclosed herein.
A putative salty or other taste specific gene or polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or any mammal. The nucleic acids and proteins of the invention include both naturally occurring or recombinant molecules. Typically these genes will encode proteins that have ion channel activity, i.e., they are permeable to sodium or lithium.
By “determining the functional effect” or “determining the effect on the cell” is meant assaying the effect of a compound that increases or decreases a parameter that is indirectly or directly under the influence of a taste gene, preferably salty taste gene identified herein e.g., functional, physical, phenotypic, and chemical effects. Such functional effects include, but are not limited to, changes in ion flux, membrane potential, current amplitude, and voltage gating, a as well as other biological effects such as changes in gene expression of any marker genes, and the like. The ion flux can include any ion that passes through the channel, e.g., sodium or lithium, and analogs thereof such as radioisotopes. Such functional effects can be measured by any means known to those skilled in the art, e.g., patch clamping, using voltage-sensitive dyes, or by measuring changes in parameters such as spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties.
“Inhibitors,” “activators,” and “modulators” of the subject taste cell expressed polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules identified using in vitro and in vivo assays of these polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of these taste specific proteins, e.g., antagonists. “Activators” are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate protein activity. Inhibitors, activators, or modulators also include genetically modified versions of the subject taste cell specific proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, peptides, cyclic peptides, nucleic acids, antibodies, antisense molecules, siRNA, ribozymes, small organic molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the subject taste cell specific protein in vitro, in cells, cell extracts, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above.
Samples or assays comprising the proteins encoded by genes identified herein that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of activation or migration modulation. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of an ion channel is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of an ion channel is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% or higher.
The term “test compound” or “drug candidate” or “modulator” or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic compound, preferably a small molecule, or a protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, lipid, fatty acid, polynucleotide, siRNA, oligonucleotide, ribozyme, etc., to be tested for the capacity to modulate cold sensation. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a “lead compound”) with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.
A “small organic molecule” refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 daltons and less than about 2500 daltons, preferably less than about 2000 daltons, preferably between about 100 to about 1000 daltons, more preferably between about 200 to about 500 daltons.
“Biological sample” include sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes. Such samples include blood, sputum, tissue, cultured cells, e.g., primary cultures, explants, and transformed cells, stool, urine, etc. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.
The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region (e.g., a gene or sequence contained in the Tables and Sequence Listing herein), when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site or the like). Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).
A preferred example of algorithm that is suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nucl. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always>0) and N (penalty score for mismatching residues; always<0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=−4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci., USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=−4, and a comparison of both strands.
“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). A particular nucleic acid sequence also implicitly encompasses “splice variants.” Similarly, a particular protein encoded by a nucleic acid implicitly encompasses any protein encoded by a splice variant of that nucleic acid. “Splice variants,” as the name suggests, are products of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced such that different (alternate) nucleic acid splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternate splicing of exons. Alternate polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any products of a splicing reaction, including recombinant forms of the splice products, are included in this definition. An example of potassium channel splice variants is discussed in Leicher, et al., J. Biol. Chem. 273(52):35095-35101 (1998).
The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence with respect to the expression product, but not with respect to actual probe sequences.
As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
The following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor and Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). “Primary structure” refers to the amino acid sequence of a particular peptide. “Secondary structure” refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains, e.g., transmembrane domains, pore domains, and cytoplasmic tail domains. Domains are portions of a polypeptide that form a compact unit of the polypeptide and are typically 15 to 350 amino acids long. Exemplary domains include extracellular domains, transmembrane domains, and cytoplasmic domains. Typical domains are made up of sections of lesser organization such as stretches of .beta.-sheet and .alpha.-helices. “Tertiary structure” refers to the complete three dimensional structure of a polypeptide monomer. “Quaternary structure” refers to the three dimensional structure formed by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.
A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide.
The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).
The phrase “stringent hybridization conditions” refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5×SSC, and 1% SDS, incubating at 42° C., or, 5×SSC, 1% SDS, incubating at 65° C., with wash in 0.2×SSC, and 0.1% SDS at 65° C.
Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary “moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 1×SSC at 45° C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.
For PCR, a temperature of about 36° C. is typical for low stringency amplification, although annealing temperatures may vary between about 32° C. and 48° C. depending on primer length. For high stringency PCR amplification, a temperature of about 62° C. is typical, although high stringency annealing temperatures can range from about 50° C. to about 65° C., depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90° C.-95° C. for 30 sec-2 min., an annealing phase lasting 30 sec.-2 min., and an extension phase of about 72° C. for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).
“Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody will be most critical in specificity and affinity of binding.
The term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv), chimeric, humanized or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990)) For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual (1999); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)).
The phrase “specifically (or selectively) binds” to an antibody or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein, often in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein at least two times the background and more typically more than 10 to 100 times background. Specific binding to an antibody under such conditions requires an antibody that is selected for its specificity for a particular protein. For example, polyclonal antibodies raised to a protein, polymorphic variants, alleles, orthologs, and conservatively modified variants, or splice variants, or portions thereof, can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with proteins and not with other proteins. This selection may be achieved by subtracting out antibodies that cross-react with other molecules. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
By “therapeutically effective dose” herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999).
Therefore, based on the foregoing, this invention provides in its generic embodiments methods for identifying taste specific genes which may be functionalized using the methods disclosed herein. These techniques have identified all of the genes contained in Tables 1-8 too be taste specific. In addition, as disclosed in the experimental examples this invention further provides specific information and characterization of certain human and primate taste specific genes identified by the rationales described in detail infra and further practical applications of these genes, gene products, and cells which express same as well as modulators of these genes. The more specific aspects of the invention are described as follows and in the examples.
Particularly, the inventors provide lists of genes in Table 6 and 7 infra which are expressed in primate taste cell subsets and describe uses of these genes in taste biology. These genes which are selectively expressed in primate fungiform papilla taste cells at the front of the tongue and circumvallate papilla taste cells at the back of the tongue were identified were identified using the afore-described gene chips/microarray methods by comparing expression in taste receptor cells compared to non-taste lingual epithelial cells isolated by laser capture micro-dissection (LCM). Since salty taste perception is most prevalent at the front of the tongue, taste receptor genes potentially including the salty taste and other taste receptor could be present within this gene set. The genes in Table 6 and Table 7 as reported therein are expressed in different subsets of primate taste cells and were identified by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis.
For example, results contained in the experimental examples and figures referred to therein reveal that FAM26A, MCTP1, TMEM30B, and TUSC3 are expressed in many TRPM5 cells, suggesting that these genes are expressed in sweet, umami, and bitter taste cells, since TRPM5 is a marker of sweet, bitter, and umami taste cells. Also, the results show that GPR113 and TMEM16G are expressed in a subset of TRPM5 cells, suggesting that these genes could be selectively expressed in sweet, umami, or bitter taste cells (or a combination thereof).
Also, the results contained in the experimental examples and figures referred to therein show that TMEM44 is expressed in cells that do not express TRPM5 (bitter, sweet, umami) or PKD1L3 (sour), indicating that the expression of this gene is a marker for a unique taste cell type that could correspond to salt, fat, or another taste modality, and, furthermore, that this gene may encode the primary salt or fat receptor.
Based on the foregoing, this invention contemplates the use of FAM26A, MCTP1, TMEM30B, and TUSC3 as markers alone or in combination with other taste specific genes contained herein for marking, isolating, enriching or ablating sweet, bitter, and umami taste cells or cells expressing TRPM5. In addition, this invention includes the use FAM26A, MCTP1, TMEM30B, and TUSC3 and compounds that enhance or inhibit these gene products in order to selectively modulate taste cell function and responses to tastants including sweet, bitter, and umami.
In addition, the results contained in the experimental examples and figures referred to therein indicate that GPR113 and TMEM16G can be used as a marker for sweet, bitter, or umami taste cells or subsets of TRPM5 cells. Therefore, the invention further describes the use of the use of GPR113 and TMEM16G as markers alone or in combination with other taste specific genes contained herein for marking, isolating, enriching or ablating sweet, bitter, and umami taste cells or cells expressing TRPM5.
In addition, the results contained in the experimental examples and figures referred to therein indicate that GPR113 and TMEM16G and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to tastants including sweet, bitter, or umami. Therefore, the invention further embraces the use of these genes and corresponding polypeptides in assays for identifying sweet, bitter or umami taste modulators.
In addition, based on the finding (as determined by in situ hybridization of primate taste bud cells) that all of TUSC3, ASCL1, FAM26A, FAM26C, IKBKAP, LOC285965, SCNN1D, SLC4A11, SLC26A7, and TMEM30B are expressed by specific taste cell subsets that these genes may be used as biomarkers and that the genes and gene products may be used isolate, mark or ablate these cells and thereby determine the taste related function of these taste bud cells. Based on this same finding the invention further relates to these isolated cells and assays using these cells and genes to identify taste modulators
Still further, the results contained in the experimental examples and figures referred to therein indicate that TMEM44 can be used as a marker for a unique, novel taste cell type that does not correspond to sweet, bitter, and umami taste cells and that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, and umami, which include salt, fat, and other tastants. Therefore, the invention further includes the use of these genes and their corresponding polypeptides in screening assays for identifying taste modulators.
Still further, the results contained in the experimental examples and figures referred to therein indicate that TMEM44 may correspond to a salt receptor or fat receptor, or a marker of immature taste cells or stem cells. Also, this suggests that TMEM44 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells). Accordingly, the invention embraces the use of these genes and polypeptides in screening assays for identifying compounds that selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells).
Still further, based on the experimental data, the invention embraces the use of these gene products and compounds that enhance or inhibit gene products can affect: selective apoptosis of taste cells responding to aversive taste modalities such as bitter and sour cells; modulation of transcription factors that control taste receptor expression; modulation of specific bitter receptor expression to minimize off-tastes of vegetables, children's medicine, and coffee; autocrine/paracrine modulation of taste cell development; prolongation of taste bud lifetime; development of supertasters (rodent model systems) to screen for chemical and biological toxins (terrorism), rancid/spoiled/contaminated food and beverage products; and activation of stem cells to differentiate into defined taste cell types.
In addition, the invention further encompasses the possibility that these gene products can also be ancillary taste receptors or primary taste receptors including receptors for salt, fat, and other taste modalities including metallic. This can be determined by the inventive methods.
Also, based on the experimental results, the invention includes the use of these gene products and compounds that enhance or inhibit gene products to modulate the function of any cell expressing a taste receptor, including but not limited to cells in the gastrointestinal tract such as enteroendocrine cells that regulate gastric motility and peptide secretion (e.g. GLP-1: glucagon-like peptide 1; GIP: gastric inhibitory peptide) as well as the other therapeutic applications of taste specific genes and modulators afore-mentioned. These applications include trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes; regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes; regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific tastes; and autocrine/paracrine modulation of taste receptor function; regeneration of taste cells as well as prophylaxis/prevention of taste cell loss following injury, chemotherapy for cancer, radiation therapy for cancer, drug-induced dysgeusia, ageusia, and taste bud loss in the geriatric population; oral hygiene, halitosis, detoxification of noxious substances in oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth; saliva composition and treatment of dry mouth in conditions of xerostomia and autoimmune disease (Sjogren's syndrome).
Still further, the results contained in the experimental examples and figures referred to therein indicate by use of double label in situ hybridization histology what specific TRPM5 cell type that GPR113 is expressed in. As disclosed infra we identify that GPR113 is not expressed in T1R1 umami cells, T1R2 sweet cells, or T2R bitter cells. Also, it was found that GPR113 is expressed in a subset of T1R3 cells that do not express T1R1 or T1R2. Thus, GPR113 cells define a new taste cell type of T1R3 only cells. Accordingly, this invention embraces the use of this gene to mark, enrich, isolate or ablate these cells.
Also, based on this discovery the invention provides for the use of GPR113 as a marker for this unique taste cell type that because it is in a unique cell population, is a GPCR (many taste receptors are already known to be GPCRs) and therefore this cell likely corresponds to a specific taste modality for which taste cells have not yet been characterized or modulates a specific taste modality such as CO2 sensation, salt, fat, metallic or astringent. Also, the invention provides for the further possibility that GPR113 may associate with T1R3 to form a novel taste receptor for sweet, umami, or other tastants.
Further, based on the foregoing experimental evidence, this invention provides for the use of GPR113 or the corresponding polypeptide as a marker to identify and isolate this unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells and its use to identify taste modulators as well as the aforementioned therapeutic applications of compounds modulating taste specific polypeptides.
Still further, the results contained in the experimental examples and figures referred to therein indicate that the genes KIT, IKBKAP, LOC285965, and SV2B are taste specific taste genes and are expressed in the specific primate taste cell subsets (see Table 7 infra). In addition, the results contained in the experimental examples and figures referred to therein indicate that another gene, MFDS4 is expressed in sensory taste cells that are not sweet, umami, bitter or sour cells, suggesting that this gene is expressed in a similar taste cell subset as TMEM44. Therefore, the invention includes the use of these genes and corresponding polypeptides in screening assays for taste modulators and therapeutics and as biomarkers of specific, unique taste cell subsets.
Still further, in Tables 1-5 of this application the inventors provide a listing of primate taste-specific genes also identified by the inventive rationales that have been demonstrated to reliably include functional taste specific genes already known. These listing of genes include genes encoding transmembrane proteins such as ion channels (sodium), GPCRs, ion transporters, as well as multi-transmembrane proteins with no function yet assigned. Therefore, the invention further includes functionalizing these genes and assessing their function in taste detection or modulation or ancillary taste cell functions.
Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B are expressed in many PKD1L3 cells, and that these genes are likely expressed in sour taste cells, since PKD1L3 is a marker of sour taste cells. Therefore, the invention embraces screening assays to assess the effect of modulators on specific taste modalities including sour, or basic taste or other tastes.
Still further, the results contained in the experimental examples and figures referred to therein indicate that KIT is expressed in cells that express the umami taste receptor component T1R1. This is predicted by the inventors to support a view that KIT is expressed in cells responsible for umami taste perception. Accordingly, KIT may modulate umami taste perception.
Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 is expressed in cells that express TRPM5 and T1R3 but not in cells that express the umami taste receptor component T1R1, or the sweet taste receptor component T1R2. These results suggest that LOC285965 is expressed in the ‘T1R3 only’ population of taste cells (similar to GPR113).
Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B are expressed in PKD1L3 sour taste cells and indicate that they can be used as markers of this taste cell population. Therefore, the invention includes the use thereof to mark, enrich, isolate or ablate these taste cells so that their effect can be assessed in vitro or in vivo.
Still further, the results contained in the experimental examples and figures referred to therein indicate that IKBKAP and SV2B and compounds that enhance or inhibit these gene products can selectively modulate taste cell function and responses to sour tastants as well as other functions of the PKD1L3 taste cell population. Accordingly, this invention includes the use of these genes and gene products in sour taste modulatory or other taste assays.
Still further, the results contained in the experimental examples and figures referred to therein indicate further that since IKBKAP is mutated in the human disease familial dysautonomia, where taste buds are absent or atrophic and individuals exhibit deficiencies in detection of sweet, bitter, sour, and salty tastants (hypogeusia) that IKBKAP expression in PKD1L3 cells may be important for taste cell development and/or maintenance. Accordingly, the invention embraces the use of this gene and gene product in assays to identify compounds that modulate taste cell development and/or maintenance.
Also, these same findings that and the fact that Botulinum neurotoxin (BoTox) enters neuronal-type cells by interacting with SV2B; indicate that BoTox may selectively modulate sour taste as well as other functions of the PKD1L3 taste cell population. Therefore, SV2B modulators identified by the inventive methods may elicit neuronal effects and may be useful in cosmetic applications.
Also, the same aforementioned findings that KIT is expressed in umami taste cells indicate that it can be used as a marker of this taste cell type. Therefore, the invention embraces the use of KIT as a marker of umami cells. Also, because these findings that indicate that KIT and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to umami tastants the invention further embraces the compounds identified and their use in modulating umami gene functions including taste and food sensing.
Also, these same findings and the fact that Gleevec (Imatinib), is an inhibitor of the KIT tyrosine kinase activity, indicate that this and other KIT tyrosine kinase inhibitors may selectively inhibit umami taste. Also, these findings suggest that individuals with gain of function mutations in KIT, for example in gastrointestinal stromal tumors (GIST), may have altered umami taste perception. Therefore, the invention further embraces the use of KIT modulators in treating gastrointestinal cancers and for detecting these conditions.
Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 is expressed in T1R3 only taste cells similar to GPR113 and indicate that this gene is useful as a marker for a unique, novel taste cell type (T1R3 only cells) that does not correspond to sweet, bitter, and umami taste cells.
Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 may correspond to a salt receptor or fat receptor or a receptor for astringency or metallic taste by itself or in combination with GPR113. Therefore, the invention further provides for this possibility.
Still further, the results contained in the experimental examples and figures referred to therein indicate that LOC285965 may be a coreceptor with T1R3 for specific sweet or umami tastants or other novel tastants such as astringent and metallic tastants.
Still further, these same findings suggest that compounds that enhance or inhibit LOC285965 can selectively modulate taste function and responses to tastants. Accordingly, the invention embraces the use of this gene and gene products in screening assays for taste modulators.
Also, these same findings suggest that LOC285965 may correspond to a marker of immature taste cells that are differentiating into sweet or umami cells. Therefore, the invention embraces the use of this gene or polypeptide as a marker of immature taste cells and/or to isolate, enrich or deplete these cells.
Also, these same findings suggest that LOC285965 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. sweet or umami taste cells). Therefore, the invention embraces the use of these compounds as sweet or umami or other taste modulators.
Still further, the results contained in the experimental examples and figures referred to therein indicate that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell function and responses to tastants other than sweet, bitter, umami, and sour which include salt, fat, and other tastants. Therefore, the invention includes the use of MFSD4 modulators to modulate taste.
Also, these same findings suggest that MFSD4 may correspond to the salt receptor or fat receptor or may be used as a marker of immature taste cells or developing taste cells or support cells. The invention Therefore includes the use of this gene in such usages.
Still further, these findings suggest that MFSD4 and compounds that enhance or inhibit this gene product can selectively modulate taste cell development and/or differentiation of specific taste cell types (i.e. bitter taste cells). Accordingly, the invention embraces the use of modulators of this gene for modulating taste cell development or differentiation.
Also, the data infra reveal that MFSD4 and TMEM44 are expressed in the same taste cell population which may respond to specific tastants. Therefore, the invention includes assays which coexpress these genes in order to identify taste modulators.
Also, the invention embraces the resultant taste receptor wherein MFSD4 and TMEM44 form a complex (heterodimer) to generate a taste receptor (such as fat, CO2, salt, metallic, or other taste modality).
Still further, the results contained in the experimental examples and figures referred to therein indicate that the ASCL1 (aka MASH1) transcription factor defines sour taste cells. ASCL1 is expressed in sour taste cells expressing the sour taste receptor gene PKD1L3; ASCL1 is not expressed in sweet, bitter, and umami taste cells expressing TRPM5. ASCL1 was previously reported to be a marker of type III taste cells. Type III taste are defined by morphological criteria which include: staining with an intermediate density by electron microscopy and making synaptic contacts with nerve fibers. Thus, our results demonstrate that type III taste cells, a cell type previously defined by morphological criteria, correspond to sour taste receptor cells defined by gene expression criteria.
Therefore, an application of this finding is that the ASCL1 transcription factor may bind to promoter elements in genes involved in sour taste perception. Thus, the genome could be screened for ASCL1 motifs to identify genes in sour cells, including sour receptor genes such as PKD2L1, PKD1L3, or additional genes that may form a complex with PKD2L1/PKD1L3 to generate a sour receptor.
Analogously, other taste receptor cells for sweet, bitter, umami, and salt are likely to express specific transcription factors that define those cell types. Therefore, the invention further embraces methods wherein the expression of all transcription factors in the genome is analyzed in taste cells by PCR and/or histology to determine which taste cell types express which transcription factors.
These finding further support other applications of this gene. For example, the invention includes the use of ASCL1 (aka MASH1) as a marker of sour taste cells and further for the isolation of Type III taste cells which correspond to sour taste receptor cells.
Moreover, because it has been determined that ASCL1 defines the sour taste cell lineage and may control sour taste cell development, the invention further provides for ASCL1 transcription factor DNA binding sequences to be used to identify sour cell genes and sour taste receptor genes. Also, the invention includes the use of such transcription factors can be used to define, mark, and/or label taste cell types. With respect thereto, each taste cell will express one or more transcription factors that define that taste modality.
Also, the invention further encompasses the use of the identified transcription factors to define taste modalities and in cell ablation studies to specifically eliminate a specific taste. Moreover, the invention includes the use of these identified transcription factors that define new taste cell types in cell studies to determine what taste modality is lacking (i.e. what taste can an animal no longer perceive).
Also, as described and supported by data infra, this invention also shows that taste cells expressing the PKD2L1 and PKD1L3 genes, previously implicated in sour taste are heterogeneous and comprise multiple cell populations. In the front of the tongue, in fungiform (FG) papilla there are cells expressing PKD2L1 only, PKD1L3 only, and both PKD2L1 plus PKD1L3. By contrast, in the back of the tongue, in circumvallate papilla (CV), most cells coexpress PKD2L1 plus PKD1L3.
Also, the invention reveals that in addition thereto there is a distinct group of taste cells that express PKD1L3 only and a smaller set of cells that express PKD2L1 only. Previous literature has suggested that cells expressing PKD2L1 (encompassing PKD2L1 and cells coexpressing PKD2L1 plus PKD1L3) respond to sour taste (Huang et al, Nature 2006 Aug. 24; 442(7105):934-8.) However, PKD1L3 cells were not previously known and no function has yet been ascribed.
Therefore, the invention further contemplates the use of PKD1L3 cells as candidate basic or salt responding cells and that PKD1L3 is involved in a different (other than sour) taste modality, e.g., basic taste perception since the related sour receptor, PKD2L1, responds to acidic taste.
Still further, the results contained in the experimental examples and figures referred to therein indicate that the FAM26C gene is expressed in TRPM5 cells (see results infra) and therefore can be used as a marker of sweet, bitter and umami cells. Therefore, the invention further includes the use of FAM26C as a marker or to isolate, enrich or purify or ablate specific taste cells including sweet, bitter and umami cells.
Also, based on these same findings the invention includes the possibility that PKD1L3 only taste cells are candidate taste cells, e.g., which modulate basic taste sensation or other taste modalities, and that PKD1L3 is a candidate taste receptor, e.g., basic taste sensation. Also, the invention provides for an embodiment wherein PKD1L3 may complex with one of the gene products identified herein to form a taste receptor.
Also, based on the findings that FAM26C is expressed in TRPM5 cells, including sweet, bitter, and umami taste cells, it can be used as a marker of this taste cell population and FAM26C and compounds that enhance or inhibit FAM26C can selectively modulate taste cell function and responses to sweet, bitter, and umami tastants as well as other functions of the TRPM5 taste cell population, including functions of the TRPM5 taste cells that are candidate salty taste cells and that coexpress T1R3.
Also, as shown infra, this invention reveals that taste cells in the bottom of the taste buds are immature whereas cells in the top half are mature and express taste receptor genes. Cells in the bottom half of the taste bud express the gene sonic hedgehog (SHH), which is a marker of developing cells. TMEM44 taste cells are localized in the bottom half of the taste bud and the expression pattern of TMEM44 is similar to SHH. Therefore, we have predicted that TMEM44 cells, (which also express MFSD4) are immature and comprise, in part, developing taste cells. Supportive of this finding, a small fraction of taste cells expressing TMEM44 also express either TRPM5 (a marker of mature sweet, bitter and umami cells) or PKD1L3 (a marker of mature sour cells). Cells expressing both TMEM44 and TRPM5 (or PKD1L3) are therefore maturing into professional taste cells. By contrast, cells s in the top half of the taste bud are mature taste cells, do not express SHH, and express taste receptor genes for the sweet, bitter, umami, and sour taste receptors. Since all mature, professional taste cells and taste receptors are localized to the top half of the taste bud, the invention further includes methods for recovery of a fraction of taste bud cells that should include virtually all the functional taste cells including the salty taste cells. Particularly, recovery of the cells in the top half of the taste buds should include cells expressing the salty taste receptor.
Therefore, the invention and methods for assaying taste specific genes and identifying specific taste receptors and taste cell subsets have shown that the taste cells in the bottom half of the taste bud are immature, that the taste cells in the top half of the taste bud are mature and express genes for sweet, bitter, umami, and sour taste receptors, and further that SHH can be used as a marker of immature and developing taste cells at the bottom of the taste bud and that TMEM44 and MFSD4 are markers of immature and developing taste cells at the bottom of the taste bud.
It is predicted based on these results that a subpopulation of TMEM44 cells may be mature taste cells corresponding to a yet unidentified taste cell, e.g., metallic, fat, astringent, CO2, and the like and that a corresponding taste receptor and taste cell will be expressed or comprised in the top taste bud cells, since all other known taste receptors are expressed in the top taste bud cells. This is a reasonable assumption based on the results obtained by the inventors herein, especially since all other known professional, mature taste cells are expressed in the top of the taste bud.
More specifically, and further relating to the foregoing, and the results and data in the experimental examples and supporting figures, the inventors have gleaned the following information relating to several subsets of taste bud cells we have identified discussed above, including:
(i) with particular respect to TMEM44 cells, the inventors have found that these cells comprise about 40% of the taste bud cell population and are located towards the bottom of the taste bud. Also, we have identified other genes expressed by these cells or in the bottom of the taste bud including MFSD4 and Sonic Hedgehog (SHH). The latter is a cytokine involved in immature cell differentiation. For this reason, we predict that TMEM44 represents an immature taste cell population that includes stem cells that replenish the taste bud cells every 2-3 weeks in the human. While these cells are immature, they may still contain a subset of mature cells that may be responsible for taste such as salt sensation.
(ii) with particular respect to GPR113 cells, the inventors have discovered that these cells represent about 10% of the taste bud cell population, and are distinct from sweet, bitter, and umami taste cells, and are located in the top of the taste bud. They express T1R3 and TRPM5 but not the G protein alpha subunit gustudin (GNAT3), suggesting that they represent a novel taste cell population that detects a new taste modality such as fat. Other cells that express TRPM5 and T1R3 include sweet cells (also express TIR2) as well as umami cells (also express T1R1). Bitter cells (also express T2Rs) express TRPM5 but not T1R3. In contrast to GPR113 cells, sweet, bitter, and umami cells all express GNAT3.
(iii) with particular respect to PKD2L1 and PKD1L3 cells, reportedly responsible for sour taste sensation, the inventors have found that they comprise about 10° A of the taste bud cell population and are located in the top of the taste bud. Also, they have observed that these cells are heterogeneous and that there are distinct PKD2L1 and PKD1L3 ‘single positive’ cell populations in addition to a PKD2L1 and PKD1L3 ‘double positive’ cell population. This heterogeneity suggests that one of these subsets could represent a salt or another type of taste sensing cell.
(iv) with particular respect to other markers, the inventors' results suggest that there is another subset of taste cells ( ̃8% of the taste bud cell population) that does not express any of the following markers: TMEM44, TRPM5, PKD2L1 or PKD1L3, which may represent another taste e.g., CO2 or salt sensing cells. As disclosed while a primary focus of this invention was the elucidation of the salty taste receptor and that these efforts have been successful as the TRPML3 gene has been shown to be a salty taste receptor there may be other salty taste receptors.
The invention further includes the use of these unique taste cell populations as part of its strategies for identifying salty and other types of taste sensing cells such as fat, metallic, astringent, CO2, et al.
Also, the invention further encompasses the use of the genes reported herein as a specific means for confirming the identity of salt and other types of taste cells. In particular, the invention includes the use of the specific taste genes reported herein in methods of cell ablation as a means to identify the specific effect of the selective removal of distinct cell subsets on taste and other ancillary taste related functions already mentioned.
One way to identify the salt cell or other taste cell modality population is to use cell ablation. This technique employs diphtheria toxin under the control of a promoter of a gene expressed in one of the taste cell subsets described above to selectively eliminate this taste cell population, while leaving all other taste cell populations intact. Cell ablation has been used successfully in other laboratories to selectively eliminate sweet (T1R2) and sour (PKD2L1) taste cell populations (work of Charles Zuker). Therefore, ablation of the afore-identified taste cell subsets described herein and others and these of the resultant ablated animals in assays of function (such as nerve recoding and licking/behavior tests will enable evaluating whether the resulting mice still sense a particular type of tastant, e.g., salt, sour, basic, metallic et al or possess an ancillary taste cell function such as taste cell differentiation, proliferation, et al.
For example, in the case of TMEM44, assuming that TMEM44 ablated mice do not sense salt but still sense sweet, bitter, umami, and sour, this result would point this population, or a subset of cells within this population, as the salt sensing cell. Alternatively, if the resulting mice lack taste buds this would suggest that the mice lose the ability to detect all 5 taste qualities because TMEM44 is expressed in immature cells or cell ablation may elicit no effect.
Alternatively, in the case of GPR113, assuming that GPR113 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to GPR113 expressing cells as the salt sensing cells. (As noted TRPML3 cells have been shown to sense salt, therefore this outcome is not probable. More likely, another taste modality would be affected.)
Alternatively, in the case of PKD2L1 assuming that PKD2L1 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD2L1 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)
Still alternatively in the case of PKD1L3, assuming that PKD1L3 ablated mice cannot sense salt but still sense sweet, bitter, umami, and sour, this result would point to PKD1L3 expressing cells as the salt sensing cells. (Again, as TRPML3 cells have been shown to sense salt, this outcome is not probable. More likely, another taste modality would potentially be affected.)
Yet alternatively, if none of these mice are deficient in salt or another taste perception, this suggests that the putative population of taste cells (8%) that do not express any of the aforementioned markers could be the salt or another desired taste cell subset, e.g., a fat or metallic taste sensing cell, or that all or multiple mature taste cell populations are capable of sensing salt.
Another means encompassed by the invention for the use in identifying salt or other types of taste cells and further based on the information provided herein relating to taste specific genes and the identified unique taste cell subsets, and the various genes they express or do not express involves generating a single cell suspension from taste buds and then performing single cell analyses with electrophysiology (patch clamping) or calcium imaging coupled with single cell PCR to identify which population(s) responds to sodium or other ions or molecules.
With respect to the foregoing, there are two main models to account for salt sensation in taste buds:
The first model is the labeled line model. In this model, a single cell type is responsible for sensing a given taste quality. This is true for sweet, bitter, umami and sour. In this model, there is a dedicated cell type responsible for salt sensation. As discussed above, we have narrowed down the list of candidate salt sensing cells and described techniques we would use to identify the salt cell.
The second model is the across fibre model where there is not a single cell type responsible for salt sensation. Instead, all or multiple cell types sense salt. In this model, a cell surface molecule, such as a receptor or ion channel, expressed in all or multiple mature taste cells would constitute the salt sensor.
The way to distinguish between these two models and to determine which is valid is to perform ell ablation experiments such as are described above.
In yet another aspect of the invention, this invention provides three primate taste specific genes expressed specifically in primate taste cells that were identified as taste specific genes by gene chip analysis, and shown to function as sodium channels in the literature. These genes, NALCN, NKAIN3 and TRPML3 were identified as being enriched in the top fraction of taste buds along with all other known taste receptor genes. Therefore, these genes are probable candidates for encoding a salty taste receptor. As described in detail, and substantiated by extensive functional data in a related patent application filed on even date as this application, cells expressing one of these genes, TRPML3 has been shown in functional assays and transgenic animals to be necessary for salty taste perception and to correspond to a salty taste receptor.
These ion channels were selected as probable candidates for the salty taste receptor based on a compilation of the rationales provide herein including the primate microarray/gene chip methods, the top versus bottom gene selection technique (these ion channels are all expressed in the top half of taste buds) and that they are identified in the qPCR methods as being expressed by isolated human taste bud cells. In addition all of these genes were selected as they correspond to previously reported putative sodium channels (but not known to be expressed specifically in taste cells much less to be expressed specifically in the top portion of the taste bud where a salty taste cell would be predicted to be present. The gene expression profiles for these 3 ion channels detected according to the inventive method is as follows:
NALCN, (aka VGCNL1), top vs. bottom ratio of 7.2, and TB vs. LE ratio of 11.2; TRPML3 (aka MCOLN3) top vs. bottom ratio of 1.6, and vs. LE ratio of 10.2; and NKAIN3 (aka FAM7D) which has a top vs. bottom ratio of 1.5, and TB vs. LE ratio of 3.3.
There has been information reported about all of these ion channels in the literature. For example, in Cell. 2007 Apr. 20; 129(2):371-83, the neuronal channel NALCN reportedly contributes resting sodium permeability and is required for normal respiratory rhythm. Also, Lu et al., describe that NALCN as a sodium leak channel. Further, in Kim et al., J. Biol. Chem. 2007 Oct. 25; [Epub ahead of print] the authors teach that a gain-of-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. Also, Kim et al., (Id.) describes TRPML3 as a channel permeable to sodium after exposure of the channel to no/low sodium (consistent with saliva), and which was deemed by the inventors to potentially correlate with a putative salt receptor. Also, with respect to the NKAIN 3 gene, in Gorokhova et al., Human Mol. Genet. 2007 Oct. 15; 16(20):3394-410. Epub 2007 Jul. 2, this gene is reported as a member of a novel family of transmembrane proteins interacting with {beta} subunits of the Na,K-ATPase. Also, Gorokhova et al., (Id.) describe a Drosophila homologue of NKAIN3 as an amiloride-insensitive sodium channel, which the inventors also concluded would potentially be consistent with a putative salt receptor.
The identification of TRPML3 gene as encoding a polypeptide that is involved in salty taste and evidence that it functions as a salty taste receptor and the therapeutic applications of this gene are discussed extensively in the utility and PCT patent applications filed on the same date as this application, incorporated by reference in their entireties herein, and therefore is not discussed herein. However, this information is relevant as it substantiates the validity of the subject rationales for identifying and functionalizing the identified primate and human taste specific genes.
However, based thereon, NALCN, and NKAIN3 may still constitute other salty taste receptors expressed in taste bud cells and/or may modulate the function of TRPML3 and/or may associate with TRPML3 to produce a functional taste receptor. Based on the foregoing, NALCN, and NKAIN3 may constitute markers to identify salty taste receptor cells.
In addition, the inventors have obtained additional information concerning NALCN taste-specific gene identified by gene chip analysis and which gene was further found to be enriched in the top fraction of taste bud cells (along with all other known taste receptor genes).
Particularly, as described in the examples infra, it was demonstrated that NALCN is a taste-specific gene by end-point PCR using purified taste buds and lingual epithelial cells isolated by laser capture microdissection. It was found that NALCN is expressed in a novel, unique taste cell type distinct from sweet, bitter, umami, and sour taste cells by immunohistochemistry with a NALCN antibody.
Therefore, since NALCN is a taste-specific gene, is expressed in a novel taste cell type, (and has been reported to function as a sodium-channel), NALCN is a candidate salty taste receptor and/or a marker of the salty taste cell population. Since NALCN and TRPML3 are both expressed in novel taste cell types, NALCN and TRPML3 may be coexpressed in the same taste cell population. Accordingly, NALCN and TRPML3 may function together in a complex; or NALCN may function independently of TRPML3 as another salty taste receptor. For example, NALCN may function downstream of TRPML3 akin to how TRPM5 functions downstream of sweet, bitter, and umami receptors. In this manner, NALCN would be involved in the signal transduction pathway for salty taste but not constitute the primary salty taste sensory receptor.
This can be determined in mice. Rodents have 3 distinct taste cell types:
Type III cells correspond to sour cells (PKD2L1 positive, SNAP-25 positive);
Type II cells correspond to sweet, bitter, and umami cells (TRPM5-positive, IP3R3 positive); and
Type I cells have no defined function.
As shown in the examples infra, the inventors have demonstrated that NALCN is not expressed in IP3R3 cells (Type II) or SNAP-25 cells (Type III) in rodent. Thus, NALCN expression is implicated in Type I cells, and Type I cells are candidate salty taste cells.
However, alternatively, Type I cells may correspond to immature taste cells and if so, would likely be coexpressed with TMEM44/MFSD4 in an immature taste cell population.
Therefore, based on the foregoing information, the invention further encompasses NALCN as an additional salty (or other taste such as metallic or fat) taste receptor candidate gene and based thereon the use thereof as a marker to identify these taste cells.
In addition, since NALCN is a sodium ion channel, and is expressed in the top half of taste buds in cells that have an indeterminate taste function NALCN may control the resting membrane potential and excitability of the taste cells it is expressed in. Related thereto, compounds that enhance or inhibit function of the NALCN channel may regulate the excitability of salty taste cells, i.e., TRPML3 cells.
Based on this modulatory property, compounds that enhance or inhibit function of the NALCN channel may increase and decrease salt perception respectively, e.g., alone or in combination with TRPML3.
Also, NALCN may associate with TRPML3 to form a salty taste receptor. (As shown in the related application ablation of TRPML3 expressing taste cells in Varitint mice results in inhibition of salty taste perception in these rodents and in vitro electrophysiological assays using this ion channel have confirmed that it is a functional sodium channels and may be used to identify TRPML3 blockers and enhancers which should modulate salty taste).
Moreover, NALCN can be used as a marker of type I taste cells, which likely include salty taste cells. Alternatively, as type I taste cells may function as precursor cells for sweet, bitter, umami and sour taste cells, modulation of NALCN function may control taste cell differentiation and development into mature taste cell types.
In addition, because TMEM44 and MFSD4 are markers of immature taste cells, NALCN may be expressed in the subset of immature taste cells expressing TMEM44/MFSD4.
Further, because type I taste cells may also function as glial (support) cells, modulation of NALCN function may indirectly control the activity of sweet, bitter, umami, and sour cells and, as a result, sweet, bitter, umami, and sour taste.
Also, compounds that enhance or inhibit function of NALCN may increase and decrease salt perception respectively.
In yet another aspect, this invention provides specific assays for identifying a compound having potential in vivo application for modulating human salty taste. One method comprises the steps of (i) contacting a cell that expresses a gene encoding an ion channel, receptor or transporter identified as a putative salty taste affecting gene according to any one of the methods above, or a gene encoding a polypeptide possessing at least 90% sequence identity to the polypeptide encoded thereby, with at least one putative enhancer compound; (ii) assaying sodium conductance, receptor activity or sodium transport in the presence and absence of said putative enhancer; and (iii) identifying the compound as a potential salty taste enhancer based on whether it increases sodium conductance, the activity of said receptor or sodium transport. In various embodiments, the gene encodes an ion channel or the gene encodes a GPCR. Preferably, the gene is a human gene. More preferably, the method further includes testing the effect of the compound or a derivative thereof in a human taste test. Preferably, the selected compound promotes sodium ion transport into taste bud cells. The putative salty taste affecting gene may be expressed in an amphibian oocyte, or in a mammalian cell, preferably a Xenopus oocyte or a mammalian cell selected from the group consisting of a HEK293, HEK293T, Swiss3T3, CHO, BHK, NIH3T3, monkey L cell, African green monkey kidney cell, Ltk-cell and COS cell. Preferably, the putative salty taste affecting gene is expressed under the control of a regulatable promoter. The putative salty taste affecting gene may be expressed stably or transiently. In a preferred mode, the putative salty taste affecting gene is selected from tables 1-8 and in the Sequence Listing.
Recombinant Expression of Taste (Salty) Gene Identified Herein
To obtain high level expression of a cloned gene, such as those cDNAs encoding the subject genes, one typically subclones the gene into an expression vector that contains a strong promoter to direct transcription, a transcription/translation terminator, and if for a nucleic acid encoding a protein, a ribosome binding site for translational initiation. Suitable eukaryotic and prokaryotic promoters are well known in the art and described, e.g., in Sambrook et al., and Ausubel et al., supra. For example, bacterial expression systems for expressing the taste specific protein are available in, e.g., E. coli, Bacillus sp., and Salmonella (Palva et al., Gene 22:229-235 (1983); Mosbach et al., Nature 302:543-545 (1983). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available. For example, retroviral expression systems may be used in the present invention. As described infra, the subject putative salty taste affecting genes are preferably expressed in human cells such as HEK-293 cells which are widely used for high throughput screening.
Selection of the promoter used to direct expression of a heterologous nucleic acid depends on the particular application. The promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.
In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding the identified gene and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.
In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.
The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as MBP, GST, and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., c-myc. Sequence tags may be included in an expression cassette for nucleic acid rescue. Markers such as fluorescent proteins, green or red fluorescent protein, β-gal, CAT, and the like can be included in the vectors as markers for vector transduction.
Expression vectors containing regulatory elements from eukaryotic viruses are typically used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, retroviral vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+, pMTO10/A−, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the CMV promoter, SV40 early promoter, SV40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.
Expression of proteins from eukaryotic vectors can also be regulated using inducible promoters. With inducible promoters, expression levels are tied to the concentration of inducing agents, such as tetracycline or ecdysone, by the incorporation of response elements for these agents into the promoter. Generally, high level expression is obtained from inducible promoters only in the presence of the inducing agent; basal expression levels are minimal.
The vectors used in the invention may include a regulatable promoter, e.g., tet-regulated systems and the RU-486 system (see, e.g., Gossen & Bujard, Proc. Nat'l Acad. Sci USA 89:5547 (1992); Oligino et al., Gene Ther. 5:491-496 (1998); Wang et al., Gene Ther. 4:432-441 (1997); Neering et al., Blood 88:1147-1155 (1996); and Rendahl et al., Nat. Biotechnol. 16:757-761 (1998)). These impart small molecule control on the expression of the candidate target nucleic acids. This beneficial feature can be used to determine that a desired phenotype is caused by a transfected cDNA rather than a somatic mutation.
Some expression systems have markers that provide gene amplification such as thymidine kinase and dihydrofolate reductase. Alternatively, high yield expression systems not involving gene amplification are also suitable, such as using a baculovirus vector in insect cells, with a gene sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.
The elements that are typically included in expression vectors also include a replicon that functions in the particular host cell. In the case of E. coli, the vector may contain a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of eukaryotic sequences. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells, if necessary.
Standard transfection methods may be used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of the desired taste specific protein, which are then purified using standard techniques (see, e.g., Colley et al., J. Biol. Chem. 264:17619-17622 (1989); Guide to Protein Purification, in Methods in Enzymology, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according to standard techniques (see, e.g., Morrison, J. Bact. 132:349-351 (1977); Clark-Curtiss & Curtiss, Methods in Enzymology 101:347-362 (Wu et al., eds, 1983). Any of the well-known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, biolistics, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the gene.
After the expression vector is introduced into the cells, the transfected cells are cultured under conditions favoring expression of the gene. In some instances, such polypeptides may be recovered from the culture using standard techniques identified below.
Assays for Modulators of Putative Taste Cell Specific Gene Products Identified Herein
Modulation of a putative taste cell specific protein, can be assessed using a variety of in vitro and in vivo assays, including cell-based models as described above. Such assays can be used to test for inhibitors and activators of the protein or fragments thereof, and, consequently, inhibitors and activators thereof. Such modulators are potentially useful in medications or as flavorings to modulate salty or other taste modalities or taste in general or for usage as potential therapeutics for modulating a taste cell related function or phenotype involving one or several of the identified taste cell specific genes reported herein.
Assays using cells expressing the subject taste specific proteins, either recombinant or naturally occurring, can be performed using a variety of assays, in vitro, in vivo, and ex vivo, as described herein. To identify molecules capable of modulating activity thereof, assays are performed to detect the effect of various candidate modulators on activity preferably expressed in a cell.
The channel activity of ion channel proteins in particular can be assayed using a variety of assays to measure changes in ion fluxes including patch clamp techniques, measurement of whole cell currents, radiolabeled ion flux assays or a flux assay coupled to atomic absorption spectroscopy, and fluorescence assays using voltage-sensitive dyes or lithium or sodium sensitive dyes (see, e.g., Vestergarrd-Bogind et al., J. Membrane Biol. 88:67-75 (1988); Daniel et al., J. Pharmacol. Meth. 25:185-193 (1991); Hoevinsky et al., J. Membrane Biol. 137:59-70 (1994)). For example, a nucleic acid encoding a protein or homolog thereof can be injected into Xenopus oocytes or transfected into mammalian cells, preferably human cells such as HEK-293 cells. Channel activity can then be assessed by measuring changes in membrane polarization, i.e., changes in membrane potential.
A preferred means to obtain electrophysiological measurements is by measuring currents using patch clamp techniques, e.g., the “cell-attached” mode, the “inside-out” mode, and the “whole cell” mode (see, e.g., Ackerman et al., New Engl. J. Med. 336:1575-1595, 1997). Whole cell currents can be determined using standard methodology such as that described by Hamil et al., Pflugers. Archiv. 391:185 (1981).
Channel activity is also conveniently assessed by measuring changes in intracellular ion levels, i.e., sodium or lithium. Such methods are exemplified herein. For example, sodium flux can be measured by assessment of the uptake of radiolabeled sodium or by using suitable fluorescent dyes. In a typical microfluorimetry assay, a dye which undergoes a change in fluorescence upon binding a single sodium ion, is loaded into the cytosol of taste cell specific ion channel-expressing cells. Upon exposure to an agonist, an increase in cytosolic sodium is reflected by a change in fluorescence that occurs when sodium is bound.
The activity of the subject taste cell specific polypeptides can in addition to these preferred methods also be assessed using a variety of other in vitro and in vivo assays to determine functional, chemical, and physical effects, e.g., measuring the binding thereof to other molecules, including peptides, small organic molecules, and lipids; measuring protein and/or RNA levels, or measuring other aspects of the subject polypeptides, e.g., transcription levels, or physiological changes that affects the taste cell specific protein's activity. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as changes in cell growth or pH changes or changes in intracellular second messengers such as IP3, cGMP, or cAMP, or components or regulators of the phospholipase C signaling pathway. Such assays can be used to test for both activators and inhibitors of KCNB proteins. Modulators thus identified are useful for, e.g., many diagnostic and therapeutic applications.
In Vitro Assays
Assays to identify compounds with modulating activity on the subject genes are preferably performed in vitro. The assays herein preferably use full length protein according to the invention or a variant thereof. This protein can optionally be fused to a heterologous protein to form a chimera. In the assays exemplified herein, cells which express the full-length polypeptide are preferably used in high throughput assays are used to identify compounds that modulate gene function. Alternatively, purified recombinant or naturally occurring protein can be used in the in vitro methods of the invention. In addition to purified protein or fragment thereof, the recombinant or naturally occurring taste cell protein can be part of a cellular lysate or a cell membrane. As described below, the binding assay can be either solid state or soluble. Preferably, the protein, fragment thereof or membrane is bound to a solid support, either covalently or non-covalently. Often, the in vitro assays of the invention are ligand binding or ligand affinity assays, either non-competitive or competitive (with known extracellular ligands such as menthol). These in vitro assays include measuring changes in spectroscopic (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein.
Preferably, a high throughput binding assay is performed in which the protein is contacted with a potential modulator and incubated for a suitable amount of time. A wide variety of modulators can be used, as described below, including small organic molecules, peptides, antibodies, and ligand analogs. A wide variety of assays can be used to identify modulator binding, including labeled protein-protein binding assays, electrophoretic mobility shifts, immunoassays, enzymatic assays such as phosphorylation assays, and the like. In some cases, the binding of the candidate modulator is determined through the use of competitive binding assays, where interference with binding of a known ligand is measured in the presence of a potential modulator. In such assays the known ligand is bound first, and then the desired compound i.e., putative enhancer is added. After the particular protein is washed, interference with binding, either of the potential modulator or of the known ligand, is determined. Often, either the potential modulator or the known ligand is labeled.
In addition, high throughput functional genomics assays can also be used to identify modulators of cold sensation by identifying compounds that disrupt protein interactions between the taste specific polypeptide and other proteins to which it binds. Such assays can, e.g., monitor changes in cell surface marker expression, changes in intracellular calcium, or changes in membrane currents using either cell lines or primary cells. Typically, the cells are contacted with a cDNA or a random peptide library (encoded by nucleic acids). The cDNA library can comprise sense, antisense, full length, and truncated cDNAs. The peptide library is encoded by nucleic acids. The effect of the cDNA or peptide library on the phenotype of the cells is then monitored, using an assay as described above. The effect of the cDNA or peptide can be validated and distinguished from somatic mutations, using, e.g., regulatable expression of the nucleic acid such as expression from a tetracycline promoter. cDNAs and nucleic acids encoding peptides can be rescued using techniques known to those of skill in the art, e.g., using a sequence tag.
Proteins interacting with the protein encoded by a cDNA according to the invention can be isolated using a yeast two-hybrid system, mammalian two hybrid system, or phage display screen, etc. Targets so identified can be further used as bait in these assays to identify additional components that may interact with the particular ion channel, receptor or transporter protein which members are also targets for drug development (see, e.g., Fields et al., Nature 340:245 (1989); Vasavada et al., Proc. Nat'l Acad. Sci. USA 88:10686 (1991); Fearon et al., Proc. Nat'l Acad. Sci. USA 89:7958 (1992); Dang et al., Mol. Cell. Biol. 11:954 (1991); Chien et al., Proc. Nat'l Acad. Sci. USA 9578 (1991); and U.S. Pat. Nos. 5,283,173, 5,667,973, 5,468,614, 5,525,490, and 5,637,463).
Cell-Based In Vivo Assays
In preferred embodiments, wild-type and mutant taste cell specific proteins are expressed in a cell, and functional, e.g., physical and chemical or phenotypic, changes are assayed to identify modulators that modulate function or which restore the function of mutant genes, e.g., those having impaired gating function. Cells expressing proteins can also be used in binding assays. Any suitable functional effect can be measured, as described herein. For example, changes in membrane potential, changes in intracellular lithium or sodium levels, and ligand binding are all suitable assays to identify potential modulators using a cell based system. Suitable cells for such cell based assays include both primary cells and recombinant cell lines engineered to express a protein. The subject taste cell specific proteins therefore can be naturally occurring or recombinant. Also, as described above, fragments of these proteins or chimeras with ion channel activity can be used in cell based assays. For example, a transmembrane domain of a ion channel or GPCR or transporter gene according to the invention can be fused to a cytoplasmic domain of a heterologous protein, preferably a heterologous ion channel protein. Such a chimeric protein would have ion channel activity and could be used in cell based assays of the invention. In another embodiment, a domain of the taste cell specific protein, such as the extracellular or cytoplasmic domain, is used in the cell-based assays of the invention.
In another embodiment, cellular polypeptide levels of the particular target taste polypeptide can be determined by measuring the level of protein or mRNA. The level of protein or proteins related to ion channel activation are measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatic ally labeled antibodies, and the like, as described herein.
Alternatively, protein expression can be measured using a reporter gene system. Such a system can be devised using a promoter of the target gene operably linked to a reporter gene such as chloramphenicol acetyltransferase, firefly luciferase, bacterial luciferase, beta-galactosidase and alkaline phosphatase. Furthermore, the protein of interest can be used as an indirect reporter via attachment to a second reporter such as red or green fluorescent protein (see, e.g., Mistili & Spector, Nature Biotechnology 15:961-964 (1997)). The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.
In another embodiment, a functional effect related to signal transduction can be measured. An activated or inhibited ion channel or GPCR or transporter will potentially alter the properties of target enzymes, second messengers, channels, and other effector proteins. The examples include the activation of phospholipase C and other signaling systems. Downstream consequences can also be examined such as generation of diacyl glycerol and IP3 by phospholipase C.
Assays for ion channel activity include cells that are loaded with ion or voltage sensitive dyes to report activity, e.g., by observing sodium influx or intracellular sodium release. Assays for determining activity of such receptors can also use known agonists and antagonists for these receptors as negative or positive controls to assess activity of tested compounds. In assays for identifying modulatory compounds (e.g., agonists, antagonists), changes in the level of ions in the cytoplasm or membrane voltage will be monitored using an ion sensitive or membrane voltage fluorescent indicator, respectively. Among the ion-sensitive indicators and voltage probes that may be employed are those disclosed in the Molecular Probes 1997 Catalog. Radiolabeled ion flux assays or a flux assay coupled to atomic absorption spectroscopy can also be used.
Animal Models
Animal models also find potential use in screening for modulators of gene activity. Transgenic animal technology results in gene overexpression, whereas siRNA and gene knockout technology results in absent or reduced gene expression following homologous recombination with an appropriate gene targeting vector. The same technology can also be applied to make knock-out cells. When desired, tissue-specific expression or knockout of the target gene may be necessary. Transgenic animals generated by such methods find use as animal models of responses related to the gene target. For example such animals expressing a gene or genes according to the invention may be used to derive supertaster phenotypes such as for use in screening of chemical and biological toxins, rancid/spoiled/contaminated foods, and beverages or for screening for therapeutic compounds that modulate taste stem cell differentiation.
Knock-out cells and transgenic mice can be made by insertion of a marker gene or other heterologous gene into an endogenous gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting an endogenous gene with a mutated version of the target gene, or by mutating an endogenous gene, e.g., by exposure to known mutagens.
A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (Robertson, ed., 1987).
Candidate Modulators
The compounds tested as modulators of the putative taste related proteins or other non-taste related functions and phenotypes involving taste cells can be any small organic molecule, or a biological entity, such as a protein, e.g., an antibody or peptide, a sugar, a nucleic acid, e.g., an antisense oligonucleotide or a ribozyme, or a lipid. Alternatively, modulators can be genetically altered versions of a protein. Typically, test compounds will be small organic molecules, peptides, lipids, and lipid analogs. In one embodiment, the compound is a menthol analog, either naturally occurring or synthetic.
Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St. Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.
In one preferred embodiment, high throughput screening methods involve providing a combinatorial small organic molecule or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.
A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks.
Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept. Prot. Res. 37:487-493 (1991) and Houghton et al., Nature 354:84-88 (1991)). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (e.g., PCT Publication No. WO 91/19735), encoded peptides (e.g., PCT Publication No. WO 93/20242), random bio-oligomers (e.g., PCT Publication No. WO 92/00091), benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)), nucleic acid libraries (see Ausubel, Berger and Sambrook, all supra), peptide nucleic acid libraries (see, e.g., U.S. Pat. No. 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science, 274:1520-1522 (1996) and U.S. Pat. No. 5,593,853), small organic molecule libraries (see, e.g., benzodiazepines, Baum C&EN, January 18, page 33 (1993); isoprenoids, U.S. Pat. No. 5,569,588; thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974; pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No. 5,288,514, and the like).
Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville Ky., Symphony, Rainin, Woburn, Mass., 433A Applied Biosystems, Foster City, Calif., 9050 Plus, Millipore, Bedford, Mass.). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, Mo., ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, Pa., Martek Biosciences, Columbia, Md.). C. Solid State and Soluble High Throughput Assays.
Additionally soluble assays can be effected using a target taste specific protein, or a cell or tissue expressing a target taste protein disclosed herein, either naturally occurring or recombinant. Still alternatively, solid phase based in vitro assays in a high throughput format can be effected, where the protein or fragment thereof, such as the cytoplasmic domain, is attached to a solid phase substrate. Any one of the assays described herein can be adapted for high throughput screening, e.g., ligand binding, calcium flux, change in membrane potential, etc.
In the high throughput assays of the invention, either soluble or solid state, it is possible to screen several thousand different modulators or ligands in a single day. This methodology can be used for assaying proteins in vitro, or for cell-based or membrane-based assays comprising an protein. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100-about 1500 different compounds. It is possible to assay many plates per day; assay screens for up to about 6,000, 20,000, 50,000, or more than 100,000 different compounds are possible using the integrated systems of the invention.
For a solid state reaction, the protein of interest or a fragment thereof, e.g., an extracellular domain, or a cell or membrane comprising the protein of interest or a fragment thereof as part of a fusion protein can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage e.g., via a tag. The tag can be any of a variety of components. In general, a molecule which binds the tag (a tag binder) is fixed to a solid support, and the tagged molecule of interest is attached to the solid support by interaction of the tag and the tag binder.
A number of tags and tag binders can be used, based upon known molecular interactions well described in the literature. For example, where a tag has a natural binder, for example, biotin, protein A, or protein G, it can be used in conjunction with appropriate tag binders (avidin, streptavidin, neutravidin, the Fc region of an immunoglobulin, etc.) Antibodies to molecules with natural binders such as biotin are also widely available and appropriate tag binders; see, SIGMA Immunochemicals 1998 catalogue SIGMA, St. Louis Mo.).
Similarly, any haptenic or antigenic compound can be used in combination with an appropriate antibody to form a tag/tag binder pair. Thousands of specific antibodies are commercially available and many additional antibodies are described in the literature. For example, in one common configuration, the tag is a first antibody and the tag binder is a second antibody which recognizes the first antibody. In addition to antibody-antigen interactions, receptor-ligand interactions are also appropriate as tag and tag-binder pairs. For example, agonists and antagonists of cell membrane receptors (e.g., cell receptor-ligand interactions such as transferrin, c-kit, viral receptor ligands, cytokine receptors, chemokine receptors, interleukin receptors, immunoglobulin receptors and antibodies, the cadherin family, the integrin family, the selectin family, and the like; see, e.g., Pigott & Power, The Adhesion Molecule Facts Book I (1993). Similarly, toxins and venoms, viral epitopes, hormones (e.g., opiates, steroids, etc.), intracellular receptors (e.g. which mediate the effects of various small ligands, including steroids, thyroid hormone, retinoids and vitamin D; peptides), drugs, lectins, sugars, nucleic acids (both linear and cyclic polymer configurations), oligosaccharides, proteins, phospholipids and antibodies can all interact with various cell receptors.
Synthetic polymers, such as polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, and polyacetates can also form an appropriate tag or tag binder. Many other tag/tag binder pairs are also useful in assay systems described herein, as would be apparent to one of skill upon review of this disclosure.
Common linkers such as peptides, polyethers, and the like can also serve as tags, and include polypeptide sequences, such as poly gly sequences of between about 5 and 200 amino acids. Such flexible linkers are known to persons of skill in the art. For example, poly(ethylene glycol) linkers are available from Shearwater Polymers, Inc. Huntsville, Ala. These linkers optionally have amide linkages, sulfhydryl linkages, or heterofunctional linkages.
Tag binders are fixed to solid substrates using any of a variety of methods currently available. Solid substrates are commonly derivatized or functionalized by exposing all or a portion of the substrate to a chemical reagent which fixes a chemical group to the surface which is reactive with a portion of the tag binder. For example, groups which are suitable for attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl groups. Aminoalkylsilanes and hydroxyalkylsilanes can be used to functionalize a variety of surfaces, such as glass surfaces. The construction of such solid phase biopolymer arrays is well described in the literature. See, e.g., Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1963) (describing solid phase synthesis of e.g., peptides); Geysen et al., J. Immunol. Meth. 102:259-274 (1987) (describing synthesis of solid phase components on pins); Frank & Doring, Tetrahedron 44:6031-6040 (1988) (describing synthesis of various peptide sequences on cellulose disks); Fodor et al., Science, 251:767-777 (1991); Sheldon et al., Clinical Chemistry 39(4):718-719 (1993); and Kozal et al., Nature Medicine 2(7):753-759 (1996) (all describing arrays of biopolymers fixed to solid substrates). Non-chemical approaches for fixing tag binders to substrates include other common methods, such as heat, cross-linking by UV radiation, and the like.
Having described the invention supra, the examples provided infra further illustrate some preferred embodiments of the invention. These examples are provided only for purposes of illustration and should not be construed as limiting the subject invention.
Practical Applications of the Invention
Compounds which modulate, preferably enhance the activity of genes identified herein in the Tables have important implications in modulation of human salty taste and potentially other taste modalities or taste in general. In addition these compounds are potentially useful in therapeutic applications involving other taste cell related functions and phenotypes such as taste cell turnover, digestive diseases, digestive function, regulation of metabolism, regulation of immunity in the oral cavity and/or digestive system and the like.
Compounds which activate taste ion channels in taste papillae on the tongue can be used to enhance salt sensation by promoting Na+ transport into taste bud cells. This has obvious consumer applications in improving the taste and palatability of low salt foods and beverages.
In addition the genes and gene products herein can be used as markers for identifying, isolating or enriching specific taste cell types or lineages including sweet, bitter, umami, sour, salt, fat, metallic et al.
Further the genes and gene products specific to taste cells identified herein can be used to identify compounds that modulate apoptosis of taste cells, modulate transcription factors that control taste receptor expression, modulate bitter receptor expression e.g., to alleviate the off-taste of some vegetables, medicines, coffee, and the like; modulate autocrine/paracrine modulation of taste cell development, prolong taste bud lifetime, yield supertaster animal phenotypes for use in screening such as for bioterrorism or animals for use in screening for compounds that induce the activation and differentiation of stem cells into taste cells in vivo.
In addition the subject genes and gene products and cells which express may be used to identify ancillary taste receptors or primary taste receptors such as fat or metallic taste cells.
Also the subject genes, gene products and cells which express same can be used in screens to identify compounds that affect digestive function such s gastric motility, food detection, food absorption or the production of digestive fluids, peptides, hormones or enzymes such as Glucagon Like Peptide-1, Glucose Dependent Insulinotropic polypeptide, pepsin, secretin, amylase, saliva, et al.
Also the subject genes, gene products and cells which express same may be used to screen for compounds that affect trafficking of taste receptors to and from the apical membrane/taste pore region to enhance or repress general or specific tastes, regulation of taste cell action potential firing frequency/membrane potential to control the intensity of general or specific tastes, regulation of neurotransmitter release to afferent nerve to control the intensity of general or specific taste, and autocrine/paracrine modulation of taste receptor function.
Further the subject genes, gene products and cells which express same can be used to identify compounds that regenerate taste cells such as in geriatric individuals or patients with cancer, chemotherapy radiation, injury or surgery affecting taste, drug-induced dysgeusia, ageusia, and for alleviating taste bud loss.
Still further the subject genes and gene products and cells which express same can be used to screen for compounds that affect oral hygiene, halitosis, detoxification of noxious substances in the oral cavity, and neutralization/elimination of bacteria, viruses, and other immunogens in the saliva/mouth or digestive tract.
Yet additionally the subject genes, gene products and cells which express same can be used in screens to identify compounds that affect saliva production and composition and treatment of dry mouth in conditions such as xerostomia and Sjogren's disease, in autoimmune or inflammatory gastrointestinal diseases, IBD, ulcerative colitis, and diverticulitis and cancers affecting the oral cavity and digestive tract.
The following examples were effected using the materials and methods described supra. These examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the subject invention, and are not intended to limit the scope of what is regarded as the invention.
EXAMPLES
Example 1
This experimental example the results of which are contained in FIG. 1 is exemplary of the results obtained with laser capture microdissection (LCM) on primate fungiform (FG) taste tissue (top row) and lingual epithelium (LE) non-taste tissue (bottom row). Shown in the top row, in the left image is FG tissue before LCM with a single FG taste bud. The middle image in FIG. 1 shows FG tissue after LCM where single FG taste bud has been removed. The right image in FIG. 1 shows collected and isolated FG taste bud used for molecular biology experiments to discover taste-specific genes. Shown in the bottom row, in the left image is tissue before LCM with LE from anterior tongue surface. The middle image in the same Figure shows tissue after LCM where a region of LE has been removed. Shown in the right image is the collected and isolated LE region used for molecular biology experiments to discover taste-specific genes.
Example 2
This experimental example the results of which are contained in FIG. 2 is exemplary of PCR quality control of primate taste and lingual cells collected by LCM. It can be seen therefrom that taste bud cells (TB), but not lingual epithelial cells (LE), specifically express the known taste-specific genes T1R2 (a component of the sweet receptor), PLCbeta2 (an enzyme involved in sweet, bitter, and umami taste detection), and GNAT3 (i.e. gustducin, a G-protein alpha subunit involved in sweet, bitter, and umami taste detection). By contrast, it can be seen that both taste and lingual cells express the ubiquitous housekeeping genes GAPDH and beta-actin, indicating that taste and lingual cell RNA is intact and of high quality. ‘+’ indicates reverse transcription and ‘−’ indicates no reverse transcription was performed.
Example 3
This example relates to the experiment contained in FIG. 3. Shown therein is an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate circumvallate (CV) taste tissue. It can be seen that TRPM5 (top; green) is not detectable in cells expressing PKD1L3 (middle; red). The overlay of TRPM5 and PKD1L3 signals is depicted in the bottom image. It can further be seen that TRPM5 and PKD1L3 signals are present in different taste cells. Particularly, TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.
Example 4
This example which is contained in FIG. 4 shows a double labeling in situ hybridization illustrating coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate circumvallate (CV) taste tissue. It can be seen therein that PKD2L1 (top; green) is coexpressed in cells expressing PKD1L3 (middle; red). The overlay of PKD2L1 and PKD1L3 signals is depicted in the bottom image in yellow. It can further be seen that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.
Example 5
This example relates to the experiments contained in FIG. 5. This experiment is an example of double labeling in situ hybridization illustrating expression of TRPM5 and PKD1L3 in different taste cells in primate fungiform (FG) taste tissue. It can be seen therein that TRPM5 (left; purple stain) is not detectable in cells expressing PKD1L3 (middle; red). The overlay of TRPM5 and PKD1L3 signals is depicted in the left image. It can further be seen therein that TRPM5 and PKD1L3 signals are present in different taste cells. Particularly, the Figure shows that TRPM5 is expressed in cells responsible for sweet, bitter, and umami taste, whereas PKD1L3 is expressed in cells responsible for sour taste.
Example 6
This example relates to the results of a double labeling in situ hybridization experiment contained in FIG. 6. The Figure illustrates the coexpression of PKD2L1 and PKD1L3 in the same taste cells in primate fungiform (FG) taste tissue. It can further be seen that PKD2L1 (left; purple stain) is coexpressed in cells expressing PKD1L3 (middle; red). The overlay of PKD2L1 and PKD1L3 signals is depicted in the right image. The Figure further reveals that that both PKD2L1 and PKD1L3 signals are present in the same taste cells. Both PKD2L1 and PKD1L3 are expressed in cells responsible for sour taste.
Example 7
This example relates to the double labeling hybridization experiment contained in FIG. 7. This experiment which again involved double label in situ hybridization of primate circumvallate papilla revealed that FAM26A (purple color; left image) colocalizes with TRPM5 (red; middle image). The results contained in the figure also show that FAM26A cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
Example 8
This example relates to the double label in situ hybridization experiment contained in FIG. 8. This hybridization experiment which again used primate circumvallate papilla revealed that the taste cell specific gene GPR113 (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can be seen from the figure that that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express GPR113 (merged image on the right), but that all GPR113 cells express TRPM5. Two taste buds are shown.
Example 9
The experiment contained in FIG. 9 is another double hybridization experiment using primate circumvallate papilla cells. The results contained in the Figure reveal that MCTP1 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can be seen that MCTP1 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the Figure.
Example 10
This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results in FIG. 10 show that TMEM16G (purple color; left image) colocalizes with a subset of TRPM5 cells (red; middle image). It can also be seen that only a fraction of cells expressing TRPM5, a marker of sweet, umami, and bitter taste cells, also express TMEM16G (merged image on the right), but that all TMEM16G cells express TRPM5.
Example 11
This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results contained in FIG. 11 show that TMEM44 (purple color; left image), a taste cell specific gene, does not colocalize with TRPM5 (red; middle image). It can be seen from the results in the figure that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown in the figure.
Example 12
This example relates to the double label in situ hybridization of primate circumvallate papilla cells contained in FIG. 12. The results contained therein reveal that TMEM44 (purple color; left image) does not colocalize with PKD1L3 (red; middle image). It can also be seen that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the right). Two taste buds are shown.
Example 13
This example relates to another double label in situ hybridization of primate circumvallate papilla cells. The results which are contained in FIG. 13 show that TUSC3 (purple color; left image), a taste cell specific gene, colocalizes with TRPM5 (red; middle image). It can also be seen that TUSC3 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
Example 14
This example shows that GPR113 is not expressed in T1R1 umami cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R1 (red; middle image). Note that GPR113 and T1R1, a marker of umami cells, are in different taste cells (merged image on the right).
Example 15
This example shows that GPR113 is not expressed in T1R2 sweet cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T1R2 (red; middle image). Note that GPR113 and T1R2, a marker of sweet cells, are in different taste cells (merged image on the right).
Example 16
This example shows that GPR113 is expressed in a subset of T1R3 cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does colocalize with a subset of T1R3 cells (red; middle image). Note that GPR113 is always expressed in cells with T1R3, but that there are T1R3 cells that do not express GPR113 (merged image on the right). These T1R3 cells that do not express GPR113 likely coexpress either T1R1 or T1R2. The T1R3 only cells are a new population of taste cells that coexpress GPR113.
Example 17
This example shows that GPR113 is not expressed in T2R bitter cells. Double label in situ hybridization of primate circumvallate papilla showing that GPR113 (purple color; left image) does not colocalize with T2R (red; middle image). Note that GPR113 and T2R, a marker of bitter cells, are in different taste cells (merged image on the right).
Example 18
This example contains an experiment that shows that TMEM44 is not expressed in TRPM5 or PKD1L3 cells in fungiform taste buds. Double label in situ hybridization experiments were conducted using primate fungiform papilla from the front of the tongue showing that TMEM44 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) or PKD1L3 (red; middle bottom image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, or PKD1L3, a marker of sour cells, in the merged images on the right.
Example 19
This example contains an experiment that shows that TMEM44 is not expressed in TRPM5 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with TRPM5 (red cells; middle image). Note that TMEM44 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the bottom).
Example 20
This example contains experiments that show that TMEM44 is not expressed in PKD1L3 cells in circumvallate papilla. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (green cells; top image) does not colocalize with PKD1L3 (red cells; middle image). Note that TMEM44 cells do not express PKD1L3, a marker of sour taste cells (merged image on the bottom).
Example 21
This example contains experiments that reveal that TMEM44 cells extend processes to the taste pore. Double label histology experiment of primate circumvallate papilla at the back of the tongue. Cytokeratin 19 protein (green; left image) is present in cells expressing TMEM44 RNA (red; middle image). Note that TMEM44 cells extend processes to the taste pore facing the saliva. Asterisk denotes a TMEM44 cell nucleus and white arrows denote the apical process of this same cell extending to the taste pore (merged image on the right). Thus, TMEM44 cells are sensory taste cells that can sample the saliva for tastants. Cytokeratin 19 is a marker of all taste cells.
Example 22
This example shows that FAM26B is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that FAM26B (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26B cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
Example 23
This example shows that SLC4A11 is expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that SLC4A11 (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that SLC4A11 cells express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right).
Example 24
This example shows that MFSD4 is not expressed in TRPM5 cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with TRPM5 (red; middle image). Note that MFSD4 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image on the right). Two taste buds are shown.
Example 25
This example shows that MFSD4 and TMEM44 are expressed in the same taste cells. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. TMEM44 (top blue/purple color) and MFSD4 (bottom blue/purple color) do not colocalize with TRPM5 (red color top and bottom images) and are expressed in taste cells in the bottom halves of taste buds. The equivalent localization, abundance, and morphology of TMEM44 and MFSD4 taste cells indicates that these cells are identical and that both TMEM44 and MFSD4 genes are expressed in the same taste cell type FIG. 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter, or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.
Example 26
Example 26 shows that ASCL1 is expressed in sour taste cells but not sweet, bitter, or umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that ASCL1 (blue/purple color; left images) does not colocalize with TRPM5 (red; middle top image) but does colocalize with PKD1L3 (red; middle bottom image). Note that ASCL1 cells do not express TRPM5, a marker of sweet, umami, and bitter taste cells, but do express PKD1L3, a marker of sour cells, in the merged images on the right.
Example 27
KIT is expressed in T1R1 umami taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that KIT (blue/purple color; left images) colocalizes with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2nd row), does colocalize with T1R3 (red; middle image 3rd row), and does not colocalize with T2Rs (red; middle image bottom row). Note that KIT cells express T1R1 and T1R3, markers of umami taste cells, but not T1R2 or T2Rs, markers of sweet and bitter cells respectively, in the merged images on the right.
Example 28
IKBKAP is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that IKBKAP (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that IKBKAP cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).
Example 29
This experiment revealed that the taste specific gene LOC285965 is expressed in T1R3 only taste cells. Double label in situ hybridization of primate circumvallate papilla from the back of the tongue showing that LOC285965 (blue/purple color; left images) does not colocalize with T1R1 (red; middle image top row), does not colocalize with T1R2 (red; middle image 2nd row), does colocalize with T1R3 (red; middle image 3rd row), and does not colocalize with T2Rs (red; middle image bottom row). Note that LOC285965 cells express T1R3, but not T1R1, T1R2 or T2Rs, markers of umami, sweet and bitter cells respectively, in the merged images on the right.
Example 30
This experiment revealed that the taste specific gene SV2B is expressed in PKD1L3 sour taste cells. Double fluorescent label in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SV2B (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) but does colocalize with PKD1L3 (red; middle image bottom). Note that SV2B cells express PKD1L3, a marker of sour taste cells (merge image bottom) but do not express TRPM5, a marker of sweet, umami, and bitter taste cells (merged image top).
Example 31
This experiment revealed that the taste specific gene MFSD4 is expressed in a unique taste cell type. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 (blue/purple color; left image) does not colocalize with PKD1L3 or TRPM5 (red; middle images) but is expressed in a unique taste cell type. Note that MFSD4 cells do not express PKD1L3, a marker of sour taste cells or TRPM5, a marker of sweet, umami, and bitter taste cells (merged images on the right). Two taste buds each are shown for PKD1L3 & TRPM5 double labels.
Example 32
This experiment revealed that the taste specific genes MFSD4 and TMEM44 are expressed in the same taste cell population. Double label in situ hybridization of primate circumvallate papilla showing that MFSD4 and TMEM44 are expressed in the same taste cell population. MFSD4 (left; green) and TMEM44 (middle; red) signals are present in the same taste cells (right; merged image).
Example 33
This experiment the results of which are contained in FIG. 33 revealed that SHH is expressed in immature taste cells in the bottom of the taste bud. Double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that SHH (blue/purple color; left images) does not colocalize with TRPM5 (red; middle image top) or PKD1L3 (red; middle image bottom). Note that SHH cells do not express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image top) or PKD1L3 (merge; right image bottom). Both TRPM5 and PKD1L3 genes are expressed in professional taste cells.
Example 34
This experiment the results of which are contained in FIG. 34 show that the taste specific genes TMEM44 and SHH are expressed in immature taste cells at the bottom of the taste bud. In situ hybridization of primate circumvallate papilla at the back of the tongue showing that TMEM44 (blue/purple color; top 3 images) is expressed in cells towards the base of the taste bud. A similar expression pattern was observed with SHH (blue/purple color; bottom 3 images). Since SHH is marker of immature, developing taste cells, these data indicate that TMEM44 is expressed in and is a marker of immature taste cells.
Example 35
This experiment relates to the experiment in FIG. 35. In situ hybridization of primate circumvallate papilla at the back of the tongue showing SHH (blue/purple color) expression at the base of the taste bud and PKD1L3 (red color) expression towards the top of the taste bud. This figure contains a schematic model of taste cell development which indicates that three is a gradient of SHH expression from high levels at the base of the taste bud (immature cells) to low levels at the top of the taste bud (mature cells). As SHH expression levels decrease, expression of taste receptor genes such as TRPM5 and PKD1L3 increase. Thus, an opposite gradient of taste cell maturation exists where taste cells progressively mature and express taste receptor genes as they differentiate from the bottom to the top of the taste bud.
Example 36
This experiment the results of which are contained in FIG. 36 show that a small fraction of TMEM44 cells express TRPM5 or PKD1L3 as they differentiate into mature taste cells. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and TMEM44 riboprobes (left pie chart) or PKD1L3 and TMEM44 riboprobes (right pie chart). Taste cells expressing TRPM5 (blue graph region; left pie chart), TMEM44 (magenta graph region; left pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; left pie chart) genes were counted and graphed in pie charts. Taste cells expressing PKD1L3 (blue graph region; right pie chart), TMEM44 (magenta graph region; right pie chart), or TRPM5 plus TMEM44 (labeled ‘both’ and yellow graph region; right pie chart) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses. A small fraction of TMEM44 cells also express TRPM5 or PKD1L3, indicating that these cells are differentiating from an immature state (TMEM44 only) to a mature state (TRPM5 or PKD1L3 only). Inset shows example of CV taste bud labeled with TMEM44 (green) and TRPM5 (red). Note cell indicated with arrow that coexpresses both TMEM44 and TRPM5 (yellow).
Example 37
This experiment the results of which are contained in FIG. 37 reveals that mature taste cells do not coexpress markers for distinct taste modalities. Double label in situ hybridization of primate circumvallate papilla was performed using TRPM5 and PKD1L3. Taste cells expressing TRPM5 (blue graph region), PKD1L3 (magenta graph region), or TRPM5 plus PKD1L3 (labeled ‘both’ and yellow graph region which is too small to see any yellow segment due to the near absence of cells within this category) genes were counted and graphed in the pie chart. Total number of counted cells is listed below the pie chart in parentheses.
Example 38
Top Versus Bottom Gene Expression in the Taste Buds
The experiments and results herein relate to a systematic method for assigning gene expression patterns within the primate taste bud for taste bud-specific genes. Specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud, the inventors were able to classify genes into one of several functional classes that include taste receptor genes. A subset of genes in this classification is likely to encode taste receptors that include those for salty taste and other yet to be defined taste specificities.
As explained previously, the rationale for comparing gene expression between the top and bottom of the primate taste bud arose from the histological localization of mRNAs for a number of candidate taste receptor genes. Expression of a subset of these genes appeared to be localized at the bottom portion of the taste bud while other genes were predominantly expressed at the top of the taste bud. These patterns of expression are exemplified by the TMEM44 and TRPM5 genes which are expressed at the bottom and top of the taste bud respectively, see FIG. 38.
In order to get more information on gene expression in both the top and bottom fractions of the taste bud we undertook an experiment to isolate the corresponding fractions of primate taste buds using laser capture microdissection (LCM). As described previously, LCM involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, we can readily identify these structures in sections of primate tongue. In this specific example tissue collection was limited to taste buds in circumvallate papillae and then to only taste buds that were sectioned sagittally and at the taste pore. We reasoned it was only from this type of section would we be able to reliably isolate top and bottom fractions. An example of sections used in sample collection is shown in FIG. 39.
Multiple LCM preparations from each of 4 animals were pooled (4 top samples, 4 bottom samples,  ̃5000 cells per sample) RNA extracted and analyzed using Affymetrix whole genome macaque Gene Chips to obtain global mRNA expression profiles for the top and bottom fractions.
The gene expression data was queried to obtain three sets of genes. The first and second sets are genes that are expressed at a higher level in the top or bottom of the primate taste bud relative to the bottom or top respectively. Top-specific genes were listed in one group of genes, and bottom specific genes are listed in a second group. Accordingly, these lists contain top enriched and bottom enriched mRNAs. The third set of genes was also identified as being expressed at a higher level in the top of the primate taste bud relative to surrounding lingual epithelium.
An exemplary experiment validating this methodology is contained in FIG. 38. This experiment contains an experiment showing that levels of gene expression define two compartments in primate taste buds. To create this overlay image sagittal sections of primate taste buds were initially stained with DAPI (4′,6-diamidino-2-phenylindole) to visualize cell nuclei; blue color. Double label in situ hybridization images of the same sections for TMEM44; green color and TRPM5+PKD1L3; pink color were then added. The overlay image shows that TMEM44 expression is restricted to the bottom third of each of the four taste buds shown and that TRPM5+PKD1L3 expression occurs predominantly in the upper regions of each of the taste buds.
FIG. 39 shows an exemplary experiment showing laser capture microdissection of top and bottom regions of primate taste buds. Panel) contains a methyl blue stained section A of macaque circumvallate taste buds. Panel B shows Section A following excision of bottom fraction of taste buds. Panel C contains the bottom fraction of taste buds. Panel D shows Section A following excision of bottom and top fractions of taste buds. Panel E shows the Top fraction of taste buds. Note, top and bottom fractions were only collected from taste buds exhibiting optimal morphology in section. In the example shown, the taste bud labeled with an arrow was excluded due to suboptimum sectioning or morphology.
The results obtained by the inventors revealed that taste receptor genes are expressed predominantly at the top of the taste bud. In contrast to what has been reported, the data of the inventors suggests that known taste receptor genes are expressed at higher level in the top fraction of the taste buds. Therefore, this technique should allow for other yet to be identified taste receptor genes to be represented in the top-enriched set of genes.
In addition, there is an apparent functional classification that can be made based on top versus bottom taste bud cells. The gene expression profiles of the top and bottom fractions of the taste bud suggest distinct functions for cells in each compartment. Functional classes of genes represented in the top cells indicate that these are mature sensory cells whereas those expressed in the bottom cells indicate these are immature progenitor cells associated with a basement membrane containing cellular environment. Examples of top specific functional classes include taste receptors, taste-specific signal transduction components and receptors. Examples of bottom-specific functional classes include extracellular metric components, growth factors and cell-cycle associated proteins.
Also, based thereon, these techniques allow for the identification of additional taste bud-specific genes. By fractionating the taste buds into top and bottom compartments the inventors were able to increase the sensitivity of mRNA detection in each compartment by a factor of approximately two. This enables us to identify another set of taste bud specific genes
Example 39
This experiment the results of which are contained in FIG. 40 establish that distinct cell populations PKD2L1, PKD1L3 and PKD2L1 plus PKD1L3. Double label in situ hybridization of primate fungiform (FG; left) and circumvallate (CV; right) was performed using PKD2L1 and PKD1L3 riboprobes. Taste cells expressing PKD2L1 (blue graph regions), PKD1L3 (magenta graph regions), or PKD2L1 plus PKD1L3 (labeled ‘both’ and yellow graph regions) genes were counted and graphed in pie charts. Total number of counted cells is listed below each pie chart in parentheses.
Example 40
This experiment the results of which are contained in FIG. 41 shows that FAM26C is expressed in TRPM5 taste cells. Therein double in situ hybridization of primate circumvallate papilla at the back of the tongue showing that FAM26C (blue/purple color; left image) colocalizes with TRPM5 (red; middle image). Note that FAM26C cells express TRPM5, a marker of sweet, bitter, and umami taste cells (merge; right image).
Example 41
This experiment the results of which are contained in FIG. 42 shows that NALCN is a taste-specific gene. The figure shows end-point PCR experiments on circumvallate taste buds (taste) and lingual epithelial cells (lingual) of non-human primate (left) and mouse (right) isolated by laser-capture microdissection demonstrating that NALCN is a taste-specific gene. NALCN is only expressed in taste cells and is not detectable in lingual cells, similar to the known taste-specific genes gustducin, T1R2, and TRPM5. β-actin is detectable in both taste and lingual samples, indicating that high-quality RNA was present in both samples. ‘+’ indicates that reverse transcription was performed and ‘−’ indicates that no reverse transcription was performed. PCR bands were only observed with reverse transcriptase indicating that PCR products are derived from mRNA and not genomic DNA. PCR products were cloned and sequenced to verify that the bands corresponded to the expected gene products.
Example 42
This experiment the results of which are contained in FIG. 43 shows that NALCN is expressed in a unique taste cell type effected at low magnification. Therein is shown a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. Numerous taste buds are shown.
Example 43
This experiment the results of which are contained in FIG. 44 also shows that NALCN is expressed in a unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel taste cell population. One to two taste buds are shown.
Example 44
This experiment the results of which are contained in FIG. 45 shows that NALCN is not expressed in TRPM5 cells. The figure contains a double label immunochemistry of circumvallate papilla from the back of the tongue showing that NALCN (red color, middle images( ) does not colocalize with TRPM5 in non-human primate (green, left image top row) or IP3R3 in rat (green; left image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since TRPM5 and IP3R3 mark sweet, bitter, and umami cells, equivalent to type II cells, NALCN is not expressed in type II cells in non-human primate and rat.
Example 45
The experiment in FIG. 46 shows that NALCN is expressed in a subset of fungiform taste cells. Therein single label immunochemistry of fungiform papilla from the front of the tongue of non-human primate showing that NALCN (red color) is expressed in a subset of taste cells. Top of the taste bud, facing saliva, if oriented towards the top in the image is shown (see arrow). unique taste cell type but at high magnification. Therein is contained a double label immunohistochemistry of rat circumvallate papilla from the back of the tongue showing that NALCN (green color; left images) does not colocalize with IP3R3 (red; middle image top row) or SNAP-25 (red; middle image bottom row). Note that red and green stains localize to different cell types in the merged images on the right. Since IP3R3 is a marker of sweet, bitter, and umami cells whereas SNAP-25 is a marker of sour cells, NALCN is not expressed in sweet, bitter, umami, or sour cells but in a unique and novel. taste cell population. One to two taste buds are shown
Example 46
Identification of Human Taste Specific Genes by Quantitative PCR
Experiments enabling the identification of human taste specific genes by quantitative polymerase chain reaction (PCR) were also effected. In the previous examples we described genes expressed in primate taste buds and we assigned gene expression patterns within the primate taste bud for all taste bud-specific genes; specifically, using a comparison of gene expression between the top and bottom sections of the primate taste bud. By these methods the inventors were able to classify genes into one of several functional classes that include taste receptor genes. In this example we demonstrate taste specific gene expression in humans (in addition to primate) and have validated the specificity of expression by a quantitative method (qPCR or “TaqMan”). The genes described in Table below, identified by these methods all encode multi-span transmembrane proteins, and it is likely that they include the salt receptor and others taste receptors whose function has yet to be defined.
In these experiments the inventors used human taste bud samples. In order to isolate human taste buds we performed laser capture microdissection (LCM). This technique has been described in detail in the provisional patent applications and incorporated by reference and supra. Briefly, it involves the excision and isolation of selected cells or groups of cells from tissue sections based on morphological distinctions. In the case of taste buds, we can readily identify these structures in sections of human tongue. In this specific example tissue collection was limited to taste buds (TB) in circumvallate papillae and, as a control, cells from the adjacent lingual epithelium (LE). An example of sections used in sample collection is shown in FIG. 47. Multiple LCM preparations from each of 3 human donors were pooled ( ̃4500 cells per sample), RNA extracted and amplified by WT-Ovation Pico RNA Amplification System (NuGEN Technologies, Inc) and analyzed using TaqMan technology to determine specific levels of gene expression in the TB and LE pools.
The expression of the taste-specific genes was quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. FIG. 47 shows the laser capture microdissection of human taste buds. Panel A shows methyl blue stained section of human circumvallate human taste buds. Panel B shows Section A following excision of taste buds. Panel C contains the captured taste buds.
A list of the analyzed human genes expressed are contained in Table 8 infra. Gene expression is measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample is determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold will be reached early in the PCR run and the CT value will be relatively low (<35) while genes with very low or no expression will not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable. For the majority of genes listed in the Table, expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35).
The group of human taste specific genes contained in Table 8 has not been described before as taste-specific in human tissue.
Therefore, these results show that by using this approach that uses LCM from post-mortem human tissue samples and a single cDNA amplification step, our data clearly indicate that postmortem LCM human tissue can be used to quantify the expression of taste specific genes using qPCR. and that human taste specific genes can be measured by quantitative PCR (TaqMan). Particularly, gene expression profiles of taste specific genes can be measured by TaqMan. This methodology validated gene expression data obtained from microarrays and/or in situ hybridization (ISH). Therefore, by using the successive approaches of gene expression via microarray in primate LCM tongue tissue; top-specific gene expression within the taste bud (akin to known taste receptors) and TaqMan quantification of gene expression in human postmortem tastes tissues, new human taste specific genes that had not been described previously were identified as contained in Table 8.
Additional Results and Tables Listing Taste Specific Genes (Human and Macaque)
The primate taste bud-specific gene list which resulted in the taste-specific genes contained in Tables 1-5 below were generated by the use of specific inclusion criteria. These inclusion criteria used Affymetrix MAS5 normalized data as follows:
Inclusion Criteria
Using Affymetrix MAS5 normalized data
FG taste bud mean expression value≧50
FG versus LE expression ratio≧2-fold up
FG versus LE expression ratio p value≦0.05


    
    
        424 probe sets
        Using Affymetrix GC-RMA normalized data

FG taste bud mean expression value≧20

FG versus LE expression ratio≧2-fold up

FG versus LE expression ratio p value≦0.05

        504 probe sets
        PLUS 3211 probe sets isolated from both data sets
        [TOTAL Number of Primate Taste Bud Specific probe Sets Equals 4139}
        TOTAL Number of Primate Taste Bud Specific Genes Equals 3455
    
    














TABLE 1






Representative
MAS5
MAS5
MAS5



Representative
Public ID:
LE
TB
fold
MAS5


Public ID
Species
mean
mean
change
p value




















XM_001085855
Mm
168.1
825.8
4.9
0.0007


XM_001106014
Mm
50.9
113.9
2.2
0.0386


XM_001084081
Mm
17.1
174.9
10.2
0.0066


XM_001099138
Mm
126.8
547.4
4.3
0.0244


XM_001101439
Mm
30.3
102.6
3.4
0.0250


XM_001113252
Mm
5.0
702.3
139.3
0.0006


XM_001107314
Mm
12.3
74.2
6.0
0.0001


XR_014466
Mm
185.9
584.9
3.1
0.0056


XR_013101
Mm
63.8
405.3
6.4
0.0103


XM_001083619
Mm
16.5
155.4
9.4
0.0496


XM_001088479
Mm
344.9
1388.2
4.0
0.0043


XM_001088853
Mm
44.9
102.2
2.3
0.1992


XM_001085289
Mm
416.8
2226.5
5.3
0.0001


XM_001086036
Mm
34.3
88.7
2.6
0.0421


XM_001114058
Mm
404.5
3269.5
8.1
0.0007


XM_001112907
Mm
81.7
715.0
8.8
0.0223


BV165948
Mm
35.9
111.9
3.1
0.0172


BV166168
Mm
11.1
93.6
8.5
0.0026


BV166439
Mm
11.0
75.4
6.9
0.0016


BV209038
Mm
35.5
154.1
4.3
0.0139


BV209579
Mm
22.4
51.7
2.3
0.0393


BV209589
Mm
18.5
109.8
5.9
0.0340


BV209803
Mm
31.9
97.2
3.0
0.0775


BV209934
Mm
40.2
104.0
2.6
0.0606


BV210562
Mm
626.9
1473.7
2.4
0.0003


BV211039
Mm
164.1
439.3
2.7
0.0026


BV445286
Mm
51.7
493.2
9.5
0.0039


BV447952
Mm
36.9
454.5
12.3
0.0001


BV447979
Mm
22.4
123.1
5.5
0.0001


BV448453
Mm
36.7
184.8
5.0
0.0333


BV448619
Mm
32.7
90.3
2.8
0.0288


BV448731
Mm
374.3
769.4
2.1
0.0179


BV448735
Mm
20.6
1485.7
72.2
0.0010


BV448827
Mm
44.4
110.9
2.5
0.0441


AL833583
Hs
31.4
267.0
8.5
0.1140


CB550378
Mm
16.2
136.4
8.4
0.0164


CN804030
Mm
431.4
1060.7
2.5
0.0387


CO774248
Mm
22.4
70.6
3.1
0.0233


NM_000166
Hs
19.1
64.4
3.4
0.0466


NM_000335
Hs
4.5
381.4
85.4
0.0003


NM_001001666
Hs
13.0
139.7
10.7
0.0009


NM_001001994
Hs
40.0
1037.3
25.9
0.0003


NM_001002796
Hs
3.7
2066.5
558.9
0.0046


NM_001004746
Hs
35.3
102.1
2.9
0.0148


NM_001010898
Hs
26.8
106.7
4.0
0.0016


NM_001011655
Hs
8.2
1258.5
154.2
0.0035


NM_001012302
Hs
28.9
64.8
2.2
0.0090


NM_001017970
Hs
348.7
1779.2
5.1
0.0000


NM_001025356
Hs
43.1
175.0
4.1
0.0071


NM_001033026
Hs
90.2
180.8
2.0
0.0091


NM_001037984
Hs
134.6
263.8
2.0
0.0032


NM_001040456
Hs
46.2
155.1
3.4
0.0019


NM_001042680
Hs
28.4
59.3
2.1
0.0495


NM_001046
Hs
41.8
182.3
4.4
0.0002


NM_001076674
Hs
174.4
351.5
2.0
0.0666


NM_001077241
Hs
52.8
129.7
2.5
0.0175


NM_001079669
Hs
245.7
3971.8
16.2
0.0000


NM_001425
Hs
29.3
60.9
2.1
0.1000


NM_001606
Hs
700.5
3503.3
5.0
0.0000


NM_002211
Hs
7.1
42.6
6.0
0.0249


NM_003615
Hs
8.4
413.3
48.9
0.0034


NM_004099
Hs
66.5
174.0
2.6
0.0010


NM_005502
Hs
223.5
611.5
2.7
0.0264


NM_005724
Hs
321.1
666.4
2.1
0.0048


NM_007213
Hs
23.6
78.8
3.3
0.0336


NM_012329
Hs
43.0
209.1
4.9
0.0577


NM_014399
Hs
2718.3
5413.0
2.0
0.0013


NM_014858
Hs
62.8
176.7
2.8
0.0597


NM_014982
Hs
18.0
86.9
4.8
0.0493


NM_015205
Hs
177.2
389.7
2.2
0.0234


NM_015257
Hs
38.7
134.4
3.5
0.0269


NM_015292
Hs
986.6
2513.0
2.5
0.0004


NM_015916
Hs
5.2
152.3
29.5
0.0057


NM_016127
Hs
1915.3
3775.3
2.0
0.0003


NM_016235
Hs
27.7
584.2
21.1
0.0007


NM_016475
Hs
49.3
143.6
2.9
0.0400


NM_017586
Hs
266.0
1076.2
4.0
0.0140


NM_017672
Hs
68.9
231.9
3.4
0.0074


NM_017744
Hs
81.3
202.7
2.5
0.0061


NM_017799
Hs
42.0
191.1
4.6
0.0047


NM_017801
Hs
78.5
154.7
2.0
0.0110


NM_017814
Hs
33.0
100.7
3.1
0.0049


NM_017849
Hs
43.5
109.5
2.5
0.0092


NM_017905
Hs
32.5
91.7
2.8
0.0382


NM_017918
Hs
48.9
232.0
4.7
0.0012


NM_018056
Hs
25.7
63.3
2.5
0.0298


NM_018452
Hs
48.4
146.0
3.0
0.0090


NM_018487
Hs
8.9
924.9
103.6
0.0004


NM_018502
Hs
14.0
47.3
3.4
0.0234


NM_019118
Hs
37.5
451.0
12.0
0.0000


NM_020215
Hs
12.9
108.0
8.4
0.0112


NM_020448
Hs
34.7
93.3
2.7
0.0445


NM_020925
Hs
27.9
480.2
17.2
0.0069


NM_021194
Hs
132.0
329.5
2.5
0.0493


NM_021259
Hs
20.1
115.0
5.7
0.0178


NM_021637
Hs
6.9
64.5
9.3
0.0032


NM_021727
Hs
46.6
106.0
2.3
0.0132


NM_022369
Hs
8.6
131.0
15.3
0.0940


NM_022458
Hs
32.9
145.1
4.4
0.0203


NM_022495
Hs
33.1
154.8
4.7
0.0239


NM_023003
Hs
16.0
157.6
9.9
0.0175


NM_023943
Hs
7.7
57.2
7.4
0.0375


NM_024628
Hs
47.5
710.7
15.0
0.0018


NM_024630
Hs
71.6
386.9
5.4
0.0159


NM_024956
Hs
64.7
129.7
2.0
0.0211


NM_025257
Hs
9.7
275.1
28.2
0.0024


NM_030651
Hs
7.1
183.8
25.9
0.0053


NM_030923
Hs
6.5
1801.8
276.3
0.0004


NM_031442
Hs
8.7
73.8
8.5
0.0415


NM_031484
Hs
88.3
881.7
10.0
0.0001


NM_032012
Hs
390.0
1480.2
3.8
0.0006


NM_032016
Hs
135.4
961.3
7.1
0.0023


NM_032295
Hs
112.6
267.8
2.4
0.0152


NM_032483
Hs
87.0
224.8
2.6
0.0200


NM_032824
Hs
90.1
335.9
3.7
0.0563


NM_032826
Hs
17.5
62.2
3.6
0.0084


NM_032890
Hs
93.4
987.6
10.6
0.0000


NM_033102
Hs
7.8
125.6
16.1
0.0202


NM_138346
Hs
573.4
2006.8
3.5
0.0001


NM_139075
Hs
48.1
138.1
2.9
0.0046


NM_144638
Hs
19.8
92.2
4.6
0.0170


NM_144649
Hs
21.9
52.6
2.4
0.1617


NM_144686
Hs
18.0
406.4
22.6
0.0034


NM_145290
Hs
44.9
192.8
4.3
0.1919


NM_152288
Hs
353.5
1590.1
4.5
0.0006


NM_152522
Hs
357.2
514.3
1.4
0.0595


NM_152588
Hs
182.1
560.3
3.1
0.0148


NM_152778
Hs
43.7
208.5
4.8
0.0139


NM_153354
Hs
38.2
118.1
3.1
0.0523


NM_153365
Hs
600.9
1850.8
3.1
0.0027


NM_153704
Hs
8.9
46.9
5.3
0.0288


NM_153811
Hs
105.8
303.3
2.9
0.0433


NM_173512
Hs
10.3
77.0
7.5
0.0169


NM_173653
Hs
159.5
357.2
2.2
0.0187


NM_174926
Hs
8.2
211.1
25.9
0.0246


NM_175861
Hs
15.1
74.4
4.9
0.0146


NM_177964
Hs
27.7
267.4
9.7
0.0016


NM_178818
Hs
54.5
167.8
3.1
0.0145


NM_181644
Hs
63.9
520.8
8.2
0.0095


NM_181787
Hs
52.3
246.1
4.7
0.0109


NM_182494
Hs
5.4
1159.4
215.5
0.0010


NM_182504
Hs
8.4
53.3
6.4
0.0151


NM_182532
Hs
4.8
74.8
15.5
0.0180


NM_182547
Hs
1722.3
3135.0
1.8
0.0023


NM_198276
Hs
35.7
127.6
3.6
0.0226


NM_207351
Hs
116.0
890.6
7.7
0.0035


XM_001128552
Hs
4.7
292.8
62.8
0.0505


XM_370997
Hs
6.3
70.5
11.2
0.0057


XM_927351
Hs
5.3
1085.9
204.3
0.0027









    
    
        This table summarizes primate taste-bud expressed genes that were identified as multi-plasma membrane proteins with little or no functional characterization. The set is consistent with this gene set including taste receptors and more particularly including salty taste receptors as the identified genes includes genes identified as sodium channels. This Table comprises the most probable candidates for salty receptor genes and genes responsible for other characterized and uncharacterized taste receptors and polypeptides that modulate taste intensity as well as genes encoding transmembrane proteins involved in other taste cell functions. Representative accession numbers are from primate (i.e. Macaca mulatta abbreviated Mm) or humans (i.e. Homo sapiens abbreviated Hs).
    
    














TABLE 2






Representative
MAS5
MAS5
MAS5



Representative
Public ID:
LE
TB
fold
MAS5


Public ID
Species
mean
mean
change
p value




















XR_011926
Mm
11.4
213.4
18.7
0.0231


XM_001099450
Mm
10.2
57.8
5.7
0.0126


XM_001098390
Mm
12.8
93.4
7.3
0.0196


XM_001086764
Mm
12.5
58.0
4.6
0.0870


XM_001114476
Mm
5.3
122.9
23.1
0.0047


XM_001110867
Mm
16.0
245.0
15.3
0.0015


R58928
Mm
5.6
50.6
9.0
0.0126


XM_001093116
Mm
8.8
121.0
13.7
0.0095


XM_001099593
Mm
9.4
126.9
13.6
0.0008


XR_010972
Mm
9.2
547.5
59.6
0.0005


XM_001084620
Mm
4.4
1917.8
433.3
0.0001


XM_001090982
Mm
34.3
229.2
6.7
0.0060


XM_001098500
Mm
20.0
1366.9
68.2
0.0022


XM_001088661
Mm
12.7
70.0
5.5
0.0327


XM_001097918
Mm
367.0
1244.3
3.4
0.0059


XM_001089122
Mm
9.9
176.2
17.8
0.0307


XM_001106548
Mm
16.7
854.3
51.2
0.0001


BV166050
Mm
12.1
108.1
8.9
0.0043


BV166421
Mm
10.3
2141.3
207.1
0.0001


BV166428
Mm
90.1
1287.4
14.3
0.0010


BV166437
Mm
13.5
253.1
18.7
0.0871


BV166724
Mm
9.6
59.6
6.2
0.0304


BV166739
Mm
150.9
719.0
4.8
0.0002


BV166741
Mm
159.5
303.8
1.9
0.0297


BV166749
Mm
56.6
156.9
2.8
0.0055


BV166757
Mm
212.7
1221.6
5.7
0.0011


BV166818
Mm
23.3
157.6
6.8
0.0822


BV208636
Mm
25.4
584.3
23.0
0.0013


BV208853
Mm
23.0
225.5
9.8
0.0043


BV209086
Mm
22.9
85.6
3.7
0.0012


BV209237
Mm
26.3
1562.2
59.5
0.0000


BV209238
Mm
302.6
964.7
3.2
0.0073


BV209550
Mm
5.3
2121.2
398.1
0.0000


BV209574
Mm
20.8
111.0
5.3
0.0154


BV210515
Mm
100.4
202.2
2.0
0.0022


BV210859
Mm
46.9
140.8
3.0
0.0156


BV210983
Mm
181.8
563.9
3.1
0.0031


BV447592
Mm
12.8
1670.7
130.7
0.0003


BV447751
Mm
4.4
406.5
91.5
0.0010


BV448581
Mm
50.3
159.8
3.2
0.0422


BV448600
Mm
6.9
179.2
26.1
0.0071


AK057677
Hs
17.8
616.2
34.6
0.0017


AK095199
Hs
6.0
189.4
31.8
0.0313


NM_000068
Hs
20.9
379.4
18.1
0.0007


NM_000112
Hs
21.3
337.8
15.9
0.0182


NM_000238
Hs
8.8
427.4
48.5
0.0019


NM_000617
Hs
72.1
238.1
3.3
0.0359


NM_001001396
Hs
18.4
116.6
6.3
0.0081


NM_001001787
Hs
414.9
2580.5
6.2
0.0006


NM_001008783
Hs
1.0
114.5
117.2
0.0196


NM_001017403
Hs
4.6
265.1
57.2
0.0086


NM_001020818
Hs
484.8
1455.0
3.0
0.0006


NM_001023587
Hs
163.3
1680.5
10.3
0.0042


NM_001024938
Hs
35.3
114.7
3.2
0.0255


NM_001029858
Hs
4.3
2244.2
523.9
0.0033


NM_001076785
Hs
6.7
128.0
19.0
0.0178


NM_001106
Hs
12.5
65.6
5.2
0.0223


NM_002241
Hs
3.2
132.8
42.1
0.0018


NM_002980
Hs
35.9
156.4
4.4
0.0119


NM_003043
Hs
213.6
900.2
4.2
0.0147


NM_003304
Hs
144.8
663.9
4.6
0.0007


NM_003641
Hs
33.5
327.9
9.8
0.0086


NM_004616
Hs
13.2
795.8
60.4
0.0022


NM_004733
Hs
314.5
810.9
2.6
0.0187


NM_004770
Hs
1.8
305.6
173.7
0.0098


NM_004974
Hs
1.9
125.3
65.7
0.0017


NM_004996
Hs
923.5
4019.0
4.4
0.0000


NM_005173
Hs
29.8
3560.0
119.4
0.0000


NM_005415
Hs
468.3
1315.2
2.8
0.0035


NM_005669
Hs
2293.8
4587.3
2.0
0.0009


NM_006054
Hs
681.2
1701.5
2.5
0.0035


NM_006435
Hs
1431.8
4294.5
3.0
0.0198


NM_006598
Hs
71.4
673.6
9.4
0.0021


NM_006608
Hs
66.8
172.7
2.6
0.1044


NM_007001
Hs
10.3
80.3
7.8
0.0472


NM_012129
Hs
303.5
542.9
1.8
0.0154


NM_014220
Hs
81.6
306.2
3.8
0.0029


NM_015236
Hs
6.2
407.8
66.3
0.0041


NM_016395
Hs
25.6
100.9
3.9
0.0407


NM_018144
Hs
75.3
214.4
2.8
0.1049


NM_018155
Hs
84.9
411.3
4.8
0.0005


NM_020724
Hs
5.7
44.6
7.8
0.0120


NM_021095
Hs
41.5
203.3
4.9
0.0262


NM_022109
Hs
763.0
1828.3
2.4
0.0046


NM_022154
Hs
20.8
552.8
26.5
0.0087


NM_022754
Hs
65.5
213.6
3.3
0.1189


NM_024534
Hs
27.0
549.1
20.3
0.1113


NM_030571
Hs
373.9
735.4
2.0
0.0062


NM_031462
Hs
6.1
51.5
8.5
0.0173


NM_033272
Hs
7.0
677.5
97.3
0.0185


NM_052885
Hs
13.8
64.7
4.7
0.0270


NM_133329
Hs
7.6
160.7
21.3
0.0078


NM_138694
Hs
11.9
227.0
19.0
0.0066


NM_144673
Hs
19.6
288.7
14.7
0.0004


NM_152264
Hs
19.3
87.7
4.5
0.0088


NM_152686
Hs
17.7
392.4
22.2
0.0099


NM_153357
Hs
9.7
84.5
8.7
0.0578


NM_178276
Hs
1442.4
2921.0
2.0
0.0028


NM_178568
Hs
9.5
48.1
5.0
0.0462


XM_370711
Hs
17.4
91.9
5.3
0.0236


XM_931948
Hs
256.3
1010.3
3.9
0.0000


XM_001084141
Mm
65.3
229.1
3.5
0.0024


XM_001108664
Mm
21.1
79.8
3.8
0.0184


XM_001103706
Mm
82.6
232.7
2.8
0.0027


NM_207627
Hs
8.1
181.4
22.3
0.0499


XM_001083115
Mm
228.6
705.3
3.1
0.0040


XM_001103565
Mm
328.5
797.1
2.4
0.0015


BV166047
Mm
10.0
98.9
9.9
0.0445


BV166216
Mm
5.9
218.2
37.0
0.0000


BV166400
Mm
160.3
1036.6
6.5
0.0001


BV166539
Mm
111.9
1279.1
11.4
0.0036


BV166725
Mm
6.7
78.5
11.6
0.0192


BV208837
Mm
41.7
209.0
5.0
0.0010


BV209241
Mm
230.8
515.4
2.2
0.0041


BV209592
Mm
42.0
303.8
7.2
0.0004


BV445228
Mm
42.3
136.5
3.2
0.0530


BV447852
Mm
4.0
120.0
30.2
0.0205


NM_018398
Hs
5.8
273.7
46.9
0.0294


NM_001035
Hs
18.1
59.4
3.3
0.0342


NM_001736
Hs
168.9
1036.9
6.1
0.0013


NM_001992
Hs
7.0
73.7
10.6
0.0081


NM_004700
Hs
5.2
114.1
22.1
0.0005


NM_005845
Hs
35.4
616.0
17.4
0.0007


NM_006218
Hs
46.6
186.2
4.0
0.0460


NM_012072
Hs
12.7
110.8
8.7
0.0448


NM_012319
Hs
16.7
165.4
9.9
0.0586


NM_013384
Hs
19.1
187.2
9.8
0.0010


NM_013388
Hs
40.4
79.5
2.0
0.0281


NM_014331
Hs
90.2
544.5
6.0
0.0006


NM_015444
Hs
38.1
134.1
3.5
0.1685


NM_017746
Hs
24.5
54.3
2.2
0.0858


NM_017839
Hs
21.9
139.0
6.3
0.0280


NM_021814
Hs
126.4
686.9
5.4
0.0006


NM_022374
Hs
777.3
1714.3
2.2
0.0027


NM_022768
Hs
10.2
95.9
9.4
0.0320


NM_024809
Hs
40.6
87.9
2.2
0.0498


NM_025141
Hs
685.7
1708.0
2.5
0.0006


NM_025154
Hs
267.0
1000.7
3.7
0.0000


NM_031301
Hs
22.8
185.8
8.1
0.0629


NM_032027
Hs
288.0
667.2
2.3
0.0548


NM_144991
Hs
13.5
40.9
3.0
0.0153


NM_152261
Hs
38.0
262.7
6.9
0.0025


NM_152621
Hs
54.5
367.4
6.7
0.0128


NM_182589
Hs
6.2
214.2
34.5
0.0258


XM_290972
Hs
44.3
225.5
5.1
0.0000









    
    
        Table 2 below summarizes primate taste-bud expressed genes that were identified as multitransmembrane domain proteins that have been functionally characterized and which are potential candidates for salty taste and other taste receptors. In addition this gene set includes genes encoding transmembrane polypeptides involved in other taste cell related functions. Representative accession numbers are from primate (i.e. Macaca mulatta abbreviated Mm) or humans (i.e. Homo sapiens abbreviated Hs).
    
    









TABLE 3





Fungiform Specific Genes and Other Potential Tate Receptor Candidates


RefSeq Transcript ID

















NM_178826



NM_021625



NM_020199



NM_014386



NM_006765



NM_016113



NM_003305



NM_007369



NM_018202



NM_005725



NM_000334



NM_002976



NM_002977



NM_030782



CK232413



NM_005669



NM_001001188



XR_018915



NM_145239



NM_012264



NM_001040151



NM_005727



NM_004621



NM_002420



NM_019841



NM_153835



NM_018653



NM_152487



NM_018022



NM_001040142



NM_000297



NM_001040107



NM_032824



NM_031457



NM_018298



BV445354



XM_001111007



BV444941



AANU01224075; AANU01224076







(CLASS 2 Genes) Putative Fatty Taste Gene Receptors






    
    
        This Table of genes was derived after compiling a list of ion channel genes permeable to sodium that were systematically tested for expression in laser capture micro-dissected primate tongue tissue from lingual epithelium and taste buds by end point PCR. Genes that were expressed in fungiform taste buds but not circumvallate taste buds or lingual epithelium were included in this list. Moreover, this list of genes includes other genes which were selected that are likely to encode multi-domain transmembrane proteins included on the macaque oligo array that did not satisfy the inclusion criteria of the systematic array and are not included in the Gene Lists contained in Tables 1 and 2 supra.
    
    









TABLE 4







Additional new taste-specific genes identified in macaque fungiform


and/or circumvallate taste-buds by gene chip analysis. These genes


all encode transmembrane proteins with no described function or that


function as ion channels, ion transporters, or G-protein coupled receptors.


Accession numbers, ratios of gene expression in taste cells (TB) to


non-taste lingual epithelial cells (LE), and the p values calculated


using a two-tailed Student's t-test are listed.











Accession number or Unigene
TB vs. LE
TB vs. LE



cluster
ratio
p value















BC017041
4.93
0.3961



XM_001094702
4.36
0.0817



XM_001093133
6.08
0.3922



NM_020141
5.00
0.1647



XM_001101699
5.16
0.0204



XM_001084342
11.25
0.0894



XM_001097482
6.19
0.0498



Hs.98728
8.99
0.0141



Mmu.5446
16.62
0.1980



XM_001113863
18.35
0.1654



Hs.568078
13.28
0.3665



Hs.136017
4.93
0.0575



XM_001086597
6.50
0.0156



XM_001103527
15.02
0.3411



Hs.127196
10.66
0.2504



Hs.21606
11.47
0.3328



XM_001083605
13.09
0.1231



XM_001083934
25.63
0.3774



XM_001085321
5.89
0.2483



Hs.88972
5.01
0.1045



Hs.47068
14.48
0.0790



XR_010355
6.71
0.1362



XM_001088824
9.47
0.0968



NM_198503
56.03
0.0551



Hs.292453
5.45
0.2891



XM_001082226
1.33
0.2803



XM_001115408
5.84
0.2666



Hs.285976.2.S1
6.57
0.0156



Hs.306723
4.72
0.0762



XM_001117492
55.50
0.0903



XM_001114070
4.99
0.3147



XM_001083482
8.39
0.1759



XM_001085289
6.53
0.0358



XM_001090289
5.70
0.2157



XM_001099752
4.72
0.0333



XM_001103706
1.53
0.6021



XM_001108095
10.17
0.2344



XM_001099350
1.50
0.7839



XM_001092868
11.47
0.0594



XM_001082482
5.76
0.0990



XM_001087669
5.40
0.2955



XM_001085445
322.37
0.1177



XM_001095050
23.94
0.3918



XM_001090844
5.21
0.0776



XM_001118514
5.56
0.0704



XR_011068
11.49
0.3387



XM_001099407
10.13
0.1970



XM_001098987
226.16
0.0153



XR_012702
9.67
0.3743



XM_001090295
10.66
0.3814



XM_001101662
9.51
0.1324



XM_001113146
5.38
0.2783



XM_001103667
5.24
0.2633



XM_001106443
5.16
0.0742



XM_001103701
5.23
0.0055



Hs.76722
7.66
0.3632



NM_052832
199.81
0.0108



XM_001114769
13.77
0.0748



Mmu.9408
5.68
0.1025



NM_001032861
7.74
0.0691



Hs.199243
8.99
0.3158



XM_001111927
2.33
0.0255



Hs.255056
10.46
0.3185



XM_001084483
1.78
0.3006



XM_001108758
0.45
0.0553



XM_001084211
77.55
0.0168



Hs.8116
24.11
0.2107



Hs.18653
21.23
0.2566



Hs.35861
1.07
0.6589



XM_001118212
5.53
0.1690



XM_001090523
29.84
0.0230



XM_001099752
16.53
0.0181



XM_001108428
14.42
0.0212



XM_001103909
22.02
0.0309



Hs.211167
7.44
0.4008



XM_001083172
57.01
0.1186



XM_001112011
5.33
0.0137



Hs.166845
9.46
0.2667



XM_001111915
34.66
0.3156



XM_001117478
112.45
0.0068



Hs.45080
11.18
0.0012






















TABLE 5





Public Transcript
Public Transcript
MAS5 LE
MAS5 TB
MAS5 fold
MAS5 p


ID
ID: Species
mean
mean
change
value




















CO583226
Mm
8.5
48.0
5.7
0.0226


CB309123
Mm
17.1
130.1
7.6
0.0367


NM_001647
Hs
21.9
119.7
5.5
0.0235


NM_016619
Hs
22.1
1139.3
51.6
0.0018


NM_207352
Hs
91.3
405.4
4.4
0.0245


NM_000229
Hs
13.4
77.3
5.8
0.0036


NM_021105
Hs
20.6
203.8
9.9
0.0000


NM_004915
Hs
17.5
139.7
8.0
0.0811


NM_001017403
Hs
4.6
265.1
57.2
0.0086


NM_002899
Hs
631.1
3718.0
5.9
0.0001


NM_001153
Hs
1778.3
3990.5
2.2
0.0000


NM_017784
Hs
144.0
348.8
2.4
0.0002


NM_001077400
Hs
16.4
197.3
12.0
0.0050


NM_000253
Hs
7.1
493.9
69.4
0.0018


NM_002336
Hs
111.3
1452.8
13.0
0.0000


NM_032360
Hs
32.8
168.5
5.1
0.0180


NM_001004746
Hs
35.3
102.1
2.9
0.0148


NM_006551
Hs
10.0
78.1
7.8
0.0191


AB220498
Mm
81.7
715.0
8.8
0.0223


XM_001086422
Mm
48.4
262.8
5.4
0.0345


NM_014349
Hs
24.4
98.5
4.0
0.0054


XM_001100224
Mm
173.6
525.8
3.0
0.0411


NM_006684
Hs
7.5
107.1
14.4
0.0465


NM_006377
Hs
405.4
2498.0
6.2
0.0000


CO583346
Mm
160.3
1036.6
6.5
0.0001









    
    
        Table 5 below contains primate genes previously described as fatty acid receptors or which contain amino acid motifs that are associated with lipid binding. This list of genes includes genes that do not encode multi-transmembrane proteins but which are reported to participate in lipid transport or binding at close to the plasma membrane.
    
    












TABLE 6







Gene Name
Cell type gene expressed in









FAM26A
Many TRPM5 cells



GPR113
Subset TRPM5 cells



MCTP1
Many TRPM5 cells



TMEM16G
Subset TRPM5 cells



TMEM30B
Many TRPM5 cells



TMEM44
Many non-TRPM5 and non-PKD1L3 cells



TUSC3
Many TRPM5 cells



FAM26C
MANY TRPM5 CELLS



FAM26B
Many TRPM5 cells



MFSD4
Many Non-TRPM5 cells



ATP8A1
Many TRPM5 and some non-TRPM5 cells



SLC4A11
Many TRPM5 cells



SLC4A7
Subset TRPM5 cells










    
    
        The 11 taste-specific genes contained in Table 6 were shown to be expressed in different subsets of primate taste cells. These genes were identified as taste-specific genes by gene chip analysis and shown to be expressed in subsets of taste cells by in situ hybridization analysis as described in the experimental examples and Figures.

Table 7 below lists 4 other primate taste specific genes identified by the inventive rationales and provides information as to the specific cell types in which these genes are expressed.

    
    












TABLE 7







Gene Name
Cell type gene expressed in









KIT
TRPM5 & T1R3 subset; T1R1 umami taste




receptor cells



IKBKAP
PKD1L3 sour taste receptor cells



LOC285965
TRPM5 & T1R3 subset; T1R3 only cells lacking




T1R1 (umami) and T1R2 (sweet)



SV2B
PKD1L3 sour taste receptor cells










    
    
        Table 8 contains a listing of the human taste-specific genes which were quantified by TaqMan in LCM derived cDNA from both LE and TB from the same donors. As noted in Example 46, gene expression was measured in TaqMan as a CT (cycle threshold) value. Briefly the CT value for a given sample was determined by the PCR cycle at which the amount of gene-specific PCR product (as measured by fluorescence) reaches a set value. For highly expressed genes, the threshold is reached early in the PCR run and the CT value is relatively low (<35) while genes with very low or no expression do not reach the threshold before cycle 35. Expression of genes with CT values >40 are defined as not detectable. For the majority of genes listed in Table 8 below, expression was not detected in LE samples (CT>40) but was readily detectable in TB samples (CT<35).
    
    












TABLE 8






Gene
TB CT
LE CT


Gene Title
Symbol
value
value*


















solute carrier family 9 (sodium/hydrogen exchanger), member 2
SLC9A2
24.63
No Ct


solute carrier family 44, member 4
SLC44A4
25.2
No Ct


membrane-spanning 4-domains, subfamily A, member 8B
MS4A8B
25.2
No Ct


tetraspanin 2
TSPAN2
25.79
No Ct


transmembrane protein 38B
TMEM38B
26.44
No Ct


family with sequence similarity 26, member C
FAM26C
26.93
No Ct


LR8 protein
LR8
28.01
No Ct


leucine-rich repeat-containing G protein-coupled receptor 6
LGR6
28.01
No Ct


G protein-coupled receptor, family C, group 5, member B
GPRC5B
28.51
38.69


solute carrier family 35, member E2
SLC35E2
28.58
39.46


G protein-coupled receptor 155
GPR155
28.64
No Ct


LAG1 longevity assurance homolog 2 (S. cerevisiae)
LASS2
29.12
No Ct


major facilitator superfamily domain containing 4
MFSD4
29.23
No Ct


transmembrane protein 108
TMEM108
29.28
No Ct


tetraspanin 17
TSPAN17
29.37
No Ct


G protein-coupled receptor 113
GPR113
29.44
No Ct


transmembrane protein 163
TMEM163
29.61
No Ct


Hypothetical protein LOC644139
LOC644139
29.93
No Ct


transmembrane protein 16G
TMEM16G
30
No Ct


transient receptor potential cation channel, subfamily C, member 1
TRPC1
30.11
No Ct


transmembrane 6 superfamily member 1
TM6SF1
30.13
36.8 


leucine-rich repeat-containing G protein-coupled receptor 5
LGR5
30.15
No Ct


transmembrane protein 44
TMEM44
30.26
No Ct


family with sequence similarity 26, member A
FAM26A
30.39
No Ct


Transmembrane protein 118
TMEM118
30.91
No Ct


chromosome 14 open reading frame 135
C14orf135
32.17
38.68


solute carrier family 8 (sodium/calcium exchanger), member 1
SLC8A1
32.72
No Ct


brain-specific angiogenesis inhibitor 2
BAI2
32.97
No Ct


hypothetical protein LOC130576
LOC130576
34.03
No Ct


potassium voltage-gated channel, KQT-like subfamily, member 1
KCNQ1
34.26
No Ct


ATPase, Class VI, type 11A
ATP11A
34.33
No Ct


ATPase, aminophospholipid transporter (APLT), Class I, type 8A,
ATP8A1
34.54
No Ct


member 1


chromosome 14 open reading frame 101
C14orf101
35.44
38.27


potassium channel, subfamily T, member 2
KCNT2
35.62
No Ct


synaptic vesicle glycoprotein 2B
SV2B
35.95
No Ct





*No Ct = CT value > 40, or, not detectable. See text.






    
    
        As afore mentioned the taste cell specific genes identified herein and the corresponding gene products and cells which express same e.g., endogenous taste or chemosensory cells and recombinant cells including the taste specific genes recited in Tables 1, 2, 3, 4, 5, 6, 7, and 8 and their orthologs, allelic variants, variants possessing at least 90% sequence identity thereto and/or genes which specifically hybridize thereto under hybridization conditions denied supra may be used in assays to identify taste modulatory compounds as well as in therapeutic screening assays.
        For example these taste specific genes, polypeptides and cells expressing same can be used to screen for compounds for treatment of digestive system disorders. These disorders include by way of example conditions affecting digestion such as dyspepsia, autoimmune and inflammatory diseases affecting the digestive system such as ulcerative colitis, inflammatory bowel syndrome, Crohn's syndrome, celiac disease, and precancers and cancers that affect the digestive system such as cancers affecting the salivary glands, taste buds, stomach, pancreas, gall bladder, esophagus, small or large intestine, anus or colon.
        Also these taste specific genes may be used in screening assays to identify compounds that affect taste cell turnover. It is known that taste cells turnover rapidly (about every couple of weeks). Moreover, many conditions including chemotherapy or radiation treatment, as well as old age may negatively affect the ability of taste cells to develop. The result is a diminished sense of taste which may result in a decreased quality of life in cancer patients or the elderly. This is particularly pronounced in patients with head and neck cancer, esophageal, stomach, lung, or pancreatic cancers. Additionally, this may evolve along with another condition, cachexia or wasting syndrome that combines to reduce the desire to eat. Lack of proper nutrition is a serious cause of morbidity and mortality in cancer patients. The subject taste specific genes contain genes expressed in stem cells suggesting that they are markers of stem cells that are the precursors of and which evolve into taste cells. These genes or cells which express same can be used to identify signals that accelerate taste cell development. These signals which likely comprise cytokine-like receptors present on taste cells likely mediate taste cell development and can be used in screens to identify compounds that induce taste cell differentiation or proliferation. The ligands therefore potentially may be isolated from saliva and may account for the ability of saliva to influence taste function. For example, patients with Sjogren's syndrome (an autoimmune disease that attacks the salivary glands) exhibit altered taste functions. The subject genes and the study of gene expression in the salivary glands by use of gene arrays will facilitate an understanding of these differentiation mechanisms.
        The subject taste cell specific genes and corresponding gene products and cells which express these genes may also be used in order to identify potential therapeutics for modulating the immune system of the oral cavity. The oral cavity is populated by normal flora as is the digestive tract. Alterations in normal flora may give rise to conditions such as gingivitis, halitosis, gastric problems and other infections that may result in tooth decay or tooth loss. Included within the taste cell specific genes identified herein are a number of immune system genes. These genes and the corresponding polypeptides or cells which express same can be used to identify therapeutics for maintaining immune homeostasis in the oral cavity, preventing overgrowth of pathogenic microbia, and for identification of the cell types in the oral cavity that are the key players in maintaining proper oral cavity immunity.
        Moreover, the subject taste cell specific genes and the corresponding gene products or cells which express same are useful in screening assays for identifying compounds for treatment of diabetes, eating disorders such as obesity, anorexia, bulimia, and other metabolic disorders. The expression of taste receptors in the digestive system likely represents a comprehensive system that detects food and different types at different places during digestion. Therefore, “sensing” the presence of food or specific types such as carbohydrates, fats, umami foods, salts, should trigger various signals that may regulate the production of molecules that participate in the regulation of digestion such as GIP (glucose-dependent insulinotrophic polypeptide) and GLP-1 (glucagon-like peptide 1) produced by the enteroendocrine cells in the intestine. It is likely that taste receptors on these cells regulate the production of other molecular signals in other cells of the digestive system when triggered. These phenomena may be studied by determining which cells express different receptors and then using gene arrays to study the molecules that these cells produce when activated.
    
    


REFERENCES


    
    
        All the references cited in this application are incorporated by reference in their entirety herein.
    
    


SEQUENCE LISTING








>gi|89886487|ref|NM_014848.3| Homo sapiens synaptic vesicle glycoprotein



2B (SV2B)


(SEQ ID NO: 1)



mRNAAGCATAACCTTCGGTGGCAGGACAAATCAGGCCAGCACGCAGTCTGCCAAGTC



 


CTGCTCGCTCCCTGTCAAGAAAAACAGCTGGATCCATTTCTAATCAACACTTCCCAACG


 


CAACACTTCTGAGTCTCTGAAGGAGACCAGAGCTTGAAACTTTCCAGACTTCCAACAG


 


ACATCGAGTGCAAAAGGATATTTAGGTTGTCTTTGCACAAATCTGGTTGATTTGAGA


 


GATAAAGGGGGGGGGAACCAGTGTGACTTTCACCTAAGAAGTCACATGAACATATTT


 


CACATTTGAACTACATAATGAATGATGGTTATTGAAATAGCCCAAACCTCTACCACAG


 


AGCGAGGGATATAGCTCAAGGGGCAACCAGGCAGTCGCAGAACCAAGGAATGGATG


 


ACTACAAGTATCAGGACAATTATGGGGGCTATGCTCCCAGTGATGGCTATTACCGCG


 


GCAATGAGTCCAACCCAGAAGAAGATGCACAGAGTGATGTCACCGAAGGCCATGAT


 


GAGGAAGACGAGATCTATGAGGGCGAGTACCAGGGTATCCCTCACCCAGATGATGT


 


CAAGGCCAAGCAGGCCAAGATGGCGCCCTCCAGAATGGACAGCCTTCGGGGCCAGA


 


CAGACCTGATGGCTGAGAGGCTGGAAGATGAGGAGCAGTTGGCCCACCAGTACGAG


 


ACCATCATGGATGAGTGTGGCCATGGCCGCTTCCAGTGGATCCTCTTTTTCGTCTTGG


 


GTTTGGCCCTGATGGCCGATGGGGTGGAAGTGTTCGTGGTGAGTTTTGCCCTGCCC


 


AGTGCAGAGAAGGACATGTGTCTGTCCAGTTCCAAAAAAGGAATGCTAGGGATGAT


 


AGTCTACTTGGGAATGATGGCGGGCGCCTTCATCCTGGGAGGCCTGGCTGATAAGC


 


TGGGAAGGAAGCGAGTCCTCAGCATGTCTCTGGCCGTCAATGCCTCCTTCGCCTCCCT


 


CTCTTCCTTCGTGCAGGGATATGGAGCCTTCCTCTTCTGCCGACTCATCTCAGGCATC


 


GGTATTGGGGGTGCTCTACCGATTGTTTTTGCCTATTTTTCTGAATTCTTGTCTCGGG


 


AGAAGCGAGGAGAACACCTCAGTTGGCTGGGCATCTTCTGGATGACTGGGGGCCTG


 


TACGCATCTGCCATGGCCTGGAGCATCATCCCACACTATGGCTGGGGCTTCAGCATG


 


GGGACCAATTACCACTTCCATAGCTGGAGAGTGTTTGTCATCGTCTGTGCTCTGCCCT


 


GCACCGTGTCCATGGTGGCCCTGAAGTTCATGCCAGAGAGCCCAAGGTTTCTGCTAG


 


AGATGGGCAAACATGATGAAGCCTGGATGATTCTCAAGCAAGTCCATGACACCAACA


 


TGAGAGCTAAGGGGACCCCAGAGAAAGTGTTCACGGTTTCCAACATCAAAACTCCCA


 


AGCAAATGGATGAATTCATTGAGATCCAAAGTTCAACAGGAACCTGGTACCAGCGCT


 


GGCTGGTCAGATTCAAGACCATTTTCAAGCAGGTCTGGGATAATGCCCTGTACTGTG


 


TGATGGGGCCCTACAGAATGAATACACTGATTCTGGCCGTGGTTTGGTTTGCCATGG


 


CATTCAGTTACTATGGACTGACAGTTTGGTTTCCTGATATGATCCGCTATTTTCAAGA


 


TGAAGAATACAAGTCTAAAATGAAGGTGTTTTTTGGTGAGCATGTGTACGGCGCCAC


 


AATCAACTTCACGATGGAAAATCAGATCCACCAACATGGGAAACTTGTGAATGATAA


 


GTTCACAAGAATGTACTTTAAACATGTACTCTTTGAGGACACATTCTTTGACGAGTGC


 


TATTTTGAAGACGTAACATCAACAGATACCTACTTCAAAAATTGTACCATTGAATCAAC


 


CATCTTTTACAACACAGACCTCTACGAGCACAAGTTCATCAACTGTCGGTTTATCAACT


 


CCACCTTCCTGGAGCAGAAGGAGGGCTGCCACATGGACTTGGAGCAAGATAATGACT


 


TCCTGATTTACCTCGTCAGCTTCCTGGGCAGCCTGTCTGTCTTACCCGGGAACATCAT


 


TTCTGCCCTGCTCATGGATAGAATTGGAAGGCTCAAGATGATTGGTGGCTCCATGCT


 


AATCTCTGCAGTCTGCTGCTTCTTCCTGTTTTTTGGCAACAGTGAGTCTGCAATGATC


 


GGCTGGCAGTGCCTGTTCTGTGGGACAAGCATTGCAGCCTGGAATGCTCTGGATGT


 


GATCACAGTGGAGCTGTATCCCACCAACCAGAGAGCAACAGCCTTCGGCATTCTCAAT


 


GGATTATGCAAATTTGGCGCCATCCTGGGAAACACCATCTTTGCTTCTTTTGTTGGGA


 


TAACCAAAGTGGTCCCCATCCTTCTGGCTGCTGCTTCTCTGGTTGGGGGTGGCCTGA


 


TTGCCCTTCGACTGCCAGAGACTCGAGAACAGGTCCTGATGTGAACAACCTATGGGA


 


AAAGGAAAGGTCGAGAGAATCTTGTCCAGGACACTGAAATGCATCCACACTTCCTGC


 


CTATCACGGTCCGGAGGACACCTTGGATAGCACGGGAGGAGAAGTTGACTTTGTGA


 


CCCCTAGTTTAGGACCCACTTCAGCTGTCAATATGTTTGTAACTCAGGTGACTGATTT


 


GGGGGTGCCCTGAGCCACCCTTAGAATCACAGAGCTGCGTGTTTAACTTCAAGTCTT


 


CCCAGTCCAAGGCAGGGAGAGGATTCTCCAGTGAGTGCACACACTATGCGAGGAGC


 


AAGCATTTCTCTAAGTCAAGTGCAAGGACTTAACTTGCGTTTGAAAAGGAATTAGAG


 


GGTCAGAAACACCCAGGTTCCTCCAGAAAGCTCCTTGGAGCCCAACAACTTAACAAAT


 


CAACTTGGCTGGAAGTTAGAGTCATTATATGAAGATTGGGCTTGAAGTATATATTTT


 


TGCATTTAAAAGTATCACCTATCATATTTTCCACTCGAAAATTGACATAGTAGCATTGA


 


GGATACTCTGATCTAGAAAGCCAAGTATTTGAGCAACATCTATAGAGATCTACTTTTC


 


TCCTATGTCTCCTAGGCTTTCCATGATAATTAGGTAATACATTTAAGAAGGATATTTAT


 


TTCTGTTTTGCTCTATTCAAAGAAACGGAATGGGATAGTTATTCTGTAAACTAAGTTT


 


GTATATAACTTTATTTGGGTTTAATTTCCACAACTGGTATCTGCAAATATTGCCAGCAT


 


TTTAGCCATATTTTGGGAGAACTTGGTGTTTGAGGTCCCAGGAAATGAGGTCTGATC


 


AAATGAAATGCAAGCACAATTTCTTACAGCCATTTAACTTTCTGTTGGGAGGATGAAT


 


TAACAAACTCACATTGTGCAGTCTGCTTAATCCAGGCACTTTTCTTTGTGCAGGTGTA


 


GTGAGTAGTTACTTCTCTCCCTTACACAGATGACTTGTGAAACTCAAGCTCACCATCTT


 


CAGTGCTGGCATTTTACTTTGCCACTACCCAAAAACAATGTGAGATGTGTTCAGTGGC


 


CTCTGGTACTCTTTGCAGGCAAGAATCAAACAACATGGGGACTGAGGGAAGGATGG


 


GGAAGTGTAGCCACAGTTCTTCCAAATGTAAATACTTTTTGTTTGTTCTAGTGGTAAA


 


ATGCAAATGCAATCCATATTTGTTAGGATGGTCAGGTCTCATGAGAAATCTATGCTAT


 


GTGTCCAGAGCTTTTGAAACAGAGTCCATTGGAGTGGGAGTTAGGGAGTGTAGTGG


 


ATGCCAAATATGTTTTTCTTCAGTGCTTAAGAGAACTGTTTCCTGAAGTCCAGCTTTG


 


AACATAAACAGGGGTGTGGGTTGGGGGAGGAGCTTAGGACAAACCTCTCTGATGAA


 


GGTCAGCAATAGACTGAAGTCTTGACTGCATGGAAGAGGAAAAACATCAGAACTGTC


 


TGACAATGGAGGGGACAGTGAGCTACGCACAACTGCCAGCGGAGGTGAACTTGCAC


 


CTGCCCAGGCCGGATGAACATCAGCCTGCAAGAACTAGTTGTTTGAGTTGATTTGCA


 


GTGCTCTCAATGGGCAAGTGCCACATTTTCCCTGGCAGAGATCTCCAAAAATTTAAAA


 


CAGAATAATAATGGCTATATCGAGTGTTTTCTCAGTATTGGAGAAATGCTTAGGTCCT


 


ATGATAGCTTCGGGACATCTTTCTGTAATTTTCCTCAATTAACGGGTTGGTAGGGGTA


 


AATCTTATGACACCTTTCCACCGTCGATTTGAGATCAGTTTTAATGGTTAAAATGTTTA


 


CTCTCCTTCTGTCAACCCTCACCTTTTTATTTACACCCCTCCCTTTTTTTCTGTACAGGG


 


AGAGAAGACATATTGACTCTGACTGGACACCCTGATTCCTCCAAATATATATACCACT


 


GTGTATTAATCTTTCTCTCAGTGTTTTATAGGAGTACTAACATTTATTGCTCTGTCAAT


 


AATGAAAGGCTCGATGTAATATAGCTGTAATTTACTTTCCATATGAATACAGTGGCTA


 


GGTTCATAAAAGAGAATTGTGTGAGTCTGGGATTACCACATCTAAAACATTATTCTTT


 


AATGGGATAATACAATTCATTGAGCAGCTACCACTTAAAAAACTTGCAGGACAGTTA


 


GAGCCTGCATTTCTAGTTAAGATGGATCTTGTAAATTTAAAATTGGATTAACATTGGA


 


GTGCTGGGGTGGCTGCAATAATTTGGGGGCTAACTCCATTTGGTTTCCAAGATCTCA


 


CTTCTGCATTATCTTTATGGCTCTTTAAACCAGCCACCTAGCCAATCAAGGGCAATTCC


 


CATCTCATCCATCACTCAGGTCTTTGTAAAGGGTGCAGCCAAGCTCTGCAGACTTTTG


 


CAGGATTGTCTAGCCTGAGTACCGGGCTACTTCTTAAATGCCGTCACTCCTGCTGAGA


 


TAAATGCGTCTTTAAAAATAGTCTCTGTGGCAGGTCACTGGGGGACAATGTACAGCA


 


TTCTGGCCATCCACTTCTTTTTCACTTCATGTTCTACCCCAAGAGACTCCCGATGTCGG


 


CTGTGGAGGGTTAAAGGGATGAGGCTTTCCTTTGTTTAGCAAATCTGTTCACAGTTC


 


TTGATGATGTATITTATGATGCCCAGCTTGGAAATAGTTGCTTTCCATAGTCTCAACT


 


GTATTGTGTCATCTCCTGATGCTGATTTTTGATCTTTTGTTTTATTAAAAATAATTAGT


 


GAAAGAGGTGTGCCTATCTGTGAAGTTTGTAGTACATCATCCTGAGGTCATGTAACA


 


AGTAAACCCCAACCCAGCGTTCCCTCCTACGTTGTGTTAGTTCATTAAAACTAAATAAT


 


AAAAATAACTGTAAGAAAACCTTAA


 


>gi|55743093|ref|NM_004316.2| Homo sapiens achaete-scute complex


homolog 1 (Drosophila) (ASCL1), mRNA


(SEQ ID NO: 2)



CTTCTGGCCAGGGAACGTGGAAGGCGCACCGACAGGGATCCGGCCAGGGAGGGCG



 


AGTGAAAGAAGGAAATCAGAAAGGAAGGGAGTTAACAAAATAATAAAAACAGCCTG


 


AGCCACGGCTGGAGAGACCGAGACCCGGCGCAAGAGAGCGCAGCCTTAGTAGGAG


 


AGGAACGCGAGACGCGGCAGAGCGCGTTCAGCACTGACTTTTGCTGCTGCTTCTGCT


 


TTTTTTTTTCTTAGAAACAAGAAGGCGCCAGCGGCAGCCTCACACGCGAGCGCCACG


 


CGAGGCTCCCGAAGCCAACCCGCGAAGGGAGGAGGGGAGGGAGGAGGAGGCGGC


 


GTGCAGGGAGGAGAAAAAGCATTTTCACTTTTTTTGCTCCCACTCTAAGAAGTCTCCC


 


GGGGATTTTGTATATATTTTTTAACTTCCGTCAGGGCTCCCGCTTCATATTTCCTTTTC


 


TTTCCCTCTCTGTTCCTGCACCCAAGTTCTCTCTGTGTCCCCCTCGCGGGCCCCGCACC


 


TCGCGTCCCGGATCGCTCTGATTCCGCGACTCCTTGGCCGCCGCTGCGCATGGAAAG


 


CTCTGCCAAGATGGAGAGCGGCGGCGCCGGCCAGCAGCCCCAGCCGCAGCCCCAGC


 


AGCCCTTCCTGCCGCCCGCAGCCTGTTTCTTTGCCACGGCCGCAGCCGCGGCGGCCG


 


CAGCCGCCGCAGCGGCAGCGCAGAGCGCGCAGCAGCAGCAGCAGCAGCAGCAGCA


 


GCAGCAGCAGGCGCCGCAGCTGAGACCGGCGGCCGACGGCCAGCCCTCAGGGGGC


 


GGTCACAAGTCAGCGCCCAAGCAAGTCAAGCGACAGCGCTCGTCTTCGCCCGAACTG


 


ATGCGCTGCAAACGCCGGCTCAACTTCAGCGGCTTTGGCTACAGCCTGCCGCAGCAG


 


CAGCCGGCCGCCGTGGCGCGCCGCAACGAGCGCGAGCGCAACCGCGTCAAGTTGGT


 


CAACCTGGGCTTTGCCACCCTTCGGGAGCACGTCCCCAACGGCGCGGCCAACAAGAA


 


GATGAGTAAGGTGGAGACACTGCGCTCGGCGGTCGAGTACATCCGCGCGCTGCAGC


 


AGCTGCTGGACGAGCATGACGCGGTGAGCGCCGCCTTCCAGGCAGGCGTCCTGTCG


 


CCCACCATCTCCCCCAACTACTCCAACGACTTGAACTCCATGGCCGGCTCGCCGGTCTC


 


ATCCTACTCGTCGGACGAGGGCTCTTACGACCCGCTCAGCCCCGAGGAGCAGGAGCT


 


TCTCGACTTCACCAACTGGTTCTGAGGGGCTCGGCCTGGTCAGGCCCTGGTGCGAAT


 


GGACTTTGGAAGCAGGGTGATCGCACAACCTGCATCTTTAGTGCTTTCTTGTCAGTG


 


GCGTTGGGAGGGGGAGAAAAGGAAAAGAAAAAAAAAAGAAGAAGAAGAAGAAAAG


 


AGAAGAAGAAAAAAACGAAAACAGTCAACCAACCCCATCGCCAACTAAGCGAGGCAT


 


GCCTGAGAGACATGGCTTTCAGAAAACGGGAAGCGCTCAGAACAGTATCTTTGCACT


 


CCAATCATTCACGGAGATATGAAGAGCAACTGGGACCTGAGTCAATGCGCAAAATGC


 


AGCTTGTGTGCAAAAGCAGTGGGCTCCTGGCAGAAGGGAGCAGCACACGCGTTATA


 


GTAACTCCCATCACCTCTAACACGCACAGCTGAAAGTTCTTGCTCGGGTCCCTTCACCT


 


CCCCGCCCTTTCTTAAAGTGCAGTTCTTAGCCCTCTAGAAACGAGTTGGTGTCTTTCG


 


TCTCAGTAGCCCCCACCCCAATAAGCTGTAGACATTGGTTTACAGTGAAACTATGCTA


 


TTCTCAGCCCTTTGAAACTCTGCTTCTCCTCCAGGGCCCGATTCCCAAACCCCATGGCT


 


TCCCTCACACTGTCTTTTCTACCATTTTCATTATAGAATGCTTCCAATCTTTTGTGAATT


 


TTTTATTATAAAAAATCTATTTGTATCTATCCTAACCAGTTCGGGGATATATTAAGATA


 


TTTTTGTACATAAGAGAGAAAGAGAGAGAAAAATTTATAGAAGTTTTGTACAAATGG


 


TTTAAAATGTGTATATCTTGATACTTTAACATGTAATGCTATTACCTCTGCATATTTTA


 


GATGTGTAGTTCACCTTACAACTGCAATTTTCCCTATGTGGTTTTGTAAAGAACTCTCC


 


TCATAGGTGAGATCAAGAGGCCACCAGTTGTACTTCAGCACCAATGTGTCTTACTTTA


 


TAGAAATGTTGTTAATGTATTAATGATGTTATTAAATACTGTTCAAGAAGAACAAAGT


 


TTATGCAGCTACTGTCCAAACTCAAAGTGGCAGCCAGTTGGTTTTGATAGGTTGCCTT


 


TTGGAGATTTCTATTACTGCCTTTTTTTTCTTACTGTTTTATTACAAACTTACAAAAATA


 


TGTATAACCCTGTTTTATACAAACTAGTTTCGTAATAAAACTTTTTCCTTTTTTTAAAAT


 


GAAAAAAAAAAAAAAAAAA


 


>gi|39725697|ref|NM_015916.3| Homo sapiens family with sequence


similarity 26, member B (FAM26B), mRNA


(SEQ ID NO: 3)



GTTAGATTAGTCTGAAGCCGCCACCAGCCCCAGGCCCCCGTGCAGAAGAAAAGCGG



 


GAGGGAACGGCGGAGGCCGCCGCTGCCCTGCACCGCCCTCCTGGAGGCCACTTGGA


 


GAGTCCGGCCCCGAGGAGGCCATGGCCACAAGTGCCCACAGCTGGCCCCAGGTTGC


 


CAGCGTCGCTACAGCCCAGACCAAGGCAGAATAATCTCCGGATGAGCTGGTGGCACC


 


GCTGAGCCTTTGGTCTCACCAGGGCTTCCTGTTGCTGGCAGGCGGGGTGGAGCGGA


 


GCTGCTGGGAGGCTGCTGGATAGGAGAGGGGTCACGGCTGCGGAAGAGGAGGTTC


 


TTCGGGACACCCGTGGATGGACACGGCAAGGAAACACCAGGCCAACCACAGCTGGG


 


GATAAAATAGCACAACCACACCCTGCCGTCCAGCGCCTCCCAGCCTGTGCCCCTTCCT


 


AGTACCACCAGCAACCATCAATCCCGTCTCCTCCTGCCTCCTCTCCTGCAATCCACCCC


 


GCCACGACTATCGCCATGGCAGCCCTGATCGCAGAGAACTTCCGCTTCCTGTCACTTT


 


TCTTCAAGAGCAAGGATGTGATGATTTTCAACGGCCTGGTGGCACTGGGCACGGTG


 


GGCAGCCAGGAGCTGTTCTCTGTGGTGGCCTTCCACTGCCCCTGCTCGCCGGCCCGG


 


AACTACCTGTACGGGCTGGCGGCCATCGGCGTGCCCGCCCTGGTGCTCTTCATCATT


 


GGCATCATCCTCAACAACCACACCTGGAACCTCGTGGCCGAGTGCCAGCACCGGAGG


 


ACCAAGAACTGCTCCGCCGCCCCCACCTTCCTCCTTCTAAGCTCCATCCTGGGACGTG


 


CGGCTGTGGCCCCTGTCACCTGGTCTGTCATCTCCCTGCTGCGTGGTGAGGCTTATG


 


TCTGTGCTCTCAGTGAGTTCGTGGACCCTTCCTCACTCACGGCCAGGGAAGAGCACTT


 


CCCATCAGCCCACGCCACTGAAATCCTGGCCAGGTTCCCCTGCAAGGAGAACCCTGAC


 


AACCTGTCAGACTTCCGGGAGGAGGTCAGCCGCAGGCTCAGGTATGAGTCCCAGCTC


 


TTTGGATGGCTGCTCATCGGCGTGGTGGCCATCCTGGTGTTCCTGACCAAGTGCCTC


 


AAGCATTACTGCTCACCACTCAGCTACCGCCAGGAGGCCTACTGGGCGCAGTACCGC


 


GCCAATGAGGACCAGCTGTTCCAGCGCACGGCCGAGGTGCACTCTCGGGTGCTCGCT


 


GCCAACAATGTGCGCCGCTTCTTTGGCTTTGTGGCGCTCAACAAGGATGATGAGGAA


 


CTGATTGCCAACTTCCCAGTGGAAGGCACGCAGCCACGGCCACAGTGGAATGCCATC


 


ACCGGCGTCTACTTGTACCGTGAGAACCAGGGCCTCCCACTCTACAGCCGCCTGCACA


 


AGTGGGCCCAGGGTCTGGCAGGCAACGGCGCGGCCCCTGACAACGTGGAGATGGCC


 


CTGCTCCCCTCCTAAGGAGGTGCTTCCCATGCTCTTTGTAAATGGCACTACTTGGTCC


 


CAAACTGAACCCCACTGCTTGCTCACATCCATATCAGAAGGGGATTTTTAAAAAACTG


 


TTATCTTCTTGGCCAGGGGAAAGGACCACAAGGCAATCTGGGGTGTGGACAGACCC


 


AGTAGACAATGGAAGCCCAGCCAGCAGGGCCAGGTGACAGTGAAGCTCACCAGTGG


 


GCTCCTTTATGGTACTCTATGCAGTTAACATGTATCTAGCTGCATAGGGACACCCAGC


 


GCAGCAGTGCACCACTGGGAAGTGGCCTCCAGTGCAGCCTCTGGCCTTATTTTATAT


 


ATTTAAATTTTTGATAAAGTTTTTCTTACTAAAAAAAAAAAAAAAAAA


 


>gi|47777332|ref|NM_001001412.1| Homo sapiens family with sequence


similarity 26, member C (FAM26C), mRNA


(SEQ ID NO: 4)



CTCTGCTCTGAGCTCTGTTGGTCCCAGCCAGGAGAGCCCGAGTCATGAGGTGGGCAC



 


CCAGTGGGCAGGGTGGGCAGCAGGGGCCCTCTTGGAGGCAGCAGTGAGTTGGGAA


 


GAGGAGGCCGGGCCCCACAGCGGGCATGATGGACAAGTTCCGGATGATCTTCCAGT


 


TCCTGCAGTCCAACCAGGAGTCCTTCATGAATGGCATCTGTGGCATCATGGCCCTGG


 


CCAGTGCCCAGATGTACTCGGCCTTCGACTTCAACTGCCCCTGCCTGCCGGGCTACAA


 


TGCGGCCTACAGCGCGGGCATCCTGCTGGCGCCACCCCTGGTGCTCTTTCTGCTTGG


 


CCTGGTCATGAACAACAACGTGTCCATGCTGGCCGAAGAGTGGAAGCGGCCACCGG


 


GCCGCCGGGCCAAGGACCCCGCTGTGTTGCGCTACATGTTCTGCTCCATGGCCCAGC


 


GCGCCCTCATCGCGCCTGTCGTCTGGGTGGCCGTCACGCTACTCGACGGCAAATGCT


 


TCCTCTGTGCCTTCTGCACTGCCGTGCCCGTGAGCGCACTGGGCAACGGCAGCCTGG


 


CACCCGGCCTTCCTGCCCCCGAGCTCGCCCGCCTGCTGGCCCGGGTGCCCTGCCCTGA


 


GATCTACGATGGCGACTGGCTGTTGGCCCGAGAGGTGGCCGTGCGTTACCTCCGCT


 


GCATCTCCCAGGCGCTGGGCTGGTCCTTCGTGCTGCTGACCACTCTGCTGGCATTCG


 


TGGTGCGCTCTGTGCGGCCCTGCTTCACGCAGGCCGCCTTCCTCAAGAGCAAGTACT


 


GGTCCCACTATATCGACATCGAGCGCAAGCTCTTCGACGAGACGTGCACGGAGCACG


 


CCAAAGCCTTTGCCAAGGTCTGCATCCAGCAGTTCTTCGAGGCCATGAACCATGACCT


 


GGAGCTGGGTCACACCAACGGGACACTGGCCACGGCCCCTGCTTCCGCAGCTGCCCC


 


CACGACCCCCGATGGTGCGGAGGAGGAAAGGGAGAAGCTGCGTGGCATCACGGAT


 


CAAGGCACCATGAACAGGCTGCTCACGAGCTGGCACAAATGCAAACCGCCTCTGCGG


 


CTGGGCCAGGAGGAGCCACCGCTGATGGGCAACGGCTGGGCTGGGGGTGGGCCCC


 


GGCCTCCGCGTAAGGAGGTGGCCACCTACTTCAGCAAAGTGTGAGGCGTGGCCAGC


 


TGAAGAGGCAGGAACGGGGATCTGAGCCCACAGCCCCTCCAACCCCCAAACCAGGTG


 


GAAAAAGGAAGGGTTTCGGTGCTGGGCAGTACTCCCCTAGGCAGATCCACACTCCGT


 


AGCACTCGCCTGCCCATTGGAGGCAGGAAATTTGGAGCTGGAAGGGGATCTGATGC


 


CTTCAGGTGTGACACTGCCCTGGATGGCCCTAGGGCAGTGGGCCCATGAGCAGTATT


 


AGTCTAAAGGGGTCGGAACTGTCATGGCAGGTACAGGGACCAATGGCTCCCCTCTGC


 


CCAGCCCTTCCCAGGCTGATGTTCACTGTCTCCTCCCAGGTTCAACAGACATCCCTGC


 


ACCAGGGTCCACCCTCGTCTGTGGCTGTTCAGTACCTCTCTTCCTTTATGCTCCGGGC


 


TCGGGGAGTGGGAATCATCAGGCGTCTCATGAAGTGGGAGCCCTCTGATTTGGGCA


 


AGCGTGTCGTAGGTGAGACTGGGTGTGCCGGGGCAGGTCCATAAGGACATGACACA


 


CAGCCTACATGGTGTGACACACCTGGGGTGACAGGCGATGAGACAAGATGTCAGAA


 


GCTAGGTTCACATGGAAGAGGTCAGAGTGTGTGGTCACCATGGGGGTCATGTGACA


 


ATTGTCCAGGTGGACTGCATGTTTATTTAGCACAAACCAAGCACAAAAGTCCTCCTGT


 


AGAGGGGTCTTTGAAAAACCACCTTAATACCCACGTCACATCCAGGTCTCCAGGGGA


 


AATCAGACCATCCCCAAGGCTTGAGAAGTTAGACACAGAAGCTGAAGTCTCTCCATTT


 


TTCTCAAAGACCCCACCTCTTGGGGATGGAGTTCTAAGAGGCTAAGAGGAGCTCCAA


 


GGCTCTAGCCCAGGTGGGATGAGGGTGGAGGAGAGCAGTGTAAAGAGAAAGCAGC


 


TCAGATTCCAGAGTGAGACAGAACTGGGTCAAATGGTGTCTCTACCACTCACAAACCC


 


TGTCCCTGGGCCAGCTGCATCACTGCCTGTGCCTTCGTTTCTTCATCTATACAATGAG


 


GATGAGGCCCCCCCGGCCCGCCATCATGGGGTTGCTGTGTGTAAAAGCACATGGCAC


 


ATAGTAGGCACCCAGCACAGGGTGGCTAATGTATTTGTTGATTICTGAACCTAAGGA


 


CTTCCTTCCTCCTCCCCTGGGCAGGGATGAGACAGCAACACAAACACTCGAGCTTCCA


 


TCTTGTTGAGGAGGAAACAGAGGTACAGATAGGTTTCTCAGCACCGCCCTCAGCTCT


 


GAGACATAAGTCCCAAGCATCTAAGGATICATTTTGATCTTGGCATGATTCCATCCTT


 


TTTTATCCATCCTTCCCTCTATTCCCACTTCTGGGGTCCAGTTTCCCTCCTCTTAATTAT


 


TTGGGAGGAGTTGCTCAGATCTTTGTGGGCCAAGGTGGGCTGGGAGGGCTCTTCCA


 


GGAGGTAGGAGTTGGTATGGGCCCTGAAGTCAGGGAGGATTAGGATGAGCAAAAA


 


ACAAGGTGTATGTTGGTGGGTGGCAGCACTTCCAGTGGGAAGAGAAGGCCCGGAG


 


GTATCAGGAGGTACAAATGTGATGAAGAGCAAAGCTTTGGGTCAGGCACACCTGAG


 


TTCAAATACCAGCACTGCAGGACTTGTGGCCAGTCACCCAGCCACTCTAAGCCTCAGT


 


GTGTCTGTCTATAAAATGGATATTAGAAGACCTGCTTGGCCAGGCGGAGTGGCTCAT


 


GCCTGTAATCCCAGCACTTGGGAGGCCAAGGAGGGAGGATCACTTGAGCCTGGGAG


 


TTGGAGACCAGCCTGGGCAACATAGCAAGACTCTGTCTCTGTAAAGTAATAATAATA


 


ATAATAAGAAGAAGAAGAAGAATAAAGAGAAGATTTATAATTTTAAAAAAAAAAAAA


 


AAAAAAAAAAAAAGAAAAAAAAAAAAAAAA


 


>gi|38569393|ref|NM_003640.2| Homo sapiens inhibitor of kappa light


polypeptide gene enhancer in B-cells, kinase complex-associated protein


(IKBKAP), mRNA


(SEQ ID NO: 5)



AGTGCTGCGGCTGCCTAGTTGACGCACCCATTGAGTCGCTGGCTTCTTTGCAGCGCT



 


TCAGCGTTTTCCCCTGGAGGGCGCCTCCATCCTTGGAGGCCTAGTGCCGTCGGAGAG


 


AGAGCGGGAGCCGCGGACAGAGACGCGTGCGCAATTCGGAGCCGACTCTGGGTGC


 


GGACTGTGGGAGCTGACTCTGGGTAGCCGGCTGCGCGTGGCTGGGGAGGCGAGGC


 


CGGACGCACCTCTGTTTGGGGGTCCTCAGAGATTAATGATTCATCAAGGGATAGTTG


 


TACTTGTCTCGTGGGAATCACTTCATCATGCGAAATCTGAAATTATTTCGGACCCTGG


 


AGTTCAGGGATATTCAAGGTCCAGGGAATCCTCAGTGCTTCTCTCTCCGAACTGAACA


 


GGGGACGGTGCTCATTGGTTCAGAACATGGCCTGATAGAAGTAGACCCTGTCTCAAG


 


AGAAGTGAAAAATGAAGTTTCTTTGGTGGCAGAAGGCTTTCTCCCAGAGGATGGAA


 


GTGGCCGCATTGTTGGTGTTCAGGACTTGCTGGATCAGGAGTCTGTGTGTGTGGCC


 


ACAGCCTCTGGAGACGTCATACTCTGCAGTCTCAGCACACAACAGCTGGAGTGTGTT


 


GGGAGTGTAGCCAGTGGTATCTCTGTTATGAGTTGGAGTCCTGACCAAGAGCTGGT


 


GCTTCTTGCCACAGGTCAACAGACCCTGATTATGATGACAAAAGATTTTGAGCCAATC


 


CTGGAGCAGCAGATCCATCAGGATGATTTTGGTGAAAGCAAGTTTATCACTGTTGGA


 


TGGGGTAGGAAGGAGACACAGTTCCATGGATCAGAAGGCAGACAAGCAGCTTTTCA


 


GATGCAAATGCATGAGTCTGCTTTGCCCTGGGATGACCATAGACCACAAGTTACCTG


 


GCGGGGGGATGGACAGTTTTTTGCTGTGAGTGTTGTTTGCCCAGAAACAGGGGCTC


 


GGAAGGTCAGAGTGTGGAACCGAGAGTTTGCTTTGCAGTCAACCAGTGAGCCTGTG


 


GCAGGACTGGGACCAGCCCTGGCTTGGAAACCCTCAGGCAGTTTGATTGCATCTACA


 


CAAGATAAACCCAACCAGCAGGATATTGTGTTTTTTGAGAAAAATGGACTCCTTCATG


 


GACACTTTACACTTCCCTTCCTTAAAGATGAGGTTAAGGTAAATGACTTGCTCTGGAA


 


TGCAGATTCCTCTGTGCTTGCAGTCTGGCTGGAAGACCTTCAGAGAGAAGAAAGCTC


 


CATTCCGAAAACCTGTGTTCAGCTCTGGACTGTTGGAAACTATCACTGGTATCTCAAG


 


CAAAGTTTATCCTTCAGCACCTGTGGGAAGAGCAAGATTGTGTCTCTGATGTGGGAC


 


CCTGTGACCCCATACCGGCTGCATGTTCTCTGTCAGGGCTGGCATTACCTCGCCTATG


 


ATTGGCACTGGACGACTGACCGGAGCGTGGGAGATAATTCAAGTGACTTGTCCAAT


 


GTGGCTGTCATTGATGGAAACAGGGTGTTGGTGACAGTCTTCCGGCAGACTGTGGT


 


TCCGCCTCCCATGTGCACCTACCAACTGCTGTTCCCACACCCTGTGAATCAAGTCACAT


 


TCTTAGCACACCCTCAAAAGAGTAATGACCTTGCTGTTCTAGATGCCAGTAACCAGAT


 


TTCTGTTTATAAATGTGGTGATTGTCCAAGTGCTGACCCTACAGTGAAACTGGGAGC


 


TGTGGGTGGAAGTGGATTTAAAGTTTGCCTTAGAACTCCTCATTTGGAAAAGAGATA


 


CAAAATCCAGTTTGAGAATAATGAAGATCAAGATGTAAACCCGCTGAAACTAGGCCT


 


TCTCACTTGGATTGAAGAAGACGTCTTCCTGGCTGTAAGCCACAGTGAGTTCAGCCCC


 


CGGTCTGTCATTCACCATTTGACTGCAGCTTCTTCTGAGATGGATGAAGAGCATGGA


 


CAGCTCAATGTCAGTTCATCTGCAGCGGTGGATGGGGTCATAATCAGTCTATGTTGC


 


AATTCCAAGACCAAGTCAGTAGTATTACAGCTGGCTGATGGCCAGATATTTAAGTACC


 


TTTGGGAGTCACCTTCTCTGGCTATTAAACCATGGAAGAACTCTGGTGGATTTCCTGT


 


TCGGTTTCCTTATCCATGCACCCAGACCGAATTGGCCATGATTGGAGAAGAGGAATG


 


TGTCCTTGGTCTGACTGACAGGTGTCGCTTTTTCATCAATGACATTGAGGTTGCGTCA


 


AATATCACGTCATTTGCAGTATATGATGAGTTTTTATTGTTGACAACCCATTCCCATAC


 


CTGCCAGTGTTTTTGCCTGAGGGATGCTTCATTTAAAACATTACAGGCCGGCCTGAG


 


CAGCAATCATGTGTCCCATGGGGAAGTTCTGCGGAAAGTGGAGAGGGGTTCACGGA


 


TTGTCACTGTTGTGCCCCAGGACACAAAGCTTGTATTACAGATGCCAAGGGGAAACT


 


TAGAAGTTGTTCATCATCGAGCCCTGGTTTTAGCTCAGATTCGGAAGTGGTTGGACA


 


AACTTATGTTTAAAGAGGCATTTGAATGCATGAGAAAGCTGAGAATCAATCTCAATCT


 


GATTTATGATCATAACCCTAAGGTGTTTCTTGGAAATGTGGAAACCTTCATTAAACAG


 


ATAGATTCTGTGAATCATATTAACTTGTTTTTTACAGAATTGAAAGAAGAAGATGTCA


 


CGAAGACCATGTACCCTGCACCAGTTACCAGCAGTGTCTACCTGTCCAGGGATCCTGA


 


CGGGAATAAAATAGACCTTGTCTGCGATGCTATGAGAGCAGTCATGGAGAGCATAAA


 


TCCTCATAAATACTGCCTATCCATACTTACATCTCATGTAAAGAAGACAACCCCAGAAC


 


TGGAAATTGTACTGCAAAAAGTACACGAGCTTCAAGGAAATGCTCCCTCTGATCCTGA


 


TGCTGTGAGTGCTGAAGAGGCCTTGAAATATTTGCTGCATCTGGTAGATGTTAATGA


 


ATTATATGATCATTCTCTTGGCACCTATGACTTTGATTTGGTCCTCATGGTAGCTGAG


 


AAGTCACAGAAGGATCCCAAAGAATATCTTCCATTTCTTAATACACTTAAGAAAATGG


 


AAACTAATTATCAGCGGTTTACTATAGACAAATACTTGAAACGATATGAAAAAGCCAT


 


TGGCCACCTCAGCAAATGTGGACCTGAGTACTTCCCAGAATGCTTAAACTTGATAAAA


 


GATAAAAACTTGTATAACGAAGCTCTGAAGTTATATTCACCAAGCTCACAACAGTACC


 


AGGATATCAGCATTGCTTATGGGGAGCACCTGATGCAGGAGCACATGTATGAGCCA


 


GCGGGGCTCATGTTTGCCCGTTGCGGTGCCCACGAGAAAGCTCTCTCAGCCTTTCTG


 


ACATGTGGCAACTGGAAGCAAGCCCTCTGTGTGGCAGCCCAGCTTAACTTTACCAAA


 


GACCAGCTGGTGGGCCTCGGCAGAACTCTGGCAGGAAAGCTGGTTGAGCAGAGGAA


 


GCACATTGATGCGGCCATGGTTTTGGAAGAGTGTGCCCAGGATTATGAAGAAGCTG


 


TGCTCTTGCTGTTAGAAGGAGCTGCCTGGGAAGAAGCTTTGAGGCTGGTATACAAAT


 


ATAACAGACTGGATATTATAGAAACCAACGTAAAGCCTTCCATTTTAGAAGCCCAGAA


 


AAATTATATGGCATTTCTGGACTCTCAGACAGCCACATTCAGTCGCCACAAGAAACGT


 


TTATTGGTAGTTCGAGAGCTCAAGGAGCAAGCCCAGCAGGCAGGTCTGGATGATGA


 


GGTACCCCACGGGCAAGAGTCAGACCTCTTCTCTGAAACTAGCAGTGTCGTGAGTGG


 


CAGTGAGATGAGTGGCAAATACTCCCATAGTAACTCCAGGATATCAGCGAGATCATC


 


CAAGAATCGCCGAAAAGCGGAGCGGAAGAAGCACAGCCTCAAAGAAGGCAGTCCGC


 


TGGAGGACCTGGCCCTCCTGGAGGCACTGAGTGAAGTGGTGCAGAACACTGAAAAC


 


CTGAAAGATGAAGTATACCATATTTTAAAGGTACTCTTTCTCTTTGAGTTTGATGAAC


 


AAGGAAGGGAATTACAGAAGGCCTTTGAAGATACGCTGCAGTTGATGGAAAGGTCA


 


CTTCCAGAAATTTGGACTCTTACTTACCAGCAGAATTCAGCTACCCCGGTTCTAGGTC


 


CCAATTCTACTGCAAATAGTATCATGGCATCTTATCAGCAACAGAAGACTTCGGTTCC


 


TGTTCTTGATGCTGAGCTTTTTATACCACCAAAGATCAACAGAAGAACCCAGTGGAAG


 


CTGAGCCTGCTAGACTGAGTGACTGCAGTTAGGAGGGATCCGACAGAGAAGACCAT


 


TTCCACTCATTCCTGTTGTCCTACCACCCCTTGCTCTTTGAGGGCTGGCTATTGAGAAC


 


TGGAAAGAGTAAAATGATAACTTACCTTAGCATTGCCAAGAACTTCAGCAGACAACA


 


AGCAATTCTATTTATTTTATGTTGTGTATACATCTTGATCATTAGCAAGACATTAAGCT


 


TTAACCATTATGGCACCATTTTGTGAGAATGATTGTTCTTTCACTTGGGCTGTTTGAG


 


AGCATAATTATGGTAATCATGAGATTAATGTTTCATGATTTCTACCTCCAAAGTGTGA


 


AGACAAGTAAAACAATGTTTCTAAATTGTCTTATTTTGTTGGCGGAGAAGATTACAAT


 


GGCTATTAGTGCTACATTTGGTCAAATGTAATCACTTAAATAGCTTCTTGTCACCTTAA


 


ACTAAAGCAGAATAAAAAGTATCCTTTGAAATTATAAGCCCTCCTTTGCTGACAGCTA


 


TTATTTTGTAACATCTTACCAGGTCATGTGCTTTCAGTTATAACTGGGCTGAGCCTCC


 


TATAATTACAATGTCTATAGGGACTGTTTTACTGCCTGTGTATTTTCTGCTAGAGAGT


 


TAGCAATGTTAGAGCTAGAACAGATTAGAATTTCTAAACAGTATCATGCACAGTTGG


 


TGTGAGTGATCAGTGTGCATTGTATGGCATGCATGGTTGTGAATTATTCTCTGTTCTC


 


CAAATACTGTTTCTTTAACTCAGATATTTTTGTTAGTGTCTAGGCCACTTCATTTATTT


 


TTCGTCATGGTACTTTACTGACTTCTCTTTATTCAATTCTCCACGCCCTCACCAAAAAA


 


AACTGTCTCAAAATGAGAATATTTTATTTTCATGGTGAGTCTAGAAAACGCCCACTTC


 


ATTCTGATTAAAAATTCTTCCATGTTTTAAATATCAGAACCAGACCTTTCTTACTGTGT


 


ATCTTAGCCCATTTGTGTCTCTATAACAACAACCAGCTTTCAAAGGAACTAATAGAGT


 


GAAAACTCACTCATTACCACGAGGATGGCACAAGCGATTCACGTAGGATCTGCCCCT


 


GTGACCAAAACACCTCCCATTGGGCCCCACTTCCAACACTGGTGATCACATTTCAACA


 


TGAGGTTTAGGGAAACAAATGCCTAAACTACAGCACTGTACATAAACTAACAGGAAA


 


TGCTGCTTTTGATCCTCAAAGAAGTGATATAGCCAAAATTGTAATTTAAGAAGCCTTT


 


GTCAGTATAGCAAGATGTTAACTATAGAATCAATCTAGGAGTATTCACTGTAAAATTC


 


AACTTTTCTGTATGTTTGAACATTTTCACAATCTCATAGGAGTTTTTAAAAAGAAGAG


 


AAAGAAGATATACTTTGCTTTGGAGAAATCTACTTTTTGACTTACATGGGTTTGCTGT


 


AATTAAGTGCCCAATATTGAAAGGCTGCAAGTACTTTGTAATCACTCTTTGGCATGGG


 


TAAATAAGCATGGTAACTTATATTGAAATATAGTGCTCTTGCTTTGGATAACTGTAAA


 


GGGACCCATGCTGATAGACTGGAAATAGAAGTAAATGTGTTTATTGAAAAAAAAAAA


 


AAAAA


 


>gi|21734229|emb|AL833583.1| Homo sapiens mRNA; cDNADKFZp686O0656


(from clone DKFZp686O0656 (LOC285965)


(SEQ ID NO: 6)



GGGAGAAAAAGGGCTCAGGACTGAGGAGTGAAGAGCTCCAGGGATTTCACTCTTCT



 


TTGTGTGTGTGAAGGAAGGTTTATTTGCAAGATGGGTTTGAGGGAATTAAGGATAA


 


AGTCTGCTGAAAGTAGCACCAGCCTCTGGATTAAAAGGGATGTTTGGATGAAGCTTC


 


AATCTCAAGAAGAGGCAAGAGAAAACTAAAGAAAAAGAAGGCAGCAACTGCTTTCG


 


GGAGCAGCTGAAGGCTGGAGATAACATGGACCTCCATGATGAGAGCTGGAATGAAG


 


TACCAGGGCAAGGGAGCTGCCTGGATGAGGAAACCAAGGCTATCTCAGTACTGCCA


 


AGGTGTTTTCATCATTCATCAAAATGCAAAAGTAAACACTGGTGAGAAAAACGATGTT


 


GATCTCCCAGGCAAGCCACTTTCCAGGAGTGTGGCTGATTATTTTCAAATGCTGCATC


 


GGAAAGTTGCAGGCCCCTTGGAAAATCTGTCACCCCTGAGAGTGATATTATTCTACA


 


GAAACAACACATCACTGGATGCCTCTCACCATGCAATCCTCTGTGCACTTGAGAAGAA


 


GACAAGACTCTCCTATTTTTAGATGGGAAAGCTGAGGCAAAACGGATGCACTTGGGC


 


AAAATCATTTGATAAAAATGGAAGCTGAACCTCCAAGTCCTGGCATCGGTAGCTGCCT


 


CATGTTCCTCCCGCCTCACTCCACCTCAGTGTACCCGCGACTGGAGGGTGCCACAGGC


 


TGGAGCACACAAAACACTGTGTGCTTCGTGATTCTGATGTGGGGCGCCAGATCCGGT


 


GGAAGGAGGGTGGCTGCGTGGGAACAGATGCTCGTGTCGCAAGGAGTTGTCTCTTG


 


TGGGCAAAGCAAGCTGGAAAGTGTTTCGATTTCTTTATTTTCATGCTCTACTCTTGGT


 


GCTTCCTTCTCCTTTGCCCACCAATCCCCCCAATGCCAGGCTTCTCCTTACCTGGGTGC


 


AGAGAGAGGAACAACTTGGAGGTGGGCAGAGAGGGACTCAGTTCATGGTGCTTGG


 


AGGTGGGAGAGCTCCCAGGCAAAATAGAGAGGAGACTGTGGAGATGCCGTGGGCA


 


GGTGTGGAGGAGAGGGAGAGCTTGAACGGTGAAAAACAAGAGATGGAGAGTCTGG


 


GAGAAGGGTGAGCAGCCAGAATGGGGATTTCCACAGTAGCTTCTGATGAGCTATGT


 


CTGGTCAGAACTATAACCTTAGCTTCCTTTATTTCCCTGGAGGGGTGGGGAGATAGG


 


AAGGAGAGGAGTATACTAGTCTCTTCCAAAGGGAGGGCCAGAGCAAAAGCGTCCTG


 


TGATTAATTACTCACCACAAAAACCCTCTTCAAGGCTGGAGACCTAGGAGGGGCTTG


 


GCACACAGACAACTCCTCTGCAGCTGTTCAGAGAAAAACAGCTCTTCCCATCTCAAGC


 


CGCCCACCTGCCCAGTGTGCTGTCTGTCCCACTGGTCACACACTTTCCCTAGAGTGCT


 


TCTTGCTTCTCTCACAGCAATTCCCACCTCCGCATGCTGGACCAGGCGGCCCCCTCTA


 


GATCCCATGGTGAAGCATCAGGTGCCCACAGGTCTAAGATGTCTTCATTTGTTCAATG


 


GCTAGAGCAGGCAGCTGGCTGTCCAGATGCATGAATGAATTCCCTAACTCTCACATG


 


TCTGCAGGAAACTGCTGTAGGAAGCCTGCACCAGTGGATTGCCATTCGGGCAGATCC


 


TCTCAACTTTGAGAGCTTAAGGCTTGCTTTTGAGTATGTGATTATGATCCTGCCTGTG


 


TGTATGTATGTCAGAATCATAGAACTCTAGAGGTCATGTTTTAATTAATTTATTCATTC


 


ATTGATTCATTAACAAATGCTTATTGAGTACCTACTATGTGTCAGGCTGTGATCTGGA


 


TACTGAGGCACAGATCAGTGAGCAAAACAGACCAAAAGCTCTGTCATCATGAAGCTT


 


ATATTCTAGAGAGAAGAGATATACTATCATCAAATTAAGTCAGTTATGTAGCATATTA


 


GAAAGTGATAAGTCCAGTGGGGTAAAATAAAGGAGGATGATGGGGAATGTGAGGG


 


GCGGCATGCAATTTTAAATAGAATGTTTGAGGAAGGCTTTCATGGGAAAGTGATATT


 


TGGTGCAAAACGTGAAGGCGGTAAAGAGGTGAATTATGTGGCTATGTCGGGGATG


 


GACATTACAGGCAGAAGAATTAGTTAGTCGGGGCTCTGAGCAGGGAGCAGGTCTGG


 


CATGTTCCCATCCCAGCAAGTAGGCCAGTGTGGCTCTGGTGGAGTAAGCAAGGATG


 


GAATTGCAGCAGGTGAGTCCAGAAGAGTGATAATGGACAGCCAGTTGGGGGTGCCT


 


TCCAGGTGATTGTGGGAACTAGGCTTTATTCTGAGTGTGATGGGTAGCCACTTGGG


 


GCTTTCAGGACAGGATGGTAAAAAAAGGATCATGCTGCCTGCTGTGTTGGGAACAG


 


ACTGTATGGGACCAGGTGAAAGCAAAGCAGTCAGCCTCAAATAATTCAGGTGAGGG


 


AAAACGTGACTTGAATAAGATTCACTGTAGAAGTGGTGAGATATAAGTGGATTCTGG


 


ATATAATAAAAATATAGAGCCAGCAGGATTTTCTGATGGATTAGCTAAGGAGTGTAA


 


AGAAATAGAGGAGTCAGAGTGACTTTTTTTTTTCCTTGAGCAACAGGAAGTGGAGAG


 


GTATCATTACCTGAAAGGAGGAAAGCCTCAGGTAGAGAAAGTTTTAGAGGAGGTAA


 


GATCAGAGGTTTAGTGCAAGACATGCTAAGTTTGAGATGTCTATTAGATACCCAAGT


 


GGATCTGTCTAATGGGTATTTAGACAGATCCACTTGGATATCTGTCTCAATGGACATG


 


TGATCTACATGTAGTTCACAGGATAAGTCCAGTTTAGAGTACCAATTTGAAGTCATCA


 


AATGTAGGTGGCATTTAAAGTGGTAAAACTGGACTGAGCACAGTGGCTTATGCCTGT


 


AACCCCTGCATTTTGGGAGGCTGAGGTGGGTGGATAACTTGAGGTCAGGAGTTCGA


 


GACCAGCTTGGCCAACATGGTGAAACCCTATCTCTACTAAAAATACAAAAAATTAGCC


 


AGGCATGGTGGCACATGCCTATAATCTGAGCCTCTCGGGAGGCTGAGGCAGGAGAA


 


TTGCTTGAATCCAGGAGGCAGAGGTTGCAGTGAGCCAAGATCGTGCGACTGCACTCC


 


AGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAAAATAAATAAATAAATAAATAAA


 


TAAAACAAAAATAAAAAATAAAGTGATAAAACTGGAGATCACTATGAGAATGAGGAT


 


AGCTAGAGAAAAGAAGGGGTCCAGAAGGTTATCCTTGCTGTGCTCCAAGGTGCTTG


 


AGTTTGGAAACATGAGACAAAACCAGAAACAGAGACCCTGGGAGAGTCTGTGGTCT


 


CCATTTTTCCGCTGAGCAAACCACAGGCTTGTGTTCTGCCTATCTCCCACTTCGCACAT


 


GTACAGCATTGTAGAATATTTACATGGAAAAGGATTCTATGATATAGTAGAGTGACT


 


TCCCCTATTGATAACAAACAATTATGTCAGTCCCTACACAACTCTTATGCTAAAGGTAA


 


TGGGGAGGGTTGAATGGTACTCATTTGGGCAGCTTTTTTTTTGGCTATGTATACTTT


 


CAGAAAGAATTTACCTCACCTAGATCACATGACTAAATATAGGAATATTAATACCCAC


 


TGTGTCTAATTGGCAGATTGTTTTGAGATTTTAAATGAGATCTATTCATGAAAACATT


 


TTGTTAATCTTAAAGCACCACACCAATATCACCTATTATATTGTACAGCCATGATCAAC


 


ACAATTTCCAATCTAGAAGTCCCTCTCAACTTTTCCTGGGACCGAGCTTTCAGGACTTA


 


GAGTTCCTTCTCCTTCTCATTCTTTTTCTGCGCATAGTCTCCCGGTAAAGTGAAAACCA


 


GCTGAGAAAAGATTCGGGCTGGACAGGCCTCCGTGGCGATTAAGAGTCACGAATGT


 


GATGATATTATTCGCAAACAGCAGTGTAGTCATGGTTCAGAATTTTGGAAACAGTGC


 


CAGGAGGATCTTGGACATAATTTTCAGGGTGTATAAGCCCTGCACTAAAGTAAAGTT


 


TACCAGTGCCAAGAGTTTGACGTTTTCTTCTTCATGTTTTCTTTGGCTGGAGCCTGGC


 


TTTAGTTGAAGAGTTCTGTCAACAAATGGAATTCTCTATTTGGGACTGGGATTCTTGA


 


TTGGTGGTGCTTCTGTCTCCTCTTGCTGTGAGTTTCCTCAAACTTAGAGTCCTGTGGG


 


ATCTGTGTTTGAACAGAGACTGGAAATGCTTACCTCATCTCCACATTTCTTAGCCATTT


 


GTCACCAGACTGTAGATTGACTGGTGGGATGCCTGTTTCTAGAGAGAAAAGATACTG


 


CTTTTCTCTGACTCCAGCTGAGAAGAGGTTGGTTAAATTACGAATCTGATGACTATCT


 


ATGAACCTAAGGAGGAAAAGTTAATTTCTTTTGAGGGTTTGCATAATGTTTTAAAACA


 


AATTTATAGAAATATAGATGATGGAAAAAAGCAATAGGGTAAACCTAAATTATTAAA


 


AATAAATAATACATAGGAAATAAACAGCATAGAAAAGAAACAAAAAAGAGATTGTTA


 


CCAAAAACCATAAGTTTTTTTTTTTTTGAAAATTCTAAGAAGGTGGATAAATTTCTGG


 


AATTTTCAATGAGCAAAAAAGTGAAAAGATACAAATGAATAAAAAATGAAAAGGTAG


 


AAATTAAAATAGGTCTAGTAGAGATTAAAAATAATAAAAGAATATTATTAAAAAGTAT


 


TGGTGGATAAAATAGGCACATATCTGAAGATAAAAGCCGAATTGACCCCCTAAAAAG


 


CAGAAAACTTACAATAACAATCATTAATGGCTTTGAATGGCTATGAAAAAATAATATC


 


TCTGCCCTCTTCACTACTCCCATGTAAAATAATTTTACGGGTAGATTTTACCAACGTTT


 


CAAGAGAGACATGATTCCCAAATATTATGTAAGTTTTTTCAGAAAAAAAAAAAAAAAA


 


AAAA


 


>gi|20336280|ref|NM_052832.2| Homo sapiens solute carrier family 26,


member 7 (SLC26A7), transcript variant 1, mRNA


(SEQ ID NO: 7)



GAATATAAGGGGAATTACTGGCGAGAGAGCTGTAGACCAACTTAACACTGAACCCAT



 


TACTTTTCCAAGACCAGAAAAAAATATTACATGAACAGGAACTACTTCTCCTTCAGATA


 


AGAATTCAAGCTTTGACATTGTAAACCACAGACGAATTGGAGCTTGGCATTGAAAGG


 


AGGTGTTCTGCAATGATTTTTTTTCTTGTTTAGAGAAGTTTACTTCTACAAGAAGAAA


 


TCTGAAAAATGACAGGAGCAAAGAGGAAAAAGAAAAGCATGCTTTGGAGCAAGATG


 


CATACCCCCCAGTGTGAAGACATTATACAGTGGTGTAGAAGGCGACTGCCCATTTTG


 


GATTGGGCACCACATTACAATCTGAAAGAAAACTTGCTTCCAGACACTGTGTCTGGG


 


ATAATGTTGGCAGTTCAACAGGTGACCCAAGGATTGGCCTTTGCTGTTCTCTCATCTG


 


TGCACCCAGTGTTTGGTTTATATGGGTCTCTGTTTCCTGCCATAATTTATGCCATATTT


 


GGAATGGGACATCATGTTGCCACAGGCACCTTTGCCTTGACATCCTTAATATCAGCCA


 


ACGCCGTGGAACGGATTGTCCCTCAGAACATGCAGAATCTCACCACACAGAGTAACA


 


CAAGCGTGCTGGGCTTATCCGACTTTGAAATGCAAAGGATCCACGTTGCTGCAGCAG


 


TTTCCTTCTTGGGAGGTGTGATTCAGGTGGCCATGTTTGTGCTGCAACTGGGCAGTG


 


CCACATTTGTGGTCACAGAGCCTGTGATCAGCGCAATGACAACTGGGGCTGCCACCC


 


ATGTGGTGACTTCACAAGTCAAATATCTCTTGGGAATGAAAATGCCATATATATCCGG


 


ACCACTTGGATTCTTTTATATTTATGCATATGTTTTTGAAAACATCAAGTCTGTGCGAC


 


TGGAAGCATTGCTTTTATCCTTGCTGAGCATTGTGGTCCTTGTTCTTGTTAAAGAGCT


 


GAATGAACAGTTTAAAAGGAAAATTAAAGTTGTTCTTCCTGTAGATTTAGTTTTGATT


 


ATTGCTGCATCATTTGCTTGTTATTGCACCAATATGGAAAACACATATGGATTAGAAG


 


TAGTTGGTCATATTCCACAAGGAATTCCCTCACCTAGAGCTCCCCCGATGAACATCCT


 


CTCTGCGGTGATCACTGAAGCTTTCGGAGTGGCACTTGTAGGCTATGTGGCCTCACT


 


GGCTCTTGCTCAAGGATCTGCCAAAAAATTCAAATATTCAATTGATGACAACCAGGAA


 


TTTTTGGCCCATGGCCTCAGCAATATAGTTTCTTCATTTTTCTTCTGCATACCAAGTGC


 


TGCTGCCATGGGAAGGACGGCTGGCCTGTACAGCACAGGAGCGAAGACACAGGTG


 


GCTTGTCTAATATCTTGCATTTTCGTCCTTATAGTCATCTATGCAATAGGACCTTTGCT


 


TTACTGGCTGCCCATGTGTGTCCTTGCAAGCATTATTGTTGTGGGACTGAAGGGAAT


 


GCTAATACAGTTCCGAGATTTAAAAAAATATTGGAATGTGGATAAAATCGATTGGGG


 


AATATGGGTCAGTACATATGTATTTACAATATGCTTTGCTGCCAATGTGGGACTGCTG


 


TTTGGTGTTGTTTGTACCATAGCTATAGTGATAGGACGCTTCCCAAGAGCAATGACT


 


GTAAGTATAAAAAATATGAAAGAAATGGAATTTAAAGTGAAGACAGAAATGGACAGT


 


GAAACCCTGCAGCAGGTGAAAATTATCTCAATAAACAACCCGCTTGTTTTCCTGAATG


 


CAAAAAAATTTTATACTGATTTAATGAACATGATCCAAAAGGAAAATGCCTGTAATCA


 


GCCACTTGATGATATCAGCAAGTGTGAACAAAACACATTGCTTAATTCCCTATCCAAT


 


GGCAACTGCAATGAAGAAGCTTCACAGTCCTGCCCTAATGAGAAGTGTTATTTAATCC


 


TGGATTGCAGTGGATTTACCTTTTTTGACTATTCTGGAGTCTCCATGCTTGTTGAGGT


 


TTACATGGACTGTAAAGGCAGGAGTGTGGATGTATTGTTAGCCCATTGTACAGCTTC


 


CTTGATAAAAGCAATGACGTATTATGGAAACCTAGACTCAGAGAAACCAATTTTTTTT


 


GAATCGGTATCTGCTGCAATAAGTCATATCCATTCAAATAAGAATTTGAGCAAACTCA


 


GTGACCACAGTGAAGTCTGAGACCCTTTTGTCACAGTACAGCTCTTGTCTTTACCAAC


 


TGCCTGAAGAGGCCATATGCTGGCATTTTGCACAACTTTTTGGTTGTTTAGATCCTAC


 


AGATGACCTCTGCTACAATAAGTACGATGTGACTTAGTAACTGCATAGCAGTTGGAA


 


AGAACTGCCAACTTTTTTTTCTCATTTTTGTTAGTAAGAAGATTCGCTTAGTTATTTTA


 


TGTAAAAATCAGTATGTGTTTAGTTTTAGTGTACTGAAGGGTAAACATGGTTTTATTT


 


TATTTTACCATATTATTTTGTGTTGTTTTATTTCTATTGTGCTGTAAGTTGATGTTTAA


 


AATTGAGAAATACTTTTGTCATAGGTAATTTGGAACATTTACAAGCCATTTGTAAAAT


 


TTTAAGATAATCTGTAACTAATACATAAAAACAACTTAGCAAATGTGCCATTTTCACAC


 


AACTTCTCTCTGTATAGGCCTCTGAAATATCAATAAGGCTAAATATTACTTTACACAGT


 


AAGATGTGAAATTCACAAAAAGTAAACCAAACAAAACGAATGAAAAACTGGAAATAA


 


TTCGTTTCCATATCTTTCCATACATCCATTTCTGAAGTATTCAGGAATGTTTTCATAAT


 


CGAAAGAAACGGGTATCCAAATAAAACCAAGTTCTTGACATTGGTCTGTTTTGCTGT


 


GAATATTGGAAATGCTTAGGATCTTCAGACCCAATAGCTCTAATTTTAACATTTCTACC


 


CAATAAGAGGCTCTGTTTTCCACTGAAGCTTTGTTGGAGAAAGAGAATATGAAAATT


 


ACACATTTTATAATTTTTAGATGAGAAAATACCACTAGCAGAATAGCTTTGTGCTATT


 


CCAGTATAAGATGAACTGTAATAATTTTTGACTTCCCTATTTCAGAGATAGTCAATAT


 


AATATGTTTATCTATATCCATATGGATGGATAGGTAGGTAGATCTTCATAGATTTTTT


 


TTTCTTTTGTTAGAGGAGAGCTTGATGTGATTATCTICAAACCCACCAAACCAACAGG


 


ATAATTGACAAATAAACGCCATAGGCTAGGCTGAACTGTATGTTACTGTTTTCATGCT


 


TATACATATATTTTCAATCACATACAAGTACATAGAATTTCACATTTTAATTTAGCAAA


 


TTGATTTACCTAGGAAAAAATTATCACCTTCAAAGATAGGCATAGACACATAATTATG


 


CTTAAGCTTTTAACAGCATTTTAACCGCTCTAAAAATTACCAGAGTAAGAAAAAGCTA


 


GGTACTTTAAAGTGAGTTTGAGAAACAAGTTGAAACTAAAATTAAAATACCAGCCATT


 


TAGGTGCTTTCTCTGGCATCTATAAAAGTAAATTCTAGTGCCTGCCAAGTGATGGATT


 


ATAATGGTCTCTAGCAAATGTGTGGTAAACATTCATATGGCCATTAATTTTAACATTA


 


AATCGTAGGTAGGGCAATGTAGTAAAATGAAAGAGAATTAAGAAAGGTTTTGAATTC


 


TTATAACATATCCAGCCATTTCAATTTTGATTGAAATGAACTACAAAGAATAGTGTTT


 


GTCCCTATGGTAGCCTCAGTCTCTTTATCACTAACTTGGATTGAAATGAGTGAGGCCA


 


ACTCACATTCCCATCAAACACTCTTCCAAGGAAAAGCAGAAGTAATAATTGGAGGTAA


 


AGTTTCCTTAGAGAAAATAATTTTATTCTGCTTTGTCCAATTAAATTATTCCAATGGCG


 


GATGGTAATATTCACCATCTCTAATTCATTGGTCACTGGTAGGTAAGCATGAGTTAAG


 


GAAAGTCAAAAATGAAAATATATTTTGCTGTGTATAAATTGATATTTTGCTATGCAAC


 


TCCTGTAATTGAATTTGTATAATGCAGGCACTTTCTAATTTATTAGAGATTATGGATC


 


AGTTCTGACATTAAAATCATAGTTAATTGATGGATGGTTTTTATAGTTTGTTGATAAA


 


GTGGACACAGTATTGTCTGAGCAGTTATATTTTAATGCATTTCAGTGTTTATAGTAGA


 


AGTTTAGTGGATAAAACTTTAAGTCCAATAACTTGGGGGTCAAATGCTAATGTTTTAT


 


TCAATGTAAAGGAAGACCAAACCATGTACCTTATGAAGACCTTTGTTTTAAGACTTCC


 


ACACACCAAGGCTACAATGACTGTTAACCTGGAGGAAGTCTCTGGTATGGAGTTCTG


 


AGAGCTTAAGAGCTAAACATGAGTTTAGACACACAAGATTCTAAAATGCAAATGTTTA


 


TTTTGAAGCAGGCATTGACAACACAAAAACTGTGTAGTGGTCTTGATGCTGGATTGT


 


TTCTAGAGTCACAATGAATTATTTTTATGAGATTACCTTATTTTTATATATGACAAACT


 


ACTTCTATAATGCTTATTATGGTAAAATAAAATTGGAAAAAATTAAAACTGACCTATA


 


AGAGTGTTAAGGACCTAATAGAGTGACATATATAAATTAAGCATAAAATATGTAACC


 


AGGAAAAGACTGTTAACATTACATTTATGCAAATTAAATGCCCTTAAATTTCACCATTT


 


GTCTTTCATTTTAAAGGTTATTTGCTCCCGATTATATGATTCAAGTGTTATAAGTTTTA


 


GCTTGAACTACTTTGCAGTAATTTATTTGACAGATCTCTATTCTATAAATGTGTAATGT


 


GATGAAGAAAGAGATCTTTCTTTTTTAATGAAAACATTAATGTGTTAATACCCTGTAT


 


GGATAATGCTTGACATTTAGTGGTTTCCAAAATATATTAGTATATTGTTGAACATACA


 


TTATGCCTTAGAAATGCACATTCTGTATTTTGTGGGATGATAATCTAATTCAGTATAG


 


AATATGCTGTTTGGCAATGAGTTTGTGGCCAGATTTCAAATAGGGAGTTAAGTGGTA


 


CTTTCACAATCCAAAGATTTTTAGTTAAAAATCATGTAGTCTAATATGCTGCAGTTATT


 


TTTTTATATTTTTCAATGCATTTAATTATCTTTTTTATAATTCTTTGTACTAACTCAGCA


 


TGTAACAACCAATTTACATGGAAATAAATCGAAATATGATAACTATTATGCAAAAAAA


 


AAAAAAAAAA


 


>gi|116256456|ref|NM_032034.2| Homo sapiens solute carrier family 4,


sodium borate transporter, member 11 (SLC4A11), mRNA


(SEQ ID NO: 8)



CTTTCTCCCTAGGGTGGCGTGGGTTGCATCCCTCGGAAGAGCGAAGGAATGAGCCA



 


GGTCGGGGGGCGGGGAGACAGGTGCACACAGGAGGTCCAGGGCTTGGTCCATGGG


 


GCTGGTGACCTTTCTGCTTCCCTTGCAGAAAACTCTCCCACCATGTCGCAGAATGGAT


 


ACTTCGAGGATTCAAGCTACTACAAGTGTGACACAGATGACACCTTCGAAGCCCGAG


 


AGGAGATCCTGGGGGATGAGGCCTTCGACACTGCCAACTCCTCCATCGTGTCTGGCG


 


AGAGTATCCGTTTTTTTGTCAATGTCAACCTTGAGATGCAGGCCACCAACACTGAGAA


 


TGAAGCGACTTCCGGTGGCTGTGTGCTCCTGCACACCTCCCGAAAGTACCTGAAGTT


 


AAAGAACTTCAAGGAAGAGATCCGTGCGCACCGCGACCTAGATGGCTTCCTGGCGCA


 


GGCCAGCATCGTCCTGAACGAGACGGCCACCTCCCTGGATAACGTGCTGCGGACCAT


 


GCTTCGCCGCTTCGCCAGGGACCCTGACAACAATGAGCCCAACTGCAACCTGGACCT


 


GCTCATGGCCATGCTCTTCACCGATGCCGGGGCACCCATGCGGGGTAAAGTCCACCT


 


GCTGTCAGATACCATCCAAGGGGTCACCGCCACAGTGACAGGGGTGCGGTACCAGC


 


AGTCGTGGCTCTGCATCATCTGTACCATGAAGGCCCTACAGAAGCGGCACGTGTGCA


 


TCAGCCGCCTGGTTCGCCCACAGAACTGGGGGGAGAATTCCTGTGAGGTTCGGTTC


 


GTCATCCTGGTGCTGGCCCCACCCAAGATGAAAAGCACTAAGACTGCGATGGAGGTG


 


GCGCGCACGTTTGCCACCATGTTCTCGGATATCGCCTTCCGCCAGAAGCTCCTGGAG


 


ACCCGCACAGAGGAGGAATTCAAGGAGGCCTTGGTGCATCAGAGACAGCTGCTCAC


 


CATGGTGAGCCACGGTCCAGTGGCGCCGAGAACGAAGGAACGCAGCACAGTCTCCC


 


TCCCTGCCCACAGACACCCAGAGCCCCCAAAGTGCAAGGACTTTGTCCCTTTTGGGAA


 


GGGCATCCGGGAGGACATCGCACGCAGGTTCCCCTTGTACCCCTTGGACTTCACTGA


 


TGGCATTATTGGGAAAAACAAGGCTGTGGGCAAATACATCACCACCACCCTGTTCCTC


 


TACTTCGCCTGCCTCCTGCCCACCATCGCTTTCGGGTCTCTCAATGACGAGAACACAG


 


ACGGGGCCATCGACGTGCAGAAGACCATAGCCGGGCAGAGCATCGGGGGCCTGCTC


 


TACGCGCTCTTCTCTGGGCAGCCATTGGTGATTCTGCTGACCACCGCGCCCCTGGCGC


 


TCTACATCCAGGTGATTCGTGTCATCTGTGATGACTATGACCTGGACTTCAACTCCTT


 


CTACGCATGGACGGGCCTGTGGAATAGTTTCTTCCTTGCGCTTTATGCCTTTTTCAAC


 


CTCAGCCTGGTCATGAGTCTCTTCAAGAGGTCGACGGAGGAGATCATCGCCCTCTTC


 


ATTTCCATCACGTTTGTGCTGGATGCCGTCAAGGGCACGGTTAAAATCTTCTGGAAG


 


TACTACTATGGGCATTACTTGGACGACTATCACACAAAAAGGACTTCATCCCTTGTCA


 


GCCTGTCAGGCCTCGGCGCCAGCCTCAACGCCAGCCTCCACACTGCCCTCAACGCCAG


 


CTTCCTCGCCAGCCCCACGGAGCTGCCCTCGGCCACACACTCAGGCCAGGCGACCGCC


 


GTGCTCAGCCTCCTCATCATGCTGGGCACGCTCTGGCTGGGCTACACCCTCTACCAAT


 


TCAAGAAGAGCCCCTACCTGCACCCCTGCGTGCGAGAGATCCTGTCCGACTGCGCCC


 


TGCCCATCGCGGTGCTCGCCTTCTCCCTCATCAGCTCCCATGGCTTCCGGGAAATCGA


 


GATGAGCAAGTTCCGCTACAACCCCAGCGAGAGCCCCTTTGCGATGGCGCAGATCCA


 


GTCGCTGTCCCTGAGGGCCGTCAGCGGTGCCATGGGCCTCGGCTTCCTGCTGTCCAT


 


GCTCTTCTTCATCGAGCAGAACTTGGTGGCCGCCTTGGTGAATGCACCGGAGAACAG


 


GCTGGTGAAGGGCACTGCCTACCACTGGGACCTCCTGCTCCTCGCCATCATCAACACA


 


GGGCTGTCTCTGTTTGGGCTGCCTTGGATCCATGCCGCCTACCCCCACTCCCCGCTGC


 


ACGTGCGAGCCCTGGCCTTAGTGGAGGAGCGTGTGGAGAACGGACACATCTATGAC


 


ACGATTGTGAACGTGAAGGAGACGCGGCTGACCTCGCTGGGCGCCAGCGTCCTGGT


 


GGGCCTGTCCCTGTTGCTGCTGCCGGTCCCGCTTCAGTGGATCCCCAAGCCCGTGCT


 


CTATGGCCTCTTCCTCTACATCGCGCTCACCTCCCTCGATGGCAACCAGCTCGTCCAGC


 


GCGTGGCCCTGCTGCTCAAGGAGCAGACTGCGTACCCCCCGACACACTACATCCGGA


 


GGGTGCCCCAGAGGAAGATCCACTACTTCACGGGCCTGCAGGTGCTTCAGCTGCTGC


 


TGCTGTGTGCCTTCGGCATGAGCTCCCTGCCCTACATGAAGATGATCTTTCCCCTCAT


 


CATGATCGCCATGATCCCCATCCGCTATATCCTGCTGCCCCGAATCATTGAAGCCAAG


 


TACTTGGATGTCATGGACGCTGAGCACAGGCCTTGACTGGCAGACCCTGCCCACGCC


 


CCATTCGCCAGCCCTCCACGTCCTCCCAGGCTGGCTCTGGAGCTGTGAGGGGAGGTG


 


TAGGTGTGTGGGTGACTGCTCTGTGCTGCGCCTTCTCATGGCTGACTCAGGCCTGGG


 


GCATCTGGGCATTGTAGGGGTGCAGTGGTATGTGCCCACCCCTCTCCCATTATCCTTT


 


AGCTTTAGGCCAAGAGCGTTGCTCAGGGCAGCTTCTGCCCAGGGTGGGTGGGACTG


 


AGCAGGATGGATTTTCTTTTGATAAAAGAGTCGATGCCTGAAAGAGAAACCATTTCC


 


TTGATTGTGTAAGGAACTTGCTGGACGCACATTAGAGAATAAAGCTCCTGTTTCTAG


 


GCTCCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


>gi|121949782|ref|NM_001017970.2| Homo sapiens transmembrane protein


30B (TMEM30B), mRNA


(SEQ ID NO: 9)



GGACACTCCCAACTTGAGACTGAAAGCTGGGCGAAAGCGGTTTGTGAAGCTAACCTA



 


AAAGACAAAATGGTCTAGAGCCACCTTTTCCCCGCAAATAACAGAGGATTAAGGATC


 


TGAAATCTTCAAGCCTCCAGGACCACGGTGCAAGCCCTCAGCAAAAATTTCTGCTGGA


 


GGCCGGAGCGCCTTTTGATTTCGGGAGACTGGCCCAGGAACTCTAGTCACTTGGAAG


 


GCGGAAGAGAAGGTGGTACCTGAGCCAGGTAGGAGCCACTCAGAGGCAGCCCGGG


 


GCCGCCACTCACCTAGGAGAGGAGGTGGAGTCCGATGACCTGGACTGAGAGGAAAC


 


GCGAGACTGAGTCTACCAGGTGAGGTAAAAAACACCCACCTGCTCACCTCGGAAGGG


 


GCGGGCGAGGTGCGGCTCCCGGTGACCCGCGGGGGTGCAGCGCACCTGGGCGGAG


 


GCGGAACTGGGAGGGTGTGGGCACTGCTCGTAGGGCCTGGAACTAAACTCACCTGT


 


GACGGAGGCAGAGGAGGGGCCCGGGCAAAAACCCACCTGAGCTGGCGGGAAACCC


 


GACCCGCGAGCAGTCCCCGGGCTTGCGCGGCGCGGAGAGGGAGGCGCCCCGCGGC


 


GGGGCCCCCACTCGGTCAGCCCGCGCGTCGGTCCCCGCGCGGCCGCCATGACCTGG


 


AGCGCCACGGCCCGGGGCGCCCACCAGCCCGACAACACCGCCTTCACTCAGCAGCGC


 


CTCCCCGCCTGGCAGCCGCTGCTGTCGGCCAGCATCGCGCTGCCGCTCTTCTTCTGCG


 


CGGGCCTGGCCTTCATCGGCCTGGGCCTGGGCCTCTACTACTCCTCCAACGGCATCAA


 


GGAGCTGGAGTACGACTATACAGGCGACCCGGGCACCGGTAACTGCTCGGTGTGCG


 


CCGCGGCTGGCCAGGGCCGGGCGCTGCCGCCCCCCTGCTCGTGCGCCTGGTACTTCT


 


CGCTGCCCGAGCTCTTCCAGGGCCCAGTGTACCTCTACTACGAGCTGACCAACTTCTA


 


CCAGAACAACCGGCGCTACGGCGTGTCCCGCGACGACGCGCAGCTGAGCGGACTCC


 


CCAGCGCGCTGCGCCACCCTGTCAACGAGTGCGCCCCCTACCAGCGCAGCGCGGCCG


 


GCCTGCCCATCGCGCCCTGCGGCGCCATCGCCAACAGCCTCTTCAACGACTCCTTCTC


 


GCTTTGGCACCAGCGCCAGCCCGGCGGGCCCTACGTCGAGGTGCCGCTCGACCGCTC


 


CGGCATCGCCTGGTGGACCGACTACCACGTCAAGTTCCGCAACCCGCCGCTGGTCAA


 


CGGCAGCCTGGCGTTGGCCITCCAGGGCACGGCGCCCCCGCCCAACTGGCGCCGGC


 


CAGTCTACGAGCTCAGCCCCGACCCCAACAACACCGGCTTCATCAATCAGGACTTCGT


 


GGTGTGGATGCGCACGGCGGCGCTGCCCACGTTCCGCAAACTGTACGCGCGCATCC


 


GCCAGGGCAACTACTCGGCCGGGCTGCCGCGGGGCGCCTACCGCGTCAACATCACCT


 


ACAACTACCCGGTGCGCGCGTTCGGCGGCCACAAGCTCCTCATCTTCAGCAGCATCTC


 


GTGGATGGGTGGCAAGAACCCCTTCCTGGGCATCGCCTACCTGGTCGTCGGCTCCCT


 


CTGCATCCTCACCGGCTTTGTCATGCTGGTCGTCTACATTCGCTACCAGGACCAGGAC


 


GACGACGACGAGGAGTGATTCCGGCTTTCCAGGGATCCCTCCTGCTTCTTGCCAAAA


 


CTCTTGCAAGGTGCTTTTGGCATCTCCTCCTCGCCCGTCACCCAATTCCAACCTCGCCT


 


AGCTTTTCCTCCCTTTGTGAATGAGGGGACCAGATAAGGGAATTACCCCCCTTGCTCT


 


TGGGGGGCTGCTAGACTGTCTTGCCGCGGGGAGGGATGTTGACTGCAGAGTGAAA


 


CATCCTTGCAAACTCTTCCCACCTCCTTCACGACACTGAGTTGCCATGTGAGGTTCTTC


 


AAGTCTGAGAGTGGAAGGGATCCCTATGGAGACTCCTATTAAACCCCTATTAGAGGA


 


AGAGATTGAGAGACCTAGCAATGTGAAGTAACAAAGATCAGGCAGCTGCAAGTGAC


 


TCCTGAATCTTGAGTCCAGGGCTTTCGCCACTACAGTACAGTGGTTTTCTTTTCTTTG


 


GTCGGGGAGAGTGGGCTGGAATGGAGAGTGAGGCCCACAAATTACCTGCAGAGAC


 


GTGGAGGCGTGAGGGAGAACATGCTTGTTAAATATGCAGGTAGATTAGGAGACACC


 


AAACAGAGATTCAGACACAGTAAGGCTGGGATGAGATCCTCGAAGCTGTGTTTTAAC


 


AAACTCCACTGGAGAGTCCCATATTCCCTCAAATTTGGGAATCACGACCCTGAACCAG


 


GTTGGGCCTGAAGCAGTCAACTGAATTCACTTTTTCGGATAGTAATTTGTTCCCAGG


 


GGCAGTGACAACCATGATGTTCCAGGTTTGGTCTGGCACTCTGCCTTGAACGTAGGA


 


AGCTCTTGATGATTTGTGGAATGAATTTTTAAAAAATTACTATCTGGGGAAAACTAGT


 


TGGCATACAGAGTTGTAGGACAGGGTTTATGTGATTCATTTGATATTTTAGTATTTTG


 


GTGTAAAAGCCAACAGGCAAACTTTGCCAGGTACTGTGTAGAAACTCGAAAATGTGA


 


GGCCAGTTTGTACAGTTCAGAGGAAATGCTTTAACGTAGAATCAGATAGCTGGAAGA


 


GATCTTCGAGGGAAAGTAAGTTCCCTAAAGTCACATCTATGTCTCCTAGCTCAGTGTT


 


CTTTGTCATTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATTAGAAAG


 


GGCTTCATTCATACCTTTTCCCTTGGACCTGGAAAAAAAATTTTTTTTATCTTTTCAAA


 


TGAAATCTATTGATTTCTAGTAATCATATTTGAATCAATGTTAAAGCATATATAGTCTT


 


ATATGTAAACTAGATTCTTAAGATTATTTGAACCTTTGAGATGAAGTTTACACTCAACT


 


AAAATCATTCCATTGATTTTATTGATTAACATCAATCAGTATGTTTAAAGTTATTCTAA


 


GAAGCAATAGTTTATTTTTAAAAACCTTGTATAGCAAAATAACTTAAAACCCTTTGTG


 


ATATCATCTTACCAGTTTATTTGGTAAAAACAAACAGTTATTTGGTATTTGTCAGAATT


 


CTTCAGTGCCTGCTATTACAGCTATTTTCCAATTACTAACTTGATTATACTCACTCAAG


 


GCAGTGCAAGATCTTGAAGTACTTTTTAGCAGTTAAGTAATATTGAATTGTATTGAAT


 


AGTTTACATAGTTTATTCTAGTCTTTGAAAATTACTGAACATGGACAATGTGCATGTC


 


ATTGACATCTGCCTTAGAACTICTGGGACAATCCTGATTCGAGAGATTCTATCCCATT


 


ATTTACATATACCAAAAATACTTTGTTAATTTAATGTGTTGGCTTCCCAACTCCTGAAC


 


ACGACACAATTTTATTATTAGATTTTGTATGGTGATTTTAGGCTATGAAAACATGATC


 


ATTATATGTATATAGATACATITTTATTTGTTACAAATGTTTGAGCAGCTCACTAGCCC


 


ACCCCTCCTCTATTTTGGGTAAGAGAATTTACTACCTTTTTTAACTATGTAGTTGAGAG


 


CAACATGTATTTTGTTATTTTTAGAATGGTCAGTATATTGCTATAAAATTTTAAATGA


 


GACTATGAAAGTTAAAGTATTCTGATTCTGGTTAAATTAACGAATATGGTTCCAGGCC


 


CTGTTCTCTGGGTTTTTGAGAGAGAATAAAGGTTATGTTTGTCTTACCTTTGTTATCG


 


AGTTTGCTGAATTCTTTTGAACGATGATCTTAAAGGCACAAACACCACCAGCCACTTT


 


GCTAATTTCTTAATAGCAGATTTACATTGCAGCAAGAAAACCATCTTTTATAGTAACAT


 


TCAGTTAAAATGAACTCAATTCATTGTTAACTTCCTAAAACAGAATTTGAACTTTATCA


 


ACCTCAACGTGTATATAAACTAGATAGTCCTCAATACTTTATCAACCTCAACATGTATA


 


TAAACTAGATAGTCCTCAAATACTGTTTGAATTTAATAAATGTCAATTTAAAAATTTTT


 


GTAGTAGTCTTCTGCATTTTACTTCAATTATAAATTGCAATTATTTATTGGATATTTTG


 


GACTTCAAAGCAGCAGAAACTTTAAAACTGAAATGGGAAACGTTTTCCTGCAATGATC


 


CCTGTGCTGTAACATTTTGTCTGGTGTCTCAGGCTTCCAGGTTCTTGTTGGCCTGAAT


 


TCCCTTGTTGCCCAGTAAATGTTCACTAGCTAGAAGTATCTTCAGGAAGTGAGATAGA


 


AAAGAGTGAACCTCAACAATTGGACTGGAAATGAGCTTTGACCTAACTTTGTAAAATA


 


AAAGCATAAAAGAGAAA


 


>gi|30410787|ref|NM_006765.2| Homo sapiens tumor suppressor candidate


3 (TUSC3), transcript variant 1, mRNA


(SEQ ID NO: 10)



GCGCCTTTCCAGGTCTTCTCCCGGTGAACCGGATGCTCTGTCAGTCTCCTCCTCTGCG



 


TCCTCGGCCGCGGCCCGGGTCCCTCGCAAAGCCGCTGCCATCCCGGAGGGCCCAGCC


 


AGCGGGCTCCCGGAGGCTGGCCGGGCAGGCGTGGTGCGCGGTAGGAGCTGGGCGC


 


GCACGGCTACCGCGCGTGGAGGAGACACTGCCCTGCCGCGATGGGGGCCCGGGGC


 


GCTCCTTCACGCCGTAGGCAAGCGGGGCGGCGGCTGCGGTACCTGCCCACCGGGAG


 


CTTTCCCTTCCTTCTCCTGCTGCTGCTGCTCTGCATCCAGCTCGGGGGAGGACAGAAG


 


AAAAAGGAGAATCTTTTAGCTGAAAAAGTAGAGCAGCTGATGGAATGGAGTTCCAG


 


ACGCTCAATCTTCCGAATGAATGGTGATAAATTCCGAAAATTTATAAAGGCACCACCT


 


CGAAACTATTCCATGATTGTTATGTTCACTGCTCTTCAGCCTCAGCGGCAGTGTTCTG


 


TGTGCAGGCAAGCTAATGAAGAATATCAAATACTGGCGAACTCCTGGCGCTATTCAT


 


CTGCTTTTTGTAACAAGCTCTTCTTCAGTATGGTGGACTATGATGAGGGGACAGACG


 


TTTTTCAGCAGCTCAACATGAACTCTGCTCCTACATTCATGCATTTTCCTCCAAAAGGC


 


AGACCTAAGAGAGCTGATACTTTTGACCTCCAAAGAATTGGATTTGCAGCTGAGCAA


 


CTAGCAAAGTGGATTGCTGACAGAACGGATGTTCATATTCGGGTTTTCAGACCACCC


 


AACTACTCTGGTACCATTGCTTTGGCCCTGTTAGTGTCGCTTGTTGGAGGTTTGCTTT


 


ATTTGAGAAGGAACAACTTGGAGTTCATCTATAACAAGACTGGTTGGGCCATGGTGT


 


CTCTGTGTATAGTCTTTGCTATGACTTCTGGCCAGATGTGGAACCATATCCGTGGACC


 


TCCATATGCTCATAAGAACCCACACAATGGACAAGTGAGCTACATTCATGGGAGCAG


 


CCAGGCTCAGTTTGTGGCAGAATCACACATTATTCTGGTACTGAATGCCGCTATCACC


 


ATGGGGATGGTTCTTCTAAATGAAGCAGCAACTTCGAAAGGCGATGTTGGAAAAAG


 


ACGGATAATTTGCCTAGTGGGATTGGGCCTGGTGGTCTTCTTCTTCAGTTTTCTACTT


 


TCAATATTTCGTTCCAAGTACCACGGCTATCCTTATAGTGATCTGGACTTTGAGTGAG


 


AAGATGTGATTTGGACCATGGCACTTAAAAACTCTATAACCTCAGCTTTTTAATTAAA


 


TGAAGCCAAGTGGGATTTGCATAAAGTGAATGTTTACCATGAAGATAAACTGTTCCT


 


GACTTTATACTATTTTGAATTCATTCATTTCATTGTGATCAGCTAGCTTATTCTTGTGT


 


ACTTTTTTTAAACTGTGGGTTTTCCTAGTAAATTTAATTTACAGAAATCAATGGTAGC


 


ATTTAGTAATCTACAAAGGAAATATCAAAGTGTTTTTCAAGCCTGTTATATTCAGTGT


 


GTGCCACAGGATTGAAATAAATGACAATGTAATTATGAAAAAAAAAAAAAAAAAAAA


 


AAAAAAAA


 


[>gi|157649067|ref|NM_006095.2| Homo sapiens ATPase, aminophospholipid


transporter (APLT), class I, type 8A, member 1 (ATP8A1), transcript variant


1, mRNA


(SEQ ID NO: 11)



AAGAGCTCGCCCAGCTCTGCGGGCGCCGCCACCTTCGCCGCCACCGCTGCCTTTCTCCTCCTCCTGTCGGCGTGCGG



 


GGGCCGCGCCCGGCGGCAGCTCTGCCCTAGGTGGGCGGCGGCGCGGCCCAGGCTGCAGCTGAGCGCTCTGCGCGGCG


 


CAGCCGGGTCTCCCGCGTGTACCACGCCGTGACAGGTGCAGAGTCCGGGCTGAGGACCCACCTGCAGCCGCCGCCGC


 


GATGCCCACCATGCGGAGGACCGTGTCGGAGATCCGCTCGCGCGCCGAAGGTTATGAGAAGACAGATGATGTTTCAG


 


AGAAGACCTCACTGGCTGACCAGGAGGAAGTAAGGACTATTTTCATCAACCAGCCCCAGCTGACAAAATTCTGCAAT


 


AACCATGTCAGCACTGCAAAATACAACATAATCACATTCCTTCCAAGATTTCTCTACTCTCAGTTCAGAAGAGCTGC


 


TAATTCATTTTTTCTCTTTATTGCACTGCTGCAGCAAATACCTGATGTGTCACCAACAGGTCGTTATACAACACTGG


 


TTCCTCTCTTATTTATTTTAGCTGTGGCAGCTATCAAAGAGATAATAGAAGATATTAAACGACATAAAGCTGATAAT


 


GCAGTGAACAAGAAACAAACGCAAGTTTTGAGAAATGGTGCTTGGGAAATTGTCCACTGGGAAAAGGTGGCAGTAGG


 


GGAGATAGTGAAAGTGACCAATGGGGAACATCTCCCAGCAGATCTCATCAGTCTGTCCTCAAGTGAGCCCCAAGCCA


 


TGTGCTACATTGAAACATCCAACTTAGATGGTGAAACAAACTTGAAAATTAGACAGGGCTTACCAGCAACATCAGAT


 


ATCAAAGACGTTGACAGTTTGATGAGGATTTCTGGCAGAATTGAGTGTGAAAGTCCAAACAGACATCTCTACGATTT


 


TGTTGGAAACATAAGGCTTGATGGACATGGCACCGTTCCACTGGGAGCAGATCAGATTCTTCTTCGAGGAGCTCAGT


 


TGAGAAATACACAGTGGGTTCATGGAATAGTTGTCTACACTGGACATGACACCAAGCTGATGCAGAATTCAACAAGT


 


CCACCACTTAAGCTCTCAAATGTGGAACGGATTACAAATGTACAAATTTTGATTTTATTTTGTATCTTAATTGCCAT


 


GTCTCTTGTCTGTTCTGTGGGCTCAGCCATTTGGAATCGAAGGCATTCTGGAAAAGACTGGTATCTCAATCTAAACT


 


ATGGTGGCGCTAGTAATTTTGGACTGAATTTCTTGACCTTCATCATCCTTTTCAACAATCTCATTCCTATCAGCTTA


 


TTGGTTACATTAGAAGTTGTGAAATTTACCCAGGCATACTTCATAAATTGGGATCTTGACATGCACTATGAACCCAC


 


AGACACTGCTGCTATGGCTCGAACATCTAATCTGAATGAGGAACTTGGCCAGGTTAAATACATATTTTCTGACAAAA


 


CTGGTACTCTGACATGCAATGTAATGCAGTTTAAGAAGTGCACCATAGCGGGAGTTGCTTATGGCCATGTCCCTGAA


 


CCTGAGGATTATGGCTGCTCTCCTGATGAATGGCAGAACTCACAGTTTGGAGATGAAAAAACATTTAGTGATTCATC


 


ATTGCTGGAAAATCTCCAAAATAATCATCCAACTGCACCTATAATATGTGAATTTCTTACAATGATGGCAGTCTGTC


 


ACACAGCAGTGCCAGAGCGAGAAGGTGACAAGATTATTTATCAAGCAGCATCTCCAGATGAGGGAGCATTGGTCAGA


 


GCAGCCAAGCAATTGAATTTTGTTTTCACTGGAAGAACACCCGACTCGGTGATTATAGATTCACTGGGGCAGGAAGA


 


AAGATATGAATTGCTCAATGTCTTGGAGTTTACCAGTGCTAGGAAAAGAATGTCAGTGATTGTTCGCACTCCATCTG


 


GAAAGTTACGACTCTACTGCAAAGGAGCTGACACTGTAATTTATGATCGACTGGCAGAGACGTCAAAATACAAAGAA


 


ATTACCCTAAAACATTTAGAGCAGTTTGCTACAGAAGGGTTAAGAACTTTATGTTTTGCTGTGGCTGAGATTTCAGA


 


GAGCGACTTTCAGGAGTGGCGAGCAGTCTATCAGCGAGCATCTACATCTGTGCAGAACAGGCTACTCAAACTCGAAG


 


AGAGTTATGAGTTGATTGAAAAGAATCTTCAGCTACTTGGAGCAACAGCCATTGAGGATAAATTACAAGATCAAGTG


 


CCTGAAACCATAGAAACGCTAATGAAAGCAGACATCAAAATCTGGATCCTTACAGGGGACAAGCAAGAAACTGCCAT


 


TAACATCGGACACTCCTGCAAACTGTTGAAGAAGAACATGGGAATGATTGTTATAAATGAAGGCTCTCTTGATGGAA


 


CAAGGGAAACTCTCAGTCGTCACTGTACTACCCTTGGTGATGCTCTCCGGAAAGAGAATGATTTTGCTCTTATAATT


 


GATGGGAAAACCCTCAAATATGCCTTAACCTTTGGAGTACGACAGTATTTCCTGGACTTAGCTTTGTCATGCAAAGC


 


TGTCATTTGCTGTCGGGTTTCTCCTCTTCAAAAATCTGAAGTTGTTGAGATGGTTAAGAAACAAGTCAAAGTCGTAA


 


CGCTTGCAATCGGTGATGGAGCAAATGATGTCAGCATGATACAGACAGCGCACGTTGGTGTTGGTATCAGTGGCAAT


 


GAAGGCCTGCAGGCAGCTAATTCCTCTGACTACTCCATAGCTCAGTTCAAATATTTGAAGAATTTACTGATGATTCA


 


TGGTGCCTGGAACTATAACAGAGTCTCCAAGTGCATCTTATACTGCTTCTACAAGAATATAGTGCTCTATATTATCG


 


AGATCTGGTTTGCCTTTGTTAATGGCTTTTCTGGACAGATCCTCTTTGAAAGATGGTGTATAGGTCTCTATAACGTG


 


ATGTTTACAGCAATGCCTCCTTTAACTCTTGGAATATTTGAGAGATCATGCAGAAAAGAGAACATGTTGAAGTACCC


 


TGAATTATACAAAACATCTCAGAATGCCCTGGACTTCAACACCAAGGTTTTCTGGGTTCATTGTTTAAATGGCCTCT


 


TCCACTCAGTTATTCTGTTTTGGTTTCCACTAAAAGCCCTTCAGTATGGTACTGCATTTGGAAATGGGAAAACCTCG


 


GATTATCTGCTACTGGGAAACTTTGTGTACACTTTTGTGGTGATAACTGTGTGTTTGAAAGCTGGATTGGAGACATC


 


ATATTGGACATGGTTCAGCCACATAGCGATATGGGGGAGCATCGCACTCTGGGTGGTGTTTTTTGGAATCTACTCAT


 


CTCTGTGGCCTGCCATTCCGATGGCCCCTGATATGTCAGGAGAGGCAGCCATGTTGTTCAGTTCTGGAGTCTTTTGG


 


ATGGGCTTGTTATTCATCCCTGTGGCATCTCTGCTCCTTGATGTGGTGTACAAGGTTATCAAGAGGACTGCTTTTAA


 


AACATTGGTCGATGAAGTTCAGGAGCTGGAGGCAAAATCTCAAGACCCAGGAGCAGTTGTACTTGGAAAAAGCCTGA


 


CCGAGAGGGCGCAACTGCTCAAGAACGTCTTTAAGAAGAACCACGTGAACTTGTACCGCTCTGAATCCTTGCAACAA


 


AATCTGCTCCATGGGTATGCGTTCTCTCAAGATGAAAATGGAATCGTTTCACAGTCTGAAGTGATAAGAGCATATGA


 


TACCACGAAACAGAGGCCCGACGAATGGTGATGGGGAGAGCCTGAAAGGCAGGCTCTGTTACCTCTCTAAGGAGAGC


 


TACCAGGTTGTCACCGCAGTCTGCTAACCAATTCCAGTCTGGTCCATGAAGAGGAAAGGTAGATCTGAGCTCATCTC


 


GCTGATGGACATTCAGATTCATGTATATTATAGACATAAGCACTGTGCAACTGTACTGTAACACCATCTCTTTTGGA


 


TTTTTTTAAGGTATTTGCTAAGTCTTTGTAAACGGAAATTGAAAATGACCTGGTATCTTGCCAGAGGGCTTTCTTAA


 


ACGGAGAATAAGTCAGTATTCTTATGCCATTACTGTGGGGCTGTAACTGACTGTCAGTTTATTGGCTGTACCACAAG


 


GTAACCAACCATTAAAAAACTCTAAATGATATTTAGTTAAAGGGACTCTTGGTATCCAGACTTAGATTTCAGGATAT


 


GCTGAAACAAACCAGCATTCTTAAGGAACTGACTCACCTTCCTGAGCAAAATTTCTAAACAAGCATTTGTGTCCAAA


 


ATTGTCTTGATAAATGTTTGCCAAAGAGGTTCAGTAAGTGTTTTTCTAGTTCAGTAGTCATATGCCCAGAAATGTAA


 


GAGAAAGTTTACTTCCAGTTCCGCTGTAAGATCTGCATGCCTGACTTTCCAAATGTAAGAGTGATTTACAAAAATGA


 


ATATTTCAAGGCATTTGCTACTAAAATCGGTGATGTTGCACCTTTGGCCTTACAAATGCTTCTTTGTTGTTTGTCGT


 


GTTTATTTGTTAGAGGACACACGTGTTAATGTGACTCTGTTGTTATGACACTGATTTTTCAAACTATGTATGTTTCA


 


GGTATTTCTGATGAAGTTTCATCATCATTTAGATTTTTCTAAAAATCTGGCTAATGCAGTAGATTGAGTGATGTCAT


 


TTTGTCTTAAAGTTTTTCCTCTTAAGAAACATATGCTACGTATTTACGTGGGATTTCCAAAGCTTCTGTTGCAATAT


 


TTGGAATAACATGTCAGATAAATGCATGGGCTTTTGTCCTGTGTTCCAGTTCCCACTAGAGATGCCTGTGTCTTGTG


 


TAGCACACCCAGTGTTATGGTGACTGCCCCCTATACTGAAGACTGAAAATTATTTCACAGTTCACTCATCAAATAGT


 


TCCCAAAATTCGTCACATGCTGCTTATTGGGACAAATAGGTAGTACATTTTCCCCATTTAAAAAATGCGGATTTTAC


 


TCAGGCCGGTAACTTTACAGTCAGAGGACACGTTCATCATGAGTAGCTTTTGTTAGTATGTTTTAAAATGTATCTTC


 


AGTTCAATTATTTTCAGCATTTACAAGACATCTGAAAATGGCTATTTTGCTACCAACAGTAAATGAAGGGGCTGTTT


 


AAAAACCACAACCAGTTTTCTACACTATTTTTTAAATAATACTTTCATTTGAAAAAAAGGAATTAGTTTTCAGATAC


 


ACTTCAGAGATTGAAGCAAACTATTTGCCTTTTACTCAAAAGCCTGCTTGCCTTTACATGGACTTACCAGCAAAATA


 


GGTAGAACTTTCTCTTTTAAAAAAAGTCAACTAGAATTGAGAAGAGGTGATTTTTTTTCAGATCGCTTCTCGAGTTT


 


AATATTTTCACATTCTTTTCACCCTTTTTCTCAATCTAGATTTAAAATTAGGATATATGTCATTTCCTTGTCTGTAT


 


TTGTAGCTCCTTAGTTACCAGTATGCCTCTCCATTTTCTACAAATAAGAGGTTATAACACATATACATAATTCTAAC


 


CTTAAGGGAACACACGTTTACATACTTTACTTCCCAAGCCCTTCCTGTTTGGGGTACAGATTGAGAGAGTCATGAAT


 


CAACACATCTAGCAAGACCACAGGTGTAAGAGTCTAAGATCGTCTTCAAAATTCTGAAGTCCCAGTCTTTACCTGTC


 


CAGTGAATGAATATTCAGAGCAGCTTTTCCTGGGCTTCCCAGTGGTGATAGCTGAGGTCAAACCACAAAAAATAAGA


 


AAGCAAGAGTGAAATGCACCCCTCCAGAGAAACACTTTGTAGTGTTTAATTCTGTTAATAGAGAAGAGCTGCTTCTG


 


TTTGCGCTCACTTCATCAGTGGCACCCTTCTGCAGAATTTTAATATAAAAACATTATGGATATAATAGAACTGGATT


 


TTCTGACTTAAAAATGTAAGTTTTATTTTAATCTTGAAACGTGGATTGTTTCTGTGGAGCTCTTAAACATGAGAAGA


 


ATACTTACGGTTGATAATGTGTAACATGATCTGAAATGTGACTAATTTGAGCCTCTTTGTCCCATCGTCCTGTTTTT


 


GAATTATTGACATTGTCAGTCTCTTTGCTTCCTGGGTGAGACTTGGGGTTTGAGGGACAGGGAATGACCTTCTTGGT


 


GAAACTTAAAATATAACATTGCAATTGCAGTGACTTTACAGTGTTAAATTAGAGAAAATAGTCTGATTTTTTAAACC


 


TTCCTTAACTGGAAAAAAGTCACATGGTTTTACCAGGATTGAAATAAACAGTCAATGTGACTTTTAACATGTGTTTT


 


TTTGAAATAAAGGGCACGTACTCTTCAATTAAAAAGTTCCTTATAGGGACTCTGGCAAATGCTAACACAGTTGCTTT


 


ACAATGTTTACAATTCAGACAATACGACTTATAATAGAAAATCCTCATTCATTTAGCATTGAAAAGCTGGAAGTTGC


 


TTCTTTAATGTTGAATAGTATACAGTGGTATTGAGCATGGACTTTCTAAATGTTTTATATATACATATAAAAATATA


 


TTGGTGTCTCACACCCAGAAAGATGTTATATTGTAGATATTATTAGGAAAACAGTGTTTCTCAGGAACGTTGTAAAT


 


TTTAAATGATATATGTACTTCCCGTCCTCCCACCTCCACTCTGTGCTCTAATGTGAGACTGCTTCAGCAGTGTTGCT


 


AAGTTAATGGAAAACTTTTTCTAATCAAGTCAGGTGAATGTGTATTCTGCTAAATAATGTTAGCCATTTACATGAAT


 


TGTATGGTCATTAAATGGAATCAGTGATTCCTCTTTAATTTCCAGAGGGGAAATGAATTATGGAAATCAGTCAGCAT


 


TCTGATCATTAAATTTTATACTTTAATTTTGCCGTTCAGCATTCTAAATATCCAATGTGAAAGTCACATGATAATTT


 


GTTTTGCATTGCGTGCACTGTACAACACTTACAACTTGTCATTTAAAATGTTTTCTCGGGAAATGAATGCTAGTCAG


 


AAAGTAATAGATTGTATTATTCATAGTTTTAAAATTATGACAATGTCATAATTACTACAAAGCTAAATAATCGTGTT


 


TATTTTTGTGCAGTTGCCCTTTGATAGTTCCTGGTTTTAAAACCTATTAAGTGTATAATCTTACAAATAGTCATCTA


 


CAAAATTTATGGAGAAAGTGCCCAGCCCATTCACATCACATGGACCAGGAATTCTTTTGTAAATGACTTAAGGTAAC


 


ATCATGCAGTTCAGTGCCTAATAAATGCTTTTTAATGATGAACATTTCTATAATGACTCGTAAGATACCATAGTCTG


 


ATTTTTCTCACATTAAAATAACTGAAGTCACTTGTGTAACGTAGTTATACTTTGCTGCATTTTAATTAACCTTCAAC


 


AGCTATTAAAGTGGAATGTAAGTTAAATTTTGAAGGAAAGGAAATAAATGTTTTCCATATTTCGTCTTGATTTACTT


 


TCTGTATGAGAACAGCTGTGTTTTTGATAGGTTTATGGTTTGCATGAGTTCATATTTAAAGTGATCCAGGCCAATGC


 


ATGGCTATTGCTGTAAATCTTGATGTTTATTTCTGCCTTGTAAAGTTCTATCACGGCCTACCTGGAATTTAAAATTC


 


AGTAGACAAATTAATTGGTCCTCTGCACAACTTTTTTAATAAGTAGATTATTTTACAAAGAAATTTGAACAAATTTA


 


ATTGAATCTTTTGTTTAGCTTGCCTCTAAGAACTTTTCTTAATAAAGCTCCCAAAACTTCTCAGCAAATAAATCTCC


 


CTTAAGTAGGAAAGCTAGATTTCATATTTGCTTACTTTGAATTAACAGCAACTTTCCACAGGTAAATCTGTTCTTGC


 


AAAGATGTGAGCAGAATAGTTAAAAATAATATTTTTATGTTTCATGGTTCTAAATGGAAGCCATAAATGCAGTAAAT


 


ACTATCTGTTGTTTAACTACTTTAATCGTCATTTTTTACATTTTCAAGTTTATTAGGTTAAGAAAAACAGGGCAGCC


 


TTGGAAGGCAGCTACTACAGAAAACTGCAGTTTTGCGTTAAAGATAAAGTAGTATTTTCAGCTCCCTGAAAAACCAT


 


TCCTGCTGAAACTGCTGTAGAAATTGTGAAGCTGCATGAGTGGAGAGTATTGAATCTGTGGTTATAGTAGTTTTCTC


 


AGGTTTGTTTATCTTGATGTTTGATGCACTGTGTTTTATAGTTATTAAAATTGAGTAATATTATTTCTATGCAGTGT


 


TATGTGTCATTGGCCTTTTGTGAATGTGCATGTTTTAAACTGCAAATTTTAAACATTTTGTCCTCTAATTGTTATTA


 


AAAATGAAATAAACTTTACCATTACTTAAAA


 


>gi|115387098|ref|NM_001703.2| Homo sapiens brain-specific angiogenesis


inhibitor 2 (BAI2), mRNA


(SEQ ID NO: 12)



TTTTCTGCACCCGCCGCCCGGGAGAGCGGGAGCCTCGGCCCTCCGCGCGGCTGCAGCTACCTACCCTGCGCCCGGCC



 


CGGTCCCCGACTTAGGGATGGCAAACTTGCGCCCCGTGGCCGCCCCCGCCAGCGCCGGCCCCCGCTCCTGCTGCTGA


 


CGGCGCCCAGGAAATCCACAGCAGTGATACATGTGACGTCCACACTGACAGTGCCCTCCTGTGGGCATGGCTCAGGT


 


TGTGCGCAGTTCCTGGCACACTGGCTGTAACTCCGCCCCTTTCTCTCCCTCTCAGTAAAGCAAGATTACGCGGTGAC


 


ATGCCTCACAGCTGATCACGACACACGGGGATGGAGAGCAAGAGTTATGGAGAATACAGGTTGGATGGGCAAGGGAC


 


ATAGGATGACCCCAGCCTGTCCCCTCTTACTGTCTGTGATTCTGTCCCTGCGCCTGGCCACCGCCTTCGACCCCGCC


 


CCCAGTGCCTGCTCTGCCCTGGCCTCGGGTGTGCTCTACGGGGCCTTCTCGCTGCAGGACCTCTTTCCTACCATCGC


 


CTCGGGCTGCTCCTGGACCCTGGAGAACCCTGACCCCACCAAGTACTCCCTCTACCTGCGCTTCAACCGCCAGGAGC


 


AGGTGTGCGCACACTTTGCCCCCCGCCTGCTGCCCCTGGACCACTACCTGGTCAACTTTACCTGCCTGCGGCCTAGC


 


CCCGAGGAGGCGGTGGCCCAGGCGGAGTCAGAGGTGGGGCGGCCAGAAGAGGAGGAGGCAGAGGCGGCAGCGGGGTT


 


GGAGCTGTGCAGCGGCTCAGGCCCCTTTACCTTCCTGCACTTCGACAAGAACTTCGTGCAGCTGTGCCTGTCGGCTG


 


AGCCCTCCGAGGCCCCGCGCCTGCTGGCGCCCGCTGCCCTAGCCTTCCGCTTTGTCGAGGTCTTGCTCATCAACAAC


 


AACAACTCTAGCCAATTCACCTGTGGTGTGCTCTGCCGCTGGAGTGAGGAGTGTGGCCGCGCTGCCGGCAGGGCCTG


 


CGGCTTTGCTCAGCCAGGCTGCAGCTGCCCTGGAGAGGCGGGGGCCGGCTCCACCACCACCACATCTCCAGGCCCTC


 


CTGCTGCCCACACCCTGTCCAATGCCCTGGTGCCCGGGGGCCCAGCCCCACCTGCTGAGGCCGATTTGCACTCGGGG


 


AGCAGCAATGATCTGTTCACAACCGAGATGAGATATGGTGAGGAGCCGGAAGAGGAACCGAAAGTGAAAACCCAGTG


 


GCCGAGGTCTGCAGATGAGCCTGGGCTATACATGGCGCAGACAGGCGACCCGGCGGCTGAGGAGTGGTCCCCGTGGA


 


GCGTGTGTTCCCTGACGTGTGGGCAGGGTCTGCAGGTGCGGACCCGCTCCTGTGTGTCCTCCCCCTATGGGACCCTG


 


TGCAGCGGGCCCCTGCGGGAGACCAGGCCCTGCAACAATTCAGCCACCTGCCCAGTGCACGGCGTGTGGGAGGAGTG


 


GGGGTCCTGGAGCCTGTGCTCCCGCAGCTGCGGGCGGGGGTCCCGGAGCCGGATGCGGACCTGCGTGCCCCCCCAGC


 


ACGGCGGCAAGGCCTGCGAGGGTCCTGAGCTGCAGACTAAGCTCTGCAGTATGGCTGCCTGCCCGGTGGAAGGCCAG


 


TGGTTAGAATGGGGTCCCTGGGGCCCATGCTCCACGTCCTGTGCCAATGGGACCCAACAGCGCAGCCGGAAGTGCAG


 


CGTGGCGGGCCCAGCCTGGGCCACATGCACGGGTGCCCTCACTGACACCCGGGAGTGCAGCAACCTCGAGTGCCCGG


 


CCACTGATAGCAAGTGGGGGCCATGGAATGCGTGGAGCCTGTGCTCTAAGACGTGTGACACAGGCTGGCAGCGCCGC


 


TTCCGCATGTGCCAGGCCACGGGCACGCAGGGCTACCCCTGCGAGGGCACCGGAGAGGAGGTGAAGCCTTGTAGTGA


 


GAAGAGGTGTCCAGCCTTCCATGAGATGTGCAGGGATGAGTACGTGATGCTGATGACGTGGAAGAAGGCAGCTGCTG


 


GCGAGATCATCTACAACAAGTGCCCCCCGAATGCCTCAGGGTCTGCCAGCCGCCGCTGTCTCCTCAGTGCCCAAGGC


 


GTGGCGTACTGGGGGCTGCCCAGCTTTGCTCGCTGCATCTCCCATGAGTACCGCTACCTGTATCTGTCACTTAGGGA


 


GCACCTGGCCAAGGGGCAGCGCATGCTGGCAGGCGAGGGCATGTCGCAGGTGGTGCGCAGCCTGCAGGAGCTACTGG


 


CCCGGCGCACCTACTATAGTGGGGACCTGCTCTTCTCTGTGGACATTCTGAGGAATGTCACTGACACCTTTAAGAGG


 


GCCACCTACGTGCCCTCGGCTGATGATGTGCAGCGCTTCTTCCAGGTGGTGAGCTTCATGGTGGATGCGGAAAACAA


 


GGAGAAGTGGGACGATGCTCAGCAGGTGTCCCCTGGCTCTGTGCACCTGCTCCGTGTCGTGGAGGACTTCATTCACC


 


TGGTGGGCGATGCTCTCAAGGCCTTCCAGAGCTCTCTGATTGTCACAGATAATCTAGTGATCAGCATTCAGCGAGAG


 


CCCGTCTCAGCTGTGTCCAGTGACATCACGTTCCCCATGCGGGGCCGCCGGGGCATGAAGGACTGGGTGCGGCACTC


 


AGAGGACCGCCTCTTCCTGCCCAAGGAGGTGCTCAGCCTCTCCTCCCCAGGGAAGCCAGCCACATCTGGGGCAGCAG


 


GCAGCCCTGGCAGGGGGAGGGGCCCAGGAACGGTGCCTCCTGGCCCAGGCCACTCCCACCAGCGCCTCCTCCCAGCA


 


GACCCTGATGAGTCCTCCTACTTTGTGATCGGTGCTGTACTCTACCGCACCCTTGGCCTCATCCTGCCGCCTCCCAG


 


GCCCCCGCTGGCCGTCACATCCCGGGTGATGACAGTGACTGTGCGCCCCCCTACCCAGCCTCCAGCTGAGCCCCTCA


 


TCACTGTGGAGCTCTCCTACATCATCAATGGGACCACGGATCCCCATTGCGCCAGCTGGGACTACTCCAGAGCAGAT


 


GCCAGCTCAGGAGACTGGGACACTGAAAATTGCCAGACCCTGGAGACCCAGGCAGCTCACACCCGCTGCCAGTGCCA


 


GCACCTGTCCACCTTTGCTGTACTAGCCCAGCCGCCCAAGGACCTGACCCTGGAGCTGGCGGGCTCCCCCTCGGTCC


 


CCCTGGTGATCGGCTGTGCAGTGTCGTGCATGGCGCTGCTCACCCTGCTCGCCATCTATGCCGCCTTTTGGAGGTTC


 


ATAAAATCTGAACGCTCCATCATCTTGCTGAACTTCTGCCTGTCCATCTTGGCATCCAACATCCTGATCCTCGTGGG


 


CCAGTCCCGGGTGCTGAGCAAGGGCGTGTGCACCATGACGGCTGCCTTCCTGCACTTCTTCTTTCTCTCCTCCTTTT


 


GCTGGGTGCTTACCGAGGCCTGGCAGTCCTACCTGGCTGTCATTGGGCGGATGCGCACCCGCCTCGTTCGCAAGCGC


 


TTCCTCTGCCTGGGCTGGGGTCTGCCTGCCCTGGTGGTGGCCGTGTCTGTTGGCTTTACCCGAACGAAAGGATACGG


 


TACATCCAGCTACTGCTGGCTCTCCCTGGAGGGCGGCCTGCTCTACGCCTTTGTGGGCCCTGCAGCCGTCATTGTCC


 


TGGTGAACATGCTCATCGGAATCATCGTCTTCAACAAGCTCATGGCACGTGATGGCATCTCCGACAAATCCAAGAAG


 


CAGAGGGCCGGGTCGGAGCGGTGCCCCTGGGCCAGCCTGCTCCTCCCCTGCTCAGCGTGTGGAGCGGTCCCCAGCCC


 


CCTGCTCAGCTCAGCCTCGGCCAGGAACGCCATGGCCTCACTCTGGAGCTCCTGCGTGGTGCTGCCCCTGCTGGCGC


 


TCACCTGGATGTCTGCCGTCCTGGCTATGACAGACCGCCGTTCCGTCCTCTTCCAGGCCCTCTTTGCTGTCTTCAAC


 


TCCGCGCAGGGCTTTGTCATCACTGCTGTGCACTGCTTCCTGCGCCGAGAGGTCCAGGATGTGGTGAAGTGCCAGAT


 


GGGGGTGTGCCGGGCTGATGAGAGCGAAGACTCCCCTGACTCGTGTAAGAACGGGCAGCTGCAGATCCTGTCAGACT


 


TTGAAAAGGATGTGGATCTGGCTTGTCAAACAGTGCTGTTCAAGGAGGTCAACACTTGCAACCCGTCCACCATCACG


 


GGCACACTATCCCGCCTGTCCCTGGATGAGGATGAGGAGCCCAAGTCCTGCCTCGTGGGCCCTGAGGGCAGCCTCAG


 


CTTCTCACCACTGCCTGGGAATATCCTGGTGCCCATGGCAGCCTCACCAGGGCTGGGGGAGCCTCCGCCCCCACAGG


 


AGGCCAACCCTGTTTACATGTGTGGGGAGGGTGGCCTGCGGCAGCTGGACCTCACATGGCTGCGGCCCACTGAGCCA


 


GGCTCTGAGGGAGACTACATGGTGCTGCCCCGGCGGACTTTGAGCCTGCAGCCTGGCGGTGGGGGTGGAGGTGGTGA


 


GGATGCCCCCAGGGCCCGGCCGGAGGGGACCCCCCGGCGAGCTGCCAAGACAGTGGCCCACACTGAAGGCTACCCCA


 


GCTTCCTGTCCGTGGACCACTCGGGCCTGGGGCTGGGCCCTGCCTATGGATCTCTCCAGAATCCCTATGGAATGACC


 


TTCCAACCGCCACCGCCGACACCCAGCGCCCGCCAAGTGCCCGAGCCAGGGGAGCGCAGCCGGACCATGCCTCGCAC


 


CGTGCCCGGCTCTACCATGAAGATGGGCTCCCTGGAGCGAAAGAAATTACGGTATTCAGACCTGGACTTTGAGAAGG


 


TGATGCACACCCGGAAACGGCATTCAGAACTCTACCACGAGCTCAACCAGAAGTTCCACACTTTCGACCGCTACCGC


 


AGCCAGTCCACGGCCAAGAGGGAGAAGCGGTGGAGTGTGTCCTCGGGTGGGGCAGCCGAGCGGAGCGTGTGCACCGA


 


TAAGCCCAGCCCTGGGGAGCGCCCCAGCTTGTCCCAACATCGGCGCCATCAGAGCTGGAGCACCTTCAAATCTATGA


 


CACTGGGCTCGCTGCCCCCCAAGCCCCGAGAACGGCTGACTCTGCACCGGGCAGCAGCCTGGGAGCCCACAGAACCA


 


CCGGATGGTGACTTCCAGACAGAGGTGTGAGTGCCACGCTGGACTGCCCACTGCATATAAATATATATATCTCTCTA


 


TTTTCACACTCCACTTTGGAACTACCCAGGAGCCAGCGCCCTCTCCCCTCTCCCGAGGGCTGGGCAGGGAGGCGCCG


 


TGGACTCAGCCAGGCTGGGGGAGCCGGACATGGCTTGGCCTGGGGTCCCAGGGCCCTTCCTTGTTTCTCAGAGGCCC


 


CTCAGCCACTGGAACCCCATCTTCAGCCCAGCCTGTCCGTCCCTGTCCCGGGCTGGGGAGGGGGGAGGGGAACTTTG


 


TTGGGAATAAACTTCACTCTGTGGAAAAAAAAAAAAAAAAAAAA


 


>gi|149158715|ref|NM_016475.3| Homo sapiens chromosome 14 open reading frame


100 (C14orf100), transcript variant 1, mRNA


(SEQ ID NO: 13)



CTAAACCCGGAAGCGAGGGAGGAACTTCGGAGCTGTCGCCCGGGTTACCGGGAGGCGGAGCCGCCGAGCTCGCTGTG



 


GCCCGGATGTTCGGTGCAGCTGCCAGATCCGCTGATCTAGTGCTTCTCGAAAAAAACCTTCAGGCGGCCCATGGCTG


 


TCGATATTCAACCAGCATGCCTTGGACTTTATTGTGGGAAGACCCTATTATTTAAAAATGGCTCAACTGAAATATAT


 


GGAGAATGTGGGGTATGCCCAAGAGGACAGAGAACGAATGCACAGAAATATTGTCAGCCTTGCACAGAATCTCCTGA


 


ACTTTATGATTGGCTCTATCTTGGATTTATGGCAATGCTTCCTCTGGTTTTACATTGGTTCTTCATTGAATGGTACT


 


CGGGGAAAAAGAGTTCCAGCGCACTTTTCCAACACATCACTGCATTATTTGAATGCAGCATGGCAGCTATTATCACC


 


TTACTTGTGAGTGATCCAGTTGGTGTTCTTTATATTCGTTCATGTCGAGTATTGATGCTTTCTGACTGGTACACGAT


 


GCTTTACAACCCAAGTCCAGATTACGTTACCACAGTACACTGTACTCATGAAGCCGTCTACCCACTATATACCATTG


 


TATTTATCTATTACGCATTCTGCTTGGTATTAATGATGCTGCTCCGACCTCTTCTGGTGAAGAAGATTGCATGTGGG


 


TTAGGGAAATCTGATCGATTTAAAAGTATTTATGCTGCACTTTACTTCTTCCCAATTTTAACCGTGCTTCAGGCAGT


 


TGGTGGAGGCCTTTTATATTACGCCTTCCCATACATTATATTAGTGTTATCTTTGGTTACTCTGGCTGTGTACATGT


 


CTGCTTCTGAAATAGAGAACTGCTATGATCTTCTGGTCAGAAAGAAAPGACTTATTGTTCTCTTCAGCCACTGGTTA


 


CTTCATGCCTATGGAATAATCTCCATTTCCAGAGTGGATAAACTTGAGCAAGATTTGCCCCTTTTGGCTTTGGTACC


 


TACACCAGCCCTTTTTTACTTGTTCACTGCAAAATTTACCGAACCTTCAAGGATACTCTCAGAAGGAGCCAATGGAC


 


ACTGAGTGTAGACATGTGAAATGCCAAAAACCTGAGAAGTGCTCCTAATAAAAAAGTAAATCAATCTTAACAGTGTA


 


TGAGAACTATTCTATCATATATGGGAACAAGATTGTCAGTATATCTTAATGTTTGGGTTTGTCTTTGTTTTGTTTAT


 


GGTTAGACTTACAGACTTGGAAAATGCAAAACTCTGTAATACTCTGTTACACAGGGTAATATTATCTGCTACACTGG


 


AAGGCCGCTAGGAAGCCCTTGCTTCTCTCAACAGTTCAGCTGTTCTTTAGGGCAAAATCATGTTTCTGTGTACCTAG


 


CAATGTGTTCCCATTTTATTAAGAAAAGCTTTAACACGTGTAATCTGCAGTCCTTAACAGTGGCGTAATTGTACGTA


 


CCTGTTGTGTTTCAGTTTGTTTTTCACCTATAATGAATTGTAAAAACAAACATACTTGTGGGGTCTGATAGCAAACA


 


TAGAAATGATGTATATTGTTTTTTGTTATCTATTTATTTTCATCAATACAGTATTTTGATGTATTGCAAAAATAGAT


 


AATAATTTATATAACAGGTTTTCTGTTTATAGATTGGTTCAAGATTTGTTTGGATTATTGTTCCTGTAAAGAAAACA


 


ATAATAAAAAGCTTACCTACATAAAATTTCAATGTTTTGACACTTAATTGTTGTTTGGCACAATAGTATGGAAGTAA


 


TTCAAACTGGTAAATAGTTTCCTCTCATATCTCGGGTATATATACATACCATATTTTATTGATCCAGAGATACTTAT


 


TTCACTTTGTGACATCTCTGAATTAGGATGCATCTTACAACTGATGGCTTATTAGATTTAATGAAATACAGAAGATA


 


CACAGAATAAAAAGGGTTTTCCTGTGGTTGGTTTGTGGTTTGTGATAGGTGTTCTGTGATGTTTATGCTTTGAAGGC


 


CTTAAGACTCATGGTTGCAACCATGGAAGCAAAATGAAATTTTTAGCTCTTAACCTAACAACCTGACCATGTTTATC


 


CATTTTTATTGTTTAGAAGTTTATTTACTGATACTTGGTGGAGGTTGTGTGAATTAGTTAAATTTTAAATGTTTAAG


 


ACTTCTATTAACAGCTGCAAAATATGAAAGTAAGTGCACTCACTTTTCCTGTAGTAGTCTGTCTTTTGAATTCACAG


 


CAGTTGTATCCTTGAGTTACTTTGTTAATGTATTTTTCTCAGTACATTTAACCACTGGGAAATGAACCCTTGTACGA


 


ATGTGTTTCTTCTTCTCTGTAGGAATAAAAATAAATATAAAAATTTTATTTGTATTGCACACAAAA


 


>gi|145580589|ref|NM_022495.5| Homo sapiens chromosome 14 open reading frame


135 (C14orf135), mRNA


(SEQ ID NO: 14)



AACGACGCTCTTGCGTAAAGGCCCGGCCCAAGGGAACGTTCAGGGCGTCTCGGCTTTCCCCGCTGCTGCTTCTGCTA



 


GGCCCAGTGCGAGACCAGAGCACGAGCGACTCCCGTCGTCCCCGGCCAGGCAGATGTTGGCCTAGTCCTGGCGCGAA


 


CGAAGCGCGCTATTTCCCTGCTTCCTCTAGGCCAAGCCTGCTTTACGGCAGGGCCCGCCTCGGGAGCGAGCACAGAC


 


CGGGGCAGCGAGGCCAGCCAGGCGCCGACGAGGTCCCCGAACGCGCACGCGCTCCGTTCAGCTCCGGGTGGCGGCCG


 


CCGGAGTAGACGTTAGCCATGGAAACCGAGAGCTGGCCCGGGCGGGGCCGCGGTGAGCTCGTTATTCGGCCGCCGCA


 


GCTTTTCTGCCTCCGCATTCGGGCACTAACCAACCTCCCGGCGGGAGCGCCCAGCCCGAGTTTACCTGCAAAAATGC


 


GGTCCCTGGGATGCCTTCGCGTCTTCTCTTCCCTCGGGTGACTTGAGGTTTGTGGTAAATATGCCAGCTCTAGAACA


 


CATGAATCAGATTTTACACATCTTGTTTGTATTTTTACCCTTTCTGTGGGCACTTGGGACTCTGCCCCCACCCGATG


 


CACTTCTCTTATGGGCAATGGAGCAGGTTTTAGAGTTCGGCCTTGGAGGCTCATCTATGTCAACCCACTTACGGTTA


 


TTAGTAATGTTCATCATGTCTGCTGGAACAGCTATAGCATCATATTTCATTCCAAGCACTGTTGGTGTGGTTCTTTT


 


CATGACTGGATTTGGTTTCTTGCTGAGTCTGAACTTAAGTGATATGGGTCACAAAATTGGAACCAAATCTAAGGATT


 


TACCCAGTGGTCCGGAAAAACATTTTTCATGGAAGGAATGCCTTTTCTACATCATTATATTAGTCTTGGCTCTTTTA


 


GAAACTAGCTTGCTTCATCACTTTGCTGGCTTCTCACAGATTTCTAAAAGCAATTCCCAGGCTATTGTGGGCTATGG


 


TTTGATGATATTACTTATAATACTGTGGATACTTAGAGAAATTCAAAGCGTATATATCATTGGAATTTTCCGAAATC


 


CCTTTTATCCGAAGGATGTGCAAACTGTGACTGTATTCTTTGAGAAGCAAACTAGGCTCATGAAGATTGGTATTGTC


 


AGACGGATTTTGCTAACTTTAGTATCACCTTTTGCCATGATAGCATTTCTTTCATTGGACAGTTCCTTACAAGGGCT


 


CCACTCAGTGTCTGTCTGTATTGGATTCACAAGAGCCTTTAGAATGGTATGGCAGAATACAGAAAATGCTTTATTGG


 


AGACAGTCATTGTATCAACAGTACACTTGATCTCCAGTACAGACATATGGTGGAACAGAAGCCTGGATACAGGACTC


 


AGACTCTTACTGGTTGGTATCATACGTGATCGTTTGATTCAGTTCATCTCTAAATTGCAGTTTGCCGTGACTGTGCT


 


TTTGACATCATGGACAGAGAAAAAACAACGTCGAAAAACAACTGCCACTTTATGTATACTCAACATTGTCTTTTCTC


 


CATTCGTGTTGGTCATCATAGTTTTTTCTACACTACTCTCTTCTCCCTTACTCCCTCTTTTCACCCTTCCTGTGTTC


 


TTGGTGGGGTTTCCCCGACCTATTCAGAGTTGGCCAGGAGCAGCAGGCACCACAGCCTGTGTGTGTGCAGATACAGT


 


GTACTACTACCAAATGGTGCCCAGGTTGACTGCTGTACTGCAGACTGCAATGGCAGCTGGAAGTTTAGGTCTCCTCC


 


TACCTGGATCTCATTACTTGGGCCGTTTTCAGGATCGTTTAATGTGGATAATGATTCTGGAATGTGGCTATACTTAC


 


TGCTCTATTAACATTAAGGGGTTAGAATTGCAGGAAACATCCTGTCATACTGCAGAAGCTCGCAGAGTTGATGAAGT


 


TTTTGAAGATGCTTTTGAGCAAGAATACACAAGAGTATGTTCCCTTAATGAACACTTTGGAAATGTCTTGACACCCT


 


GTACTGTTTTGCCTGTGAAATTGTATTCTGATGCCAGGAATGTTCTATCAGGCATAATTGATTCTCATGAAAACTTA


 


AAAGAATTTAAAGGTGACCTCATTAAAGTACTTGTGTGGATACTTGTTCAATACTGCTCCAAAAGGCCTGGCATGAA


 


AGAGAATGTTCACAACACTGAAAATAAAGGGAAAGCACCTCTAATGTTGCCTGCTTTGAACACTTTGCCACCTCCCA


 


AATCCCCAGAAGACATAGACAGTTTAAATTCAGAAACTTTTAATGACTGGTCTGATGATAATATTTTTGATGATGAG


 


CCAACTATCAAAAAAGTAATAGAAGAAAAACATCAGTTGAAAGATTTGCCAGGTACAAATTTGTTTATTCCAGGATC


 


AGTAGAATCACAGAGGGTTGGTGATCATTCTACAGGCACTGTTCCTGAAAACGATCTTTACAAAGCAGTTCTATTAG


 


GATACCCTGCTGTTGACAAAGGAAAACAAGAGGACATGCCATATATTCCTCTCATGGAGTTCAGTTGTTCACATTCT


 


CACTTAGTATGCTTACCCGCAGAGTGGAGGACTAGCTGTATGCCCAGTTCCAAAATGAAGGAGATGAGCTCGTTATT


 


TCCAGAAGACTGGTACCAATTTGTTCTAAGGCAGTTGGAATGTTATCATTCAGAAGAGAAGGCCTCAAATGTACTGG


 


AAGAAATTGCCAAGGACAAAGTTTTAAAAGACTTTTATGTTCATACAGTAATGACTTGTTATTTTAGTTTATTTGGA


 


ATAGACAATATGGCTCCTAGTCCTGGTCATATATTGAGAGTTTACGGTGGTGTTTTGCCTTGGTCTGTTGCTTTGGA


 


CTGGCTCACAGAAAAGCCAGAACTGTTTCAACTAGCACTGAAAGCATTCAGGTATACTCTGAAACTAATGATTGATA


 


AAGCAAGTTTAGGTCCAATAGAAGACTTTAGAGAACTGATTAAGTACCTTGAAGAATATGAACGTGACTGGTACATT


 


GGTTTGGTATCTGATGAAAAGTGGAAGGAAGCAATTTTACAAGAAAAGCCATACTTGTTTTCTCTGGGGTATGATTC


 


TAATATGGGAATTTACACTGGGAGAGTGCTTAGCCTTCAAGAATTATTGATCCAAGTGGGAAAGTTAAATCCTGAAG


 


CTGTTAGAGGTCAGTGGGCCAATCTTTCATGGGAATTACTTTATGCCACAAACGATGATGAAGAACGTTATAGTATA


 


CAAGCTCATCCACTACTTTTAAGAAATCTTACGGTACAAGCAGCAGAACCTCCCCTGGGATATCCGATTTATTCTTC


 


AAAACCTCTCCACATACATTTGTATTAGAGCTCATTTTGACTGTAATGTCATCAAATGCAATGTTTTTATTTTTTCA


 


TCCTAAAAAAGTAACTGTGATTCTTGTAACTTGAGGACTTCTCCACACCCCCATTCAGATGCCTGAGAACAGCTAAG


 


CTCCGTAAAGTTGGTTCTCTTAGCCATCTTAATGGTTCTAAAAAACAGCAAAAACATCTTTATGTCTAAGATAAAAG


 


AACTATTTGGCCAATATTTGTGCCCTCTGGACTTTAGTAGGCTTTGGTAAATGTGAGAAAACTTTTGTAGAATTATC


 


ATATAATGAATTTTGTAATGCTTTCTTAAATGTGTTATAGGTGAATTGCCATACAAAGTTAACAGCTATGTAATTTT


 


TACATACTTAAGAGATAAACATATCAGTGTTCTAAGTAGTGATAATGGATCCTGTTGAAGGTTAACATAATGTGTAT


 


ATATTTGTTTGAAATATAATTTATAGTATTTTCAAATGTGCTGATTTATTTTGACATCTAATATCTGAATGTTTTTG


 


TATCAAGTAGTTTGTTTTCATAGACTTCAATTCATAAACTTTAAAAAACTTTTAATAAAATATTTTCCTTCCTTTTC


 


AAATAAAAAAAAAAAAAAAAAAAAA


 


>gi|8922115|ref|NM_017586.1| Homo sapiens chromosome 9 open reading frame 7


(C9orf7), mRNA


(SEQ ID NO: 15)



ACGCGGCCGGCTACCGAGCCCTTTGTGAGGGCTGTGAGCTGCGCCTGACGGTGGCACCATGAGCAGCTCAGGTGGGG



 


CGCCCGGGGCGTCCGCCAGCTCTGCGCCGCCCGCGCAGGAAGAGGGCATGACGTGGTGGTACCGCTGGCTGTGTCGC


 


CTGTCTGGGGTGCTGGGGGCAGTCTCTTGCGCGATCTCTGGCCTCTTCAACTGCATCACCATCCACCCTCTGAACAT


 


CGCGGCCGGCGTGTGGATGATCATGAATGCCTTCATCTTGTTGCTGTGTGAGGCGCCCTTCTGCTGCCAGTTCATCG


 


AGTTTGCAAACACAGTGGCGGAGAAGGTGGACCGGCTGCGCTCCTGGCAGAAGGCTGTCTTCTACTGCGGGATGGCG


 


GTCGTTCCCATCGTCATCAGCCTGACCCTGACCACGCTGCTGGGCAACGCCATCGCCTTTGCTACGGGGGTGCTGTA


 


CGGACTCTCTGCTCTGGGCAAAAAGGGCGATGCGATCTCCTATGCCAGGATCCAGCAGCAGAGGCAGCAGGCGGATG


 


AGGAGAAGCTCGCGGAGACCCTGGAGGGGGAGCTGTGAAGGGCTGGGCGCCCCTCCCTCCCTGTCCCCTCTTCTGGC


 


TCTGTGTGGGTCCAAGTGAGGCCTGGACTGTCCACGCTGAGGCACAGCCTGGAGAGGGGCCTTTGCACGTGTCCCTA


 


CACCTGGAGTCCTCTGCTCCTTTCTCCAGACTGGCTTAAGCCAGGAGCCACTGGCTGCTGGTGTGAGGGTCTGGGCT


 


GCTGGACTTGAGGCAGAGCCTGCAGCAGCTGTGTGGACACTACCCAGCCCTACTCCTCTGCTGGGTGGGTCTGCAGA


 


TCTCACACCACAGACAGGGCTGCCTGTGACCTGCTGTGACCTGGGAGCAGCTTCCCCTGGAGATGCTGGTCCTGGCT


 


TGAGGGGAGGGGCAAGTGGGACCCTGCCACCTGGGCACTGAGCAGAGGGACCTCCCCCAGCTCTCTTAGCAGGTGGA


 


GCCCCAGGGCCTGGGACAGCCTGCCGCTGCCAGCAACCTCCCACTGCTGCCTAGGGTGCAGCGCCCACTGTCACCCT


 


GCCTTCTGAAGAAGCCCACAGGGCTCCTAAGGTGCACCCCGGTACCTGGAACTGCAGCCTTGGCAGTGACTGGACAG


 


CTGGGTGGGGGATGCTCCCTGCTGGCCCTGGGAACCTTGGACAGGCCACCTCAAGGCCCCTCGGCTGCCCCTCCTCC


 


CTGGGCCTGCTGGGGCCCCTAGGTTCTGCCCATCACCCCCCGCCCCTGCTGGCCTTGGTGCTAAGGAAGTGGGGAGA


 


GCAGGCTCTCCCTGGCACCGAGGGTGCCCACCCTCTCCCTGGTGTGGCCCCGTCAACATCAGCCACAGCCCAGCCCC


 


ATTAGTGGGTTAGCGGGTCTGACCTCAGCCCCACTCAGGTGCTCCTGCTGGCCTGCCCAAGCCCTGCCCTCAGGGAG


 


CTTCTGCCTTTTAAGAACTGGGCAGAGGCCACAGTCACCTCCCCACACAGAGCTGTCCCCACTGCCCTGGGTGCCAG


 


GCTGTCCGGAGCCAGGCCTACCCAGGGAGGATGCAGAGAGCTGGTGCCCAGGATGTGCACCCCCATATTCCCTCTGC


 


CCTGTGGCCTCAGCCCGCTGGCCTCTCTGACCGTGAGGCTGGCTCTCAGCCATCGGGCAGGTGCCTGGTCGGGCCTG


 


GCTTAGCCCAGGTGGGGCTTGGCAGAAGCGGGCGGGTGTGGAAGATATTCCATCTGGGGCCAACCCCAGGCTGGGCC


 


TGCGCTGAGCTTCTGGAGCGCAGGTACTGGGTCTTGCTAAGTGAACTGTTTCCCAGGAACACCTCTCGGGCCCATCT


 


GCGTCTGAGGCTGGGAGTGGCATCTGAGGCCGGGAGTGGCATCTGAGGCCAGGAGTGGCAGGCTGGTGGGCTGGGCG


 


TGGGGTTTTCTGGGCCCTGCCCAGTACTGCCCTGGGGACTTGGTGGGCTCCTGGGTCAGCAGCATCCCACCCCTGGG


 


AGTCTGGCCAGCTGAGCCCCAGGGTGGCAGGGGCATTATAGCCTGGTGGACATGTGCCTTCAGGGTTCCTCCGGGGC


 


CACCTTCCTCAGGCCAGTGCTGGGTTCAAAGGGCTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTATATGTGTGTGG


 


GTGCACACATCTGTCCCATGTATGCAGTGAGACCTGTCTACCTCCCACAAGGAGCAAGGGCTCTGCCCGCCCTCTGC


 


TCATTCCTACCCAGGTAGTGGGACCCCGGGCCCCCTTCTGCCTGGCTTGCCTGCTTCTGCCCTTTCCAGAGGGGTCT


 


CACTGACAGCCAGAGACAGCAGGAGAAGGGTTGGCTGTGGATCAAGGAAGGCTGCCCCTGTACCCTGTGGGGAAATG


 


GTGGGTGCATGGCTGGATGCAGAGGTGGAAGGCCCTGGGCCACAGGCGAGAGTGGGCGTGTCACCTGTCCCAGGTTC


 


CCAGCAAGTCTGCAGCTGTGCAGTCCTGGGGTCCCTGACCCTGTCGCCCAGGGGGCGTGCTGTCCAGCAGGGGCCCT


 


GCCTTGCAAGGAACGTCTCTTCCGGCGGCTGGGCCGCTCCTGCCTGGTCTGGGCTGTGTGTGGCGCCCTTTCCTTCT


 


TGTTTGTTCCTCTGTGTTCTGTGTGCGTCTTAAGCAATAAAGCGTGGCCGTGGCTCGCGAAAAAAAAAAAAAAAAAA


 


>gi|169188371|ref|XM_001725818.1| PREDICTED: Homo sapiens family with


sequence similarity 26, member A (FAM26A), mRNA


(SEQ ID NO: 16)



CCCTGCCTTAAGTGCCTACTGGATCCCGGGAGCCTGGGCTGGGGCCTGGGCACTGCTTCCTCCTTGGCCCCTCAGGC



 


CCTTGGAAGCAGAGAGAGAACCTCTTGCAGATCCCAGGCTCGTCCCCAGCACAGCAGACACCAGGAAGGTGGCCAGA


 


GCCTCACTGAGCCGAACCGACGGCCGCCCACCCACCCAGGCTGGAGCCATGGATAAATTCCGCATGCTCTTCCAGCA


 


CTTCCAGTCAAGCTCGGAGTCGGTGATGAATGGCATCTGCCTGCTGCTGGCTGCGGTCACCGTCAAGCTGTACTCCT


 


CCTTTGACTTCAACTGTCCCTGCCTGGTGCACTACAATGCACTCTACGGCCTGGGCCTGCTGCTGACGCCCCCGCTC


 


GCCCTGTTTCTCTGCGGCCTCCTCGCCAACCGGCAGTCTGTGGTGATGGTCGAGGAGTGGCGCCGGCCCGCAGGGCA


 


CCGGAGGAAGGACCCAGGCATCATCAGGTACATGTGCTCCTCTGTGCTGCAGAGGGCGCTGGCCGCCCCCCTGGTCT


 


GGATCCTGCTGGCCCTCCTTGACGGGAAGTGCTTCGTGTGTGCCTTCAGCAGCTCTGTGGACCCTGAGAAGTTTCTG


 


GACTTTGCCAACATGACCCCCAGCCAGGTACAGCTCTTCCTGGCCAAGGTTCCCTGCAAGGAGGATGAGCTGGTCAG


 


GGATAGCCCTGCTCGGAAGGCAGTGTCTCGCTACCTGCGGTGCCTGTCACAGGCCATCGGCTGGAGCGTCACCCTGC


 


TGCTGATCATCGCGGCCTTCCTGGCCCGCTGCCTGAGGCCCTGCTTCGACCAGACAGTCTTCCTGCAGCGCAGATAC


 


TGGAGCAACTACGTGGACCTGGAGCAGAAGCTCTTCGACGAGACCTGCTGTGAGCATGCGCGGGACTTCGCGCACCG


 


CTGCGTGCTGCACTTCTTTGCCAGCATGCGGAGTGAGCTGCAGGCGCGGGGGCTGCGCCGGGGCAATGCAGGCAGGA


 


GACTCGAGCTCCCCGCAGTGCCTGAGCCCCCAGAAGGCCTGGATAGTGGAAGTGGGAAGGCCCACCTGCGCGCAATC


 


TCCAGCCGGGAGCAGGTGGACCGCCTCCTAAGCACGTGGTACTCCAGCAAGCCGCCGCTGGACCTGGCTGCATCCCC


 


CGGGCTCTGCGGGGGTGGCCTTAGCCACCGCGCCCCTACCTTGGCACTGGGCACGAGGCTGTCACAACACACCGACG


 


TGTAGGGTCCTGGCCAGGCTTGAAGCGGCAGTGTTCGCAGGTGAAATGCCGCGCTGACAAAGTTCTGGAGTCTTTCC


 


AGGCCGTGGGGACCCCACGGCAGGCACCCTAAGTCTTGTTAGCCTCCTTTTTAAAGTAGCCCAATCTCTGCCTAGTT


 


TCTGGGTGTGGCCTCCAGCGCGCTTCACAAACTTTAATGTGGACTCGGTTCACCGAGGGCCTTGTTAAATACAGGTT


 


CAGACAGTGTAGCCAGGACCGAGTCTGAGATTCTGCATTTTAAACAAGCTCCTGGAGGCTGATGTGCTTTTGGTCAG


 


TGAACCAAACTTTGAGTAGCAAGAATCTAAGTAAATCTGCCATGGGTTCTGGGTTCTAGATGTCAATTCTAAATAAT


 


AATAATGACCTTAGTCTGCTGCCTCGATA


 


>gi|47777332|ref|NM_001001412.1| Homo sapiens family with sequence similarity


26, member C (FAM26C), mRNA


(SEQ ID NO: 17)



CTCTGCTCTGAGCTCTGTTGGTCCCAGCCAGGAGAGCCCGAGTCATGAGGTGGGCACCCAGTGGGCAGGGTGGGCAG



 


CAGGGGCCCTCTTGGAGGCAGCAGTGAGTTGGGAAGAGGAGGCCGGGCCCCACAGCGGGCATGATGGACAAGTTCCG


 


GATGATCTTCCAGTTCCTGCAGTCCAACCAGGAGTCCTTCATGAATGGCATCTGTGGCATCATGGCCCTGGCCAGTG


 


CCCAGATGTACTCGGCCTTCGACTTCAACTGCCCCTGCCTGCCGGGCTACAATGCGGCCTACAGCGCGGGCATCCTG


 


CTGGCGCCACCCCTGGTGCTCTTTCTGCTTGGCCTGGTCATGAACAACAACGTGTCCATGCTGGCCGAAGAGTGGAA


 


GCGGCCACCGGGCCGCCGGGCCAAGGACCCCGCTGTGTTGCGCTACATGTTCTGCTCCATGGCCCAGCGCGCCCTCA


 


TCGCGCCTGTCGTCTGGGTGGCCGTCACGCTACTCGACGGCAAATGCTTCCTCTGTGCCTTCTGCACTGCCGTGCCC


 


GTGAGCGCACTGGGCAACGGCAGCCTGGCACCCGGCCTTCCTGCCCCCGAGCTCGCCCGCCTGCTGGCCCGGGTGCC


 


CTGCCCTGAGATCTACGATGGCGACTGGCTGTTGGCCCGAGAGGTGGCCGTGCGTTACCTCCGCTGCATCTCCCAGG


 


CGCTGGGCTGGTCCTTCGTGCTGCTGACCACTCTGCTGGCATTCGTGGTGCGCTCTGTGCGGCCCTGCTTCACGCAG


 


GCCGCCTTCCTCAAGAGCAAGTACTGGTCCCACTATATCGACATCGAGCGCAAGCTCTTCGACGAGACGTGCACGGA


 


GCACGCCAAAGCCTTTGCCAAGGTCTGCATCCAGCAGTTCTTCGAGGCCATGAACCATGACCTGGAGCTGGGTCACA


 


CCAACGGGACACTGGCCACGGCCCCTGCTTCCGCAGCTGCCCCCACGACCCCCGATGGTGCGGAGGAGGAAAGGGAG


 


AAGCTGCGTGGCATCACGGATCAAGGCACCATGAACAGGCTGCTCACGAGCTGGCACAAATGCAAACCGCCTCTGCG


 


GCTGGGCCAGGAGGAGCCACCGCTGATGGGCAACGGCTGGGCTGGGGGTGGGCCCCGGCCTCCGCGTAAGGAGGTGG


 


CCACCTACTTCAGCAAAGTGTGAGGCGTGGCCAGCTGAAGAGGCAGGAACGGGGATCTGAGCCCACAGCCCCTCCAA


 


CCCCCAAACCAGGTGGAAAAAGGAAGGGTTTCGGTGCTGGGCAGTACTCCCCTAGGCAGATCCACACTCCGTAGCAC


 


TCGCCTGCCCATTGGAGGCAGGAAATTTGGAGCTGGAAGGGGATCTGATGCCTTCAGGTGTGACACTGCCCTGGATG


 


GCCCTAGGGCAGTGGGCCCATGAGCAGTATTAGTCTAAAGGGGTCGGAACTGTCATGGCAGGTACAGGGACCAATGG


 


CTCCCCTCTGCCCAGCCCTTCCCAGGCTGATGTTCACTGTCTCCTCCCAGGTTCAACAGACATCCCTGCACCAGGGT


 


CCACCCTCGTCTGTGGCTGTTCAGTACCTCTCTTCCTTTATGCTCCGGGCTCGGGGAGTGGGAATCATCAGGCGTCT


 


CATGAAGTGGGAGCCCTCTGATTTGGGCAAGCGTGTCGTAGGTGAGACTGGGTGTGCCGGGGCAGGTCCATAAGGAC


 


ATGACACACAGCCTACATGGTGTGACACACCTGGGGTGACAGGCGATGAGACAAGATGTCAGAAGCTAGGTTCACAT


 


GGAAGAGGTCAGAGTGTGTGGTCACCATGGGGGTCATGTGACAATTGTCCAGGTGGACTGCATGTTTATTTAGCACA


 


AACCAAGCACAAAAGTCCTCCTGTAGAGGGGTCTTTGAAAAACCACCTTAATACCCACGTCACATCCAGGTCTCCAG


 


GGGAAATCAGACCATCCCCAAGGCTTGAGAAGTTAGACACAGAAGCTGAAGTCTCTCCATTTTTCTCAAAGACCCCA


 


CCTCTTGGGGATGGAGTTCTAAGAGGCTAAGAGGAGCTCCAAGGCTCTAGCCCAGGTGGGATGAGGGTGGAGGAGAG


 


CAGTGTAAAGAGAAAGCAGCTCAGATTCCAGAGTGAGACAGAACTGGGTCAAATGGTGTCTCTACCACTCACAAACC


 


CTGTCCCTGGGCCAGCTGCATCACTGCCTGTGCCTTCGTTTCTTCATCTATACAATGAGGATGAGGCCCCCCCGGCC


 


CGCCATCATGGGGTTGCTGTGTGTAAAAGCACATGGCACATAGTAGGCACCCAGCACAGGGTGGCTAATGTATTTGT


 


TGATTTCTGAACCTAAGGACTTCCTTCCTCCTCCCCTGGGCAGGGATGAGACAGCAACACAAACACTCGAGCTTCCA


 


TCTTGTTGAGGAGGAAACAGAGGTACAGATAGGTTTCTCAGCACCGCCCTCAGCTCTGAGACATAAGTCCCAAGCAT


 


CTAAGGATTCATTTTGATCTTGGCATGATTCCATCCTTTTTTATCCATCCTTCCCTCTATTCCCACTTCTGGGGTCC


 


AGTTTCCCTCCTCTTAATTATTTGGGAGGAGTTGCTCAGATCTTTGTGGGCCAAGGTGGGCTGGGAGGGCTCTTCCA


 


GGAGGTAGGAGTTGGTATGGGCCCTGAAGTCAGGGAGGATTAGGATGAGCAAAAAACAAGGTGTATGTTGGTGGGTG


 


GCAGCACTTCCAGTGGGAAGAGAAGGCCCGGAGGTATCAGGAGGTACAAATGTGATGAAGAGCAAAGCTTTGGGTCA


 


GGCACACCTGAGTTCAAATACCAGCACTGCAGGACTTGTGGCCAGTCACCCAGCCACTCTAAGCCTCAGTGTGTCTG


 


TCTATAAAATGGATATTAGAAGACCTGCTTGGCCAGGCGGAGTGGCTCATGCCTGTAATCCCAGCACTTGGGAGGCC


 


AAGGAGGGAGGATCACTTGAGCCTGGGAGTTGGAGACCAGCCTGGGCAACATAGCAAGACTCTGTCTCTGTAAAGTA


 


ATAATAATAATAATAAGAAGAAGAAGAAGAATAAAGAGAAGATTTATAATTTTAAAAAAAAAAAAAAAAAAAAAAAA


 


AAGAAAAAAAAAAAAAAAA


 


>gi|46048468|ref|NM_152599.2| Homo sapiens hypothetical protein FLJ35773


(FLJ35773), mRNA


(SEQ ID NO: 18)



GATCGCGGCGCCGCCCCAGACCGGGGGCGCAGTCCCACTCGCTCCGAGCCCCGGTCCCCCAAGCCTCCCTCCCGGGT



 


ACCTGGGGCCGCGCCCGCCCTGCGCCCAGCTCCGCCCTCCGTCGGCCCAGGCCTGACAGAGCCCGGCAGCCATGAGT


 


GCCAACCCCCGGTGGGACATCAGCAGGGCGCTGGGGGTGGCCAAGCTCTTCCACCTGGTGTGCGGGGTGCGGGAAGC


 


CTGCGTGACCCCGTTCCTGACCCTTTACCTGAGGCAGCTGGGCTTGGCCGCGCCCTGGGTGGGCACCCTAATGGGAA


 


CCAAGCACCTAATCGCTGCCTTCTGGGCTCCCGTCTGTGCCTTCCTGGCCAAAAGCTACCGGAAAAGGAGAGCGCTT


 


CTGATCGGCTCCCTGCTCGGCTCGGTGGGGGCCAGCCTGCTGATGGTCCTGGTCCCACCGGTAGACAAAAATCGGGT


 


GCACTTCCCTTGTAATGGAAGCAGCGGCCTGACCAGCACAGACGCACTCCCGGGGGTCACGCTACCTGTGAACATCA


 


CCTCGGCCCAAGAGTCTGCCTCCAGCCACCCAGCCAAGAGGACTGCAGAGGTGGAAATGCCTGGCTTCAGAAACCCA


 


CCTGGTGAAAGTGACCGAGAAACTTTCCGTGATCTGCACGTCTACTTAGCGCCCTCCGTTGAAGGAGCTAGGACCAC


 


ATCCCAAGCTCTCCTCCATCCTGTCACTTCGGGGCTGAAAGATCATCCCTGGGAAGTTACTTTTGAGGTGGTCAAGA


 


CAGCCCTCCCCTTGCTTACTGGGGGGAAAGGGCCCGGGAATCCAGCCAATTTGTCAGGGACCAAGGGGAAAGCCTGG


 


GCTTTTGACCTGTCCTTGGAGGCGTTGCGGCGGACTTTTATCCTCTCCTTGGGGTCCGTGGCGTTCTGGGAGCTGCT


 


GACAGCGCCTCTGGAGCAGGTGGCAGATGACAGCCTTTATGAGTTCCTGGATTTTGTGGATGCCACTGACCGATACA


 


GAAGCCTGTGGGTCTGGAGGTTGCTGGGCATGTCGGCAGGCGTGTGTGGCATCACAGCCTTGGTGGGGCAGCTGGAC


 


TGCTTCCTGATGACCAGTGGCCCCCGAGGTGTGGTCCACTTCTATGGGTACTCGGTGGTCAGCACCCTGGCCTTACT


 


GGTGAGCATTGCCTTTCCCATTCCCATCTGTCAGCAGTGGGAGCCCAGCTACAAAAGGGTCAAAGCACTGTCCATTG


 


TGGGGGGTGACCCCCACCTCATTCTCCTCGCCTCCACCACTGTTTTGGTAGGAGCCATCGTCAGTACTGTCCAGAAC


 


TTTCTGTTCTGGCACATGAAGGACCATGGGAGCGGCGAGCTGGTCATGGGTTTCTCGGTCGCCCTCAGCTTGCTGGG


 


GGAAATTCTGCTTCATCCGTTCAAAGCTACATTGCTTAGGAAACTGTCCAGGACGGGCCTGGTGGGGCTGGGGCTGA


 


GCTGCCTCGCTGGGCAGCTGCTGTACTACTCTTTCCTCTGGAGCTGGTGGTCCGTCCTCCCCATTCAGATCTTGAGT


 


GCCATTAGCAACAGAGCTTTGTGGTGGGCTGTGGGGGCCTCAGTAGAGGACCTGGCCACTCCCCGCATGGAGAGGGC


 


TCTGAGTGCCTTGTTCCGAGGCCACTTTTACGGGAGTGGCTGTAGCCTGGGCAGCTTTGTCGGGGGCTTCGTGGTGA


 


TGCGCTTCAGCCTGGCTGTGCTCTACCAGGCCTGCTGTGTGGCCCTGTTGCTCTGGTTGGCCTTGCTCCTGTCCATA


 


CAGCGGAGGCTGCCCCGAGAGCGGAAAATCAAGTACTCGAAGCTGCTGTCCATGGAGGTGAGTGACACCAGTGACTC


 


TGAGCAGGGGACAGAACAGGACTGGCTTGTGAAGGCCATGAGGGAGGAACACTCAGACTGAAAGGGCTGAGAAATCC


 


AGAGTGTGCTGATCCAGCAAGGAACGAATGGACTGAACAAAACTCAGCCTGCTGAGGACAGAAACCTGCCCTGGACT


 


GCTGGGAGCCGGGGAAGAGAGGATGGGTCTGTGCTGAAGGCCCAACAGGATCATCTCATTGCATGATTTTCTTTACT


 


TTTGAAGTAAAAGGAGATTTAACTTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAA


 


>gi|148230774|ref|NM_153835.3| Homo sapiens G protein-coupled receptor 113


(GPR113), mRNA


(SEQ ID NO: 19)



CTCCCTTTCATCTGGTGGCCCTAGCGCCACAAGCTGCCGCTTAGGAAGTCCCTGCCGGGAGCAGAAGTGGAGACATC



 


AGCAGGATGGCATCGGCAAGTCGCTCCCCTCCCGGGCCTCATCTGCCAAACGATCATCTCCTCCTCCGAAGTTGTAT


 


GCATGACAGGCGAGTGGAAACTTCACTAAAATGAAGGCGATTGACACAACAGAAGGAACTCCATCCTTTCGGGGGCT


 


TACGAAAATAATAAGTTTAAAAAAAATAGGAAGGGAATTCCCTCGCTCCATGATCACTGAGCGCTCTCCTAAGGAAA


 


AGGAAATCTCCCGGGGGGTGCCGACTACGGGCGGCGGGCTTAGGATGCTCCCACGCTCCCCGACCCCCAATCCCCAG


 


GACCCGCAGGACCTCCGGAGGAACGCCCGCCAGCCCGCCCGGAGCCACGCGGCACAAGGTGACACGGACCGCGCCGC


 


GCGGGCCCCTCAGCCGCCTGGGCGAGGCCGGGAGCAGGGAGAGGGGCATCCGCCGGCCCGCGGTACCTTGTACTTAT


 


CAAAGCCAGCCAGCTGCTCCGGGCTCACGTATTCGTAGCCAGCCATGACGACCCGAAAACTGAGCGCCCACTCGGCA


 


GCGACTCCCGGCTACAAGGCTGTGACACACAAGCACCACACCGGCTGGGCAAGGATGGCAAAGACTGGGCTGCCCGA


 


GAAGGGACAGAGTCAGGCTGGAGGGGAATCTGGATCTGGGCAGCTCCTGGACCAAGAGAATGGAGCAGGGGAATCAG


 


CGCTGGTCTCCGTCTATGTACATCTGGACTTTCCAGATAAGACCTGGCCCCCTGAACTCTCCAGGACACTGACTCTC


 


CCTGCTGCCTCAGCTTCCTCTTCCCCAAGGCCTCTTCTCACTGGCCTCAGACTCACAACAGGTGAGTACATGAGCTG


 


CTTCGAGGCCCAGGGCTTCAAGTGGAACCTGTATGAGGTGGTGAGGGTGCCCTTGAAGGCGACAGATGTGGCTCGAC


 


TTCCATACCAGCTGTCCATCTCCTGTGCCACCTCCCCTGGCTTCCAGCTGAGCTGCTGCATCCCCAGCACAAACCTG


 


GCCTACACCGCGGCCTGGAGCCCTGGAGAGGGCAGCAAAGCTTCCTCCTTCAACGAGTCAGGCTCTCAGTGCTTTGT


 


GCTGGCTGTTCAGCGCTGCCCGATGGCTGACACCACGTACGCTTGTGACCTGCAGAGCCTGGGCCTGGCTCCACTCA


 


GGGTCCCCATCTCCATCACCATCATCCAGGATGGAGACATCACCTGCCCTGAGGACGCCTCGGTGCTCACCTGGAAT


 


GTCACCAAGGCTGGCCACGTGGCACAGGCCCCATGTCCTGAGAGCAAGAGGGGCATAGTGAGGAGGCTCTGTGGGGC


 


TGACGGAGTCTGGGGGCCGGTCCACAGCAGCTGCACAGATGCGAGGCTCCTGGCCTTGTTCACTAGAACCAAGCTGC


 


TGCAGGCAGGCCAGGGCAGTCCTGCTGAGGAGGTGCCACAGATCCTGGCACAGCTGCCAGGGCAGGCGGCAGAGGCA


 


AGTTCACCCTCCGACTTACTGACCCTGCTGAGCACCATGAAATACGTGGCCAAGGTGGTGGCAGAGGCCAGAATACA


 


GCTTGACCGCAGAGCCCTGAAGAATCTCCTGATTGCCACAGACAAGGTCCTAGATATGGACACCAGGTCTCTGTGGA


 


CCCTGGCCCAAGCCCGGAAGCCCTGGGCAGGCTCGACTCTCCTGCTGGCTGTGGAGACCCTGGCATGCAGCCTGTGC


 


CCACAGGACCACCCCTTCGCCTTCAGCTTACCCAATGTGCTGCTGCAGAGCCAGCTGTTTGGACCCACGTTTCCTGC


 


TGACTACAGCATCTCCTTCCCTACTCGGCCCCCACTGCAGGCTCAGATTCCCAGGCACTCACTGGCCCCATTGGTCC


 


GTAATGGAACTGAAATAAGTATTACTAGCCTGGTGCTGCGAAAACTGGACCACCTTCTGCCCTCAAACTATGGACAA


 


GGGCTGGGGGATTCCCTCTATGCCACTCCTGGCCTGGTCCTTGTCATTTCCATCATGGCAGGTGACCGGGCCTTCAG


 


CCAGGGAGAGGTCATCATGGACTTTGGGAACACAGATGGTTCCCCTCACTGTGTCTTCTGGGATCACAGTCTCTTCC


 


AGGGCAGGGGGGGTTGGTCCAAAGAAGGGTGCCAGGCACAGGTGGCCAGTGCCAGCCCCACTGCTCAGTGCCTCTGC


 


CAGCACCTCACTGCCTTCTCCGTCCTCATGTCCCCACACACTGTTCCGGAAGAACCCGCTCTGGCGCTGCTGACTCA


 


AGTGGGCTTGGGAGCTTCCATACTGGCGCTGCTTGTGTGCCTGGGTGTGTACTGGCTGGTGTGGAGAGTCGTGGTGC


 


GGAACAAGATCTCCTATTTCCGCCACGCCGCCCTGCTCAACATGGTGTTCTGCTTGCTGGCCGCAGACACTTGCTTC


 


CTGGGCGCCCCATTCCTCTCTCCAGGGCCCCGAAGCCCGCTCTGCCTTGCTGCCGCCTTCCTCTGTCATTTCCTCTA


 


CCTGGCCACCTTTTTCTGGATGCTGGCGCAGGCCCTGGTGTTGGCCCACCAGCTGCTCTTTGTCTTTCACCAGCTGG


 


CAAAGCACCGAGTTCTCCCCCTCATGGTGCTCCTGGGCTACCTGTGCCCACTGGGGTTGGCAGGTGTCACCCTGGGG


 


CTCTACCTACCTCAAGGGCAATACCTGAGGGAGGGGGAATGCTGGTTGGATGGGAAGGGAGGGGCGTTATACACCTT


 


CGTGGGGCCAGTGCTGGCCATCATAGGCGTGAATGGGCTGGTACTAGCCATGGCCATGCTGAAGTTGCTGAGACCTT


 


CGCTGTCAGAGGGACCCCCAGCAGAGAAGCGCCAAGCTCTGCTGGGGGTGATCAAAGCCCTGCTCATTCTTACACCC


 


ATCTTTGGCCTCACCTGGGGGCTGGGCCTGGCCACTCTGTTAGAGGAAGTCTCCACGGTCCCTCATTACATCTTCAC


 


CATTCTCAACACCCTCCAGGGCGTCTTCATCCTATTGTTTGGTTGCCTCATGGACAGGAAGATACAAGAAGCTTTGC


 


GCAAACGCTTCTGCCGCGCCCAAGCCCCCAGCTCCACCATCTCCCTGGCCACAAATGAAGGCTGCATCTTGGAACAC


 


AGCAAAGGAGGAAGCGACACTGCCAGGAAGACAGATGCTTCAGAGTGAACCACACACGGACCCATGTTCCTGCAAGG


 


GAGTTGAGGCTGTGTGCTTGAACCCACCAGATGAGCCCTGGCCCAATGCTCTGAACTCTTCCCGCCTCCCGGAGCTC


 


AGCCCTTGAGAAAGGCAGGCTTATATTTCCCTTAGTGACACTCATTTATCTTACAGCTCACCCCTTCTCATTTCTAA


 


AGTATCCAGCAAGAATAGCAGGAAAAATTAGCTAAAGGCACCTAATGAATAAGCCTGCCTTTGCTCCAGAAATAATC


 


GACAGATATCAAAGTGCGGAATAATTACAAGTAAACTTTCTCAACCAGTTTTTAACTACAACAATACATGTTGTGAA


 


TGAATATATTTGATAAAAATGGTTTTAATTGACCTATTCAGCGATTTCTGATTATTTCTTTTTCAATAGTTATGAAG


 


AAAGGATGACTTACTTGACAGGAACCTCTGATCTTTCAAACATTGGAGATGAAGGGCAGAATTTGGTTTGTCTTTTC


 


AAGTTTAGGAAAAGGTGAAGTTAATTGGTCCCTCTTTCTTTAACCTTTAAAAAATCAATATAAAATGTAAGTTTCTT


 


AACCATATCCATGTATAGAGGCATTGATTGATATGAGCACGTTGTAAGAATAGGTTATAAAAATTTAAAGTTTAATA


 


TAAATTTATATCAATTAATAAAGTTTAATTTATATTTAAAAATGAATACTAGAAGAAAATCTTTTTGAAGACACCAA


 


GATATCTATCTGGCTGAATTAACTTATGGAATTCACAAGAGGAAGATGACAGGATTCTGAGAAATTTTTAAACTAGA


 


TACGTGAAAAAAGTCTGATGAATCGGTCTTTGTTAATTATGCAATTCATGGATATTTTTTATAAAATGGGACGGGGG


 


CATTTTCTGTTAAAATAAAAATGGTTATGCTATCACGAAAAAAAAAAAAAAA


 


>gi|74315998|ref|NM_152529.5| Homo sapiens G protein-coupled receptor 155


(GPR155), transcript variant 10, mRNA


(SEQ ID NO: 20)



CTCGCGGCCGGCGAGGGGCTGAGCTGACAGGGCCGCATCGGCTTACCCCACCTTACTTTATCGGAACGTGCCTAAGC



 


TGCTGCAGCTGGCACCCGGTTGCGCTCGGCGAAGAGGGCTGGGGGCGGGAGATGACGGTGGTCTTCTCCCTGCTTGG


 


CACCCTGCGAGCACCAGCTCCCTTCTCCTCGCCACTCCAAGGTTGCAGACGAAGCAGAGATCTGGTTGGAGTTGGAG


 


GGTGAGAGAAAATGAATTCTAATTTACCTGCAGAGAACTTAACCATTGCAGTCAATATGACCAAGACTTTGCCTACA


 


GCAGTAACGCATGGATTTAATTCCACTAATGACCCACCTTCAATGTCAATTACAAGGCTTTTTCCAGCCTTACTGGA


 


ATGCTTTGGCATTGTCCTTTGTGGCTACATAGCAGGAAGGGCCAATGTCATAACATCAACCCAGGCCAAAGGACTAG


 


GAAATTTTGTCTCCAGATTTGCACTTCCAGCTTTATTATTCAAAAACATGGTTGTACTTAATTTTTCCAATGTGGAC


 


TGGTCCTTCCTATATAGTATCTTAATTGCCAAAGCTTCTGTATTTTTCATTGTATGTGTATTAACCTTATTGGTTGC


 


CAGTCCTGATAGTCGATTTAGCAAAGCTGGACTATTCCCTATTTTTGCTACACAAAGTAATGACTTTGCATTGGGAT


 


ACCCTATAGTTGAAGCTTTATATCAAACTACATACCCAGAATATCTCCAGTACATTTATTTGGTGGCACCAATATCT


 


CTTATGATGTTAAACCCTATAGGGTTTATTTTCTGTGAAATCCAAAAGTGGAAAGACACTCAAAATGCTTCTCAAAA


 


TAAAATAAAAATTGTGGGACTCGGACTCCTGCGTGTATTACAGAACCCAATAGTATTTATGGTCTTCATTGGCATCG


 


CCTTCAATTTTATTCTTGATCGAAAGGTACCTGTATATGTCGAAAATTTTCTTGATGGACTTGGAAATTCTTTTTCT


 


GGATCAGCCCTATTTTATCTTGGTCTCACGATGGTGGGAAAAATAAAGAGACTGAAGAAGTCGGCATTTGTAGTACT


 


AATTCTTCTCATCACAGCTAAACTTCTGGTGCTGCCACTTCTGTGCAGAGAAATGGTGGAACTCTTGGACAAGGGCG


 


ACAGTGTGGTGAACCATACAAGTTTATCAAATTATGCATTTCTGTATGGTGTATTTCCTGTAGCACCAGGAGTGGCT


 


ATCTTTGCAACACAATTCAACATGGAAGTAGAAATTATAACCTCAGGGATGGTGATAAGCACATTTGTGTCTGCTCC


 


CATCATGTACGTTTCTGCCTGGTTACTGACCTTTCCCACTATGGACCCTAAGCCATTGGCATATGCCATCCAGAATG


 


TTAGTTTTGATATAAGTATTGTCAGCCTGATCTCCTTGATCTGGTCTCTGGCTATTCTTCTTTTGAGTAAGAAATAT


 


AAACAGCTTCCTCATATGCTTACAACTAATTTACTCATTGCTCAGTCTATTGTCTGTGCTGGAATGATGATATGGAA


 


TTTTGTTAAAGAAAAAAATTTTGTTGGACAAATTTTGGTGTTTGTTCTATTGTACAGCTCCCTCTATAGCACCTACC


 


TGTGGACAGGCCTTCTAGCAATTTCTTTGTTTCTTTTGAAAAAGCGAGAGAGGGTACAAATTCCTGTTGGAATAATC


 


ATAATATCTGGCTGGGGAATTCCTGCTCTCCTTGTTGGTGTTCTTTTGATAACTGGAAAACACAATGGAGATAGCAT


 


TGACTCAGCCTTCTTTTATGGAAAAGAACAGATGATCACCACAGCAGTCACCCTGTTCTGCAGCATCCTGATAGCTG


 


GCATATCCCTCATGTGCATGAACCAGACTGCCCAAGCAGGAAGCTATGAAGGTTTCGATCAGTCTCAGAGCCACAAA


 


GTGGTGGAGCCTGGAAATACTGCTTTTGAGGAGAGTCCAGCACCAGTAAATGAACCAGAACTTTTTACAAGCTCTAT


 


TCCAGAAACAAGTTGCTGCTCCTGCTCCATGGGAAATGGTGAATTACACTGCCCATCAATAGAGCCAATAGCAAACA


 


CAAGCACCAGTGAGCCTGTGATTCCTTCGTTTGAGAAAAACAATCATTGTGTGAGTCGCTGTAACTCCCAGAGCTGC


 


ATATTAGCCCAGGAAGAAGAACAGTATCTACAGAGTGGAGACCAGCAACTGACCCGACATGTGTTGCTGTGTTTACT


 


TCTCATCATTGGCCTGTTCGCTAATCTTTCCAGTTGTTTATGGTGGCTATTCAACCAAGAGCCTGGAAGACTTTATG


 


TTGAGTTACAGTTTTTCTGTGCCGTGTTTAACTTTGGTCAGGGATTTATTTCCTTTGGAATCTTTGGATTAGATAAA


 


CATTTAATCATCCTGCCTTTCAAAAGAAGACTTGAATTCCTATGGAACAATAAAGACACAGCAGAAAACAGGGATTC


 


TCCTGTTTCAGAGGAAATAAAAATGACCTGTCAACAATTTATCCATTATCACCGTGACCTCTGTATCCGAAACATTG


 


TCAAAGAAAGAAGGTGTGGTGCAAAGACTTCTGCTGGAACTTTCTGTGGCTGTGACCTGGTGAGCTGGCTAATTGAA


 


GTCGGCCTTGCCTCCGACCGTGGTGAAGCTGTGATATACGGAGACAGGCTGGTACAAGGGGGAGTCATCCAACATAT


 


TACCAACGAGTATGAATTCCGGGATGAGTACTTGTTTTACAGATTTCTTCAAAAGAGTCCTGAACAGAGTCCTCCTG


 


CTATTAATGCAAACACTCTCCAACAGGAAAGATATAAAGAAATTGAGCATTCATCCCCACCCTCACATTCCCCTAAG


 


ACCTAAATTATGCAGGGGAGAACCCTACATGGAATCATATTCTAGCCGCGTATTCATTAGTTTTTAGCTGGGTGACC


 


TTGGGCAAGTTAACAGAGGCAACCTCTCTGAGCCTCAGTTGTCTCTTCTGTAAAATGTGAAAAGATGTGCTCCCACC


 


ACATGCGCAGGGTCTGTGATTTTACATGTATGTAAAACACATAGGAAGCTGACTTAGGAAAAAGAGAAAACCAAATT


 


AAAGTTCTGATAATGAATATAATATAGTCATCCTTTAGTATCCAAGGGGATTGGTTCCAGGACTCCTGAAGATCCCA


 


AAATCTGAGGATACTCAAGTCCCTTATATAAAATGGTGTAGGCCGGGCATGGTGGCTCACGCCTGTAATCCCAGTAC


 


TTTGGGAGGCCGAGTCAGGTGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACATGGCGAAACCCCGTC


 


TCTACTATAAAATACAAAAAATTAGTTGGGTGTGGTGGCGGGTGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCA


 


GGAGAATCGCTTGAATCTGGGAGGCAGAGGTTGCTGTGAGCCGAGATCGTGCCACTGCACTCCAGCCTGAGCAACAG


 


AGCAAGACTCTATCTCAAAAATAAAATAAAATAAAATAAAATAATTAATAAAATGGTGTAGTATTTGCATATAACCT


 


ATGCACATTCTCCCATATAGTTTAATCATCTTTAGATACTTATAATGCCTAATACAATGTAAATGCTATGTAAATAG


 


TTGTTGTTATACTGTATTGTTTAGGGAATAACAATAAGAAAAACAGTCTGTACATGTTCACTACAGATGCAACCATT


 


GTTAAGCCTGACTACATCTTTTTATCTGCGGTTGATTGAATCTATGGATGTGGAACCTGTGCATATGGAGGGTCAAC


 


TGTACTATAAATAATACGAATATGCCAACATTATATAATCATTGCTTTCTGCAACTGTTTACTATAATTTCAAAATT


 


AATATCCTATTAACTGTTCCTATAAATTATCAAATTTGGCAAGTGTATTACTAGCAGGAGATGGACCTTAAATTATG


 


ACAACTTTATATTTTTTGATAGCATCTCTTGAAAAAGAATTTTAATGATTCTAATAAGAGGTTCTTTTTCTTTTTTC


 


CATTTCCTTGACAAATAGTACTCATTTAAAAACTAGAGGGCTAGGCTTAGTGGCTCACGCCTGTAATCTCAGCACTT


 


TGGGAGGCTGAGGCGGGCAGATCGCTTGAGGTCAGGAGTTCAAGACCAGCCCGGGCAACGTGGTGAAACCCGGTCTG


 


TACTAAAAAAAAAAAAAAAGAAAAAGAAAAAGAAAAAAGAATACCCAGGTGTGGTAGTGCATGCCTGTAGTCCCAGC


 


TACTTTGGAGACTGAGGTGGGAGTACCCCTTGAGCCTGGGAGGCGCAGGTTGCAGTGAACCAAGATCACATCACTGC


 


ACTTCAACCTGGGTGACAGAGCAAGACCCTGTCTCAAAAACAAAAAACAAGCAAAAAAAACCTAGAGGCACTATTTT


 


TTTTTAAAGTTTGTCTTTTCTTTTCTACCCAAATTACTAATCTATGCCATTAAGGAAAGGAATAAGAACCTCCATAT


 


GTATTATTATCTCCACAGTCCTGCAGAAGTACAATCTGATCTTTAACTTTCATGCTACAAATAATAATTTGAGTAGA


 


TTAATTTGAATTTTATCAACAAAATTATTGCCATATGATGTATCATTTCTGTGTTTGAACAAAGCATCGTAATGCAG


 


GATAACTTCTACTTTATTCCCTGTAGTTAAAAAAAAAAAAACTATATAGTTCAAGCCAATATTTAAAAATTCTAAAC


 


CTAGGCTGGGCATGGTGACTCATACCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGAATTGCTTCAGCCCAG


 


GAGTTCGAGACCAGCCTGGCCAATGTGGTGAAACCCCATCTCTACTAAAAAAAAAAAAAAAAAAAAAAATTAGCCAG


 


GTGTGGTGGTGTGCACCTGTAATCCCAGCTACCCAGGAGGCTGAGGCAGGAAAATTGCTTGAAACCAGGAGGCAGAG


 


GTTGCAGTGAGCTGAGATCGTGCCACTGCACTCCAGCCTGAGTGTCAGAGTGAGACTCTGTCTCAGAAAAAAAAAAA


 


AAAATTCTAAAGATTACATTTAGAATTTAGTCTTTTTAAAGTGTCCATGTATAAAAATATATAATTTTTAAAATTAC


 


TAAATGTTGCCTTTTCTCTTAGTCTAATATTTTAGCTACTAAAACAAAATATAAACTGGATAGCTTATAAACAACAT


 


AAACTTATTTCTCACAGTTTTGGAGGCTGTGAAGTCCAAGATTAAGGCACTAACAGATCTAGTGTCTGGTAAGGCAA


 


ATTTCTGGCTCATAGATGGTACCTTCTTGCTGTGTCCCCACATGGTAGATGGGAAGAACTGGTCTCATTGGCCCCTT


 


ATAAGGACATTAATTCCACTCAATAGGCTCCACCCTCATGATCTAATAACCTCTCAAAGGCCCTACCTCCTAATACT


 


AACACATTGAGGATGTGACTTCAACTTTACATTTCTACAGGCAGAGAAGTGGGGCTGTGTAAATTCTTCCCATCAGT


 


ACTTGAATGTTCATTTAACAAATAACTTATCGAGCATCTAGCATGTTCCAGACACAATCTGAACACTGAGCACACAA


 


CAGTTGGAACAAATATGATTCCTATCCTCATGGAGCTTCTATTCTCCTGTGAAAAACAGATGTTAAACATGATTGAG


 


GATTAGGTTTCAACATAAGAATTCTAGGAGGACACAGACATTTAGACCATAGCATCTTCAGGTAAACTTTATCTTCA


 


GTAAATTAAAGAGATCTATTTAGATGACCTTTGAGCATCTTAATTATTAGATGTCAGTGCTAGTTTAACTTATTTTA


 


AACGTTTCAGATATTTATTTAATTATACTTTAAGTGTCTCATGTAAAAAAGTTATTTATAAAATAATTTATAGGGTT


 


AGAGTCATTGCCCTTTTAATGCAACAAATAAACAGTTTTTTAAAAACCTGCATGGGGGCCAGGCGCGGTGGTTCATA


 


CCTGCAATCCCAGCACTTTGGGAGGTCGAGGCTGGCGGATCACGAGGTCAGGAGATCGAGACCACCCTGATTAATGC


 


GGTGAAATCCCGTCTCTACTAAAAATACAAAAAATTAGCCAGACGTGGTGGTGGGCACCTATAGTCCCAGCTACTCG


 


GGAGGCTGAGGCAGGAGAATGGCATGAACCCGGAAGGCGGAGCTTGCAGTGAACCAAGATCGCGCCACTGCACTCCA


 


GCCTGGGCGACAGAGTGAGACTCCATCGCAAAAAAAAAAAAAAAAAAACCTGCATGGAAGCCTAGTATATTTATTAA


 


TAACAAATAAATTATACTTTAGTGTACTATTAACCTATACCAATTTTAAGTTGTGATTAGGGAATGGGGATGTTTTT


 


AAGCTGAATTGTCTTGCTGCGGAACTTTCCTTTTTTAATAAGACCATATTATGACTCTGAATGCTCAAGGGTAAGTC


 


TAAGGCCTCATTGCTGTTACCAGGAGATTTTTCTAGTTACAGTAATAAAGATGTTAATTCACATGCATGCAGACAAC


 


TGAAACTCAAGTGGAGAATTTGTTTGTGAACAAGTCATACTACTTCTGTTATTTGCATGAATGGAATCTGCAATATC


 


TTTTTCCATGGGAGACCCTAAAAGAAAACCCTGGATCAGAATGATCTGCAGTTTCAGATAATAAAGGCTTTTAAGAG


 


ACATTTTTAGAATTAAAAATATGCTAATTTTATTAAATGAAAATATTTGTAACTGTTAACTTTCTCACTGACAAAGC


 


AAGTTTCTCAATAAAATACCTATTTTAACTTGCATTACTGACATCTTTTCTTTGAGTAATCTGAATAATGCAGAAGC


 


CATCATAGAGGTCTTTTCTATACATTCTCAATGTTTTCTTAAATGGGTTTCCTGAGTTCTGTTCTTCATGACTCTGG


 


GCTCTGCAAACAGGGTTTCCCAATTACGCATTCTATAAACACTTTTATGAATGAGTCAATATGACATTGAGTCCTTT


 


TCATACATTTCATCATTTCCAATATGTAGAGTGACAGCTAGAAAAATGATAAAATTTTGATTAAAACCTATCTCTTT


 


TTCTTCAGCATAGTCAATTGTTTTCTTAACTCTCAATGAGTAACTCCATGCCTAGCTTGTGCTTAGCTTTCAATATT


 


TTTAGACTAAGACAAAGTGTATTTGGCATTTTGAGAACAACAATTAATGGTCAGTAAATTTCTAAAGCAAGAAAAAT


 


GTGAAACTAGTGTTTTATATGTTTGTTACGCAGCAGAATGCGGCTCTTAGTGTTTGCCCCTTCATATCTCATCATGT


 


AAAATATTAAATTACTTTAGGCCACTGCACATAGGTAGTCCTGTCATGAGTGATGGCTGGAGAAAAGTTCAGGATCA


 


TAAATGTTA


 


>gi|142356892|ref|NM_080817.3| Homo sapiens G protein-coupled receptor 82


(GPR82), mRNA


(SEQ ID NO: 21)



AGTTGGTGTCATGCAAGAATCTATTCACACTGACTAAAGATATTGGAAGAGTGAAGATCAGAGAATTTTAAGTCTGA



 


AATTTGGCATCACTGCCCTGAACAATATAACCTTAGTTGGCATAAACTACTCATACAGACAAAGGCATTATCCATCA


 


CAATAAGTAACTTTTTGTCTTTATTTCAACCGGACAATCGTGATTAGAAAAGCTCCTGTGACAAAATTCAAGAAAAC


 


CTGACATAAATGAACAACAATACAACATGTATTCAACCATCTATGATCTCTTCCATGGCTTTACCAATCATTTACAT


 


CCTCCTTTGTATTGTTGGTGTTTTTGGAAACACTCTCTCTCAATGGATATTTTTAACAAAAATAGGTAAAAAAACAT


 


CAACGCACATCTACCTGTCACACCTTGTGACTGCAAACTTACTTGTGTGCAGTGCCATGCCTTTCATGAGTATCTAT


 


TTCCTGAAAGGTTTCCAATGGGAATATCAATCTGCTCAATGCAGAGTGGTCAATTTTCTGGGAACTCTATCCATGCA


 


TGCAAGTATGTTTGTCAGTCTCTTAATTTTAAGTTGGATTGCCATAAGCCGCTATGCTACCTTAATGCAAAAGGATT


 


CCTCGCAAGAGACTACTTCATGCTATGAGAAAATATTTTATGGCCATTTACTGAAAAAATTTCGCCAGCCCAACTTT


 


GCTAGAAAACTATGCATTTACATATGGGGAGTTGTACTGGGCATAATCATTCCAGTTACCGTATACTACTCAGTCAT


 


AGAGGCTACAGAAGGAGAAGAGAGCCTATGCTACAATCGGCAGATGGAACTAGGAGCCATGATCTCTCAGATTGCAG


 


GTCTCATTGGAACCACATTTATTGGATTTTCCTTTTTAGTAGTACTAACATCATACTACTCTTTTGTAAGCCATCTG


 


AGAAAAATAAGAACCTGTACGTCCATTATGGAGAAAGATTTGACTTACAGTTCTGTGAAAAGACATCTTTTGGTCAT


 


CCAGATTCTACTAATAGTTTGCTTCCTTCCTTATAGTATTTTTAAACCCATTTTTTATGTTCTACACCAAAGAGATA


 


ACTGTCAGCAATTGAATTATTTAATAGAAACAAAAAACATTCTCACCTGTCTTGCTTCGGCCAGAAGTAGCACAGAC


 


CCCATTATATTTCTTTTATTAGACAAAACATTCAAGAAGACACTATATAATCTCTTTACAAAGTCTAATTCAGCACA


 


TATGCAATCATATGGTTGACTTTTGAATGGAAAACCCCACAATATTAAGAAAAGCATTCATGTGACTTTATTAGGGA


 


CACTAAACTACATCATTAACATGTCACAGCTTGGTTGACAATAATCACCAAGAAAATCTCTTTGGTTTTTAAAAATA


 


AATAAACATATATTCATAAAACTCGAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


>gi|153266935|ref|NM_018970.5| Homo sapiens G protein-coupled receptor 85


(GPR85), mRNA


(SEQ ID NO: 22)



AATCTCACCACCCAGCAATGAGGTATTTTACTGCTGTCTCAAGATCAGATTATTACTGTAGAGAAGATTTTTATTTT



 


TTGTTTCATTAACAGATTATTATAAAGCAAAAAGCATGCAGAAAAAGAAGCAGACGTTTTACATTGGGAATTAATGA


 


AAGCGTGTCTGCTAGTTTTGGGTAGGAGAACTGGGAAGTTGTTGCTTAAAATTTTATATCACCTCCACAAACAAAAC


 


TCTTCGGAAATGGTAAAATAAGAAAATGCATGATTCTAGAGGCATTCCTAAGCACCCACGTGTCAGGCTTTGTGGTG


 


TCTGTGGTATCATCCGACCGTTTGGACTGGTGGCTTACTGAGAGCTCCATTTCTGGAAAGCCTTACAAGACTGAGGA


 


ATATCAGACTGCGAATCACCGGGAACGGTTCCTTTGCAGCACAGAAGCAATCTCTCTCCCCATCTTCGCATATTCTG


 


ATGGCAAAACAAGTGGAAGAAAAGAGGAAGCATGACTGCAGATCAGATCAGTTCTCTTTGTGGATTATATTTTCAGT


 


AAAATGTATGGATCTATCTTTTCCTTGTTCTTATATCTAGATCATGAGACTTGACTGAGGCTGTATCCTTATCCTCC


 


ATCCATCTATGGCGAACTATAGCCATGCAGCTGACAACATTTTGCAAAATCTCTCGCCTCTAACAGCCTTTCTGAAA


 


CTGACTTCCTTGGGTTTCATAATAGGAGTCAGCGTGGTGGGCAACCTCCTGATCTCCATTTTGCTAGTGAAAGATAA


 


GACCTTGCATAGAGCACCTTACTACTTCCTGTTGGATCTTTGCTGTTCAGATATCCTCAGATCTGCAATTTGTTTCC


 


CATTTGTGTTCAACTCTGTCAAAAATGGTTCTACCTGGACTTATGGGACTCTGACTTGCAAAGTGATTGCCTTTCTG


 


GGGGTTTTGTCCTGTTTCCACACTGCTTTCATGCTCTTCTGCATCAGTGTCACCAGATACTTAGCTATCGCCCATCA


 


CCGCTTCTATACAAAGAGGCTGACCTTTTGGACGTGTCTGGCTGTGATCTGTATGGTGTGGACTCTGTCTGTGGCCA


 


TGGCATTTCCCCCGGTTTTAGACGTGGGCACTTACTCATTCATTAGGGAGGAAGATCAATGCACCTTCCAACACCGC


 


TCCTTCAGGGCTAATGATTCCTTAGGATTTATGCTGCTTCTTGCTCTCATCCTCCTAGCCACACAGCTTGTCTACCT


 


CAAGCTGATATTTTTCGTCCACGATCGAAGAAAAATGAAGCCAGTCCAGTTTGTAGCAGCAGTCAGCCAGAACTGGA


 


CTTTTCATGGTCCTGGAGCCAGTGGCCAGGCAGCTGCCAATTGGCTAGCAGGATTTGGAAGGGGTCCCACACCACCC


 


ACCTTGCTGGGCATCAGGCAAAATGCAAACACCACAGGCAGAAGAAGGCTATTGGTCTTAGACGAGTTCAAAATGGA


 


GAAAAGAATCAGCAGAATGTTCTATATAATGACTTTTCTGTTTCTAACCTTGTGGGGCCCCTACCTGGTGGCCTGTT


 


ATTGGAGAGTTTTTGCAAGAGGGCCTGTAGTACCAGGGGGATTTCTAACAGCTGCTGTCTGGATGAGTTTTGCCCAA


 


GCAGGAATCAATCCTTTTGTCTGCATTTTCTCAAACAGGGAGCTGAGGCGCTGTTTCAGCACAACCCTTCTTTACTG


 


CAGAAAATCCAGGTTACCAAGGGAACCTTACTGTGTTATATGAGGGAGCATCTGTAAATCTTTAGCCTTGTGAAAAC


 


TAACCTTCTCTGCTGAGCAATTGTGGCCCATAGCCATATTTTGAGAAGAAATTCAAGAATGGAATCAGCAGTTTTAA


 


GGATTTGGGCAACATTCTGCAGTCTTTGCAATAGTTCACCTATAATCCTATTTTAAATCTCAGAGTGATCCTGCTGA


 


CTGCCAGCAAAGGTTTGTAATTAAGAAGGGACTGAACCACTGCCCTAAGTTTCTTTATGTGGTCAAAAACTAGATAA


 


TGAAAGTAGCAGGTGCTAAGTATCAGTGCTAAATGCTCTGTATGTCACTACATATGAAAAAACATCAAAAAACAATT


 


AGCATTGGACATCTTAATAAATTAAGTTGACATGAGGTAAATGTGTTGATAAAAACTAATTTTAGAAGTTTGAAGAC


 


TTTAAAACATTTCATACTACTATTGTTTTGCAAAGACTAAAATATTTGGGGACTTAAAGTACTGTAATCCACTAAAG


 


ACGTGCCAATGAATTATTGGAATATCACACTTTAAAAACCGCCTTGTAAGTTCTGGGGAGCATTCCAAAGCAGTATA


 


TTGGTTCCAATTAGAGTTTACTTTTTTTGTATTAATACATTGCTATTTCTAAATACCACTTTCCTCATCTACTAGTA


 


AGATTGCTAGCATTGAACTGTATTATGTGGTTTTTGTTGATTTGGTATAAAGTTTTTCCAATTCATTTATATTTTAC


 


AAATGCTAGATATTGGTCTGGGAGGCAACATTAATGGTACCAGCCTGTCACAACTGAGCAGTTCTAATAATGCAGAA


 


TAAATACATGTTGCCTTAAAGGGTTATCTAGTATCCTTCATCTTATTTAGCACTGGAGCAAATAGCCAAGGGAAATC


 


AAATCAGTAACTGGTCATGGTCATGCATCTAAAAGTGCATGGAAGATCATTTATTACTTTTTCCTTTTTTCTCACAT


 


GGTTTGAAACTTAAAGTGCACATCACTGAAATAATGAGATTTTCTTCTACGGTGTGCTACCCTTTCTAAACTGTTCT


 


AAGAAGCAGGCAGTTGATGTATGTTTATATTTTAAGTCAGCTGTCAAGGGGAGACCACAGCCTTAGTATGACATCCT


 


GCACAATTTGTGAAGCATTTATTCTACTGAAGGCACAGTCTTGTTTATACTTTCTGCACATTCAGTGTATTGGTAAT


 


TTAAATTATTTCAGTTTTAACTTGTGAAAGCTTATATTATGATTTCTGGTATTTTAGAAATACATTAGAGTCTGTGA


 


GTCTCATTCTTTAAGATACAGATGTGTGAACTTCAATATAAAGTTGCATTTGCCAAAATTTACCCGTGTAGCCTGTT


 


AATTTTCTTGAAATAAGTTTTACATTTTTGGCACATAACAACTTTTTTTTTAATTTGGGAGGCAAGCACAAACTAGG


 


AAGACTAGCTTTATTATGGTTTTGCTTTTTGATTCTTGTAGCTACTACATTCCAGACTGGAAATGTATGAATGATAA


 


TCAACATAATGCTGATAAACTGACATAATATTATCTGTAAAAGCATTATTTGGTAGTTTATTATAATCATCCCTCTA


 


TTATTCTTAAATGCCAGTAGTATTTAGAGATGTGTACCTGCTTAGTTAATTGGCTCAGAATTTTAATATAAACATCA


 


CACTTTAATTTGGAGCATAGTACCATAGAAATTTGGGGTTCTAAATATACAACTTGTAAGAAGAATGGTTTACACTA


 


ACATTATGACAAAACTAGAAAAAGTTATTATTTTTGTTTGCTTTCTGTTGTTTTGTTTATTGGTTGGTTTTTGTGAA


 


GTTTATTTTTTTTTGGTATTTGATAATTAAGATTAGGAATCTAATAACACAGAATTCCATATTGCTATAGTACTTCT


 


GTAAAGAGAATATCAATATAAATAAGGAAAATAAATCAATGAAATGTTTCAATGATATATGCAACTATTCAGTTTTG


 


CTCTTATAAGGACAGCTCAAGCCATGAATTAGTGAGCATTCTGACCTCATTTTTACTTTACACCAAAGTTGATTAGA


 


TCTGAGACAAAATTTAATGCACAACAGTGAGTTGGATCTAGCAATAAAGTCTCCTTGGTACTGAAATCATTATCTAA


 


AATAAAGGAAATGTTATCAAAAGATGTTCTGATAACATTGTGATTGTAACTCAAAAAAATTTATAGTAGAAACGTAA


 


TTGCAATGATGATAATAACTAACTCTGCTTAGAGGTTCAAATATCACCAGCAATCAGTAAAAAATTCAGCAATAATC


 


TTAAGGCCAGAGAGAACAGGTTCACCATTGCATAGACAAGAAAACAGATATGGGTTAAGAGTTGGGGACTGAGGAGT


 


CAAGAGCAACGGCCACGTGAAGCTGCCTGACTCCACCTAGCTATTTGGAATAACCGATTCCCACAGTTTTGGTAAGA


 


AACCAGCCCCAGTAATCAGTAAGTCAGGCTGAACTGCAGTGACTTTTATTTAAGCCTACTCCTGACTAACTTGGCAT


 


TTGCAGGTCAAGCAGGAAGCAGTTGACAAGACACATCCTCAGTGAATCAATGCCATTTGTAACTCAACTGGTAACAG


 


TAGTAATCATACAAAATAAAAACCTGCTTCAGTGTCTTAATGACCAAATCACATTATCTATTTTAGCACTCATTCCA


 


AAATTCAGTATTTAATGTAATTAATCTTTAATCCATAAAAATACATCCCCACTGTAGCGGGGCAGGGGGTGTCCAAC


 


TTCCCTGTGAGACTGATTATCAATAATAATGTGTCTCCCTCTTGGACTGAGCACACATCTGAGCTGAACGGCCTTTA


 


AATTGTTTTTCATAATAGTGGTGATATGTTTGCGTGGATACGTCTGTACTATTTCATCTGGTTCATTTTGCATGTAA


 


TAGATTTATCTGTGAGATGCCTGGCTGAAGCTAGGCATTCAGTCTGTGACTGTGGAATCCTATGCAGGTATTAACCA


 


AGGCAGAAAGAGGTGAGTAACTTGCCCATTTCTCCACAGAGACCCCATTTAAATAACACAAAATTGACCACAGTGAT


 


TAGATGAAAAAATTATTTGTAGATAGGATAATCTATTGACTGAATTATCTTTTGCAGATATCAGCTGGTTGGATTTC


 


TCACCAGGATTGTCTATAGAAGTTAACTGATTTATGATTGTTAACACATAAATATGGCCACTTATCCATTTGCCTCA


 


ACTTCAAAAAAAAAAAAAAAGAAAAAAAAAAAAAAAA


 


>gi|32479526|ref|NM_000218.2| Homo sapiens potassium voltage-gated channel,


KQT-like subfamily, member 1 (KCNQ1), transcript variant 1, mRNA


(SEQ ID NO: 23)



GCGGCGGGGCTGGCAGCAGTGGCTGCCCGCACTGCGCCCGGGCGCTCGCCTTCGCTGCAGCTCCCGGTGCCGCCGCT



 


CGGGCCGGCCCCCCGGCAGGCCCTCCTCGTTATGGCCGCGGCCTCCTCCCCGCCCAGGGCCGAGAGGAAGCGCTGGG


 


GTTGGGGCCGCCTGCCAGGCGCCCGGCGGGGCAGCGCGGGCCTGGCCAAGAAGTGCCCCTTCTCGCTGGAGCTGGCG


 


GAGGGCGGCCCGGCGGGCGGCGCGCTCTACGCGCCCATCGCGCCCGGCGCCCCAGGTCCCGCGCCCCCTGCGTCCCC


 


GGCCGCGCCCGCCGCGCCCCCAGTTGCCTCCGACCTTGGCCCGCGGCCGCCGGTGAGCCTAGACCCGCGCGTCTCCA


 


TCTACAGCACGCGCCGCCCGGTGTTGGCGCGCACCCACGTCCAGGGCCGCGTCTACAACTTCCTCGAGCGTCCCACC


 


GGCTGGAAATGCTTCGTTTACCACTTCGCCGTCTTCCTCATCGTCCTGGTCTGCCTCATCTTCAGCGTGCTGTCCAC


 


CATCGAGCAGTATGCCGCCCTGGCCACGGGGACTCTCTTCTGGATGGAGATCGTGCTGGTGGTGTTCTTCGGGACGG


 


AGTACGTGGTCCGCCTCTGGTCCGCCGGCTGCCGCAGCAAGTACGTGGGCCTCTGGGGGCGGCTGCGCTTTGCCCGG


 


AAGCCCATTTCCATCATCGACCTCATCGTGGTCGTGGCCTCCATGGTGGTCCTCTGCGTGGGCTCCAAGGGGCAGGT


 


GTTTGCCACGTCGGCCATCAGGGGCATCCGCTTCCTGCAGATCCTGAGGATGCTACACGTCGACCGCCAGGGAGGCA


 


CCTGGAGGCTCCTGGGCTCCGTGGTCTTCATCCACCGCCAGGAGCTGATAACCACCCTGTACATCGGCTTCCTGGGC


 


CTCATCTTCTCCTCGTACTTTGTGTACCTGGCTGAGAAGGACGCGGTGAACGAGTCAGGCCGCGTGGAGTTCGGCAG


 


CTACGCAGATGCGCTGTGGTGGGGGGTGGTCACAGTCACCACCATCGGCTATGGGGACAAGGTGCCCCAGACGTGGG


 


TCGGGAAGACCATCGCCTCCTGCTTCTCTGTCTTTGCCATCTCCTTCTTTGCGCTCCCAGCGGGGATTCTTGGCTCG


 


GGGTTTGCCCTGAAGGTGCAGCAGAAGCAGAGGCAGAAGCACTTCAACCGGCAGATCCCGGCGGCAGCCTCACTCAT


 


TCAGACCGCATGGAGGTGCTATGCTGCCGAGAACCCCGACTCCTCCACCTGGAAGATCTACATCCGGAAGGCCCCCC


 


GGAGCCACACTCTGCTGTCACCCAGCCCCAAACCCAAGAAGTCTGTGGTGGTAAAGAAAAAAAAGTTCAAGCTGGAC


 


AAAGACAATGGGGTGACTCCTGGAGAGAAGATGCTCACAGTCCCCCATATCACGTGCGACCCCCCAGAAGAGCGGCG


 


GCTGGACCACTTCTCTGTCGACGGCTATGACAGTTCTGTAAGGAAGAGCCCAACACTGCTGGAAGTGAGCATGCCCC


 


ATTTCATGAGAACCAACAGCTTCGCCGAGGACCTGGACCTGGAAGGGGAGACTCTGCTGACACCCATCACCCACATC


 


TCACAGCTGCGGGAACACCATCGGGCCACCATTAAGGTCATTCGACGCATGCAGTACTTTGTGGCCAAGAAGAAATT


 


CCAGCAAGCGCGGAAGCCTTACGATGTGCGGGACGTCATTGAGCAGTACTCGCAGGGCCACCTCAACCTCATGGTGC


 


GCATCAAGGAGCTGCAGAGGAGGCTGGACCAGTCCATTGGGAAGCCCTCACTGTTCATCTCCGTCTCAGAAAAGAGC


 


AAGGATCGCGGCAGCAACACGATCGGCGCCCGCCTGAACCGAGTAGAAGACAAGGTGACGCAGCTGGACCAGAGGCT


 


GGCACTCATCACCGACATGCTTCACCAGCTGCTCTCCTTGCACGGTGGCAGCACCCCCGGCAGCGGCGGCCCCCCCA


 


GAGAGGGCGGGGCCCACATCACCCAGCCCTGCGGCAGTGGCGGCTCCGTCGACCCTGAGCTCTTCCTGCCCAGCAAC


 


ACCCTGCCCACCTACGAGCAGCTGACCGTGCCCAGGAGGGGCCCCGATGAGGGGTCCTGAGGAGGGGATGGGGCTGG


 


GGGATGGGCCTGAGTGAGAGGGGAGGCCAAGAGTGGCCCCACCTGGCCCTCTCTGAAGGAGGCCACCTCCTAAAAGG


 


CCCAGAGAGAAGAGCCCCACTCTCAGAGGCCCCAATACCCCATGGACCATGCTGTCTGGCACAGCCTGCACTTGGGG


 


GCTCAGCAAGGCCACCTCTTCCTGGCCGGTGTGGGGGCCCCGTCTCAGGTCTGAGTTGTTACCCCAAGCGCCCTGGC


 


CCCCACATGGTGATGTTGACATCACTGGCATGGTGGTTGGGACCCAGTGGCAGGGCACAGGGCCTGGCCCATGTATG


 


GCCAGGAAGTAGCACAGGCTGAGTGCAGGCCCACCCTGCTTGGCCCAGGGGGCTTCCTGAGGGGAGACAGAGCAACC


 


CCTGGACCCCAGCCTCAAATCCAGGACCCTGCCAGGCACAGGCAGGGCAGGACCAGCCCACGCTGACTACAGGGCCG


 


CCGGCAATAAAAGCCCAGGAGCCCATTTGGAGGGCCTGGGCCTGGCTCCCTCACTCTCAGGAAATGCTGACCCATGG


 


GCAGGAGACTGTGGAGACTGCTCCTGAGCCCCCAGCTTCCAGCAGGAGGGACAGTCTCACCATTTCCCCAGGGCACG


 


TGGTTGAGTGGGGGGAACGCCCACTTCCCTGGGTTAGACTGCCAGCTCTTCCTAGCTGGAGAGGAGCCCTGCCTCTC


 


CGCCCCTGAGCCCACTGTGCGTGGGGCTCCCGCCTCCAACCCCTCGCCCAGTCCCAGCAGCCAGCCAAACACACAGA


 


AGGGGACTGCCACCTCCCCTTGCCAGCTGCTGAGCCGCAGAGAAGTGACGGTTCCTACACAGGACAGGGGTTCCTTC


 


TGGGCATTACATCGCATAGAAATCAATAATTTGTGGTGATTTGGATCTGTGTTTTAATGAGTTTCACAGTGTGATTT


 


TGATTATTAATTGTGCAAGCTTTTCCTAATAAACGTGGAGAATCACAGGCTGGGCTGGGCACTGCTCTCACCTTGGT


 


TCCTGGGGCATCCATGGGGTCTCTCACAGACAGGACCCCTGCAGTTCCCCTGGAAGCAGTGCCCAGGTGGCTGTGGA


 


ATAGGAACGCTAAAAAAAAAAAAAAAAA


 


>gi|41349442|ref|NM_198503.2| Homo sapiens potassium channel, subfamily T,


member 2 (KCNT2), mRNA


(SEQ ID NO: 24)



CTTTCTTTCTCCCTCCTCTCCTCCATTTGTTGTTTGATGTTTCCCACTCTTTGAGGAAGGATGGTTGATTTGGAGAG



 


CGAAGTGCCCCCTCTGCCTCCCAGGTACAGGTTTCGAGATTTGCTGCTAGGGGACCAAGGATGGCAAAACGACGACA


 


GGGTACAAGTTGAATTCTATATGAATGAAAATACATTTAAAGAAAGACTAAAATTATTTTTCATAAAAAACCAGAGA


 


TCAAGTCTAAGGATACGCCTGTTCAATTTTTCTCTCAAATTACTAAGCTGCTTATTATACATAATCCGAGTACTACT


 


AGAAAACCCTTCACAAGGAAATGAATGGTCTCATATCTTTTGGGTGAACAGAAGTCTACCTTTGTGGGGCTTACAGG


 


TTTCAGTGGCATTGATAAGTCTGTTTGAAACAATATTACTTGGTTATCTTAGTTATAAGGGAAACATCTGGGAACAG


 


ATTTTACGAATACCCTTCATCTTGGAAATAATTAATGCAGTTCCCTTCATTATCTCAATATTCTGGCCTTCCTTAAG


 


GAATCTATTTGTCCCAGTCTTTCTGAACTGTTGGCTTGCCAAACATGCCTTGGAAAATATGATTAATGATCTACACA


 


GAGCCATTCAGCGTACACAGTCTGCAATGTTTAATCAAGTTTTGATTTTAATATCTACATTACTATGCCTTATCTTC


 


ACCTGCATTTGTGGGATCCAACATCTGGAACGAATAGGAAAGAAGCTGAATCTCTTTGACTCCCTTTATTTCTGCAT


 


TGTGACGTTTTCTACTGTGGGCTTCGGGGATGTCACTCCTGAAACATGGTCCTCCAAGCTTTTTGTAGTTGCTATGA


 


TTTGTGTTGCTCTTGTGGTTCTACCCATACAGTTTGAACAGCTGGCTTATTTGTGGATGGAGAGACAAAAGTCAGGA


 


GGAAACTATAGTCGACATAGAGCTCAAACTGAAAAGCATGTCGTCCTGTGTGTCAGCTCACTGAAGATTGATTTACT


 


TATGGATTTTTTAAATGAATTCTATGCTCATCCTAGGCTCCAGGATTATTATGTGGTGATTTTGTGTCCTACTGAAA


 


TGGATGTACAGGTTCGAAGGGTACTGCAGATTCCAATGTGGTCCCAACGAGTTATCTACCTTCAAGGTTCAGCCCTT


 


AAAGATCAAGACCTATTGAGAGCAAAGATGGATGACGCTGAGGCCTGTTTTATTCTCAGTAGCCGTTGTGAAGTGGA


 


TAGGACATCATCTGATCACCAAACAATTTTGAGAGCATGGGCTGTGAAAGATTTTGCTCCAAATTGTCCTTTGTATG


 


TCCAGATATTAAAGCCTGAAAATAAATTTCACATCAAATTTGCTGATCATGTTGTTTGTGAAGAAGAGTTTAAATAC


 


GCCATGTTAGCTTTAAACTGTATATGCCCAGCAACATCTACACTTATTACACTACTGGTTCATACCTCTAGAGGGCA


 


AGAAGGCCAGCAATCGCCAGAACAATGGCAGAAGATGTACGGTAGATGCTCCGGGAATGAAGTCTACCACATTGTTT


 


TGGAAGAAAGTACATTTTTTGCTGAATATGAAGGAAAGAGTTTTACATATGCCTCTTTCCATGCACACAAAAAGTTT


 


GGCGTCTGCTTGATTGGTGTTAGGAGGGAGGATAATAAAAACATTTTGCTGAATCCAGGTCCTCGATACATTATGAA


 


TTCTACAGACATATGCTTTTATATTAATATTACCAAAGAAGAGAATTCAGCATTTAAAAACCAAGACCAGCAGAGAA


 


AAAGCAATGTGTCCAGGTCGTTTTATCATGGACCTTCCAGATTACCTGTACATAGCATAATTGCCAGCATGGGTACT


 


GTGGCTATAGACTTGCAAGATACAAGCTGTAGATCAGCAAGTGGCCCTACCCTGTCTCTTCCTACAGAGGGAAGCAA


 


AGAAATAAGAAGACCTAGCATTGCTCCTGTTTTAGAGGTTGCAGATACATCATCGATTCAAACATGTGATCTTCTAA


 


GTGACCAATCAGAAGATGAAACTACACCAGATGAAGAAATGTCTTCAAACTTAGAGTATGCTAAAGGTTACCCACCT


 


TATTCTCCATATATAGGAAGTTCACCCACTTTTTGTCATCTCCTTCATGAAAAAGTACCATTTTGCTGCTTAAGATT


 


AGACAAGAGTTGCCAACATAACTACTATGAGGATGCAAAAGCCTATGGATTCAAAAATAAACTAATTATAGTTGCAG


 


CTGAAACAGCTGGAAATGGATTATATAACTTTATTGTTCCTCTCAGGGCATATTATAGACCAAAGAAAGAACTTAAT


 


CCCATAGTACTGCTATTGGATAACCCGCCAGATATGCATTTTCTGGATGCAATCTGTTGGTTTCCAATGGTTTACTA


 


CATGGTGGGCTCTATTGACAACCTAGATGACTTACTCAGGTGTGGAGTGACTTTTGCTGCTAATATGGTGGTTGTGG


 


ATAAAGAGAGCACCATGAGTGCCGAGGAAGACTACATGGCAGATGCCAAAACCATTGTGAACGTGCAGACACTCTTC


 


AGGTTGTTTTCCAGTCTCAGTATTATCACAGAGCTAACTCACCCCGCCAACATGAGATTCATGCAATTCAGAGCCAA


 


AGACTGTTACTCTCTTGCTCTTTCAAAACTGGAAAAGAAAGAACGGGAGAGAGGCTCTAACTTGGCCTTTATGTTTC


 


GACTGCCTTTTGCTGCTGGGAGGGTGTTTAGCATCAGTATGTTGGACACTCTGCTGTATCAGTCATTTGTGAAGGAT


 


TATATGATTTCTATCACGAGACTTCTGTTGGGACTGGACACTACACCAGGATCTGGGTTTCTTTGTTCTATGAAAAT


 


CACTGCAGATGACTTATGGATCAGAACTTATGCCAGACTTTATCAGAAGTTGTGTTCTTCTACTGGAGATGTTCCCA


 


TTGGAATCTACAGGACTGAGTCTCAGAAACTTACTACATCTGAGTCTCAAATATCTATCAGTGTAGAAGAGTGGGAA


 


GACACCAAAGACTCCAAAGAACAAGGGCACCACCGCAGCAACCACCGCAACTCAACATCCAGTGACCAGTCGGACCA


 


TCCCTTGCTGCGGAGAAAAAGCATGCAGTGGGCCCGAAGACTGAGCAGAAAAGGCCCAAAACACTCTGGTAAAACAG


 


CTGAAAAAATAACCCAGCAGCGACTGAACCTCTACAGGAGGTCAGAAAGACAAGAGCTTGCTGAACTTGTGAAAAAT


 


AGAATGAAACACTTGGGTCTTTCTACAGTGGGATATGATGAAATGAATGATCATCAAAGTACCCTCTCCTACATCCT


 


GATTAACCCATCTCCAGATACCAGAATAGAGCTGAATGATGTTGTATACTTAATTCGACCAGATCCACTGGCCTACC


 


TTCCAAACAGTGAGCCCAGTCGAAGAAACAGCATCTGCAATGTCACTGGTCAAGATTCTCGGGAGGAAACTCAACTT


 


TGATAAAAATAAAATGAGAAACTTTTTTCCTACAAAGACCTTGCTTGAAACCACAAAAGTTTTGCTGGCACGAAAGA


 


AACTAGATGGAAATATATGTAATTCTCTCATATTTAAAAACGTAATCTCTTCTCTTAGAAGTATAGATCATTTTGAA


 


ACTTAATGTACTACTTACTGGTACTCTCCCTATTAATATTTGAAGGACCTCAATGGAATAAATTTGAAAAGCTAAAT


 


TAAAATACAAAAATTTAAATCTGACATTTAATTGTTTTATAATAATCCAAACTCTATGAAAGCAATTTTAAAAATTA


 


TTAAGGTTTTATGAAGTTGACAAAATCTAACTATATTTGGTGCATCACAATGGACACAGAATGCTGCTGCTCCTCTT


 


AAAAATTAAATGTGTCATATTATATTCTTTAAACTTACTGTTTTACAAAATTGAGCTCATCGTAAATGTCTAGTCTT


 


CTCACATAGAGATTAACCAACAAACTTGTGTGGCTGACTTTTGTGTAAGAATCATAGTTTGCTTTAGAATACAAATC


 


TTTAAGTCATTTTAACTTTTTTTTCTGCCTTACGATATAAAAATATTTATCTTAGAATTTGAGATGTTCATAGCATG


 


TTTTATTACATTGAAGAAACTAAAACATAAATGAAAAGAAACACTAGGTTCCTGCACTTTTTGGTAACTTTATGTCT


 


AGCAAATATTTTATGCCAAGAAAAGCATACTATAAAGCAAATATCTATTATTCTCCTAAACGAATGCCTAGCATAGA


 


GAAAATACTTAATACACATTTGTTGACTTAAATTTAATTCAAGGATTGAAAAATTAACTGGATATCTTGAAATATAC


 


AGTAATGATTGTCCTTAGACTCTTGAACTTTACCATCTTTCCTATTCATATATCTATATAGTAAATTTCACTAGAAA


 


AATTCTTTTAAAATTGACAGAAGATAATTTATACCTTTTATGGACTCTGAAGACACTTCAAAACATTAAAAGTCCTT


 


ATGTCTTTGGTAATGAAACAATAACACTCAATGAAGGATGTATTAAAATTTTTGACTTAATTTTGAAATCGTATATA


 


TGAGCTATACTTTAACATTATGAGAGAAAAGCATAAAACAAAAATAGGTAGTTCTTGGCTTTTAACATTAATGCAAA


 


TCATGCAGAATTTGAGTTATAAATTTAAATATAAATTGACCATTGATGATATCCAGTTTTTCATTTTTTACCTGTAT


 


TGCATTTTCCCCCTAGAGAAATAGATCAAAAGAGCACAAGAGTATGCGTACATAGTTTACCAGGTAGTAGAAGTGTG


 


TTAAAATGTTCCTGTAAAAGAAACATTGGTAAATTTAAATACATACTGTTCTAATTTTGTATTTTTTAATTTTTGAA


 


TTTGACATTGAGTTTAATTCAGCAACAACAAAAAATACATATAAAACTAGAAAGGGACTTTTTTTCCTTTCTTTTCA


 


TAATGAAGCAGATCAACTTAAAGGATAATAAAATTTTTAAAGAAAAGATATTCTAATGTACTCTCAATAATTCTACA


 


GAAATAAAACTGTAAAGTGCAATGTGAAATCAAAGATTATAGTCATTGTATAATTTGGCTTGGAGGCTATGAAATGT


 


CTTTTTTTCTTTTTGGTATTTTACATTATTCACATTTTAGAATAACAAGAACACCAAGAATTACCCCTAAAACAGAG


 


ACCCTGTATTTAATCTACTTTGATCAGAGAAGTAGAATTTATAACAGGTTAGCTAAAATTGGGAGCATGCCTTAAAA


 


CTTAAAGATTGTATGCATATATGTGTATATGTTATAAACGTGAAATATATTTGACACACACATTCACATATAAATTG


 


TTAAAAACTGAAGGCAGAATGGAACTAATATATGTAACAGAGAAAAACAATAAATTTTATGAACTTGTTTTATATTT


 


GCATATCAAGAGTCAAGTATGATGTTTCTTTAAGTTGACTTTTTTTACTTCATTATTTTTAGGAATAAATGTAAGAT


 


TTTACAAATCTTTTATTTCCCCACAAGATCTGAAGTTTGGTATTTTTGCATTATGACAGTTGTTGAGACTAGGATTT


 


TAAGCTAGGATATGATTATATTTCCTATATAACTAAAAATTTTGTTTCATAAATTTTAAAATAATTATTTTTGACTA


 


TGAACATTAGTCCAAATTTAATATTTGACACAGTTCATACCAGCTTGCTACAATAATGATAATTTATTAGTCTTTCT


 


GTTATTTAAAGAATAAAAACATGCTTATAAAAGACTTTTAATGAAATGTTGCCTTTTTAAAATAATTATACTTGCAC


 


ATGAAAATAAAATATAAAGTCAATAATAGTCCTTGTAGCCCAATGGGAATTGATTCTGTTTATTGTCTGTACCATTT


 


TGCTACCAGTTACATTGAACTGCTTTAAAATAAATAATAAAATTATTTCTAATGATG


 


>gi|157502196|ref|NM_014738.4| Homo sapiens KIAA0195 (KIAA0195), mRNA


(SEQ ID NO: 25)



CTGAACTTTAGCTCTCTGGCCGGCGCCTCTGTTGCCCGGAAGGGAGGCAAGCCCCCTTAGAGTTGCCAGTAACGGAC



 


ATGGCTGCGGCCCCCGGAGGAGGGGACGTGAAGTGAGGAGGGGGTTGGGAGGGGAGAGGACGCGGGCGAGGAAGACC


 


AGCCCCGGGGCCCCGATGTTGTGACTGTGACAGACTCACTGGGGTTTGTACATGCTGGGGAGGAGCCTTCCTTTCAG


 


GGGTGACCACATTCATCTGGGCATGCCTGCAGTACTCTTGGCCCATGGACCTGAAGGAGAAGCACCTGGGCGAGCCT


 


CCCTCAGCCCTGGGCCTGTCCACGCGGAAGGCCCTCAGCGTCCTGAAGGAGCAGCTGGAGGCAGTGCTGGAAGGACA


 


TCTCAGGGAGCGGAAGAAGTGTCTGACGTGGAAGGAGGTGTGGAGAAGCAGCTTCCTCCACCACAGTAACCGCTGCT


 


CCTGCTTCCACTGGCCGGGGGCCTCACTCATGCTACTGGCCGTGCTGCTGCTGCTGGGCTGCTGCGGGGGACAGCCA


 


GCCGGGAGCCGTGGGGTGGGGCTGGTGAATGCCTCGGCCTTGTTCCTGTTACTGCTTCTCAACCTTGTGCTCATCGG


 


GCGGCAAGACCGGCTGAAGCGTCGGGAGGTAGAGCGGAGGCTGCGAGGGATCATTGACCAAATCCAAGATGCCCTCA


 


GGGATGGCAGGGAGATCCAGTGGCCCAGTGCCATGTATCCAGACCTCCACATGCCTTTTGCGCCATCCTGGTCCTTG


 


CACTGGGCCTACAGAGACGGACACCTGGTCAACCTGCCAGTCAGCCTGCTGGTTGAAGGAGACATCATAGCTTTGAG


 


GCCTGGCCAGGAATCGTTTGCTTCTCTGAGGGGGATCAAGGATGACGAGCACATCGTCCTGGAGCCGGGAGACCTCT


 


TCCCCCCCTTCTCCCCTCCACCCTCACCCCGGGGAGAAGTGGAGAGAGGGCCACAGAGCCCCCAGCAGCACCGGCTT


 


TTCCGTGTCCTTGAGACCCCTGTGATTGACAACATCAGATGGTGCCTGGACATGGCCCTGTCCCGACCAGTCACTGC


 


CCTGGACAATGAGCGGTTCACAGTGCAGTCGGTGATGCTACACTATGCTGTGCCCGTGGTCCTGGCCGGCTTCCTCA


 


TCACCAATGCCCTGCGCTTCATCTTCAGTGCCCCGGGGGTCACTTCCTGGCAGTACACCCTCCTCCAGCTCCAGGTG


 


AATGGCGTCCTGCCCATCCTCCCCCTGCTCTTTCCAGTCCTCTGGGTTCTGGCAACTGCCTGTGGAGAGGCCCGTGT


 


CCTGGCCCAGATGAGCAAGGCCTCACCCAGCTCCCTGCTGGCTAAGTTCTCAGAGGATACTCTCAGCAGCTATACGG


 


AGGCTGTCTCCTCTCAGGAAATGCTGCGCTGCATTTGGGGCCACTTCCTGAGGGTGCTCGGGGGGACATCGCCAACG


 


CTGAGCCACAGTTCCAGCCTGCTGCACAGCCTGGGCTCTGTCACGGTCCTGTGCTGTGTGGACAAACAGGGGATCCT


 


GTCATGGCCAAATCCCAGCCCAGAGACTGTACTGTTCTTCAGCGGGAAGGTGGAGCCCCCTCACAGCAGCCATGAGG


 


ACCTCACCGATGGCCTATCCACCCGCTCCTTCTGCCATCCCGAGCCCCATGAACGAGACGCCCTCCTGGCTGGCTCC


 


CTGAACAACACCCTGCACCTTTCCAATGAGCAGGAGCGTGGCGACTGGCCTGGCGAGGCTCCCAAGCCCCCCGAGCC


 


CTATTCACACCACAAAGCGCATGGCCGCAGCAAACACCCATCTGGCTCCAACGTGAGCTTCAGCAGGGACACCGAGG


 


GTGGTGAAGAAGAGCCCAGCAAGACCCAGCCTGGGATGGAGAGCGACCCCTACGAAGCAGAGGACTTTGTGTGTGAC


 


TACCACCTGGAGATGCTGAGCCTGTCCCAGGACCAGCAGAACCCCTCCTGCATCCAGTTTGATGACTCCAACTGGCA


 


GCTGCACCTCACCTCCCTCAAACCCCTGGGCCTCAATGTGCTGCTGAACCTGTGTGATGCCAGCGTCACCGAGCGCC


 


TGTGCCGATTCTCCGACCACCTGTGCAACATCGCCCTGCAAGAGAGCCACAGCGCCGTGCTGCCCGTCCATGTGCCC


 


TGGGGCCTCTGCGAGCTTGCCCGCCTCATTGGCTTCACTCCTGGGGCCAAGGAGCTTTTCAAGCAGGAGAACCATCT


 


GGCGCTGTACCGCCTCCCCAGTGCCGAGACAATGAAGGAGACATCGCTGGGGCGGCTCTCCTGTGTCACCAAGCGGC


 


GGCCTCCCCTCAGCCACATGATCAGCCTCTTCATTAAAGACACCACCACCAGCACAGAGCAGATGCTGTCCCATGGC


 


ACCGCTGATGTGGTCTTAGAGGCCTGCACAGACTTCTGGGACGGAGCTGACATCTACCCTCTCTCGGGATCTGACAG


 


AAAGAAAGTGCTGGACTTCTACCAGCGAGCCTGCCTGTCTGGGTATTGCTCTGCCTTCGCCTACAAGCCCATGAACT


 


GCGCCCTGTCCTCTCAGCTCAATGGCAAGTGCATCGAGCTGGTACAGGTGCCCGGCCAAAGCAGCATCTTCACCATG


 


TGCGAGCTGCCCAGCACCATCCCCATCAAGCAGAACGCCCGCCGCAGCAGCTGGAGCTCTGACGAAGGGATCGGGGA


 


GGTGCTGGAGAAGGAAGACTGCATGCAGGCCCTGAGCGGCCAGATCTTCATGGGCATGGTGTCCTCCCAGTACCAGG


 


CCCGGCTGGACATCGTGCGCCTCATTGATGGGCTTGTCAACGCCTGCATCCGCTTTGTCTACTTCTCTTTGGAGGAT


 


GAGCTCAAAAGCAAGGTGTTTGCAGAAAAAATGGGCCTGGAGACAGGCTGGAACTGCCACATCTCCCTCACACCCAA


 


TGGTGACATGCCTGGCTCCGAGATCCCCCCCTCCAGCCCCAGCCACGCAGGCTCCCTGCATGATGACCTGAATCAGG


 


TGTCCCGAGATGATGCAGAAGGGCTCCTCCTCATGGAGGAGGAGGGCCACTCGGACCTCATCAGCTTCCAGCCTACG


 


GACAGCGACATCCCCAGCTTCCTGGAGGACTCCAACCGGGCCAAGCTGCCCCGGGGTATCCACCAAGTGCGGCCCCA


 


CCTGCAGAACATTGACAACGTGCCCCTGCTAGTGCCCCTTTTCACCGACTGCACCCCAGAGACCATGTGTGAGATGA


 


TAAAGATCATGCAAGAGTACGGGGAGGTGACCTGCTGCCTGGGCAGCTCTGCCAACCTGCGGAACAGCTGCCTCTTC


 


CTCCAGAGCGACATCAGCATTGCCCTGGATCCCCTGTACCCATCCCGTTGCTCCTGGGAGACCTTTGGCTACGCCAC


 


CAGCATCAGCATGGCCCAGGCCTCGGATGGCCTTTCTCCCCTGCAGCTGTCAGGGCAGCTCAACAGCCTGCCCTGTT


 


CCCTGACCTTTCGCCAGGAGGAGACCATCAGCATCATCCGGCTTATCGAACAGGCTCGGCATGCCACCTATGGCATC


 


CGTAAGTGCTTCCTCTTCCTGCTGCAGTGCCAGCTGACTCTTGTGGTCATCCAGTTCCTTTCTTGCCTGGTCCAGCT


 


GCCGCCACTCCTGAGTACCACCGACATCCTGTGGCTGTCCTGCTTTTGCTACCCTCTGCTCAGCATCTCTCTGCTGG


 


GGAAGCCCCCCCATAGCTCCATCATGTCTATGGCAACGGGGAAAAACCTCCAGTCCATTCCCAAGAAGACCCAGCAC


 


TACTTCCTGCTCTGCTTCCTGCTCAAGTTCAGCCTCACCATCAGCTCCTGCCTCATCTGCTTTGGCTTCACACTGCA


 


GAGCTTCTGTGACAGCTCCCGGGACCGCAACCTCACCAACTGCTCCTCCGTCATGCTGCCCAGCAACGACGACAGGG


 


CTCCAGCCTGGTTTGAGGACTTTGCCAATGGACTGCTGTCGGCTCAGAAGCTCACGGCCGCCCTGATTGTCCTGCAC


 


ACTGTCTTCATTTCCATCACCCATGTGCATCGCACCAAGCCCCTGTGGAGAAAGAGCCCCTTGACCAACCTCTGGTG


 


GGCCGTGACAGTGCCTGTGGTGCTGCTGGGTCAGGTGGTCCAGACGGCTGTGGACCTGCAGCTGTGGACACACAGGG


 


ACAGCCACGTCCACTTTGGCCTGGAGGACGTGCCCCTGCTGACATGGCTCCTGGGCTGCCTGTCCCTGGTCCTTGTG


 


GTGGTGACCAATGAGATCGTGAAGCTACATGAGATTCGGGTCCGAGTCCGCTACCAGAAGCGACAGAAGCTGCAGTT


 


TGAAACTAAGCTGGGCATGAACTCTCCCTTCTGAGCCACTGGCTGTGGTGGCTGTAGTTGCCCCCGTCCCTGGGGCT


 


AAAGCCAGACCCATTTCTGAACAGGGGAGTTTGTATCATGAATGTTTCCAGGTTTGCTCCTGCACCCGTGGCACTGG


 


AAACCCAGCTCCCCGTGTCAGACCCCGCTGTCTTCCTGAGCCCTGGGGCTCACTGTGGAGGAGCTGACGGCCTGGGC


 


CCTTGGCCAGTCCTGGCTCTTCCCTGGGCCTCACCAGGGACACTCTTGAATGTATGGCCTCAGGCGCTCCCTAGAGG


 


GGCCCTAAACCCCCTCACCTGTGAGCTACCCCCTTTAGGGATCCCTTGCCCCCTTGGAGATCCCTTGCCCCCCAGTG


 


CCTCTGCTCGTGGGTCCCTGGACACGGCCTTGAAGCCAACCTTCTTTGGAGGAGCAACAGCAGCAGCCTTGGCCGAC


 


GCGTCCAACTCCCAAGGCTGCCGTGGAGGGCAGGGGGGTGGTGCTTGCCTGGATGTGGCCCCGAGTGCCTCCCCTCC


 


CTCCCTCTGTGGGGGAGTCTCCCGCCTGAACCTGAAGATGGAGCAGGGCCCCCGCTTCGCCCTGGAGCCTCTTCCTG


 


TGCCTGGCTCAAGCTGGCTGCCTGTCAGTCTTGGGGAATCTGGCCCAGGTCTCCTCAGCCTCTGCCCCAGTTCTGGG


 


AGAAGTTTCTACTGGTGTATATTTTTTACTGGAAATGAGCCTTTTAGGAATGAATGTAGACTGGTTTGTATTAAAAT


 


GTGTCAATTGCTAAGAAATACCTGTGGCTGGTCTGTAAGGCCACTCCAGGGTCTGCCCACCCCCGGCGGTGGCTGGC


 


AAAGGGAGGCCTAAACCTTCCTCCATCTACGCGGGTGGGTCCCTCAGGTCTGGCTCAGGCGAGACCCCTAGGGTCAG


 


GGGTCCCCATGTCACAGAGGCAAACACACAGCCCAGTCACGTGGAATGGTGTTTTCATTGGTGTTAGTTGGGGGAAG


 


AGGTTAATGGTTACAGAGCCAGGGCCTGGGCCAATGGGGTCAGGCTCTCCCTGCCCTCAGGTGGGCAGTCGGGGCTC


 


CTGCTGTGGTCCGAAGCCCCTCCCCCATTGTGTCCTCTCAGGCAGTTGATAGAATAAATTCCATTTAAAATATAAAA


 


AAAAA


 


>gi|24475886|ref|NM_003667.2| Homo sapiens leucine-rich repeat-containing G


protein-coupled receptor 5 (LGR5), mRNA


(SEQ ID NO: 26)



TGCTGCTCTCCGCCCGCGTCCGGCTCGTGGCCCCCTACTTCGGGCACCATGGACACCTCCCGGCTCGGTGTGCTCCT



 


GTCCTTGCCTGTGCTGCTGCAGCTGGCGACCGGGGGCAGCTCTCCCAGGTCTGGTGTGTTGCTGAGGGGCTGCCCCA


 


CACACTGTCATTGCGAGCCCGACGGCAGGATGTTGCTCAGGGTGGACTGCTCCGACCTGGGGCTCTCGGAGCTGCCT


 


TCCAACCTCAGCGTCTTCACCTCCTACCTAGACCTCAGTATGAACAACATCAGTCAGCTGCTCCCGAATCCCCTGCC


 


CAGTCTCCGCTTCCTGGAGGAGTTACGTCTTGCGGGAAACGCTCTGACATACATTCCCAAGGGAGCATTCACTGGCC


 


TTTACAGTCTTAAAGTTCTTATGCTGCAGAATAATCAGCTAAGACACGTACCCACAGAAGCTCTGCAGAATTTGCGA


 


AGCCTTCAATCCCTGCGTCTGGATGCTAACCACATCAGCTATGTGCCCCCAAGCTGTTTCAGTGGCCTGCATTCCCT


 


GAGGCACCTGTGGCTGGATGACAATGCGTTAACAGAAATCCCCGTCCAGGCTTTTAGAAGTTTATCGGCATTGCAAG


 


CCATGACCTTGGCCCTGAACAAAATACACCACATACCAGACTATGCCTTTGGAAACCTCTCCAGCTTGGTAGTTCTA


 


CATCTCCATAACAATAGAATCCACTCCCTGGGAAAGAAATGCTTTGATGGGCTCCACAGCCTAGAGACTTTAGATTT


 


AAATTACAATAACCTTGATGAATTCCCCACTGCAATTAGGACACTCTCCAACCTTAAAGAACTAGGATTTCATAGCA


 


ACAATATCAGGTCGATACCTGAGAAAGCATTTGTAGGCAACCCTTCTCTTATTACAATACATTTCTATGACAATCCC


 


ATCCAATTTGTTGGGAGATCTGCTTTTCAACATTTACCTGAACTAAGAACACTGACTCTGAATGGTGCCTCACAAAT


 


AACTGAATTTCCTGATTTAACTGGAACTGCAAACCTGGAGAGTCTGACTTTAACTGGAGCACAGATCTCATCTCTTC


 


CTCAAACCGTCTGCAATCAGTTACCTAATCTCCAAGTGCTAGATCTGTCTTACAACCTATTAGAAGATTTACCCAGT


 


TTTTCAGTCTGCCAAAAGCTTCAGAAAATTGACCTAAGACATAATGAAATCTACGAAATTAAAGTTGACACTTTCCA


 


GCAGTTGCTTAGCCTCCGATCGCTGAATTTGGCTTGGAACAAAATTGCTATTATTCACCCCAATGCATTTTCCACTT


 


TGCCATCCCTAATAAAGCTGGACCTATCGTCCAACCTCCTGTCGTCTTTTCCTATAACTGGGTTACATGGTTTAACT


 


CACTTAAAATTAACAGGAAATCATGCCTTACAGAGCTTGATATCATCTGAAAACTTTCCAGAACTCAAGGTTATAGA


 


AATGCCTTATGCTTACCAGTGCTGTGCATTTGGAGTGTGTGAGAATGCCTATAAGATTTCTAATCAATGGAATAAAG


 


GTGACAACAGCAGTATGGACGACCTTCATAAGAAAGATGCTGGAATGTTTCAGGCTCAAGATGAACGTGACCTTGAA


 


GATTTCCTGCTTGACTTTGAGGAAGACCTGAAAGCCCTTCATTCAGTGCAGTGTTCACCTTCCCCAGGCCCCTTCAA


 


ACCCTGTGAACACCTGCTTGATGGCTGGCTGATCAGAATTGGAGTGTGGACCATAGCAGTTCTGGCACTTACTTGTA


 


ATGCTTTGGTGACTTCAACAGTTTTCAGATCCCCTCTGTACATTTCCCCCATTAAACTGTTAATTGGGGTCATCGCA


 


GCAGTGAACATGCTCACGGGAGTCTCCAGTGCCGTGCTGGCTGGTGTGGATGCGTTCACTTTTGGCAGCTTTGCACG


 


ACATGGTGCCTGGTGGGAGAATGGGGTTGGTTGCCATGTCATTGGTTTTTTGTCCATTTTTGCTTCAGAATCATCTG


 


TTTTCCTGCTTACTCTGGCAGCCCTGGAGCGTGGGTTCTCTGTGAAATATTCTGCAAAATTTGAAACGAAAGCTCCA


 


TTTTCTAGCCTGAAAGTAATCATTTTGCTCTGTGCCCTGCTGGCCTTGACCATGGCCGCAGTTCCCCTGCTGGGTGG


 


CAGCAAGTATGGCGCCTCCCCTCTCTGCCTGCCTTTGCCTTTTGGGGAGCCCAGCACCATGGGCTACATGGTCGCTC


 


TCATCTTGCTCAATTCCCTTTGCTTCCTCATGATGACCATTGCCTACACCAAGCTCTACTGCAATTTGGACAAGGGA


 


GACCTGGAGAATATTTGGGACTGCTCTATGGTAAAACACATTGCCCTGTTGCTCTTCACCAACTGCATCCTAAACTG


 


CCCTGTGGCTTTCTTGTCCTTCTCCTCTTTAATAAACCTTACATTTATCAGTCCTGAAGTAATTAAGTTTATCCTTC


 


TGGTGGTAGTCCCACTTCCTGCATGTCTCAATCCCCTTCTCTACATCTTGTTCAATCCTCACTTTAAGGAGGATCTG


 


GTGAGCCTGAGAAAGCAAACCTACGTCTGGACAAGATCAAAACACCCAAGCTTGATGTCAATTAACTCTGATGATGT


 


CGAAAAACAGTCCTGTGACTCAACTCAAGCCTTGGTAACCTTTACCAGCTCCAGCATCACTTATGACCTGCCTCCCA


 


GTTCCGTGCCATCACCAGCTTATCCAGTGACTGAGAGCTGCCATCTTTCCTCTGTGGCATTTGTCCCATGTCTCTAA


 


TTAATATGTGAAGGAAAATGTTTTCAAAGGTTGAGAACCTGAAAATGTGAGATTGAGTATATCAGAGCAGTAATTAA


 


TAAGAAGAGCTGAGGTGAAACTCGGTTTAAA


 


>gi|62912469|ref|NM_001017403.1| Homo sapiens leucine-rich repeat-containing


G protein-coupled receptor 6 (LGR6), transcript variant 1, mRNA


(SEQ ID NO: 27)



ATGCCCAGCCCGCCGGGGCTCCGGGCGCTATGGCTTTGCGCCGCGCTGTGCGCTTCCCGGAGGGCCGGCGGCGCCCC



 


CCAGCCCGGCCCGGGGCCCACCGCCTGCCCGGCCCCCTGCCACTGCCAGGAGGACGGCATCATGCTGTCTGCCGACT


 


GCTCTGAGCTCGGGCTGTCCGCCGTTCCGGGGGACCTGGACCCCCTGACGGCTTACCTGGACCTCAGCATGAACAAC


 


CTCACAGAGCTTCAGCCTGGCCTCTTCCACCACCTGCGCTTCTTGGAGGAGCTGCGTCTCTCTGGGAACCATCTCTC


 


ACACATCCCAGGACAAGCATTCTCTGGTCTCTACAGCCTGAAAATCCTGATGCTGCAGAACAATCAGCTGGGAGGAA


 


TCCCCGCAGAGGCGCTGTGGGAGCTGCCGAGCCTGCAGTCGCTGCGCCTAGATGCCAACCTCATCTCCCTGGTCCCG


 


GAGAGGAGCTTTGAGGGGCTGTCCTCCCTCCGCCACCTCTGGCTGGACGACAATGCACTCACGGAGATCCCTGTCAG


 


GGCCCTCAACAACCTCCCTGCCCTGCAGGCCATGACCCTGGCCCTCAACCGCATCAGCCACATCCCCGACTACGCGT


 


TCCAGAATCTCACCAGCCTTGTGGTGCTGCATTTGCATAACAACCGCATCCAGCATCTGGGGACCCACAGCTTCGAG


 


GGGCTGCACAATCTGGAGACACTAGACCTGAATTATAACAAGCTGCAGGAGTTCCCTGTGGCCATCCGGACCCTGGG


 


CAGACTGCAGGAACTGGGGTTCCATAACAACAACATCAAGGCCATCCCAGAAAAGGCCTTCATGGGGAACCCTCTGC


 


TACAGACGATACACTTTTATGATAACCCAATCCAGTTTGTGGGAAGATCGGCATTCCAGTACCTGCCTAAACTCCAC


 


ACACTATCTCTGAATGGTGCCATGGACATCCAGGAGTTTCCAGATCTCAAAGGCACCACCAGCCTGGAGATCCTGAC


 


CCTGACCCGCGCAGGCATCCGGCTGCTCCCATCGGGGATGTGCCAACAGCTGCCCAGGCTCCGAGTCCTGGAACTGT


 


CTCACAATCAAATTGAGGAGCTGCCCAGCCTGCACAGGTGTCAGAAATTGGAGGAAATCGGCCTCCAACACAACCGC


 


ATCTGGGAAATTGGAGCTGACACCTTCAGCCAGCTGAGCTCCCTGCAAGCCCTGGATCTTAGCTGGAACGCCATCCG


 


GTCCATCCACCCCGAGGCCTTCTCCACCCTGCACTCCCTGGTCAAGCTGGACCTGACAGACAACCAGCTGACCACAC


 


TGCCCCTGGCTGGACTTGGGGGCTTGATGCATCTGAAGCTCAAAGGGAACCTTGCTCTCTCCCAGGCCTTCTCCAAG


 


GACAGTTTCCCAAAACTGAGGATCCTGGAGGTGCCTTATGCCTACCAGTGCTGTCCCTATGGGATGTGTGCCAGCTT


 


CTTCAAGGCCTCTGGGCAGTGGGAGGCTGAAGACCTTCACCTTGATGATGAGGAGTCTTCAAAAAGGCCCCTGGGCC


 


TCCTTGCCAGACAAGCAGAGAACCACTATGACCAGGACCTGGATGAGCTCCAGCTGGAGATGGAGGACTCAAAGCCA


 


CACCCCAGTGTCCAGTGTAGCCCTACTCCAGGCCCCTTCAAGCCCTGTGAGTACCTCTTTGAAAGCTGGGGCATCCG


 


CCTGGCCGTGTGGGCCATCGTGTTGCTCTCCGTGCTCTGCAATGGACTGGTGCTGCTGACCGTGTTCGCTGGCGGGC


 


CTGTCCCCCTGCCCCCGGTCAAGTTTGTGGTAGGTGCGATTGCAGGCGCCAACACCTTGACTGGCATTTCCTGTGGC


 


CTTCTAGCCTCAGTCGATGCCCTGACCTTTGGTCAGTTCTCTGAGTACGGAGCCCGCTGGGAGACGGGGCTAGGCTG


 


CCGGGCCACTGGCTTCCTGGCAGTACTTGGGTCGGAGGCATCGGTGCTGCTGCTCACTCTGGCCGCAGTGCAGTGCA


 


GCGTCTCCGTCTCCTGTGTCCGGGCCTATGGGAAGTCCCCCTCCCTGGGCAGCGTTCGAGCAGGGGTCCTAGGCTGC


 


CTGGCACTGGCAGGGCTGGCCGCCGCGCTGCCCCTGGCCTCAGTGGGAGAATACGGGGCCTCCCCACTCTGCCTGCC


 


CTACGCGCCACCTGAGGGTCAGCCAGCAGCCCTGGGCTTCACCGTGGCCCTGGTGATGATGAACTCCTTCTGTTTCC


 


TGGTCGTGGCCGGTGCCTACATCAAACTGTACTGTGACCTGCCGCGGGGCGACTTTGAGGCCGTGTGGGACTGCGCC


 


ATGGTGAGGCACGTGGCCTGGCTCATCTTCGCAGACGGGCTCCTCTACTGTCCCGTGGCCTTCCTCAGCTTTGCCTC


 


CATGCTGGGCCTCTTCCCTGTCACGCCCGAGGCCGTCAAGTCTGTCCTGCTGGTGGTGCTGCCCCTGCCTGCCTGCC


 


TCAACCCACTGCTGTACCTGCTCTTCAACCCCCACTTCCGGGATGACCTTCGGCGGCTTCGGCCCCGCGCAGGGGAC


 


TCAGGGCCCCTAGCCTATGCTGCGGCCGGGGAGCTGGAGAAGAGCTCCTGTGATTCTACCCAGGCCCTGGTAGCCTT


 


CTCTGATGTGGATCTCATTCTGGAAGCTTCTGAAGCTGGGCGGCCCCCTGGGCTGGAGACCTATGGCTTCCCCTCAG


 


TGACCCTCATCTCCTGTCAGCAGCCAGGGGCCCCCAGGCTGGAGGGCAGCCATTGTGTAGAGCCAGAGGGGAACCAC


 


TTTGGGAACCCCCAACCCTCCATGGATGGAGAACTGCTGCTGAGGGCAGAGGGATCTACGCCAGCAGGTGGAGGCTT


 


GTCAGGGGGTGGCGGCTTTCAGCCCTCTGGCTTGGCCTTTGCTTCACACGTGTAAATATCCCTCCCCATTCTTCTCT


 


TCCCCTCTCTTCCCTTTCCTCTCTCCCCCTCGGTGAATGATGGCTGCTTCTAAAACAAATACAACCAAAACTCAGCA


 


GTGTGATCTATAGCAGGATGGCCCAGTCCCTGGCTCCACTGATCACCTCTCTCCTGTGACCATCACCAACGGGTGCC


 


TCTTGGCCTGGCTTTCCCTTGGCCTTCCTCAGCTTCACCTTGATACTGGGCCTCTTCCTTGTCATGTCTGAAGCTGT


 


GGACCAGAGACCTGGACTTTTGTCTGCTTAAGGGAAATGAGGGAAGTAAAGACAGTGAAGGGGTGGAGGGTTGATCA


 


GGGCACAGTGGACAGGGAGACCTCACAGAGAAAGGCCTGGAAGGTGATTTCCCGTGTGACTCATGGATAGGATACAA


 


AATGTGTTCCATGTACCATTAATCTTGACATATGCCATGCATAAAGACTTCCTATTAAAATAAGCTTTGGAAGAGAT


 


TACACATGATGTCTTTTTCTTAGAGATTCACAGTGCATGTTAGTGTAATAAAGAGATAAGTCCTACAGTA


 


>gi|40255209|ref|NM_177964.3| Homo sapiens hypothetical protein LOC130576


(LOC130576), mRNA


(SEQ ID NO: 28)



ACTTCCTGAGCCGGGCTGGCTGGGTGGGAACAGGCTCCTTGCCGCCTCCCCAGCGCTGGCCACTACCACACTGCCGC



 


CCGCCTGGGCCTCCTTTCAACCTCGTGGTGGAGCCCTGCGGTTTCCCAGCGGAGCCGGGCCCGGGGCTGCTCCCTCG


 


CGGGCGAGGCTCACCTGTCCCGGCCCGGCCCCCTCCCGCGCCCCAGGTGGTTCAGGGCGGGGAGGAGCCGCGCCCCG


 


CCCCGCGCGGTAGCAGCCAACGCCGGCCCCAGGCGGGTGCGCTGGGAGCCTGGGCCGGGAGCCGGGTGAGGGCGCCG


 


AGAGGCTCGGTGGGCGCGGGCGGCGAGATATGCCACACTTCTGCCTGCTGTTGGCAACCCTCCTGGACTAGGCTGCT


 


CTTGTTAATCACATGGATGTTGCTGATTACTCTGAGTGCAAACCTTTTCACTGTTCCAGAGAGGAGCCTGACAACCA


 


CATTCTCCTTCTCAAGATATAAGAGTTCGGACCGCCCAGCACACAAGGTCAGCATGCTGCTCCTCTGTCACGCTCTC


 


GCTATAGCTGTTGTCCAGATCGTTATCTTCTCAGAAAGCTGGGCATTTGCCAAGAACATCAACTTCTATAATGTGAG


 


GCCTCCTCTCGACCCTACACCATTTCCAAATAGCTTCAAGTGCTTTACTTGTGAAAACGCAGGGGATAATTATAACT


 


GCAATCGATGGGCAGAAGACAAATGGTGTCCACAAAATACACAGTACTGTTTGACAGTTCATCACTTCACCAGCCAC


 


GGAAGAAGCACATCCATCACCAAAAAGTGTGCCTCCAGAAGTGAATGTCATTTTGTCGGTTGCCACCACAGCCGAGA


 


TTCTGAACATACGGAGTGTAGGTCTTGCTGTGAAGGATGATCTGCAATGTAGAATTACCCACCAATCACACTAATG


 


CAGTGTTTGCCGTAATGCACGCTCAGAGAACATCTGGCAGCAGTGCCCCCACACTCTACCTACCAGTGCTTGCCTGG


 


GTCTTTGTGCTTCCATTGCTGTGATGCCACCATTCCTAGGAGAGGCAGAGACCAGCCTCTAAAGCACAAGCCAAAAA


 


CTGTGTGAACGGTGAACTTTGGAGTGAAGATCAATCTTGCACTTGGTGAAGAGTGCACATTGGACCTCAAGGCGAAA


 


GCCAGTGGTTTGCTTGGATAAAATGTTCCCGCATGAGGCCACAGGACTGAGGATGGGAATTTGGCAGGGCCTGAGAA


 


GATGGTCTGACTTCCAGGCTTCCTGGTCAAAGAGAGCTACGTTTGGGCAGTTCTGCAGAGAGGATCCTGGCAACTAG


 


TCCCACCTGACTAGGCCTTTAGCTGAAAGGATTTCTTGACCTCCTTGACTGCCTCAGAGGCTGCCAGGTCAAACCCT


 


CTTGTTTATGTGATTAGCTCAGAGCATCTCTATGAAATCTAACCCTTCCCCTCATGAGAAAGCAGTTTTCCCCACCA


 


ACAGCATAGTCAATGAGAAAGGCGACTGTACGAAGAAAACTTCCAGTGGAACTAATATGAAATCTATTTGCAAATTA


 


TGGGGGGAAATAAAGCTTTTAAATTATACAATGAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


>gi|157426880|ref|NM_001101387.1| Homo sapiens hCG1776018 (LOC644139), mRNA


(SEQ ID NO: 29)



AGTTGCTGGGATTCACAACACACTGACTTCTGGACGTGGTCAGGGTGGCTTTCTCTGGCTGGCATGGACTTGAGCAG



 


AAACTCATTGCCGGCTTCCTCCTTGCACGAGCACCAAGTGATTCCCAGGTCCCCCATCCTCCCCTGGGACATCGAGG


 


ACACACAAAAACCTTGTTCACCCTCCACTGAGAGCGGGGCTAGAGATGGATGCTGAGTACAGGAAGGGTGTGTGAGG


 


ATTCCTTTGGCTCCACTCTTGTTTCCAACTATTGCTGGTCCTAGGCGCCCAGTCCTGAGCAACCATGACGATGGAGA


 


CTCTCCCCAAGGTTCTAGAGGTCGATGAGAAGTCTCCAGAAGCCAAGGACCTGCTGCCCAGCCAGACCGCCAGCTCC


 


CTGTGCATCAGCTCCAGGAGCGAGTCTGTCTGGACCACCACCCCCAGGAGTAACTGGGAAATCTACCGCAAGCCCAT


 


CGTTATCATGTCAGTGGGCGGTGCCATCCTGCTTTTCGGCGTGGTCATCACCTGCTTGGCCTACACCTTGAAGCTGA


 


GTGACAAGAGTCTCTCCATCCTCAAAATGGTAGGGCCTGGCTTCCTGTCCCTGGGACTCATGATGCTGGTGTGCGGG


 


CTGGTGTGGGTGCCCATCATCAAAAAGAAACAGAAGCACAGACAGAAGTCGAATTTCTTACGCAGCCTCAAGTCCTT


 


CTTCCTGACTCGCTGATGGTGGTTTCCGCATCTCCCTGCCACCTTGACTGGGAGAAGATCTGATGACCAACATCCGA


 


CATCCCTGTCTCCTCTGTGGGGTGCCATAAAACTGATCCAGGAAAATGCTCTTCCTGACCCTGTGGGGAAGATAGAG


 


CTTGGGGCTCCACCCTCCATGCAGCCGGGAATGTTGCCAGATGTATCCACTTGATCTCTATTCTGACTGATGCTTCC


 


TTGGATCCCGGCTGTGGCCTTCCCTTTGGTCACTCTAACCCCCTGCCCCTGCATCCAGGCATCATTCATCCAACTCT


 


CTCTGCCAAGTGCAATGCATGCTGGGAAATTCTTCGAAGGTGGGCTATGCCCAAGGGAGAACCTCATGTTTACATAT


 


CTGAGTGCCAGAGCTGGATTCTTCATTTGCATACTTCTGGAACCAAAACTGACCCACGGAGGTCCTTTACAGAGGAG


 


GGAGGGATGGCTGAGCTCTGACCCATTGGGTTTGACAGCCCTAGCTCCCTTAGCAGACTTTCAAGATCACAAGTATC


 


AAACATTCCAAAGACTGAACAATGAAGGGAGGCCTGGGAAAAATACTCTCCAAGATGGCACGTGCCCCTGGACATGA


 


CAACATGACTCTAGGGGTTAGTCAGCTGAAGAAGTTTAGTTCCTAATTATATAATATTTACATCAGAGGCAGTGGGG


 


TAGGCTAGGGGATGTCACTGTTTCCGCTTGACCTTATCTTTCTCATTGACCACTGTCTTCTCTGAACTTGATCATTA


 


GCCAAGGACAAAATGCATGTTGCCCTAATTTCTTTCCTACCCCTGCCTCTATCTCTGCATCTAGAACAGCTAAATGG


 


AAAGATACAGAGGGATCCTGTAAGGTTGTTTTCCCTTTCACGTCCATCAAGATCAAAATTGAGAGAATCAAGTTCCA


 


TATCTGAATGATCTGTAGGTTTCTAGAGATGGAATTCACGTCAGAAAATTCCAACTTCTGTTATCCCTGCCCCCACC


 


CACCAAAAAAGCCAACATTTATTAAGTGTCGCATTCTGGGATAAGCCCTGGCTGGGGGCAAGACACGGTCCCTGATG


 


TCTTCTTGCTTCCCGAGGTGAGAGAGGCAGCCAAGCCAACTGGCGAAATGTGGGTGGGTGTGGGAACACAGGCGGTG


 


TCTACCCTAGACTTGATAGAGGACGGAGAAATTCCTGGAGGCCATGTCCTCCAACCCAAAAACAAAAGGAAAGATAA


 


GAGTTACCAAAGAGGGGAAAGAATGGCATTGGAAGCAGCAGGAGCTGCTATGCGTGTGCAGGAGTAGCTTGGGGAAG


 


GAGAAGCATGATGGAATTAGGAAACTGCACGGCCATTTGTCTGACCTCCCAGATGTTTTTACTTCATCCCTCTCTTT


 


CCCGGCTTCCCACCTCTTCACCAAGTGCCTAGCGCAGCTTCTCCTGGAGGCACATTGAGGGCCTCCTGGTGTCTATG


 


GTAGAGACGGGAAGTGGGTTTCCAGAGGGCCTGGCAAGCAAAGAGTCCCTGAGAAGTGCTTCTGTAACTCCCTGTGG


 


CAACCAAGAGGCCCGTAGGTGAAAGAACAGAAGCAGTACCTGTGAGGGAGCCAGCCACGCTGCCCTAGGCCAAAGAC


 


CCCTGGAGAGCATTTGGTAATGAGGTGTGAGAGGAGAGCATCCTGCACCAGAATCACCCTTGTCTTGAGCTAATTCT


 


CTTCACTCCTCAGCCTTGTGGCCTTCCCAGTCACCATGGCCCTCCAGATATCCCCATCCTGCATGGCAGTTCCATAT


 


GCAGAGCCAGAATCCATCCTTGTTCCTTCTGCATTGTGAGAAAATCCATGGAGGAAAGCACTTGTGTCATGGGGACC


 


ACCCCTACCTGACCCACCCACGGAGTCAGAGTTTGGGGAACTCATGGCCGTTGAGGCTCACCCAGGATGGCCATAGC


 


CTTCATGGAGACCCATGCCAGTGTGGCCATGTCTCTAGCTCACCTCTAGCCCTGCACACAGGTGGTCAGGACCAATC


 


TTGGGAGTGTTGCAAGTGCTATGTCGTTAATTGTAGTTTTAGTGCCTCAGTGACAAACCTTGCAGATCATTTCCCTT


 


CTTCTGAGATGAATGCAGATTTGATGGCCCTATAATATTACTCTTGCATTCCTCGATGCATTCTTAAATGGGAGCAA


 


ATGGGATGGGCCCCAGATCACTCACTGGAAACCCACACTCCAGGTGCCTCATTTCCTCTGCCCAGGAGATTGTAGCC


 


TGGGCACAGCTATATGAGGAGGGCCCATTTGGATACTGCTATCATGGATGTCTTAGTGGAAGGAAGTTTAGGGATAA


 


CCACAACTCTAGAAGTCCAGGTTCTGGACTCACTTTGCAGACTCTAGCAGTACCTGCCTCCATTCCCTGCCCACTCA


 


AGCTAGTTTCTCAGCAAAGAGAATATGAGGAAATATCCCCAAACATCGTCATCCCCACTGGGATCCTCCACATGAGT


 


GTGGGCTGGAAAGGTTCCAGGGTCACACTGAGGCAGGACATTTTTTGCCAATGCCTGTTACCCCATGGAAGGCTGAG


 


GTACGGATGCACCTGATCTGGAAATGCAGCCCAGGTCAGACTCCACATTTCTGCAACAAAGCATCACCTGCAATGAC


 


TCTTTTCACGTCAGTGGGTCAAAGGACAGAACCAGCTTCCGTGTTTTAGGCTCACTAGATTGTCTCATGCTCCCCAT


 


GGCTATTCTGTTTGGGAGAATTTGATCTAACCCGAAGCCTAAAGGAATCAATGTAATGTTGAATTGTATTCTATGTA


 


A


 


>gi|93277116|ref|NM_031484.2| Homo sapiens MARVEL domain containing 1


(MARVELD1), mRNA


(SEQ ID NO: 30)



GAAAGGAGGAGAGGAAGAGAGGACTAAGAGGGGAGCAAGGCGAGGAGGCCGCGGCGGGCGCAGCGGGCACCTGGGCC



 


GTGCTGCCCCCGCGAGCAAGGCGCCGCCATTCCGCTGCTCGGGGCGCCGCCGCCGCCGCCACCGCGCCCAGGGGCCA


 


TGCTCCCGCCGCCCCCGCGCCAGCCGCCGCCCCAGGCGCGTGCGGCCCGCGGCGCGGTGCGCCTGCAGCGGCCCTTC


 


CTGCGCAGCCCGCTGGGCGTGTTGCGGCTGCTGCAGCTGCTGGCCGGCGCTGCCTTCTGGATCACTATCGCCACCAG


 


CAAGTACCAGGGCCCCGTGCACTTCGCGCTCTTCGTGTCCGTGCTCTTCTGGCTGCTCACCCTGGGCCTCTACTTCC


 


TCACGCTGCTGGGCAAGCACGAGCTGGTCCCCGTGCTGGGCTCGCGCTGGCTCATGGTCAACGTGGCGCACGATGTG


 


CTGGCGGCCGCGCTCTACGGCGCCGCCACCGGCATCATGAGCGACCAGATGCAGCGCCACAGCTACTGCAACCTCAA


 


GGATTACCCGCTCCCCTGCGCCTACCACGCCTTCCTGGCGGCCGCCGTCTGCGGCGGCGTCTGCCACGGCCTCTACC


 


TGCTTTCGGCGCTCTATGGCTGCGGGCGTCGCTGCCAGGGCAAGCAGGAGGTGGCGTGAGGCCGCCCGCGCCCGCCG


 


CGGCCCCGATCGGGGCGGGGGAATCCCCGGAGACCAGCCTCCTTAATCCCTTCCCCCGCCGCCGCCCCGCGCGGGTG


 


CGCCCTGGCACCCTCTCCCTGCCCTCCAGCGTTTCCACTGTCGCCCGCGCCCGGGAACCCTGACGCTCAGCTCCCGC


 


CCGACGGCAGCGCCGCCGCCGCCCAGAATCCCAGCCCAGAATCCCGACCGCCGCGCCGGACGCGCCGTCTCCCGGGA


 


CAAGCGCAGGCTGCGATCCGAGGGGCTGACACACACTCGCAGACGAGCCGCCCCGAGGCGAAACCTCGCGGTTCCTC


 


TTCCCTTCCCTGCTGAGACTAAGACGTGGACAGGGGCCGCGCAGATCCGGGGGAGGCTCCCAAATTGGAACCAGGCT


 


TCTGGCTGCCCCCTTCCCTCCCGCCCCGTGGTCGGAAGAGCACTCCCTTCCCTGGCCCCTCATCCAGCCTCCGGTGC


 


TGTAAAACGCAGGCGCTGGGCCGCGGGCGGAGCTGAGGACAGGCCTTGGCTGGTCCCAGGATGAGCGACGAGTTTGG


 


TTTTAGCTGGGGATTGTGCTGGCATCCTGCGAAGCTCCTCCCAGCCGGTCTCTCTGTGCTCGGTTGTCTTGGGGTGG


 


GGCCCATCCGCCGAGGTGGGGACCGATAGGAGAAGCCGGTGGGTTGTACCCTTACACTTGTGGAGTCTCCTCTTGCC


 


TCTACCTACTCCGCCTTTGTCCTTAAGGTTTTTGCAGGCCAGTGCCAAACACACACTAACTGTCCTGGCCTCTCCGT


 


GACACAAGTCTCTTCCCAGCCTTCCTCACAGGCTTCTGCCGCCCCCCTCATCTCCACCCTCCCCCATATCTGTTTGC


 


ATTAGGAGTTCCACGACCATGGTGGAATGTTAAGGTGAACCCCACCCCTTCTTACAGATGGGGACCCAGAGCCTGCT


 


CTTGGGAACAGCCAGAGTAAGATTGGAACCCAGACTTGCAGTCCAGCGCTGTTTGCATTAAAAGGGTGGGTGAGTCA


 


GGACCCCTGGCTCAGGAGCCGCCTCTCCTAAAAGAGGGTTTCAAGGCCAAATGGGTTTGTCAACGGTGCTGTCTCCC


 


TTTCTTGGAGATGCTCATTAGCTTATCAAAGACTGAGAAGTCCCGCTGTTACAGAAATAATTTAGTTTGCTGTATTA


 


ACTGCTCCTGGGCCTGGAGCAGTATTCCCACCTTAAGATTCCCAGCATCCCTGTGCTGTCCCGGCTCTCATTCATGC


 


CGAAGGGCCCAACCCATTGGCTGTGTTCTGTTTGAAGATTTGGGGGGCGCCTTCTCTTTCTTCCCCAGGGAATTCTC


 


TAGCAGAGGGAGGGGACCCACCCCAGTGAGGAAGTAGATTGCTGCCTCTAGCCAGAGACCTGAACTGGGGAATTTGA


 


ACATTCCTTTACATTGTTGGAGAAATGAAGCCAAAGTTATTCAGATGGTTTTCCCAGGCTAAAGGAAAGTCACCTGC


 


AAGAGATCCCGGCACTGATCTGGAGCAGCTGACAGGGTGGGTCTCCCTTACCAAAGAGAAGAACCACTCTCTGGCGC


 


TGGGGTGACCTGCTGGCTGGGCCTGTAAGGTTTCCATGTTGCTGAGGCCATGGAGATTCCCAGAGCTGGTCACACCG


 


ACCGCTCTCAGGGCCCGCTGCCCTGGGCTGGCAACACCATTCTGGCCTTGGCCTGCAGAAGCTTTCAGAGTCTTCAC


 


TGGCAGTAGGGGGAGATGGGGAGAGGAATGATCTCTGCCCAGCCCCTTCCTTTCCAAACCATGCAATGGAAGAGCCC


 


AGATGGGTGAAGATTGATTTTGCCTTAACTCAAGAGAATTCCTGTTCTCCTTGTGCTATGATTTGGACACAAGATTC


 


TGGATACCTGGAACTTAGCTGTGTACTCCTGTACCCTAAACAGTGGATTTGAGTTCCAGCGTTTATTCTTTTTTCCT


 


TTTTTCAGATCACCATCTAAGTTACATCTTTAGCTCAGGTCCATCCTTCTCAAGATCTCCTTCTTAGCCCCCCAGCC


 


CCTGGTGCTGTCTGTGGTCAGGTGACCTTACTCAGGAGCAGATATCTCCTTGGCCGCCATGGAGCCTCATCCATCCA


 


CACGTGCCTGTAGCATTCCAGAGCTCACTGCCCTTCTAGATGTGCCTTCCCGCTTGGCTTCCAGCGGCTTGTGCTCA


 


CTCTGTCTGCCAGGTATGAGAAGAACACGTAAGACCGCCACCACACTCACCCTCCCTCAAGGCCCTGTGCCATAGGG


 


GTGGCCACCCGACCTGCCCCCAGAACTTTTGGATACTGGAGGCAGTTGCATAGGTCTCCCTCTCTGGGCACCAGGAC


 


TCAGTCCAGCCCAAGACTACTCTGGGCAGCTCCCATCCCAGTCTGGGGCCATTTGCAGACTCAGGAAAGGATTTCTA


 


CAGTGTTCTATAAAAGCCAAAAGAGAGAGTGGGTTTGGGAAGAGTGAGGGTGGTTGGGGAGAGGGGACCGATGTGCC


 


TCATTGTTTAGTGGTGATTACAAATATGCTTTTCTGGATAAAGTTTGGTTGTTTGCTCTTAAAAAAAAAAAAAAAAA


 


AAAA


 


gi|50582984|ref|NM_024717.3| Homo sapiens multiple C2 domains, transmembrane


1 (MCTP1), transcript variant L,


>gi|50582995|ref|NM_001002796.1| Homo sapiens multiple C2 domains,


transmembrane 1 (MCTP1), transcript variant S, mRNA


(SEQ ID NO: 31)



ATGCTAGACAGCTGCAAGCTGAAAAGTGCCTGCAATTTGCCATTTATTTGTAATAAGAAAATAATAAACACTGCTGG



 


AACCAGTAATGCAGAAGTCCCCTTGGCTGATCCCGGAATGTACCAGCTGGACATTACATTAAGAAGGGGTCAAAGTT


 


TAGCTGCTCGAGATCGAGGAGGGACGAGTGATCCATATGTGAAGTTTAAAATCGGAGGAAAAGAAGTTTTTAGAAGT


 


AAGATAATACACAAGAACCTCAACCCTGTGTGGGAAGAAAAAGCTTGTATTCTGGTTGATCATCTTAGGGAGCCATT


 


GTATATAAAGGTATTTGACTATGATTTTGGACTACAGGATGACTTTATGGGCTCAGCCTTTCTGGATCTGACACAAT


 


TGGAGTTAAACAGGCCCACAGATGTGACCCTTACTCTGAAAGATCCTCATTATCCTGACCATGATCTTGGAATCATT


 


TTGCTCTCAGTCATCCTTACCCCTAAAGAAGGAGAGTCCAGGGATGTGACAATGCTAATGAGGAAGAGTTGGAAAAG


 


ATCAAGTAAGGAACTTTCAGAAAATGAAGTGGTTGGATCTTATTTCTCTGTGAAGTCTCTCTTTTGGAGGACGTGCG


 


GCAGGCCAGCTCTTCCTGTCCTGGGCTTCTGCAGAGCAGAGCTTCAGAATCCTTATTGCAAAAATGTACAATTTCAG


 


ACCCAAAGTTTACGCCTATCAGACCTACACAGAAAATCGCATCTTTGGAGAGGAATAGTCAGCATCACCTTGATTGA


 


AGGGAGAGACCTCAAGGCCATGGATTCCAACGGGTTGAGCGATCCCTACGTGAAGTTCCGGCTTGGGCATCAGAAGT


 


ACAAGAGCAAGATTATGCCAAAAACGTTGAATCCTCAGTGGAGGGAACAATTTGATTTTCACCTTTATGAAGAAAGA


 


GGAGGAGTCATTGATATCACTGCATGGGACAAAGATGCTGGGAAAAGGGATGATTTCATTGGCAGGTGCCAGGTCGA


 


CCTGTCAGCCCTCAGTAGGGAACAGACGCACAAGCTGGAGTTGCAGCTGGAAGAGGGTGAGGGACACCTGGTGCTGC


 


TGGTCACTCTGACAGCATCAGCCACAGTCAGCATCTCTGACCTGTCTGTCAACTCCCTGGAGGACCAGAAGGAACGA


 


GAGGAGATATTAAAGAGATATAGCCCATTGAGGATATTTCACAACCTGAAAGATGTGGGATTTCTCCAGGTGAAAGT


 


CATCAGAGCGGAAGGGTTAATGGCTGCCGACGTCACTGGAAAAAGTGACCCATTTTGTGTGGTAGAACTGAACAACG


 


ATAGACTGCTAACACATACTGTCTACAAAAATCTCAATCCTGAGTGGAATAAAGTCTTCACGTTCAACATTAAAGAT


 


ATCCATTCAGTTCTTGAAGTGACAGTTTATGATGAAGATCGGGATCGAAGTGCTGACTTTCTGGGCAAAGTTGCTAT


 


ACCATTGCTGTCTATTCAAAATGGTGAACAGAAAGCCTACGTCTTGAAAAACAAGCAGCTGACAGGGCCAACAAAGG


 


GGGTCATCTATCTTGAAATAGATGTGATTTTTAATGCTGTGAAAGCCAGCTTACGAACATTAATACCCAAAGAACAG


 


AAGTACATTGAAGAGGAAAACAGACTCTCTAAACAGCTGCTACTAAGAAACTTTATCAGAATGAAACGTTGTGTCAT


 


GGTGCTGGTAAATGCTGCATACTACGTTAATAGTTGCTTTGATTGGGATTCACCCCCAAGGAGTCTCGCTGCTTTTG


 


TGCTCTTTCTCTTTGTTGTCTGGAACTTTGAGCTCTACATGATACCACTGGTTTTGTTGTTACTATTGACATGGAAC


 


TACTTCTTGATAATATCAGGGAAAGATAACAGGCAACGTGATACAGTAGTGGAGGACATGCTAGAGGACGAGGAAGA


 


AGAAGATGACAAAGATGACAAGGACAGTGAAAAAAAGGGATTTATAAATAAAATCTATGCCATCCAGGAGGTATGTG


 


TCAGTGTCCAGAACATCCTAGATGAAGTGGCTTCCTTTGGCGAAAGGATTAAGAATACTTTCAACTGGACTGTCCCA


 


TTCTTAAGCTGGCTGGCCATTGTAGCCCTCTGTGTGTTCACAGCCATCCTGTACTGCATTCCGCTGAGATACATTGT


 


CCTTGTCTGGGGCATCAATAAATTTACAAAAAAGCTTCGGAGTCCATATGCAATTGATAACAATGAACTACTTGACT


 


TCCTTTCCAGAGTCCCTTCAGATGTACAAGTGGTGCAATACCAAGAACTGAAACCAGATCCTTCTCATAGCCCATAT


 


AAAAGAAAGAAAAACAATCTTGGCTAG


 


>gi|141802338|ref|NM_181644.3| Homo sapiens major facilitator superfamily


domain containing 4 (MFSD4), mRNA


(SEQ ID NO: 32)



GCAGGGACCAGATCCGCGAGCCCGTCAGCCTGCGCCATGGGCTGCGACGGCCGCGTGTCGGGGCTGCTCCGCCGCAA



 


CCTGCAGCCCACGCTCACCTACTGGAGCGTCTTCTTCAGCTTCGGCCTGTGCATCGCCTTCCTGGGGCCCACGCTGC


 


TGGACCTGCGCTGTCAGACGCACAGCTCGCTGCCCCAGATCTCCTGGGTCTTCTTCTCGCAGCAGCTCTGCCTCCTG


 


CTGGGCAGCGCCCTCGGGGGCGTCTTCAAAAGGACCCTGGCCCAGTCACTATGGGCCCTGTTCACCTCCTCTCTGGC


 


CATCTCCCTGGTGTTTGCCGTCATCCCCTTCTGCCGCGACGTGAAGGTGCTGGCCTCAGTCATGGCGCTGGCGGGCT


 


TGGCCATGGGCTGCATCGACACCGTGGCCAACATGCAGCTGGTAAGGATGTACCAGAAGGACTCGGCCGTCTTCCTC


 


CAGGTGCTCCATTTCTTCGTGGGCTTTGGTGCTCTGCTGAGCCCCCTTATTGCTGACCCTTTCCTGTCTGAGGCCAA


 


CTGCTTGCCTGCCAATAGCACGGCCAACACCACCTCCCGAGGCCACCTGTTCCATGTCTCCAGGGTGCTGGGCCAGC


 


ACCACGTAGATGCCAAGCCTTGGTCCAACCAGACGTTCCCAGGGCTGACTCCAAAGGACGGGGCAGGGACCCGAGTG


 


TCCTATGCCTTCTGGATCATGGCCATCATCAATCTTCCAGTGCCCATGGCTGTGCTGATGCTGCTGTCCAAGGAGCG


 


GCTGCTGACCTGCTGTCCCCAGAGGAGGCCCCTGCTTCTGTCTGCTGATGAGCTTGCCTTGGAGACACAGCCTCCTG


 


AGAAGGAAGATGCCTCCTCACTGCCCCCAAAGTTTCAGTCACACCTAGGGCATGAGGACCTGTTCAGCTGCTGCCAA


 


AGGAAGAACCTCAGAGGAGCCCCTTATTCCTTCTTTGCCATCCACATCACGGCCGCCCTGGTCCTGTTCATGACGGA


 


TGGGTTGACGGGTGCCTATTCCGCCTTCGTGTACAGCTATGCTGTGGAGAAGCCCCTGTCTGTGGGACACAAGGTGG


 


CTGGCTACCTCCCCAGCCTCTTCTGGGGCTTCATCACACTGGGCCGGCTCCTCTCCATTCCCATATCCTCAAGAATG


 


AAGCCGGCCACCATGGTTTTCATCAACGTGGTTGGCGTGGTGGTGACGTTCCTGGTGCTGCTTATTTTCTCCTACAA


 


CGTCGTCTTCCTGTTCGTGGGGACGGCAAGCCTGGGCCTGTTTCTCAGCAGCACCTTTCCCAGCATGCTGGCCTACA


 


CGGAGGACTCGCTGCAGTACAAAGGCTGTGCAACCACAGTGCTGGTGACAGGGGCAGGAGTTGGCGAGATGGTGCTG


 


CAGATGCTGGTTGGTTCGATATTCCAGGCTCAGGGCAGCTATAGTTTCCTGGTCTGTGGCGTGATCTTTGGTTGTCT


 


GGCTTTTACCTTCTATATCTTGCTCCTGTTTTTCCACAGGATGCACCCTGGACTCCCATCAGTTCCTACCCAAGACA


 


GATCAATTGGAATGGAAAACTCTGAGTGCTACCAGAGGTAAAACTGGGTGAAGAAGGCAAGAGAAGACTTTCAGCCT


 


CTTGATCACCAGCACGACCATACTGTTTCAGAAAGCTGGGTGGTGGTGGAGGCGCTATCTCAATGGCTATTCAAGTC


 


TTCTCCACTAAAACTTGGTTGGGTAGAGGAAATTAAATTGAGTCCTGGTACCTGGTCAAAATCATTAGAAGTTTACC


 


TGGCTTCTCAAGTTATCTTCTTCCCTGGTTCAGACTGTTGGTAAGAGCTGTCCAGATACCCAGATGGGAAGGAAGGA


 


GACAGCCGCGCGCTTCACTCCATTTGTCACCTCATGCATGGACCATACTCTGGGTTTGAGATCATTCTTCATTGAAG


 


TTTGTAAAAATAGGTTGAAATTGTAAAGCTCCATGATCATTGCTATGTAGATATATTTCAATTTAAGCAAAACAAGC


 


TGCAAGTTATTCCCTGGCATGCTCAAAGGATTTTCGTGCTTTTCACTTAATAGTCCAAAGTCTCTTAAATTCCTGCT


 


GCAGACATCAATAGCTTATCTATATTCTCAAACACCAAAAGGAAAAGTTGAATCTTGCTCTCTTTGGTATACTAATG


 


TAGTGGTATGCTAAGCTGGCTCATACCAACTTAGAAAAGCTGATTGTAAAATTTTCATTTTGACAGCTGGTTATTAA


 


ATGCAGCCATTATTAAAAATCAAATCATACAAACTTATAATTAAATCAATTACATTTAAAACAAAGGTAATAAATAT


 


TCAAAGCATATCACTTCCTAATTTGATCTTGATGCTCTTGAGGTAATTTACGTCCATGGTACCTGTGTGGTGGAATT


 


ACTATATATGATGGTGTGCTACTGTGCACCTTGTCTCAACTCCACTCTTCGTGATAGCATGTTGGTAGCTTGAAATC


 


AGCCTGGTGGGAGTATTACCATGGACACTGGCAAAAGCTACAGATCCCGGAGAGCCAGTGGTTAAACATTTACCAGC


 


ATACCACTGCTAGTAATCAAGGCTAACTGGTCCAGAAATCGCCCAGGAGAATGAAATGGATGTTCCATTTTTTTCTA


 


CTGACATTGACTAGCATATAAAAGGTATAGAAACAGCACTAAGACTTTCTGAAAATACCTAATGAAAATTTTACATC


 


TTTTTTTGTTTTTGTTTTTGTTTTTGAGACAGAGTCTCACTCTGTTGCCAGGCTGGAATGCAGTGGCGTCATCTCGG


 


CTCACTGCAACCTCCGCCTCCCAGTTTCAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGTGACTACAGGCGCA


 


TGCCATCACGCACAGCTAATTTTTTGTATTTTTAGTAGAGACGGGATTTCACCGTGTTAGCCAGGATGGTCTTGATC


 


TCCTGACCTCATGATCTGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTGCACCCAGCCAAA


 


AATTTTACATCTTTTATAGAGGGAAAAAAACTCTTTATACCATGGCAAGGCCTTTTCTTTCACAAAAAGCTGGGCCT


 


ACTGAACAATTCAAGCTGTGCAGTAGTAGACTGAAAGCAGGATTTGTTGAGGAGTTACAGCTCCTGTCCAGAGCAAA


 


TCCTGTAGTGATACAAGGAGAATGTAAACTTGCCAGCTTAGACAGGGATCAGTCCTGAGACTGCTGGCAGTAGCAAA


 


TGGCTATTAGAGTAACTGTATAATGGTTTTGCCTGCACTTTCTCTATGTATATACAAATGTACATGTATAAATATAA


 


AAATTAAGTGATCATGAAAGAAAAAAAAAAAA


 


>gi|115387119|ref|NM_016499.3| Homo sapiens HSPC244 (MGC13379), mRNA


(SEQ ID NO: 33)



CCAAGGTCCTCCCCCGCACCCCTGAGGTCCTGCAGACGACGGCGTCGTGGGTGGTCACCGTTATCCCTTAGGTCTGG



 


AGAGGGGACATCCGAGCGAGGGCCACTTGCGGCCAGGCCCGAGCTCGTCCAGCTCCGGGTGACCACAGAGTGCCGCG


 


GGCGGGCAGAGGGGCCGGAAACCCAGGCCGCTTCGTCCCTGTTTCCGGCAGCGCCGCGCTGCTCCGGGAGCCGCTGT


 


GGCAGCGTATGCTGCCACGGGGACTGAAGATGGCGCCGCGAGGTGAGATTCCGGAGGTAAACGGTTGTCCTCCACCC


 


CGCTGGAAATCCTGTTCTTTCTGAACGGGTGGTATAATGCTACCTATTTCCTGCTGGAACTTTTCATATTTCTGTAT


 


AAAGGTGTCCTGCTACCATATCCAACAGCTAACCTAGTACTGGATGTGGTGATGCTCCTCCTTTATCTTGGAATTGA


 


AGTAATTCGCCTGTTTTTTGGTACAAAGGGAAACCTCTGCCAGCGAAAGATGCCGCTCAGTATTAGCGTGGCCTTGA


 


CCTTCCCATCTGCCATGATGGCCTCCTATTACCTGCTGCTGCAGACCTACGTACTCCGCCTGGAAGCCATCATGAAT


 


GGCATCTTGCTCTTCTTCTGTGGCTCAGAGCTTTTACTTGAGGTGCTCACCTTGGCTGCTTTCTCCAGTATGGACAG


 


GATTTGAAGTACAGAATTTCAGCCAGCAGCCCATCAGGCTGACACCACACATATTGCTTCTGGTACTTTAGCCACAC


 


CAGTGAGAATTGGTGGGGCAAGTTGTCCTGAGAAAGGCTGTGTGGCTTTTCTTCAGCACAGACATTTGGGCAAGCAA


 


CTCAGCATAAGGCCAGTGGGTACCATCTTCTAAACCAGGACCATCAGCCCAAGAGACTCTTCTACACTCCAGTATAG


 


GGAGGGGCAAGGTTATTCCCATCCTGCCCCTTCTCAGAACCAGTCCCCTGCTGACCTCAAGTTCTCCTCCTTGATCA


 


CCGTGGCCAGAGCATCTCGTGTGGACCATCTAGGCTCCTTGGGCTTCAAGCAGGACCTGAGCCACATGCTCCCTGTA


 


CGAGCTGTGCTATACCTGTCCCACATGAGCACGGAGAGCCTCATGTTGGTGGGTTTCCAGAGTGATGTGAAAGCCTC


 


TCACCCCAATCCTCGGAGACTGAGTTCCACAACTTTTTTAGTAGCTCATAGTGTTATTTTTCTACTCTCTTCATGAA


 


ACTAACTTTATTTTATAATAAATATGTATTTTCTGTTGTGGGGAAAAAAAAAAAAAAAAAAAA


 


>gi|13899294|ref|NM_031457.1| Homo sapiens membrane-spanning 4-domains,


subfamily A, member 8B (MS4A8B), mRNA


(SEQ ID NO: 34)



AAACAGGAAATAAATACGAATGAAACTGAGCTCTAAGCAGCATGTAACCTGGCCTGCATCCAGGAAATAGAGGACTT



 


CGGATCCTTCTAACCCTACCACCCAACTGGCCCCAGTACATTCATTCTCTCAGGAAAAAAAACAAGGTCCCCACAGC


 


AAAGAAAAGGAATAGGATCAAGAGATACGTGGCTGCTGGCAGAGCAAGCATGAATTCGATGACTTCAGCAGTTCCGG


 


TGGCCAATTCTGTGTTGGTGGTGGCACCCCACAATGGTTATCCTGTGACCCCAGGAATTATGTCTCACGTGCCCCTG


 


TATCCAAACAGCCAGCCGCAAGTCCACCTAGTTCCTGGGAACCCACCTAGTTTGGTGTCGAATGTGAATGGGCAGCC


 


TGTGCAGAAAGCTCTGAAAGAAGGCAAAACCTTGGGGGCCATCCAGATCATCATTGGCCTGGCTCACATCGGCCTCG


 


GCTCCATCATGGCGACGGTTCTCGTAGGGGAATACCTGTCTATTTCATTCTACGGAGGCTTTCCCTTCTGGGGAGGC


 


TTGTGGTTTATCATTTCAGGATCTCTCTCCGTGGCAGCAGAAAATCAGCCATATTCTTATTGCCTGCTGTCTGGCAG


 


TTTGGGCTTGAACATCGTCAGTGCAATCTGCTCTGCAGTTGGAGTCATACTCTTCATCACAGATCTAAGTATTCCCC


 


ACCCATATGCCTACCCCGACTATTATCCTTACGCCTGGGGTGTGAACCCTGGAATGGCGATTTCTGGCGTGCTGCTG


 


GTCTTCTGCCTCCTGGAGTTTGGCATCGCATGCGCATCTTCCCACTTTGGCTGCCAGTTGGTCTGCTGTCAATCAAG


 


CAATGTGAGTGTCATCTATCCAAACATCTATGCAGCAAACCCAGTGATCACCCCAGAACCGGTGACCTCACCACCAA


 


GTTATTCCAGTGAGATCCAAGCAAATAAGTAAGGCTACAGATTCTGGAAGCATCTTTCACTGGGACCAAAAGAAGTC


 


CTCCTCCCTTTCTGGGCTTCCATAACCCAGGTCGTTCCTGTTCTGACAGCTGAGGAAACGTCTCTCCCACTGTTTGT


 


ACTCTCACCTTCATTCTTCAATTCAGTCTAGGAAACCATGCTGTTTCTCTATCAAGAAGAAGACAGAGATTTTAAAC


 


AGATGTTAACCAAGAGGGACTCCCTAGGGCACATGCATCAGCACATATGTGGGCATCCAGCCTCTGGGGCCTTGGCA


 


CACACACATTCGTGTGCTCTGCTGCATGTGAGCTTGTGGGTTAGAGGAACAAATATCTAGACATTCAATCTTCACTC


 


TTTCAATTGTGCATTCATTTAATAAATAGATACTGAGCATTCAAAAAAAAAAAAAAAAAA


 


>gi|6005793|ref|NM_007213.1| Homo sapiens PRA1 domain family, member 2


(PRAF2), mRNA


(SEQ ID NO: 35)



CACATTAACCGGCAGGATGTCGGAGGTGCGGCTGCCACCGCTACGCGCCCTGGACGACTTTGTTCTGGGGTCGGCGC



 


GTCTGGCGGCTCCGGATCCATGCGACCCGCAGCGATGGTGCCACCGCGTCATCAACAACCTCCTCTACTACCAAACC


 


AACTACCTTCTCTGCTTCGGCATCGGCCTCGCTCTCGCCGGGTACGTGCGGCCACTTCATACGCTCCTGAGCGCGCT


 


GGTAGTGGCGGTGGCCCTCGGCGTGCTGGTGTGGGCAGCTGAGACCCGCGCAGCTGTGCGCCGCTGCCGCCGCAGCC


 


ACCCTGCAGCCTGCCTGGCCGCAGTGCTTGCCGTCGGCCTCCTGGTGCTCTGGGTCGCGGGCGGCGCTTGCACCTTC


 


CTGTTCAGCATCGCCGGGCCGGTGCTTCTGATCCTGGTGCACGCCTCGTTGCGCCTGCGCAACCTTAAGAACAAGAT


 


TGAGAACAAGATCGAGAGCATTGGTCTCAAGCGGACGCCAATGGGCCTGCTACTAGAGGCACTGGGACAAGAGCAGG


 


AGGCTGGATCCTAGGCCCCTGGGATCTGTACCCAGGACCTGGAGAATACCACCCCACCCCCAGCCCATAATTGGGAC


 


CCAGAGCCCTTTCCCAGCACTTAAAACAGGAGCCTAGAGCCCCCTGCCCAAACAAAACAGGACATCTGTGACCGCCC


 


TACCCCCACGCCAGCCCCAAACTAAGATATCCCTCACACCCAGCCCCCATTACCTAGGGACAAGAGTCTTCCCCAGC


 


CTTGAACCTAGGACCAAGAGCCACCTACATCCAGCCCCAAAACTGGGGCTTCAGGCCAGAGCATCCATGGCCAATTT


 


CAAATTGTGAACCCAGAGACACTCCCATCCACCCTTCTCCATGCTCATCCCCAAACTGGGGCCTGGAGCAAGGCACT


 


CTCAAATCTTGAACCCTGGACCAAAGCTTTTCCAGACCCCACCCTACCTTCCAACCCAGGTCAAGACATTGCCAAAT


 


CTTGAACTCAGAACCCAAGTGTTCCATGCCCCTGTGTGGATGGAGTCGGGTATCCTGACTGTTGGACCCCTGGTCCA


 


GGTGATCCCGACCCTCACCAGTCCCATTTGCCTCCCTCCAGCTCTGCTTAGGCATTTTGCCCCTCACCCCAATGTTC


 


CACACCATCGACAACCAAGGGGTGAGGTGGGGACAGGCCTCAGCAGGGAATGGGGCGTATATGTTAGTGTTGCTGCA


 


ACAATAAAGCCTGTTGCATCTCTCATGCCAA


 


>gi|158186613|ref|NM_001109903.1| Homo sapiens ring finger protein,


transmembrane 2 (RNFT2), transcript variant 1, mRNA


(SEQ ID NO: 36)



ACATGCTGCCCAGGCTGCGCGGGTGATTGGCTTGGCTGGACCTGAATGATGCGGCTGTGATTGCTGAATTGTCTGGG



 


CAGGTTTGGAGTCTCTGGCAAGCTCCCCTGACTGTGCATCCCTCTGGAGACGAAGAGGAGGGGGAGGCCTGTCCTCT


 


CTGGGATCCATTGGTCACATCCCCCTGAGGATTCCCGAATGCCTACCTCCAGTGTCGTCAACATGGAGTTCTGAAGT


 


CCATGTGGCTCTTCACAGTGAATCAGGTGTTAAGGAAGATGCAGAGACGCCACAGCAGCAACACGGATAACATTCCA


 


CCTGAAAGAAACCGCAGCCAGGCGCTCAGCTCCGAGGCGAGTGTGGATGAAGGTGGCGTCTTTGAGAGTCTGAAGGC


 


AGAGGCAGCCTCCCCACCAGCGCTCTTCTCGGGCTTATCAGGCAGCCTCCCCACCAGCTCGTTCCCCTCCAGCCTGG


 


TGCTGGGCTCCTCGGCTGGCGGCGGGGACGTGTTCATCCAGATGCCCGCGTCCAGGGAGGAAGGAGGGGGCCGGGGC


 


GAGGGGGGCGCCTACCACCACCGCCAGCCCCACCACCATTTCCACCATGGCGGCCACCGCGGGGGCTCCCTGCTGCA


 


GCACGTGGGTGGGGACCACCGGGGGCACTCGGAGGAGGGAGGCGACGAGCAGCCTGGGACGCCCGCCCCCGCCCTGT


 


CCGAGCTGAAGGCTGTGATCTGCTGGCTCCAGAAAGGACTCCCCTTCATCCTGATCCTCCTGGCCAAACTGTGCTTT


 


CAGCATAAGCTCGGCATTGCTGTGTGCATCGGGATGGCCAGCACCTTCGCCTATGCCAACTCCACGCTTCGAGAACA


 


GGTCTCACTGAAGGAGAAGAGGTCAGTGCTGGTCATCTTGTGGATCCTGGCCTTTCTGGCGGGGAACACCCTCTATG


 


TGCTTTATACATTCAGCTCCCAGCAGCTGTACAACAGCCTCATATTCCTGAAGCCCAACCTGGAGATGCTGGACTTC


 


TTTGACCTGCTATGGATTGTGGGGATCGCAGACTTTGTTCTGAAGTACATCACCATCGCCCTCAAGTGCCTCATCGT


 


GGCCCTGCCCAAGATCATCCTGGCTGTCAAGTCCAAGGGAAAGTTCTATCTGGTCATCGAGGAGCTGAGCCAGCTGT


 


TCCGATCCCTTGTCCCCATCCAGCTGTGGTACAAATACATCATGGGTGACGACTCCTCCAACAGCTACTTCCTGGGC


 


GGGGTCCTGATCGTTCTCTACAGCCTCTGCAAGTCCTTCGACATCTGTGGACGTGTGGGCGGAGTTAGGAAAGCCCT


 


GAAGCTTCTCTGTACCTCTCAGAACTATGGAGTCCGAGCCACCGGGCAGCAGTGCACAGAAGCTGGTGACATCTGCG


 


CCATCTGTCAGGCCGAGTTCCGAGAGCCTCTGATTCTCCTGTGCCAGCACGTGTTCTGTGAGGAGTGCCTCTGCCTG


 


TGGCTGGACCGTGAGCGCACCTGCCCGCTCTGCCGCTCGGTCGCCGTGGACACCCTGCGCTGCTGGAAGGACGGCGC


 


CACGTCCGCACACTTCCAGGTGTACTAGGACCGAACACTGAGGACACCCAGAAGGACGCCAAGGATTCAGGACATTT


 


GCCCCTGTGTGCCACCAAACCAGGACTTTCCCCTTGGCTTGGCATCCCTGGCTCTCTCCTGGTACCCAGCAAGACGT


 


CTGTTCCAGGGCAGTGTAGCATCTTTCAAGCTCCGTTACTATGGCGATGGCCATGATGTTACAATCCCACTTGCCTG


 


AATAATCAAGTGGGAAGGGGAAGCAGAGGGAAATGGGGCCATGTGAATGCAGCTGCTCTGTTCTCCCTACCCTGAGG


 


AAAAACCAAAGGGAAGCAACAGGAACTTCTGCAACTGGTTTTTATCGGAAAGATCATCCTGCCTGCAGATGCTGTTG


 


AAGGGGCACAAGAAATTGGAGCTGGAGAAGATTGATGAAAGTGCAGGTGTGTAAGGAAATAGAACAGTCTGCTGGGA


 


GTCAGACCTGGAATTCTGATTCCAAACTCTTTATTACTTTGGGAAGTCACTCAGCCTCCCTGTAGCCATCTCCAGGG


 


TGACGGAACCCAGTGTATTACCTGCTGGAACCAAGGAAACTAACAATGTAGGTTACTAGTGAATACCCCAATGGTTT


 


CTCCAATTATGCCCATGCCACCAAAACAATAAAACAAAATTCTCTAACACTGCAAAGAGTGAGCCATGCCTGTTAAC


 


ACTGTAAAGAATGTAACATGTGGGGGACACACAGGGGCAGATGGGATGGTTTAGTTTAGGATTTTATTAGTGCATGC


 


CCTACCCTCTGGGGGAACGTCCCATCTGAGGTTTTCTTCTCGGTGGGGGGATTTAACTTCTGTCCTAGGGAAAACAG


 


TGTCTGATGAGGAGTGTTTCCAACACAGGCTACATGAATTCCCCTATACCAGTGCGAAAGCAGCCAGGAGTCCCCGT


 


TGGAAAAGAACAATGCCACTCTCTTTTATGTATCTTGGTTCTGCAACTCATTTGTTGTAAGTAGGGTTAATCGAGTA


 


TCAGGTTCACAGTATCCTGCCCTTATTATTTTATGATTCACTGACTCAAGTTCCACGAAGTCCTTAGAAATGGACCT


 


CTTCATGTAAAATATCTTGAGAATAATAAATGTGAGGGAATAAGAAAGGCAAGCTTTGGACACAGATATGATAGGTG


 


CATCAGCTTCGGAAGAGAAGAATGATGTGCAGAGTGTTAGGAAGACATCCGGGCTGCTGAGACTCGGGATTAGAAGA


 


AAGAGAGGTAAATAAAGTGGGTCCTGGAATCTTTTAGGACTTCTGCTGTAGGACAAACAGCTGCCTTTGGTGTTTTA


 


ATGTCTCCCAAAGTACCCTTCAGCCAATAAATACCATCTGTTGGTGCAAAAAAAAAAAAAAAAAA


 


>gi|116235461|ref|NM_182556.2| Homo sapiens solute carrier family 25, member


45 (SLC25A45), transcript variant 1, mRNA


(SEQ ID NO: 37)



AGATCCTTGAAAGGGTTTTGGTTTTGACTGAGCAGAATGGTGCCATTGCAGATCAACACGCACTTTAAATAATCAAA



 


ACCCCTATCTTTCCCCTGGGAAGGAGGAAGCCGAGGAAGGCTGTGTTTCTGACTCACACGGGGGAGTCGGGGGAGTC


 


GTAAACAACCCTGAAGAGAACAGCCAGGCCTGTTCCCGCAAGCCCAGACAATGCCGGTGGAGGAATTTGTGGCTGGC


 


TGGATCTCTGGCGCTCTGGGCTTGGTCCTGGGACACCCGTTTGACACTGTAAAGGTGAGGCTGCAGACCCAGACCAC


 


CTACCGGGGCATCGTTGATTGCATGGTCAAGATTTACCGCCATGAGTCCCTCCTGGGCTTCTTCAAGGGAATGAGCT


 


TCCCCATTGCCAGCATAGCTGTGGTCAACTCTGTCCTGTTTGGGGTCTATAGCAACACCCTGCTGGTGCTCACGGCC


 


ACCTCCCACCAGGAGCGGCGGGCCCAGCCGCCCAGCTACATGCACATCTTCCTAGCGGGCTGCACCGGGGGGTTCCT


 


GCAGGCCTACTGTCTGGCTCCTTTTGACCTCATCAAAGTCCGGCTACAAAACCAGACAGAGCCAAGGGCCCAGCCAG


 


GGAGCCCCCCACCCCGGTACCAGGGGCCCGTGCACTGTGCAGCCTCCATCTTCCGGGAGGAGGGGCCCCGGGGGCTG


 


TTCCGAGGAGCCTGGGCCCTGACGCTGAGGGACACCCCCACGGTGGGGATCTACTTCATCACCTATGAAGGGCTCTG


 


TCGCCAGTACACACCAGAAGGCCAGAATCCCAGCTCAGCCACGGTGCTGGTGGCAGGGGGCTTTGCAGGCATTGCTT


 


CCTGGGTGGCAGCCACGCCCTTAGACATGATCAAGTCCCGGATGCAGATGGATGGACTGAGACGCAGAGTGTACCAG


 


GGGATGCTGGACTGCATGGTGAGCAGCATCCGGCAGGAAGGACTGGGAGTCTTCTTCCGGGGGGTCACCATCAACAG


 


TGCCCGCGCCTTTCCCGTCAATGCTGTCACCTTCCTCAGCTACGAATATCTCCTCCGCTGGTGGGGATGAGCCCTGC


 


GGCAATGCCAGCAGCTCCCCATCAGGCCCACGGCCTGGAGGCCAGTTTGAGATTGGAGGCCAGGTTGAAAGCTTGCA


 


AATCAGTGCAAGAGGCTCAGCCCTTCCTAACCAAGGTGCCTCCCACCCGCGCAGATCTGGGCTGGGCAGACACCTGT


 


GGGAGCCGGAAGCCAGGGGGCCTGTGCAGCCTCCCTGTGTAGCTGGCCTTGACTCCTTTGCCTCCCACATCTGTGAA


 


ACAGGGAGCATGAGGCACAAGTGAGCTGGCAAGTGGTGCTGGTGACATCCCAGCTCCTGTCCTGTGCCTTCACCTCT


 


TTTTTTTTTTTTTTTTTTTTTTGAGATGGAGTCTTTCTCTGTCACCCAGGCTGGAATGCAGTGGCGTGATCTCGGCT


 


CACTGCAACCTCCGCCTTTCCACCTTCCGGGTTCAAGCAACTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTATA


 


GGCGCCCGCCACCACACCCAGCTAAATTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTCAGCCAGGATGGTC


 


TTGATCTCCTGACTTTGTGATCCGCCCGCGTCGGCCTCTCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCG


 


GCTGCCTTCACCTCTTAAGGAGCTCTGAGACTCCACTTCTGAGAGTCCCTGCGGCCTCCCACCTCCCTGCCTTTCAA


 


AGCTCTCTCCCCCATGACCCAGGATAACCCTATGTCTCCTCCCCCAGAATCCTTCAGTGGCTCTCATCACCTTCAGG


 


AAAAGCCCAAACTCCTTCCACCCTCCAGGTTCCTCCCTCCCCACGAGGCTTTGTTCTCCTGGGGTTGCTTCCTGGAC


 


CCTGAACAAGTTGTGCTCTCATTGGCCGGGCCTGGCCAGCAGTGCACAGTGCCTGGCAGGTTGACTCTACCATCCCC


 


GGGGCTGGCCCCGCTCTCCTCCGAGACCCAGGCTGAGCCCAGTCCCCTCACCCTTCCTTGACTTACCTCCCCACCTG


 


AGGCTGACTTTGGGGTTCCCAGACACCCTACCCACACACATGCCTTGATCATAGCACTTGCCTGCGCTTCTTCAGAG


 


TCATTAATTTGCTTCTCGGCTTCCCCACTGGACTGTGAGCTGCCTGAGGTCAGGGATTGCGCTTTGGATGGTTTCCA


 


GCCTGAGCCTGGTGCTTGAACAGACGTGTGCAATAAATGCTCGTTAAATGATG


 


>gi|33469136|ref|NM_182838.1| Homo sapiens solute carrier family 35, member


E2 (SLC35E2), mRNA


(SEQ ID NO: 38)



GGGGCACTGAGGAGCGGCGCCCGCGGGGCAGCGAGGAGCCCGATGCAGGGTTCTGCGCGTCATTTCCGGTCCCGCGG



 


GCGCCCCGTGAAGCCCACCTGGATCCGCCAGCGCTGTGCCACTCCCCAGTGCCGAGCTCCGAGCTGTCTCCGCGGCC


 


TCGCGCCCGGCCCCTCCACCGCGCACCTCTTAGGCCCCGCCCGCCAGCGTCCCTTTGTTGTGAAGGCGCCGGGGCCT


 


AGCGCTATGCCTGCGGCGGAGACTGCATCAGGCTCTCGCGTCTGCTTCTACGCTTTGCCTGGGAGAGGCCCTGGTGG


 


CCTCGTTCCTGGCGCCCGGAGTCCCTGCTGCGGCCCCACCCCCGGGCGGTCACGGTGACCCATGCTGCCCAGCCTGG


 


AGGTAAAATCGTTCGTGGCTGTGGCTTCAGCATGTCGTCCTCGGTGAAAACCCCAGCACTGGAAGAGCTGGTTCCTG


 


GCTCCGAAGAGAAGCCGAAAGGCAGGTCGCCTCTCAGCTGGGGCTCTCTGTTTGGTCACCGAAGTGAGAAGATTGTT


 


TTTGCCAAGAGCGACGGCGGCACAGATGAGAACGTACTGACCGTCACCATCACGGAGACCACGGTCATCGAGTCAGA


 


CTTGGGTGTGTGGAGCTCGCGGGCGCTGCTCTACCTCACGCTGTGGTTCTTCTTCAGCTTCTGCACGCTCTTCCTCA


 


ACAAGTACATCCTGTCCCTGCTGGGAGGCGAGCCCAGCATGCTAGGTGCGGTGCAGATGCTGTCCACCACGGTTATC


 


GGGTGTGTGAAAACCCTCGTTCCTTGCTGTTTATATCAGCACAAGGCCCGGCTTTCCTACCCACCCAACTTCCTTAT


 


GACGATGCTGTTTGTGGGTCTGATGAGGTTTGCAACTGTGGTTTTGGGTTTGGTCAGCCTGAAAAATGTGGCGGTTT


 


CGTTTGCTGAGACGGTGAAGAGCTCCGCCCCCATCTTCACGGTGATCATGTCTCGGATGATTCTGGGGGAGTACACA


 


GGACGTCCCAGTGATCGGGAGGAGCGGGAAGAGCTTCAGCTACAACCAGGACGTGGTGCTGCTGCTTCTGACAGACG


 


GAGTCCTGTTCCACCTTCAGAGCGTCACGGCGTACGCCCTCATGGGGAAAATCTCCCCGGTGACTTTCAGGTCCCGC


 


AGGCCCTGCACCGAGTCGCCTTGTCCATGGCGCTGCCCTGCCCCATGCTTCCTGCGTCCTGAGTAGGAGGTATCTCC


 


GAGACAGGAAAAGTGGCCGCTCTCTCTCACTTTTTCTGGAACTCATGGTGGTCTCCTGGGCTTGGTCACTGTCTCTC


 


ACCAGCATGTTTCTTTGTGCGGTCAGGAATTATTTCCAAATGCTCCTGAAGCCTAGTGTTTTAGTGAACATTAGTGA


 


TTGTTAGCAGTGGTTCAAAAAAAAAAAACTTTTTTTTTTTTTTT


 


>gi|83921601|ref|NM_001037984.1| Homo sapiens solute carrier family 38,


member 10 (SLC38A10), transcript variant 1, mRNA


(SEQ ID NO: 39)



CGCCGCGGCGGCAGCTGAGTTGGGCTGAGGTGTCCCTAGCTGGCTCTGCGGCTCTTCCGGGTCTGGGCTCGGAGATT



 


CACAGGCGGCCCGCGAGGCCGAGCGAGGGACGCATGGCCCTGAGGCGGCCGCAGGGCTTGGCGGGGTCCGGAGGTTG


 


ACCTCGCCCCCGCAGCCGGCCTTCGAGGCTGCCTCCTCCAGGCAGCCTCTGGGGCCCGCGCCCGCGCCTGCTCAGGC


 


TCCCGTGTTCAGGCTGCCCATCCCCTCCCCACCGGCGTCCCGGACGTTGGGACCTGTGACCGTGGCCTCGGGCTGGG


 


CTTCCAAAGCCGGCCGCAGCCCGGCGACCCCCGAGGCCTCTCGCCCCGGGCCCCTAGACCTCTCACTATGACCGCGG


 


CCGCCGCCTCCAACTGGGGGCTGATCACGAACATCGTGAACAGCATCGTAGGGGTCAGTGTCCTCACCATGCCCTTC


 


TGCTTCAAACAGTGCGGCATCGTCCTGGGGGCGCTGCTCTTGGTCTTCTGCTCATGGATGACGCACCAGTCGTGCAT


 


GTTCTTGGTGAAGTCGGCCAGCCTGAGCAAGCGGAGGACCTACGCCGGCCTGGCATTCCACGCCTACGGGAAGGCAG


 


GCAAGATGCTGGTGGAGACCAGCATGATCGGGCTGATGCTGGGCACCTGCATCGCCTTCTACGTCGTGATCGGCGAC


 


TTGGGGTCCAACTTCTTTGCCCGGCTGTTCGGGTTTCAGGTGGGCGGCACCTTCCGCATGTTCCTGCTGTTCGCCGT


 


GTCGCTGTGCATCGTGCTCCCGCTCAGCCTGCAGCGGAACATGATGGCCTCCATCCAGTCCTTCAGCGCCATGGCCC


 


TCCTCTTCTACACCGTGTTCATGTTCGTGATCGTGCTCTCCTCTCTCAAGCACGGCCTCTTCAGTGGGCAGTGGCTG


 


CGGCGGGTCAGCTACGTCCGCTGGGAGGGCGTCTTCCGCTGCATCCCCATCTTCGGCATGTCCTTCGCCTGCCAGTC


 


CCAGGTGCTGCCCACCTACGACAGCCTGGATGAGCCGTCAGTGAAAACCATGAGCTCCATATTTGCTTCCTCCCTTA


 


ATGTGGTCACCACCTTCTACGTCATGGTGGGGTTTTTCGGCTACGTCAGCTTCACCGAGGCCACGGCCGGCAACGTG


 


CTCATGCACTTTCCCTCCAACCTGGTGACGGAGATGCTCCGTGTGGGCTTCATGATGTCAGTGGCTGTGGGCTTCCC


 


CATGATGATCCTGCCATGCAGGCAGGCCCTGAGCACGCTGCTGTGTGAGCAGCAGCAAAAAGATGGCACCTTTGCAG


 


CAGGGGGCTACATGCCCCCTCTCCGGTTTAAAGCACTTACCCTCTCTGTGGTGTTTGGAACCATGGTTGGTGGCATC


 


CTTATCCCCAACGTGGAGACCATCCTGGGCCTCACAGGAGCGACCATGGGAAGCCTCATCTGCTTCATCTGCCCGGC


 


GCTGATCTACAAGAAAATCCACAAGAACGCACTTTCCTCCCAGGTGGTGCTGTGGGTCGGCCTGGGCGTCCTGGTGG


 


TGAGCACTGTCACCACACTGTCTGTGAGCGAGGAGGTCCCCGAGGACTTGGCAGAGGAAGCCCCTGGCGGCCGGCTT


 


GGAGAGGCCGAGGGTTTGATGAAGGTGGAGGCAGCGCGGCTCTCAGCCCAGGATCCGGTTGTGGCCGTGGCTGAGGA


 


TGGCCGGGAGAAGCCGAAGCTGCCGAAGGAGAGAGAGGAGCTGGAGCAGGCCCAGATCAAGGGGCCCGTGGATGTGC


 


CTGGACGGGAAGATGGCAAGGAGGCACCGGAGGAGGCACAGCTCGATCGCCCTGGGCAAGGGATTGCTGTGCCTGTG


 


GGCGAGGCCCACCGCCACGAGCCTCCTGTTCCTCACGACAAGGTGGTGGTAGATGAAGGCCAAGACCGAGAGGTGCC


 


AGAAGAGAACAAACCTCCATCCAGACACGCGGGCGGAAAGGCTCCAGGGGTCCAGGGCCAGATGGCGCCGCCTCTGC


 


CCGACTCAGAAAGAGAGAAACAAGAGCCGGAGCAGGGAGAGGTTGGGAAGAGGCCTGGACAGGCCCAGGCCTTGGAG


 


GAGGCGGGTGATCTTCCTGAAGATCCCCAGAAAGTTCCAGAAGCAGATGGTCAGCCAGCTGTCCAGCCTGCAAAGGA


 


GGACCTGGGGCCAGGAGACAGGGGCCTGCATCCTCGGCCCCAGGCAGTGCTGTCTGAGCAGCAGAACGGCCTGGCGG


 


TGGGTGGAGGGGAAAAGGCCAAGGGGGGACCGCCGCCAGGCAACGCCGCCGGGGACACAGGGCAGCCCGCAGAGGAC


 


AGCGACCACGGTGGGAAGCCTCCCCTCCCAGCGGAGAAGCCGGCTCCAGGGCCTGGGCTGCCGCCCGAGCCTCGCGA


 


GCAGAGGGACGTGGAGCGAGCGGGTGGAAACCAGGCGGCCAGCCAGCTGGAGGAAGCTGGCAGGGCGGAGATGCTGG


 


ACCACGCCGTCCTGCTTCAGGTGATCAAAGAACAGCAGGTGCAGCAAAAGCGCTTGCTGGACCAGCAGGAGAAGCTG


 


CTGGCGGTGATCGAGGAGCAGCACAAGGAGATCCACCAGCAGAGGCAGGAGGACGAGGAGGATAAACCCAGGCAGGT


 


GGAGGTGCATCAAGAGCCCGGGGCAGCGGTGCCCAGAGGCCAGGAGGCCCCTGAAGGCAAGGCCAGGGAGACGGTGG


 


AGAATCTGCCTCCCCTGCCTTTGGACCCTGTCCTCAGAGCTCCTGGGGGCCGCCCTGCTCCATCCCAGGACCTTAAC


 


CAGCGCTCCCTGGAGCACTCTGAGGGGCCTGTGGGCAGAGACCCTGCTGGCCCTCCTGACGGCGGCCCTGACACAGA


 


GCCTCGGGCAGCCCAGGCCAAGCTGAGAGATGGCCAGAAGGATGCCGCCCCCAGGGCAGCTGGCACTGTGAAGGAGC


 


TCCCCAAGGGCCCGGAGCAGGTGCCCGTGCCAGACCCCGCCAGGGAAGCCGGGGGCCCAGAGGAGCGCCTCGCAGAG


 


GAATTCCCTGGGCAAAGTCAGGACGTTACTGGCGGTTCCCAAGACAGGAAAAAACCTGGGAAGGAGGTGGCAGCCAC


 


TGGCACCAGCATTCTGAAGGAAGCCAACTGGCTCGTGGCAGGGCCAGGAGCAGAGACGGGGGACCCTCGCATGAAGC


 


CCAAGCAAGTGAGCCGAGACCTGGGCCTTGCAGCGGACCTGCCCGGTGGGGCGGAAGGAGCAGCTGCACAGCCCCAG


 


GCTGTGTTACGCCAGCCGGAACTGCGGGTCATCTCTGATGGCGAGCAGGGTGGACAGCAGGGCCACCGGCTGGACCA


 


TGGCGGTCACCTGGAGATGAGAAAGGCCCGCGGGGGGGACCATGTGCCTGTGTCCCACGAGCAGCCGAGAGGCGGGG


 


AGGACGCTGCTGTCCAGGAGCCCAGGCAGAGGCCAGAGCCAGAGCTGGGGCTCAAACGAGCTGTCCCGGGGGGCCAG


 


AGGCCGGACAATGCCAAGCCCAACCGGGACCTGAAACTGCAGGCTGGCTCCGACCTCCGGAGGCGACGGCGGGACCT


 


TGGCCCTCATGCAGAGGGTCAGCTGGCCCCGAGGGATGGGGTCATCATTGGCCTTAACCCCCTGCCTGATGTCCAGG


 


TGAACGACCTCCGTGGCGCCCTGGATGCCCAGCTCCGCCAGGCTGCGGGGGGAGCTCTGCAGGTGGTCCACAGCCGG


 


CAGCTTAGACAGGCGCCTGGGCCTCCAGAGGAGTCCTAGCACCTGCTGGCCATGAGGGCCACGCCAGCCACTGCCCT


 


CCTCGGCCAGCAGCAGGTCTGTCTCAGCCGCATCCCAGCCAAACTCTGGAGGTCACACTCGCCTCTCCCCAGGGTTT


 


CATGTCTGAGGCCCTCACCAAGTGTGAGTGACAGTATAAAAGATTCACTGTGGCATCGTTTCCAGAATGTTCTTGCT


 


GTCGTTCTGTTGCAGCTCTTAGTCTGAGGTCCTCTGACCTCTAGACTCTGAGCTCACTCCAGCCTGTGAGGAGAAAC


 


GGCCTCCGCTGCGAGCTGGCTGGTGCACTCCCAGGCTCAGGCTGGGGAGCTGCTGCGTCTGTGGTCAGGCCTCCTGC


 


TCCTGCCAGGGAGCACGCGTGGTCTTCGGGTTGAGCTCGGCCGTGCGTGGAGGTGCGCATGGCTGCTCATGGTCCCA


 


ACACAGGCTACTGTGAGAGCCAGCATCCAACCCCACGCTTGCAGTGACTCAGAATGATAATTATTATGACTGTTTAT


 


CGATGCTTCCCACAGTGTGGTAGAAAGTCTTGAATAAACACTTTTGCCTTCACCCAGAAAAAAAAAAA


 


>gi|27735136|ref|NM_173512.1| Homo sapiens solute carrier family 38, member


11 (SLC38A11), mRNA


(SEQ ID NO: 40)



AGAAACATCCTGCAGCATCTCCGTCTCCGGAGGAAAAATACATTTGTCTGGGCGAACTCCGGTGGAAAAGCGCCCCA



 


GGCTGCCACAGCCTAGAGATCTTGGGGCTGCAGCCCTCGCGGCCTGCCGAGGGAGCAGGGGGCGCCCGTGGAACTGG


 


CTCCCTGCAGCTCTGCGGCTACACGCGGACCTCGGCTGTGTGCGAGGTGGCGGAGGAGGCTGGCCGGGTGCGAATCC


 


GTACCCAGCCCCAGCATCTTCCACCTGCTGAGGACCACCGCTCAGCCATGGGCTACCAGAGGCAGGAGCCTGTCATC


 


CCGCCGCAGGATTGCCTTATTCAATGAAGCAAGCTGGGTTTCCTTTGGGAATATTGCTTTTATTCTGGGTTTCATAT


 


GTTACAGACTTTTCCCTTGTTTTATTGATAAAAGGAGGGGCCCTCTCTGGAACAGATACCTACCAGTCTTTGGTCAA


 


TAAAACTTTCGGCTTTCCAGGGTATCTGCTCCTCTCTGTTCTTCAGTTTTTGTATCCTTTTATAGTTGATCCTGAAA


 


ACGTGTTTATCGGTCGCCACTTCATTATTGGACTTTCCACAGTTACCTTTACTCTGCCTTTATCCTTGTACCGAAAT


 


ATAGCAAAGCTTGGAAAGGTCTCCCTCATCTCTACAGGTTTAACAACTCTGATTCTTGGAATTGTAATGGCAAGGGC


 


AATTTCACTGGGTCCACACATACCAAAAACAGAAGACGCTTGGGTATTTGCAAAGCCCAATGCCATTCAAGCGGTCG


 


GGGTTATGTCTTTTGCATTTATTTGCCACCATAACTCCTTCTTAGTTTACAGTTCTCTAGAAGAACCCACAGTAGCT


 


AAGTGGTCCCGCCTTATCCATATGTCCATCGTGATTTCTGTATTTATCTGTATATTCTTTGCTACATGTGGATACTT


 


GACATTTACTGGCTTCACCCAAGGGGACTTATTTGAAAATTACTGCAGAAATGATGACCTGGTAACATTTGGAAGAT


 


TTTGTTATGGTGTCACTGTCATTTTGACATACCCTATGGAATGCTTTGTGACAAGAGAGGTAATTGCCAATGTGTTT


 


TTTGGTGGGAATCTTTCATCGGTTTTCCACATTGTTGTAACAGTGATGGTCATCACTGTAGCCACGCTTGTGTCATT


 


GCTGATTGATTGCCTCGGGATAGTTCTAGAACTCAATGGTGTGCTCTGTGCAACTCCCCTCATTTTTATCATTCCAT


 


CAGCCTGTTATCTGAAACTGTCTGAAGAACCAAGGACACACTCCGATAAGATTATGTCTTGTGTCATGCTTCCCATT


 


GGTGCTGTGGTGATGGTTTTTGGATTCGTCATGGCTATTACAAATACTCAAGACTGCACCCATGGGCAGGAAATGTT


 


CTACTGCTTTCCTGACAATTTCTCTCTCACAAATACCTCAGAGTCTCATGTTCAGCAGACAACACAACTTTCTACTT


 


TAAATATTAGTATCTTTCAATGAGTTGACTGCTTTAAAAATATGTATGTTTTCATAGACTTTAAAACACATAACATT


 


TACGCTTGCTTTAGTCTGTATTTATGTTATATAAAATTATTATTTTGGCTTTTATCAAGACTTGGCTTTTATGAGTA


 


GTGC


 


>gi|56549672|ref|NM_001008485.1| Homo sapiens solute carrier family 41,


member 3 (SLC41A3), transcript variant 1, mRNA


(SEQ ID NO: 41)



CCCGGGCCCCCGGCGGGGCTCTGCGCTGCCGGAGCTTGGGCGTCTGCTGCTGTCCCGGAGCGCCAAGTCGTCCGAGG



 


TCCGGCCGCCCGGCCGGGGCGGGGCCAGGGAGGCCCGGCCTTCCCGCTTCCTGCCTGAGCCGCAGGCCCGCCCCTGC


 


GTCCTCCGCCCGCCTCTTTCCCGCCGCCGCCTGGGAGGGGACCCGGGCTGCCAGGCGCCCAGCTGTGCCCAGATGGA


 


TGGGACAGAGACCCGGCAGCGGAGGCTGGACAGCTGTGGCAAGCCAGGGGAGCTGGGGCTTCCTCACCCCCTCAGCA


 


CAGGAGGACTCCCTGTAGCCTCAGAAGATGGAGCTCTCAGGGCCCCTGAGAGCCAAAGCGTGACCCCCAAGCCACTG


 


GAGACTGAGCCTAGCAGGGAGACCGCCTGGTCCATAGGCCTTCAGGTGACCGTGCCCTTCATGTTTGCAGGCCTGGG


 


ACTGTCCTGGGCCGGCATGCTTCTGGACTATTTCCAGCACTGGCCTGTGTTTGTGGAGGTGAAAGACCTTTTGACAT


 


TGGTGCCGCCCCTGGTGGGCCTGAAGGGGAACCTGGAGATGACACTGGCATCCAGACTCTCCACAGCTGCCAACACT


 


GGACAAATTGATGACCCCCAGGAGCAGCACAGAGTCATCAGCAGCAACCTGGCCCTCATCCAGGTGCAGGCCACTGT


 


CGTGGGGCTCTTGGCTGCTGTGGCTGCGCTGCTGTTGGGCGTGGTGTCTCGAGAGGAAGTGGATGTCGCCAAGGTGG


 


AGTTGCTGTGTGCCAGCAGTGTCCTCACTGCCTTCCTTGCAGCCTTTGCCCTGGGGGTGCTGATGGTCTGTATAGTG


 


ATTGGTGCTCGAAAGCTCGGGGTCAACCCAGACAACATTGCCACGCCCATTGCAGCCAGCCTGGGAGACCTCATCAC


 


ACTGTCCATTCTGGCTTTGGTTAGCAGCTTCTTCTACAGACACAAAGATAGTCGGTATCTGACGCCGCTGGTCTGCC


 


TCAGCTTTGCGGCTCTGACCCCAGTGTGGGTCCTCATTGCCAAGCAGAGCCCACCCATCGTGAAGATCCTGAAGTTT


 


GGCTGGTTCCCAATCATCCTGGCCATGGTCATCAGCAGTTTCGGAGGACTCATCTTGAGCAAAACCGTTTCTAAACA


 


GCAGTACAAAGGCATGGCGATATTTACCCCCGTCATATGTGGTGTTGGTGGCAATCTGGTGGCCATTCAGACCAGCC


 


GAATCTCAACCTACCTGCACATGTGGAGTGCACCTGGCGTCCTGCCCCTCCAGATGAAGAAATTCTGGCCCAACCCG


 


TGTTCTACTTTCTGCACGTCAGAAATCAATTCCATGTCAGCTCGAGTCCTGCTCTTGCTGGTGGTCCCAGGCCATCT


 


GATTTTCTTCTACATCATCTACCTGGTGGAGGGTCAGTCAGTCATAAACAGCCAGACCTTTGTGGTGCTCTACCTGC


 


TGGCAGGCCTGATCCAGGTGACAATCCTGCTGTACCTCGCAGAAGTGATGGTTCGGCTGACTTGGCACCAGGCCCTG


 


GATCCTGACAACCACTGCATCCCCTACCTTACAGGGCTGGGGGACCTGCTCGGTTCAAGCTCCGTGGGCCACACTGC


 


TGCTGTGCCAAGAAGGTGTACAGCCTCCCCAGGATGGGGCCTCATACAACCCTTCATCTGCACTCAACATTTAATCG


 


TGTCCTTGCTGTCTTTTTATTTTCCTTTTTGTTTGTTAGCAAAAACCTCTATTTAGATTTCAATAATCAGAGAAGTG


 


TAAAATAAAACAGATTATATTGTACTTGAAAAAA


 


>gi|148612886|ref|NM_025257.2| Homo sapiens solute carrier family 44, member


4 (SLC44A4), mRNA


(SEQ ID NO: 42)



AGGGCGGGGCGGGCAGCAGGTGAGACGCCAGGTCTCCAGGGCTCCAATCACTCCGGAGACTGAGCCATGGGGGGAAA



 


GCAGCGGGACGAGGATGACGAGGCCTACGGGAAGCCAGTCAAATACGACCCCTCCTTTCGAGGCCCCATCAAGAACA


 


GAAGCTGCACAGATGTCATCTGCTGCGTCCTCTTCCTGCTCTTCATTCTAGGTTACATCGTGGTGGGGATTGTGGCC


 


TGGTTGTATGGAGACCCCCGGCAAGTCCTCTACCCCAGGAACTCTACTGGGGCCTACTGTGGCATGGGGGAGAACAA


 


AGATAAGCCGTATCTCCTGTACTTCAACATCTTCAGCTGCATCCTGTCCAGCAACATCATCTCAGTTGCTGAGAACG


 


GCCTACAGTGCCCCACACCCCAGGTGTGTGTGTCCTCCTGCCCGGAGGACCCATGGACTGTGGGAAAAAACGAGTTC


 


TCACAGACTGTTGGGGAAGTCTTCTATACAAAAAACAGGAACTTTTGTCTGCCAGGGGTACCCTGGAATATGACGGT


 


GATCACAAGCCTGCAACAGGAACTCTGCCCCAGTTTCCTCCTCCCCTCTGCTCCAGCTCTGGGGCGCTGCTTTCCAT


 


GGACCAACGTTACTCCACCGGCGCTCCCAGGGATCACCAATGACACCACCATACAGCAGGGGATCAGCGGTCTTATT


 


GACAGCCTCAATGCCCGAGACATCAGTGTTAAGATCTTTGAAGATTTTGCCCAGTCCTGGTATTGGATTCTTGTTGC


 


CCTGGGGGTGGCTCTGGTCTTGAGCCTACTGTTTATCTTGCTTCTGCGCCTGGTGGCTGGGCCCCTGGTGCTGGTGC


 


TGATCCTGGGAGTGCTGGGCGTGCTGGCATACGGCATCTACTACTGCTGGGAGGAGTACCGAGTGCTGCGGGACAAG


 


GGCGCCTCCATCTCCCAGCTGGGTTTCACCACCAACCTCAGTGCCTACCAGAGCGTGCAGGAGACCTGGCTGGCCGC


 


CCTGATCGTGTTGGCGGTGCTTGAAGCCATCCTGCTGCTGATGCTCATCTTCCTGCGGCAGCGGATTCGTATTGCCA


 


TCGCCCTCCTGAAGGAGGCCAGCAAGGCTGTGGGACAGATGATGTCTACCATGTTCTACCCACTGGTCACCTTTGTC


 


CTCCTCCTCATCTGCATTGCCTACTGGGCCATGACTGCTCTGTACCTGGCTACATCGGGGCAACCCCAGTATGTGCT


 


CTGGGCATCCAACATCAGCTCCCCCGGCTGTGAGAAAGTGCCAATAAATACATCATGCAACCCCACGGCCCACCTTG


 


TGAACTCCTCGTGCCCAGGGCTGATGTGCGTCTTCCAGGGCTACTCATCCAAAGGCCTAATCCAACGTTCTGTCTTC


 


AATCTGCAAATCTATGGGGTCCTGGGGCTCTTCTGGACCCTTAACTGGGTACTGGCCCTGGGCCAATGCGTCCTCGC


 


TGGAGCCTTTGCCTCCTTCTACTGGGCCTTCCACAAGCCCCAGGACATCCCTACCTTCCCCTTAATCTCTGCCTTCA


 


TCCGCACACTCCGTTACCACACTGGGTCATTGGCATTTGGAGCCCTCATCCTGACCCTTGTGCAGATAGCCCGGGTC


 


ATCTTGGAGTATATTGACCACAAGCTCAGAGGAGTGCAGAACCCTGTAGCCCGCTGCATCATGTGCTGTTTCAAGTG


 


CTGCCTCTGGTGTCTGGAAAAATTTATCAAGTTCCTAAACCGCAATGCATACATCATGATCGCCATCTACGGGAAGA


 


ATTTCTGTGTCTCAGCCAAAAATGCGTTCATGCTACTCATGCGAAACATTGTCAGGGTGGTCGTCCTGGACAAAGTC


 


ACAGACCTGCTGCTGTTCTTTGGGAAGCTGCTGGTGGTCGGAGGCGTGGGGGTCCTGTCCTTCTTTTTTTTCTCCGG


 


TCGCATCCCGGGGCTGGGTAAAGACTTTAAGAGCCCCCACCTCAACTATTACTGGCTGCCCATCATGACCTCCATCC


 


TGGGGGCCTATGTCATCGCCAGCGGCTTCTTCAGCGTTTTCGGCATGTGTGTGGACACGCTCTTCCTCTGCTTCCTG


 


GAAGACCTGGAGCGGAACAACGGCTCCCTGGACCGGCCCTACTACATGTCCAAGAGCCTTCTAAAGATTCTGGGCAA


 


GAAGAACGAGGCGCCCCCGGACAACAAGAAGAGGAAGAAGTGACAGCTCCGGCCCTGATCCAGGACTGCACCCCACC


 


CCCACCGTCCAGCCATCCAACCTCACTTCGCCTTACAGGTCTCCATTTTGTGGTAAAAAAAGGTTTTAGGCCAGGCG


 


CCGTGGCTCACGCCTGTAATCCAACACTTTGAGAGGCTGAGGCGGGCGGATCACCTGAGTCAGGAGTTCGAGACCAG


 


CCTGGCCAACATGGTGAAACCTCCGTCTCTATTAAAAATACAAAAATTAGCCGAGAGTGGTGGCATGCACCTGTCAT


 


CCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCGGGAGGCAGAGGTTGCAGTGAGCCGAGATCGCGC


 


CACTGCACTCCAACCTGGGTGACAGACTCTGTCTCCAAAACAAAACAAACAAACAAAAAGATTTTATTAAAGATATT


 


TTGTTAACTCAGTAAAAAAAAAAAA


 


>gi|148536860|ref|NM_006933.4| Homo sapiens solute carrier family 5 (inositol


transporters), member 3 (SLC5A3), mRNA


(SEQ ID NO: 43)



CGGACCGTGCTTTCGCCGCCTGGGAGCCGTCCGGCGCAGCAGTTTCTAGGTCCCCACTGTCCCCGCCGTCCCGCCCC



 


TTCGCGTCCCGGGAACCGGCTGGCTTCCGAGCCGCACTCGCCGATCCTCCAGGCATGCCCCGCTACGAGCTGGCTTT


 


AATCCTGAAAGCCATGCAGCGGGGTTGGTACAGTAGGCTTCACTAGACTTAGCTGCAACTCAGAATTTCTCCTCCAG


 


CACCTGAGTAAATGCTGATGGTCTTGTGGAGAGTGGATTAAGAGTACGAGCTAAGTTCTCAATCCCAATTAAGAAGC


 


GGAAAATTTAAACTGTCTTCTTCAAAGTTTATCACAACCACCACCATCAAGACAGCAAACCAAAGGACAAAGACTTT


 


GACCCTGCTGTGTTGCTCTGTGTAGTCCAGTTCACGTATGGTTTACAGACTTGGCTGGGGTTACTAAAAATAAATAA


 


AAAGTTGGACACTTCTGTCATTGGAGCGCTATTATTCACAAGTTACCAGAATGAGAGCTGTACTGGACACAGCAGAC


 


ATTGCCATAGTGGCCCTGTATTTTATCCTGGTCATGTGCATTGGTTTTTTTGCCATGTGGAAATCTAATAGAAGCAC


 


CGTGAGTGGATACTTCCTGGCGGGGCGCTCTATGACCTGGGTAACAATTGGTGCCTCTCTGTTTGTGAGCAATATTG


 


GGAGTGAGCACTTCATTGGGCTGGCAGGATCTGGAGCTGCAAGTGGATTTGCAGTGGGCGCATGGGAATTCAATGCC


 


TTACTGCTTTTACAACTTCTGGGATGGGTTTTCATCCCAATTTACATCCGGTCAGGGGTATATACCATGCCTGAATA


 


CTTGTCCAAGCGATTTGGTGGCCATAGGATTCAGGTCTATTTTGCAGCCTTGTCTCTGATTCTCTATATTTTCACCA


 


AGCTCTCGGTGGATCTGTATTCGGGTGCCCTTTTTATCCAGGAGTCTTTGGGTTGGAATCTTTATGTGTCTGTCATC


 


CTGCTCATTGGCATGACTGCTTTGCTGACTGTCACCGGAGGCCTTGTTGCAGTGATCTACACAGACACTCTGCAGGC


 


TCTGCTCATGATCATTGGGGCACTTACACTTATGATTATTAGCATAATGGAGATTGGCGGGTTTGAGGAAGTTAAGA


 


GAAGGTACATGTTGGCCTCACCCGATGTCACTTCCATCTTATTGACATACAACCTTTCCAACACAAATTCTTGTAAT


 


GTCTCCCCTAAGAAAGAAGCCCTGAAAATGCTGCGGAATCCAACAGATGAAGATGTTCCTTGGCCTGGATTCATTCT


 


TGGGCAGACCCCAGCTTCAGTATGGTACTGGTGTGCTGACCAAGTCATCGTGCAGAGGGTCCTTGCAGCCAAAAACA


 


TTGCTCATGCCAAAGGCTCTACTCTTATGGCTGGCTTCTTAAAGCTCCTGCCAATGTTTATCATAGTTGTCCCAGGA


 


ATGATTTCCAGGATACTGTTTACTGATGATATAGCTTGCATCAACCCAGAGCACTGCATGCTGGTGTGTGGAAGCAG


 


AGCTGGTTGCTCCAATATTGCTTACCCACGCCTGGTGATGAAGCTGGTTCCTGTGGGCCTTCGGGGTTTAATGATGG


 


CAGTGATGATTGCAGCTCTGATGAGTGACTTAGACTCTATCTTTAACAGTGCCAGTACCATATTCACCCTCGATGTG


 


TACAAACTTATCCGCAAGAGCGCAAGCTCCCGGGAGTTAATGATTGTGGGGAGGATATTTGTGGCATTTATGGTGGT


 


GATCAGCATAGCATGGGTGCCAATCATCGTGGAGATGCAAGGAGGCCAGATGTACCTTTACATTCAGGAGGTAGCAG


 


ATTACCTGACACCCCCAGTGGCAGCCTTGTTCCTGCTGGCAATTTTCTGGAAGCGCTGCAATGAACAAGGGGCTTTC


 


TATGGTGGAATGGCTGGCTTTGTTCTTGGAGCAGTCCGTTTGATACTGGCCTTTGCCTACCGTGCCCCAGAATGTGA


 


CCAACCTGATAATAGGCCGGGCTTCATCAAAGACATCCATTATATGTATGTGGCCACAGGATTGTTTTGGGTCACGG


 


GACTCATTACTGTAATTGTGAGCCTTCTCACACCACCTCCCACAAAGGAACAGATTCGAACCACCACCTTTTGGTCT


 


AAGAAGAACCTGGTGGTGAAGGAGAACTGCTCCCCAAAAGAGGAACCATACCAAATGCAAGAAAAGAGCATTCTGAG


 


ATGCAGTGAGAATAATGAGACCATCAACCACATCATTCCCAACGGGAAATCTGAAGACAGCATTAAGGGCCTTCAGC


 


CTGAAGATGTTAATCTGTTGGTAACCTGCAGAGAGGAGGGCAACCCAGTGGCATCCTTAGGTCATTCAGAGGCAGAA


 


ACACCAGTTGACGCTTACTCCAATGGGCAAGCAGCTCTCATGGGTGAGAAAGAGAGAAAGAAAGAAACGGATGATGG


 


AGGTCGGTACTGGAAGTTCATAGACTGGTTTTGTGGCTTTAAAAGTAAGAGCCTCAGCAAGAGGAGTCTCAGAGACC


 


TGATGGAAGAGGAGGCTGTTTGTTTACAGATGCTAGAAGAGACTCGGCAAGTTAAAGTAATACTAAATATTGGACTT


 


TTTGCTGTGTGTTCACTTGGAATTTTCATGTTTGTTTATTTCTCCTTATGAACTTAAGGATATGGTGAGACACTAAC


 


TTAAGACAATACTGACTGGTCTTTGGGGAAAAAAGTTATGTAACTGTGCATCTCTCAGGCATTGTTTACGCTGTAGG


 


TTTTAGCCAAATTTTACTTAGCAGAAAATCATCTAATTACAAGACTTTATTTTCCCAGAGATGGATTAAAGTAAATC


 


TTCAACTTAAGTGAAGCCAAACCTAACAGACTGAATTGTGCAAATGTGGTTTTAAATTTTGCATACCAAAGTAAGAA


 


GAGACCAATTATTCTCACAGAGCACTTAGAGCAGAATATATGTTAAGTTACCATGAATTAAGGTATACTGTCTGCAC


 


TGCCAAGTCTTGGCAGACCTTACCCTGAAGTAGAAGATTTGCTCATTTCTAAAGTTTTTTTTCTGTCTCTGTAATCC


 


CTCCTACCATTAAGAAAAACTTATTTCTTAGACATTGTACAATCAGTTATGTACTGAAAATCGAATGTGCTTGTGTG


 


ATACTTGTTTCAGGACAAGTTCATTTGCCAGGTTCATTTTGTTAGCATGAGCCTACGGATTCTGATTTCCCAAAGAA


 


AGAATGTTTTCCTGTAGGTATTTTTGTACCACCAGTATATGGAATGTTAGGGAAAAACTTTGTTCCAGTTCCTTTTT


 


TTTTTTCTTTCTACTTTCAAGTTTAAGTGAACCATACTGAAATGACCAACAAGTCTGCCTGTAAAGTTACATGTCAT


 


GATTGTGTTGTTAAATGATTATGGGGGAGAAAATGAAGTAAATGTTGCTGATGATCCCCATATTTATTGATCATATT


 


AAGGTTGTTTATATAGTTTGGAAATGACCAGCCCCCTAAGCAGTGTTTGATTAACTTATGCTAATCAGATGATTACT


 


CATATATTCTGCTAATTTTCTAGCTTTATTCTTGTTATTTGGAAAAATTATTAGCCAAATGCCTTCCTAGGTGGATC


 


CAGTTGGAAGATATGTCCAGAAACCTGAAGAAAAATTGACGCTGCCTTTGTGTGCTGGATTGCTCTACTTGATTAGA


 


TCATGATATATCAAGGTTGAATTTTTAGAGGGAAAATTTAATTCTGATATCTTATTGCATCCTTGATAAGTTTTTCC


 


CTGATTTTTTTTTTCCTCAAAAGACTTTCCATCTGTACACAGCCTCTACATTTTTGTTGTAGTGACTTAGAGCATAA


 


GGATGTTTCAGTGCAAACTGGCCGTCGGTAACAGAAAACTCAGTGCATACTTTGCTGTTGTTAGGTTGTCAATATAG


 


TCTTTCTGTAGGATGGATAGCATGTTTGAGAGGTGCCAAACAAGAACTTTTGGGGTTAGTAGTGTGTCTTGTGGAGG


 


GTATTACAGGACTGTGTAATTATAGGACTCTAACTTGACATGGCTTGGCACCCACTTGCAGCTAGTGGGTACAGGGT


 


ACAAAAGATGTTAGAGAAAAGCTCTACAGATTACGTACTTCTGTGTCTTCGTATGCTCAACACTGTCCTTTGTCCTC


 


CATGAAAGATGAAGGAAGCAAATTATGTATGTACTTTCTTTGACCTTCTTTAATCTCTGATACTTTTTAGATTGCAT


 


GATTTTACTAGGCTTGTATTTAGGGAAATTACTTTCATAAATACTTTTGTAGATTTTGAATCAAAACTCAGTCTTTT


 


TAATTTTTTTGTAGTCTATAAACTAGTTTCATTATGATGGACTTGATTAGTCCAAAGTTAATTTTAGAAATTGTCAG


 


GTAGCATAGTGTCTTCCCATGATCAGGAGGCTTTCTGAAGGACTGAGTCTGTAAATGAAAAAATAATTTATGTATGA


 


ATAGCATGTATTTCTGAAGAGCTTAGAGTGCCTTGTAGAATTTTTTTCTCAATTTTATTCTTGAGGTTTATAATTTG


 


GGGGCCAAATAGATAGAGCTCATCATTTTCTTGTTTGGAAGTTGAGGCTGCGACATGTCCAAGGTTATGAAGTCTCT


 


TTTGGGAAGAACAGAAACCAGGTCTCCAAATCTGGACTCATGGTTTGTTCAGATGTGTCTGGACAAATGGTTGTCAA


 


TGTTTTGTCCTGTTTTTTCAAAGGAACTGTTCTTCCTTTGGGACAACCTTTTGGTGTTTGGGAAAGTAATAAGATCT


 


TGGATTTTTCAAATTAACATTAAGTTGTAAGAACTAAAATTTTCTTTGAACCACATTACTGTGTAATTCACTGATAA


 


TTGACATATTGGCTGGGCAGCCTATCTCTTCCATATCCAGCGTAAATGAATAGGAGGTGTTTGTGATTTTTTTTTTC


 


TCCCTTTATTTAACATTGAGTCCTAGTAGTTTGGAGAATTAGGGTCCCTCTACCTTCTTTCTGCTCTTGTCTTAGTA


 


AGATACATAAGGTACATCATCTTGTGTCTGTGTGTATATAGCAGTAGGTCAAGTTTAGAGTACTAAAGTCTGTAAAT


 


AAGGAATGACTATTAGCATATTCATTAGAATTGTTTATTCTTGCCAGTATAAACATCATTTTATTTAGACTAAAGTC


 


CCTGAAGCTTGTCTTTCTTATTGCTTCCCAGTAATAGATAATGTGCTCGAGTAAGTTTGTGAATTGCTGATTGCAAC


 


TTAATTCAGGGACCAGTCTTCAATCTATATTTCATTAGAATGATTGTTCCTGGAATGATCATACATGGACTGTCTTA


 


AGCTAGCAAAATGTTCATACTTTACACTGACTAAATGGGTCCTAAATGATGACATTGGTCTTTAGACATTAACATGT


 


GTATATTTTTATATTAGCTCAAGCTAAGGTTCAGAATTGAAGCTTGATATTGACTAGAATAGCTAAAAGTCAAAATG


 


AGGTGAGGACACTGGTCTTGGAAGGTAGAGAAAAATAAATGTCTTACCAGGTGTTAATGGTATCCCCAGTTCTTAGA


 


CTTTTGTCTTCTCAGGCAATTTTCATCTCAAGATCTGATGAGAAGGGCATATTACATTGGTATGCAGGATGATTATT


 


GCATATTTTGTGGGACCTCTAATTTCCCTGGTCATCTTTCAGAATATTCTGTTCTGCCACCCCCAGAGAGTAAACAC


 


TTGAGCCGATTTCTTCTTCCCCAGCTATTCTTTCCTGGGGGTAATTATGCTTTGTCTTTAGATTAGAGAAGCATCAA


 


GCAATAGCAATGGTGCTGTGTCCTTCGGCCTAAATTCAATAGATCTCATCTCCTAGGGCTTCCTTTTCACTTGGCTC


 


AAAGGATCCATTGTATTTTGGCACAAAGAGCCTGGCCAGGGTCATGTAGCCATAGCTCTTAGGGATGATACCTCAAG


 


AAATTAGCTGGGACCCATCACTCTGTGAAACTTCACATTTTAAGAACTGAGTTGAGGGGGTTGTTATGCACTTCTGT


 


AACTTGAGGCTAAGCAAGGGGTTAACTCTTGTGAGAGCCAATAGAGTGTGTCTGTATTCGCAGTCCATGGCTCATTT


 


TCTTTATAGTAGGCATATGGATCTTCCCCTCTGACTTTGAATATCATTTGGTGTGGCCTGTGGGTTATTTTCATTCT


 


TTACCACCAAATAAAGCGGCTTATTAGCTACTCAGTTACTTGCTACTCAAAGGTTAGGTCTTCCCTGTTCCTGCTTG


 


GCAGTGTTAAAGCTTACAGGGTTAACTTATGATGATTCTCCTGGCTCATTTTCATCAGAGGCATGATGACTGGAAAG


 


GGATCACATGGGTCGTTGGTGGTGACACCTCACTGTTTCCTAGGTTTGGATAGAGAGATGTATACAAGACCTTTCCT


 


GTTAAATTACGTGACTACAGAGACTTGCCAGGACAAAATTTTCCTAAGAAATCAGAAAAATGATTAAGTGAGATAAG


 


TACCTGGGTGACACAGATATTAGCCCGTTGGTAAAAGACAACAAATATTAGCTTAAAATCTGCATATGTAGAATCAT


 


TTTCATTAGATTTAGAGCTTGAAGCACCTTGGCTCTCAGCTACTTTAAACTCCTCCCCATATAAATCAGGGCACCAA


 


TAAATAAGTTTCAGCTTTTTAAACCCTGGTTTGATGTTAAGCATTATAAAGTACGAAGTTTGTTACCACAGTAGAGA


 


TAATTTAGTAGAAAAATGCTTTGAGGCTTCAGTATTTGTAAGATTTTGCATTAGCCAGATGCTAGGTTGTTGAAGGC


 


ATTTCAGTGTTGATAATAGCCTGAGCAGACTTCTTTACAAATGGGATCTGTTTCTATATGTGTATATGCCCACTTAC


 


CATTCAGAGAGACTGGTCTTTCTCTTTGTCTTCCTTCACATTGCTGTGTCAGTTCTACACCTAGTCTTTTCAGCACT


 


TAGCAAATTCAAATTTTGATTTTTTTGTCAGCTTAGTTCACTTTAAGGCATATTGGCATGGTGTGTGAAAGTGATGT


 


TTTGCCCCAGTATTGAGGACTTTTAGATCCAAATAATGACTCATTAAATATAATTATGTTTTAAGTATACTGAATTT


 


CTGTTAGCTTAAAATGTTAATTCTCAGGAATGATTTTCTCACACTTTGTGTTGGCTAATAATAAAAGCACTGTTTTA


 


TTCTCAAAACTCCTTTTTCAAAAATTAGGGAGAGAGCAGTAGTGATCATTTATGTGAGCCCCTTTGAAATGATGGTG


 


TCAGAGTGCAGAGAAACAATGGAGTTTTGATGCCAAAAAGGTTTTTTTGCAGTAAAAGTAAAAATTTGGAATTAGTT


 


GGCATATAGAGGAACCCTTTTGTACTGGAACGTATGAGGCTGGATTGTGAAAAGGTAATCTTTCGATTGCTAGACTT


 


GGTTAACTTAGGGCTGCAAATCTTTTTCTTCTGTCAAGGTCACTTAATATGGAATGTTTTTGTCAGACTGTCCTTTG


 


TTGGAATACTTTAGCTGTTCAGCTACTTTGACTCCTAGGAGAGAATTTAGTTAAGGTTCAAAGTAATTAACTGGCTT


 


TGCCAGTGGTGAGTCCCACACCATTATTCACTTAGTAGTCATATAAATGTTTTTATTTAAACTTCTCTCTCTTCAAT


 


GCTGAGAATAAGGCTTTAAATTACTGATTCACCTTTAAAGGAATGTTGTGAGAATTGATGTAATTTCTGTTTCTGTT


 


TCCATCTAAACTTCTTTATAAAAAGAGGGATTAGTTTTTTTGTTTTGGGGTAAGCACCTAATTTATCCAGTAACCAA


 


CAACCCTAACCATTGGCATATATAGTCTTTCACTCAGAAATAAACAAAAACTGTTTGGTATATCTGTATCATTGCTA


 


ATCTTGTGCACTTTACTTTTTGGGCAGTACCATACATAGTCTGAGGCTATTGACTTAAACCAATAACTGTACTTTAT


 


GTAATGACTCTTAAATTTGGTTACCTGGGTTCACAGCTTGCTTGAAGAGAAAGGATGCTAGAATAAAGTAAGCAGCT


 


GAAGAGCGAGCAAATCAAGACAAAACACAGTGGTCTCAGATTTTTCGTAGTGTGGGAACAGTGGTTTTGCTCTATAC


 


CACTGAAAAGCACTATAACATAATTGTTGTCCATGATACTGAAGCTTTTCCCCTCACTTCTAGGTTGTTTACATTCA


 


GAGCTCTATCAATAAGAGGAATACATATTACAGTGAATTCGACAACCGCACAAGTTGGCAGTAGGTATCCCCAACCT


 


AATTTATCTTGGTAAATTCACCCTGTTTCCTAGTGCTGCTGGATAAAAGAGTGTTTACTTTTTATTGCTCTTAGACA


 


GAGTAGTCTAGATAAGTTTTCAATTTATCAACATAGCCTAGACTTCTGTAAGTGGAATGTTCATTAGTAACTCATCT


 


TTTTGTTGTTATAATTGGAAACAGAAACGAGGCTTATTGCTATTGCAGAAATCCCAAACTGGCAAAGGCCAGTATAT


 


ATGGTATTCCATAATATAACCAGCTTTTGAAATTTATGTGTTTGGATTAGTGCCTTCTGGTTACCAGTATTGACTCT


 


GCTAGTTTGCACCTTTCCGTTCTTAACAGAAAATTTGTATTTGTTATTCCTCTTAAATTTTGTCGTAACTAGTGAAG


 


GAAGTAAAAAAAAAAAAAAAACATGCATTACATTGACATACTTTATGTGCAGCCTTTATTTAGGTTCAGTGAAACCA


 


GGTAGTTCTGTATTTGTGTTGTAGCCTAAATGTTGTTTCTTTTATATCCATTAAAAACTTAAAGTTACTTATGTTCT


 


GTGATCTTAATTTTGTTGTGTTTCCATTGTAGGTTGATAGGTATATCGAGAACAGGTACGTGACAACAGTTTATATT


 


CCATGATAGAAAGCTAAAGTCCATAGAAAGCACAAAATCGTGTTCACACATTAGTGTACCCACACATAGAAAGCACA


 


AGACTAATAGTATTCTCTGTATCCCACAAGTGCCAGTCATAAAGGCCACCAGGTATTTGTCTCAGAGTTGCTATGAG


 


CACTACAGTATTGATAAGCCCAAGACAATGCGGTATCTAAACTGGTCCTAATGGTAAGGGACCCAAAGGAATAATCT


 


CAATAAGTTTGTACCACATTGATGGAGGGAGAGAATATAAATGTCAAGAATGCCAAAATTATATTTGGGGGTTACTA


 


GCTAAAATGGGGTTTGAGGGCTTTTTACTGCAACTTGAAACTGGAGAAATAGGGACAGATGTCTAGGTTTTTGGTGG


 


GTGGAACAGGTGACATATTTCTGTTTTAAGCTGTAGTGTGATTGGGGTTTTTTGTAAAAAATCTTAAATCTTTTAGG


 


AAATATTACCTCTTAACAGTGCCCCCCCAAACATGCAGAAAGTCATACTTTAACAGGGCAAATACTACTTGTCTTTG


 


ATTTTTTTTGTGTACGTTTGTATGTGAGAGATGAAGTTACCTTTATTTTTTTCCTATACTTGACTGTGCTTCATTTT


 


AATAAAGGATAATTTGATCTGAGTGTTCTGAGCATCAGACTAATTCTGAAGCATATTTGCTAGAGGAGCTACTTTGC


 


TTTTCACAATGGGGTGGAGAGGATTCTTTCACTTGTCCCATTAACCCTCTTCTAGTCTAGATGAGATGAAATCTGTT


 


AATGTGTGTGTAGAAGAAAACGTATGTTCTTCTACTCAGCATTGCCCTTTTCCACCTCCTCACTTCACCTCCGAGTA


 


GCTTGTTTATCAAGAATGAATGAATGTCTTTGTCTTAAATTTTGCCCATGTGTTAAAAGATGTAATTCTCAGAATGG


 


GAGAGAAATGACTACCTTTGTTCCTACTCTTTTATATAATTATCCTTTTAGGGAAAGACTTGGTCAACTCTAATATA


 


TCTAGAAGGAAGACTATATCTGGTGTAGACTAATATGAGATGTTTTAGAAGAGTTAACCTGAACACTTTGAGGGAGA


 


GATTATTCTTGCCAGCAAAAAGCTAGCCAGGAATGAGCCTACCACATTATTTGAGAATATCAAACCTCAGGCCTGGG


 


GGGATGAGGGGAAGAAGATTACCAGAAGTGCAGGAAAGAGAAGTTTGAGGAACACCCTTGGCTTAGCAACATGTGAT


 


AATGCAAAGCTGTTATAACCTGTTAATCCTACGTACTATGTGTTCTGTACCTTTACATGTTTTTAAATTTAAGATAG


 


TTTGTAAGAACTGTACAAAAAAATGCTTCTGGAGATTTCTTTGGCAGAAATGCCTTTCATCTATAATTTCATGGAGA


 


ACTGCTTTAATTAGCCTAGGTGAAAAGTAGTCCTAGCAGTGTAAATATGTATAATTAGAGTTTTCTAATTTCACTGT


 


GAGATCTCTAACTTTTGAGTGGCAAACAGATCAAGTCTTTTGCTCATAGACTTTTCTGTGGGGTTATTAAAATGCAA


 


AAGCTTTATTTTTTTTAATAATGCCATACTCCATTAGTGTCAGATGATGGTATGGAATTTGTTCCCTTGCTTTCCCC


 


CACTGTTACTGCTTCAGTTTATAGATTGCCAGCAGAGTTCAGAAATAGAGCAGGGATTTACCCGTTCTTTGCTTGGA


 


CATCCCATTTTCTTTTGTCCAGACCCATGTTGGCAATCATGTATGAACTGTGTTATACTTCTCAGTGCTTTCTTTTT


 


TCTTTTTGATAAGATGGATATCAAAAATAGTTGCTGTGCAAAAGTTAGTAGTCTTCTTCAAGAAGAAAACCAATTCT


 


TTTTCTAATAATATCCTGTGAAATTGCTTCATTCATTCATTTATTTTTAAGCCAAATGTCAGCAGAGTGCTGCTGCT


 


TTTATCTAGTAATTTTGATATGTAAGTATTAATGCATTTTTAAAAGATGTCTACATTGAAACATGTTCTTCCCAGTG


 


TCCTGCTTATGATGCTTTGTTCAGATTTTTTGTAAGAGACCAGTTAGTACACTGGGGGTGTATATTGTGTACATGTG


 


TCATTTTAGTTAGGCATTGTAGGCCAAATGTGATTATAAATGAAGTTGATGAACATTAATTTTGTTATTAGTGAGTT


 


TTTTGAATTGTAAATGGATTTCCAGTTTACCTTCTGTTGTCTACAGCTTTTTTAATTTTAAGGTTTGACTAATTGTA


 


TCCATCTCATTGTACAGTGTTTTAGTTGCAAGCAGAAAGTAGAATTTGGTATAAAGCAGGTTATTTCTATATTGAAA


 


GGAGTACAGTTGAAATTGTAGATTTAAGATTGTTAAAATCATGACAATTCTAACTTGTCTATTCTAACCTATTGTGT


 


ACAATCTGATTTTTTAAAATTGTAAACATGTATGATCTTGGTTTCATGTGTTTTTGAAAGTGTTATTGTTTAAAAAA


 


TGAAAAAAGCATATCTGCTAAAGAGCTGTCAGTTTTCATTACTGACTCTGTAAAATACACTGTTCTTTGTGTACTGT


 


GTGTTATTTTGCCAGCTGCTGCATTAGCCTTCAAAAGTATTTGGAAACTTAAGATGAACTACATTTCTTGCAAAGTA


 


CATTCCTTTCTGTGGTATTTTGTCCTGTAACTGAAGTATAGTAATTATTTTATGGAAATGTTAGCAATTCTGTACCA


 


ACTTTGAATAAAATGAAAAATTTATAAAA


 


>gi|115529447|ref|NM_021097.2| Homo sapiens solute carrier family 8


(sodium/calcium exchanger), member 1 (SLC8A1), transcript variant A, mRNA


(SEQ ID NO: 44)



TAGGTTGTGACAGTTGGAAGTGTCATGTACAACATGCGGCGATTAAGTCTTTCACCCACCTTTTCAATGGGATTTCA



 


TCTGTTAGTTACTGTGAGTCTCTTATTTTCCCATGTGGACCATGTAATTGCTGAGACAGAAATGGAAGGAGAAGGAA


 


ATGAAACTGGTGAATGTACTGGATCATATTACTGTAAGAAAGGGGTGATTTTGCCCATTTGGGAACCCCAAGACCCT


 


TCTTTTGGGGACAAAATTGCTAGAGCTACTGTGTATTTTGTGGCCATGGTCTACATGTTTCTTGGAGTCTCTATCAT


 


AGCTGATCGGTTCATGTCCTCTATAGAAGTCATCACATCTCAAGAAAAAGAAATAACCATAAAGAAACCCAATGGAG


 


AGACCACCAAGACAACTGTGAGGATCTGGAATGAAACAGTTTCTAACCTGACCTTGATGGCCCTGGGATCTTCTGCT


 


CCTGAGATTCTCCTTTCAGTAATTGAAGTGTGTGGCCATAACTTCACTGCAGGAGACCTCGGTCCTAGCACCATCGT


 


GGGAAGTGCTGCATTCAATATGTTCATCATTATTGCACTCTGTGTTTATGTGGTGCCTGACGGAGAGACAAGGAAGA


 


TTAAGCATTTGCGTGTCTTCTTTGTGACAGCAGCCTGGAGCATCTTTGCCTACACCTGGCTTTACATTATTTTGTCT


 


GTCATATCTCCTGGTGTTGTGGAGGTCTGGGAAGGTTTGCTTACTTTCTTCTTCTTTCCCATCTGTGTTGTGTTCGC


 


TTGGGTAGCGGATAGGAGACTTCTGTTTTACAAGTATGTCTACAAGAGGTATCGAGCTGGCAAGCAGAGGGGGATGA


 


TTATTGAACATGAAGGAGACAGGCCATCTTCTAAGACTGAAATTGAAATGGACGGGAAAGTGGTCAATTCTCATGTT


 


GAAAATTTCTTAGATGGTGCTCTGGTTCTGGAGGTGGATGAGAGGGACCAAGATGATGAAGAAGCTAGGCGAGAAAT


 


GGCTAGGATTCTGAAGGAACTTAAGCAGAAGCATCCAGATAAAGAAATAGAGCAATTAATAGAATTAGCTAACTACC


 


AAGTCCTAAGTCAGCAGCAAAAAAGTAGAGCATTTTATCGCATTCAAGCTACTCGCCTCATGACTGGAGCTGGCAAC


 


ATTTTAAAGAGGCATGCAGCTGACCAAGCAAGGAAGGCTGTCAGCATGCACGAGGTCAACACTGAAGTGACTGAAAA


 


TGACCCTGTTAGTAAGATCTTCTTTGAACAAGGGACATATCAGTGTCTGGAGAACTGTGGTACTGTGGCCCTTACCA


 


TTATCCGCAGAGGTGGTGATTTGACTAACACTGTGTTTGTTGACTTCAGAACAGAGGATGGCACAGCAAATGCTGGG


 


TCTGATTATGAATTTACTGAAGGAACTGTGGTGTTTAAGCCTGGTGATACCCAGAAGGAAATCAGAGTGGGTATCAT


 


AGATGATGATATCTTTGAGGAGGATGAAAATTTCCTTGTGCATCTCAGCAATGTCAAAGTATCTTCTGAAGCTTCAG


 


AAGATGGCATACTGGAAGCCAATCATGTTTCTACACTTGCTTGCCTCGGATCTCCCTCCACTGCCACTGTAACTATT


 


TTTGATGATGACCACGCAGGCATTTTTACTTTTGAGGAACCTGTGACTCATGTGAGTGAGAGCATTGGCATCATGGA


 


GGTGAAAGTATTGAGAACATCTGGAGCTCGAGGAAATGTTATCGTTCCATATAAAACCATCGAAGGGACTGCCAGAG


 


GTGGAGGGGAGGATTTTGAGGACACTTGTGGAGAGCTCGAATTCCAGAATGATGAAATTGTCAAAACAATATCAGTC


 


AAGGTAATTGATGATGAGGAGTATGAGAAAAACAAGACCTTCTTCCTTGAGATTGGAGAGCCCCGCCTGGTGGAGAT


 


GAGTGAGAAGAAAGCCCTGTTATTGAATGAGCTTGGTGGCTTCACAATAACAGGAAAATACCTGTTTGGCCAACCTG


 


TCTTCAGGAAGGTTCATGCTAGAGAACATCCGATTCTCTCTACTGTAATCACCATTGCAGACGAATATGATGACAAG


 


CAGCCACTGACCAGCAAAGAGGAAGAGGAGAGGCGCATTGCAGAAATGGGGCGCCCCATCCTGGGAGAGCACACCAA


 


GTTGGAAGTGATCATTGAAGAATCCTATGAATTCAAGAGTACTGTGGACAAACTCATTAAGAAGACAAACCTGGCCC


 


TTGTGGTTGGGACTAACAGCTGGAGAGAACAGTTCATTGAAGCTATCACTGTCAGTGCTGGGGAAGATGATGACGAC


 


GATGAATGTGGGGAAGAGAAGCTGCCCTCCTGTTTCGATTACGTGATGCACTTTCTGACTGTGTTCTGGAAGGTCCT


 


GTTTGCCTTCGTCCCCCCTACTGAATACTGGAATGGCTGGGCGTGTTTCATTGTCTCCATCCTCATGATTGGCCTAC


 


TGACAGCTTTCATTGGAGACCTGGCTTCCCACTTTGGCTGCACCATTGGCCTGAAAGATTCTGTGACTGCAGTCGTG


 


TTCGTCGCACTTGGAACATCAGTGCCAGACACATTTGCCAGCAAAGTGGCAGCCACCCAGGACCAGTATGCAGACGC


 


CTCCATAGGTAACGTCACGGGCAGCAACGCGGTGAATGTCTTCCTGGGAATCGGTGTGGCCTGGTCCATCGCTGCCA


 


TCTACCACGCAGCCAATGGGGAACAGTTCAAAGTGTCCCCTGGCACACTAGCTTTCTCTGTCACTCTCTTCACCATT


 


TTTGCTTTCATCAATGTGGGGGTGCTGCTGTATCGGCGGAGGCCAGAAATCGGAGGTGAGCTGGGTGGGCCCCGGAC


 


TGCCAAGCTCCTCACATCCTGCCTCTTTGTGCTCCTATGGCTCTTGTACATTTTCTTCTCCTCCCTGGAGGCCTACT


 


GCCACATAAAAGGCTTCTAAAGGAACTATCAGATATAGTAAATTTATATATATACATATATATACATAAAAATTATG


 


TATAATGGACAGAGGAAACTGACATTTGTCATGTTCACTTACCTGCTGATGGAATCCAGCTTCAAGAGCATACTCTG


 


TACTAGGGCCGAAGTAAAAAACCATCACCTCCCATTCCCAGGGGCATCATCATGTTCAACAAGGCATGGAGGCAGGG


 


CCATCTTTGCAGCTCAGTCTAGAAGGGCTGCACTCTCTCCAGGTTGATAAATCCTTAAGGCTTTGATTTGTTTTGTT


 


TTTGGTTTTGTTTTCAGTGGAGCTGGGGAGGTAGTTAATGTTTGGCTTTATTTTTGTTATTTTGTTTTGTTTTGTTT


 


TTTTGGGAGAGTCAGGGTTGTTGCTTTTCTTTGTGGAAAGTGAAACCATCCAAATGTAAATGGGTTTTGGTAAAAAT


 


TTAAATCATTAGTATTCCCCCTCACCTCCCCCAATCACTTTAAAACTTATTTTGGATTAAGAAAAAATCTGGGCATG


 


GAAGAAGAAAGAAGCATGTCTTCATCGTATTACCAAAGTTCATGCTTATCTCCGGAATGTGAGTGGAGGTGAAGCTG


 


CCTCCAAGAAGAAGCATAAAAGTGGAATGGAGCCAGGAAATCCGATGGTTCTAGAAATAGTCTGATATTTAAACATG


 


TGATACCTGGCAGTCTCGTTTAACAGGTACAAGGAAAACGTGCCTAGATTCCCAGGAACGTGCAAAATCCTTTCTTT


 


CTTATCTCTTTAGCTCTGGACTGTGATTGGCAAGGTCCTTCTTCCAGCATTCAGCCCAGCTAAGCCCCCAGGTGCCC


 


CATCCCAACCCTGTTCCTCCTGTCCACCTGCCATCCCCTATGCAAACAGTAAGAATAACCCCATTCAAAAAGCACAT


 


CATCGTTTTCCATTTGCATTAACATGTGTCTCAGTCCCATGTTGCCGTTGCTTGGGATTGTCTGTCAGTTTTATTTT


 


CAAAGGCATCCATGGCTTGCACAATCCTGTTCCAGTCATGACTGAACATTTGCTCCTTCTTCATGTGCCGTTCGGAA


 


ATGTTGTTGTGATACCTGTTACACAGTGCATGGTGAAAAACAAATAAAACAAAACAAAGAGTATCTGTATATAGTAG


 


AGTATAGTACATACTGTTCTCCCATTTGGCAATGTTGATTGGACATTGAAGACATAAGTGAGTTTTCTTTTCACCTG


 


AGTTGTTACTTTTGTGCTGTTATTGAGTTTGATTAATTACTAGGGATAAAAGGAGAAAATGGATTATTGTTCACGGT


 


TCTGCACATTCATTTCTAAGAAGCAATAACTGTCATGTGGGGAGAAGTTAAAGCTATTGAGAGGATAGCAGGCAAAC


 


TACAAAGATCTTCATGGAAAATTAGCCATGTGGAACACATCAGAGGCCTCTAAAAATCACCCATTAATTCAGGAAGG


 


CCAAGGAGAAAGGCCTTATAGAGACGTTGATATGTTGGATGTGCCTAGGCTTTCAGAGCCACCCTTTCCACAACACC


 


CCTCCCTGCAAAGTATTTATTTCACATCTGCACTGTCTGGCACAGATGGTAGATAGTGCTGGTTTGTTCATTTTATT


 


TTTTTACTTAAAAGGCTATTTTGAGCCCTGTTTCTTTCACTGTCCAGTCTAGTCCTCTTTGATTATATCAGTAGTTG


 


CTGAGTAAGAAAGAAGCCAGGGTGACCAACGGGCCTTTAAAAGTGTTGTCTCCTCTACTTATGCTGAAAGAGAAGGC


 


AATTAAATAAGACTAGTACCTCCCAGGAGGATTGGACTGGGATATTTTTAACCCTTTAAAAAGAATAGCTGTTTCTA


 


TGTTAAAATACCAAAGAACATGGATAAACCCAACATTCCAAAGTAGTGAGTCCACTAATGAGAAAAATAATAGAATG


 


ACTTTGGTCACCTCTCGGAGACTTCTGTGTCTATAAGGAATCCCAGGCTGGAGACATTCCTAGCCCTCTGTATTGAT


 


TCAAAAATACTTAATAAATTAAAGCTGTTGAGACTTATTTTTTCTTCTGTCACTCAGTAACCATGATCCTTCCTCAT


 


TTAATAAACATTTGGTGACTGAATGAGTAATTAAATGCTGGTTACCCACTTAATGTGCCAGGTAGTATGATACTTTC


 


TGGGGACTAAGCCATGAACAAAACAGTCTAGATCCCTGCCCTCAGAAGGGTTACAGTTTATGTGATTACTATTTTCA


 


TGAGTAAAAGTGAAGAAAGCCATATGGAAAGATTTTTATCTTGCAAGAAAAAACAATTATGAAACTCTTTTAACATA


 


AACACACTGAAACTGTATCAAAGCAATTGTCCAAATTGTATTTATACCCAAGAATTTCTTTAACTAAGAGAGCATAA


 


GGCATATGTTTGGAAAACCACCCTCTTTATCTTTGACCGACTTGCAGATAAATATATCTCTCCATTTTAAACCAAGA


 


AGGGCAATCATGTTGGTGATCCAGATCACTGAGAAAGCCCAGTGTATCCCATCTTTTATCTTTGTTGGCAATGGAAC


 


TTTTCTATGGCCCACACTTTACAATTCTTTGTCATTCTAACCCATCCTTCCCATCCTTATTTTTTTTTTTTTTGAGA


 


ATTGCTAAATGGAAAGCTAGCCTAGAAGCACCAAGTAAATATATTCAAGGAATATAAGTTGTTTAAACATTAGAAAA


 


ATTTTTGCACTCATTTTTTAGCTGTATTAGGAATGTCAATAATCCTGTAGCAAATTTTCACAGAGAACTTTAAGAAA


 


TTCTTGCATTGGTCGATTTCAATTTGAAAGCTTTTTGGTTTGTTTGCTTTTTAAATTTTCATGTTCTAGGAAACTAT


 


GATTCTGGTTGTTCAGGATTGTTATTATTATAGTTGTGTAAAATTATTTTATTTTGTGTGTATTGTGCACAGCTTGG


 


GGGGGGGGCGGGAAATGCACTAATTGTGCTCTTCCTTATAAATGGTACATATTACTGACACAGACAAATAAAGTTTC


 


TAATTGTTTCTGATTTAATCACTAGTGATACAGCATATTCTGTATGAAATGTTTTCTCCTTTCTCATTGTCATCTAC


 


TTCATTTTTTGTTTTCATGTTTTGAAGAAATAAAAACCAAAATGGTA


 


>gi|38569454|ref|NM_003048.3| Homo sapiens solute carrier family 9


(sodium/hydrogen exchanger), member 2 (SLC9A2), mRNA


(SEQ ID NO: 45)



CCGGTGCCGCAGCAGCGGCGGGTGGCTGTCGCTGCCCTGCCCTGCACGGGGCAGGGCGGAGCGGGCTGAGCAGCCCG



 


GGCGCGATGCGTTGAGCGCTCGGAGGGCCAACCGCCGGTCCCCTTGGCGGCAACCGGCGGCACCCATGGAACCACTG


 


GGCAACTGGAGGAGCCTGCGGGCGCCACTGCCTCCGATGCTGTTGCTGCTGCTCCTGCAGGTGGCGGGGCCCGTGGG


 


CGCCCTGGCGGAGACCTTGCTGAACGCGCCGAGGGCCATGGGCACCAGTTCCAGCCCGCCTAGCCCTGCGAGCGTGG


 


TGGCTCCCGGAACGACGCTGTTCGAGGAGAGCCGGCTGCCTGTGTTTACGCTGGATTACCCCCACGTGCAGATCCCC


 


TTCGAGATCACCCTTTGGATCCTGCTGGCCTCCCTGGCCAAGATTGGCTTCCATCTGTATCACAAGTTGCCCACAAT


 


AGTGCCTGAGAGCTGCCTTCTTATAATGGTTGGACTTCTACTAGGTGGGATTATTTTTGGTGTTGATGAGAAGTCTC


 


CCCCTGCAATGAAGACTGATGTATTTTTCTTGTACCTCCTCCCACCCATCGTGCTGGATGCCGGCTATTTCATGCCC


 


ACTCGCCCATTCTTTGAGAACATTGGCACGATTTTCTGGTATGCTGTGGTAGGGACACTTTGGAATTCCATTGGCAT


 


TGGGGTGTCTTTGTTTGGTATCTGCCAGATCGAAGCATTCGGCCTCAGCGACATCACTTTGCTCCAGAACCTGCTCT


 


TTGGCAGCTTAATCTCAGCTGTCGATCCTGTGGCTGTGCTTGCTGTCTTTGAGAACATTCACGTCAATGAGCAGCTC


 


TACATCCTGGTCTTTGGAGAGTCCCTGCTGAATGATGCAGTAACAGTGGTCCTGTACAACTTGTTCAAGTCGTTTTG


 


CCAGATGAAAACCATTGAGACCATTGATGTGTTTGCAGGAATCGCCAACTTCTTTGTTGTGGGAATCGGTGGGGTGC


 


TGATTGGCATCTTCTTGGGCTTTATAGCGGCATTTACTACTCGATTCACCCATAATATCCGAGTGATCGAGCCACTG


 


TTTGTTTTCCTGTACAGTTATTTGTCCTACATCACAGCTGAAATGTTTCACCTCTCAGGCATCATGGCAATCACTGC


 


TTGTGCAATGACTATGAATAAGTACGTAGAAGAAAATGTATCTCAGAAATCCTACACGACCATCAAGTACTTCATGA


 


AGATGCTGAGCAGTGTCAGCGAAACCTTGATCTTCATCTTCATGGGTGTGTCTACCGTGGGCAAGAACCACGAGTGG


 


AACTGGGCCTTCGTCTGCTTCACCCTGGCCTTCTGCCTCATGTGGCGAGCCCTGGGTGTTTTTGTCCTGACTCAGGT


 


CATTAATAGGTTCCGGACCATTCCCCTGACCTTTAAGGACCAGTTCATCATTGCCTATGGAGGACTTCGAGGTGCCA


 


TCTGTTTTGCGTTAGTGTTTCTCCTTCCTGCTGCTGTGTTTCCTCGGAAAAAATTGTTTATTACGGCTGCCATTGTT


 


GTCATATTCTTTACTGTCTTCATTCTGGGAATAACTATTCGACCACTGGTGGAGTTTCTTGATGTCAAGAGGTCCAA


 


TAAGAAACAACAAGCTGTCAGTGAAGAAATCTATTGTCGGTTGTTTGATCATGTGAAGACTGGAATTGAAGATGTTT


 


GTGGACATTGGGGTCACAACTTTTGGAGAGACAAGTTTAAGAAGTTTGATGATAAATATCTGCGGAAGCTTTTGATT


 


CGGGAAAACCAACCAAAGTCAAGTATTGTATCTTTATATAAAAAGCTTGAAATAAAACATGCCATTGAGATGGCAGA


 


GACTGGGATGATAAGTACTGTCCCTACATTTGCATCTCTAAATGATTGTCGTGAAGAAAAAATAAGGAAGGTCACGT


 


CCAGTGAAACTGATGAAATTCGAGAACTCTTATCAAGAAATCTCTATCAAATCCGTCAGCGAACTTTATCCTACAAC


 


AGACACAGTCTGACAGCCGACACAAGTGAGAGACAAGCCAAGGAGATTCTGATTCGCCGGCGACACAGTTTGCGAGA


 


AAGCATTAGGAAGGACAGCAGCTTGAATCGAGAACACAGGGCTTCCACTTCAACCTCCCGATATTTATCCTTACCTA


 


AAAATACGAAGCTTCCAGAAAAGCTACAAAAGAGGAGGACTATTTCTATTGCAGATGGCAATAGCAGCGACTCAGAC


 


GCAGATGCCGGGACCACCGTGCTCAATTTGCAGCCCAGAGCCAGGCGCTTCTTGCCAGAACAGTTCTCCAAGAAATC


 


CCCCCAGTCCTATAAAATGGAATGGAAGAATGAGGTAGATGTTGATTCTGGCCGAGATATGCCCAGCACCCCCCCAA


 


CACCCCACAGCAGAGAAAAGGGCACCCAGACGTCAGGCTTACTACAGCAGCCCCTTCTCTCTAAAGACCAGTCTGGC


 


TCAGAGAGGGAAGACAGTTTGACTGAAGGCATCCCGCCCAAGCCGCCACCACGGCTGGTCTGGAGGGCATCGGAACC


 


TGGAAGCCGGAAAGCCCGATTTGGGAGTGAGAAGCCTTAAGAGAAGCAGCGAAAGCAGATCTGAGTGTCTGACCCAG


 


GACAGCTGTGGTTTGTCACTCTGAAACCTGATGCAACAGTGGAATCCATGTAAAACTCTCTGTGCATCTAAATACTT


 


CTGGAGGGCGACAGATTCATGCCACGGATAAATGAGGCAAATCCGAAGAAAAGGAAAATCGAATAAAAAATAGTCCC


 


ACAAAATACCTTTTGTGACTAATGGGTAGCAATCGTATTATTTGCTGGCCTGAAGAGAAAAAATGGTAATGTGTGCC


 


TTTATTGAACTTGAATGACAGAACTTGAAATTTTTAACACATCCTTCTTGGTGAAGATTTTAATATATTACTTATAT


 


GCTTCAAATTTTATTTATGAAAAAATATGTATATCTGTAATCAGTTGTTAAGTGAATGGCACTAAAAGTATCGAGAA


 


CAGCTTTCTTTCCCAGGGGTGAAGGATGGCGCTCGGGGGTGACTCCTAAGCTCAGCGTGGAAGCTTTTCCCTGTCCT


 


GACCCGATGGAGCAGCCGGTAAGTGAAGAGCACAGCTGGAAGCAGAGACACCTTATGACTCAAACTGGGCAAACAAT


 


CGGAACGTCATGCAGAAGGAATGGCCTGACTCCTGCAGTGCAGATTGGAGGCCCCAGAACTCCTATGAACTACTGAG


 


AGTCTACTGGTTTTTAACTTGTTCCTCTGTCTACTGTGTGTTTGGGGGTGACATCTAAATTCCATTTCTTCTTCTTG


 


TTTAAATGGTGCAGAGAGAAAGGTTGCCCAGACATCCACCAGCTTACTGTGTTGACAGATTTGGGAGCAGCTTTTGA


 


TGAAGTTCCACCCATGAGGGTCCATGTGGCAAGTAGGGCCACAGGGCAGCACCTGGTTACAACTTGCTGGTGGGTTT


 


TATGTTGTGCAATACTAGGAGGAGGAGGCAGGTGATCTATGCTGATCTATGATCACCTGCTTCAGTAGAATTTTTCT


 


GTAGAGTGTTGTTTGAATTTTGAGCCTCCAGGTTAGAGGCTCCAAGCAGACAAAGAAGAAAGTTTGTAGACACAATA


 


TTCTAACATTGCACAAGTTGATGAGATATCAAGTTTTGAATATTATTCAGGAAGCACTTTGGAGAATGTGGGAGTCC


 


TACTGTTTTGCACTAGTCTGTAATTTGTTACCTCTCCCCATTCGATAATATAGTAACTCAGAATTTTCATATAAAAT


 


TGAATTCTACTCATTAGAGTACTTTTTAAAAGTACAGCAGAAAGAAAAGAAGTGGAACATAAGCATTCAAGATTAAT


 


ATTTGATTCTCTATCTCTTAACTGTAGATTTTATTGGCCTGTTTTTTTTTTCTAAATAATTCTTTAAAACTTGACTG


 


GAACATGCCTCTGCATTTCTGAGTGTAGAAATTAAATGAAGCCACTCACAGTCCTTTGATTTCCCACTGAAGATACC


 


CCAAAGGATGCAAGTGCCTACAGTATTATCAGGAGGAGAACATGAAAATATTAAGACAAAAATCCTCAGCAGTTGTT


 


CTCCACCCCTTCTCCACCTCCACCAGCAAGGAGAAGTCAATCTACACTTTTTTCTCATGTTCTAAAGTCTTAGAATA


 


CTGCTGGATTGTTGAGCATGAGACAGAGCAAAGGTTAGATACACAAGGTACAAGTTCATAGGAGCACAATTCCTTGA


 


TTCAGGGAAAGTAGCACAGAATGCAATTTGAAAACTACAGGCTTAGGACTCTGTGCCAAAAATCTCTATTTTAAATG


 


AAAATATTTATATAAAAATACATTTATTCTGCTTAACACAAATTAAAACTGACATAAAATTTTATGATAATAACATG


 


ATTCAAGAAATGTGATGTAGATTTTTGAGAATGCCAAAAATCAGGTTTCAGAAAAGCTACAGTATGAAATCTGAAAA


 


GCAACAGAAATTGAAAGTGACCTTAAAGAATAAATTTCCTAATTTTTCCCAGTTTCCTATGTTTATAACTATTATAA


 


AGAGTTTAACTTTCTGGAACTGAAGGAGAAAACATGAAAATGTTTATATTGCTTCTTGTTAAGCAGGTAGACCAAAT


 


TCCGCTTTCAGTAATTCATCCATACAGAATTTGGATGACTATGTATAAAGGAAAACTTAAATCTTAATTATTATCAG


 


TTTAAATTTTTTTTGTTTGTTGAATGACAAAGGCAATAAAAATAAATTTGACTTTAGCTTTTTTTCTATACTTTCCT


 


CTTTTTGTAATTCTTAAATTCTAGTCACTAGTCATTATGAGAGTATTGACTAAATATTTTCACAATCTAAATATTGT


 


CACAATCTAAATTTCTGTAGTACAGAGAGCCGTAGCCCTTTGTAAAGGCTTTCGTTCGTCCAAACAACACTTGATCC


 


AACCAAAGTTCCAATGTGACTGTGGATCTTTGATAGGTCTTTGGTGTTGGTTGTAACAAAATTTGATTTGAACTACC


 


TATAAATGAAAAGTCGGGGTTTATTACTTTATATGTAATGCTGAGAGGAGACTGTTGGGAACAGTTATGTCAATGAG


 


CAAACTAGAAATTGGCTTCAAAGTCTGATACTTTTAAAAGCATGTGTTTTGTGTATATGCTCACAAAATGTCTGTGA


 


AGAGATTTCTTTCAGCTTTTGCTCAGCTTTATGGTGGGGTGTACTGTTTTATCTGGGCGGTGAGGGTATTGATTTAC


 


ATAAAAACTGTAGACAAACACAGTACGAGTCTCAGCACGTTTTGCATTTATTGTACTGCCCAAATTGTTTTTATGTT


 


AAAAGTCACGTTTCATAATCTGCAATATTTTTGTCAAAGTGCACACTGTACTTTCTTCTTAAAAACGTGATTAAAGA


 


GATCACTTTGTCCGGATGAAGCAGCTGTTGGCATTATCCGCTGAGGCTTGAAAAAA


 


>


>gi|141803413|ref|NM_023003.2| Homo sapiens transmembrane 6 superfamily


member 1 (TM6SF1), mRNA


(SEQ ID NO: 46)



GGGGCGGGGCGCCCAGCGGGATGCGGTGAAGGGCGAGCGGCGCGGCGGCTGCGATGAGTGCCTCTGCGGCCACCGGG



 


GTCTTCGTGCTGTCCCTCTCGGCCATCCCGGTCACCTATGTCTTCAACCACCTGGCGGCCCAGCATGATTCCTGGAC


 


TATTGTAGGGGTTGCTGCCCTCATCCTGTTCCTGGTAGCACTGCTGGCTCGTGTCCTCGTCAAAAGAAAACCACCCC


 


GGGACCCACTGTTCTATGTGTATGCAGTTTTTGGATTTACCAGCGTGGTGAACCTCATCATAGGACTGGAGCAAGAT


 


GGAATCATTGACGGGTTCATGACACACTACTTGAGAGAGGGTGAACCGTATCTGAACACCGCATATGGGCACATGAT


 


CTGCTACTGGGATGGCTCTGCTCATTATCTGATGTACCTGGTGATGGTGGCAGCCATAGCATGGGAGGAAACTTATA


 


GAACCATTGGCCTATATTGGGTTGGATCTATTATTATGAGTGTTGTTGTTTTTGTGCCAGGAAACATTGTAGGGAAG


 


TATGGAACACGAATTTGCCCTGCTTTTTTCTTAAGCATACCATATACTTGTCTTCCTGTCTGGGCTGGTTTCAGAAT


 


CTATAATCAGCCATCAGAAAATTATAATTACCCCTCAAAGGTTATTCAAGAAGCCCAAGCGAAAGACCTGCTGAGAA


 


GACCATTTGATTTAATGTTGGTTGTGTGTCTCCTCCTGGCAACTGGATTTTGCCTGTTCAGAGGTTTGATTGCTTTG


 


GATTGCCCATCTGAGCTCTGCCGATTATATACGCAATTTCAAGAGCCCTATCTAAAGGATCCTGCTGCTTATCCTAA


 


AATTCAGATGCTGGCATATATGTTCTATTCTGTTCCTTACTTTGTGACTGCACTGTATGGCTTAGTGGTTCCTGGAT


 


GTTCCTGGATGCCTGACATCACATTGATACATGCTGGAGGTCTGGCTCAGGCTCAGTTTTCTCACATTGGTGCATCT


 


CTTCATGCTAGAACTGCTTATGTCTACAGAGTCCCTGAAGAAGCAAAAATCCTTTTTTTAGCATTAAACATAGTATA


 


TGGAGTTCTTCCTCAGCTCTTGGCCTATCGTTGTATCTACAAACCAGAGTTCTTCATAAAAACAAAGGCAGAAGAAA


 


AAGTGGAATAAAAATATTACTTCATGTTCCTCCTTTCTAAATTACTAACTTTTGTTATACTGGTACTGATATTTTGT


 


CCCATTTCACTCTCTTCTCATACGTGAGTACTTAAGAATATGTACATTCTTGCTCTGCACTGTATGTGTGAGCTATA


 


TGGTATTGTGTAAATTTTTTTTGAAGGAAAATGGAAATTCTTGAGAAACAGTTTGTTTAAAGAAATATATTCAAAAT


 


CATTTGTGAATAAACTTGATCATCCATCTCAAAAAAAAAAAAAAAAAAAAAAAA


 


>gi|45387950|ref|NM_023943.1| Homo sapiens transmembrane protein 108


(TMEM108), mRNA


(SEQ ID NO: 47)



GGAGGGAGCCGGAGCGCTTCTCCCGAGTTGGTGATAGATTGGTGGTCATCCAACATGCAGAAATGAATGAGCAGTGA



 


AAAGCAGCAGAGCCGATGGGTCATGAGGATGTAAGTGCGTTTGAAGGCTTCCACACCCTCTACTCCAGGACAGAATC


 


ATGAATAAACTGGAGGATAAGCAGGACCAGATGATACCATGAAGAGAAGTTTACAGGCCCTCTATTGCCAACTGTTA


 


AGTTTCCTGCTGATCTTGGCACTGACCGAAGCGCTGGCATTTGCCATCCAGGAACCATCTCCCAGGGAATCTCTTCA


 


GGTCCTCCCTTCAGGCACTCCCCCGGGAACCATGGTGACAGCACCCCACAGCTCTACCAGACATACTTCTGTGGTGA


 


TGCTGACCCCCAATCCCGATGGACCCCCCTCACAGGCTGCAGCTCCCATGGCAACACCGACACCCCGTGCAGAGGGG


 


CACCCTCCTACGCACACCATCTCCACCATCGCTGCGACAGTAACCGCCCCCCATTCTGAAAGCTCCCTGTCCACAGG


 


GCCCGCTCCAGCAGCCATGGCAACCACATCCTCCAAGCCAGAGGGCCGCCCTCGAGGGCAGGCTGCCCCCACCATCC


 


TGCTGACAAAGCCACCGGGGGCCACCAGCCGCCCCACCACAGCGCCCCCCCGCACTACCACACGCAGGCCCCCCAGG


 


CCCCCAGGCTCTTCCCGAAAAGGGGCTGGTAATTCATCACGCCCTGTCCCGCCTGCACCTGGTGGCCACTCCAGGAG


 


TAAAGAAGGACAGCGAGGACGAAATCCAAGCTCCACACCTCTGGGGCAGAAGCGGCCCCTGGGGAAAATCTTTCAGA


 


TCTACAAGGGCAACTTCACAGGGTCTGTGGAACCGGAGCCCTCTACCCTCACCCCCAGGACCCCACTCTGGGGCTAC


 


TCCTCTTCACCACAGCCCCAGACAGTGGCTGCGACCACAGTGCCCAGCAATACCTCATGGGCACCCACCACCACCTC


 


CCTGGGGCCTGCAAAGGACAAGCCAGGCCTTCGCAGAGCAGCCCAGGGGGGTGGTTCTACCTTCACCAGCCAAGGAG


 


GGACACCAGATGCCACAGCAGCCTCAGGTGCCCCTGTCAGTCCACAAGCTGCCCCAGTGCCTTCTCAGCGCCCCCAC


 


CACGGTGACCCACAGGATGGCCCCAGCCATAGTGACTCTTGGCTTACTGTTACCCCTGGCACCAGCAGACCTCTGTC


 


TACCAGCTCTGGGGTCTTCACGGCTGCCACGGGGCCCACCCCAGCTGCCTTCGATACCAGTGTCTCAGCCCCTTCCC


 


AGGGGATTCCTCAGGGAGCATCCACAACCCCACAAGCTCCAACCCATCCCTCCAGGGTCTCAGAAAGCACTATTTCT


 


GGAGCCAAGGAGGAGACTGTGGCCACCCTCACCATGACCGACCGGGTGCCCAGTCCTCTCTCCACAGTGGTATCCAC


 


AGCCACAGGCAATTTCCTCAACCGCCTGGTCCCCGCCGGGACCTGGAAGCCTGGGACAGCAGGGAACATCTCCCATG


 


TGGCCGAGGGGGACAAACCGCAGCACAGAGCCACCATCTGCCTGAGCAAGATGGATATCGCCTGGGTGATCCTGGCC


 


ATCAGCGTGCCCATCTCCTCCTGCTCTGTCCTGCTGACGGTGTGCTGCATGAAGAGGAAGAAGAAGACCGCCAACCC


 


GGAGAACAACCTGAGCTACTGGAACAACACCATCACCATGGACTACTTCAACAGGCATGCTGTGGAGCTGCCCAGGG


 


AGATCCAGTCCCTTGAAACCTCTGAGGACCAGCTCTCAGAGCCCCGCTCCCCAGCCAATGGCGACTATAGAGACACT


 


GGGATGGTCCTTGTTAACCCCTTCTGTCAAGAAACACTGTTTGTGGGAAACGATCAAGTATCTGAGATCTAACTACA


 


GCAGGCATCACTTTGCCATTCCGTATTTTTCGTCTCTAAATTATAAATATACAAATATATATATTATAAATATAACC


 


TTTGTGTAACCCTGACTTAATGAGAAACATTTTCAGCTTTTTTTCCTATGAATTGTCAACATCTTTTTTACAAGTGT


 


GGTTTAAAAAAAAAAAAACTTTACAGAATGATCTGTGGCTTTATAAAATAAAGGTATTTCTAAGCAAAAAAAAAAAA


 


AAAAAA


 


>gi|39725660|ref|NM_032927.2| Homo sapiens transmembrane protein 128


(TMEM128), mRNA


(SEQ ID NO: 48)



CCAAGATGGACTCCTCGCGGGCCCGGCAGCAGCTCCGGCGGCGATTCCTCCTCCTGCCGGACGCCGAGGCCCAGCTG



 


GACCGCGAGGGTGACGCCGGGCCGGGTGAGGCGCGCACCAAGCCGCCCCGAGGTTCTCAGAGGCGAGGCGTCGGAAA


 


ACGGCCGGCCTCCGGCAGCCCTGGCCCAGTCTGGAAGGACTGAGTTTCGGCTTTGCAAGTCGAATATTTAATGTCAG


 


GGAAGATCCTTAGAATCGCGGAGTGCTGTGCATCGTCATTTCAGCTGCGCTTCAGAATTCTCTGGAGAGCTGATTTG


 


ACACCTATTTGGAAATAGCGATTAAAATTAAAAATACCCACCAGTTTTAAGTCTTAAGGATTTACCAGAAACATGCG


 


TGTACCGCAGTGTACAATGATGTGCGCAGTGTTTCACTTCAGGATTGCTTGTAATAGCGAATTACTAGAAATATCTG


 


CCTTGCCCGTCAGCAGAAAGCTGTTTAAGTAAATTTGGGTATATGTATACCTGACACATCAGGTCGACTCGTATGTA


 


CCAATGGGGATGATTTTCAAAGGGAAGTGTGGAACACTATGGTATGCCGCCATTTGGGTACAAAACAGAAACCTCCA


 


CAGCTGTTGAGAAAAAGGAGAAACCTCTTCCAAGACTTAATATCCATTCTGGATTCTGGATTTTGGCATCCATTGTT


 


GTGACCTATTATGTTGACTTCTTTAAAACCCTTAAAGAAAACTTCCACACTAGCAGCTGGTTTCTCTGTGGCAGTGC


 


CTTGTTGCTTGTCAGTTTATCAATTGCATTTTACTGCATAGTCTACCTGGAATGGTATTGTGGAATTGGAGAATATG


 


ATGTCAAGTATCCAGCCTTGATACCCATTACCACTGCCTCCTTTATTGCAGCAGGAATTTGCTTCAACATTGCTTTA


 


TGGCATGTGTGGTCGTTTTTCACTCCATTGTTGTTGTTTACCCAGTTTATGGGGGTTGTCATGTTTATCACACTCCT


 


TGGATGATTTCCGAAGAGACAGGGTCTTCTATGTTGCCCAGGCTGTCTTTGAACTCCTGGGATCAAGTGATCCTCCT


 


GCCTCAGCCTTCGAAGTAGTTGGGACTACAGGCCCACGCCACCGTGCCTGGCTGGACATGTAAATTTGAAGTGAATG


 


GTTAAACATCCAGCTAGCTGAAAGCATGGCAGACCCTAACAGAAAAGCTACAGTGTGTTTTTGCAGCTATGAAGTGA


 


ATGGTTTCCTGGGGAAAATTGTGACTTTGTATAACTGTTGTTGAAACCAGAATAAATTATATTTCACTTGCATATGC


 


ATAAATTATTAAAATTTTCAGAAGTCAGTGATACAGAAGTACTATTTTGCAATGTTAATCTGTTTGAGTCTTTGGAG


 


AAAGTGGTTTCATTGTAGGTACATAGTGCACTGTTAATATTTTAAACAAGTAGTTCACTCTTCCATTTAAGGGATAG


 


CAGTTCCTTGTATAAAATGACTGGATGTGTATAAAGGAATTATGTTGTCATGTGCCTTTAACCAGCTTTAGTAATTA


 


CTATAATCTCATATTTATGATAGTTTTGTTAGGTGACAGGACCAAATGAAAATATTTTATGTTTTCTCATCACTTTA


 


GATTTTATCATTATGTACATTACTGGGTTTTTAGCATTTCCTAATGTGAAGTTTTAATCACTTTTAAGTATACATTT


 


TTTTCTGTATCATTTAAATAAAATATTTTTATAACTTTAAAAAAAAAAAAAAAAAA


 


>gi|141801971|ref|NM_030923.3| Homo sapiens transmembrane protein 163


(TMEM163), mRNA


(SEQ ID NO: 49)



GCATTTCTGACTCGAGTCCCCGCCGCGCTTGTCGTCGCCGCAGCCGGGATCCGCAGCCCCGCGCCATGGAGCCGGCC



 


GCGGGCATCCAGCGCCGCAGCTCCCAGGGGCCCACCGTCCCGCCGCCGCCCCGGGGCCACGCGCCACCGGCTGCCGC


 


CCCCGGCCCGGCCCCGCTGAGCTCCCCGGTGCGCGAGCCGCCCCAGCTGGAGGAGGAGCGGCAGGTGCGGATCAGCG


 


AGAGCGGCCAGTTCAGCGACGGGCTGGAGGACCGAGGCTTACTAGAAAGCAGCACCCGCCTGAAACCTCACGAAGCC


 


CAGAACTACAGGAAGAAGGCATTGTGGGTGTCCTGGTTCTCCATCATTGTCACCCTGGCCCTCGCGGTGGCTGCCTT


 


TACTGTCTCCGTTATGAGGTACAGCGCCTCTGCTTTTGGGTTTGCATTTGATGCCATCCTGGACGTCCTGTCATCGG


 


CGATTGTCCTGTGGCGTTACAGCAACGCGGCCGCTGTGCACTCTGCCCATAGGGAGTACATAGCCTGTGTCATCTTG


 


GGGGTGATATTCCTTCTGTCATCCATATGTATAGTGGTCAAAGCCATCCATGACCTCTCAACTAGGCTGCTCCCAGA


 


AGTGGACGATTTCCTGTTCAGTGTCTCCATTTTAAGTGGGATTCTTTGCAGCATCCTGGCCGTGTTGAAGTTCATGC


 


TGGGGAAGGTTCTGACCAGTAGAGCACTCATAACAGATGGGTTTAACTCCCTCGTGGGTGGCGTGATGGGCTTCTCC


 


ATTCTTCTGAGCGCGGAAGTGTTCAAGCATGACTCAGCGGTCTGGTACCTGGACGGCAGCATAGGCGTTCTGATCGG


 


CCTCACCATATTTGCCTATGGGGTCAAACTCCTCATCGACATGGTGCCGAGGGTGAGGCAGACACGTCACTACGAGA


 


TGTTTGAGTGAAGGGGGCCAGCATCCGCATGAGACCATTGAGATGAGGAGTTTCCACATAGGCAAAGGGTGCCAATA


 


TTTAACTGAACATCTGGTTTCTTTTTGGAAGTTTTCTTTCACATGGTTTGTCATTACAAGACAAGGTCTGCCCAGCC


 


AGGTGGATCTACCTTGCCCCCATCACCTGCCGCCCCCATCAAACATGTTGGGACAATGCCCATAGGAATGGACCTCC


 


TTCCCCGTCTCCAGCTGGGACTGGTGTTTTTTTAGTCTCTGGAGTATGATGGTTCTCATGGGTAGGATGAGATCTTT


 


GGCAGAAAGGTCTTCGGTGGTGCTCTGAGCCTGCGCTGCATAGGACTGAGCAGACCCACCTCCTCCAGCTTGGGTGG


 


CCCTGCCACTCCTGGTTCCAAGTCTCTCCTTTCCTGGCAGGTCTTAAGGGAAGATTGTACCCCTCACCCTTTACATA


 


CCCAGAATCATCAGTATGTCACTTCCTAATTTCTATCAGTGTATCTCATTATTTCATACTGTTTTACTAATCCTAAG


 


TCTAAACAGATTTGCTCAAAAGGAGACCATTCTATTTTTTAAAGTACTTAGTGATACACGTATAAGCTTTGCATGGA


 


CGAATTAAATAAGCACATTGACCTTTTCTTGTACATTCAGAACCTGAACATCCATGTGAAAACTGGGTCCATTTTTG


 


AGAGATGTGAAACTACAGTTTATTTGTAATAAATAAATATAATCTAAAAAAAAAAAAAAAA


 


>gi|145207957|ref|NM_001001891.3| Homo sapiens transmembrane protein 16G


(TMEM16G), transcript variant NGEP-L, mRNA


(SEQ ID NO: 50)



AAAGATAGATCCTGCTCCAGGAGCCGGGAAGCCTTGCCCTGGCCAGCTGTGCTGGGCACCTCCCCTGCCTGCTTCCT



 


GGCCCACTTGCAGGCAAGGTGAGGGCATGCGAATGGCTGCCACTGCCTGGGCGGGGCTCCAAGGGCCACCCCTCCCC


 


ACCCTCTGTCCCGCAGTGAGGACGGGACTCTACTGCCGAGACCAGGCTCACGCTGAGAGGTGGGCCATGACCTCCGA


 


GACCTCTTCCGGAAGCCACTGTGCCAGGAGCAGGATGCTGCGGCGACGGGCCCAGGAAGAGGACAGCACCGTCCTGA


 


TCGATGTGAGCCCCCCTGAGGCAGAGAAGAGGGGCTCTTACGGGAGCACAGCCCACGCCTCGGAGCCAGGTGGACAG


 


CAAGCGGCCGCCTGCAGAGCTGGGAGTCCTGCCAAGCCCCGGATCGCAGACTTCGTCCTCGTTTGGGAGGAGGACCT


 


GAAGCTAGACAGGCAGCAGGACAGTGCCGCCCGGGACAGAACAGACATGCACAGGACCTGGCGGGAGACTTTTCTGG


 


ATAATCTTCGTGCGGCTGGGCTGTGTGTAGACCAGCAGGACGTCCAGGACGGGAACACCACAGTGCACTACGCCCTC


 


CTCAGCGCCTCCTGGGCTGTGCTCTGCTACTACGCCGAAGACCTGCGCCTGAAGCTGCCCTTGCAGGAGTTACCCAA


 


CCAGGCCTCCAACTGGTCGGCCGGCCTGCTGGCATGGCTGGGCATCCCCAACGTCCTGCTGGAGGTTGTGCCAGACG


 


TACCCCCCGAGTACTACTCCTGCCGGTTCAGAGTGAACAAGCTGCCACGCTTCCTCGGGAGTGACAACCAGGACACC


 


TTCTTCACAAGCACCAAGAGGCACCAAATTCTGTTTGAGATCCTGGCCAAGACCCCGTATGGCCACGAGAAGAAAAA


 


CCTGCTTGGGATCCACCAGCTGCTGGCAGAGGGTGTCCTCAGTGCCGCCTTCCCCCTGCATGACGGCCCCTTCAAGA


 


CGCCCCCAGAGGGCCCGCAGGCTCCACGCCTCAACCAGCGCCAAGTCCTTTTCCAGCACTGGGCGCGCTGGGGCAAG


 


TGGAACAAGTACCAGCCCCTGGACCACGTGCGCAGGTACTTCGGGGAGAAGGTGGCCCTCTACTTCGCCTGGCTCGG


 


GTTTTACACAGGCTGGCTCCTGCCAGCGGCAGTGGTGGGCACACTGGTGTTCCTGGTGGGCTGCTTCCTGGTGTTCT


 


CAGACATACCCACGCAGGAACTGTGTGGCAGCAAGGACAGCTTCGAGATGTGCCCACTTTGCCTCGACTGCCCTTTC


 


TGGCTGCTCTCCAGCGCCTGTGCCCTGGCCCAGGCCGGCCGGCTGTTCGACCACGGCGGCACCGTGTTCTTCAGCTT


 


GTTCATGGCACTGTGGGCCGTGCTGCTGCTGGAGTACTGGAAGCGGAAGAGCGCCACGCTGGCCTACCGCTGGGACT


 


GCTCTGACTACGAGGACACTGAGGAGAGGCCTCGGCCCCAGTTTGCCGCCTCAGCCCCCATGACAGCCCCGAACCCC


 


ATCACGGGTGAGGACGAGCCCTACTTCCCTGAGAGGAGCCGCGCGCGCCGCATGCTGGCCGGCTCTGTGGTGATCGT


 


GGTGATGGTGGCCGTGGTGGTCATGTGCCTCGTGTCTATCATCCTGTACCGTGCCATCATGGCCATCGTGGTGTCCA


 


GGTCGGGCAACACCCTTCTCGCAGCCTGGGCCTCTCGCATCGCCAGCCTCACGGGGTCTGTAGTGAACCTCGTCTTC


 


ATCCTCATCCTCTCCAAGATCTATGTATCCCTGGCCCACGTCCTGACACGATGGGAAATGCACCGCACCCAGACCAA


 


GTTCGAGGACGCCTTCACCCTCAAGGTGTTCATCTTCCAGTTCGTCAACTTCTACTCCTCACCCGTCTACATTGCCT


 


TCTTCAAGGGCAGGTTTGTGGGATACCCAGGCAACTACCACACCTTGTTTGGAGTCCGCAATGAGGAGTGCGCGGCT


 


GGAGGCTGCCTGATCGAGCTGGCACAGGAGCTCCTGGTCATCATGGTGGGCAAGCAGGTCATCAACAACATGCAGGA


 


GGTCCTCATCCCGAAGCTAAAGGGCTGGTGGCAGAAGTTCCGGCTTCGCTCCAAGAAGAGGAAGGCGGGAGCTTCTG


 


CAGGGGCTAGCCAGGGGCCCTGGGAGGACGACTATGAGCTTGTGCCCTGTGAGGGTCTGTTTGACGAGTACCTGGAA


 


ATGGTGCTGCAGTTCGGCTTCGTCACCATCTTCGTGGCCGCCTGTCCGCTCGCGCCGCTCTTCGCCCTGCTCAACAA


 


CTGGGTGGAGATCCGCTTGGACGCGCGCAAGTTCGTCTGCGAGTACCGGCGCCCGGTGGCCGAGCGCGCCCAGGACA


 


TCGGCATCTGGTTCCACATCCTGGCGGGCCTCACGCACCTGGCGGTCATCAGCAACGCCTTCCTCCTGGCCTTCTCG


 


TCCGACTTCCTGCCGCGCGCCTACTACCGGTGGACCCGCGCCCACGACCTGCGCGGCTTCCTCAACTTCACGCTGGC


 


GCGAGCCCCGTCCTCCTTCGCCGCCGCGCACAACCGCACGTGCAGGTATCGGGCTTTCCGGGATGACGATGGACATT


 


ATTCCCAGACCTACTGGAATCTTCTTGCCATCCGCCTGGCCTTCGTCATTGTGTTTGAGCATGTGGTTTTCTCCGTT


 


GGCCGCCTCCTGGACCTCCTGGTGCCTGACATCCCAGAGTCTGTGGAGATCAAAGTGAAGCGGGAGTACTACCTGGC


 


TAAGCAGGCACTGGCTGAGAATGAGGTTCTTTTTGGAACGAACGGAACAAAGGATGAGCAGCCCGAGGGCTCAGAGC


 


TCAGCTCCCACTGGACACCCTTCACGGTTCCCAAGGCCAGCCAGCTGCAGCAGTGACGCCTGGAAGGACATCTGGTG


 


GTCCTTAGGGGAGTGGCCCCTCCTGAGCCCTGCGAGCAGCGTCCTTTTCCTCTTCCCTCAGGCAGCGGCTGTGTGAA


 


CCGCTGGCTGCTGTTGTGCCTCATCTCTGGGCACATTGCCTGCTTCCCCCCAGCGCCGGCTTCTCTCCTCAGAGCGC


 


CTGTCACTCCATCCCCGGCAGGGAGGGACCGTCAGCTCACAAGGCCCTCTTTGTTTCCTGCTCCCAGACATAAGCCC


 


AAGGGGCCCCTGCACCCAAGGGACCCTGTCCCTCGGTGGCCTCCCCAGGCCCCTGGACACGACAGTTCTCCTCAGGC


 


AGGTGGGCTTTGTGGTCCTCGCCGCCCCTGGCCACATCGCCCTCTCCTCTTACACCTGGTGACCTTCGAATGTTTCA


 


GAGCGCAGGGCCGTTCTCCCTCGTGTCCTCTGGACCCACCCGCCCCTTCCTGCCCTGTTTGCGCAGGGACATCACCC


 


ACATGCCCCAGCTCTCGGACCCTGCAGCTCTGTGTCCCAGGCCACAGCAAAGGTCTGTTGAACCCCTCCCTCCATTC


 


CCAGTTATCTGGGTCCTCTGGATTCTTCTGTTTCTTGAATCAGGCTCTGCTTTCCCCCTAGCCACTACAGGCAGCCT


 


CTGACAGTGCCGCTTTACTTGCATTCTGCAGCAATTACATGTGTCCTTTTGATCCTTGCCCAACTTCCCTCCCTCTC


 


CCAGCTCCTGGCCCCTGGCCCAGGGCCCCTCTTGCTGTTTTTACCTCTGTTCCTTGGGGCCTAGTACCCAGCAAGCA


 


CCCAAATGGGGGAGGTTTTGGGATGAGAGGAGGAAACGTGTATACCTGTAACATCTGGTGGCTCTTCCCCCAGAAGT


 


TTGTGTTCATACATAATTGTTTTCCACGCTGGATCATAATGTGACGTGCAGTTCTGCCCTGTGCTGGGGAGCCACAT


 


GAAGCTTCCCCTGGCTAACTTGCTACCCCGCAGCAATCCCAGTGTGGCCGTCTGCTTGCTAAAAAATGGATCTGTGC


 


TCATCTGTATTGATGTCCTTGGAGTTCTACAAGTGGAACTTAAGTGTCAAAAAGAATATGTGGTTTTTAGCTGAGCG


 


TGGTGGCTCACACCTGTAATCCCAGGACTTTGGGAGGCTGAGGCAGGAGGATTACAAGGTCAGGAGTTCGGGACTAG


 


CCTGTCCAACATGGTGAAACCCTGTCTTTACTAAAAATGCAAAAATT


 


>gi|156416013|ref|NM_014020.3| Homo sapiens transmembrane protein 176B


(TMEM176B), transcript variant 1, mRNA


(SEQ ID NO: 51)



GCTGACCATGCTGGAACTGCGGCGACTACAGAGCCTGCGGGAACCTCCCCTTTCGCCCAAGATCTGCTCTGTCCCCC



 


TCATCCTCCTCCCAGGGCCCTGGCGTCTGGGTCAAGCAGCGCCCCACACCTCGACCCCTCACCCCCTCCTCCCGGGC


 


TCTTCCTGCGGCCTCCCCTCCACAGTCCGCAGGCTCTGGGACAGGACCGAGTCCTTGGCTGCCTGTGGAGCTCCTGT


 


GCCAGCAGCTGCGCCCCGGCTGCGCTCCGGATACCCCCATCCCCGCCACCGCCGACCTCCCGCTCCACCGACTGCTG


 


CTCACGCCCGACGGGTTCACGCCGCCCCTGCCCCGTGAAGGACCGCGCTGCGGTGCGGAGGCAGGATGACGCAAAAC


 


ACGGTGATTGTGAATGGAGTTGCTATGGCCTCTAGGCCATCCCAGCCCACCCACGTCAACGTCCACATCCACCAGGA


 


GTCAGCTTTGACACAACTGCTGAAAGCTGGAGGTTCTCTGAAGAAGTTTCTTTTTCACCCTGGGGACACTGTGCCTT


 


CCACAGCCAGGATTGGTTATGAGCAGCTGGCTCTAGGGGTGACTCAGATATTGCTGGGGGTTGTGAGTTGTGTTCTT


 


GGAGTGTGTCTCAGCTTGGGGCCCTGGACTGTGCTGAGTGCCTCAGGCTGTGCCTTCTGGGCGGGGTCTGTGGTGAT


 


CGCAGCAGGAGCTGGGGCCATTGTCCATGAGAAGCACCCGGGCAAACTTGCTGGCTATATATCCAGCCTGCTCACCC


 


TGGCAGGCTTTGCTACAGCTATGGCTGCTGTTGTCCTCTGCGTGAATAGCTTCATCTGGCAAACTGAACCCTTTTTA


 


TACATCGACACTGTGTGTGATCGCTCAGACCCTGTCTTCCCTACCACTGGGTACAGATGGATGCGGCGAAGTCAAGA


 


GAACCAATGGCAGAAGGAGGAGTGTAGAGCTTACATGCAGATGCTGAGGAAGTTGTTCACAGCAATCCGTGCCCTGT


 


TCCTGGCTGTCTGTGTCTTGAAGGTCATTGTGTCCTTGGTTTCCTTGGGAGTAGGTCTTCGAAACTTGTGTGGCCAG


 


AGCTCCCAGCCCCTGAATGAGGAAGGATCAGAGAAGAGGCTACTGGGGGAGAATTCAGTGCCCCCTTCGCCCTCTAG


 


GGAGCAGACCTCCACTGCCATTGTCCTGTGAGCTGCCAAAGACCCCACGGGGTGCCCGCATGTCCCTGTCTAGGGCA


 


GCCCAGGGCCCCCACTCCTGGCTCCTCACACTTGCCTCCCCTATGGCCGCTCTCCAGACCCTCCTCCTTTCTTCTCC


 


CCACATCCGCACCTGCTGTTCCCACTCTGGGGTTCTCAAGTCCATGAACAGATATTGTTGCATTTTCCACAATGCTG


 


ATTAAACATAATAAACAATCCAGAAAAGCAGTTTTGCCCAGAAAAAAAAAAAAAAAAA


 


>gi|153792041|ref|NM_020823.1| Homo sapiens transmembrane protein 181


(TMEM181), mRNA


(SEQ ID NO: 52)



CGCGGAGGCGGATGGGCGCGGCTCCCTCCCCCACTCAGGCCTCTTCACGGGGCGGGGGGCCGGGTCCCCCAGCCCCC



 


ACCCGCGCCGTGTCCAGCTCCTCGCGTGCTCGCGGCGGAGCCCTGAGCGCACTGGGTCCGAGTCCTGCGCGCCCCCT


 


CACCACCTCCCCCGCACCTGCTCCTCCTCCTCGGTCCCGCCCAGCGCGCCAGCAGCCCGATCCCCAGTGCTGGGAGA


 


AGAGAGGGGGCGCAGGCGGCGACACAAAGGGTGGAGCGGCGGGACCGGGACCCGGGAGGCTGCGCGGCATGGACGCC


 


GAGTACCCTGCCTTTGAGCCCCCGCTCTGCAGCGAGCTCAAGCACCTGTGCCGGCGGCTGCGGGAAGCGTACCGCGA


 


GCTCAAGGAGGACCTCACGCCCTTCAAGGATGACCGCTACTACAGGCTGGCGCCCATGCGGCTCTACACGCTCTCCA


 


AGCGCCACTTTGTCCTCGTGTTTGTCGTCTTCTTCATCTGCTTTGGCCTGACCATCTTCGTTGGGATCAGAGGACCT


 


AAAGTGATCCAGACTTCTGCGGCTAATTTTTCACTAAATAATAGCAAAAAGCTAAAGCCAATTCAAATACTTTCAAA


 


TCCACTGTCTACATACAATCAGCAACTATGGCTGACATGTGTTGTTGAGTTGGATCAATCAAAAGAAACTTCTATTA


 


AGACAAGCTTTCCCATGACTGTTAAAGTCGATGGTGTAGCTCAAGATGGAACCACGATGTACATTCATAACAAAGTT


 


CACAACCGGACAAGGACCCTCACATGTGCAGGGAAATGTGCGGAGATTATTGTGGCTCACCTTGGCTACCTGAACTA


 


CACTCAGTATACAGTGATAGTGGGATTTGAACACCTGAAGCTCCCCATCAAGGGAATGAACTTCACATGGAAGACTT


 


ATAACCCTGCCTTCTCCCGGTTGGAAATCTGGTTCCGGTTTTTCTTTGTGGTGCTCACCTTCATCGTCACTTGCCTG


 


TTTGCGCATTCCCTCCGGAAATTTTCCATGAGAGACTGGGGCATCGAGCAGAAGTGGATGTCTGTTCTCCTGCCTCT


 


GCTGCTACTTTACAATGATCCGTTCTTCCCCCTCTCCTTCCTGGTCAACAGCTGGCTCCCAGGGATGCTGGATGACC


 


TCTTTCAGTCCATGTTCCTGTGCGCCCTGCTGCTCTTCTGGCTGTGCGTGTACCACGGGATTCGTGTCCAGGGAGAA


 


AGAAAGTGTTTAACTTTCTATTTGCCTAAATTCTTCATTGTTGGACTATTGTGGTTGGCTTCTGTTACGCTAGGAAT


 


ATGGCAAACAGTTAACGAATTACATGATCCAATGTACCAGTATCGAGTTGATACCGGAAATTTTCAGGGAATGAAGG


 


TCTTCTTCATGGTGGTGGCAGCGGTGTACATTCTGTACCTCTTGTTCTTGATAGTGCGGGCGTGTTCCGAGCTACGT


 


CACATGCCTTATGTGGATCTCAGGTTGAAATTTTTGACTGCATTGACTTTCGTAGTACTTGTCATTAGCATCGCCAT


 


CCTTTATTTGAGATTTGGGGCGCAAGTACTACAAGACAATTTTGTAGCAGAGCTGTCAACTCACTACCAGAATTCAG


 


CCGAGTTCTTATCTTTCTATGGCCTGTTGAACTTCTATCTCTACACCTTGGCCTTTGTATATTCTCCATCGAAGAAT


 


GCCCTCTATGAGTCCCAGCTGAAAGACAATCCTGCCTTCTCCATGCTGAATGACTCGGATGATGATGTGATTTATGG


 


GAGTGACTATGAGGAAATGCCGCTGCAGAACGGCCAGGCCATCCGGGCCAAGTACAAGGAGGAGTCAGATAGTGACT


 


GAGCCCCGGCCAGCCCAGCGAGGCGACAAGATGCCTGGATGCTTTCCCCGGTGACCGTCTGCTGACCTTCCCCTGTT


 


ATATTCAGATTTTTCTTACAAGCAGAGATTTCCTGTTCATTTGTTTACATATTTTTTTAAAGGAAAACCAAAACTGA


 


GGGTAAATTTAAATGTTTAGCCAAATTTATTGTCATGGTGGCTACGAGAAGAGGCATTGATAACAAGTTTCAACAGC


 


CAAATCCTTTTTTACAGAGATTTCAGATGAGCGTGTTTTCAGTGATGAGGAAATTTCACGTTTTTAGTACAGTGAAT


 


TATGTACTTTTTTTTCCTGTAATCATTCACTGATTCCAAGTTCACGGGCAGCCTGTGACTAGGTCCTCAGCGTGACA


 


GCATCACCCTCTTTCTTCCCTTTTCCATGGTACTGTTTTGTGACCCTTTAAACTCAAAGGGAAGCCTTATCTGTGGC


 


TGCTTCAGGGCAGTCCTTCCTCGTTGAGTGGCCAGTGCCCTGGGTAACCAGGTGGCTGAAGTGATTGGTCAGTTATG


 


TGGACTGCGTTTTGTGCAGTGTGTGAGTTATGACTCATCGGGAATGGGAGATGCTGGGGTTCCAACCCTTCACGTCA


 


CCAAAGGGGAAGTAATAGTGTGGAGTTCTGAGGAGGGTTTGATAAGTTGAATAAGGAAAGGCTAAGATAATTTACAG


 


GTTACCAACTCATGTGGGGAAGGTCTTACTGCCATGGTGCTTTTCAGGGGCCTGTGTGTACACACATGATTAAATGG


 


ATTTGCCTGTGGGAGGTATGGGCAGGAGAGGAACCCTTACCATTCCAGTAAATAGCAGTTTCTGCAATTCTGTTGAA


 


TATGAAATGCCATAGAGCTTTATTTATTTATGTAAGTAAAAGCTAAATGAGGGGCCAGGTGCAGTGGCTCACATCTG


 


TAATCTCAACACTTTGGGAGGCCAAGGTGGGAGGATCACTTGAGCCCAGGAGTTTGAGACCAGCCTGGGCAACACAG


 


GGAGACCCCGTCTCTATAAAACATTTAGAAAGTTGGCTGGGCATGCTGGGGCATGCCCATAGTCCCAGCTACTCAGG


 


AGGCTGAGGTGGGAGGATTGCTTGAGCCCTGGAGGTCAAGGCTGCAGTGAGCCATGATTGCACCACTGCACTCCAGC


 


CTGGGTGTCAGAGCGAGAACCCGTGTCATAAATAAATAAAGCTACATGAAAGATTGATAGAATATTTTAGATTATTT


 


ATTGGCCAAAAGTTTTTAAAACTCATATTTGGAAGCAAAATGAAAAGCAAGTAAAATGTTTTAAATGGTTCATGGAA


 


AACGTATTTGGGTAGAAGGCAACTCGTGCTTCCGGAAGGGGTTCCCTGTCCTCCATGTGTCCACATGGCGGTCAGGT


 


AGGGACGACCTGTTCTGTAAAGTCCTTGGCACTGCTGAATCTGTGGCATCATAGAAGGCCCTGGAGCTTCCCCGTTC


 


CTTTCAGTCAGGGACTCCATATAGAGTCTCATGTGGACGTCTCCCGTGCTTTCCTCTTGACCTCTACAGTCACACTT


 


CTGTTAACATCTGGTAACTGTGGGCAACCTGACTGATGCCGTCTTGGCAATTGAGGTCCAGAAGATGATAGTTCCGC


 


AACGCAAGCAGTACCTACTTTTTTTCTTCATCTATGCATTGACTCTCAGATTACCATGCAGAGCTTCACGTTATCAT


 


CCACGTTAAGTAGTGCTAGGTAGGACCTTAGAGATGTTCATGAGAAACTATTTGTTATGACTTTCCTTTGTATCTTT


 


CCTTTTAATTTAAACTTTAATGATAATGTACTTTTAATATGGATTCTATTCACATTTGTTTTAAAAACCTTGTAAAT


 


ATGAATGTTTAAGACAACTTACTGCAAGGGTAATTCAAGTTTACATGATTTTTAAATTTGCAATGATGTTTTTTTTA


 


TTCTGTGTATTGAAAAAAATTTTCTGTTACCAAATTTTACAACTTCTAATAAGACTACTATAACTTTATGTAAACTG


 


ATGAAGATGTGCTGATTAACATATTCTGTGATATGGTTTACAACTTTTAATCATAATTGTCCATGATTTTGGAATGC


 


TGTTATTTATCAGTAAATGTAAAATATTTGAGGCATTTAGCCATACACACACTAGAACTTTTTAAAACTTTGTCCTA


 


TAGTGTAATTATAAACTGATGACTATTATCTTCATACATTGAGTCTTCATGCATCAATGAAATGAAAAATATAGGAT


 


TATTTATTTACTTTTTGTAACTAAGTGGGAAATAAGAAAAAAAGTTAGAAAGTACTTAAGGGGAAAATCGTTCTTAC


 


TAAGTCATGTATTTTCAACTTGTCTTCCCTGGTATATCATAAATACCGACATATTACATACCCCATGTAAAATTTTG


 


CTTAAACTCTCTAGCACTTGGCATGTAGAATATGTACCATAGGTATCAGGTTAAAACACTAAAGTCTGCCAGAAACT


 


TTTGACAGTAGCAAGAAAATTGTTGAAGAAAAAATAAATTATTTACTGAGGGTAGTTATGTTAAAGTTTTGCGAACT


 


TAAAGGGCTGACTTTAGTTCCTTCATGGTAATGGCTTGAGTAACATCATCTTTGGGATTTTTTAAATACTGGTCCAG


 


TCTAGGAGAACCTGGAAGATGACCAGAGGTATTTCAGTTTCCCTAGGGAGAGCTTCGTTATCCATGTGGATGATAAG


 


TCTGCTTGATTTATTATTAAATCATTATAGCAGTGAAGTGGTGCCATTTTCTCTCTCTTAAGCCCCATTTGAAAGGC


 


TAGAGAAGGGGATATATATACTATGTTCAAGGTTTGTAAGGTTGTTAATGTACATAATTGCAGATTGCAATAAAAGC


 


TTAGATACATTTTGTAAACCCAACCCACTAAATGAGCAGGTTACAAGACAAATGTCACCAGCCTCAAGTATTTTATG


 


AACTATTTACTGAGGGTAGTTATGTTAAATAGATTATAATGTGGTAAATTATTTCCTGAATCCTTTATCACAGGAAA


 


AACACAGACCCTCATAAAAGGGATAATTAAAACGGATGTGTCTGAACATTTAGTGAAGATGAGACTTAAAACATGAA


 


AGTGTATTTGTGTATTTTGAGGGTTTTAGAAACCGGTTGCCTTAGAGGTTAGACTTTTGAAGAAAAAAAAAAAAAGA


 


TACAGATCTTTTCCCCTGGCCAAAGGGAAGTTGTATTAGTCTGTGACATCTTGTGATGCTGTTTATCTTGGTTTGAC


 


ATTGGAGATACGCTAGTAACTGTGATACCATACTATAAAACAGAAGAATTTTCTGCTACTAAAAACTGCCTTTTTAC


 


AAAATGACTGTAAATATTTGTAAAATAAAATAACACTAAACTTTAAGCCCAAAAGGAGAGATAGAGCCATGTGTTCA


 


GTTGTGGACCTGTCCGTGGGGCACAGTGCCACCCCATCACAGTGTTGCTGTCATCAGGCAAAAGTGAATGTTTGTTT


 


ATGGCAAATTCGTCTTTTGCGAATGGCTTAATTCTGACACTACCTTTCTGGGAAATGTTAATAAATTTTTAATATTC


 


ACTTCTA


 


>gi|58533180|ref|NM_138399.3| Homo sapiens transmembrane protein 44 (TMEM44),


transcript variant 1, mRNA


(SEQ ID NO: 53)



CGCCCGGGAGCGCGCCCTTCTCTGCCCGCGGTCGGTGCGCTCGGCCGGAGGCGCCGCGGCGGAACGGAACCCAGAGA



 


AGGGGACGCGGGGCGGCGGCGCTCGGGGCTTGCCCGCGGCGAGGGAGGCTGCGCCCAGGTCCCCGGCCCCGCGCCGC


 


GCGCCCAGCCGCGCCATGGGGGAGGCGCCCAGCCCCGCGCCCGCGCTCTGGGACTGGGACTACCTGGACCGCTGCTT


 


CGCCCGCCACCGCGTCTGCATCTCCTTCGGCCTGTGGATCTGCGCCTCCTCCTGCTGGATCGCCGCCCACGCGCTGC


 


TTCTCTATCTGAGATGTGCACAGAAACCCAGACAGGACCAGTCGGCACTGTGTGCTGCGTGCTGCCTCCTGACCAGT


 


CTGTGTGACACCGTCGGGGCTCTTCTGGCCAGACAGCTCACAATCCAGGTTTTCACTGGTGCCTACCTAGCAGCTAT


 


TGACTTAGTGAACTTTATGTTCATTCTCTTCCCAGTCTGTGGATCCAAATTCAAGTCTAATTCAGATCGGGAAGCCC


 


GAGAGAGGAAGAGGAGGCGGCAGCTCAGGGCCAGTGTGTTTGCCCTGGCCCTGCCGCTGAGCCTGGGCCCGTGCTGG


 


GCTCTGTGGGTTGCTGTCCCGAAGGCTTCAGCCACCATCCGGGGGCCACAGCGGAGGCTGCTAGCGAGCCTGCTGCA


 


GGAAAATACTGAGATCCTCGGCTACCTGCTGGGTAGCGTTGCTGCCTTTGGCTCCTGGGCTTCTCGGATCCCCCCTC


 


TCTCCAGAATTTGCCGGGGGAAGACATTTCCCTCCATCCACCTGTGGACCCGGCTCCTGTCGGCCCTGGCTGGCCTC


 


CTCTATGCCTCGGCCATTGTGGCCCACGACCAGCACCCTGAGTACCTGCTGCGGGCCACACCCTGGTTCCTGACCTC


 


CCTCGGCCGTGCGGCACTGGACCTCGCTATTATTTTCCTTTCGTGTGTGATGAAGAGCAAGATGAGACAGGCCTTAG


 


GATTTGCCAAGGAAGCCAGAGAGAGCCCTGACACCCAAGCCCTTTTGACCTGTGCAGAGAAAGAGGAAGAAAACCAG


 


GAGAATTTGGATTGGGTGCCTCTCACCACACTGTCACACTGCAAGTCACTGAGGACAATGACAGCAATCAGTCGCTA


 


CATGGAGCTGACCATCGAGCCTGTGCAGCAGGCAGGCTGCAGTGCCACCAGGCTGCCAGGTGACGGGCAGACGAGCG


 


CCGGAGATGCGTCCCTGCAGGACCCCCCGTCGTACCCTCCCGTTCAGGTCATCCGGGCCCGGGTGTCTTCCGGCAGC


 


TCCTCTGAGGTCTCCTCCATCAACTCCGACCTGGAGCAGAAGTATTGGGAGGCCCTAAACTCGGAGCAGTGGGACCC


 


TGAAGATGTGAACCTCGAAGGCAGCAAAGAAAATGTGGAGCTACTGGGATCCCAGGTGCACCAGGACTCTGTGAGGA


 


CAGCACACCTGAGTGATGATGATTAACACCTTCTGGAGCCAGCTCATCAGCTCAGAGCCCAGGGTCAGGAGTTCGTT


 


CAGTAACGCAGCGGGAATCAATCTGCACTGACACCGCGGCAGGAACTGAAGCTGCCCTGGCAAGTGAGGAACCAGGA


 


GCCGTCACTGAGTGTGGCTGGGCTACATCATAGCTCATCACGGAGCTACGACTTTGGGTACTGCGGACAGACCTGGA


 


TAGGCCCAGCATTCGTTCTGAAGATCACAGTTCACAGAAGCTTTTGCTTCGTAAAGATAATCCAAAGGATCTCAGAC


 


CCGCTCTTCCTTTTCCCTTCATTCCCTTGAGAGTCAGCCATGAACGGAATACCTGCTAGGTTCCAGGAATGAGCTCA


 


CCTAACAGATAGCAAATGTGTCTGGTTAGATCTCAGCAGAGCCCATTCTGCAAGACCTGGCTGAGCCAGATGAGAGG


 


GTGGGCCCTGTGCTGGGGGGCCTTGGGTCACACACAGGAACCGAGACCTGGCTTCCACCCCCCAGTCACCCACTTGG


 


GTTATCTGCTGGAAGTTATCGATAGGACTGTGTGGCCAACCAAGTGCTTGTGAGATCACTGACACTGCAAAAACAAA


 


GCAAACTGCTCCGGGTACCAGGACTTCCTCCAACCTGGCAAGGGTGTGCGCTGAGGCGGGGCTTGCAGGTGAGGGGG


 


CTGTATGCTTCAGGAACTAACTAAATGCATGCAGAAGGTAAGAGGCATGATGGGAGGTGTTCAAGCACAGCAATCCC


 


ATTTGGGAGTTATTTTGATACTGCGATGAGTAAGGGTAAGGGCGCATGGAATGGGGCTAAGGTGGGAGTGAACACTG


 


GGGTGAATAAATTTTAAATCAATTCAAGTATCTCAAAAAAAAAAAAAA


 


>gi|83415183|ref|NM_175861.2| Homo sapiens transmembrane and


tetratricopeptide repeat containing 1 (TMTC1), mRNA


(SEQ ID NO: 54)



AGATAGAAAAAGTAGTTTGCTTGGCATCTCCCAAATTATCTTGAGCAAACAATAAAATAAGAAATGTTTCAGAAGAC



 


AATTCGGCTCCCAGGCCCAAACCAAAACTCGAACCTGGTACTTTTTGTAAGTGCGGGCCAAGAAAGGGGCTGTAAAG


 


TTAAAGAGCCGGTGGCGCCTCTGAACACACCCGGGCAGGGCGAGCAGGATGTCCTTGTCCAGGGAGACCCCTTCTCC


 


TGGCTTTGAGGAAGGTGCTCCCTATCCCCGCGGGTTCCTCCGCCAAGCGGGACGCCGCGCCGGGCGGGTGAGAGAAA


 


GCCCGGGCAGGAGAGCACAGAGCCGGCGACTGGACGCGAGCGCGGGGCGGGTGGAGAGCGTCTCTCCGGGCGCCGCT


 


GCTGTTGTCCCGGGTGCTGAAAAGCCGGGAACTTCCCGGGAAGCAGCGGCACTTTTCTCCCTGGAAGGCTAAACATA


 


TTTTTGACTGGTATGAACCCATTCTACTTTCATGCAGTAAATATAATTTTACACTGCTTAGTGACTCTTGTGCTGAT


 


GTACACCTGTGATAAAACTGTCTTCAAGAATCGTGGACTTGCTTTTGTAACGGCATTGCTTTTTGCTGTACATCCTA


 


TTCATACTGAGGCGGTGGCTGGGATCGTTGGCAGAGCGGACGTGTTAGCGTGTCTGCTGTTTCTATTGGCCTTTCTC


 


TCGTACAACAGGAGTCTGGATCAGGGCTGTGTTGGGGGAAGTTTCCCTTCCACGGTGTCTCCCTTCTTCTTGCTGCT


 


CAGTTTGTTTCTGGGGACCTGTGCGATGCTGGTGAAAGAGACAGGCATCACGGTGTTTGGAGTGTGCTTGGTTTATG


 


ACCTCTTTTCCCTTTCCAACAAGCAAGACAAGTCGAGCAATGGGGCCCTCTGTCCACGCAGCCCACAGCAGCCCGGG


 


AGCCCCCAGCCCTCCTCACTGCCAGGCCATCCTCACCGGGAGAATGGGAAGCAGCAGCGGTTCCCTCACAAAGGAGC


 


TTGGGGTGGCTGCCACTCTCCACTGCCACCAGAACCCAAGAGCAGTGGATTCCCAGTGTCCCCACGAGCTGTGTGGT


 


CCATGATGAGATTCCTCACCTATTCCTACCTCTTGGCCTTCAATGTGTGGCTTCTGCTTGCACCCGTGACCCTGTGC


 


TATGACTGGCAGGTCGGCAGTATTCCTCTGGTAGAGACCATATGGGACATGCGGAACTTAGCCACCATCTTTCTGGC


 


GGTTGTGATGGCCTTATTGAGCCTGCACTGCTTAGCAGCCTTTAAGAGACTGGAGCACAAGGAGGTTTTAGTCGGCT


 


TGTTGTTCCTGGTGTTCCCGTTCATTCCAGCCAGCAACCTCTTCTTCAGGGTGGGTTTTGTGGTGGCGGAGAGAGTC


 


CTTTACATGCCTAGCATGGGCTACTGCATCCTTTTTGTGCATGGACTGAGCAAGCTCTGCACTTGGCTGAATCGATG


 


TGGGGCCACCACCCTGATTGTGTCCACTGTGTTGCTGCTGTTGCTTTTCTCTTGGAAAACTGTGAAACAGAATGAAA


 


TTTGGCTGTCAAGAGAGTCCCTATTCAGGTCTGGAGTTCAAACTCTGCCCCACAATGCCAAGGTTCACTACAACTAT


 


GCCAATTTCCTGAAGGACCAAGGTCGGAACAAGGAAGCGATCTACCACTACAGAACAGCTCTCAAGTTGTATCCACG


 


CCATGCAAGTGCGCTCAACAACCTTGGAACACTGACGAGAGACACAGCAGAGGCAAAGATGTACTATCAGAGGGCTC


 


TCCAGCTCCATCCACAGCATAACCGGGCTCTTTTCAATCTGGGGAATCTCCTCAAGTCCCAGGAGAAAAAGGAAGAA


 


GCTATCACCTTACTGAAGGATTCCATCAAATATGGTCCAGAGTTTGCAGATGCATATTCAAGCTTAGCTTCGTTATT


 


GGCTGAGCAGGAGCGGTTTAAAGAAGCTGAAGAAATATACCAAACTGGAATAAAGAACTGTCCAGACAGCTCAGATT


 


TACACAACAACTATGGGGTTTTCTTAGTTGATACTGGCTTACCAGAAAAGGCAGTGGCCCATTACCAGCAGGCCATC


 


AAACTTAGCCCCAGTCATCACGTGGCCATGGTGAACTTGGGAAGACTCTACAGGTCACTGGGAGAGAACAGCATGGC


 


TGAAGAATGGTACAAGCGCGCCCTGCAGGTGGCACACAAAGCTGAGATATTGTCACCTTTGGGAGCACTGTATTACA


 


ACACTGGCCGATACGAAGAGGCTTTGCAGATTTACCAGGAAGCTGCAGCACTTCAGCCTTCTCAGAGGGAGCTCCGC


 


TTGGCACTGGCTCAGGTTTTGGCCGTGATGGGTCAGACAAAAGAAGCTGAAAAGATGACCAATCACATTGTGTCAGA


 


GGAGACCGGATGCCTTGAATGCTATCGCCTCTTGTCAGCCATCTATAGCAAGCAGGAGAACCACGACAAGGCACTTG


 


ATGCTATAGACAAGGCTCTCCAGCTGAAACCAAAGGACCCAAAAGTCATTTCTGAACTTTTTTTCACAAAAGGAAAC


 


CAATTAAGAGAGCAGAACCTTCTCGACAAAGCTTTTGAGAGCTATAGAGTGGCTGTGCAACTAAACCCAGACCAAGC


 


ACAGGCCTGGATGAACATGGGTGGCATCCAACACATCAAGGGAAAATATGTGTCTGCAAGAGCTTATTATGAGAGAG


 


CCTTACAGCTGGTTCCAGACAGCAAACTGCTGAAGGAAAATCTTGCCAAATTGGATCGCCTAGAAAAACGATTACAA


 


GAAGTTCGAGAAAAGGATCAAACATAGCACCACCGTCTGACCCAACCTCATAGGATAATGTGGTGCCTCTGAAAGGG


 


GAGTGATGGAAGCCTTGCTTTCACATCAGCAGGGGCACAACTAATGAGATTTTCTCTCATTCCGAGTTCAGGGTGAC


 


ACATTTTGGGACATCTGCTGGTAGCCCAGTGCTGAAGGACTTGCTTTTCCATGAAGAAGACGAAAACAGCAAACAAG


 


GGCAAGAAGGTCTGAGAGGGAAGGAGAATGACATTTACACATTTTACAGATTTTTGTTTGGTTTAACTCCAGATTTC


 


TCTTGATATATCTCTGTGCTTTTGAGACCTGGAGATCTAATTCTGTTTAGACATTTTTTGTCCCAGAAATACAGAAG


 


CTTGAAATGCTATGAAGGCAGAGCTTCTATTCTTTATGGGATGAAATATTTCAAAAGAGGATAAATCCTCTGTGGTA


 


AGCCATTTGGAAAATCCTACCAAGAATTGGCTTATTTAATTTTCCAGAACCAGGAATGAGTATCTAATAGCTTTTGT


 


AGAACCTTCCAGAATATGTGGGGAAAAAGGGCTATTGCTAAGTGAGCTTTATCTAATATCCTCCTAAGAGTTTTACT


 


AGTGCTTTTTTGAGGAATTACAGGGAAGCTCCTGGAATTGTACATGGATATCTTTATCCCTAGGGGGAAATCAAGGA


 


GCTGGGCACCCCTAATTCTTTATGGAAGTGTTTAAAACTATTTTAATTTTATTACAAGTATTACTAGAGTGGTGGTT


 


CTACTCTAAGATTTCAAAAGTGCATTTAAAATCATACATGTTCCCGCCTGCAAATATATTGTTATTTTGGTGGAGAA


 


AAAAATAGTATATTCTACATAAAAAATTAAAGATATTAACTAAGAGAAATGTCCTACTTTATTATCTTAATGTTCAG


 


ACATCATGAGATTTATTATTTTTTTGAAAAATATATTGAACCATTGAGGAACCTTTATGATGTATCACAGAAATCTT


 


CATAGATTCTAACTAGATGGAAAAAGAGCTCTATTTATTTGTGTTCCTAGGCTTAATGAGAATTCTGGGCTTAGAAC


 


ATCAACGATTAATACCCAGAATTCTTTGTTTTGAGAATATTATGGAGAATGCTCTAAAAATCTAGGGTAAAGATCTA


 


AATTCAAATTTTAAATATATATTTATATTTAAGAAATAGGAAAGGCAAAGTTGAACTCACAATTTGACATTTATTTT


 


TAGTGTTATTTATTTCATAACTTATAAAATATTTAATATATACATACACACTCTTCTTTTTTCTCTGTACAAAGTGG


 


TTTTAATATCAGCTTTCAAAACTGATCTTATAAAATGTAAATCTAAATTGTAAAATAGTTAAGTTTTAACAGTCCCT


 


CCCAAACTTTGTGTTGATTATTCACTTGCTAAAGAGATGTGAGGAATCAGCCTTCAGTTTTTTGGCAGTAGTATATT


 


TTGGAAGTGAAGAAATTGGAACACCTGTTTCTAATTTGGTCTTCATCATTAGAGACAAAACCAAAACACTCCAGGCA


 


GTACTGTTTATAGTGCTGAGCCAGGTAGCACACAGACATAGTAGCCTAAAGGCTCACATAATTCGCATGCTCAGGCC


 


AGGGCAGGGTAAAAATAGCCTTCTGCTTCTTTCAACCCAGTATCAGGAAGCACTACCCCAGTGTTATTATTTGTTTT


 


GTCAAGGTAAGTCTAAATAAACAAGAAAAACTTCTTCGGAAGGCATGGCGAAGGGAGTATTTTAAATGAAAATGATT


 


ACAGAATTTGAATTAGCATGCATCTCTTTGTGTGCAACAGTAATCCAAGAATGTATATGTTACCACTACAACCATTT


 


GTTTCTAATAGTTTTTTCATGTTATATAACATAAATGTATCCACAACCTTAATTAAGAACTATTCTTCCCCCAAAAT


 


CATAGTCCTAGTGTCAAGAAACATACTCCAGTGTTTATTGTAAAATAACAACCACACCCTCAAATTGAAAAAAGTGA


 


ATGTCTAGGACTTTATTACAACTTTTCAGAATAATCTGTAATGAAAACTCATGCTTAAAAATTTAATGGAAAAGACT


 


GAGCCCCAAATTTTGAATAGTGATTACGCCTTACTTGAAGTGCTAATAAAGGTAGGAGAGTACATTTGTTGGAATAA


 


CAGAAATGGTGATTTCAGCCTAAAAGTTTCTGAGGGTAAAGGATCACATGACCTTCAGGAAACTCTCTGCCTCCTGT


 


AGGTGCTTTCCTATCTCCCCCATCCTTCCCTACCCCTTTTCCCTTTTCCTTCCTCTCTTTTTCTCTCACTGTCACTC


 


TGTCTACACACACTGGCATCTTTTGAACACTAAAAGTAAGCACTGTTTTTTAAAAAAGTAATTATTTGTTGGATCAG


 


ATACTTTTATCCCAAGTGAATACCTTCACTGAGATGTGGCCAATGCAATAGTTTCACAGTAAAAACAGTGCCTATAA


 


GAAAATAGATCACATACTATTTTTCAATGATATTAAGTGTATTTTGTAACTATTTTCATTTGGTCCTTGTAACATGA


 


AATAATACATGGAACTTACCTTTATAATAAAAATGGAGTGCCCTGGTTCATCATAGAGGTGCATCTAGTTTGCCCTT


 


AATGGAAGTATACTTGCTGTGTGGATTGATAGCACCTTCTTGAAATGGAGGAGCTCAGCTGGCCTCATGGATGTGCA


 


ATTTTTGCAGTCCCACAGGGCCTTGCATACAGAAGCACCCCGAGCTCAGTTGAATGTCTGTTTGATTTTTTCTTATT


 


TATTTTTTTGAGACACAGTTCCACTTTGTCTTTTTGTCACCCAGGATGGAGTTCAGTGGCACAAACATGGCTCACTG


 


TAGCCTCGACCTCCCTGGCTGAAGGGATCCTCCCACCTCAGCCTCCCAAGTAACCGAGACTACAGGCATATGCCAGC


 


ATGTCCAGCTAATTTTTGTATTTTTTGTAGAGACAGGGTTTCACCATGTTGCCCAGGCTGGTCTCAAACTCCTGGGC


 


TCAAGCGATCTGCCCACCTCTGCCTCCCAAAGTGCTGGGATTAAAGGCATAAGCCACCATGTCCAACTGAAATTCTT


 


AATAATTAATAATTTTTGAGCAAGAGGTCCACACTTTCATTTTGCACTGGGTTCCCAAACAGGTCCTGGGTAGGAAG


 


GATGGCTGAGGATAAAACAGGAGTTGCTTTGGCCTGGCTGAACATTTGAACCAATGATCAGAGTTTCATTTTATGAT


 


TGTGTTACTCTGAACAGATTTGCTATTTTTTTCCAGCTACATTTAGAGTTCCTCATGTATATATCACCCCTCTTTTT


 


CCAGTCCATCTAACCTCTCCTTTTTTTTGTGCCTAGAATCAGTTCTCCTTGCCTTCAAAATCCCTGATAAGTGTCCA


 


TTTCTTTTTGTATCCTTTGATGTAGAAGCCACAAGAATGGCTTTAGCAGCTTATTTTAATCTTATGAATTATTCATT


 


CAGGATTTTTTAAATGATTCAGATGCTTTCAATCTGTTAACAGTATTTATAAAACATGTTTCAGTGATACAACATAG


 


GTGAACTAAACCAAAGATGCAAATGCCTTGGAGGAAAAGAAATTGTATTATAGAGAATCCTGAGATATATCCTTTTG


 


GGTTGTTTAATTTAAAGCCTATCACAAAACAAAGAGAATTGTCGCACTTTAATTCCAACCTCCTGCAGTACTTCACA


 


ACCCTTAGCATAAGATTCTGAAATTTGTAATAGGTGGTACCTAGTTTGATGCAGGGTTTTGCAGCAGTTGTGCGAAT


 


GCCTCTGCGCAACGGCCTTTCAGTCAGACTAAATGAGAAAATCCAAACTGTCCTATCAAAACTGACCCACAATAACT


 


GTACTCTGAGGCGAAACAGAGCAAATGTGGGTTTCCTGTTTTCATTGTAAAACATTCCAGGTTCTCAGATTGAAGAG


 


CTACATTCAGCTGATAGTTGACATCTGTTCCCTCACACGTAGTGGCTCTCAACACGGGCTGCACTTTGGAATCACCT


 


GAGGACCTTTCGGAATCTTCGGTTGAATCATCCTGGCTGTCCTGGTGATGCTTCTTATGTGCAGCTAGGCTGGAGAA


 


CCACTACAGGGCTGACACCTGGAATGGGAGCTTGTAACTTTTACAAAATAATAGATGTTTATCATCTTTTGCAATTT


 


TTACTTTTAAGTCTATACTAAAATGAGCCAAAGAAGTCTTAACAATGATGTATGGCACAATTGGTTGGTTGAGGCTA


 


TCATTCCATGATTACAAATAGGTGGTTATGTGGGGTGGTTTTGCACTTGTGGCAATTGGACTGCAATTTGGCCTTAA


 


AATGACACAATTCCTCGTTCTCAGATGGAGAGGAATTGCCTTGAAATTTGCATGTACCAGACTAAGTGCCAGTATAT


 


ATATGACTGATATTTTCGTGACTCATAGAAGGTGTCCATGGTATAGAGTTTATGCCTACATCTCTATCTTTATTTTG


 


GGCACACATGAGCTTTTGTTAATTATTTCTTTGTACTTGTTAGAATCTGTTTTTGAAAAAAAAAAAAACTTTTGCTT


 


TGATTTGTGGTGGATTCACCTTCTTAAAATAATAAATTTAGAGGATATTAGGAATGACATTCAAAACAAATATAGTG


 


AGAGGTGATTTTTTAAAAATTTTTGTTCCTGGTTTCCAAATTATGTTTACTTTGATTTGATTATATGTTGGTATCTC


 


CCAAATATAGGTTAACTTAGCTATTTAAATGGTATCTTTTGACATTTAAAAAGAATTAAGTACCTGTCAAATCTAGC


 


ATTGAGGTTGCAGTTGAATAAGATAAAAGCTTAGGATGTCAAAAAATAATATAGAGAAATATTATAAGATTTTATGA


 


TTATTCTTGACGTTTTTGATGCAAAAGGAAAATATGCTGAATAGTTCTTCCAAAAAATATTATTTCCCTCAATATTT


 


TATTTGTAGCCATGTAATTTAAAGAGAACAGAAAATAACTGCAATCAAAAGTATGGTTTAATATCAATCAAAGTGGC


 


ACAACAGAATTGATAAGATCTTTATAACAATCAATTGGCTGATATTAAAATATTGATTTTAATTGATCTTTTCAATT


 


AAAATCTTTAGGGCCTGTAACTCATAAAATCAGCATCCACCACAATATATGGTCATTATTGGTTTGTAAGCATAGAT


 


CACCATTGACTCCTACCTGGAGAGACATGTCTATTTCTAAAAATCCAGTAGTTTCTTTGCATTCTCAGTAGTACACG


 


TTGTATATATATATATGTAACAAATTTGGTAGTTTTCAGTATGTGTGATGTCCTTTGGGGGTTATTTATCTTGCTGG


 


TCCATAGGAGGGGTACACTACCCCAAGAATCAAGACATCTGAGTTCTAGTTCTAGTTCTAGCTCTGCCACTGAAGAG


 


CCACCTTACCTGGGGCAAGTTAGCCATTGTCTCCCAGTCATGTTTACCACCCATGAAAGGACTCGTCGGTTTGATGT


 


TTCCATTAAGCTCAATGAGTAACTCTAATAGTTACTCTTGAATCTGGATTGAAAAACACCATGCATCTGATGAGATA


 


ATTCATAAATGTTGCCCCTTTTTTAAATGATACAACCCTAAAAGTGACTGAATTGCCCAAGTGCTTGAACATGGCAG


 


AGGTAGTTACTCCTATTTTGCAGTTTGTGCACTTAAAAATTCCTACAGTGATTGTTACTTTACTGGGGAAAAAAGAT


 


GAGGTGAAACTTCCTCCCAAGGAATTAAAATATCTGTAGAAGCCATGGCTTGCTTTTATAATGTGGAAATCATTTGA


 


TTTGCTGTAATTCACGCAGATCCCTCCTTTTGTCAGGGGGAAATGATTTGCATCATGTTCTTTTTTCATAATGCTTT


 


TACTTCCTGTTTGGATCAGTTGTATGTAAATGTACATTTTTGTTACTTTGGCTGTGCCCGTTAGAATTTATCTTCCA


 


TAAAGTATTTCTCCCATTGAGTCTAATGATGTATACTTTGCCTAGGTCTTTCCAAAATTAAATTTATGTAAATGTCT


 


ATTTTATATAAAATATGATTAAAATAAGTATGTCTGGTTTCAA


 


>gi|118766329|ref|NM_032813.2| Homo sapiens transmembrane and


tetratricopeptide repeat containing 4 (TMTC4), transcript variant 1, mRNA


(SEQ ID NO: 55)



GCGCGGCGGGCGGCCCCTCCCCCTGCCAGGTCCGGGCGGGTGCCTGGAGCCGCCAGAGTTTCCGCACCCGGGAGGGA



 


GATGCGGCCGGGGCTCAGGCTCCTTGCAGTTGTAATTTAGATTCGAGAAGTGGTTTATCCTTTGACTGGAAAAGAAA


 


AGTAGCTGCAGTATTCCCCCAGCACTTGCTGAGAGCATGCCGTATGCCAGGCTGTGAGGCTCGAGAGACAAGCAGTG


 


GAAGAGTTGCGGCCTGTTTCATCTCTGGATTGTAAATCTGAGCCTCCTTCTGGCCCCTGGAAGGGGACAGCATCACC


 


ATGGAATGATTCCTAACCAGCATAATGCTGGAGCCGGGAGCCACCAACCTGCAGTTTTCAGAATGGCCGTGTTGGAC


 


ACTGATTTGGATCACATTCTTCCATCTTCTGTTCTTCCTCCATTCTGGGCTAAGTTAGTAGTGGGATCGGTTGCCAT


 


TGTGTGTTTTGCACGCAGCTATGATGGAGACTTTGTCTTTGATGACTCAGAAGCTATTGTTAACAATAAGGACCTCC


 


AAGCAGAAACGCCCCTGGGGGACCTGTGGCATCATGACTTCTGGGGCAGTAGACTGAGCAGCAACACCAGCCACAAG


 


TCCTACCGGCCTCTCACCGTCCTGACTTTCAGGATTAACTACTACCTCTCGGGAGGCTTCCACCCCGTGGGCTTTCA


 


CGTGGTCAACATCCTCCTGCACAGTGGCATCTCTGTCCTCATGGTGGACGTCTTCTCGGTTCTGTTTGGCGGCCTGC


 


AGTACACCAGTAAAGGCCGGAGGCTGCACCTCGCCCCCAGGGCGTCCCTGCTGGCCGCGCTGCTGTTTGCTGTCCAT


 


CCTGTGCACACCGAGTGTGTTGCTGGTGTTGTCGGCCGTGCAGACCTCCTGTGTGCCCTGTTCTTCTTGTTATCTTT


 


CCTTGGCTACTGTAAAGCATTTAGAGAAAGTAACAAGGAGGGAGCGCATTCTTCCACCTTCTGGGTGCTGCTGAGTA


 


TCTTTCTGGGAGCAGTGGCCATGCTGTGCAAAGAGCAAGGGATCACTGTGCTGGGTTTAAATGCGGTATTTGACATC


 


TTGGTGATAGGCAAATTCAATGTTCTGGAAATTGTCCAGAAGGTACTACATAAGGACAAGTCATTAGAGAATCTCGG


 


CATGCTCAGGAACGGGGGCCTCCTCTTCAGAATGACCCTGCTCACCTCTGGAGGGGCTGGGATGCTCTACGTGCGCT


 


GGAGGATCATGGGCACGGGCCCGCCGGCCTTCACCGAGGTGGACAACCCGGCCTCCTTTGCTGACAGCATGCTGGTG


 


AGGGCCGTAAACTACAATTACTACTATTCATTGAATGCCTGGCTGCTGCTGTGTCCCTGGTGGCTGTGTTTTGATTG


 


GTCAATGGGCTGCATCCCCCTCATTAAGTCCATCAGCGACTGGAGGGTAATTGCACTTGCAGCACTCTGGTTCTGCC


 


TAATTGGCCTGATATGCCAAGCCCTGTGCTCTGAAGACGGCCACAAGAGAAGGATCCTTACTCTGGGCCTGGGATTT


 


CTCGTTATCCCATTTCTCCCCGCGAGTAACCTGTTCTTCCGAGTGGGCTTCGTGGTCGCAGAGCGTGTCCTCTACCT


 


CCCCAGCGTTGGGTACTGTGTGCTGCTGACTTTTGGATTCGGAGCCCTGAGCAAACATACCAAGAAAAAGAAACTCA


 


TTGCCGCTGTCGTGCTGGGAATCTTATTCATCAACACGCTGAGATGTGTGCTGCGCAGCGGCGAGTGGCGGAGTGAG


 


GAACAGCTTTTCAGAAGTGCTCTGTCTGTGTGTCCCCTCAATGCTAAGGTTCACTACAACATTGGCAAAAACCTGGC


 


TGATAAAGGCAACCAGACAGCTGCCATCAGATACTACCGGGAAGCTGTAAGATTAAATCCCAAGTATGTTCATGCCA


 


TGAATAATCTTGGAAATATCTTAAAAGAAAGGAATGAGCTACAGGAAGCTGAGGAGCTGCTGTCTTTGGCTGTTCAA


 


ATACAGCCAGACTTTGCCGCTGCGTGGATGAATCTAGGCATAGTGCAGAATAGCCTGAAACGGTTTGAAGCAGCAGA


 


GCAAAGTTACCGGACAGCAATTAAACACAGAAGGAAATACCCAGACTGTTACTACAACCTCGGGCGTCTGTATGCAG


 


ATCTCAATCGCCACGTGGATGCCTTGAATGCGTGGAGAAATGCCACCGTGCTGAAACCAGAGCACAGCCTGGCCTGG


 


AACAACATGATTATACTCCTCGACAATACAGGTAATTTAGCCCAAGCTGAAGCAGTTGGAAGAGAGGCACTGGAATT


 


AATACCTAATGATCACTCTCTCATGTTCTCGTTGGCAAACGTGCTGGGGAAATCCCAGAAATACAAGGAATCTGAAG


 


CTTTATTCCTCAAGGCAATTAAAGCAAATCCAAATGCTGCAAGTTACCATGGTAATTTGGCTGTGCTTTATCATCGT


 


TGGGGACATCTAGACTTGGCCAAGAAACACTATGAAATCTCCTTGCAGCTTGACCCCACGGCATCAGGAACTAAGGA


 


GAATTACGGTCTGCTGAGAAGAAAGCTAGAACTAATGCAAAAGAAAGCTGTCTGATCCTGTTTCCTTCATGTTTTGA


 


GTTTGAGTGTGTGTGTGCATGAGGCATATCATTAATAGTATGTGGTTACATTTAACCATTTAAAAGTCTTAGACATG


 


TTATTTTACTGATTTTTTTCTATGAAAACAAAGACATGCAAAAAGATTATAGCACCAGCAATATACTCTTGAATGCG


 


TGATATGATTTTTCATTGAAATTGTATTTTTTCAGACAACTCAAATGTAATTCTAAAATTCCAAAAATGTCTTTTTT


 


AATTAAACAGAAAAAGAGAAAAAATTATCTTGAGCAACTTTTAGTAGAATTGAGCTTACATTTGGGATCTGAGCCTT


 


GTCGTGTATGGACTAGCACTATTAAACTTCAATTATGACCAAGAAAGGATACACTGGCCCCTACAATTTGTATAAAT


 


ATTGAACATGTCTATATATTAGCATTTTTATTTAATGACAAAGCAAATTAAGTTTTTTTATCTCTTTTTTTTAAAAC


 


AACATACTGTGAACTTTGTAAGGAAATATTTATTTGTATTTTTATGTTTTGAATAGGGCAAATAATCGAATGAGGAA


 


TGGAAGTTTTAACATAGTATATCTATATGCTTTTCCCCATAGGAAGAAATTGACTCTTGCAGTTTTTGGATGCTCTG


 


ACTTGTGCAATTTCAATACACAGGAGATTATGTAATGTAATATTTTACATAAGCGGTTACTATCAATTGAAAGTTCA


 


AGCCATGCTTTAGGCAAGAGCAGGCAGCCTCACATCTTTATTTTTGTTACATCCAAGGTGAAGAGGGCAACACATCT


 


GTGTAAGCTGCTTTTTAGTGTGTTTATCTGAAGGCCGTTTTCCATTTTGCTTAATGTAACTACAGACATTATCCAGA


 


AAATGCAAAATTTTCTATCAAATGGAGCCACATTCGGGGAATTCGTGGTATTTTTAAGAATTGAGTTGTTCCTGCTG


 


TTTTTTATTTGATCCAAACAATGTTTTGTTTTGTTCTTCTCTGTATGCTGTTGACCTAATGATTTATGCAATCTCTG


 


TAATTTCTTATGCAGTAAAATTACTACACAAACTAGCATGAAAATGTCATATTGCCTTCTTAATCAATTATTTTCAA


 


GTAGTGAACTTTGTATCCTCCTTTACCTTAAAATGAAATCAAACTGACCAAATCATCAAAAAAAAAAAAAAAAAA


 


>gi|93141224|ref|NM_003304.4| Homo sapiens transient receptor potential


cation channel, subfamily C, member 1 (TRPC1), mRNA


(SEQ ID NO: 56)



CGGGCCTCGAGCCGAGGCAGCAGTGGGAACGACTCATCCTTTTTCCAGCCCTGGGGCGTGGCTGGGGTCGGGGTCGG



 


GGTCGGGGCCGGTGGGGGCCCCGCCCCCGTCTCCTGGCCTGCCCCCTTCATGGGCCGCGATGATGGCGGCCCTGTAC


 


CCGAGCACGGACCTCTCGGGCGCCTCCTCCTCCTCCCTGCCTTCCTCTCCATCCTCTTCCTCGCCGAACGAGGTGAT


 


GGCGCTGAAGGATGTGCGGGAGGTGAAGGAGGAGAATACGCTGAATGAGAAGCTTTTCTTGCTGGCGTGCGACAAGG


 


GTGACTATTATATGGTTAAAAAGATTTTGGAGGAAAACAGTTCAGGTGACTTGAACATAAATTGCGTAGATGTGCTT


 


GGGAGAAATGCTGTTACCATAACTATTGAAAACGAAAACTTGGATATACTGCAGCTTCTTTTGGACTACGGTTGTCA


 


GAAACTAATGGAACGAATTCAGAATCCTGAGTATTCAACAACTATGGATGTTGCACCTGTCATTTTAGCTGCTCATC


 


GTAACAACTATGAAATTCTTACAATGCTCTTAAAACAGGATGTATCTCTACCCAAGCCCCATGCAGTTGGCTGTGAA


 


TGCACATTGTGTTCTGCAAAAAACAAAAAGGATAGCCTCCGGCATTCCAGGTTTCGTCTTGATATATATCGATGTTT


 


GGCCAGTCCAGCTCTAATAATGTTAACAGAGGAGGATCCAATTCTGAGAGCATTTGAACTTAGTGCTGATTTAAAAG


 


AACTAAGTCTTGTGGAGGTGGAATTCAGGAATGATTATGAGGAACTAGCCCGGCAATGTAAAATGTTTGCTAAGGAT


 


TTACTTGCACAAGCCCGGAATTCTCGTGAATTGGAAGTTATTCTAAACCATACGTCTAGTGACGAGCCTCTTGACAA


 


ACGGGGATTATTAGAAGAAAGAATGAATTTAAGTCGTCTAAAACTTGCTATCAAATATAACCAGAAAGAGTTTGTCT


 


CCCAGTCTAACTGCCAGCAGTTCCTGAACACTGTTTGGTTTGGACAGATGTCGGGTTACCGACGCAAGCCCACCTGT


 


AAGAAGATAATGACTGTTTTGACAGTAGGCATCTTTTGGCCAGTTTTGTCACTTTGTTATTTGATAGCTCCCAAATC


 


TCAGTTTGGCAGAATCATTCACACACCTTTTATGAAATTTATCATTCATGGAGCATCATATTTCACATTTCTGCTGT


 


TGCTTAATCTATACTCTCTTGTCTACAATGAGGATAAGAAAAACACAATGGGGCCAGCCCTTGAAAGAATAGACTAT


 


CTTCTTATTCTGTGGATTATTGGGATGATTTGGTCAGACATTAAAAGACTCTGGTATGAAGGGTTGGAAGACTTTTT


 


AGAAGAATCTCGTAATCAACTCAGTTTTGTCATGAATTCTCTTTATTTGGCAACCTTTGCCCTCAAAGTGGTTGCTC


 


ACAACAAGTTTCATGATTTTGCTGATCGGAAGGATTGGGATGCATTCCATCCTACACTGGTGGCAGAAGGGCTTTTT


 


GCATTTGCAAATGTTCTAAGTTATCTTCGTCTCTTTTTTATGTATACAACCAGCTCTATCTTGGGTCCATTACAGAT


 


TTCAATGGGACAGATGTTACAAGATTTTGGAAAATTTCTTGGGATGTTTCTTCTTGTTTTGTTTTCTTTCACAATTG


 


GACTGACACAACTGTATGATAAAGGATATACTTCAAAGGAGCAGAAGGACTGTGTAGGCATCTTCTGTGAACAGCAA


 


AGCAATGATACCTTCCATTCGTTCATTGGCACCTGCTTTGCTTTGTTCTGGTATATTTTCTCCTTAGCGCATGTGGC


 


AATCTTTGTCACAAGATTTAGCTATGGAGAAGAACTGCAGTCCTTTGTGGGAGCTGTCATTGTTGGTACATACAATG


 


TCGTGGTTGTGATTGTGCTTACCAAACTGCTGGTGGCAATGCTTCATAAAAGCTTTCAGTTGATAGCAAATCATGAA


 


GACAAAGAATGGAAGTTTGCTCGAGCAAAATTATGGCTTAGCTACTTTGATGACAAATGTACGTTACCTCCACCTTT


 


CAACATCATTCCCTCACCAAAGACTATCTGCTATATGATTAGTAGCCTCAGTAAGTGGATTTGCTCTCATACATCAA


 


AAGGCAAGGTCAAACGGCAAAACAGTTTAAAGGAATGGAGGAATTTGAAACAGAAGAGAGATGAAAACTATCAAAAA


 


GTGATGTGCTGCCTAGTGCATCGTTACTTGACTTCCATGAGACAGAAGATGCAAAGTACAGATCAGGCAACTGTGGA


 


AAATCTAAACGAACTGCGCCAAGATCTGTCAAAATTCCGAAATGAAATAAGGGATTTACTTGGCTTTCGGACTTCTA


 


AATATGCTATGTTTTATCCAAGAAATTAACCATTTTCTAAATCATGGAGCGAATAATTTTCAATAACAGATCCAAAA


 


GACTATATTGCATAACTTGCAATGAAATTAATGAGATATATATTGAAATAAAGAATTATGTAAAAGCCATTCTTTAA


 


AATATTTATAGCATAAATATATGTTATGTAAAGTGTGTATATAGAATTAGTTTTTTAAACCTTCTGTTAGTGGCTTT


 


TTGCAGAAGCAAAACAGATTAAGTAGATAGATTTTGTTAGCATGCTGCTTGGTTTTCTTACTTAGTGCTTTAAAATG


 


TTTTTTTTTATGTTTAAGAGGGGCAGTTATAAATGGACACATTGCCCAGAATGTTTTGTAAAATGAAGACCAGCAAA


 


TGTAGGCTGATCTCCTTCACAGGATACACTTGAAATATAGAAGTTATGTTTTAAATATCTCTGTTTTAGGAGTTCAC


 


ATATAGTTCAGCATTTATTGTTTAGGAGTATAATTTTATTTTATCTAAAATAATAGTCTATTTTTTCTTTTGTATTT


 


TGTTATAATCTTAAGCAACAAAGAAAAAACCCTAATATTTGAATCTATTTATGTCTTTCAATTTAAATTCACTTCAG


 


TTTTTGTTATTGTAATATATTTACTTTTACATGGTTATAATCACTTTATATTTTTAATGTTTTTTTCACTTAATATT


 


TTATATATACATTTCCATGTATTGATGTAGTTAGTCCACATTTAAATTTTTATAGAATTATATAGTTTTTGAAAAAT


 


ACAGTCAGTAGATGTTTTATTTTTTAGCTATTCAGTTATGTTTATAAGTTTGCATAGCTACTTCTCGACATTTGGTT


 


TGTTTTAATTTTTTTGTATCATAATAGTCCTATTTTTTTTTCAAGTTGGAGTGAATGTTTTTAGTTTTAAGATAGAT


 


AGGAGACACTTTTTTATCACATGTAGTCACAACCTGTTTTGTTTTTGTAAAACATAGGAAGTCTCTTTAATGCAATG


 


ATTTGTTTTATATTTGGACTAAGGTTCTTGAGCTTATCTCCCAAGGTACTTTCCATAATTTAACACAGCTTCTATAA


 


AAGTGACTTCATGCTTACTTGTGGATCATTCTTGCTGCTTAAGATGAAAAGCATTGGTTTTTTAAAATTAGAGAATA


 


AAATATGTATTTAAATTTTTGGTGTGTTCACATAAAGGGATGTAGCTAAAATGTTTTCATAGGCTATTATATATTCT


 


CGCAGCATTTCCAGTTAAGAGGATATTAGGTATATAATTCTCTTCTTAACCGAATGTCAGATGGTCTTACGCCACAG


 


GGTGCAGGTAACCCTTGGTCTGTAAGCACCACCGATCCAGGGATCATTGTCTAAATAGGTTACTATTGTTTGTTTCA


 


TCTTGCTTTTGCATTTTTATTTTTTAATTTCCAAATTTTAAGTGTTCCCTCTTTGGGGCAAATTCTTATAAAAATGT


 


TTATTGTAAAGTTATATATTTTGTCTACGATGGGATTATGCACTTCCCAATTGGGATTTTACATCTGGATTTTTAGT


 


CATTCTAAAAAACACCTAATTATTAAAACATTTATAGAGTGCCTACTGTATGCATGAGTTGAGTTGCTTCTGAGGTA


 


CATTTTGAATGACAGCATATTGTAAGAAAAAAAAAGGTGAATAAAATTTGACATTAGATTATAAAAAAAAAAA


 


>gi|21264577|ref|NM_005727.2| Homo sapiens tetraspanin 1 (TSPAN1), mRNA


(SEQ ID NO: 57)



GTGAGAGCCAGGCGTCCCTCTGCCTGCCCACTCAGTGGCAACACCCGGGAGCTGTTTTGTCCTTTGTGGAGCCTCAG



 


CAGTTCCCTCTTTCAGAACTCACTGCCAAGAGCCCTGAACAGGAGCCACCATGCAGTGCTTCAGCTTCATTAAGACC


 


ATGATGATCCTCTTCAATTTGCTCATCTTTCTGTGTGGTGCAGCCCTGTTGGCAGTGGGCATCTGGGTGTCAATCGA


 


TGGGGCATCCTTTCTGAAGATCTTCGGGCCACTGTCGTCCAGTGCCATGCAGTTTGTCAACGTGGGCTACTTCCTCA


 


TCGCAGCCGGCGTTGTGGTCTTTGCTCTTGGTTTCCTGGGCTGCTATGGTGCTAAGACTGAGAGCAAGTGTGCCCTC


 


GTGACGTTCTTCTTCATCCTCCTCCTCATCTTCATTGCTGAGGTTGCAGCTGCTGTGGTCGCCTTGGTGTACACCAC


 


AATGGCTGAGCACTTCCTGACGTTGCTGGTAGTGCCTGCCATCAAGAAAGATTATGGTTCCCAGGAAGACTTCACTC


 


AAGTGTGGAACACCACCATGAAAGGGCTCAAGTGCTGTGGCTTCACCAACTATACGGATTTTGAGGACTCACCCTAC


 


TTCAAAGAGAACAGTGCCTTTCCCCCATTCTGTTGCAATGACAACGTCACCAACACAGCCAATGAAACCTGCACCAA


 


GCAAAAGGCTCACGACCAAAAAGTAGAGGGTTGCTTCAATCAGCTTTTGTATGACATCCGAACTAATGCAGTCACCG


 


TGGGTGGTGTGGCAGCTGGAATTGGGGGCCTCGAGCTGGCTGCCATGATTGTGTCCATGTATCTGTACTGCAATCTA


 


CAATAAGTCCACTTCTGCCTCTGCCACTACTGCTGCCACATGGGAACTGTGAAGAGGCACCCTGGCAAGCAGCAGTG


 


ATTGGGGGAGGGGACAGGATCTAACAATGTCACTTGGGCCAGAATGGACCTGCCCTTTCTGCTCCAGACTTGGGGCT


 


AGATAGGGACCACTCCTTTTAGGCGATGCCTGACTTTCCTTCCATTGGTGGGTGGATGGGTGGGGGGCATTCCAGAG


 


CCTCTAAGGTAGCCAGTTCTGTTGCCCATTCCCCCAGTCTATTAAACCCTTGATATGCCCCCTAGGCCTAGTGGTGA


 


TCCCAGTGCTCTACTGGGGGATGAGAGAAAGGCATTTTATAGCCTGGGCATAAGTGAAATCAGCAGAGCCTCTGGGT


 


GGATGTGTAGAAGGCACTTCAAAATGCATAAACCTGTTACAATGTTAAAAAAAAAAAAAAAAAAA


 


>gi|122937465|ref|NM_001080509.1| Homo sapiens tetraspanin 11 (TSPAN11), mRNA


(SEQ ID NO: 58)



AGACTGTCCCGAGCTTCCCCCGGGCGGGCAGAGGGAAGCCGGCTGGGGATGAGGAGTGGAGGAGGCAGGAATGCCTG



 


GGACACTCGCGGGGCATGTGAGCAGGCCCAGAAGCCATGGCCCACTATAAGACTGAGCAGGACGACTGGCTGATCAT


 


CTACTTGAAGTATTTACTCTTTGTCTTCAACTTCTTCTTCTGGGTCGGGGGAGCAGCCGTCCTGGCTGTGGGCATCT


 


GGACCCTGGTGGAGAAGAGTGGCTACCTCAGCGTCCTGGCCTCCAGCACCTTTGCCGCCTCCGCCTACATCCTCATC


 


TTTGCGGGCGTACTTGTCATGGTGACCGGCTTCCTGGGCTTCGGTGCCATCCTCTGGGAGCGGAAGGGCTGCCTCTC


 


CACGTATTTCTGCCTGTTGCTCGTCATCTTCCTGGTTGAGCTGGTGGCGGGAGTCCTGGCCCATGTGTATTACCAGA


 


GGCTGAGTGATGAACTGAAGCAGCACTTGAACCGGACTCTGGCTGAGAACTACGGGCAGCCCGGAGCCACGCAGATC


 


ACCGCCTCAGTGGACCGACTCCAGCAGGATTTCAAGTGCTGTGGAAGCAACAGCTCAGCCGACTGGCAGCACAGCAC


 


GTACATCCTGTTGCGGGAGGCCGAGGGCCGCCAGGTGCCCGACAGCTGCTGCAAGACAGTGGTGGTGCGCTGCGGCC


 


AGCGGGCCCACCCCTCCAACATCTATAAGGTGGAGGGAGGCTGCCTCACCAAGCTGGAGCAGTTCCTGGCCGACCAC


 


CTGCTGCTTATGGGGGCAGTGGGCATCGGGGTGGCCTGCCTGCAGATCTGCGGGATGGTTCTCACCTGCTGCTTGCA


 


CCAGAGGCTCCAGCGGCATTTTTACTAATGGCCAACCACCTCCTCTTCCAACTGCCCCTCAAGACAACATGTGGCCA


 


CATGCCATCTGCAAGGCCTGCAGAGTTAGCACCAGCTCCACTAGGGCCATAGATGCCCCCTCCTTTGTGCCTAGCTC


 


CTGCGAATCCACCGAGTGCCTGAGACCATAGCTTCTGTGCCCACCCAGGCAGAGACCCTCGGCCCCCTCTCCTCCAT


 


TTCTGAGCCCCCATGGCCAGATCCTGGGCAGGGAAATGATCCTTTCAGGAGACAACCAGAGCCCCTCACCAGGAACG


 


GGGGCACCCGTGGACTACGGGAGGGTGGCGGTTGGGTTCTCTGCTCCCTCCCAGCTCCTGAACCTGGAACAATCGGC


 


AGAAAACCCAGGAACCCCGGCACTCCTGCATTCAGCACGGGATTCCCCCACCCATGCCCAGAAGCCCTGACCTTGCT


 


GTTTCTGGAAAAAGCATGGGGTGGGGCAGGGAGGGCTGGCATTTCCCCCAGAAGACCTTGCCCTTTGACCTGCCCAC


 


TCTCCACACTGCCTCACCTGGAAAGCCATGTCCTGCTGGCCTCATTCCTTCCTGAAGGGCCTAGGAGTGGGGAGGCC


 


TGGGTAGGGCAGCCACA


 


>gi|48255911|ref|NM_012338.3| Homo sapiens tetraspanin 12 (TSPAN12), mRNA


(SEQ ID NO: 59)



GGCCCTGGCTGCCGCCGCTGCCTCGTCCGGACTCGGAGAGGACTTGGGAGGGACAGCGGCGCTGGGAGGTGGCTTAG



 


CAGAGACTTTCCAGCAACTGCTGCCCAGGACTTTTTTTTTTTTTTTTCTTTTTCCCAGGAGGCGGCGACGGCGGCGG


 


CGGGGGGAGAGGAAGAGAAAGAAGCGTCTCCAGCTGAAGCCAATGCAGCCCTCCGGCTCTCCGCGAAGAAGTTCCCT


 


GCCCCGATGAGCCCCCGCCGTGCGTCCCCGACTATCCCCAGGCGGGCGTGGGGCACCGGGCCCAGCGCCGACGATCG


 


CTGCCGTTTTGCCCTTGGGAGTAGGATGTGGTGAAAGGATGGGGCTTCTCCCTTACGGGGCTCACAATGGCCAGAGA


 


AGATTCCGTGAAGTGTCTGCGCTGCCTGCTCTACGCCCTCAATCTGCTCTTTTGGTTAATGTCCATCAGTGTGTTGG


 


CAGTTTCTGCTTGGATGAGGGACTACCTAAATAATGTTCTCACTTTAACTGCAGAAACGAGGGTAGAGGAAGCAGTC


 


ATTTTGACTTACTTTCCTGTGGTTCATCCGGTCATGATTGCTGTTTGCTGTTTCCTTATCATTGTGGGGATGTTAGG


 


ATATTGTGGAACGGTGAAAAGAAATCTGTTGCTTCTTGCATGGTACTTTGGAAGTTTGCTTGTCATTTTCTGTGTAG


 


AACTGGCTTGTGGCGTTTGGACATATGAACAGGAACTTATGGTTCCAGTACAATGGTCAGATATGGTCACTTTGAAA


 


GCCAGGATGACAAATTATGGATTACCTAGATATCGGTGGCTTACTCATGCTTGGAATTTTTTTCAGAGAGAGTTTAA


 


GTGCTGTGGAGTAGTATATTTCACTGACTGGTTGGAAATGACAGAGATGGACTGGCCCCCAGATTCCTGCTGTGTTA


 


GAGAATTCCCAGGATGTTCCAAACAGGCCCACCAGGAAGATCTCAGTGACCTTTATCAAGAGGGTTGTGGGAAGAAA


 


ATGTATTCCTTTTTGAGAGGAACCAAACAACTGCAGGTGCTGAGGTTTCTGGGAATCTCCATTGGGGTGACACAAAT


 


CCTGGCCATGATTCTCACCATTACTCTGCTCTGGGCTCTGTATTATGATAGAAGGGAGCCGGGGACAGACCAAATGA


 


TGTCCTTGAAGAATGACAACTCTCAGCACCTGTCATGTCCCTCAGTAGAACTGTTGAAACCAAGCCTGTCAAGAATC


 


TTTGAACACACATCCATGGCAAACAGCTTTAATACACACTTTGAGATGGAGGAGTTATAAAAAGAAATGTCACAGAA


 


GAAAACCACAAACTTGTTTTACTGGACTTGTGAATTTTTGAGTACATACTATGTGTTTCAGAAATATGTAGAAATAA


 


AAATGTTGCCATAAAATAACACCTAAGCATATACTATTCTATGCTTTAAAATGAGGATGGAAAAGTTTCATGTCATA


 


AGTCACCACCTGGACAATAATTGATGCCCTTAAAATGCTGAAGACAGATGTCATACCCACTGTGTAGCCTGTGTATG


 


ACTTTTACTGAACACAGTTATGTTTTGAGGCAGCATGGTTTGATTAGCATTTCCGCATCCATGCAAACGAGTCACAT


 


ATGGTGGGACTGGAGCCATAGTAAAGGTTGATTTACTTCTACCAACTAGTATATAAAGTACTAATTAAATGCTAACA


 


TAGGAAGTTAGAAAATACTAATAACTTTTATTACTCAGCGATCTATTCTTCTGATGCTAAATAAATTATATATCAGA


 


AAACTTTCAATATTGGTGACTACCTAAATGTGATTTTTGCTGGTTACTAAAATATTCTTACCACTTAAAAGAGCAAG


 


CTAACACATTGTCTTAAGCTGATCAGGGATTTTTTGTATATAAGTCTGTGTTAAATCTGTATAATTCAGTCGATTTC


 


AGTTCTGATAATGTTAAGAATAACCATTATGAAAAGGAAAATTTGTCCTGTATAGCATCATTATTTTTAGCCTTTCC


 


TGTTAATAAAGCTTTACTATTCTGTCCTGGGCTTATATTACACATATAACTGTTATTTAAATACTTAACCACTAATT


 


TTGAAAATTACCAGTGTGATACATAGGAATCATTATTCAGAATGTAGTCTGGTCTTTAGGAAGTATTAATAAGAAAA


 


TTTGCACATAACTTAGTTGATTCAGAAAGGACTTGTATGCTGTTTTTCTCCCAAATGAAGACTCTTTTTGACACTAA


 


ACACTTTTTAAAAAGCTTATCTTTGCCTTCTCCAAACAAGAAGCAATAGTCTCCAAGTCAATATAAATTCTACAGAA


 


AATAGTGTTCTTTTTCTCCAGAAAAATGCTTGTGAGAATCATTAAAACATGTGACAATTTAGAGATTCTTTGTTTTA


 


TTTCACTGATTAATATACTGTGGCAAATTACACAGATTATTAAATTTTTTTACAAGAGTATAGTATATTTATTTGAA


 


ATGGGAAAAGTGCATTTTACTGTATTTTGTGTATTTTGTTTATTTCTCAGAATATGGAAAGAAAATTAAAATGTGTC


 


AATAAATATTTTCTAGAGAGTAAAAAAAAAAAAAAAAA


 


>gi|54859559|ref|NM_012171.1| Homo sapiens tetraspanin 17 (TSPAN17),


transcript variant 1, mRNA


(SEQ ID NO: 60)



GGCGGGGCCCGGTCCAGAGGCGGGGACAGCAGGGCTCCGGGCAAGGAGGTCTGGATGCTGAGGGCGGTCCCTGAGGG



 


GCGGGCGGGGCCCGACCGGCGCTCTGTGTGGCCGAGGCCATGAAGCCGCAGCCGCCCGGCTAGGCCCCGGGCGGCTC


 


TAGCCCAGGGCGGCCCGCGGGGCGCTGGGCCTGGCTCCCGGCTCCGGTTTCCGGGCCGGCGGGTGGCCGCTCACCAT


 


GCCCGGCAAGCACCAGCATTTCCAGGAACCTGAGGTCGGCTGCTGCGGGAAATACTTCCTGTTTGGCTTCAACATTG


 


TCTTCTGGGTGCTGGGAGCCCTGTTCCTGGCTATCGGCCTCTGGGCCTGGGGTGAGAAGGGCGTTCTCTCGAACATC


 


TCAGCGCTGACAGATCTGGGAGGCCTTGACCCCGTGTGGCTGTTTGTGGTAGTTGGAGGCGTCATGTCGGTGCTGGG


 


CTTTGCTGGCTGCATTGGGGCCCTCCGGGAGAACACCTTCCTGCTCAAGTTTTTCTCCGTGTTCCTCGGTCTCATCT


 


TCTTCCTGGAGCTGGCAACAGGGATCCTGGCCTTTGTCTTCAAGGACTGGATTCGAGACCAGCTCAACCTCTTCATC


 


AACAACAACGTCAAGGCCTACCGGGACGACATTGACCTCCAGAACCTCATTGACTTTGCTCAGGAATACTGGTCTTG


 


CTGCGGAGCCCGAGGCCCCAATGACTGGAACCTCAATATCTACTTCAACTGCACTGACTTGAACCCCAGCCGGGAGC


 


GCTGCGGGGTGCCCTTCTCCTGCTGCGTCAGGGACCCTGCGGAGGATGTCCTCAACACCCAGTGTGGCTACGACGTC


 


CGGCTCAAACTGGTGAGAGGGGAGCTGGAGCAGCAGGGCTTCATCCACACCAAAGGCTGCGTGGGCCAGTTTGAGAA


 


GTGGCTGCAGGACAACCTGATTGTGGTGGCGGGAGTCTTCATGGGCATCGCCCTCCTCCAGATCTTTGGCATCTGCC


 


TGGCCCAGAACCTCGTGAGTGACATCAAGGCAGTGAAAGCCAACTGGAGCAAATGGAATGATGACTTTGAAAACCAC


 


TGGCTTACGCCCACCATTTCCGAGGTCCTGTCCACGGCGGGGCCTCAGCAGAACTCTCTGACTGGGGCCCCTGGCCC


 


GGCCCCACCCAGCCGACATGTTTTCTTTGGCCTGGGTGGTTTATACCCTGAGCCAACCTTTAAAAATTGGTAGATTT


 


CACATAAAAGTCCAGATCCACAGCTTCTCTTGAAGAATGACCACCTGGCTACGCCGGCTCTTCGGTGGCAACACTAC


 


CTGGGACACTGCCTCCCCAGTCACCAAGGGCCCCAGCTGGCCCGTTCTACTCACCTAAGTGCCGCCTGACCCTTGTA


 


CACTAGGAGCTGGCCTCCCACCTCTGCAGGGTTATTCCCTGCACCTCGAGGCCGCTGCGGGCCAATCTGGAGTGAAA


 


CACGGGGACCTGAAGGATGGAGAGGCTGGACCCCGCTTTGAAGAGGGTGCAGCCTGGGAAGGGCGGCCTTGCTGGGG


 


ACTGCGGTGGGAGTAGAGTGCCCAGGAGAGGGTCTGAGGGGTGGGATGGGGGTCAGGACAATTTTGCAAAAGAAGTA


 


GCTGGAAGCCATGGGACTGGCGGGAGCCTGTTTGGGGGATCTGGATGGTTGACTCCTAGGAGTCAAGTTCAGCATCT


 


TCACCGTGGCTGCAGAGCTGCCTGATGGGCACTAGAGGGCATGCCAGCCCCACACTCCCTGGGTCTGGCTTCCTCCC


 


GCAACCTCACTCTAGTAGAGCCTGTGCCTGCCTACTAGCGCTCTGGGGTTCGGAGAGTTTGGGAATTTCTCAGAGCC


 


AACTGGCTCAGGCTTGGGAAGGCTGGCTGCTGCCCTCAGCTCCGCCTCATCAGCTATGTGAAGGGGTGTGTGTGGAG


 


TGATCCTGCCGCCCCCTCCCTGGGCTCGTCCAGAGATCTCAAACTCCGATGCCCCTGGGGCCACGTATGTTGTATAA


 


ATGGATGAAACAGGCCCTTGAGTTGGGAGCCTGCTTCACTTTGACTTTCCCACTGTTGCTGGAGACAAAGACATCGT


 


GATGAGAGAAAGTTCGCACAATCTAGTCGGTAACAGCCACTTTCCTTGAGACCAAGAGAGTGCGGTGGGGATGGGGG


 


GGAGAGCACGGGTCCCCGTCTGACAGTGGCCGCTGCCATATTCAGGTGTAGCTAATTGCTCTGGTGTGGGAATGCAG


 


GCCTAATGACAGAAATCTGGAGAAGCCAGAAATACAGATTTGTATGTGAGATGTCCTGATTTTTTAAGTTGTTGGCA


 


GAAATTAATTCAGAAATCAAATCTGCAGGCCAAACAAGGTGCAGGACCCAGCTTTGGCCCCATGCCCCTGTAGGTCC


 


CTCTGGGACAGTCACCGCTGGGGTCCTGGCTGCTCTGTCATTGAGGGATGCTGGGCACTGCTGCCGGGTGGCCAGGG


 


TATGGGGCATGTGCCCAGCAATGTGGCTCCTTGGCCCCGCTGGCCAGTGTCCTGGGCCCCTGACAGGCGCTGGCTGT


 


GAGTGGTTTGTACATGCTACAATAAATGCAGCTGGCAGCATTGTGCAAAAAAAAAAAAAAAAAA


 


>gi|21265107|ref|NM_004616.2| Homo sapiens tetraspanin 8 (TSPAN8), mRNA


(SEQ ID NO: 61)



AGTGCCCCAGGAGCTATGACAAGCAAAGGAACATACTTGCCTGGAGATAGCCTTTGCGATATTTAAATGTCCGTGGA



 


TACAGAAATCTCTGCAGGCAAGTTGCTCCAGAGCATATTGCAGGACAAGCCTGTAACGAATAGTTAAATTCACGGCA


 


TCTGGATTCCTAATCCTTTTCCGAAATGGCAGGTGTGAGTGCCTGTATAAAATATTCTATGTTTACCTTCAACTTCT


 


TGTTCTGGCTATGTGGTATCTTGATCCTAGCATTAGCAATATGGGTACGAGTAAGCAATGACTCTCAAGCAATTTTT


 


GGTTCTGAAGATGTAGGCTCTAGCTCCTACGTTGCTGTGGACATATTGATTGCTGTAGGTGCCATCATCATGATTCT


 


GGGCTTCCTGGGATGCTGCGGTGCTATAAAAGAAAGTCGCTGCATGCTTCTGTTGTTTTTCATAGGCTTGCTTCTGA


 


TCCTGCTCCTGCAGGTGGCGACAGGTATCCTAGGAGCTGTTTTCAAATCTAAGTCTGATCGCATTGTGAATGAAACT


 


CTCTATGAAAACACAAAGCTTTTGAGCGCCACAGGGGAAAGTGAAAAACAATTCCAGGAAGCCATAATTGTGTTTCA


 


AGAAGAGTTTAAATGCTGCGGTTTGGTCAATGGAGCTGCTGATTGGGGAAATAATTTTCAACACTATCCTGAATTAT


 


GTGCCTGTCTAGATAAGCAGAGACCATGCCAAAGCTATAATGGAAAACAAGTTTACAAAGAGACCTGTATTTCTTTC


 


ATAAAAGACTTCTTGGCAAAAAATTTGATTATAGTTATTGGAATATCATTTGGACTGGCAGTTATTGAGATACTGGG


 


TTTGGTGTTTTCTATGGTCCTGTATTGCCAGATCGGGAACAAATGAATCTGTGGATGCATCAACCTATCGTCAGTCA


 


AACCCCTTTAAAATGTTGCTTTGGCTTTGTAAATTTAAATATGTAAGTGCTATATAAGTCAGGAGCAGCTGTCTTTT


 


TAAAATGTCTCGGCTAGCTAGACCACAGATATCTTCTAGACATATTGAACACATTTAAGATTTGAGGGATATAAGGG


 


AAAATGATATGAATGTGTATTTTTACTCAAAATAAAAGTAACTGTTTACGTTAAAAAAAAAAAAAAAAAAAAAAAAA


 


AAAA


 


>gi|24371240|ref|NM_024630.2| Homo sapiens zinc finger, DHHC-type containing


14 (ZDHHC14), transcript variant 1, mRNA


(SEQ ID NO: 62)



GAAGGAGTGGACCCAACCTGGCCGCGCCGCAGAAGTGGCTCCCGAGGAAGCCGGCGCCGGGGCCGCCGCCTCGTGTC



 


CCCTCGGGGCGCAGTGCTCGGGGGTCGGCGGGCCAGAGCCGAGGCGCGGCCGGGGAGCCGGGGGCTGCGGGGCCGAG


 


CGGGCAGCCGCGCGAGGGGGCGGGCGCTCGGCGACCCGGGGGCCGGCCGGGCTGAGCCCCGCGCCCCGGGACGCGGG


 


CTGGAAGCGACGGAGGAGTGCTGCCGCGGGCTGCGGACCAGCGCCGTCCCCTCACGGAGCGGGGATTCTGCTATGAC


 


AGTTGGGCTCCCCGGAGGGTTAACCTGGGTGTCCTCGGCAAAGTTGTCGCCGAGCCGGGAGCCCGTGTAGGGGCCGC


 


GGCGCCGCGGCTCGGGGGGCGGCCGGGCGGCCGGCGGCGGTCGTGGCTCGGCGGGGCCCGCGCGGCCGGGGGGCTCC


 


TGGGGGTGTGCGCCCCCAGCCGGCTGCCCTCGTGGATGCCTCCCGGCGGCGGCGGGCCCATGAAAGACTGCGAGTAC


 


AGCCAGATCAGCACCCACAGCTCCTCCCCCATGGAGTCGCCCCACAAGAAGAAGAAAATCGCGGCCCGGAGGAAATG


 


GGAGGTGTTCCCGGGAAGAAACAAGTTCTTCTGTAACGGGAGGATCATGATGGCCCGGCAGACGGGCGTCTTCTACC


 


TGACGCTCGTCCTCATCCTGGTCACTAGCGGACTCTTCTTCGCCTTCGACTGTCCGTACCTGGCGGTGAAAATCACC


 


CCTGCCATCCCTGCAGTCGCTGGCATCCTGTTCTTCTTTGTGATGGGGACCCTGCTCCGCACCAGCTTCAGCGACCC


 


CGGAGTCCTCCCACGAGCCACGCCTGATGAAGCCGCCGATCTGGAAAGGCAAATAGATATCGCAAACGGCACCAGTT


 


CAGGGGGGTACCGCCCGCCTCCCAGAACCAAAGAAGTCATCATCAATGGCCAGACCGTGAAACTTAAATACTGTTTC


 


ACCTGCAAGATTTTCCGGCCCCCTCGCGCCTCCCATTGCAGCCTTTGTGATAACTGCGTAGAACGGTTTGATCACCA


 


CTGTCCCTGGGTAGGCAACTGTGTGGGGAAAAGAAACTACAGATTTTTTTATATGTTTATTTTATCTCTGTCTTTTC


 


TGACAGTCTTTATATTTGCATTCGTTATCACCCACGTCATTCTTCGTTCACAGCAAACAGGATTCCTAAATGCCCTT


 


AAGGACAGTCCTGCAAGCGTCCTGGAGGCTGTGGTGTGCTTCTTCTCTGTCTGGTCCATCGTTGGCCTCTCAGGATT


 


CCACACCTACTTGATCAGCTCCAACCAGACAACAAATGAGGACATTAAAGGATCCTGGTCAAATAAAAGAGGTAAAG


 


AAAATTACAATCCCTACAGCTACGGAAATATCTTTACCAACTGCTGTGTTGCCCTGTGTGGGCCCATCTCACCAAGC


 


CTGATCGACAGAAGAGGGTACATCCAGCCCGACACGCCGCAGCCAGCAGCACCCTCCAATGGCATCACCATGTACGG


 


GGCCACGCAGTCACAGAGTGACATGTGCGACCAAGACCAGTGCATTCAGAGCACCAAATTCGTTTTGCAGGCTGCAG


 


CCACGCCCCTGCTGCAGAGCGAGCCCAGCCTCACCAGCGACGAGCTGCACCTGCCCGGGAAGCCTGGCCTGGGCACG


 


CCCTGCGCCAGCCTCACACTGGGCCCGCCCACACCGCCCGCCTCCATGCCCAACCTCGCCGAGGCCACGCTCGCGGA


 


CGTGATGCCCCGGAAAGATGAGCACATGGGCCACCAGTTCCTGACGCCCGATGAGGCGCCCTCGCCCCCCAGGCTAC


 


TGGCGGCGGGCAGCCCCCTGGCGCACAGCCGCACCATGCACGTGCTGGGCCTGGCCAGCCAGGACTCCCTGCATGAG


 


GACTCTGTGCGCGGCCTGGTGAAGCTCAGCTCCGTGTGACCCACATGGCCCCAGGCCGGGGGACACCAGAGGCTCCT


 


CCATGGGCAGCAGGAGTGAGCGGAGGGGTGTGTCCCACAGCGACTTTCCCAGCCAATGCCACGGTGGAGATGACAGC


 


CCCAGGTCTGGGGTACAGAGACCACTTAGGATGGCACAGGGTGGCTGGCCCCGGATGCTGAGAGCTTGGTTTCATTT


 


GAATTTTCTTCCCCAACCTGAGTGCTTTGACAACAATGGAAATAGAGAAGTGGCTGCTTTCTTTTGGTGACCCTCCA


 


GGGGTGGAATCGGAGTGTGTCTGCCCGCCCTTGTGACAGACACACGGAAGGCTTCTGACGCTTGTGGCCAGACTGCA


 


ATTGCACTTATGTGTTATGCTACTAATATTTGAAACAGACCTGCCATTCCATTTGTTAATTAAAAAAAAAAAAAATC


 


CTAAAGGGAAAAAACCGACCAGGTGTGGATCTGCATGCCACGCTGCCGTCTGTGTTACAGTGGTGTTGCTATTTCCA


 


AGGAAGTGCTGCTTTCTTTTTCTTTTTTTAATTTTGTGAATTTTCAAGTGCTGTTTTGTTGGAAGACAGTGCAACGA


 


ACTGAGACTAATGGACAGTGTCATCACTCAGCTTACTGGGCTGAGGCGTCTGTGGAGAGGTGGCACCGGGGCTGCAG


 


AGGGCGGCTGGGGTTCCGTCGTGTCGGGTGTCACTTCACCTTCTGTTTGGCCGCTCGATGAGGTCTCGTGTTGAGAT


 


ATTGTGTGCCACAACCCCCACAGTCTTCACCTCCGTGTGTGATGAAACTTCCCGTGGACAGCCAATAAAATGACGTC


 


CTCTGTTATTTTGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA


 


>gi|148005048|ref|NM_000222.2| Homo sapiens v-kit Hardy-Zuckerman 4 feline


sarcoma viral oncogene homolog (KIT), transcript variant 1, mRNA


(SEQ ID NO: 63)



TCTGGGGGCTCGGCTTTGCCGCGCTCGCTGCACTTGGGCGAGAGCTGGAACGTGGACCAGAGCTCGGATCCCATCGC



 


AGCTACCGCGATGAGAGGCGCTCGCGGCGCCTGGGATTTTCTCTGCGTTCTGCTCCTACTGCTTCGCGTCCAGACAG


 


GCTCTTCTCAACCATCTGTGAGTCCAGGGGAACCGTCTCCACCATCCATCCATCCAGGAAAATCAGACTTAATAGTC


 


CGCGTGGGCGACGAGATTAGGCTGTTATGCACTGATCCGGGCTTTGTCAAATGGACTTTTGAGATCCTGGATGAAAC


 


GAATGAGAATAAGCAGAATGAATGGATCACGGAAAAGGCAGAAGCCACCAACACCGGCAAATACACGTGCACCAACA


 


AACACGGCTTAAGCAATTCCATTTATGTGTTTGTTAGAGATCCTGCCAAGCTTTTCCTTGTTGACCGCTCCTTGTAT


 


GGGAAAGAAGACAACGACACGCTGGTCCGCTGTCCTCTCACAGACCCAGAAGTGACCAATTATTCCCTCAAGGGGTG


 


CCAGGGGAAGCCTCTTCCCAAGGACTTGAGGTTTATTCCTGACCCCAAGGCGGGCATCATGATCAAAAGTGTGAAAC


 


GCGCCTACCATCGGCTCTGTCTGCATTGTTCTGTGGACCAGGAGGGCAAGTCAGTGCTGTCGGAAAAATTCATCCTG


 


AAAGTGAGGCCAGCCTTCAAAGCTGTGCCTGTTGTGTCTGTGTCCAAAGCAAGCTATCTTCTTAGGGAAGGGGAAGA


 


ATTCACAGTGACGTGCACAATAAAAGATGTGTCTAGTTCTGTGTACTCAACGTGGAAAAGAGAAAACAGTCAGACTA


 


AACTACAGGAGAAATATAATAGCTGGCATCACGGTGACTTCAATTATGAACGTCAGGCAACGTTGACTATCAGTTCA


 


GCGAGAGTTAATGATTCTGGAGTGTTCATGTGTTATGCCAATAATACTTTTGGATCAGCAAATGTCACAACAACCTT


 


GGAAGTAGTAGATAAAGGATTCATTAATATCTTCCCCATGATAAACACTACAGTATTTGTAAACGATGGAGAAAATG


 


TAGATTTGATTGTTGAATATGAAGCATTCCCCAAACCTGAACACCAGCAGTGGATCTATATGAACAGAACCTTCACT


 


GATAAATGGGAAGATTATCCCAAGTCTGAGAATGAAAGTAATATCAGATACGTAAGTGAACTTCATCTAACGAGATT


 


AAAAGGCACCGAAGGAGGCACTTACACATTCCTAGTGTCCAATTCTGACGTCAATGCTGCCATAGCATTTAATGTTT


 


ATGTGAATACAAAACCAGAAATCCTGACTTACGACAGGCTCGTGAATGGCATGCTCCAATGTGTGGCAGCAGGATTC


 


CCAGAGCCCACAATAGATTGGTATTTTTGTCCAGGAACTGAGCAGAGATGCTCTGCTTCTGTACTGCCAGTGGATGT


 


GCAGACACTAAACTCATCTGGGCCACCGTTTGGAAAGCTAGTGGTTCAGAGTTCTATAGATTCTAGTGCATTCAAGC


 


ACAATGGCACGGTTGAATGTAAGGCTTACAACGATGTGGGCAAGACTTCTGCCTATTTTAACTTTGCATTTAAAGGT


 


AACAACAAAGAGCAAATCCATCCCCACACCCTGTTCACTCCTTTGCTGATTGGTTTCGTAATCGTAGCTGGCATGAT


 


GTGCATTATTGTGATGATTCTGACCTACAAATATTTACAGAAACCCATGTATGAAGTACAGTGGAAGGTTGTTGAGG


 


AGATAAATGGAAACAATTATGTTTACATAGACCCAACACAACTTCCTTATGATCACAAATGGGAGTTTCCCAGAAAC


 


AGGCTGAGTTTTGGGAAAACCCTGGGTGCTGGAGCTTTCGGGAAGGTTGTTGAGGCAACTGCTTATGGCTTAATTAA


 


GTCAGATGCGGCCATGACTGTCGCTGTAAAGATGCTCAAGCCGAGTGCCCATTTGACAGAACGGGAAGCCCTCATGT


 


CTGAACTCAAAGTCCTGAGTTACCTTGGTAATCACATGAATATTGTGAATCTACTTGGAGCCTGCACCATTGGAGGG


 


CCCACCCTGGTCATTACAGAATATTGTTGCTATGGTGATCTTTTGAATTTTTTGAGAAGAAAACGTGATTCATTTAT


 


TTGTTCAAAGCAGGAAGATCATGCAGAAGCTGCACTTTATAAGAATCTTCTGCATTCAAAGGAGTCTTCCTGCAGCG


 


ATAGTACTAATGAGTACATGGACATGAAACCTGGAGTTTCTTATGTTGTCCCAACCAAGGCCGACAAAAGGAGATCT


 


GTGAGAATAGGCTCATACATAGAAAGAGATGTGACTCCCGCCATCATGGAGGATGACGAGTTGGCCCTAGACTTAGA


 


AGACTTGCTGAGCTTTTCTTACCAGGTGGCAAAGGGCATGGCTTTCCTCGCCTCCAAGAATTGTATTCACAGAGACT


 


TGGCAGCCAGAAATATCCTCCTTACTCATGGTCGGATCACAAAGATTTGTGATTTTGGTCTAGCCAGAGACATCAAG


 


AATGATTCTAATTATGTGGTTAAAGGAAACGCTCGACTACCTGTGAAGTGGATGGCACCTGAAAGCATTTTCAACTG


 


TGTATACACGTTTGAAAGTGACGTCTGGTCCTATGGGATTTTTCTTTGGGAGCTGTTCTCTTTAGGAAGCAGCCCCT


 


ATCCTGGAATGCCGGTCGATTCTAAGTTCTACAAGATGATCAAGGAAGGCTTCCGGATGCTCAGCCCTGAACACGCA


 


CCTGCTGAAATGTATGACATAATGAAGACTTGCTGGGATGCAGATCCCCTAAAAAGACCAACATTCAAGCAAATTGT


 


TCAGCTAATTGAGAAGCAGATTTCAGAGAGCACCAATCATATTTACTCCAACTTAGCAAACTGCAGCCCCAACCGAC


 


AGAAGCCCGTGGTAGACCATTCTGTGCGGATCAATTCTGTCGGCAGCACCGCTTCCTCCTCCCAGCCTCTGCTTGTG


 


CACGACGATGTCTGAGCAGAATCAGTGTTTGGGTCACCCCTCCAGGAATGATCTCTTCTTTTGGCTTCCATGATGGT


 


TATTTTCTTTTCTTTCAACTTGCATCCAACTCCAGGATAGTGGGCACCCCACTGCAATCCTGTCTTTCTGAGCACAC


 


TTTAGTGGCCGATGATTTTTGTCATCAGCCACCATCCTATTGCAAAGGTTCCAACTGTATATATTCCCAATAGCAAC


 


GTAGCTTCTACCATGAACAGAAAACATTCTGATTTGGAAAAAGAGAGGGAGGTATGGACTGGGGGCCAGAGTCCTTT


 


CCAAGGCTTCTCCAATTCTGCCCAAAAATATGGTTGATAGTTTACCTGAATAAATGGTAGTAATCACAGTTGGCCTT


 


CAGAACCATCCATAGTAGTATGATGATACAAGATTAGAAGCTGAAAACCTAAGTCCTTTATGTGGAAAACAGAACAT


 


CATTAGAACAAAGGACAGAGTATGAACACCTGGGCTTAAGAAATCTAGTATTTCATGCTGGGAATGAGACATAGGCC


 


ATGAAAAAAATGATCCCCAAGTGTGAACAAAAGATGCTCTTCTGTGGACCACTGCATGAGCTTTTATACTACCGACC


 


TGGTTTTTAAATAGAGTTTGCTATTAGAGCATTGAATTGGAGAGAAGGCCTCCCTAGCCAGCACTTGTATATACGCA


 


TCTATAAATTGTCCGTGTTCATACATTTGAGGGGAAAACACCATAAGGTTTCGTTTCTGTATACAACCCTGGCATTA


 


TGTCCACTGTGTATAGAAGTAGATTAAGAGCCATATAAGTTTGAAGGAAACAGTTAATACCATTTTTTAAGGAAACA


 


ATATAACCACAAAGCACAGTTTGAACAAAATCTCCTCTTTTAGCTGATGAACTTATTCTGTAGATTCTGTGGAACAA


 


GCCTATCAGCTTCAGAATGGCATTGTACTCAATGGATTTGATGCTGTTTGACAAAGTTACTGATTCACTGCATGGCT


 


CCCACAGGAGTGGGAAAACACTGCCATCTTAGTTTGGATTCTTATGTAGCAGGAAATAAAGTATAGGTTTAGCCTCC


 


TTCGCAGGCATGTCCTGGACACCGGGCCAGTATCTATATATGTGTATGTACGTTTGTATGTGTGTAGACAAATATTT


 


GGAGGGGTATTTTTGCCCTGAGTCCAAGAGGGTCCTTTAGTACCTGAAAAGTAACTTGGCTTTCATTATTAGTACTG


 


CTCTTGTTTCTTTTCACATAGCTGTCTAGAGTAGCTTACCAGAAGCTTCCATAGTGGTGCAGAGGAAGTGGAAGGCA


 


TCAGTCCCTATGTATTTGCAGTTCACCTGCACTTAAGGCACTCTGTTATTTAGACTCATCTTACTGTACCTGTTCCT


 


TAGACCTTCCATAATGCTACTGTCTCACTGAAACATTTAAATTTTACCCTTTAGACTGTAGCCTGGATATTATTCTT


 


GTAGTTTACCTCTTTAAAAACAAAACAAAACAAAACAAAAAACTCCCCTTCCTCACTGCCCAATATAAAAGGCAAAT


 


GTGTACATGGCAGAGTTTGTGTGTTGTCTTGAAAGATTCAGGTATGTTGCCTTTATGGTTTCCCCCTTCTACATTTC


 


TTAGACTACATTTAGAGAACTGTGGCCGTTATCTGGAAGTAACCATTTGCACTGGAGTTCTATGCTCTCGCACCTTT


 


CCAAAGTTAACAGATTTTGGGGTTGTGTTGTCACCCAAGAGATTGTTGTTTGCCATACTTTGTCTGAAAAATTCCTT


 


TGTGTTTCTATTGACTTCAATGATAGTAAGAAAAGTGGTTGTTAGTTATAGATGTCTAGGTACTTCAGGGGCACTTC


 


ATTGAGAGTTTTGTCTTGGATATTCTTGAAAGTTTATATTTTTATAATTTTTTCTTACATCAGATGTTTCTTTGCAG


 


TGGCTTAATGTTTGAAATTATTTTGTGGCTTTTTTTGTAAATATTGAAATGTAGCAATAATGTCTTTTGAATATTCC


 


CAAGCCCATGAGTCCTTGAAAATATTTTTTATATATACAGTAACTTTATGTGTAAATACATAAGCGGCGTAAGTTTA


 


AAGGATGTTGGTGTTCCACGTGTTTTATTCCTGTATGTTGTCCAATTGTTGACAGTTCTGAAGAATTCTAATAAAAT


 


GTACATATATAAATCAAAAAAAAAAAAAAAA


 


Homo sapiens TRPML3 (NM_018298)


(SEQ ID NO: 64)



ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG



 


CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG


 


AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT


 


AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC


 


TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA


 


TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC


 


AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG


 


CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA


 


TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG


 


ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA


 


ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC


 


AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC


 


GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG


 


GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT


 


AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG


 


ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT


 


AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG


 


AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT


 


TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT


 


CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTCGTGTGGC


 


TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT


 


CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAGCTATGATTTACTTAG


 


GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT


 


GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG


 


TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT


 


ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT


 


GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC


 


GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA


 


TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG(SEQ ID NO: 67)


 


Homo sapiens TRPML3 (NM_018298)


(SEQ ID NO: 65)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIATGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS


 


LILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQ


 


AKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLG


 


YCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFI


 


SLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFC


 


CCKK (SEQ ID NO: 68)


 


Homo sapiens TRPML3 A419P


(SEQ ID NO: 66)



ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG



 


CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG


 


AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT


 


AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC


 


TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA


 


TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC


 


AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG


 


CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA


 


TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG


 


ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA


 


ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC


 


AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC


 


GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG


 


GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT


 


AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG


 


ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT


 


AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG


 


AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT


 


TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT


 


CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTCGTGTGGC


 


TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT


 


CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTCCAGCTATGATTTACTTAG


 


GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT


 


GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG


 


TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT


 


ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT


 


GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC


 


GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA


 


TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG(SEQ ID NO: 66)


 


Homo sapiens TRPML3 A419P


(SEQ ID NO: 67)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS


 


LILCIRSVIRGLQLQQEFVNFFLLHYKKEVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEIQ


 


AKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCPAMIYLG


 


YCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFI


 


SLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLFC


 


CCKK (SEQ ID NO: 67)


 


Homo sapiens TRPML1 (NM_020533)


(SEQ ID NO: 68)



ATGACAGCCCCGGCGGGTCCGCGCGGCTCAGAGACCGAGCGGCTTCTGACCCCCAAC



 


CCCGGGTATGGGACCCAGGCGGGGCCTTCACCGGCCCCTCCGACACCCCCAGAAGAG


 


GAAGACCTTCGCCGTCGTCTCAAATACTTTTTCATGAGTCCCTGCGACAAGTTTCGAG


 


CCAAGGGCCGCAAGCCCTGCAAGCTGATGCTGCAAGTGGTCAAGATCCTGGTGGTCA


 


CGGTGCAGCTCATCCTGTTTGGGCTCAGTAATCAGCTGGCTGTGACATTCCGGGAAG


 


AGAACACCATCGCCTTCCGACACCTCTTCCTGCTGGGCTACTCGGACGGAGCGGATG


 


ACACCTTCGCAGCCTACACGCGGGAGCAGCTGTACCAGGCCATCTTCCATGCTGTGG


 


ACCAGTACCTGGCGTTGCCTGACGTGTCACTGGGCCGGTATGCGTATGTCCGTGGTG


 


GGGGTGACCCTTGGACCAATGGCTCAGGGCTTGCTCTCTGCCAGCGGTACTACCACC


 


GAGGCCACGTGGACCCGGCCAACGACACATTTGACATTGATCCGATGGTGGTTACTG


 


ACTGCATCCAGGTGGATCCCCCCGAGCGGCCCCCTCCGCCCCCCAGCGACGATCTCAC


 


CCTCTTGGAAAGCAGCTCCAGTTACAAGAACCTCACGCTCAAATTCCACAAGCTGGTC


 


AATGTCACCATCCACTTCCGGCTGAAGACCATTAACCTCCAGAGCCTCATCAATAATG


 


AGATCCCGGACTGCTATACCTTCAGCGTCCTGATCACGTTTGACAACAAAGCACACAG


 


TGGGCGGATCCCCATCAGCCTGGAGACCCAGGCCCACATCCAGGAGTGTAAGCACCC


 


CAGTGTCTTCCAGCACGGAGACAACAGCTTCCGGCTCCTGTTTGACGTGGTGGTCAT


 


CCTCACCTGCTCCCTGTCCTTCCTCCTCTGCGCCCGCTCACTCCTTCGAGGCTTCCTGC


 


TGCAGAACGAGTITGTGGGGTTCATGTGGCGGCAGCGGGGACGGGTCATCAGCCTG


 


TGGGAGCGGCTGGAATTTGTCAATGGCTGGTACATCCTGCTCGTCACCAGCGATGTG


 


CTCACCATCTCGGGCACCATCATGAAGATCGGCATCGAGGCCAAGAACTTGGCGAGC


 


TACGACGTCTGCAGCATCCTCCTGGGCACCTCGACGCTGCTGGTGTGGGTGGGCGT


 


GATCCGCTACCTGACCTTCTTCCACAACTACAATATCCTCATCGCCACACTGCGGGTG


 


GCCCTGCCCAGCGTCATGCGCTTCTGCTGCTGCGTGGCTGTCATCTACCTGGGCTACT


 


GCTTCTGTGGCTGGATCGTGCTGGGGCCCTATCATGTGAAGTTCCGCTCACTCTCCAT


 


GGTGTCTGAGTGCCTGTTCTCGCTCATCAATGGGGACGACATGTTTGTGACGTTCGC


 


CGCCATGCAGGCGCAGCAGGGCCGCAGCAGCCTGGTGTGGCTCTTCTCCCAGCTCTA


 


CCTTTACTCCTTCATCAGCCTCTTCATCTACATGGTGCTCAGCCTCTTCATCGCGCTCA


 


TCACCGGCGCCTACGACACCATCAAGCATCCCGGCGGCGCAGGCGCAGAGGAGAGC


 


GAGCTGCAGGCCTACATCGCACAGTGCCAGGACAGCCCCACCTCCGGCAAGTTCCGC


 


CGCGGGAGCGGCTCGGCCTGCAGCCTTCTCTGCTGCTGCGGAAGGGACCCCTCGGA


 


GGAGCATTCGCTGCTGGTGAAT (SEQ ID NO: 68)


 


Homo sapiens TRPML1 (NM_020533)


(SEQ ID NO: 69)



MTAPAGPRGSETERLLTPNPGYGTQAGPSPAPPTPPEEEDLRRRLKYFFMSPCDKFRAKG



 


RKPCKLMLQVVKILVVTVQLILFGLSNQLAVTFREENTIAFRHLFLLGYSDGADDTFAAY


 


TREQLYQAIFHAVDQYLALPDVSLGRYAYVRGGGDPWTNGSGLALCQRYYHRGHVDPA


 


NDTFDIDPMVVTDCIQVDPPERPPPPPSDDLTLLESSSSYKNLTLKFHKLVNVTIHFRLKTI


 


NLQSLINNEIPDCYTFSVLITFDNKAHSGRIPISLETQAHIQECKHPSVFQHGDNSFRLLFD


 


VVVILTCSLSFLLCARSLLRGFLLQNEFVGFMWRQRGRVISLWERLEFVNGWYILLVTSDV


 


LTISGTIMKIGIEAKNLASYDVCSILLGTSTLLVWVGVIRYLTFFHNYNILIATLRVALPSVM


 


RFCCCVAVIYLGYCFCGWIVLGPYHVKFRSLSMVSECLFSLINGDDMFVTFAAMQAQQGR


 


SSLVWLFSQLYLYSFISLFIYMVLSLFIALITGAYDTIKHPGGAGAEESELQAYIAQCQDSPT


 


SGKFRRGSGSACSLLCCCGRDPSEEHSLLVN (SEQ ID NO: 69)


 


Homo sapiens TRPML2 (NM_153259)


(SEQ ID NO: 70)



ATGGCCCGGCAGCCTTATCGTTTTCCCCAGGCAAGGATTCCGGAGAGAGGATCAGGT



 


GTTTTCAGGTTAACCGTCAGAAACGCAATGGCACATCGTGATTCTGAGATGAAAGAA


 


GAATGTCTAAGGGAAGACCTGAAGTTTTACTTCATGAGCCCTTGTGAAAAATACCGA


 


GCCAGACGCCAGATTCCGTGGAAACTGGGTTTGCAGATTTTGAAGATAGTCATGGTC


 


ACCACACAGCTTGTTCGTTTTGGTTTAAGTAACCAGCTGGTGGTTGCTTTCAAAGAAG


 


ATAACACTGTTGCTTTTAAGCACTTGTTTTTGAAAGGATATTCTGGTACAGATGAAGA


 


TGACTACAGCTGCAGTGTATATACTCAAGAGGATGCCTATGAGAGCATCTTTTTTGCT


 


ATTAATCAGTATCATCAGCTAAAGGACATTACCCTGGGGACCCTTGGTTATGGAGAA


 


AATGAAGACAATAGAATTGGCTTAAAAGTCTGTAAGCAGCATTACAAGAAAGGGACC


 


ATGTTTCCTTCTAATGAGACACTGAATATTGACAACGACGTTGAGCTCGATTGTGTTC


 


AATTAGACCTTCAGGACCTCTCCAAGAAGCCTCCGGACTGGAAGAACTCATCATTCTT


 


CAGACTGGAATTTTATCGGCTCTTACAGGTTGAAATCTCCTTTCATCTTAAAGGCATT


 


GACCTACAGACAATTCATTCCCGTGAGTTACCAGACTGTTATGTCTTTCAGAATACGA


 


TTATCTTTGACAATAAAGCTCACAGTGGCAAAATCAAAATCTATTTTGACAGTGATGC


 


CAAAATTGAAGAATGTAAAGACTTGAACATATTTGGATCTACTCAGAAAAATGCTCAG


 


TATGTCCTGGTGTTTGATGCATTTGTCATTGTGATTTGCTTGGCATCTCTTATTCTGT


 


GTACAAGATCCATTGTTCTTGCTCTAAGGTTACGGAAGAGATTTCTAAATTTCTTCCT


 


GGAGAAGTACAAGCGGCCTGTGTGTGACACCGACCAGTGGGAGTTCATCAACGGCT


 


GGTATGTCCTGGTGATTATCAGCGACCTAATGACAATCATTGGCTCCATATTAAAAAT


 


GGAAATCAAAGCAAAGAATCTCACAAACTATGATCTCTGCAGCATTTTTCTTGGAACC


 


TCTACGCTCTTGGTTTGGGTTGGAGTCATCAGATACCTGGGTTATTTCCAGGCATATA


 


ATGTGCTGATTTTAACAATGCAGGCCTCACTGCCAAAAGTTCTTCGGTTTTGTGCTTG


 


TGCTGGTATGATTTATCTGGGTTACACATTCTGTGGCTGGATTGTCTTAGGACCATAC


 


CATGACAAGTTTGAAAATCTGAACACAGTTGCTGAGTGTCTGTTTTCTCTGGTCAACG


 


GTGATGACATGTTTGCAACCTTTGCCCAAATCCAGCAGAAGAGCATCTTGGTGTGGC


 


TGTTCAGTCGTCTGTATTTATATTCCTTCATCAGCCTTTTTATATATATGATTCTCAGTC


 


TTTTTATTGCACTTATTACAGATTCTTATGACACCATTAAGAAATTCCAACAGAATGGG


 


TTTCCTGAAACGGATTTGCAGGAATTCCTGAAGGAATGCAGTAGCAAAGAAGAGTAT


 


CAGAAAGAGTCCTCAGCCTTCCTGTCCTGCATCTGCTGTCGGAGGAGGAAAAGAAGT


 


GATGATCACTTGATACCTATTAGC (SEQ ID NO: 70)


 


Homo sapiens TRPML2 (NM_153259)


(SEQ ID NO: 71)



MARQPYRFPQARIPERGSGVFRLTVRNAMAHRDSEMKEECLREDLKFYFMSPCEKYRAR



 


RQIPWKLGLQILKIVMVTTQLVRFGLSNQLVVAFKEDNTVAFKHLFLKGYSGTDEDDYS


 


CSVYTQEDAYESIFFAINQYHQLKDITLGTLGYGENEDNRIGLKVCKQHYKKGTMFPSN


 


ETLNIDNDVELDCVQLDLQDLSKKPPDWKNSSFFRLEFYRLLQVEISFHLKGIDLQTIHSR


 


ELPDCYVFQNTIIFDNKAHSGKIKIYFDSDAKIEECKDLNIFGSTQKNAQYVLVFDAFVIV


 


ICLASLILCTRSIVLALRLRKRFLNFFLEKYKRPVCDTDQWEFINGVVYVLVIISDLMTIIGSIL


 


KMEIKAKNLTNYDLCSIFLGTSTLLVWVGVIRYLGYFQAYNVLILTMQASLPKVLRFCACA


 


GMIYLGYTFCGWIVLGPYHDKFENLNTVAECLFSLVNGDDMFATFAQIQQKSILVWLFS


 


RLYLYSFISLFIYMILSLFIALITDSYDTIKKFQQNGFPETDLQEFLKECSSKEEYQKESSAFL


 


SCICCRRRKRSDDHLIPIS (SEQ ID NO: 71)


 


Mus musculus TRPML3 (NM_134160)


(SEQ ID NO: 72)



ATGGCAAATCCCGAGGTGCTGGTTAGCAGCTGCAGAGCTCGCCAAGATGAAAGCCCC



 


TGCACTTTCCACCCGAGCTCGTCCCCGTCAGAGCAGCTTCTCTTAGAAGACCAGATGA


 


GGCGGAAACTCAAGTTCTTTTTTATGAATCCTTGTGAGAAGTICTGGGCTCGGGGTA


 


GGAAGCCATGGAAACTTGCCATACAGATTCTGAAAATCGCGATGGTGACTATCCAGC


 


TGGTTCTGTTTGGACTAAGTAACCAGATGGTAGTAGCTTTCAAAGAGGAGAACACTA


 


TAGCCTTCAAACACCTCTTCCTAAAGGGCTACATGGATCGAATGGACGACACCTATGC


 


AGTGTACACTCAGAGTGAAGTGTATGACCAGATCATCTTTGCAGTGACCCAGTACTT


 


GCAGCTTCAGAACATCTCCGTGGGCAATCACGCTTATGAGAACAAGGGGACTAAGCA


 


GTCGGCGATGGCAATCTGTCAGCACTTCTACAGGCAAGGAACCATCTGCCCCGGGAA


 


CGACACCTTTGACATCGATCCAGAAGTTGAAACAGAATGTTTCCTTGTAGAGCCAGAT


 


GAAGCTTCCCACCTTGGAACGCCTGGAGAAAATAAACTCAACCTGAGCCTGGACTTCC


 


ACAGACTTCTGACGGTGGAGCTCCAGTTTAAGCTCAAAGCCATCAATCTGCAGACAG


 


TTCGACACCAGGAGCTTCCTGACTGTTACGACTTTACGCTGACTATAACATTCGACAA


 


CAAGGCTCACAGTGGAAGAATCAAAATAAGCTTAGACAACGACATTTCTATCAAAGA


 


ATGCAAAGACTGGCATGTGTCTGGATCAATTCAGAAGAACACACACTACATGATGAT


 


CTTTGATGCCTTTGTCATTCTGACCTGCTTGGCCTCACTGGTGCTGTGTGCCAGGTCT


 


GTGATTAGGGGTCTTCAGCTTCAGCAGGAGTTTGTCAACTTCTTCCTTCTTCACTACA


 


AGAAGGAAGTTTCGGCCTCTGATCAGATGGAGTTCATCAACGGGTGGTACATTATGA


 


TCATCATTAGTGACATATTGACAATCGTTGGATCAGTTCTGAAAATGGAAATCCAAGC


 


CAAGAGTCTCACAAGCTATGATGTCTGCAGCATACTTCTCGGGACGTCAACTATGCTC


 


GTGTGGCTTGGAGTTATCCGATACCTGGGTTTCTTTGCGAAGTACAATCTCCTTATTC


 


TGACCCTCCAGGCAGCGCTGCCCAACGTCATGAGGTTCTGTTGCTGCGCTGCTATGA


 


TCTATCTAGGCTATTGCTTTTGCGGATGGATTGTGCTGGGCCCTTACCATGAGAAGT


 


TCCGTTCCCTGAACAGGGTCTCCGAGTGCCTGTTCTCGCTGATAAACGGAGACGATA


 


TGTTTTCCACATTTGCGAAAATGCAGCAGAAGAGTTACCTGGTGTGGCTGTTCAGCC


 


GAGTCTACCTGTACTCGTTCATCAGCCTCTTCATTTACATGATTCTGAGCCTTTTCATC


 


GCGCTCATCACAGACACATACGAAACAATTAAGCACTACCAGCAAGATGGCTTCCCAG


 


AGACGGAACTTCGAAAGTTTATAGCGGAATGCAAAGACCTCCCCAACTCCGGAAAAT


 


ACAGATTAGAAGATGACCCTCCGGGTTCTTTACTCTGCTGCTGCAAAAAG (SEQ ID


 


NO: 72)


 


Mus musculus TRPML3 (NM_134160)


(SEQ ID NO: 73)



MANPEVLVSSCRARQDESPCTFHPSSSPSEQLLLEDQMRRKLKFFFMNPCEKFWARGRKP



 


WKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQ


 


SEVYDQIIFAVTQYLQLQNISVGNHAYENKGTKQSAMAICQHFYRQGTICPGNDTFDID


 


PEVETECFLVEPDEASHLGTPGENKLNLSLDFHRLLTVELQFKLKAINLQTVRHQELPDC


 


YDFTLTITFDNKAHSGRIKISLDNDISIKECKDWHVSGSIQKNTHYMMIFDAFVILTCLASL


 


VLCARSVIRGLQLQQEFVNFFLLHYKKEVSASDQMEFINGWYIMIIISDILTIVGSVLKMEI


 


QAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVMRFCCCAAMIY


 


LGYCFCGWIVLGPYHEKFRSLNRVSECLFSLINGDDMFSTFAKMQQKSYLVWLFSRVYLY


 


SFISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRKFIAECKDLPNSGKYRLEDDPPGS


 


LLCCCKK (SEQ ID NO: 73)


 


Gallus gallus TRPML3 (XM_426647)


(SEQ ID NO: 74)



ATGATCACCCGTGGTTTCCGTTCAGGCTTTTACGGCTGTAGCAATCGATATAGTGGT



 


GCTAAGTGCCAGTTAGTTGCTCAGACGTTTGTCATTTCAGCAATGGAGACTCCTGAA


 


GTGGCTGTAAGCAGCTGCAGTGCTCGGGATGACGAAGGGCTCTGCAGCTACGGACA


 


ACACCTATTGCTGCCACAAGAGCTGGTGGCGGAAGACCAGCTGAGGAGGAAGCTGA


 


AGTTCTTCTTCATGAACCCATGTGAAAAATTCTGGGCTCGGGGCAGAAAACCTTGGA


 


AACTTGGGATTCAGCTGCTCAAAATAGCAATGGTTACCATTCAGCTGGTGCTTTTTGG


 


ATTGAGCAATCAAATGGTGGTTGCTTTCAAAGAAGAGAACACTATTGCATTCAAACAT


 


CTCTTCTTGAAAGGGTACATGGACAGAATGGATGATACCTATGCGGTATACACACAG


 


ACAGATGTCTATGACCAAATATTCTTTGCCATCAATCAGTACTTACAGTTGCCCAACAT


 


TTCTGTTGGAAACCATGCTTATGAGAAGAAAGGAGCAGAAGAGACAGCTCTGGCTG


 


TATGTCAACAGTTCTACAAGCAAGGAACCATCTGTCCTGGAAATGACACCTTTGATAT


 


AGACCCAGAGATTGTGACTGACTGCTTGTACATTGAGCCGATGATGTCTTTAGACAA


 


CAGAACAGTGGGAAAGCACAATTTGAATTTCACTCTGGATTTCCACAGGCTCGTGGC


 


AGTGCAACTCATGTTCAATCTGAAGGCAATCAACCTCCAGACCGTCCGTCACCACGAG


 


CTCCCTGACTGTTACGATTTCACCCTGACGATAGTGTTTGATAATAAAGCCCACAGTG


 


GAAGAATCAAAATCAGTCTAGACAACGACATAGAGATCAGGGAATGTAAAGACTGGC


 


ACGTTTCTGGATCAATACAGAAGAATACGCATTACATGATGATCTTCGATGCTTTTGT


 


CATACTGATCTGTCTGAGCTGATTGATCCTTTGCACTCGATCAGTAGTCAAAGGAATT


 


CGGCTCCAAAGAGAATTTGTAAGTTTTTTCCTATATTATTACAAGAAAGAGGTATCTT


 


ACAATGATCAGATGGAATTTGTCAATGGCTGGTATATCCTCATTATGGTTAGTGATGT


 


CCTCACTATCGTTGGATCAACTCTCAAAATGGAGATACAGGCCAAGAGTCTGACAAG


 


TTACGACGTCTGTAGCATACTCTTAGGAACATCCACTATGCTGGTGTGGCTTGGAGT


 


CATTCGCTACCTCGGTTTCTTTCAGAAGTATAATCTTCTCATTCTAACGCTGCGAGCAG


 


CACTACCCAACGTCATGAGGTTCTGCTGTTGTGCTGCTATGATCTATCTAGGTTATTG


 


TTTCTGCGGATGGATTGTACTGGGGCCATACCACGTGAAGTTCCGTTCTCTGAATGT


 


GGTTTCTGAATGCCTCTTTTCATTGATAkATGGAGATGACATGTTTGCCACTTTTGCA


 


AAAATGCAGCAGAAAAGTTACTTGGTTTGGTTATTCAGTAGAATCTACCTCTACTCCT


 


TCATCAGCCTGTTCATCTACATGGTGCTAAGTCTCTTCATTGCACTCATTACAGATACA


 


TATGAAACTATCAAGCACTACCAACAAGATGGCTTTCCAGAGACAGAACTTCAGAGAT


 


TTATATCACAGTGCAAAGACTTACCAAACTCTGGAAGGTACAGATTAGAAGAGGAAG


 


GTTCTGTATCTCTCTTCTGTTGTTGCAGTGGTCCTAGTGAACATATC (SEQ ID NO: 74)


 


Gallus gallus TRPLM3 (XM_426647)


(SEQ ID NO: 75)



MITRGFRSGFYGCSNRYSGAKCQLVAQTFVISAMETPEVAVSSCSARDDEGLCSYGQHLLL



 


PQELVAEDQLRRKLKFFFMNPCEKFWARGRKPWKLGIQLLKIAMVTIQLVLFGLSNQMV


 


VAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQTDVYDQIFFAINQYLQLPNISVGNHAY


 


EKKGAEETALAVCQQFYKQGTICPGNDTFDIDPEIVTDCLYIEPMMSLDNRTVGKHNLN


 


FTLDFHRLVAVQLMFNLKAINLQTVRHHELPDCYDFTLTIVFDNKAHSGRIKISLDNDIEI


 


RECKDWHVSGSIQKNTHYMMIFDAFVILICLSSLILCTRSVVKGIRLQREFVSFFLYYYKKE


 


VSYNDQMEFVNGWYILIMVSDVLTIVGSTLKMEIQAKSLTSYDVCSILLGTSTMLVWLGVI


 


RYLGFFQKYNLLILTLRAALPNVMRFCCCAAMIYLGYCFCGWIVLGPYHVKFRSLNVVSE


 


CLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMVLSLFIALITDTYETIKHYQ


 


QDGFPETELQRFISQCKDLPNSGRYRLEEEGSVSLFCCCSGPSEHI (SEQ ID NO: 75)


 


Canis familiaris TRPML3 (XM_547306)


(SEQ ID NO: 76)



ATGACCCCTTTTGGCAGCTTGGCTTCTGCAAAGGCTTCAAACTCAAGAGCTGCCTGGA



 


AGATTGTGGTGGATTCATTCAGCTCGCAGCACACGCCCCAGGTGGGCACTGGTGGTC


 


CCCAGGAATCAGACAAGGCCCTTACCTTCGGAGAGTTAACGTTCTCCCACTCATCTCC


 


ATTCTTCATCTGCGCCAGCCCTTCTCTCCCACCGTTGCACAGCAGTGGGCTAGACGAT


 


GAGCCATACTGCTGGACAGGTTTTCACTGCATCAAGTACCTCGCGGGCCCAGCGAGT


 


GTCCCAAACTCCCTTGAAAGAGGGAGT,kAGATATTGGTTTCCCAAGCCTCCTTTCCCA


 


TCCGGACCTCCCCTTACCTGACACTGCTAAGCCGAGGGGAAAAGAAGCCTCTCTGCA


 


GTTCCGTGGAGAAAAGGCCTTTGGGGGTTTTGGAGATGGGAAGTCTGACTCTCCTCT


 


CGGAAGAGCTCAAACGGCAGCTCCCCGGCACGCTGTTGCTAGGACAACCTCCGTTGC


 


TAAGGGAAAGAGGCGGCTCCTCTGCTGAGATTGACAAGACGCCGCTACCAATAGGG


 


CGTCTACTCTCCGGCCGCCTCTTCAAGGCCGCACTTGTGATTGGCTGCTGTCGTGCTG


 


ACGTCACGCAACTCGAACCGCCGAGAGATCCTGGGTTTTCGCCCGCTCGGCAGGAGG


 


TGTGCGGTTTGGGTTCCCGCGTGGAGGGTGCTGCTGGCTCGAATGTAAACAATCTTT


 


TTTTTTTTCTCCCCCTAGAGATGGCAAATCCTACGGTTGTTATAAGTAGCTGCAGCTC


 


TCATGAAGAGGAAAATCGTTGCACTTTTAGCCAGCACACATCGCCCTCTGAGGAGCTT


 


CTGTTAGAAGACCAGATAAGGCGAAAACTCAAATTTTTTTTCATGAATCCTTGTGAAA


 


AGTTCTGGGCTCGAGGTAGAAAACCATGGAAGCTTGCCATACAAATTCTAAAAATTG


 


CAATGGTGACTATCCAGCTGGTCTTTTTTGGGCTAAGTAACCAGATGGTTGTAGCTTT


 


CAAGGAAGAAAACACTATAGCATTCAAACACCTCTTCTTAAAAGGATATATGGACCGA


 


ATGGATGACACATATGCAGTGTACACACAACGTGATGTATATGATCAGATCATCTTTG


 


CAGTGAACCAGTACTTGCTTCTACGCAATACCTCGGTTGGGAATCATGCTTATGAGAA


 


CAAGGGGACGGAACAGTCTGCTATGGCAATCTGTCAGCACTTCTACAAGCAGGGAAA


 


CATCTGTCCTGGAAATGATACCTTCGACATTGATCCAGAGATTGAAACTGAGTGTTTC


 


TCTGTAGAGCCAGCTGAGCCTTTCCACGTCGGAACACTGGAAGAAAATAAACTCAAC


 


TTAACGCTGGACTTTCACAGACTCCTCACGGTGGACCTGCAGTTTAAGCTGAAGGCC


 


ATTAATCTGCAGACCATTCGGCATCACGAGCTCCCTGACTGTTATGACTTTACTCTCAC


 


TATAACATTTGACAATAAGGCCCATAGTGGAAGAATTAAGATAAGTTTAGATAATGA


 


TATTTCCATCAGAGAATGTAAAGACTGGCATGTATCGGGATCAATTCAGAAGAACAC


 


TCACTACATGATGATCTTTGATGCCTTTGTTATTCTGACATGCTTGGCTTCACTAACCC


 


TGTGCCTTCGATCTGTAATTAGAGGACTTCAGCTTCAACAGGAATTTGTCAATTTTTT


 


CCTCCTCCATTATAAGAAGGAAGTTTCTGTTTCTGATCGAATGGAATTTGTCAATGGA


 


TGGTACATTATGATTATTATTAGTGACATGTTGACAATTATTGGATCAATTCTGAAAA


 


TGGAAATTCAAGCTAAGAGTCTAACAAGTTATGATGTTTGTAGCATACTTCTTGGGAC


 


TTCCACCATGCTTGTGTGGCTTGGAGTTATTCGATACCTCGGCTTCTTTCAGAAGTAC


 


AATCTCCTTATTCTGACCCTGCAGGCAGCACTGCCCAGTGTCATCAGGTTCTGTTGCT


 


GTGCCGCTATGATTTATTTAGGCTATTGCTTCTGTGGATGGATTGTGCTGGGGCCGT


 


ACCATGATAAGTTCCGTTCTCTGAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAAT


 


GGAGATGATATGTTTGCCACATTTGCAAAAATGCAACAAAAAAGTTACTTGGTCTGG


 


CTGTTTAGCAGAATTTATCTCTACTCATTCATCAGCCTCTTTATATATATGATTTTAAG


 


TCTTTTCATCGCACTGATCACTGATACGTATGAAACAATTAAGCATTACCAACAAGAT


 


GGCTTTCCAGAGACTGAACTTCGTACATTTATATCAGAGTGCAAAGATCTACCCAATT


 


CTGGAAAATACAGATTAGAAGATGACACTCCAATATCTATATTCTGCTGTTGTAAAAA


 


G (SEQ ID NO: 76)


 


Canis familiaris TRPML3 (XM_547306)


(SEQ ID NO: 77)



MTPFGSLASAKASNSRAAWKIVVDSFSSQHTPQVGTGGPQESDKALTFGELTFSHSSPFFI



 


CASPSLPPLHSSGLDDEPYCWTGFHCIKYLAGPASVPNSLERGSKILVSQASFPIRTSPYLTL


 


LSRGEKKPLCSSVEKRPLGVLEMGSLTLLSEELKRQLPGTLLLGQPPLLRERGGSSAEIDK


 


TPLPIGRLLSGRLFKAALVIGCCRADVTQLEPPRDPGFSPARQEVCGLGSRVEGAAGSNVN


 


NLFFFLPLEMANPTVVISSCSSHEEENRCTFSQHTSPSEELLLEDQIRRKLKFFFMNPCEKF


 


WARGRKPWKLAIQILKIAMVTIQLVFFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMD


 


DTYAVYTQRDVYDQIIFAVNQYLLLRNTSVGNHAYENKGTEQSAMAICQHFYKQGNIC


 


PGNDTFDIDPEIETECFSVEPAEPFHVGTLEENKLNLTLDFHRLLTVDLQFKLKAINLQTI


 


RHHELPDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDA


 


FVILTCLASLTLCLRSVIRGLQLQQEFVNFFLLHYKKFVSVSDRMEFVNGWYIMIIISDMLTI


 


IGSILKMEIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFQKYNLLILTLQAALPSVIRFC


 


CCAAMIYLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVW


 


LFSRIYLYSFISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRTFISECKDLPNSGKYRLE


 


DDTPISIFCCCKK (SEQ ID NO: 77)


 


Danio rerio TRPML3 (XM_688418)


(SEQ ID NO: 78)



ATGTCTGACCGAGCGTCACACACTCATGAAAGCGCAACACTTCTGGACCCGGAGTGT



 


GTGGAAAGCTTAAGGAGAAAACTCAAGTATTTCTTCATGAGTCCGTGTCAGAAATAC


 


AGCACTAGAGGACGGATACCATGGAAGATGATGCTTCAGATACTCAAGATTTGTTTA


 


GTATTCATCTACCTGGTCTCTTTTGGATTGAGCAACGAGATGATGGTGACGTTCAAA


 


GAGGAAAATCTCATCGCCTTCAAGCACTTCTTTCTGAAAAACTACAAGGACAGCAATA


 


AACATTACGCCTTGTACACAAAACATGAAGTTCACGACCACATCCTCTACACCATCAGA


 


CGGTATCTACAGCTACAAAACCTGACGATTGGCAATCAAGCGCTGGAGATGATCGAT


 


GGTCTGGCGACTCCTCTGTCTCTCTGTCAGCAGTTGTATCGACATGCGCGCGTCGTG


 


CCGTCTAATGAGACGTTTGAAATCGATCCACATGTAGAGACAGAGTGTGTTTCTGTG


 


TATCCCCTTTCTCCCATCACGACTGACAGTCTGGAAAACTCCCTGAACTTGACTTTAGA


 


TTTTCAAAGGTTGTTAGCGGTAAACATTTATCTGAAGATCAAGGCTATCAACATTCAG


 


ACGGTTCGCCATCAAGAGTTACCAGACTGCTACGACTTCAGCATTAATATCATGTTTG


 


ACAATCGTGCACACAGCGGACAGATCAAGATCTCTCTCAGCAGCGGCGTGCAGATAA


 


ACGTCTGTAAGGACTGGAACATTTCTGGCTCAAGTAAGTTGAACAGCCACTTTGCGC


 


TGATTGTGGTGTTTGACTGTTTGATCATCTGCTTCTGTCTGCTGTCACTCATCCTCTGC


 


ACGCGCTCAGTCCACACAGGATTTCTCCTACAGACTGAATACAGAAGATTCATGTCCA


 


GTCAGCACAGTAAAAGCGTCTCATGGTCTGAGAGGCTGGAGTTCATCAACGGCTGGT


 


ACATCCTCATCATCATCAGCGATGCGCTGACTATTGCAGGCTCAATCCTCAAAATCTG


 


CATACAGAGCAAAGAACTGACGAGCTATGACGTGTGCAGTATTCTGCTGGGCACTGC


 


AACAATGCTGGTGTGGATTGGAGTAATGCGCTACCTCAGTTTCTTCCAGAAATATTAT


 


ATCCTCATCCTCACCCTGAAGGCTGCACTTCCCAATGTGATTCGATTCTCCATCTGCGC


 


TGTTATGATCTACCTGAGTTACTGCTTCTGCGGATGGATCGTTTTGGGGCCACACCAT


 


GAAAATTTTCGCACATTCAGTAGGGTTGCTGGCTGTCTTTTCTCCATGATTAATGGGG


 


ATGAAATCTACTCCACGTTCACCAAGCTCCGGGAATACAGCACTCTGGTGTGGCTGTT


 


CAGCAGACTCTACGTCTACAGCTTCATCCCGGTCTTCACATACATGGTTCTGAGTGTC


 


TTCATCGCCCTCATCACAGACACGTATGAAACCATCAGGGTGAGTTATTTCAGCTTCA


 


GTGAGAGTAGCTGCAAA (SEQ ID NO: 78)


 


Danio rerio TRPML3 (XM_688418)


(SEQ ID NO: 79)



MSDRASHTHESATLLDPECVESLRRKLKYFFMSPCQKYSTRGRIPWKMMLQILKICLVFIY



 


LVSFGLSNEMMVTFKEENLIAFKHFFLKNYKDSNKHYALYTKHEVHDHILYTIRRYLQL


 


QNLTIGNQALEMIDGLATPLSLCQQLYRHARVVPSNETFEIDPHVETECVSVYPLSPITTD


 


SLENSLNLTLDFQRLLAVNIYLKIKAINIQTVRHQELPDCYDFSINIMFDNRAHSGQIKISLS


 


SGVQINVCKDWNISGSSKLNSHFALIVVFDCLIICFCLLSLILCTRSVHTGFLLQTEYRRFMS


 


SQHSKSVSWSERLEFINGWYILIIISDALTIAGSILKICIQSKELTSYDVCSILLGTATMLVWIG


 


VMRYLSFFQKYYILILTLKAALPNVIRFSICAVMIYLSYCFCGWIVLGPHHENFRTFSRVAG


 


CLFSMINGDEIYSTFTKLREYSTLVWLFSRLYVYSFIPVFTYMVLSVFIALITDTYETIRVSYFS


 


FSESSCK (SEQ ID NO: 79)


 


Homo sapiens TRPML3 Codon-optimized


(SEQ ID NO: 80)



ATGGCCGACCCTGAGGTGGTGGTGTCCTCCTGCTCTAGCCACGAGGAAGAGAACCG



 


GTGCAACTTCAACCAGCAGACCAGCCCCAGCGAGGAACTGCTGCTGGAAGATCAGAT


 


GCGGCGGAAGCTGAAGTTCTTCTTCATGAACCCCTGCGAGAAGTTCTGGGCCAGAG


 


GCCGGAAGCCTTGGAAGCTGGCCATCCAGATCCTGAAGATCGCCATGGTGACCATCC


 


AGCTGGTGCTGTTCGGCCTGAGCAACCAGATGGTGGTGGCCTTCAAAGAGGAAAAC


 


ACAATCGCCTTCAAGCACCTGTTTCTGAAGGGCTACATGGACCGGATGGACGACACC


 


TACGCCGTGTACACCCAGAGCGACGTGTACGACCAGCTGATCTTCGCCGTGAACCAG


 


TACCTGCAGCTGTACAACGTGAGCGTGGGCAACCACGCCTACGAGAACAAGGGCACC


 


AAGCAGAGCGCCATGGCCATCTGCCAGCACTTCTACAAGCGGGGCAACATCTACCCC


 


GGCAACGACACCTTCGACATCGACCCCGAGATCGAGACAGAGTGCTTCTTCGTGGAG


 


CCCGACGAGCCTTTCCACATCGGCACCCCTGCCGAGAACAAGCTGAACCTGACCCTGG


 


ACTTCCACCGGCTGCTGACCGTGGAGCTGCAGTTCAAGCTGAAGGCCATCAACCTGC


 


AGACCGTGCGGCACCAGGAACTGCCCGACTGCTACGACTTCACCCTGACCATCACCTT


 


CGATAACAAGGCCCACAGCGGCCGGATCAAGATCAGCCTGGACAACGACATCAGCAT


 


CCGGGAGTGCAAGGACTGGCACGTGAGCGGCAGCATCCAGAAAAACACCCACTACA


 


TGATGATCTTCGACGCCTTCGTGATCCTGACCTGCCTGGTGTCCCTGATCCTGTGCAT


 


CAGAAGCGTCATCAGGGGCCTGCAGCTCCAGCAGGAATTCGTCAACTTCTTCCTGCT


 


GCACTACAAGAAAGAAGTGTCCGTCAGCGACCAGATGGAATTTGTGAACGGCTGGT


 


ACATCATGATCATCATCAGCGACATCCTGACAATCATCGGCAGCATTCTGAAGATGGA


 


AATCCAGGCCAAGAGCCTGACCAGCTACGACGTGTGCAGCATTCTGCTGGGAACCTC


 


CACCATGCTGGTCTGGCTCGGCGTGATCAGATACCTGGGCTTCTTCGCCAAGTACAA


 


CCTGCTGATTCTGACACTGCAGGCCGCCCTGCCCAACGTGATCCGGTTCTGCTGCTGC


 


GCCGCCATGATCTACCTGGGCTACTGCTTCTGCGGCTGGATCGTGCTGGGCCCCTAC


 


CACGACAAGTTCCGGTCCCTGAACATGGTGTCCGAGTGCCTGTTCAGCCTGATCAAC


 


GGCGACGACATGTTCGCCACCTTCGCCAAGATGCAGCAGAAAAGCTACCTGGTCTGG


 


CTGTTCAGCCGGATCTACCTGTACAGCTTCATCAGCCTGTTCATCTACATGATCCTGA


 


GCCTGTTTATCGCCCTGATCACCGATACCTACGAGACAATCAAGCAGTACCAGCAGGA


 


CGGCTTCCCCGAGACAGAGCTGCGGACCTTCATCAGCGAGTGTAAGGACCTGCCCAA


 


CAGCGGCAAGTACCGGCTGGAAGATGACCCCCCCGTGTCCCTGTTCTGCTGTTGCAA


 


GAAG (SEQ ID NO: 80)


 


Homo sapiens TRPML3 CDS variant C1149T silent mutation


(SEQ ID NO: 81)



ATGGCAGATCCTGAGGTAGTTGTGAGTAGCTGCAGCTCTCATGAAGAGGAAAATCG



 


CTGCAATTTTAACCAGCAAACATCTCCATCTGAGGAGCTTCTATTAGAAGACCAGATG


 


AGGCGAAAACTCAAATTTTTTTTCATGAATCCCTGTGAGAAGTTCTGGGCTCGAGGT


 


AGAAAACCATGGAAACTTGCCATACAAATTCTAAAAATTGCAATGGTGACTATCCAGC


 


TGGTCTTATTTGGGCTAAGTAACCAGATGGTGGTAGCTTTCAAGGAAGAGAATACTA


 


TAGCATTCAAACACCTTTTCCTAAAAGGATATATGGACCGAATGGATGACACATATGC


 


AGTGTACACACAAAGTGACGTGTATGATCAGTTAATCTTCGCAGTAAACCAGTACTTG


 


CAGCTATACAATGTCTCCGTTGGGAATCATGCTTATGAGAACAAAGGTACCAAGCAA


 


TCTGCTATGGCAATCTGTCAGCACTTCTACAAGCGAGGAAACATCTACCCTGGAAATG


 


ATACCTTTGACATCGATCCAGAAATTGAAACTGAGTGTTTCTTTGTGGAGCCAGATGA


 


ACCTTTTCACATTGGGACACCAGCAGAAAATAAACTGAACTTAACACTGGACTTCCAC


 


AGACTCCTAACAGTGGAGCTTCAGTTTAAACTGAAAGCCATTAATCTGCAGACAGTTC


 


GTCATCAAGAACTCCCTGACTGTTATGACTTTACTCTGACTATAACATTTGACAACAAG


 


GCCCATAGTGGAAGAATTAAAATAAGTTTAGATAATGACATTTCCATCAGAGAATGT


 


AAAGACTGGCATGTATCTGGATCAATTCAGAAGAACACTCATTACATGATGATCTTTG


 


ATGCCTTTGTCATTCTGACTTGCTTGGTTTCATTAATCCTCTGCATTAGATCTGTGATT


 


AGAGGACTTCAGCTTCAGCAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGG


 


AAGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTAT


 


TAGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGAGT


 


CTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTACCATGCTTGTGTGGC


 


TTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTCCTCATTTTGACCCTT


 


CAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAGCTATGATTTACTTAG


 


GTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATGACAAGTTTCGTTCTCT


 


GAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGATGATATGTTTGCCACG


 


TTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTTAGTAGAATTTACCTCT


 


ACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTCATTGCACTGATCACT


 


GATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCCCAGAGACTGAACTTC


 


GTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAAATACAGATTAGAAGA


 


TGACCCTCCAGTATCTTTATTCTGCTGTTGTAAAAAG (SEQ ID NO: 81)


 


Rattus norevigus (NM_00102059.1)(GI: 58865683)


(SEQ ID NO: 82)











gttcgacaga agcttgtgat ttatggtcca aggaatccag tgtcagatca atagacaaaa



 


61
tgccccaggg aagttgtgtg tgcattctac tggacagatc agagactggt cagaacaggt


 


121
gcttggctgg cggtgcgtcc aaacctcaga gatggcaaat cctgaggtgg tggtaagcag


 


181
ctgcagttct caccaggatg aaagtccctg cactttctac ccgagctcat cccagtccga


 


241
gcagcttctc ttagaagatc agatgaggcg gaaactcaaa ttctttttta tgaatccttg


 


301
cgagaagttc tgggctcggg gtaggaagcc atggaaactt gccatacaga ttctgaaaat


 


361
cgctatggtg actatccagc tggttctgtt tggactaagt aaccagatgg tagtagcttt


 


421
caaggaagag aacacgatag ccttcaaaca cctcttcctg aaaggctaca tggaccgaat


 


481
ggacgacacc tacgcggtgt acactcagaa tgatgtgtac gaccagatca tctttgcagt


 


541
gacccggtac ttgcaacttc gaaacatctc cgtcggcaac catgcttatg agaacaaggg


 


601
gactaagcag tcagcaatgg cagtctgtca gcacttctac aggcaaggca ccatctgccc


 


661
cgggaacgat accttcgaca tcgatccaga agtcgaaaca gactgtttcc ttatagagcc


 


721
agaggaagct ttccacatgg gaacacctgg agaaaacaaa ctcaacctga ccctggactt


 


781
ccacagactt ctgacagtgg agctccaatt taagctcaaa gccatcaacc tgcagacagt


 


841
tcgccaccag gagcttcctg actgttacga ctttaccctg actataacat tcgacaacaa


 


901
ggcacacagt ggaagaatca aaataagttt agacaacgac atttctatca gagaatgcaa


 


961
agattggcac gtgtctggat caattcagaa gaacacccac tacatgatga tcttcgatgc


 


1021
ctttgttatc ctgacctgct tgtcctcgct ggtgctctgc gccaggtctg tgattcgggg


 


1081
tcttcagctt cagcaggagt ttgtcaactt tttccttctt cactacaaga aggaagtttc


 


1141
ggcctctgat cagatggagt tcatcaacgg gtggtacatt atgatcatcg ttagtgacat


 


1201
actgacgatc gttggatcga ttctgaaaat ggaaatccaa gccaagagtc ttacaagcta


 


1261
cgatgtctgt agcatacttc ttgggacttc caccatgctc gtgtggcttg gcgttatccg


 


1321
atacctgggt ttctttgcga agtacaatct ccttatcctg accctccagg cagcgctgcc


 


1381
caatgtcatc aggttctgtt gctgtgcggc tatgatctat cttgggtatt gcttttgcgg


 


1441
atggattgtg ctgggccctt accatgagaa gttccgctct ctgaacaagg tctctgagtg


 


1501
cctattctca ctgataaatg gagacgacat gttttccacg ttcgcgaaaa tgcagcagaa


 


1561
aagttacctg gtgtggctgt tcagccgcgt ctacctgtac tcgttcatca gcctcttcat


 


1621
ctacatgatc ttgagccttt tcatcgcgct catcacagac acgtacgaaa ccattaagca


 


1681
ctaccagcaa gatggcttcc cagagacgga acttcgaaag tttatcgctg aatgcaaaga


 


1741
cctccccaac tctggaaaat acagattgga agatgaccct ccaggttctt tattctgctg


 


1801
ctgcaaaaag taactgtcgg gtttctctgt gcctgggagg aaaatacagt gtgtggatga


 


1861
gtcagagaca atatggatta ttggtaatca cgcaacagtg tgttcagata ctagtgttct


 


1921
gagttaactc acagctatga ctttgcgggg cctgttaaat atatttttaa atattaaaaa


 


1981
aaaaaaaaaa aaaaaaaaaa


 








Rattus norevigus (NP_00102059.1)(GI: 58865684)



(SEQ ID NO: 83)



MANPEVVVSSCSSHQDESPCTFYPSSSQSEQLLLEDQMRRKLKFFFMNPCEKFWARGRKP



 


WKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYTQ


 


NDVYDQIIFAVTRYLQLRNISVGNHAYENKGTKQSAMAVCQHFYRQGTICPGNDTFDID


 


PEVETDCFLIEPEEAFHMGTPGENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPDC


 


YDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLSSL


 


VLCARSVIRGLQLQQEFVNFFLLHYKKEVSASDQMEFINGWYIMIIVSDILTIVGSILKMEI


 


QAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYL


 


GYCFCGWIVLGPYHEKFRSLNKVSECLFSLINGDDMFSTFAKMQQKSYLVWLFSRVYLYS


 


FISLFIYMILSLFIALITDTYETIKHYQQDGFPETELRKFIAECKDLPNSGKYRLEDDPPGSL


 


FCCCKK


 


Sus scrofa (AB271930)(GI: 146741299)(Partial)


(SEQ ID NO: 84) 










1
gtgaaatggc agatcctgag cctgtcataa gtagctgcag ctctcgtgaa gaggaaaatc



 


61
gctgcacttt taaccagcac acatgtccct ctgaggagcg tctattagaa gaccagatga


 


121
ggcgaaaact caaatttttt ttcatgactc cttgtgagaa gttctggact cgaggtcgaa


 


181
aaccatggaa acttgccatg caagttctaa aaattgcgat ggtgactatc cagctgatct


 


241
ttttcgggct aagtaaccag atggtggtag ctttcaagga agagaacacg atagcattta


 


301
aacacctctt tctaaagggc tatgtggacc agatggatga cacatatgcc gtgtacaccc


 


361
aaagcgacgt atacgatcgg atcgtcttcg cagtgaacca gtacttgcag ctacgcagca


 


421
tctcggttgg gaaccacgct tacgagaaca agggcgcgga gcagtcggcc atggcgatct


 


481
gttggcactt ctacaagcaa ggaaacatct gtcctggaaa tgacaccttt gacgttgatc


 


541
cagaagtaaa aactgaatgt ttctttgttg agccggatga agctgttgac actggaacac


 


601
tggaggagaa taagctcaac ttaacccttg actttcacag actcctaacg gtggagctgc


 


661
agtttaaact caaggccatt aatctgcaga cgattcgcca tcacgaactc cctgactgtt


 


721
atgacttcac cctgaccata acatttgaca a


 








Sus scrofa (BAF62305.1)(GI: 14671300)(Partial)



(SEQ ID NO: 85)



MADPEPVISSCSSREEENRCTFNQHTCPSEERLLEDQMRRKLKFFFMTPCEKFWTRGRKP



 


WKLAMQVLKIAMVTIQLIFFGLSNQMVVAFKEENTIAFKHLFLKGYVDQMDDTYAVYT


 


QSDVYDRIVFAVNQYLQLRSISVGNHAYENKGAEQSAMAICWHFYKQGNICPGNDTFD


 


VDPEVKTECFFVEPDEAVDTGTLEENKLNLTLDFHRLLTVELQFKLKAINLQTIRHHELP


 


DCYDFTLTITFD


 


Pan troglytes TRPML3 (XM_001140555.1) (GI: 114557485)


(SEQ ID NO: 86)










1
cttactccaa tcaagcctct gcccgccagg aataggtaac ctgtgtgtgt ccgtttgctc



 


61
cttctaagag catgcctgat agatacttcg gtagcctctc cggatggccc cttcgtcggg


 


121
tagcctctcc tgatggggtc cttcgcccac cctgcctccc gcgccggcgc tccgggtgaa


 


181
tgtcaagggt ggctggctgc gaatacctcc ttcagctgct ggggttcccg acagtttgca


 


241
gtttttaaaa gtgcaccctc ggaagggctt ttcagactgg gtaaagctga cttttccaag


 


301
agatggcaga tcctgaggta gttgtgagta gctgcagctc tcatgaagag gaaaatcgct


 


361
gcaattttaa ccagcaaaca tctccatctg aggagcttct attagaagac cagatgaggc


 


421
gaaaactcaa attttttttc atgaatccct gtgagaagtt ctgggctcga ggtagaaaac


 


481
catggaaact tgccatacaa attctaaaaa ttgcaatggt gactatccag ctggtcttat


 


541
ttgggctaag taaccagatg gtggtagctt tcaaggaaga gaatactata gcattcaaac


 


601
accttttcct aaaaggatat atggaccgaa tggatgacac atatgcagtg tacacacaaa


 


661
gtgacgtgta tgatcagtta atcttcgcag taaaccagta cttgcagcta tacaatgtct


 


721
ccgttgggaa tcatgcttat gagaacaaag gtaccaagca atctgctatg gcaatctgtc


 


781
agcacttcta caagcgagga aacatctacc ctggaaatga tacctttgac atcgatccag


 


841
aaattgaaac tgagtgtttc tttgtggagc cagatgaacc ttttcacatt gggacaccag


 


901
cagaaaataa actgaactta acactggact tccacagact cctaacagtg gagcttcagt


 


961
ttaaactgaa agccattaat ctgcagacag ttcgtcatca agaactccct gactgttatg


 


1021
actttactct gactataaca tttgacaaca aggcccatag tggaagaatt aaaataagtt


 


1081
tagataatga catttccatc agagaatgta aagactggca tgtatctgga tcaattcaga


 


1141
agaacactca ttacatgatg atctttgatg cctttgtcat tctgacttgc ttggtttcat


 


1201
taatcctctg cattagatct gtgattagag gacttcagct tcagcaggta gggaacgttg


 


1261
ctttctagga atgctactga cattttgatt gacagagaca ttcactgtgc ctcccctctt


 


1321
ttccctaaag gagtttgtca attttttcct cctccattat aagaagggag tttctgtttc


 


1381
tgatcaaatg gaatttgtca atggatggta cattatgatt attattagtg acatattgac


 


1441
aatcattgga tcaattctaa aaatggaaat ccaagctaag gtaatttttt tcctaatcat


 


1501
gctattgtta gtgtcagatt tgcactaatg gtaatgtatt tttccagaat gtaagaattt


 


1561
tcagaatgaa ttgtttcttc caaactgtat atcaagtaga cttgaaattg gtaatggtaa


 


1621
ttttcttaaa tctagtcagg aggtctctta ggcagagttt ttcaaagtgt gatccacaaa


 


1681
ccattgcatc agaatcattg ggtgcctggt aaagtgtacc atgttagacc tactgaattc


 


1741
agactcttcg gcggggcctg tgaattctta cacacaccaa aattcataca caaccaaggt


 


1801
aactaaggta agagtttttt ttttttttaa atcttacaag aaatgctcaa atctttaaca


 


1861
aaaatgagtg ggtctatagg ggaaagtgag gtcaaggcac tatggtgtgc atgcttgcat


 


1921
ttgtttcctc cgtccattca aagtgagaat gctcccattt tcttacttta ccattgatgt


 


1981
gctacaagct tatttatttt aagactaacc tagcctaaaa atcaactgtc cccacaaaat


 


2041
aaaaatcaca ttaaaaaaac taatagtgtt cagactaatc ttgctcaaac ttatgtttcc


 


2101
ctagtcttga tgcgactgat tgagtcacct ggggagttgg ttataaacct gggcagagac


 


2161
cccaaatgca atggctcaga gaagatagga gcttatttct gtcttatgca atagtcagaa


 


2221
tgggttttac agactggtga gtagctcaac atctcacagt cattcaggca cccatgttcc


 


2281
tcccattttg tttctctgcc atcccttaag gacttgccct gactgcatga ttattgctgt


 


2341
gttgcctcaa acaggttgca gcttatggga agcaaaaaca cggtatggtg gaagctctcc


 


2401
catagactga tggcttggct caagagtggc cgactttatt tctgtacata tcccactgga


 


2461
tagaatttag tcaatcctaa ctgcagaggg agccagggaa cacagcccag gcatgtgcct


 


2521
aggaagggga gaatgggttt aggttgacac ttagcagctg ccactatatg tggctatagt


 


2581
atgtatcatt ggaatagatg tttaacttta gggacaaata aacaaaaaac caaaacaaaa


 


2641
aaaggagtaa ggggagagat ttgcagcaaa tctttatttt taccaacctc aactatcatt


 


2701
aatttcagtg aaccctaaat ggtgtccaac aaaatatctt tctagaccat tcaccgtctc


 


2761
tgcctcatag atgatcatat catgttttct tctcttctga aacctctaat acccttgtcc


 


2821
tatcctcatt ctaagctgat gaccttactt cctatttcac aaaaataata gaaaaaaaaa


 








Pan troglytes TRPML3 (XP_001140555.1)(GI: 469371)



(SEQ ID NO: 87)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS


 


LILCIRSVIRGLQLQQVGNVAF


 


Pan troglytes TRPML3 (XM_001140401.1)(GI: 114557483)


(SEQ ID NO: 88)










1
cctctagaga tggcagatcc tgaggtagtt gtgagtagct gcagctctca tgaagaggaa



 


61
aatcgctgca attttaacca gcaaacatct ccatctgagg agcttctatt agaagaccag


 


121
atgaggcgaa aactcaaatt ttttttcatg aatccctgtg agaagttctg ggctcgaggt


 


181
agaaaaccat ggaaacttgc catacaaatt ctaaaaattg caatggtgac tatccagctg


 


241
gtcttatttg ggctaagtaa ccagatggtg gtagctttca aggaagagaa tactatagca


 


301
ttcaaacacc ttttcctaaa aggatatatg gaccgaatgg atgacacata tgcagtgtac


 


361
acacaaagtg acgtgtatga tcagttaatc ttcgcagtaa accagtactt gcagctatac


 


421
aatgtctccg ttgggaatca tgcttatgag aacaaaggta ccaagcaatc tgctatggca


 


481
atctgtcagc acttctacaa gcgaggaaac atctaccctg gaaatgatac ctttgacatc


 


541
gatccagaaa ttgaaactga gtgtttcttt gtggagccag atgaaccttt tcacattggg


 


601
acaccagcag aaaataaact gaacttaaca ctggacttcc acagactcct aacagtggag


 


661
cttcagttta aactgaaagc cattaatctg cagacagttc gtcatcaaga actccctgac


 


721
tgttatgact ttactctgac tataacattt gacaacaagg cccatagtgg aagaattaaa


 


781
ataagtttag ataatgacat ttccatcaga gaatgtaaag actggcattc tccctccgtc


 


841
gcccagcctg gaaacactca ttacatgatg atctttgatg cctttgtcat tctgacttgc


 


901
ttggtttcat taatcctctg cattagatct gtgattagag gacttcagct tcagcaggag


 


961
tttgtcaatt ttttcctcct ccattataag aagggagttt ctgtttctga tcaaatggaa


 


1021
tttgtcaatg gatggtacat tatgattatt attagtgaca tattgacaat cattggatca


 


1081
attctaaaaa tggaaatcca agctaagagt ctaactagtt atgatgtctg tagcatactt


 


1141
cttgggactt ctaccatgct tgtgtggctt ggagtcatcc gatacctcgg tttctttgca


 


1201
aagtacaatc tcctcatttt gacccttcag gcagcactgc ccaatgtcat caggttctgc


 


1261
tgctgtgcag ctatgattta cttaggttac tgcttctgtg gatggatcgt gctggggcct


 


1321
taccatgaca agtttcgttc tctgaacatg gtctctgagt gccttttctc tctgataaat


 


1381
ggagatgata tgtttgccac gtttgcaaaa atgcagcaaa aaagttactt agtctggctg


 


1441
tttagtagaa tttacctcta ctcattcatc agcctcttta tatatatgat tttaagtctt


 


1501
ttcattgcac tgatcactga tacatacgaa acaattaagc aataccaaca agatggcttc


 


1561
ccagagactg aacttcgtac atttatatca gaatgcaaag atctacccaa ctctggaaaa


 


1621
tacagattag aagatgaccc tccagtatct ttattctgct gttgtaaaaa gtagctatca


 


1681
ggtttatctg tactttagag gaaaatataa tgtgtagctg agttagaaca ctgtggatat


 


1741
tctgagatca gatgtagtat gtttgaagac tgttattttg agctaattga gacctataat


 


1801
tcaccaataa ctgtttatat ttttaaaagc aatatttaat gtctttgcag ctttatgctg


 


1861
ggcttgtt


 








Pan troglytes TRPML3 XP_001140401.1 (GI: 114557484)



(SEQ ID NO: 89)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKFENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHSPSVAQPGNTHYMMIFDAFVILTCL


 


VSLILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKM


 


EIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMI


 


YLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYL


 


YSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVS


 


LFCCCKK


 


Pan troglytes TRPML3 (XM_524756.2) (GI: 114557481)


(SEQ ID NO: 90)










1
tcctctagag atggcagatc ctgaggtagt tgtgagtagc tgcagctctc atgaagagga



 


61
aaatcgctgc aattttaacc agcaaacatc tccatctgag gagcttctat tagaagacca


 


121
gatgaggcga aaactcaaat tttttttcat gaatccctgt gagaagttct gggctcgagg


 


181
tagaaaacca tggaaacttg ccatacaaat tctaaaaatt gcaatggtga ctatccagta


 


241
cttgcagcta tacaatgtct ccgttgggaa tcatgcttat gagaacaaag gtaccaagca


 


301
atctgctatg gcaatctgtc agcacttcta caagcgagga aacatctacc ctggaaatga


 


361
tacctttgac atcgatccag aaattgaaac tgagtgtttc tttgtggagc cagatgaacc


 


421
ttttcacatt gggacaccag cagaaaataa actgaactta acactggact tccacagact


 


481
cctaacagtg gagcttcagt ttaaactgaa agccattaat ctgcagacag ttcgtcatca


 


541
agaactccct gactgttatg actttactct gactataaca tttgacaaca aggcccatag


 


601
tggaagaatt aaaataagtt tagataatga catttccatc agagaatgta aagactggca


 


661
tgtatctgga tcaattcaga agaacactca ttacatgatg atctttgatg cctttgtcat


 


721
tctgacttgc ttggtttcat taatcctctg cattagatct gtgattagag gacttcagct


 


781
tcagcaggag tttgtcaatt ttttcctcct ccattataag aagggagttt ctgtttctga


 


841
tcaaatggaa tttgtcaatg gatggtacat tatgattatt attagtgaca tattgacaat


 


901
cattggatca attctaaaaa tggaaatcca agctaagagt ctaactagtt atgatgtctg


 


961
tagcatactt cttgggactt ctaccatgct tgtgtggctt ggagtcatcc gatacctcgg


 


1021
tttctttgca aagtacaatc tcctcatttt gacccttcag gcagcactgc ccaatgtcat


 


1081
caggttctgc tgctgtgcag ctatgattta cttaggttac tgcttctgtg gatggatcgt


 


1141
gctggggcct taccatgaca agtttcgttc tctgaacatg gtctctgagt gccttttctc


 


1201
tctgataaat ggagatgata tgtttgccac gtttgcaaaa atgcagcaaa aaagttactt


 


1261
agtctggctg tttagtagaa tttacctcta ctcattcatc agcctcttta tatatatgat


 


1321
tttaagtctt ttcattgcac tgatcactga tacatacgaa acaattaagc aataccaaca


 


1381
agatggcttc ccagagactg aacttcgtac atttatatca gaatgcaaag atctacccaa


 


1441
ctctggaaaa tacagattag aagatgaccc tccagtatct ttattctgct gttgtaaaaa


 


1501
gtagctatca ggtttatctg tactttagag gaaaatataa tgtgtagctg agttagaaca


 


1561
ctgtggatat tctgagatca gatgtagtat gtttgaagac tgttattttg agctaattga


 


1621
gacctataat tcaccaataa ctgtttatat ttttaaaagc aatatttaat gtctttgcag


 


1681
ctttatgctg ggcttgtttt taaaacaact ttaatgagga aagctattgg attattatta


 


1741
tttcttgttt attttgccat ggctttagaa tgtattctgt atgcctctct tttgctctga


 


1801
tactcttgct tcctgctatt ctgattgtgc agactgtgta attagtggaa aacaatcctt


 


1861
ggtctgactg tgactttgga caactcagta accctggctt ggaccactct caggagtcca


 


1921
tccttgagag agtgggtgta gttaccattt atacagtaat cattgcattt taaaatctgc


 


1981
tcttgaaagg aagaataaga gtgcaccaga ataagagcgc accagaataa gagcgcacca


 


2041
gctaacaatg tgatacggcc atatgtcact taaggataga gatatgttct gagaaatgtg


 


2101
tcattaggcg attttgtcat taaacatcat agcatgtact tccacaaacc tagatggtat


 


2161
agcctactac acacctaggc tatttggtat agcctgttga tcctggggta caaatctgta


 


2221
caacatgtta ctgtattgaa tacagtaggc aattgtaaca caatggtaag tatctaaaca


 


2281
tagaaaaggg acagtaaaaa tatggtttta taatcttctg ggaccaccat tgtatatgcg


 


2341
gtacatcgtt gaccaaaaca tcgttatcca gcatatgact gtatttggtt atgaaagcca


 


2401
actgttactt gattctgctt ttagttctta agaggatcag gtttttaaat actcatttac


 


2461
aagttttcta tcctccttca gtgttaaagt agaaagtaaa aagagtatct tatacatgca


 


2521
tgaaattaaa gcatatacca aatgca


 








Pan troglytes TRPML3 (XP_524756.2)(GI: 114557482)



(SEQ ID NO: 91)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDT


 


FDIDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQEL


 


PDCYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTC


 


LVSLILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKM


 


EIQAKSLTSYDVCSILLGTSTMLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMI


 


YLGYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYL


 


YSFISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVS


 


LFCCCKK


 


Pan troglytes TRPML3 (XM_00114082.1)(GI: 114557479)


(SEQ ID NO: 92)










1
tcctctagag atggcagatc ctgaggtagt tgtgagtagc tgcagctctc atgaagagga



 


61
aaatcgctgc aattttaacc agcaaacatc tccatctgag gagcttctat tagaagacca


 


121
gatgaggcga aaactcaaat tttttttcat gaatccctgt gagaagttct gggctcgagg


 


181
tagaaaacca tggaaacttg ccatacaaat tctaaaaatt gcaatggtga ctatccagct


 


241
ggtcttattt gggctaagta accagatggt ggtagctttc aaggaagaga atactatagc


 


301
attcaaacac cttttcctaa aaggatatat ggaccgaatg gatgacacat atgcagtgta


 


361
cacacaaagt gacgtgtatg atcagttaat cttcgcagta aaccagtact tgcagctata


 


421
caatgtctcc gttgggaatc atgcttatga gaacaaaggt accaagcaat ctgctatggc


 


481
aatctgtcag cacttctaca agcgaggaaa catctaccct ggaaatgata cctttgacat


 


541
cgatccagaa attgaaactg agtgtttctt tgtggagcca gatgaacctt ttcacattgg


 


601
gacaccagca gaaaataaac tgaacttaac actggacttc cacagactcc taacagtgga


 


661
gcttcagttt aaactgaaag ccattaatct gcagacagtt cgtcatcaag aactccctga


 


721
ctgttatgac tttactctga ctataacatt tgacaacaag gcccatagtg gaagaattaa


 


781
aataagttta gataatgaca tttccatcag agaatgtaaa gactggcatg tatctggatc


 


841
aattcagaag aacactcatt acatgatgat ctttgatgcc tttgtcattc tgacttgctt


 


901
ggtttcatta atcctctgca ttagatctgt gattagagga cttcagcttc agcaggagtt


 


961
tgtcaatttt ttcctcctcc attataagaa gggagtttct gtttctgatc aaatggaatt


 


1021
tgtcaatgga tggtacatta tgattattat tagtgacata ttgacaatca ttggatcaat


 


1081
tctaaaaatg gaaatccaag ctaagagtct aactagttat gatgtctgta gcatacttct


 


1141
tgggacttct accatgcttg tgtggcttgg agtcatccga tacctcggtt tctttgcaaa


 


1201
gtacaatctc ctcattttga cccttcaggc agcactgccc aatgtcatca ggttctgctg


 


1261
ctgtgcagct atgatttact taggttactg cttctgtgga tggatcgtgc tggggcctta


 


1321
ccatgacaag tttcgttctc tgaacatggt ctctgagtgc cttttctctc tgataaatgg


 


1381
agatgatatg tttgccacgt ttgcaaaaat gcagcaaaaa agttacttag tctggctgtt


 


1441
tagtagaatt tacctctact cattcatcag cctctttata tatatgattt taagtctttt


 


1501
cattgcactg atcactgata catacgaaac aattaagcaa taccaacaag atggcttccc


 


1561
agagactgaa cttcgtacat ttatatcaga atgcaaagat ctacccaact ctggaaaata


 


1621
cagattagaa gatgaccctc cagtatcttt attctgctgt tgtaaaaagt agctatcagg


 


1681
tttatctgta ctttagagga aaatataatg tgtagctgag ttagaacact gtggatattc


 


1741
tgagatcaga tgtagtatgt ttgaagactg ttattttgag ctaattgaga cctataattc


 


1801
accaataact gtttatattt ttaaaagcaa tatttaatgt ctttgcagct ttatgctggg


 


1861
cttgttttta aaacaacttt aatgaggaaa gctattggat tattattatt tcttgtttat


 


1921
tttgccatgg ctttagaatg tattctgtat gcctctcttt tgctctgata ctcttgcttc


 


1981
ctgctattct gattgtgcag actgtgtaat tagtggaaaa caatccttgg tctgactgtg


 


2041
actttggaca actcagtaac cctggcttgg accactctca ggagtccatc cttgagagag


 


2101
tgggtgtagt taccatttat acagtaatca ttgcatttta aaatctgctc ttgaaaggaa


 


2161
gaataagagt gcaccagaat aagagcgcac cagaataaga gcgcaccagc taacaatgtg


 


2221
atacggccat atgtcactta aggatagaga tatgttctga gaaatgtgtc attaggcgat


 


2281
tttgtcatta aacatcatag catgtacttc cacaaaccta gatggtatag cctactacac


 


2341
acctaggcta tttggtatag cctgttgatc ctggggtaca aatctgtaca acatgttact


 


2401
gtattgaata cagtaggcaa ttgtaacaca atggtaagta tctaaacata gaaaagggac


 


2461
agtaaaaata tggttttata atcttctggg accaccattg tatatgcggt acatcgttga


 


2521
ccaaaacatc gttatccagc atatgactgt atttggttat gaaagccaac tgttacttga


 


2581
ttctgctttt agttcttaag aggatcaggt ttttaaatac tcatttacaa gttttctatc


 


2641
ctccttcagt gttaaagtag aaagtaaaaa gagtatctta tacatgcatg aaattaaagc


 


2701
atataccaaa tgca


 








Pan troglytes TRPML3 (XP_00114082.1)(GI: 114557480)



(SEQ ID NO: 93)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHFYKRGNIYPGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS


 


LILCIRSVIRGLQLQQEFVNFFLLHYKKGVSVSDQMEFVNGWYIMIIISDILTIIGSILKMEI


 


QAKSLTSYDVCSILLGTSTMLATWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYL


 


GYCFCGWIVLGPYHDKFRSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYS


 


FISLFIYMILSLFIALITDTYETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVSLF


 


CCCKK


 


Xenopus tropicalis (Silurana tropicalis)(NM_001016804.2)(GI: 77682897)


(SEQ ID NO: 94)










1
ttgcaactag gtctgacagt aggacaatgt ggcaggtcac gtgacagcag tgctgatggt



 


61
agagatgcgc cagcattcag gtctgagagc agaaagaaaa gctggccaaa acaaaggaca


 


121
ttctctttgc tgcttcgcta gctgagacgc tgctatagta tagcagacat ggaaaaccca


 


181
gagctaataa agacatgcaa ctctttggat gaacatgatg gtccctactg ctgcaagcag


 


241
tgccctatga ctgatgagct acttatggaa gaccagctac gaaggaaact taaattcttt


 


301
ttcatgaacc catgtgagaa gttccgtgcc cgtggacgaa agccttggaa gctttgtatt


 


361
caaattttaa aaattgcaat ggtgacaatc caattagttt tatttggact cagtaatgaa


 


421
atggtagtca cctttaaaga ggagaacact gtagctttta agcatctgtt tttgaaagga


 


481
tataaggatg gacatgatga cacatatgct atctacagtc aagaagatgt tcatgctcat


 


541
ataaacttta caattaaaag gtacctagag ctacaaaaca tatctgttgg aaatcatgca


 


601
tatgaaagta atggtaaagg tcaaactgga atgtcattat gtcaacatta ctataaacaa


 


661
gggagtatct ttcctggaaa tgaaacattt gaaattgacc cacaaataga tactgaatgt


 


721
ttccatattg atccatcaac tctgtgttct aatgacacac ctgcagaata ctactggtct


 


781
aatatgacac tagacttcta tagacttgtt tcagttgaaa ttatgtttaa gcttaaagca


 


841
attaatcttc aaaccattcg tcatcatgaa cttccagact gctatgactt catggttata


 


901
ataacatttg ataataaggc acacagtgga aggataaaaa tcagcttaga taatgatgtt


 


961
ggaatccagg aatgcaaaga ctggcatgtg tctggatcta ttcaaaaaaa tactcattac


 


1021
atgatgattt ttgatgctgc tgttattttg gtctgcttat cttccataac actctgcatt


 


1081
cgctccgtgg ttaaaggaat tcacctacaa aaagaatatg taaacttttt ccagcatcgt


 


1141
tttgcaagga ctgtgtcctc agctgatcgc atggaatttg tcaatggctg gtacattatg


 


1201
ataatcatca gtgatgtttt gtcaattatt ggctcaatct tgaagatgga gatccaagca


 


1261
aagagcctca ccagttatga tgtctgcagt attctcttgg gaacatccac cttattagtg


 


1321
tggcttggag ttattcgcta cttgggattt tttaagaaat acaatcttct gatcctgaca


 


1381
cttagggcag ccttacctaa tgtgatacga ttctgctgtt gtgctgctat gatctacctg


 


1441
ggctactgct tctgtggctg gattgttctg gggccttacc atgtaaagtt caggtccctg


 


1501
aacatggttt cagagtgcct gttctccctt attaatggag acgatatgtt tacaacgttt


 


1561
tcaatcatgc aggagaagag ctacttggtt tggctgttta gtcgcattta tttgtattcc


 


1621
tttataagtc tcttcatata catggttctg agtctcttca ttgcacttat tactgacaca


 


1681
tacgatacaa tcaagaatta ccagatcgat ggctttccag aatcagaact tcacacattt


 


1741
gtatccgagt gcaaagattt gccaacctct ggtcgatata gggaacaaga cgagacctcc


 


1801
tgtttgtcta tgctgtgttg taatcggtaa aaaagaatcc cagaagaagc actttatcca


 


1861
tggcctttaa aaatctgcaa aaaaaaaaaa aaaaaa


 








Xenopus tropicalis (Silurana tropicalis)(NP_001016804.2)(GI: 62857333)



(SEQ ID NO: 95)



MENPELIKTCNSLDEHDGPYCCKQCPMTDELLMEDQLRRKLKFFFMNPCEKFRARGRK



 


PWKLCIQILKIAMVTIQLVLFGLSNEMVVTFKEENTVAFKHLFLKGYKDGHDDTYAIYSQ


 


EDVHAHINFTIKRYLELQNISVGNHAYESNGKGQTGMSLCQHYYKQGSIFPGNETFEID


 


PQIDTECFHIDPSTLCSNDTPAEYYWSNMTLDFYRLVSVEIMFKLKAINLQTIRHHELPDC


 


YDFMVIITFDNKAHSGRIKISLDNDVGIQECKDWHVSGSIQKNTHYMMIFDAAVILVCLS


 


SITLCIRSVVKGIHLQKFYVNFFQHRFARTVSSADRMEFVNGWYIMIIISDVLSIIGSILKMEI


 


QAKSLTSYDVCSILLGTSTLLVWLGVIRYLGFFKKYNLLILTLRAALPNVIRFCCCAAMIYL


 


GYCFCGWIVLGPYHVKFRSLNMVSECLFSLINGDDMFTTFSIMQEKSYLVWLFSRIYLYSFI


 


SLFIYMVLSLFIALITDTYDTIKNYQIDGFPESELHTFVSECKDLPTSGRYREQDETSCLSML


 


CCNR


 


Xenopus tropicalis (Silurana tropicalis)(CR855599.2)(GI: 77623768)


(SEQ ID NO: 96)










1
ttgcaactag gtctgacagt aggacaatgt ggcaggtcac gtgacagcag tgctgatggt



 


61
agagatgcgc cagcattcag gtctgagagc agaaagaaaa gctggccaaa acaaaggaca


 


121
ttctctttgc tgcttcgcta gctgagacgc tgctatagta tagcagacat ggaaaaccca


 


181
gagctaataa agacatgcaa ctctttggat gaacatgatg gtccctactg ctgcaagcag


 


241
tgccctatga ctgatgagct acttatggaa gaccagctac gaaggaaact taaattcttt


 


301
ttcatgaacc catgtgagaa gttccgtgcc cgtggacgaa agccttggaa gctttgtatt


 


361
caaattttaa aaattgcaat ggtgacaatc caattagttt tatttggact cagtaatgaa


 


421
atggtagtca cctttaaaga ggagaacact gtagctttta agcatctgtt tttgaaagga


 


481
tataaggatg gacatgatga cacatatgct atctacagtc aagaagatgt tcatgctcat


 


541
ataaacttta caattaaaag gtacctagag ctacaaaaca tatctgttgg aaatcatgca


 


601
tatgaaagta atggtaaagg tcaaactgga atgtcattat gtcaacatta ctataaacaa


 


661
gggagtatct ttcctggaaa tgaaacattt gaaattgacc cacaaataga tactgaatgt


 


721
ttccatattg atccatcaac tctgtgttct aatgacacac ctgcagaata ctactggtct


 


781
aatatgacac tagacttcta tagacttgtt tcagttgaaa ttatgtttaa gcttaaagca


 


841
attaatcttc aaaccattcg tcatcatgaa cttccagact gctatgactt catggttata


 


901
ataacatttg ataataaggc acacagtgga aggataaaaa tcagcttaga taatgatgtt


 


961
ggaatccagg aatgcaaaga ctggcatgtg tctggatcta ttcaaaaaaa tactcattac


 


1021
atgatgattt ttgatgctgc tgttattttg gtctgcttat cttccataac actctgcatt


 


1081
cgctccgtgg ttaaaggaat tcacctacaa aaagaatatg taaacttttt ccagcatcgt


 


1141
tttgcaagga ctgtgtcctc agctgatcgc atggaatttg tcaatggctg gtacattatg


 


1201
ataatcatca gtgatgtttt gtcaattatt ggctcaatct tgaagatgga gatccaagca


 


1261
aagagcctca ccagttatga tgtctgcagt attctcttgg gaacatccac cttattagtg


 


1321
tggcttggag ttattcgcta cttgggattt tttaagaaat acaatcttct gatcctgaca


 


1381
cttagggcag ccttacctaa tgtgatacga ttctgctgtt gtgctgctat gatctacctg


 


1441
ggctactgct tctgtggctg gattgttctg gggccttacc atgtaaagtt caggtccctg


 


1501
aacatggttt cagagtgcct gttctccctt attaatggag acgatatgtt tacaacgttt


 


1561
tcaatcatgc aggagaagag ctacttggtt tggctgttta gtcgcattta tttgtattcc


 


1621
tttataagtc tcttcatata catggttctg agtctcttca ttgcacttat tactgacaca


 


1681
tacgatacaa tcaagaatta ccagatcgat ggctttccag aatcagaact tcacacattt


 


1741
gtatccgagt gcaaagattt gccaacctct ggtcgatata gggaacaaga cgagacctcc


 


1801
tgtttgtcta tgctgtgttg taatcggtaa aaaagaatcc cagaagaagc actttatcca


 


1861
tggcctttaa aaatctgcaa aaaaaaaaaa aaaaaa








//



 


Xenopus tropicalis (Silurana tropicalis)(CAJ83717.1)(GI: 89273945)


(SEQ ID NO: 97)



MENPELIKTCNSLDEHDGPYCCKQCPMTDELLMEDQLRRKLKFFFMNPCEKFRARGRK



 


PWKLCIQILKIAMVTIQLVLFGLSNEMVVTFKFENTVAFKHLFLKGYKDGHDDTYAIYSQ


 


EDVHAHINFTIKRYLELQNISVGNHAYESNGKGQTGMSLCQHYYKQGSIFPGNETFEID


 


PQIDTECFHIDPSTLCSNDTPAEYYWSNMTLDFYRLVSVEIMFKLKAINLQTIRHHELPDC


 


YDFMVIITFDNKAHSGRIKISLDNDVGIQECKDWHVSGSIQKNTHYMMIFDAAVILVCLS


 


SITLCIRSVVKGIHLQKEYVNFFQHRFARTVSSADRMEFVNGWYIMIIISDVLSIIGSILKMEI


 


QAKSLTSYDVCSILLGTSTLLVWLGVIRYLGFFKKYNLLILTLRAALPNVIRFCCCAAMIYL


 


GYCFCGWIVLGPYHVKFRSLNMVSECLFSLINGDDMFTTFSIMQEKSYLVWLFSRIYLYSFI


 


SLFIYMVLSLFIALITDTYDTIKNYQIDGFPESELHTFVSECKDLPTSGRYREQDETSCLSML


 


CCNR


 


Homo sapiens Sodium Leak Channel, Non-Selective (NALCN), mRNa (NM_052867.2)


GI: 93277089


(SEQ ID NO: 98)



gi|93277089|ref|NM_052867.2| Homo sapiens sodium leak channel, non-selective (NALCN),



mRNA


CGCGCTGCCTGAGCTGAGCCGCCGTAGGTGAGGGGCCCGCGTCCCCGCCCGCCCTG


 


GGCGCCGCGCCTGGCACTGATCCTGCCGGTCGCCCACTGTCGCCGCCGCCGCCGCCC


 


GCGGGCACCATGACAGCTCTGAGCGCTGGGGTTACAGACTGTGGTTTTGTGCTTGCT


 


CACCAAAGCTAACCTCAGCATGCTCAAAAGGAAGCAGAGTTCCAGGGTGGAAGCCCA


 


GCCAGTCACTGACTTTGGTCCTGATGAGTCTCTGTCGGATAATGCTGACATCCTCTGG


 


ATTAACAAACCATGGGTTCACTCTTTGCTGCGCATCTGTGCCATCATCAGCGTCATTTC


 


TGTTTGTATGAATACGCCAATGACCTTCGAGCACTATCCTCCACTTCAGTATGTGACC


 


TTCACTTTGGATACATTATTGATGTTTCTCTACACGGCAGAGATGATAGCAAAAATGC


 


ACATCCGGGGCATTGTCAAGGGGGATAGTTCCTATGTGAAAGATCGCTGGTGTGTTT


 


TTGATGGATTTATGGTCTTTTGCCTTTGGGTTTCTTTGGTGCTACAGGTGTTTGAAAT


 


TGCTGATATAGTTGATCAGATGTCACCTTGGGGCATGTTGCGGATTCCACGGCCACT


 


GATTATGATCCGAGCATTCCGGATTTATTTCCGATTTGAACTGCCAAGGACCAGAATT


 


ACAAATATTTTAAAGCGATCGGGAGAACAAATATGGAGTGTTTCCATTTTTCTACTTT


 


TCTTTCTACTTCTTTATGGAATTTTAGGAGTTCAGATGTTTGGAACATTTACTTATCAC


 


TGTGTTGTAAATGACACAAAGCCAGGGAATGTAACCTGGAATAGTTTAGCTATTCCA


 


GACACACACTGCTCACCAGAGCTAGAAGAAGGCTACCAGTGCCCACCTGGATTTAAA


 


TGCATGGACCTTGAAGATCTGGGACTTAGCAGGCAAGAGCTGGGCTACAGTGGCTT


 


TAATGAGATAGGAACTAGTATATTCACCGTCTATGAGGCCGCCTCACAGGAAGGCTG


 


GGTGTTCCTCATGTACAGAGCAATTGACAGCTTTCCCCGTTGGCGTTCCTACTTCTAT


 


TTCATCACTCTCATTTTCTTCCTCGCCTGGCTTGTGAAGAACGTGTTTATTGCTGTTAT


 


CATTGAAACATTTGCAGAAATCAGAGTACAGTTTCAACAAATGTGGGGATCGAGAAG


 


CAGCACTACCTCAACAGCCACCACCCAGATGTTTCATGAAGATGCTGCTGGAGGTTG


 


GCAGCTGGTAGCTGTGGATGTCAACAAGCCCCAGGGACGCGCCCCAGCCTGCCTCCA


 


GAAAATGATGCGGTCATCCGTTTTCCACATGTTCATCCTGAGCATGGTGACCGTGGA


 


CGTGATCGTGGCGGCTAGCAACTACTACAAAGGAGAAAACTTCAGGAGGCAGTACG


 


ACGAGTTCTACCTGGCGGAGGTGGCTTTTACAGTACTTTTTGATTTGGAAGCACTTCT


 


GAAGATATGGTGTTTGGGATTTACTGGATATATTAGCTCATCTCTCCACAAATTCGAA


 


CTACTACTCGTAATTGGAACTACTCTTCATGTATACCCAGATCTTTATCATTCACAATT


 


CACGTACTTTCAGGTTCTCCGAGTAGTTCGGCTGATTAAGATTTCACCTGCATTAGAA


 


GACTTTGTGTACAAGATATTTGGTCCTGGAAAAAAGCTTGGGAGTTTGGTTGTATTT


 


ACTGCCAGCCTCTTGATTGTTATGTCAGCAATTAGTTTGCAGATGTTCTGCTTTGTCG


 


AAGAACTGGACAGATTTACTACGTTTCCGAGGGCATTTATGTCCATGTTCCAGATCCT


 


CACCCAGGAAGGATGGGTGGACGTAATGGACCAAACTCTAAATGCTGTGGGACATA


 


TGTGGGCACCCGTGGTTGCCATCTATTTCATTCTCTATCATCTTTTTGCCACTCTGATC


 


CTCCTGAGTTTGTTTGTTGCTGTTATTTTGGACAACTTAGAACTTGATGAAGACCTAA


 


AGAAGCTTAAACAATTAAAGCAAAGTGAAGCAAATGCGGACACCAAAGAAAAGCTCC


 


CTTTACGCCTGCGAATCTTTGAAAAATTTCCAAACAGACCTCAAATGGTGAAAATCTC


 


AAAGCTTCCTTCAGATTTTACAGTTCCTAAAATCAGGGAGAGTTTTATGAAGCAGTTT


 


ATTGACCGCCAGCAACAGGACACATGTTGCCTCCTGAGAAGCCTCCCGACCACCTCTT


 


CCTCCTCCTGCGACCACTCCAAACGCTCAGCAATTGAGGACAACAAATACATCGACCA


 


AAAACTTCGCAAGTCTGTTTTCAGCATCAGGGCAAGGAACCTTCTGGAAAAGGAGAC


 


CGCAGTCACTAAAATCTTAAGAGCTTGCACCCGACAGCGCATGCTGAGCGGATCATT


 


TGAGGGGCAGCCCGCAAAGGAGAGGTCAATCCTCAGCGTGCAGCATCATATCCGCCA


 


AGAGCGCAGGTCACTAAGACATGGATCAAACAGCCAGAGGATCAGCAGGGGAAAAT


 


CTCTTGAAACTTTGACTCAAGATCATTCCAATACAGTGAGATATAGAAATGCACAAAG


 


AGAAGACAGTGAAATAAAGATGATTCAGGAAAAAAAGGAGCAAGCAGAGATGAAAA


 


GGAAAGTGCAAGAAGAGGAACTCAGAGAGAACCACCCATACTTCGATAAGCCACTGT


 


TCATTGTCGGGCGAGAACACAGGTTCAGAAACTTTTGCCGGGTGGTGGTCCGAGCA


 


CGCTTCAACGCATCTAAAACAGACCCTGTCACAGGAGCTGTGAAAAATACAAAGTACC


 


ATCAACTTTATGATTTGCTGGGATTGGTCACTTACCTGGACTGGGTCATGATCATCGT


 


AACCATCTGCTCTTGCATTTCCATGATGTTTGAGTCCCCGTTTCGAAGAGTCATGCAT


 


GCACCTACTTTGCAGATTGCTGAGTATGTGTTTGTGATATTCATGAGCATTGAGCTTA


 


ATCTGAAGATTATGGCAGATGGCTTATTTTTCACTCCAACTGCTGTCATCAGGGACTT


 


CGGTGGAGTAATGGACATAITTATATATCTTGTGAGCTTGATATTTCTTTGTTGGATG


 


CCTCAAAATGTACCTGCTGAATCGGGAGCTCAGCTTCTAATGGTCCTTCGGTGCCTGA


 


GACCTCTGCGCATATTCAAACTGGTGCCCCAGATGAGGAAAGTIGTTCGAGAACTTT


 


TCAGCGGCTTCAAGGAAATTTTTTTGGTCTCCATTCTTTTGCTGACATTAATGCTCGTT


 


TTTGCAAGCTTTGGAGTTCAGCTTTTTGCTGGAAAACTGGCCAAGTGCAATGATCCCA


 


ACATTATTAGAAGGGAAGATTGCAATGGCATATTCAGAATTAATGTCAGTGTGTCAA


 


AGAACTTAAATTTAAAATTGAGGCCTGGAGAGAAAAAACCTGGATTTTGGGTGCCCC


 


GTGTTTGGGCGAATCCTCGGAACTTTAATTTCGACAATGTGGGAAACGCTATGCTGG


 


CGTTGTTTGAAGTTCTCTCCTTGAAAGGCTGGGTGGAAGTGAGAGATGTTATTATTC


 


ATCGTGTGGGGCCGATCCATGGAATCTATATTCATGTTTTTGTATTCCTGGGTTGCAT


 


GATTGGACTGACCCTTTTTGTTGGAGTAGTTATTGCTAATTTCAATGAAAACAAGGG


 


GACGGCTTTGCTGACCGTCGATCAGAGAAGATGGGAAGACCTGAAGAGCCGACTGA


 


AGATCGCACAGCCTCTTCATCTTCCGCCTCGCCCGGATAATGATGGTTTTAGAGCTAA


 


AATGTATGACATAACCCAGCATCCATTTTTTAAGAGGACAATCGCATTACTCGTCCTG


 


GCCCAGTCGGTGTTGCTCTCTGTCAAGTGGGACGTCGAGGACCCGGTGACCGTACCT


 


TTGGCAACAATGTCAGTTGTTTTCACCTTCATCTTTGTTCTGGAGGTTACCATGAAGA


 


TCATAGCAATGTCGCCTGCTGGCTTCTGGCAAAGCAGAAGAAACCGATACGATCTCC


 


TGGTGACGTCGCTTGGCGTTGTATGGGTGGTGCTTCACTTTGCCCTCCTGAATGCAT


 


ATACTTACATGATGGGCGCTTGTGTGATTGTATTTAGGTTTTTCTCCATCTGTGGAAA


 


ACATGTAACGCTAAAGATGCTCCTCTTGACAGTGGTCGTCAGCATGTACAAGAGCTTC


 


TTTATCATAGTAGGCATGTTTCTCTTGCTGCTGTGTTACGCTTTTGCTGGAGTTGTTT


 


TATTTGGTACTGTGAAATATGGGGAGAATATTAACAGGCATGCAAATTTTTCTTCGG


 


CTGGAAAAGCTATTACCGTACTGTTCCGAATTGTCACAGGTGAAGACTGGAACAAGA


 


TTATGCATGACTGTATGGTTCAGCCTCCGTTTTGTACTCCAGATGAATTTACATACTG


 


GGCAACAGACTGTGGAAATTATGCTGGGGCACTTATGTATTTCTGTTCATTTTATGTC


 


ATCATTGCCTACATCATGCTAAATCTGCTTGTAGCCATAATTGTGGAGAATTTCTCCTT


 


GTTTTATTCCACTGAGGAGGACCAGCTTTTAAGTTACAATGATCTTCGCCACTTTCAA


 


ATAATATGGAACATGGTGGATGATAAAAGAGAGGGGGTGATCCCCACGTTCCGCGT


 


CAAGTTCCTGCTGCGGCTACTGCGTGGGAGGCTGGAGGTGGACCTGGACAAGGACA


 


AGCTCCTGTTTAAGCACATGTGCTACGAAATGGAGAGGCTCCACAATGGCGGCGACG


 


TCACCTTCCATGATGTCCTGAGCATGCTTTCATACCGGTCCGTGGACATCCGGAAGAG


 


CTTGCAGCTGGAGGAACTCCTGGCGAGGGAGCAGCTGGAGTACACCATAGAGGAGG


 


AGGTGGCCAAGCAGACCATCCGCATGTGGCTCAAGAAGTGCCTGAAGCGCATCAGA


 


GCTAAACAGCAGCAGTCGTGCAGTATCATCCACAGCCTGAGAGAGAGTCAGCAGCAA


 


GAGCTGAGCCGGTTTCTGAACCCGCCCAGCATCGAGACCACCCAGCCCAGTGAGGAC


 


ACGAATGCCAACAGTCAGGACAACAGCATGCAACCTGAGACAAGCAGCCAGCAGCAG


 


CTCCTGAGCCCCACGCTGTCGGATCGAGGAGGAAGTCGGCAAGATGCAGCCGACGC


 


AGGGAAACCCCAGAGGAAATTTGGGCAGTGGCGTCTGCCCTCAGCCCCAAAACCAAT


 


AAGCCATTCAGTGTCCTCAGTCAACTTACGGTTTGGAGGAAGGACAACCATGAAATC


 


TGTCGTGTGCAAkATGAACCCCATGACTGACGCGGCTTCCTGCGGTTCTGAAGTTAA


 


GAAGTGGTGGACCCGGCAGCTGACTGTGGAGAGCGACGAAAGTGGGGATGACCTT


 


CTGGATATTTAGGTGGATGTCAATGTAGATGAATTTCTAGTGGTGGAAACCGTTTTC


 


TAATAATGTCCTTGATTGTCCAGTGAGCAATCTGTAATTGATCTATAACTGAATTCCA


 


GCTTGTCACAAGATGTTTATAAATTGATTTTCATCCTGCCACAGAAAGGCATAAGCTG


 


CATGTATGATGGGTTACTATCAATCATTGCTCAAAAAAATTTTTGTATAATGACAGTA


 


CTGATAATATTAGAAATGATACCGCAAGCAAATGTATATCACTTAAAAATGTCATATA


 


TTCTGTCTGCGTAAACTAAGGTATATATTCATATGTGCTCTAATGCAGTATTATCACC


 


GCCCCGCAAAAGAGTGCTAAGCCCAAAGTGGCTGATATTTAGGGTACAGGGGTTATA


 


GCTTTAGTTCACATCTTTCCCATTTCCACTAGAAATATTTCTCTTGAGAGAATTTATTA


 


TTTATGATTGATCTGAAAAGGTCAGCACTGAACTTATGCTAAAATGATAGTAGTTTTA


 


CAAACTACAGATTCTGAATTTTAAAAAGTATCTTCTTTTTCTCGTGTTATATTTTTAAA


 


TATACACAAGACATTTGGTGACCAGAACAAGTTGATTTCTGTCCTCAGTTATGTTAAT


 


GAAACTGTTGCCTCCTTCTAAGAAAATTGTGTGTGCAAGCACCAGGCAAAGAAATGG


 


ACTCAGGATGCTTAGCGGTTTAAAACAAACCTGTAGATAAATCACTTGAGTGACATA


 


GTTGCGCAAAGATGTTAAGTTTCTTAAGAAACCTTTTAATAACTGAGTTTAGCAAAAA


 


GAATAAAACTATATAGCTCAATTTATTTAAAAAAATCTTTGCATGTGTGATGTTATCAT


 


TGGCTTCATTTCTTACCCAAGGTATGTCTGTTTTGCCATAAATCAGCAGAGTCATTTCA


 


TTCTGGGTGATCCTAACACACCATTGCTACGTTAGATTTGAAATGACATCTCTGTTAA


 


AAGAATCTTCTATGGAAATAATGGTGCCCTGCAAAATCTTCCTTTGAACTCACAGGTT


 


AGGGATCACACAACTTACTTAATCGTTTITTGTTTTTGTTTTTTTTCCTTATATGTCAAT


 


GGCCCATGTCCTCCGGGAAAATTAGAAAAGCAAAATGATTACAAAGTGCTGTTAGAT


 


TTCTTGTGCTGGGCCAGCCAAGTAGAAGTGGACTTGACTTGGACCTTTAACTATTTTA


 


TTACAGATTGGACATTTGCTGTTCAGATGTTTTTTAACAGAGGGATTATCTCAGAATC


 


CTGTGACCTCCAGGTTGTTTTATAATCTATTTTTCTCTATTTAACATTCCTCAGATAGA


 


TAGGCAAATAGGACATTCCTTCTGTGTCACAGAAGTATCGTGGTAGTGGCAGTCTAC


 


AGTTTATATGATTCATTGTAACTATGAGATAAAGAACAACCAGTCATGTGGCCAAAAG


 


GATTAGATTTGATTTGATGTTCACTTGGAGTTTACTTTTTGTACATACAAGATAAAAT


 


AAATATTGGATTTGTAAAAT


 


Homo sapiens Sodium Leak Channel, Non-Selective (NALCN), Polypeptide


(NP_443099.1) GI: 24119274


(SEQ ID NO: 99)



MLKRKQSSRVEAQPVTDFGPDESLSDNADILWINKPWVHSLLRICAIISVISVCMNTPMTF



 


EHYPPLQYVTFTLDTLLMFLYTAEMIAKMHIRGIVKGDSSYVKDRWCVFDGFMVFCLWV


 


SLVLQVFEIADIVDQMSPWGMLRIPRPLIMIRAFRIYFRFELPRTRITNILKRSGEQIWSVSIF


 


LLFFLLLYGILGVQMFGTFTYHCVVNDTKPGNVTWNSLAIPDTHCSPELEEGYQCPPGFK


 


CMDLEDLGLSRQELGYSGFNEIGTSIFTVYEAASQEGWVFLMYRAIDSFPRWRSYFYFITLI


 


FFLAWLVKNVFIAVIIETFAEIRVQFQQMWGSRSSTTSTATTQMFHEDAAGGWQLVAVD


 


VNKPQGRAPACLQKMMRSSVFHMFILSMVTVDVIVAASNYYKGENFRRQYDEFYLAEVA


 


FTVLFDLEALLKIWCLGFTGYISSSLHKFELLLVIGTTLHVYPDLYHSQFTYFQVLRVVRLI


 


KISPALEDFVYKIFGPGKKLGSLVVFTASLLIVMSAISLQMFCFVEELDRFTTFPRAFMSMF


 


QILTQEGWVDVMDQTLNAVGHMWAPVVAIYFILYHLFATLILLSLFVAVILDNLELDEDL


 


KKLKQLKQSEANADTKEKLPLRLRIFEKFPNRPQMVKISKLPSDFTVPKIRESFMKQFIDR


 


QQQDTCCLLRSLPTTSSSSCDHSKRSAIEDNKYIDQKLRKSVFSIRARNLLEKFTAVTKILR


 


ACTRQRMLSGSFEGQPAKFRSILSVQHHIRQERRSLRHGSNSQRISRGKSLETLTQDHSNT


 


VRYRNAQREDSEIKMIQEKKEQAEMKRKVQEEELRENHPYFDKPLFIVGREHRFRNFCR


 


VVVRARFNASKTDPVTGAVKNTKYHQLYDLLGLVTYLDWVMIIVTICSCISMMFESPFRR


 


VMHAPTLQIAEYVFVIFMSIELNLKIMADGLFFTPTAVIRDFGGVMDIFIYLVSLIFLCWMP


 


QNVPAESGAQLLMVLRCLRPLRIFKLVPQMRKVVRELFSGFKEIFLVSILLLTLMLVFASFG


 


VQLFAGKLAKCNDPNIIRREDCNGIFRINVSVSKNLNLKLRPGEKKPGFWVPRVWANPR


 


NFNFDNVGNAMLALFEVLSLKGWVEVRDVIIHRVGPIHGIYIHVFVFLGCMIGLTLFVGV


 


VIANFNENKGTALLTVDQRRWEDLKSRLKIAQPLHLPPRPDNDGFRAKMYDITQHPFFK


 


RTIALLVLAQSVLLSVKWDVEDPVTVPLATMSVVFTFIFVLEVTMKIIAMSPAGFWQSRRN


 


RYDLLVTSLGVVWVVLHFALLNAYTYMMGACVIVFRFFSICGKHVTLKMLLLTVVVSMY


 


KSFFIIVGMFLLLLCYAFAGVVLFGTVKYGENINRHANFSSAGKAITVLFRIVTGEDWNKI


 


MHDCMVQPPFCTPDEFTYWATDCGNYAGALMYFCSFYVIIAYIMLNLLVAIIVENFSLFYS


 


TEEDQLLSYNDLRHFQIIWNMVDDKREGVIPTFRVKFLLRLLRGRLEVDLDKDKLLFKH


 


MCYEMERLHNGGDVTFHDVLSMLSYRSVDIRKSLQLEELLAREQLEYTIEEEVAKQTIRM


 


WLKKCLKRIRAKQQQSCSIIHSLRESQQQELSRFLNPPSIETTQPSEDTNANSQDNSMQPE


 


TSSQQQLLSPTLSDRGGSRQDAADAGKPQRKFGQWRLPSAPKPISHSVSSVNLRFGGRTT


 


MKSVVCKMNPMTDAASCGSEVKKWWTRQLTVESDESGDDLLDI


 


Homo sapiens Sodium / Potassium Transporting ATPase Interacting 3 (NKAIN3)


(NP_173688.2) GI: 14538007


(SEQ ID NO: 100)










1
agccgcgagc ggcggccgcg gggccgagga gcctgggccg ggccgggcgg ggactactcc



 


61
ggagtcagga ggcagcagcg gcggaggacg aggatctctg gcagtcagcg ccgctcggac


 


121
gccgccggca ccatgggctg ctgcaccgga cgctgctcgc tcatctgcct ctgcgcgctg


 


181
cagttggtct cagcattaga gaggcagatc tttgacttcc ttggtttcca gtgggcgcct


 


241
attcttggaa attttctaca cataatagtt gtcatattgg gtttgtttgg gaccattcag


 


301
tacagacctc gatacataat ggtgtataca gtgtggactg ccctctgggt cacctggaat


 


361
gtgttcatta tctgctttta tttggaagta ggtggactct caaaggacac cgatctaatg


 


421
acattcaata tctctgtaca tcggtcatgg tggagagaac atgggcctgg ttgtgtcaga


 


481
agagtgctgc ctccctcagc ccatggcatg atggacgatt acacgtacgt ctctgtcaca


 


541
ggctgcatcg ttgacttcca gtacctggag gtcatccaca gtgctgtcca aatactactc


 


601
tctttggtgg gttttgtgta tgcctgttat gtgatcagta tttccatgga agaagaagac


 


661
acatattcat gtgatctgca agtatgcaaa catcttttta tccagatgct gcaaattatt


 


721
gaataagcaa gaattagtaa gatattatca ccaaattgtc acatcagtca agcctcatgt


 


781
gcttcctaag aactgaggtg atgcattatt ttagagtgtc attctaaacc ccagattcaa


 


841
catcttccta atctttctag tgcagtctaa tatataaatt ttatgaaaag cataggtttt


 


901
tttttaacca gcagtgctct ttgagaattt acattgattc ctaaagattg ccattgcttt


 


961
gtataaaatg ttataaatta tcttagcatc ttacctggaa tttccactaa attcaccaat


 


1021
ttatgatttg tgaaatctga ttttactttt tgaaaatttt catgtgaatt tcccattttc


 


1081
agtgttgtag cacctctctc ttcctctaag atcctccaag ctcatcaaaa gccatgatct


 


1141
tattatacca gcagttttat ttattcaatc tttcaacaag tagttattga acttctataa


 


1201
tgtgccaggc tctggagctc gccttacacc aaacagacac aatcgatcca ttcgaagtgt


 


1261
cgtaattaca cattgaggga ccaactagac cttttctcat tgtaaacttg gagcaaaagt


 


1321
aaattcatta aaataaattt acattatagt gccacaaaaa aatgaacaga accagaaagc


 


1381
attttttaca aaaattaaca gaacagtgtg atagagggga aaaggatgtg agatcatggt


 


1441
gccctacctt caatagggtg gccagaaaac acctctctga agaagcagca tttgagctga


 


1501
gacctgaaga acgaggagtc agtgatgcag agaacctcag gagatgcctt ccaatctgag


 


1561
aaaaga


 








Homo sapiens Sodium / Potassium Transporting ATPase Interacting 3 (NKAIN3)



Polypeptide (NP_775959.1) GI: 27735000


(SEQ ID NO: 101)



MGCCTGRCSLICLCALQLVSALERQIFDFLGFQWAPILGNFLHIIVVILGLFGTIQYRPRYIM



 


VYTVWTALWVTWNVFIICFYLEVGGLSKDTDLMTFNISVHRSWWREHGPGCVRRVLPPS


 


AHGMMDDYTYVSVTGCIVDFQYLEVIHSAVQILLSLVGFVYACYVISISMEEEDTYSCDLQ


 


VCKHLFIQMLQIIE


 


Homo sapiens Mucolipin 3, mRNA gi|38174237|gb|BC060765.1|


(SEQ ID NO: 102)



TGGAGTCGCTCGCTGACTCGCCCTGCGCCCTCGCCGCGGACACCGGAGCTGCGGCCG



 


CTCCCCGCTGTCCCCCAGCTTACTCCAATCAAGCCTCTGCCCGCCAGGAACAGGTAAC


 


CTGTGTGTGTCCGTTTGCTCCTTCTAAGAGCATGCCTGATAGATACTTCGGTAGCCTC


 


TCCGGATGGCCCCTTCGTCGGGTAGCCTCTCCTGATGGGGTCCTTCGCCCACCCTGCC


 


TCCCGCGCCGGCGCTCCGGGTGAATGTCAAGGGTGGCTGGCTGCGAATACCTCCTTC


 


AGCTGCTGGGGTTCCCGACAGTTTGCAGTTTTTAAAAGTGCACCCTCGGAAGGGCTT


 


TTCAGACTGGGTAAACCTGACTTTTCCAAGAGATGGCAGATCCTGAGGTAGTTGTGA


 


GTAGCTGCAGCTCTCATGAAGAGGAAAATCGCTGCAATTTTAACCAGCAAACATCTCC


 


ATCTGAGGAGCTTCTATTAGAAGACCAGATGAGGCGAAAACTCAAATTTTTTTTCATG


 


AATCCCTGTGAGAAGTTCTGGGCTCGAGGTAGAAAACCATGGAAACTTGCCATACAA


 


ATTCTAAAAATTGCAATGGTGACTATCCAGCTGGTCTTATTTGGGCTAAGTAACCAGA


 


TGGTGGTAGCTTTCAAGGAAGAGAATACTATAGCATTCAAACACCTTTTCCTAAAAGG


 


ATATATGGACCGAATGGATGACACATATGCAGTGTACACACAAAGTGACGTGTATGA


 


TCAGTTAATCTTCGCAGTAAACCAGTACTTGCAGCTATACAATGTCTCCGTTGGGAAT


 


CATGCTTATGAGAACAAAGGTACCAAGCAATCTGCTATGGCAATCTGTCAGCACTTAT


 


ACAAGCGAGGAAACATCTACCCTGGAAATGATACCTTTGACATCGATCCAGAAATTG


 


AAACTGAGTGTTTCTTTGTGGAGCCAGATGAACCTTTTCACATTGGGACACCAGCAG


 


AAAATAAACTGAACTTAACACTGGACTTCCACAGACTCCTAACAGTGGAGCTTCAGTT


 


TAAACTGAAAGCCATTAATCTGCAGACAGTTCGTCATCAAGAACTCCCTGACTGTTAT


 


GACTTTACTCTGACTATAACATTTGACAACAAGGCCCATAGTGGAAGAATTAAAATAA


 


GTTTAGATAATGACATTTCCATCAGAGAATGTAAAGACTGGCATGTATCTGGATCAAT


 


TCAGAAGAACACTCATTACATGATGATCTTTGATGCCTTTGTCATTCTGACTTGCTTG


 


GTTTCATTAATCCTCTGCATTAGATCTGTGATTAGAGGACTTCAGCTTCAGCAGGTAG


 


GGAACGTTGCTTTCTAGGAATGCTACTGACATTTTGATTGACAGAGACATTCACTGTG


 


CCTCCCCTCTTTTCCCTAAAGGAGTTTGTCAATTTTTTCCTCCTCCATTATAAGAAGGA


 


AGTTTCTGTTTCTGATCAAATGGAATTTGTCAATGGATGGTACATTATGATTATTATT


 


AGTGACATATTGACAATCATTGGATCAATTCTAAAAATGGAAATCCAAGCTAAGGTAA


 


TTTTTTTCCTAATCATGCTATTGTTAGTGTCAGATTTGCACTAATGGTAATGTATTTTT


 


CCAGAATGTAAGAATTTTCAGAATGAATTGTTTCTTCCAAACTGTATATCAAGTAGAC


 


TTGAAATTGGTAATGGTAATTTTCTTAAATCTAGTCAGGAGGTCTCTTAGGCAGAGTT


 


TTTCAAAGTGTGATCCACAAACCATTGCATCAGAATCATTGGGTGCCTGGTAAAGTGT


 


ACCATGTTAGACCTACTGAATTCAGACTCTTCGGCGGGGCCTGTGAATTCTTACACAC


 


ACCAAAATTCATACACAACCAAGGTAACTAAGGTAAGAGTTTTTTTTTTTTTTTAATCT


 


TACAAGAAATGCTCGAATCTTTAACAAAAATGAGTGGGGCTATAGGGGAAAGTGAG


 


GTCAAGGCACTATGGTGTGCATGCTTGCATTTGTTTCCTCCGTCCATTCAAAGTGAGA


 


ATGCTCCCATTTTCTTACTTTACCATTGATGTGCTACAAGCTTATTTATTTTAAGACTA


 


ACCTAGCCTAAAAATCAACTGTCCCCACAAAATAAAAATCACATTAAAAAAACTAATAG


 


TGTTCAGACTAATCTTGCTCAAACTTATGTTTCCCTAGTCTTGATGCAACTGATTGAGT


 


CACCTGGGGAGTTGGTTATAAACCTGGGCAGAGACCCCAAATGCAATGGCTCAGAG


 


AAGATAGGAGCTTATTTCTGTCTTATGCAATAGTCAGAATGGGTTTTACAGACTGGT


 


GAGTAGCTCAACATCTCACAGTCATTCAGGCACCCATGTTCCTCCCATTTTGTTTCTCT


 


GCCACCCCTTAAGGACTTGCCCTGACTGCATGATTATTGCCGTGTTGCCTCAAACAGG


 


TTGCAGCTTATGGGAAGCAAAAACACGGTATGGTAGAAGCTCTCCCATAGACTGATG


 


GCTTGGCTCAAGAGTGGCCGACTTTATTTCTGTACATATCCCACTGGATAGAATTTAG


 


TCAATCCTAACTGCAGAGGGAGCCAGGGAACACAGCCCAGGCATGTGCCTAGGAAG


 


GGGAGAATGGGTTTAGGTTGACACTTAGCAGCTGCCACTATATGTGGCTATAGTATG


 


TATCATTGGAATAGATGTTTAACTTTAGGGACAAATAAAAAACCAAAACAAAAAAAG


 


GAGTAAGGGGAGAGATTTGCAGCAAATCTTTATTTTTACCAACCTCAACTATCATTAA


 


TTTCAGTGAACCCTAAATGGTATCCAACAAAATATCTTTCTAGACCATTCACCGTCTCT


 


GCCTCATAGATGATCATATCATGTTTTCTTCTCTTCTGAAACCTCTAATACCCTTGTCCT


 


ATCCTCATTCTAAGCTGATGACCTTACTTCCTATTTCACAAAAATAATAGAAAAAAAAA


 


AAAAAAA


 


> > Homo sapiens Mucolipin 3, cDNA gi|21752911|dbj|AK093948.1|


Homo sapiens cDNA FLJ36629


(SEQ ID NO: 103)



ATAGCCTTTCAAATTTCGGTTAATGGTAACTCTCATCAGTTACTCAAGCCAAAAATCTT



 


GGATTCATCACAGACTCCTCTCTTTCACTAATCTCTTCTTCCCCACATCTAATCCAAGA


 


GGAAATCCTATTGTTCTACCTTCATTGGCCAGGCACTGTGACTCATATAATCCCAGCA


 


CATTGGGAGGCTGAGGCGGGAGGATGGCTTGAGCCCAGGAGTTCCAGACCAGCCTG


 


GGAAACATAGTGAGGCCCCATCTCTACAAAAAATTAAAAAAATTAGCAGTCAAGGTG


 


GCATGTGTCTGTAATCCAAGCTACTTGGGGGGCTGAGGTGGGAGGATTTCTTGAGC


 


CCGGGAAGTCGAGGCTGCATTGAGCCACGGTTGTGCCACGGCACTCCAGCCTGGGT


 


GACAGAGTGAGACCCCTGTTTCCAAAAAAAAAAAAAAAAAAAAAGAATAAAAATCAC


 


CTGGTCAACTCCACTATTACCAGCCTGGTCCAAGCTACTATCTCTCATTTATATTATTG


 


CAATAGCCTCCTCACTCCTCCAACAACCTGCTGTCAACCACAGCAGCCAACATCTGATC


 


ATATCACTTCTGTTTGTGGTTCTCAAATCTCCCCAATTGAGTTACAGTAAAAGACAAAC


 


TTGGTGAGTGCCACCTTATCTCTATAACTGTATACCCTTTCTATTGCTCACTCCAGCCA


 


GATGCAATATCCTTGCCAAGCACCCTCCTGTCTCAGGGCCTTTGCACTTGCCAGTCCC


 


TGTGCCTGGAAGGCTTCTCCCCTAGATTTTTGCATGACTTCTCCCTCCCTCCCTTCAGA


 


TCTTTGCTCAAATGCCTTCTTTTTAGTGTATGTAAAATGACAAACCCATACCCATTCCT


 


TATCCCCTCCTCTGAATTTTCTCTTCAGCAATTATCAGCAGCAAGTGTCCCAAAGTTTC


 


TATTAACTTATTTCTGTTGTCTCTTTCTTCCCTCCACTAGAATGTAAGCTTTATGAGAG


 


CAGAGACTTTTGTTTGTTCACTGCTTTATCCTTAGCACCTAAAACAGTGCCTTACTCAT


 


AGTTACCTCAATATTTATTGCCAAATGAATTTCTGCTTTATAATCTGATTATATTTTTCC


 


ACTCTCTCTTAGAGTCTAACTAGTTATGATGTCTGTAGCATACTTCTTGGGACTTCTAC


 


CATGCTTGTGTGGCTTGGAGTCATCCGATACCTCGGTTTCTTTGCAAAGTACAACCTC


 


CTCATTTTGACCCTTCAGGCAGCGCTGCCCAATGTCATCAGGTTCTGCTGCTGTGCAG


 


CTATGATTTACTTAGGTTACTGCTTCTGTGGATGGATCGTGCTGGGGCCTTACCATG


 


ACAAGTTTCGTTCTCTGAACATGGTCTCTGAGTGCCTTTTCTCTCTGATAAATGGAGA


 


TGATATGTTTGCCACGTTTGCAAAAATGCAGCAAAAAAGTTACTTAGTCTGGCTGTTT


 


AGTAGAATTTACCTCTACTCATTCATCAGCCTCTTTATATATATGATTTTAAGTCTTTTC


 


ATTGCACTGATCACTGATACATACGAAACAATTAAGCAATACCAACAAGATGGCTTCC


 


CAGAGACTGAACTTCGTACATTTATATCAGAATGCAAAGATCTACCCAACTCTGGAAA


 


ATACAGATTAGAAGATGACCCTCCAGTAACTTTATTCTGCTGTTGTAAAAAGTAGCTA


 


TCAGGTTTATCTGTACTTTAGAGGAAAATATAATGTGTAGCTGAGTTGGAACACTGT


 


GGATATTCTGAGATCAGATGTAGTATGTTTGAAGACTGTTATTTTGAGCTAATTGAG


 


ACCTATAATTCACCAATAACTGTTTATATTTTTAAAAGCAATATTTAATGTCTTTGCAA


 


CTTTATGCTGGGATTGTTTTTAAAAAAAACTTTAATGAGGAAAGCTATTGGATTATTA


 


TTATTTCTTGTTTATTTTGCCATGGCTTTAGAATGTATTCTGTATGCCTCTCTTTTGCT


 


CTGATACTGTTGCTCCTGCTATTCTGATTGTGCAGACTGTATAATTAGTGGAAAACAA


 


TCCTTGGTCTGACTGTGACTTTGGACAACTCAGTAACCCTGGCTTGGACCACTCTCAG


 


GAGTCCATCCTTGAGAGAGTGGGTGTAGTTACCATTTATACAGTAATCATTGCATTTT


 


AAAATCTTCTCTTGAAAGGAAGAATAAGAGTGCACCAGAATAAGAGCGCACCAGAAT


 


AAGAGCACACCAGCTAACAATGTGATACGGCCATATGTCACTTAAGGATGGAGATAT


 


GTTCTGAGAAATGTGTCATTAGGCGATTTTGTCATTAAACATCATAGCATGTACTTCC


 


ACAAACCTAGATGGTATAGCCTACTACACACCTAGGCTATTTGGTATAGCCTGTTGGT


 


CCTGGGGTACAAATCTGTACAACATGTTACTGTATTGAATACAGTAGGCAATTGTAAC


 


TCAATGGTAAGTATCTAAACATAGAAAAGGGACAGTAAAAATATGGTTTTATAATCTT


 


CTGGGACCACCATTGTATATGCGGTACATCATTGACCAAAACATCGTTATCCAGCATA


 


TGACTGTATTTGGTTATGAAAGCCAACTGTTACTTGATTCTGCTTTTAGTTCTTAAGA


 


GGATCAGGCTTTTAAATACTCATTTACAAGCTTTCTATCCTCCTTCAGTGTTAAAGTAG


 


AAAGTAAAAAGAGTATCTTATACATGCATGAAATTAAAGCATATACCAAATGC


 


>HUMAN TRPML3 POLYPEPTIDE AK093948 open reading frame


(SEQ ID NO: 104)



MLVWLGVIRYLGFFAKYNLLILTLQAALPNVIRFCCCAAMIYLGYCFCGWIVLGPYHDKF



 


RSLNMVSECLFSLINGDDMFATFAKMQQKSYLVWLFSRIYLYSFISLFIYMILSLFIALITDTY


 


ETIKQYQQDGFPETELRTFISECKDLPNSGKYRLEDDPPVTLFCCCKK.


 


> HUMAN TRPML3 POLYPEPTIDE BC060765 open reading frame


(SEQ ID NO: 105)



MADPEVVVSSCSSHEEENRCNFNQQTSPSEELLLEDQMRRKLKFFFMNPCEKFWARGRK



 


PWKLAIQILKIAMVTIQLVLFGLSNQMVVAFKEENTIAFKHLFLKGYMDRMDDTYAVYT


 


QSDVYDQLIFAVNQYLQLYNVSVGNHAYENKGTKQSAMAICQHLYKRGNIYPGNDTFD


 


IDPEIETECFFVEPDEPFHIGTPAENKLNLTLDFHRLLTVELQFKLKAINLQTVRHQELPD


 


CYDFTLTITFDNKAHSGRIKISLDNDISIRECKDWHVSGSIQKNTHYMMIFDAFVILTCLVS


 


LILCIRSVIRGLQLQQVGNVAF
























p value





Ratio Top
Top





verus
versus


Probe Set ID
Gene Title
Gene Symbol
Bottom
Bottom



















MmugDNA.12222.1.S1_at
chloride channel, calcium activated, family member 1
CLCA1
28.26
0.0794


MmugDNA.18105.1.S1_at
ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 1
ST8SIA1
25.30
0.0112


MmugDNA.11091.1.S1_at
—
—
14.48
0.0463


MmugDNA.15011.1.S1_at
toll-like receptor 10 precursor
LOC697980
14.47
0.0262


MmugDNA.41559.1.S1_at
taste receptor, type 2, member 16
TAS2R16
13.96
0.0356


MmugDNA.24584.1.S1_at
hypothetical protein LOC703243
LOC703243
13.55
0.0725


MmugDNA.15361.1.S1_at
phosphatidylinositol glycan, class N
LOC699219
12.99
0.0249


Mmu.10677.1.S1_at
matrix metalloproteinase 7
MMP7
11.87
0.0181


MmuSTS.783.1.S1_at
taste receptor T2R7
LOC717909
11.70
0.0671


MmugDNA.25181.1.S1_at
3-hydroxysteroid epimerase
LOC713549
11.52
0.0396


MmugDNA.9747.1.S1_at
—
—
11.31
0.0934


MmugDNA.10468.1.S1_at
hypothetical protein LOC709833
LOC709833
11.21
0.0379


MmugDNA.7746.1.S1_at
Protein FAM3B precursor (Cytokine-like protein 2-21)
LOC722516
11.10
0.0882


MmugDNA.11368.1.S1_at
proprotein convertase subtilisin/kexin type 2
PCSK2
10.97
0.0486


MmugDNA.26966.1.S1_at
—
—
10.92
0.0376


MmugDNA.15380.1.S1_at
taste receptor T2R13
LOC718046
10.82
0.0924


MmugDNA.32635.1.S1_at
—
—
10.78
0.0891


MmugDNA.37045.1.S1_at
—
—
10.61
0.0029


MmugDNA.36075.1.S1_at
potassium voltage-gated channel, shaker-related subfamily,
KCNA2
10.45
0.0060



member 2


MmugDNA.35060.1.S1_at
kinesin-like motor protein C20orf23
LOC695167
10.35
0.0420


MmugDNA.13207.1.S1_at
—
—
10.20
0.0665


MmunewRS.875.1.S1_at
neuroligin 4
NLGN4X
10.13
0.0053


MmugDNA.35863.1.S1_at
zinc finger protein 533
LOC704204
10.10
0.0657


MmugDNA.121.1.S1_at
golgi SNAP receptor complex member 2 isoform A
LOC716841
10.09
0.0493


MmugDNA.38131.1.S1_at
kelch-like 8
LOC700864
9.90
0.0023


MmugDNA.41159.1.S1_at
interleukin 17B receptor
IL17RB
9.77
0.0005


MmugDNA.11591.1.S1_s_at
dipeptidase 2
LOC701570
9.73
0.0020


MmugDNA.5167.1.S1_at
male sterility domain containing 1
LOC710740
9.37
0.0930


MmugDNA.656.1.S1_at
—
—
9.25
0.0001


MmugDNA.7006.1.S1_at
sialyltransferase 7E
LOC705908
9.24
0.0467


MmugDNA.3684.1.S1_at
G protein-coupled receptor 85
GPR85
9.18
0.0664


MmugDNA.1571.1.S1_at
—
—
9.09
0.0263


MmugDNA.24639.1.S1_at
—
—
9.04
0.0042


MmuSTS.906.1.S1_at
taste receptor, type 2, member 14
LOC718111
9.00
0.0288


MmugDNA.30874.1.S1_at
transmembrane protein 45B
LOC718735
9.00
0.0000


MmugDNA.34847.1.S1_at
apoptosis inhibitor 5
API5
8.45
0.0755


MmuSTS.778.1.S1_at
Taste receptor type 2 member 49 (T2R49) (T2R56)
TAS2R49
8.44
0.0007


MmuSTS.2869.1.S1_at
tachykinin 1 isoform alpha precursor
TAC1
8.44
0.0726


MmugDNA.30525.1.S1_at
FCH and double SH3 domains 1
—
8.37
0.0258


MmugDNA.42433.1.S1_at
—
—
8.36
0.0058


MmugDNA.10579.1.S1_at
dopamine receptor interacting protein
—
8.30
0.0060


MmugDNA.16546.1.S1_at
CMP-N-acetylneuraminic acid hydroxylase
LOC574186
8.25
0.0649


MmugDNA.29722.1.S1_at
—
—
8.18
0.0717


MmuSTS.4056.1.S1_at
Cornifin B (Small proline-rich protein IB) (SPR-IB) (14.9 kDa
LOC717850
7.96
0.0689



pancornulin)


MmugDNA.30502.1.S1_at
NIPA-like domain containing 2
LOC703585
7.94
0.0421


MmugDNA.6642.1.S1_at
leprecan-like 1
LOC704118
7.86
0.0183


MmugDNA.23279.1.S1_at
transmembrane protein 46
LOC702501
7.85
0.0427


MmugDNA.3909.1.S1_at
CG2698-PA
LOC710299
7.80
0.0116


MmugDNA.39327.1.S1_at
—
—
7.78
0.0960


MmugDNA.3544.1.S1_at
solute carrier family 22 (organic cation transporter), member
LOC710102
7.72
0.0869



15


MmugDNA.39807.1.S1_at
protocadherin beta 13 precursor
LOC700999
7.71
0.0311


MmugDNA.17676.1.S1_at
PXR2b protein
PEX5L
7.65
0.0969


MmugDNA.30327.1.S1_at
—
—
7.62
0.0341


MmugDNA.6455.1.S1_at
F11 receptor
F11R
7.58
0.0487


MmugDNA.3223.1.S1_at
—
—
7.57
0.0247


MmugDNA.11678.1.S1_at
3(2),5-bisphosphate nucleotidase 1 (Bisphosphate 3-
—
7.57
0.0034



nucleotidase 1) (PAP-inositol-1,4-phosphatase) (PIP)


MmugDNA.7247.1.S1_at
nemo-like kinase
NLK
7.56
0.0087


MmugDNA.10209.1.S1_at
PHD finger protein 14
PHF14
7.51
0.0000


MmuSTS.3737.1.S1_at
protein tyrosine phosphatase, receptor type, C isoform 1
LOC712657
7.42
0.0139



precursor


MmuSTS.1381.1.S1_at
basic helix-loop-helix domain containing, class B, 5
LOC701485
7.39
0.0378


MmugDNA.20444.1.S1_at
formin 2
LOC708376
7.38
0.0999


MmuSTS.1175.1.S1_at
Taste receptor type 2 member 10 (T2R10) (Taste receptor
TAS2R10
7.36
0.0445



family B member 2) (TRB2)


MmuSTS.2644.1.S1_s_at
taste receptor T2R55
LOC695053
7.36
0.0182


MmuSTS.3441.1.S1_at
annexin A9
ANXA9
7.32
0.0133


MmugDNA.9493.1.S1_at
—
—
7.30
0.0007


MmugDNA.4334.1.S1_at
tyrosine aminotransferase
TAT
7.18
0.0194


MmuSTS.1040.1.S1_at
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5
ST8SIA5
7.18
0.0759


MmugDNA.25088.1.S1_at
GTP-binding protein Rit2 (Ras-like protein expressed in
RIT2
7.14
0.0292



neurons) (Ras-like without CAAX protein 2)


MmugDNA.689.1.S1_at
hypothetical protein LOC707842
LOC707842
7.11
0.0615


MmugDNA.4223.1.S1_at
echinoderm microtubule associated protein like 5
LOC718818
7.08
0.0053


MmugDNA.29749.1.S1_at
—
—
7.02
0.0598


MmugDNA.1798.1.S1_at
doublecortin and CaM kinase-like 3
LOC699654
6.99
0.0589


MmuSTS.1232.1.S1_at
copine IV
LOC717868 ///
6.98
0.0579




LOC719231


MmuSTS.784.1.S1_at
taste receptor, type 2, member 8
LOC717924
6.95
0.0189


MmugDNA.26125.1.S1_at
—
—
6.94
0.0509


MmuSTS.2013.1.S1_at
protocadherin beta 10
PCDHB10
6.92
0.0000


MmugDNA.19056.1.S1_at
somatostatin receptor 1
SSTR1
6.90
0.0040


MmugDNA.43165.1.S1_at
—
—
6.88
0.0378


MmugDNA.34029.1.S1_at
secernin 1
SCRN1
6.83
0.0410


MmugDNA.40941.1.S1_at
—
—
6.81
0.0380


MmugDNA.21034.1.S1_at
—
—
6.68
0.0782


MmugDNA.31223.1.S1_at
protocadherin beta 3
PCDHB3
6.68
0.0261


MmugDNA.10620.1.S1_at
Rho GTPase activating protein 18
LOC711107
6.67
0.0000


MmugDNA.35495.1.S1_at
—
—
6.67
0.0569


MmugDNA.23300.1.S1_at
KIAA0828 protein
KIAA0828
6.65
0.0692


MmugDNA.20297.1.S1_at
hypothetical protein LOC705695
LOC705695
6.64
0.0273


MmugDNA.43474.1.S1_at
protection of telomeres 1
POT1
6.62
0.0587


MmuSTS.1939.1.S1_at
Fibroblast growth factor 11 (FGF-11) (Fibroblast growth
FGF11
6.61
0.0983



factor homologous factor 3) (FHF-3)


MmugDNA.26964.1.S1_at
calponin like transmembrane domain protein
LOC709910
6.59
0.0179


MmugDNA.33339.1.S1_at
—
—
6.58
0.0179


MmugDNA.32991.1.S1_at
ectonucleotide pyrophosphatase/phosphodiesterase 6
LOC693950
6.54
0.0834


MmugDNA.34284.1.S1_at
Sodium channel beta-3 subunit precursor
LOC714673
6.52
0.0945


MmugDNA.20971.1.S1_at
—
—
6.49
0.0462


MmugDNA.9521.1.S1_at
glutaminyl-peptide cyclotransferase
QPCT
6.49
0.0528


MmuSTS.1179.1.S1_s_at
taste receptor, type 2, member 43
LOC694161
6.47
0.0060


MmugDNA.25858.1.S1_at
—
—
6.47
0.0087


MmugDNA.38257.1.S1_at
hypothetical protein LOC701675
LOC701675
6.46
0.0506


MmugDNA.41639.1.S1_at
phosphodiesterase 1C, calmodulin-dependent 70 kDa
PDE1C
6.44
0.0007


MmugDNA.33151.1.S1_at
—
—
6.42
0.0253


MmugDNA.1887.1.S1_at
zinc finger protein 395
LOC698947
6.41
0.0237


MmuSTS.1713.1.S1_at
WNT1 inducible signaling pathway protein 3
WISP3
6.37
0.0601


MmugDNA.8585.1.S1_at
—
—
6.34
0.0451


MmugDNA.17339.1.S1_s_at
leucine rich repeat neuronal 3
LOC701932
6.31
0.0171


MmuSTS.527.1.S1_at
platelet-derived growth factor C precursor
—
6.30
0.0362


MmugDNA.15109.1.S1_s_at
—
—
6.29
0.0096


MmugDNA.2733.1.S1_s_at
Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-
—
6.23
0.0651



associated fatty acid-binding protein homolog) (PA-FABP)


MmugDNA.35813.1.S1_at
—
—
6.23
0.0411


MmugDNA.20157.1.S1_at
nel-like 1 precursor
LOC701438
6.21
0.0389


MmugDNA.39143.1.S1_at
—
—
6.20
0.0333


MmuSTS.2452.1.S1_at
McLeod syndrome-associated, Kell blood group protein
LOC696407
6.20
0.0099


MmugDNA.33888.1.S1_at
egl nine homolog 1
LOC713410
6.18
0.0609


MmugDNA.7614.1.S1_at
ADP-ribosylation factor-like 6
LOC696616
6.17
0.0002


MmuSTS.1330.1.S1_at
dual-specificity tyrosine-(Y)-phosphorylation regulated
DYRK2
6.16
0.0203



kinase 2


MmuSTS.3090.1.S1_at
latrophilin 3
LPHN3
6.16
0.0063


MmugDNA.23556.1.S1_at
—
—
6.14
0.0144


MmuSTS.1177.1.S1_at
taste receptor, type 2, member 39
TAS2R39
6.10
0.0094


MmugDNA.14803.1.S1_s_at
Fibroblast growth factor 12 (FGF-12) (Fibroblast growth
LOC705813
6.05
0.0344



factor homologous factor 1) (FHF-1)


Mmu.3466.1.S1_at
—
—
6.03
0.0171


MmugDNA.35142.1.S1_at
—
—
6.01
0.0002


MmuSTS.3438.1.S1_at
ankyrin 2
ANK2
6.01
0.0264


MmugDNA.16713.1.S1_at
potassium channel tetramerisation domain containing 4
LOC701916
6.00
0.0289


MmugDNA.23811.1.S1_at
sel-1 suppressor of lin-12-like
LOC708651
5.97
0.0664


MmunewRS.311.1.S1_at
—
—
5.95
0.0419


MmugDNA.2511.1.S1_at
—
—
5.93
0.0561


MmugDNA.5134.1.S1_at
thrombospondin 4
THBS4
5.90
0.0003


MmugDNA.27291.1.S1_at
—
—
5.90
0.0192


MmugDNA.35237.1.S1_at
—
—
5.89
0.0799


MmugDNA.29494.1.S1_at
coagulation factor II receptor
F2R
5.86
0.0249


MmugDNA.41193.1.S1_at
phosducin-like 3
—
5.86
0.0302


MmugDNA.27343.1.S1_s_at
DnaJ (Hsp40) homolog, subfamily C, member 3
LOC695757
5.83
0.0649


MmugDNA.8284.1.S1_at
—
—
5.77
0.0007


MmuSTS.909.1.S1_at
taste receptor, type 2, member 50
LOC693513
5.76
0.0712


MmuSTS.2673.1.S1_at
calmegin
CLGN
5.76
0.0576


MmugDNA.37138.1.S1_at
Discs large homolog 2 (Postynaptic density protein PSD-93)
LOC704826
5.76
0.0582



(Channel-associated protein of synapse-110) (Chapsyn-



110)


MmugDNA.15905.1.S1_at
—
—
5.68
0.0480


MmugDNA.32064.1.S1_at
butyrophilin-like 8
BTNL8
5.67
0.0176


MmugDNA.34572.1.S1_at
decay accelerating factor for complement
LOC714370
5.65
0.0083


MmugDNA.22059.1.S1_at
integrin alpha 2
ITGA2
5.64
0.0227


MmuSTS.861.1.S1_at
CG7231-PB, isoform B
LOC715256
5.62
0.0968


MmugDNA.29329.1.S1_at
—
—
5.61
0.0108


MmugDNA.14073.1.S1_at
microtubule-associated protein 6 isoform 2
LOC696223
5.60
0.0103


MmugDNA.27825.1.S1_at
alpha 4 type IV collagen
COL4A4
5.59
0.0662


MmugDNA.34698.1.S1_at
ankyrin repeat domain 43
LOC708755
5.57
0.0236


MmuSTS.2650.1.S1_at
adenylate kinase 5 isoform 1
LOC706248
5.57
0.0477


MmugDNA.21615.1.S1_at
—
—
5.56
0.0504


MmugDNA.18178.1.S1_at
autotaxin
ENPP2
5.56
0.0036


MmuSTS.1143.1.S1_at
Beta-synuclein
SNCB
5.53
0.0727


MmugDNA.40607.1.S1_at
hypothetical protein LOC717552
LOC717552
5.53
0.0701


MmugDNA.18538.1.S1_s_at
serine (or cysteine) proteinase inhibitor, clade I
SERPINI1
5.53
0.0790



(neuroserpin), member 1


MmugDNA.5368.1.S1_at
—
—
5.50
0.0256


MmugDNA.30317.1.S1_at
Baculoviral IAP repeat-containing protein 4 (Inhibitor of
LOC698057
5.49
0.0475



apoptosis protein 3) (X-linked inhibitor of apoptosis protein)



(X-linked IAP) (IAP-like protein) (HILP)


MmugDNA.35810.1.S1_at
adenosine A2b receptor
ADORA2B
5.48
0.0099


MmugDNA.22262.1.S1_at
neurotrypsin precursor
LOC704461
5.46
0.0150


Mmu.9266.1.S1_x_at
alpha-defensin 3 precursor
LOC574310
5.46
0.0796


MmugDNA.1819.1.S1_at
chromodomain helicase DNA binding protein 5
—
5.44
0.0524


MmugDNA.37049.1.S1_at
Dipeptidyl aminopeptidase-like protein 6
LOC718148
5.42
0.0278



(Dipeptidylpeptidase VI) (Dipeptidylpeptidase 6) (Dipeptidyl



peptidase IV-like protein) (Dipeptidyl aminopeptidase-



related protein) (DPPX)


MmugDNA.26844.1.S1_at
hypothetical protein LOC716906
LOC716906
5.40
0.0620


MmugDNA.40160.1.S1_at
—
—
5.34
0.0828


MmugDNA.13497.1.S1_at
runt-related transcription factor 2 isoform b
LOC703331
5.33
0.0463


MmugDNA.35702.1.S1_at
ADAMTS-like 1
ADAMTSL1
5.33
0.0106


Mmu.335.1.S1_at
carboxypeptidase E
CPE
5.30
0.0493


MmugDNA.13656.1.S1_at
—
—
5.30
0.0030


MmugDNA.22297.1.S1_at
lysozyme
LOC718361
5.29
0.0804


MmugDNA.28583.1.S1_at
—
—
5.25
0.0006


MmugDNA.18724.1.S1_s_at
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase 6
B4GALT6
5.25
0.0461


MmugDNA.38162.1.S1_at
—
—
5.24
0.0001


MmugDNA.27108.1.S1_at
matrix metalloproteinase 19
MMP19
5.21
0.0313


MmugDNA.24659.1.S1_at
mesothelin isoform 1 preproprotein
LOC698095
5.19
0.0431


Mmu.11741.1.S1_at
N-ethylmaleimide-sensitive factor
LOC715297
5.19
0.0035


MmugDNA.1267.1.S1_s_at
cytochrome P450 3A64 /// Cytochrome P450 3A7
CYP3A64 ///
5.18
0.0847



(CYPIIIA7) (P450-HFLA)
LOC718917


MmuSTS.3164.1.S1_at
cathepsin C
CTSC
5.16
0.0003


MmugDNA.2042.1.S1_at
dual specificity phosphatase 10
DUSP10
5.16
0.0148


MmuSTS.4822.1.S1_at
GATA binding protein 6
LOC699591
5.15
0.0204


MmugDNA.28021.1.S1_at
zinc finger and BTB domain containing 10
LOC704721
5.15
0.0905


MmugDNA.32990.1.S1_at
protocadherin beta 5
PCDHB5
5.14
0.0458


MmugDNA.27188.1.S1_at
hypothetical protein LOC694387
LOC694387
5.11
0.0446


MmugDNA.18606.1.S1_at
—
—
5.10
0.0278


MmugDNA.36968.1.S1_at
microsomal triglyceride transfer protein large subunit
MTTP
5.07
0.0525


MmugDNA.12625.1.S1_at
Ras protein-specific guanine nucleotide-releasing factor 2
LOC711350
5.07
0.0298


MmuSTS.597.1.S1_s_at
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)
LOC709186
5.07
0.0051



(HGPRTase)


MmugDNA.8387.1.S1_at
S-acyl fatty acid synthase thioesterase, medium chain
THEDC1
5.06
0.0290



(Thioesterase II) (Thioesterase domain-containing protein 1)


MmugDNA.19071.1.S1_at
—
—
5.06
0.0453


MmugDNA.1497.1.S1_at
vacuolar protein sorting 13A isoform A
LOC705323
5.04
0.0367


MmugDNA.26354.1.S1_at
GEM 1 protein
GEM 1
5.04
0.0011


MmunewRS.58.1.S1_at
—
—
5.04
0.0241


MmuSTS.531.1.S1_at
UDP-GlcNAc:betaGal beta-1,3-N-
LOC693396
5.04
0.0968



acetylglucosaminyltransferase 1


MmugDNA.38025.1.S1_at
glycoprotein M6B
GPM6B
5.03
0.0248


MmuSTS.1448.1.S1_at
v-yes-1 Yamaguchi sarcoma viral related oncogene
LYN
5.03
0.0807



homolog


MmugDNA.1649.1.S1_at
DHHC-containing protein 20
LOC705802
5.02
0.0886


MmugDNA.38429.1.S1_at
hypothetical protein LOC698744
LOC698744
5.00
0.0001


MmugDNA.3432.1.S1_at
plexin C1
LOC711320
4.99
0.0000


MmugDNA.30924.1.S1_at
mothers against decapentaplegic homolog 4
SMAD4
4.97
0.0151


MmugDNA.43332.1.S1_at
—
—
4.96
0.0931


MmuSTS.4050.1.S1_at
diacylglycerol kinase, beta
DGKB
4.95
0.0176


MmugDNA.31803.1.S1_at
calcium binding protein 39-like
CAB39L
4.88
0.0227


MmugDNA.42361.1.S1_at
—
—
4.87
0.0521


MmugDNA.36141.1.S1_at
—
—
4.87
0.0504


MmuSTS.2022.1.S1_at
Glutathione-requiring prostaglandin D synthase
PGDS
4.87
0.0504



(Glutathione-dependent PGD synthetase) (Prostaglandin-H2



D-isomerase) (Hematopoietic prostaglandin D synthase) (H-



PGDS)


MmugDNA.20560.1.S1_at
tripartite motif protein 9
TRIM9
4.86
0.0363


MmuSTS.1776.1.S1_at
SATB family member 2
SATB2
4.86
0.0000


MmugDNA.17660.1.S1_s_at
ectonucleotide pyrophosphatase/phosphodiesterase 4
LOC703680
4.83
0.0657



(putative function)


MmugDNA.8441.1.S1_s_at
GalNAc-4-sulfotransferase 2
LOC703877
4.83
0.0984


MmugDNA.10568.1.S1_at
—
—
4.81
0.0080


MmugDNA.5130.1.S1_at
neuropilin- and tolloid-like protein 2 precursor
LOC716468
4.81
0.0436


MmugDNA.10470.1.S1_at
cyclic nucleotide gated channel beta 1
LOC708851
4.80
0.0916


MmugDNA.25697.1.S1_at
—
—
4.80
0.0646


MmugDNA.2214.1.S1_at
protocadherin beta 14
PCDHB14
4.79
0.0153


MmuSTS.1120.1.S1_s_at
protocadherin alpha 9
PCDHA9
4.78
0.0373


MmugDNA.33308.1.S1_at
tetratricopeptide repeat domain 7B
LOC696029
4.76
0.0022


MmugDNA.9526.1.S1_at
Kelch repeat and BTB domain-containing protein 11 (Kelch
KBTBD11
4.75
0.0031



domain-containing protein 7B)


MmugDNA.42933.1.S1_at
hypothetical protein LOC712344
LOC712344
4.74
0.0099


MmugDNA.28339.1.S1_at
c-myc promoter binding protein
LOC709675
4.74
0.0345


MmugDNA.16977.1.S1_at
—
—
4.73
0.0001


MmugDNA.9216.1.S1_s_at
tripartite motif protein 31 isoform alpha
—
4.71
0.0045


MmugDNA.29917.1.S1_at
—
—
4.69
0.0000


MmugDNA.8704.1.S1_at
stanniocalcin 2 precursor
LOC703900
4.69
0.0960


MmugDNA.11746.1.S1_at
hypothetical protein LOC716531
LOC716531
4.64
0.0001


MmugDNA.7242.1.S1_at
ring finger protein 183
LOC705679
4.63
0.0183


MmugDNA.34448.1.S1_at
—
—
4.62
0.0856


MmugDNA.12226.1.S1_at
KIAA1946
LOC712442
4.61
0.0021


MmugDNA.16242.1.S1_at
—
—
4.61
0.0284


MmugDNA.42287.1.S1_at
Beta crystallin A2 (Beta-A2-crystallin)
LOC701178
4.59
0.0674


MmugDNA.13689.1.S1_at
acyl-Coenzyme A oxidase 3, pristanoyl
ACOX3
4.58
0.0836


MmugDNA.35429.1.S1_at
—
—
4.58
0.0297


MmugDNA.42474.1.S1_at
neural cell adhesion molecule 1
NCAM1
4.58
0.0986


MmugDNA.42278.1.S1_at
—
—
4.58
0.0006


MmugDNA.15856.1.S1_at
—
—
4.57
0.0006


MmugDNA.26231.1.S1_at
protein phosphatase 1, regulatory (inhibitor) subunit 14B
—
4.56
0.0040


MmuSTS.1471.1.S1_at
guanylate cyclase activator 1A (retina)
LOC695552
4.56
0.0712


MmugDNA.38210.1.S1_at
—
—
4.56
0.0013


MmugDNA.8341.1.S1_at
potassium voltage-gated channel, subfamily H, member 7
LOC702259
4.55
0.0691



isoform 2


MmugDNA.40476.1.S1_at
CG17660-PA
LOC698581
4.55
0.0164


MmugDNA.21371.1.S1_at
L1 cell adhesion molecule
L1CAM
4.54
0.0016


MmugDNA.10362.1.S1_at
—
—
4.54
0.0247


MmugDNA.34200.1.S1_at
solute carrier family 16, member 10
LOC696132
4.54
0.0008


MmugDNA.10673.1.S1_at
—
—
4.53
0.0098


MmugDNA.34348.1.S1_at
—
—
4.51
0.0776


MmugDNA.14801.1.S1_at
—
—
4.51
0.0800


MmugDNA.16806.1.S1_at
—
—
4.51
0.0104


MmugDNA.26715.1.S1_at
hypothetical protein LOC705319
LOC705319
4.50
0.0377


MmugDNA.29516.1.S1_at
Transcribed locus
—
4.50
0.0131


MmugDNA.35871.1.S1_at
alpha-fetoprotein
AFP
4.49
0.0827


MmuSTS.3720.1.S1_at
prostaglandin-endoperoxide synthase 1
PTGS1
4.49
0.0550


MmugDNA.13337.1.S1_at
—
—
4.48
0.0825


MmugDNA.42244.1.S1_at
—
—
4.48
0.0930


MmugDNA.21236.1.S1_at
arginine/serine-rich coiled-coil 1
LOC704232
4.47
0.0144


MmugDNA.36820.1.S1_at
1-acylglycerol-3-phosphate O-acyltransferase 5
AGPAT5
4.47
0.0076


MmugDNA.37762.1.S1_at
methylenetetrahydrofolate dehydrogenase (NADP+
LOC705222
4.47
0.0074



dependent) 1-like


MmugDNA.3018.1.S1_at
Corticotropin-lipotropin precursor (Pro-opiomelanocortin)
POMC
4.46
0.0858



(POMC)


MmugDNA.30526.1.S1_at
breast cancer membrane protein 11
LOC714517
4.46
0.0302


MmuSTS.2215.1.S1_at
carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2
LOC713994
4.45
0.0820


MmuSTS.1144.1.S1_at
Jun dimerization protein p21SNFT
LOC710551
4.45
0.0023


MmugDNA.33092.1.S1_s_at
alpha-2-glycoprotein 1, zinc
LOC710136
4.44
0.0971


MmugDNA.34402.1.S1_at
taste receptor, type 1, member 2
LOC714666
4.44
0.0587


MmugDNA.583.1.S1_at
phosphatidylinositol transfer protein, cytoplasmic 1 isoform a
LOC718773
4.43
0.0076


MmugDNA.10551.1.S1_at
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-
MGAT2
4.42
0.0455



acetylglucosaminyltransferase (Mannoside



acetylglucosaminyltransferase 2) (N-glycosyl-



oligosaccharide-glycoprotein N-



acetylglucosaminyltransferase II) (Beta-1,2-N-



acetylglucosaminyltransferase II) . . .


MmugDNA.10172.1.S1_at
—
—
4.42
0.0763


MmugDNA.7644.1.S1_at
amyloid beta (A4) precursor-like protein 2
APLP2
4.42
0.0771


MmuSTS.4251.1.S1_at
DnaJ (Hsp40) homolog, subfamily B, member 9
LOC701094
4.42
0.0012


MmugDNA.30872.1.S1_at
Tescalcin (TSC)
TESC
4.41
0.0018


MmugDNA.16779.1.S1_at
solute carrier organic anion transporter family member 4A1
SLCO4A1
4.41
0.0008


MmugDNA.36628.1.S1_at
—
—
4.39
0.0293


MmugDNA.39982.1.S1_at
hydrogen voltage-gated channel 1
LOC709745
4.39
0.0378


MmugDNA.12304.1.S1_at
—
—
4.39
0.0926


MmugDNA.22401.1.S1_at
goosecoid
LOC702308
4.39
0.0452


MmugDNA.3017.1.S1_at
—
—
4.39
0.0176


MmugDNA.40588.1.S1_at
—
—
4.38
0.0736


MmugDNA.9680.1.S1_at
—
—
4.38
0.0521


MmugDNA.27684.1.S1_at
guanine nucleotide binding protein (G protein), alpha 14
LOC705448
4.38
0.0003


MmugDNA.24197.1.S1_at
—
—
4.37
0.0840


MmugDNA.28806.1.S1_at
—
—
4.37
0.0872


MmugDNA.21653.1.S1_at
Y17G7B.10b
LOC704285
4.37
0.0535


MmugDNA.26796.1.S1_at
beta-galactoside alpha-2,6-sialyltransferase II
LOC713552
4.37
0.0025


MmugDNA.41976.1.S1_s_at
probable nucleolar complex protein 14
LOC720068
4.37
0.0973


MmuSTS.63.1.S1_at
hemochromatosis protein
HFE
4.37
0.0581


MmugDNA.17587.1.S1_at
molybdenum cofactor synthesis 3
MOCS3
4.36
0.0773


MmugDNA.22799.1.S1_at
—
—
4.35
0.0910


MmugDNA.43244.1.S1_at
—
—
4.35
0.0287


MmugDNA.4726.1.S1_at
—
—
4.35
0.0236


MmugDNA.27474.1.S1_at
NIF3 NGG1 interacting factor 3-like 1
—
4.34
0.0009


MmuSTS.113.1.S1_at
monogenic, audiogenic seizure susceptibility 1
LOC697794
4.34
0.0120


MmugDNA.13225.1.S1_at
—
—
4.34
0.0230


MmugDNA.40434.1.S1_at
ataxin-1 ubiquitin-like interacting protein
LOC714928
4.34
0.0944


MmuSTS.3087.1.S1_at
RAD50 homolog isoform 1
LOC710718
4.33
0.0858


MmugDNA.2856.1.S1_at
—
—
4.32
0.0586


MmugDNA.24690.1.S1_at
—
—
4.32
0.0188


MmugDNA.17638.1.S1_at
—
—
4.32
0.0420


Mmu.4140.1.S1_at
peptidylglycine alpha-amidating monooxygenase isoform b,
LOC707733
4.31
0.0208



preproprotein


MmuSTS.1399.1.S1_at
complement factor B
CFB
4.31
0.0450


MmugDNA.28599.1.S1_at
dedicator of cytokinesis 10
DOCK10
4.30
0.0532


MmugDNA.5642.1.S1_at
—
—
4.28
0.0091


MmugDNA.33945.1.S1_at
—
—
4.28
0.0090


MmugDNA.845.1.S1_at
N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase precursor
AGA
4.28
0.0049



(Glycosylasparaginase) (Aspartylglucosaminidase) (N4-(N-



acetyl-beta-glucosaminyl)-L-asparagine amidase) (AGA)


MmugDNA.14017.1.S1_at
dedicator of cytokinesis 9
DOCK9
4.28
0.0381


MmugDNA.1746.1.S1_at
—
—
4.27
0.0148


MmugDNA.7878.1.S1_at
—
—
4.27
0.0396


MmugDNA.42983.1.S1_s_at
tripeptidyl-peptidase I precursor
LOC709838
4.27
0.0116


MmugDNA.17468.1.S1_at
protocadherin beta 6
PCDHB6
4.27
0.0080


MmugDNA.27490.1.S1_at
—
—
4.26
0.0588


MmugDNA.25045.1.S1_at
—
—
4.26
0.0872


MmugDNA.21311.1.S1_at
ankyrin repeat and SOCS box-containing protein 4
ASB4
4.26
0.0713


MmugDNA.12780.1.S1_at
BMX non-receptor tyrosine kinase
BMX
4.26
0.0018


MmugDNA.39574.1.S1_at
RWD domain containing 2
RWDD2
4.25
0.0242


MmugDNA.23856.1.S1_at
—
—
4.24
0.0588


MmugDNA.10231.1.S1_at
mannosidase, endo-alpha
LOC716710
4.24
0.0469


MmugDNA.38293.1.S1_at
quiescin Q6 isoform a
LOC718589
4.23
0.0244


MmugDNA.32049.1.S1_at
transmembrane protein 64
LOC695826
4.23
0.0216


MmugDNA.10078.1.S1_at
allantoicase
ALLC
4.22
0.0463


MmugDNA.34409.1.S1_at
—
—
4.22
0.0589


MmugDNA.3676.1.S1_at
—
—
4.22
0.0067


MmugDNA.27799.1.S1_at
hypothetical protein LOC703244
LOC703244
4.20
0.0047


MmugDNA.35140.1.S1_at
UDP-glucuronate decarboxylase 1
LOC718456
4.20
0.0026


MmugDNA.12308.1.S1_at
—
—
4.20
0.0676


MmugDNA.29177.1.S1_at
DNA polymerase zeta catalytic subunit (Seizure-related
LOC703920
4.19
0.0016



protein 4)


MmugDNA.366.1.S1_at
fucosyltransferase 11 (alpha (1,3) fucosyltransferase)
LOC706552
4.19
0.0249


MmugDNA.31712.1.S1_at
polypeptide N-acetylgalactosaminyltransferase 6
GALNT6
4.18
0.0496


MmuSTS.649.1.S1_at
interleukin 25 isoform 1 precursor
LOC713943
4.18
0.0789


MmugDNA.41214.1.S1_at
—
—
4.16
0.0827


MmugDNA.28831.1.S1_at
G protein-regulated inducer of neurite outgrowth 1
LOC697365
4.16
0.0458


MmugDNA.8787.1.S1_at
Protein C10orf70
—
4.15
0.0040


MmuSTS.3573.1.S1_at
protocadherin 8
PCDH8
4.15
0.0273


MmugDNA.13403.1.S1_at
complement component 5 receptor 1 (C5a ligand)
C5AR1
4.14
0.0245


MmugDNA.21971.1.S1_at
N-acylsphingosine amidohydrolase (acid ceramidase) 1
LOC703699
4.13
0.0000



preproprotein isoform a


MmugDNA.17057.1.S1_at
RECK protein precursor
—
4.13
0.0061


MmugDNA.22311.1.S1_at
—
—
4.12
0.0879


MmugDNA.8200.1.S1_at
transglutaminase 7
LOC712676
4.12
0.0472


MmugDNA.42341.1.S1_at
rabconnectin-3 beta isoform 2
LOC695302
4.11
0.0175


MmugDNA.601.1.S1_at
SPRY domain-containing SOCS box protein SSB-4
LOC715278
4.10
0.0041


MmugDNA.27605.1.S1_at
Spir-1 protein isoform 1
LOC722155
4.09
0.0878


MmugDNA.17977.1.S1_at
neurexin 1
NRXN1
4.09
0.0029


MmugDNA.9585.1.S1_at
histone deacetylase 9 isoform 3
LOC708314
4.08
0.0429


MmugDNA.43369.1.S1_at
T-cell immunomodulatory protein
LOC716435
4.08
0.0209


MmuSTS.2480.1.S1_at
zinc finger protein 287
LOC695524
4.08
0.0212


MmugDNA.37092.1.S1_at
down-regulator of transcription 1 (predicted)
DR1
4.08
0.0606


MmugDNA.30978.1.S1_at
desmoglein 2
DSG2
4.06
0.0049


MmuSTS.3837.1.S1_at
solute carrier organic anion transporter family, member 2A1
SLCO2A1
4.05
0.0641


MmugDNA.26101.1.S1_at
—
—
4.04
0.0842


MmugDNA.25428.1.S1_at
zinc finger protein 382
LOC713048
4.04
0.0143


MmugDNA.4774.1.S1_at
—
—
4.04
0.0319


MmugDNA.30877.1.S1_at
zyg-11 homolog B (C. elegans)-like
LOC715671
4.04
0.0081


MmugDNA.24520.1.S1_at
synapsin II isoform IIa
LOC695412
4.04
0.0046


MmugDNA.11034.1.S1_at
—
—
4.04
0.0031


MmugDNA.21096.1.S1_at
zinc finger protein 275
ZNF275
4.03
0.0093


MmugDNA.43413.1.S1_at
immunoglobin superfamily, member 21
LOC701539
4.03
0.0227


MmugDNA.42897.1.S1_at
hypothetical protein LOC701560
LOC701560
4.03
0.0379


MmugDNA.19620.1.S1_at
—
—
4.02
0.0364


MmugDNA.15063.1.S1_s_at
phosphatidate cytidylyltransferase 1
LOC706649
4.02
0.0319


MmugDNA.21133.1.S1_at
—
—
4.01
0.0911


MmugDNA.12118.1.S1_at
—
—
4.00
0.0007


MmugDNA.20406.1.S1_at
GLE1-like, RNA export mediator isoform 1
LOC717474
4.00
0.0184


MmugDNA.34611.1.S1_at
—
—
4.00
0.0155


MmugDNA.19800.1.S1_at
vang-like 1
LOC709730
3.99
0.0971


MmugDNA.6828.1.S1_at
zinc finger protein 233
LOC713398
3.99
0.0396


MmugDNA.32366.1.S1_at
—
—
3.99
0.0269


MmugDNA.13572.1.S1_at
—
—
3.99
0.0080


MmugDNA.23433.1.S1_at
—
—
3.98
0.0701


MmugDNA.22715.1.S1_s_at
—
—
3.98
0.0039


MmugDNA.334.1.S1_at
serine (or cysteine) proteinase inhibitor, clade B
SERPINB2
3.96
0.0921



(ovalbumin), member 2


MmuSTS.1861.1.S1_at
cholinergic receptor, nicotinic, alpha polypeptide 10
LOC718133
3.96
0.0531


MmugDNA.28216.1.S1_at
CDC42-binding protein kinase alpha isoform B
LOC697811
3.95
0.0269


MmugDNA.33930.1.S1_at
LIN-7 homolog A (LIN-7A) (mLin-7) (Mammalian LIN-seven
LOC697557
3.95
0.0069



protein 1) (MALS-1) (Vertebrate LIN 7 homolog 1) (Veli-1



protein)


MmugDNA.2196.1.S1_at
—
—
3.94
0.0044


MmuSTS.1116.1.S1_at
—
—
3.94
0.0137


MmugDNA.29351.1.S1_at
alpha-synuclein isoform NACP140
LOC706985
3.94
0.0198


MmugDNA.12808.1.S1_at
hypothetical protein LOC694824
LOC694824
3.94
0.0695


MmugDNA.9043.1.S1_at
ADP-ribosylation factor-like 6 interacting protein 2
LOC710647
3.94
0.0582


Mmu.937.1.S1_at
hypothetical protein LOC710176
LOC710176
3.94
0.0314


MmugDNA.13793.1.S1_at
—
—
3.93
0.0047


MmugDNA.22471.1.S1_at
—
—
3.93
0.0011


MmugDNA.13861.1.S1_at
fatty acid 2-hydroxylase
LOC710403
3.92
0.0262


MmugDNA.31129.1.S1_at
G protein-coupled receptor, family C, group 5, member B
GPRC5B
3.92
0.0025


MmugDNA.41489.1.S1_at
—
—
3.91
0.0302


MmugDNA.12173.1.S1_at
hypothetical protein LOC695417
LOC695417
3.91
0.0320


MmugDNA.37274.1.S1_s_at
secretin receptor
SCTR
3.91
0.0497


MmugDNA.10795.1.S1_at
SVH protein
LOC695210
3.90
0.0590


MmugDNA.24744.1.S1_at
homeodomain leucine zipper protein
LOC713087
3.90
0.0347


MmugDNA.39071.1.S1_at
—
—
3.89
0.0087


MmugDNA.818.1.S1_at
—
—
3.89
0.0375


MmugDNA.4556.1.S1_at
Sorting nexin-5
—
3.89
0.0175


MmugDNA.13966.1.S1_s_at
regulator of G-protein signalling 8
RGS8
3.89
0.0312


MmunewRS.597.1.S1_at
Ral GEF with PH domain and SH3 binding motif 2 isoform 2
LOC717165
3.89
0.0520


MmuSTS.4601.1.S1_at
interleukin 19 isoform 1 precursor
LOC694806
3.89
0.0032


MmugDNA.13652.1.S1_at
—
—
3.87
0.0550


MmugDNA.7329.1.S1_s_at
—
—
3.86
0.0750


MmugDNA.40738.1.S1_at
—
—
3.86
0.0007


MmugDNA.2633.1.S1_at
small nuclear RNA activating complex, polypeptide 1, 43 kDa
LOC704797
3.86
0.0327


MmugDNA.7168.1.S1_at
—
—
3.86
0.0832


MmugDNA.36780.1.S1_at
—
—
3.85
0.0778


Mmu.14893.1.S1_x_at
cytochrome P450 3A64
CYP3A64
3.84
0.0771


MmugDNA.19443.1.S1_at
ataxin 2-binding protein 1 isoform 1
LOC713147
3.84
0.0099


MmugDNA.30992.1.S1_at
SH3 and multiple ankyrin repeat domains 2 isoform 1
LOC708192
3.84
0.0487


MmugDNA.33696.1.S1_at
hyaluronan binding protein 4
LOC710213
3.82
0.0699


MmugDNA.20527.1.S1_at
—
—
3.82
0.0945


MmugDNA.9900.1.S1_at
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
LOC710601
3.82
0.0643



dependent 2 isoform C


MmuSTS.3411.1.S1_at
Ribose-phosphate pyrophosphokinase I (Phosphoribosyl
LOC702529
3.82
0.0608



pyrophosphate synthetase I) (PRS-I)


MmugDNA.4816.1.S1_at
hypothetical protein LOC719170
LOC719170
3.81
0.0018


MmugDNA.35136.1.S1_at
transmembrane protein 35
LOC702205
3.81
0.0773


MmugDNA.25086.1.S1_at
glucosidase, alpha; neutral C
GANC
3.80
0.0077


MmugDNA.1845.1.S1_at
—
—
3.80
0.0967


MmugDNA.29812.1.S1_at
adaptor-related protein complex 3, beta 2 subunit
AP3B2
3.79
0.0056


MmuSTS.4436.1.S1_at
—
—
3.79
0.0006


MmuSTS.782.1.S1_at
potassium voltage-gated channel, Shab-related subfamily,
KCNB2
3.79
0.0129



member 2


MmugDNA.3088.1.S1_at
WNK lysine deficient protein kinase 3
WNK3
3.79
0.0093


MmuSTS.3509.1.S1_at
Complement component 6
C6
3.78
0.0826


MmugDNA.41339.1.S1_at
GTP cyclohydrolase I (GTP-CH-I)
GCH1
3.78
0.0160


MmugDNA.14784.1.S1_at
—
—
3.77
0.0005


MmugDNA.9742.1.S1_at
—
—
3.77
0.0120


MmugDNA.5664.1.S1_at
—
—
3.76
0.0445


MmugDNA.480.1.S1_at
—
—
3.75
0.0159


MmugDNA.34213.1.S1_at
cDNA sequence BC021395
LOC709217
3.74
0.0930


MmugDNA.16508.1.S1_at
—
—
3.73
0.0079


MmugDNA.17649.1.S1_at
Sp3 transcription factor
SP3
3.73
0.0274


MmugDNA.41644.1.S1_at
spermatogenesis associated 5-like 1
LOC713376
3.72
0.0074


MmugDNA.9202.1.S1_at
—
—
3.72
0.0472


MmugDNA.17057.1.S1_s_at
tumor suppressor candidate 3 isoform a
LOC701123
3.72
0.0011


MmuSTS.56.1.S1_at
hypothetical protein LOC715723
LOC715723
3.72
0.0043


MmugDNA.39898.1.S1_at
—
—
3.71
0.0068


MmugDNA.40119.1.S1_s_at
HIV-1 Tat interactive protein 2, 30 kDa
LOC701908
3.71
0.0078


MmugDNA.27371.1.S1_at
hypothetical protein LOC697751
LOC697751
3.71
0.0857


MmugDNA.16327.1.S1_at
pad-1-like
DOPEY2
3.70
0.0023


MmuSTS.3363.1.S1_at
phosphodiesterase 2A, cGMP-stimulated
PDE2A
3.70
0.0029


MmugDNA.14309.1.S1_at
activated leukocyte cell adhesion molecule
LOC703777
3.70
0.0030


MmugDNA.24681.1.S1_at
CTAGE family, member 5
—
3.70
0.0392


MmuSTS.101.1.S1_at
acyl-Coenzyme A oxidase isoform b
LOC705197
3.69
0.0138


MmugDNA.27013.1.S1_at
—
—
3.69
0.0484


MmugDNA.29538.1.S1_at
—
—
3.69
0.0315


MmugDNA.43028.1.S1_at
—
—
3.68
0.0468


MmugDNA.34314.1.S1_at
synovial sarcoma, X breakpoint 2 interacting protein
SSX2IP
3.67
0.0570


MmugDNA.33133.1.S1_at
hypothetical protein LOC711218
LOC711218
3.67
0.0227


MmugDNA.11493.1.S1_at
—
—
3.67
0.0378


MmugDNA.16985.1.S1_at
ets variant gene 1
ETV1
3.67
0.0532


MmuSTS.1797.1.S1_at
—
—
3.67
0.0668


MmuSTS.2054.1.S1_at
protein (peptidyl-prolyl cis/trans isomerase) NIMA-
LOC699273
3.67
0.0431



interacting, 4 (parvulin)


MmugDNA.18533.1.S1_at
phospholipase D family, member 5
LOC706256
3.66
0.0682


MmuSTS.1511.1.S1_at
RNA binding motif protein 15B
LOC700716
3.66
0.0181


MmugDNA.15936.1.S1_at
—
—
3.66
0.0183


MmugDNA.29618.1.S1_at
K09A9.6
LOC712623
3.65
0.0282


MmugDNA.831.1.S1_at
—
—
3.65
0.0675


MmugDNA.22531.1.S1_s_at
—
—
3.65
0.0988


MmugDNA.6653.1.S1_at
tudor repeat associator with PCTAIRE 2
PCTAIRE2BP
3.65
0.0018


MmugDNA.25839.1.S1_at
RAD1 homolog isoform 1
LOC703720
3.64
0.0444


MmugDNA.6534.1.S1_at
hypothetical protein LOC701296
LOC701296
3.64
0.0007


MmugDNA.30983.1.S1_at
—
—
3.64
0.0165


MmugDNA.18313.1.S1_at
arrestin beta 1 isoform A
LOC695250
3.64
0.0141


MmugDNA.25553.1.S1_at
retinitis pigmentosa GTPase regulator interacting protein 1
LOC697345
3.63
0.0105


MmugDNA.31716.1.S1_s_at
molybdenum cofactor sulfurase
LOC715633
3.62
0.0761


MmugDNA.41201.1.S1_at
—
—
3.62
0.0012


MmugDNA.7740.1.S1_at
—
—
3.61
0.0206


MmugDNA.1555.1.S1_at
C29E4.8
LOC714698
3.61
0.0795


MmugDNA.27957.1.S1_at
ganglioside induced differentiation associated protein 2
LOC714615
3.59
0.0280


MmugDNA.2255.1.S1_at
phosphatidylinositol-4-phosphate 5-kinase, type I, beta
LOC700538
3.59
0.0003



isoform 2


MmugDNA.23037.1.S1_at
Ephrin type-B receptor 2 precursor (Tyrosine-protein kinase
LOC720107
3.59
0.0647



receptor EPH-3) (Neural kinase) (Nuk receptor tyrosine



kinase) (SEK-3)


MmugDNA.41938.1.S1_at
proline-rich protein PRP2
LOC702863
3.59
0.0012


MmugDNA.7947.1.S1_at
—
—
3.59
0.0538


MmugDNA.4820.1.S1_at
Rho GTPase activating protein 6
ARHGAP6
3.59
0.0726


MmugDNA.31476.1.S1_at
Ras-related protein Rab-28 (Rab-26)
LOC694111
3.58
0.0643


MmugDNA.16749.1.S1_at
—
—
3.58
0.0095


MmugDNA.39259.1.S1_at
—
—
3.57
0.0161


MmugDNA.3689.1.S1_at
nuclear factor of kappa light polypeptide gene enhancer in
LOC694844
3.57
0.0001



B-cells inhibitor, beta isoform a


MmugDNA.17315.1.S1_at
—
—
3.57
0.0712


MmugDNA.23019.1.S1_at
—
—
3.56
0.0014


MmugDNA.37589.1.S1_at
Ubiquitin-conjugating enzyme E2S (Ubiquitin-conjugating
—
3.55
0.0112



enzyme E2-24 kDa) (Ubiquitin-protein ligase) (Ubiquitin



carrier protein) (E2-EPF5)


MmugDNA.17498.1.S1_at
—
—
3.55
0.0024


MmugDNA.13233.1.S1_at
brain expressed X-linked 2
LOC696048
3.55
0.0065


MmugDNA.22053.1.S1_at
gamma-glutamyl carboxylase
GGCX
3.55
0.0254


MmugDNA.35529.1.S1_at
PARK2 co-regulated
PACRG
3.55
0.0412


MmugDNA.40108.1.S1_at
hypothetical protein LOC698322
LOC698322
3.54
0.0882


Mmu.1639.1.S1_at
solute carrier family 15 (H+/peptide transporter), member 2
SLC15A2
3.54
0.0400


MmugDNA.19566.1.S1_at
Type I iodothyronine deiodinase (Type-I 5deiodinase) (DIOI)
DIO1
3.54
0.0037



(Type 1 DI) (5DI)


MmuSTS.106.1.S1_at
Elongation factor 1-delta (EF-1-delta) (Antigen NY-CO-4)
—
3.54
0.0407


MmugDNA.41451.1.S1_s_at
F33H2.6
LOC710209
3.52
0.0008


MmugDNA.39857.1.S1_at
hypothetical protein LOC703607
LOC703607
3.52
0.0070


MmuSTS.3342.1.S1_at
SET and MYND domain containing 3
SMYD3
3.52
0.0919


MmugDNA.31877.1.S1_at
calreticulin 3
LOC719532
3.52
0.0899


MmugDNA.13028.1.S1_at
periaxin
LOC707626
3.52
0.0013


MmugDNA.29176.1.S1_at
MEGF11 protein
LOC714198
3.51
0.0977


MmuSTS.4142.1.S1_at
—
—
3.51
0.0060


MmugDNA.17878.1.S1_at
CG5359-PA
LOC711098
3.51
0.0020


MmugDNA.41017.1.S1_at
—
—
3.50
0.0855


MmugDNA.12740.1.S1_at
—
—
3.49
0.0567


MmugDNA.2965.1.S1_at
butyrate-induced transcript 1
LOC709590
3.49
0.0306


MmuSTS.4796.1.S1_at
flavin containing monooxygenase 4
FMO4
3.49
0.0927


MmuSTS.4569.1.S1_at
MAD, mothers against decapentaplegic homolog 9
SMAD9
3.48
0.0297


MmuSTS.3579.1.S1_at
—
—
3.48
0.0321


MmugDNA.29168.1.S1_at
Collagen alpha-1(III) chain precursor
LOC719369
3.47
0.0245


MmugDNA.24379.1.S1_at
tissue factor pathway inhibitor
TFPI
3.47
0.0251


MmugDNA.6495.1.S1_at
hypothetical protein LOC701956
LOC701956
3.47
0.0063


MmugDNA.31684.1.S1_at
Protein C6orf78 homolog
LOC714815
3.47
0.0341


MmugDNA.8650.1.S1_at
solute carrier family 6, member 17
LOC701162
3.47
0.0032


MmuSTS.2222.1.S1_at
synaptic vesicle protein 2B homolog
LOC710980
3.46
0.0052


MmuSTS.2708.1.S1_at
ADAM metallopeptidase domain 10
ADAM10
3.46
0.0615


MmugDNA.4023.1.S1_at
—
—
3.46
0.0005


MmugDNA.3743.1.S1_at
transmembrane and coiled-coil domains 3
LOC716185
3.46
0.0184


MmuSTS.3521.1.S1_at
arginyltransferase 1
ATE1
3.45
0.0116


MmugDNA.35799.1.S1_at
—
—
3.45
0.0060


MmugDNA.3417.1.S1_at
—
—
3.45
0.0480


MmugDNA.14546.1.S1_at
testis specific, 10 interacting protein
LOC715217
3.45
0.0517


MmugDNA.41404.1.S1_at
cytoplasmic polyadenylation element binding protein 3
LOC698133
3.45
0.0022


MmugDNA.40609.1.S1_at
—
—
3.45
0.0449


MmugDNA.15703.1.S1_at
putative homeodomain transcription factor 1
PHTF1
3.44
0.0091


MmugDNA.6582.1.S1_at
hypothetical protein LOC701911
LOC701911
3.44
0.0206


MmugDNA.28101.1.S1_at
ST3 beta-galactoside alpha-2,3-sialyltransferase 5
ST3GAL5
3.44
0.0116


MmugDNA.41240.1.S1_at
—
—
3.44
0.0124


MmugDNA.8735.1.S1_at
—
—
3.44
0.0204


MmugDNA.14126.1.S1_at
hypothetical protein LOC694536
LOC694536
3.44
0.0688


MmugDNA.31606.1.S1_at
—
—
3.43
0.0033


MmugDNA.34884.1.S1_at
CUB and zona pellucida-like domains 1
LOC706861
3.43
0.0890


MmugDNA.23074.1.S1_at
plexin A2
LOC713800
3.43
0.0004


MmuSTS.1012.1.S1_at
USP6 N-terminal like
USP6NL
3.43
0.0199


MmugDNA.40409.1.S1_at
Y55F3AM.9
LOC703159
3.42
0.0256


MmuSTS.3876.1.S1_at
solute carrier family 6 (amino acid transporter), member 14
SLC6A14
3.42
0.0305


MmugDNA.38177.1.S1_at
F-box only protein 21 isoform 2
LOC693647
3.41
0.0637


MmugDNA.35235.1.S1_at
hypothetical protein LOC710443
LOC710443
3.41
0.0899


MmugDNA.19514.1.S1_at
—
—
3.41
0.0487


MmugDNA.25771.1.S1_at
Protein C20orf22 homolog
LOC706758
3.41
0.0889


MmugDNA.3375.1.S1_at
ankyrin repeat domain 28
LOC696592
3.41
0.0355


MmunewRS.255.1.S1_at
—
—
3.41
0.0055


MmugDNA.38350.1.S1_s_at
Potassium channel, subfamily K, member 5
—
3.41
0.0273


MmugDNA.29156.1.S1_at
cyclin T2 isoform b
LOC708813
3.40
0.0315


MmugDNA.1804.1.S1_at
—
—
3.40
0.0046


MmugDNA.13727.1.S1_at
beta-site APP-cleaving enzyme 1
BACE1
3.40
0.0104


MmugDNA.36294.1.S1_at
dopa decarboxylase (aromatic L-amino acid decarboxylase)
DDC
3.40
0.0052


MmugDNA.18015.1.S1_at
HLA class II histocompatibility antigen, DM beta chain
LOC717870
3.40
0.0951



precursor (MHC class II antigen DMB)


MmugDNA.10946.1.S1_at
—
—
3.40
0.0129


MmugDNA.35307.1.S1_at
IQ motif containing G
LOC714807
3.39
0.0051


MmugDNA.40386.1.S1_at
hypothetical protein LOC718008
LOC718008
3.39
0.0568


MmuSTS.1442.1.S1_at
—
—
3.39
0.0810


MmugDNA.30491.1.S1_at
neurexin 3
LOC678699
3.39
0.0046


MmugDNA.40498.1.S1_at
—
—
3.38
0.0141


MmuSTS.3629.1.S1_at
EMI domain containing 1
LOC717414
3.38
0.0283


MmugDNA.42049.1.S1_at
synaptotagmin-like 5
LOC697915
3.38
0.0543


MmugDNA.33991.1.S1_at
ELOVL family member 6, elongation of long chain fatty
LOC698870
3.37
0.0453



acids (FEN1/Elo2, SUR4/Elo3-like, yeast)


MmugDNA.30419.1.S1_at
—
—
3.37
0.0108


MmugDNA.38819.1.S1_at
hypothetical protein LOC716712
LOC716712
3.37
0.0815


MmugDNA.11736.1.S1_at
—
—
3.37
0.0918


MmugDNA.8760.1.S1_at
—
—
3.37
0.0545


MmugDNA.21748.1.S1_at
FXYD domain containing ion transport regulator 4
LOC717636
3.37
0.0147


MmugDNA.40624.1.S1_at
—
—
3.37
0.0144


MmugDNA.34981.1.S1_at
CG17687-PA
LOC716031
3.36
0.0598


MmugDNA.21769.1.S1_at
transmembrane protein 141
LOC721687
3.36
0.0278


MmugDNA.12396.1.S1_at
zinc finger protein 621
LOC717189
3.36
0.0150


MmugDNA.35827.1.S1_s_at
glucosaminyl (N-acetyl) transferase 2, I-branching enzyme
LOC697468
3.35
0.0492



isoform B


MmugDNA.31910.1.S1_at
—
—
3.35
0.0987


MmugDNA.39573.1.S1_s_at
—
—
3.35
0.0001


MmugDNA.27074.1.S1_at
hypothetical protein LOC707868
LOC707868
3.35
0.0014


MmugDNA.4152.1.S1_at
esophageal cancer related gene 4 protein
LOC713611
3.34
0.0126


MmugDNA.28574.1.S1_at
zinc finger protein 483
ZNF483
3.34
0.0050


MmugDNA.14788.1.S1_at
CG14868-PA
LOC715968
3.34
0.0385


Mmu.2046.1.S1_at
Hypothetical protein LOC693623
—
3.34
0.0130


MmugDNA.38470.1.S1_at
hypothetical protein LOC704380
LOC704380
3.33
0.0041


MmugDNA.43475.1.S1_at
inositol polyphosphate-4-phosphatase, type 1
INPP4A
3.33
0.0395


MmugDNA.11863.1.S1_at
receptor expression enhancing protein 1
LOC697390
3.32
0.0807


MmugDNA.12356.1.S1_at
peroxin1
LOC702392
3.32
0.0067


MmugDNA.34502.1.S1_at
bactericidal/permeability-increasing protein-like 2
LOC717287
3.32
0.0813


MmugDNA.28096.1.S1_at
KIAA1799 protein
LOC696830
3.32
0.0034


MmugDNA.19117.1.S1_at
—
—
3.32
0.0948


MmugDNA.22544.1.S1_at
lysosomal-associated membrane protein 2
LAMP2
3.32
0.0120


MmugDNA.2026.1.S1_at
neuraminidase
NEU1
3.32
0.0176


MmuSTS.2482.1.S1_at
zinc finger protein 3 isoform 2
LOC719069
3.31
0.0772


MmugDNA.8202.1.S1_at
—
—
3.31
0.0236


MmugDNA.12374.1.S1_at
5-nucleotidase, cytosolic III isoform 1
LOC708743
3.31
0.0020


MmugDNA.18151.1.S1_at
—
—
3.31
0.0350


MmugDNA.40189.1.S1_at
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
HMGCR
3.31
0.0110


MmugDNA.43623.1.S1_s_at
disabled homolog 2
DAB2
3.31
0.0650


MmugDNA.22195.1.S1_at
prospero-related homeobox 1
LOC709465
3.31
0.0373


MmugDNA.12057.1.S1_at
hypothetical protein LOC708157
LOC708157
3.31
0.0963


MmugDNA.29604.1.S1_at
—
—
3.30
0.0482


MmugDNA.36778.1.S1_at
ADAMTS-like 3
LOC712844
3.30
0.0777


MmugDNA.43352.1.S1_at
chromobox homolog 2 isoform 1
LOC717462
3.30
0.0674


MmugDNA.41900.1.S1_at
nudix-type motif 10
LOC695921
3.30
0.0511


MmugDNA.5215.1.S1_at
—
—
3.30
0.0039


MmugDNA.3581.1.S1_at
—
—
3.29
0.0050


MmugDNA.42978.1.S1_at
—
—
3.29
0.0052


MmugDNA.11001.1.S1_at
transcription factor-like nuclear regulator
—
3.29
0.0396


MmugDNA.32117.1.S1_at
—
—
3.28
0.0977


MmugDNA.4792.1.S1_at
—
—
3.28
0.0123


MmugDNA.14682.1.S1_at
—
—
3.28
0.0017


MmuSTS.1437.1.S1_at
L-plastin
LCP1
3.27
0.0624


Mmu.1276.1.S1_at
serine protease inhibitor, Kunitz type, 2
LOC714755
3.27
0.0799


MmugDNA.29558.1.S1_at
leucine rich repeat containing 7
LOC702347
3.27
0.0047


MmugDNA.36803.1.S1_at
—
—
3.26
0.0986


MmugDNA.37994.1.S1_at
—
—
3.26
0.0694


MmugDNA.37151.1.S1_at
—
—
3.26
0.0730


MmuSTS.2193.1.S1_at
acid sphingomyelinase-like phosphodiesterase 3A
LOC713696
3.25
0.0359


MmugDNA.15609.1.S1_at
—
—
3.25
0.0134


MmugDNA.34021.1.S1_at
ARP3 actin-related protein 3 homolog
ACTR3
3.25
0.0910


MmugDNA.13552.1.S1_at
—
—
3.25
0.0538


MmugDNA.14095.1.S1_at
calpain 9
CAPN9
3.25
0.0723


MmugDNA.20778.1.S1_at
transcriptional regulator ATRX isoform 2
LOC705735
3.24
0.0808


MmuSTS.3264.1.S1_at
norrin
LOC702203
3.24
0.0996


MmugDNA.21014.1.S1_at
—
—
3.24
0.0033


MmugDNA.26007.1.S1_at
—
—
3.24
0.0467


Mmu.14792.1.S1_at
solute carrier family 40 (iron-regulated transporter), member 1
SLC40A1
3.24
0.0230


MmugDNA.14237.1.S1_at
Dynein heavy chain at 16F CG7092-PA
LOC694115
3.24
0.0962


MmuSTS.4208.1.S1_at
glucosaminyl (N-acetyl) transferase 3, mucin type
LOC702754
3.22
0.0016


MmugDNA.19093.1.S1_at
—
—
3.22
0.0397


MmugDNA.8868.1.S1_at
hypothetical protein LOC710705
LOC710705
3.21
0.0002


MmugDNA.16163.1.S1_at
—
—
3.21
0.0003


MmugDNA.30042.1.S1_at
CG1 protein (F18)
LOC703003
3.21
0.0622


MmugDNA.100.1.S1_at
—
—
3.20
0.0940


MmugDNA.10033.1.S1_at
poliovirus receptor
LOC714190
3.20
0.0577


MmugDNA.26257.1.S1_at
echinoderm microtubule associated protein like 1 isoform b
LOC705977
3.20
0.0866


MmugDNA.37272.1.S1_at
zinc finger protein 467
LOC712106
3.20
0.0577


MmugDNA.30904.1.S1_at
—
—
3.19
0.0072


MmuSTS.772.1.S1_at
cytosolic sialic acid 9-O-acetylesterase homolog
LOC711816
3.19
0.0375


MmugDNA.1780.1.S1_at
—
—
3.19
0.0140


MmuSTS.1855.1.S1_at
cadherin 2, type 1 preproprotein
LOC711526
3.19
0.0108


MmugDNA.36726.1.S1_at
NG22 protein
SLC44A4
3.18
0.0184


MmugDNA.28522.1.S1_at
—
—
3.18
0.0106


MmugDNA.40772.1.S1_at
—
—
3.18
0.0538


MmugDNA.40592.1.S1_at
reticulon 4 receptor-like 1
LOC720246
3.18
0.0448


MmugDNA.41621.1.S1_at
F54C1.5a
LOC702261
3.18
0.0527


MmugDNA.20138.1.S1_at
CXXC finger 6
LOC707759
3.17
0.0697


MmugDNA.30196.1.S1_at
—
—
3.17
0.0365


Mmu.16247.1.S1_at
EF hand domain family, member A1
LOC706065
3.17
0.0044


MmugDNA.24683.1.S1_at
—
—
3.17
0.0121


MmugDNA.21254.1.S1_at
hypothetical protein LOC695666
LOC695666
3.16
0.0344


MmugDNA.30331.1.S1_at
multiple C2-domains with two transmembrane regions 1
LOC697733
3.16
0.0017



isoform S


MmugDNA.14053.1.S1_at
—
—
3.16
0.0862


MmuSTS.72.1.S1_at
hephaestin isoform a
LOC709879
3.15
0.0624


Mmu.12852.1.S1_at
Nedd4 family interacting protein 1
LOC705716
3.15
0.0181


MmugDNA.21162.1.S1_at
1D-myo-inositol-trisphosphate 3-kinase B
LOC698185
3.15
0.0210


MmugDNA.2522.1.S1_at
gamma-aminobutyric acid (GABA) A receptor, beta 3
GABRB3
3.15
0.0383



isoform 2 precursor


MmugDNA.1070.1.S1_at
—
—
3.15
0.0660


MmugDNA.11921.1.S1_at
CG7071-PA, isoform A
LOC708298
3.15
0.0754


MmuSTS.2765.1.S1_at
class III alcohol dehydrogenase 5 chi subunit
ADH5
3.14
0.0011


MmugDNA.40331.1.S1_at
—
—
3.14
0.0007


MmugDNA.25139.1.S1_at
carboxypeptidase D precursor
LOC712407
3.14
0.0055


MmugDNA.12314.1.S1_at
—
—
3.14
0.0034


MmugDNA.32572.1.S1_at
Fibroblast growth factor 14 (FGF-14) (Fibroblast growth
FGF14
3.14
0.0082



factor homologous factor 4) (FHF-4)


MmugDNA.3590.1.S1_at
—
—
3.13
0.0150


MmugDNA.13879.1.S1_at
mannosidase, alpha, class 2A, member 1
LOC705480
3.13
0.0429


MmugDNA.3209.1.S1_at
microfibrillar-associated protein 3-like
MFAP3L
3.12
0.0120


MmugDNA.7233.1.S1_at
—
—
3.12
0.0851


MmugDNA.15955.1.S1_at
TAO kinase 2
TAOK2
3.12
0.0021


MmugDNA.38589.1.S1_at
lethal (2) k00619 CG4775-PA
LOC715015
3.12
0.0309


MmugDNA.546.1.S1_at
alpha glucosidase II alpha subunit isoform 2
LOC718672
3.12
0.0262


MmugDNA.41951.1.S1_at
LPS-responsive vesicle trafficking, beach and anchor
LOC693823
3.12
0.0005



containing


MmugDNA.1873.1.S1_at
—
—
3.11
0.0183


MmugDNA.18551.1.S1_at
inositol polyphosphate-5-phosphatase, 75 kDa
INPP5B
3.11
0.0058


MmugDNA.15348.1.S1_at
ERO1-like
ERO1L
3.10
0.0079


MmugDNA.20795.1.S1_at
slit homolog 1
LOC697716
3.10
0.0012


MmugDNA.28842.1.S1_at
CKLF-like MARVEL transmembrane domain containing 7
LOC704329
3.10
0.0648



isoform b


MmugDNA.10278.1.S1_at
slit and trk like 3 protein
LOC700660
3.10
0.0457


MmugDNA.41181.1.S1_at
—
—
3.09
0.0747


MmugDNA.42278.1.S1_s_at
—
—
3.09
0.0003


Mmu.12401.1.S1_at
SECIS binding protein 2
LOC697442
3.09
0.0551


MmugDNA.7049.1.S1_at
—
—
3.09
0.0652


MmugDNA.11735.1.S1_at
—
—
3.08
0.0835


MmugDNA.42396.1.S1_at
germ cell-less
LOC701545
3.08
0.0538


MmugDNA.26488.1.S1_at
—
—
3.08
0.0363


MmugDNA.2284.1.S1_at
notch 2 preproprotein
LOC713798
3.08
0.0619


MmugDNA.28250.1.S1_at
—
—
3.08
0.0459


MmugDNA.17056.1.S1_s_at
reticulon 4 receptor precursor
LOC694382
3.08
0.0373


MmunewRS.972.1.S1_at
glutamate decarboxylase-like 1
LOC706457
3.08
0.0098


MmugDNA.11045.1.S1_s_at
microtubule-associated protein 7
LOC705355
3.07
0.0015


MmuSTS.1473.1.S1_at
mitogen-activated protein kinase 9 isoform 1
LOC699736
3.07
0.0243


MmugDNA.31498.1.S1_at
—
—
3.07
0.0225


MmuSTS.4269.1.S1_at
glutamate receptor, metabotropic 8
GRM8
3.07
0.0386


MmugDNA.18449.1.S1_s_at
zinc finger, ZZ type with EF hand domain 1
—
3.06
0.0534


MmugDNA.11192.1.S1_at
CG8312-PA, isoform A
LOC705659
3.06
0.0538


MmugDNA.1116.1.S1_at
—
—
3.06
0.0407


MmugDNA.30277.1.S1_at
—
—
3.06
0.0039


MmugDNA.14729.1.S1_at
CD82 antigen isoform 2
CD82
3.06
0.0323


MmugDNA.27419.1.S1_at
actin-related protein 3-beta isoform 1
LOC715965
3.06
0.0384


MmuSTS.3981.1.S1_at
SH3-domain GRB2-like 2
SH3GL2
3.05
0.0871


MmugDNA.37217.1.S1_at
—
—
3.05
0.0935


MmugDNA.15075.1.S1_at
hypothetical protein LOC716982
LOC716982
3.05
0.0080


MmugDNA.16118.1.S1_at
hect domain and RLD 3
HERC3
3.05
0.0004


MmunewRS.326.1.S1_at
hypothetical protein LOC717316
LOC717316
3.05
0.0589


MmugDNA.9126.1.S1_at
lin-7 homolog C
LIN7C
3.05
0.0998


MmugDNA.10794.1.S1_at
—
—
3.04
0.0857


MmugDNA.32230.1.S1_at
nucleolar protein 1, 120 kDa
—
3.04
0.0954


MmugDNA.37502.1.S1_at
—
—
3.04
0.0417


MmugDNA.17117.1.S1_at
hypothetical protein LOC700172
LOC700172
3.04
0.0173


MmugDNA.9078.1.S1_at
zinc finger protein 141 (clone pHZ-44)
ZNF141
3.03
0.0537


MmugDNA.9853.1.S1_at
arachidonate 5-lipoxygenase
ALOX5
3.03
0.0808


MmugDNA.22211.1.S1_at
PET112-like
LOC694983
3.03
0.0437


MmugDNA.26554.1.S1_at
UDP glycosyltransferase 3 family, polypeptide A1
LOC700115
3.03
0.0736


MmugDNA.3964.1.S1_at
chromosome 2 open reading frame 30
LOC716460
3.03
0.0238


MmugDNA.36028.1.S1_at
—
—
3.03
0.0039


MmugDNA.19859.1.S1_at
hypothetical protein LOC700866
LOC700866
3.03
0.0654


MmugDNA.15510.1.S1_s_at
beta-amyloid binding protein precursor
LOC694282
3.02
0.0002


MmugDNA.16151.1.S1_at
zinc finger protein 567
LOC713173
3.02
0.0327


MmugDNA.43512.1.S1_at
Transcribed locus
—
3.02
0.0112


MmuSTS.1643.1.S1_at
transient receptor potential cation channel, subfamily M,
LOC705070
3.02
0.0082



member 5


MmugDNA.24619.1.S1_at
WD repeat domain 56
LOC705146
3.01
0.0331


MmuSTS.3607.1.S1_at
cadherin 11, type 2 preproprotein
LOC708826
3.01
0.0107


MmugDNA.29541.1.S1_at
—
—
3.00
0.0050


MmugDNA.36083.1.S1_s_at
—
—
3.00
0.0042


MmugDNA.15113.1.S1_at
endoplasmic reticulum oxidoreductin 1-Lbeta
LOC710912
3.00
0.0927


MmuSTS.2617.1.S1_at
—
—
3.00
0.0676


Mmu.380.1.S1_at
tetratricopeptide repeat domain 27
LOC707021
3.00
0.0738


MmuSTS.898.1.S1_at
engulfment and cell motility 1 isoform 1 /// hypothetical
LOC705818 ///
3.00
0.0255



protein LOC713462
LOC713462


MmugDNA.21372.1.S1_at
formin binding protein 3
PRPF40A
3.00
0.0062


MmugDNA.6394.1.S1_at
microtubule-associated protein tau
MAPT
3.00
0.0052


MmugDNA.10807.1.S1_at
HESB like domain containing 1
—
2.99
0.0965


MmugDNA.34681.1.S1_at
sortilin-related receptor containing LDLR class A repeats
LOC713011
2.99
0.0129



preproprotein


MmugDNA.6380.1.S1_at
ankylosis, progressive homolog
LOC717689
2.99
0.0159


MmugDNA.4142.1.S1_at
RAB3B, member RAS oncogene family
LOC712683
2.99
0.0030


MmugDNA.20373.1.S1_at
galactosylceramidase
GALC
2.98
0.0973


MmugDNA.29366.1.S1_at
Transitional endoplasmic reticulum ATPase (TER ATPase)
LOC698707
2.98
0.0020



(15S Mg(2+)-ATPase p97 subunit) (Valosin-containing



protein) (VCP)


MmugDNA.33876.1.S1_s_at
olfactomedin 2
LOC711336
2.98
0.0088


MmugDNA.7330.1.S1_at
mannosidase, alpha, class 1C, member 1
MAN1C1
2.98
0.0027


MmuSTS.2879.1.S1_at
transforming growth factor, beta receptor III (betaglycan,
LOC705053
2.98
0.0240



300 kDa)


MmugDNA.39004.1.S1_at
sweet taste receptor T1r isoform b
LOC720987
2.98
0.0973


MmugDNA.32903.1.S1_at
Protein C9orf116 (Pierce 1)
LOC720855
2.97
0.0828


MmugDNA.23567.1.S1_at
HMT1 hnRNP methyltransferase-like 6
PRMT6
2.97
0.0334


MmugDNA.24770.1.S1_at
hypothetical protein LOC696555
LOC696555
2.97
0.0271


MmugDNA.39298.1.S1_at
EGF-like-domain, multiple 5
MEGF9
2.97
0.0006


MmugDNA.39357.1.S1_at
—
—
2.97
0.0237


MmugDNA.6683.1.S1_at
—
—
2.96
0.0069


MmugDNA.17131.1.S1_at
—
—
2.96
0.0290


MmuSTS.2496.1.S1_at
zinc finger protein 618
LOC708866
2.95
0.0450


MmugDNA.17574.1.S1_at
polycystic kidney disease 2-like 1
PKD2L1
2.95
0.0062


MmuSTS.4419.1.S1_at
FXYD domain-containing ion transport regulator 6
LOC698456
2.95
0.0109


MmuSTS.546.1.S1_at
membrane associated guanylate kinase, WW and PDZ
LOC698092
2.95
0.0917



domain containing 1 isoform a


MmugDNA.5553.1.S1_at
hypothetical protein LOC695259
LOC695259
2.95
0.0337


MmugDNA.1170.1.S1_at
—
—
2.94
0.0216


MmugDNA.39293.1.S1_at
—
—
2.94
0.0220


MmugDNA.36751.1.S1_at
—
—
2.94
0.0034


MmugDNA.2580.1.S1_at
adaptor-related protein complex 3, beta 1 subunit
AP3B1
2.94
0.0353


MmugDNA.42089.1.S1_at
ectonucleoside triphosphate diphosphohydrolase 3
ENTPD3
2.94
0.0140


MmugDNA.5339.1.S1_at
transportin 1
LOC707195
2.94
0.0080


MmugDNA.37020.1.S1_at
dedicator of cytokinesis 1
DOCK1
2.94
0.0400


MmuSTS.2157.1.S1_at
Scm-like with four mbt domains 1
LOC694961
2.93
0.0548


MmuSTS.2057.1.S1_at
phosphoinositide-specific phospholipase C beta 1 isoform a
LOC718387
2.93
0.0630


MmugDNA.32391.1.S1_at
hepatocellular carcinoma-associated antigen 112
LOC713786
2.93
0.0012


MmugDNA.15308.1.S1_s_at
—
—
2.93
0.0128


MmuSTS.1570.1.S1_at
neurobeachin
NBEA
2.93
0.0050


MmugDNA.22319.1.S1_at
histidine triad nucleotide binding protein 3
LOC712779
2.93
0.0091


MmugDNA.32797.1.S1_at
CTAGE family, member 5 isoform 1
LOC699511
2.93
0.0027


MmugDNA.9436.1.S1_at
—
—
2.92
0.0507


MmugDNA.28664.1.S1_at
guanine nucleotide binding protein, alpha stimulating activity
LOC694289
2.92
0.0333



polypeptide 1 isoform c


MmugDNA.21110.1.S1_at
zinc finger protein 398 isoform 1
LOC710358
2.92
0.0141


MmugDNA.5715.1.S1_at
tissue inhibitor of matrix metalloproteinase-1
TIMP-1
2.92
0.0113


MmugDNA.13442.1.S1_at
ATPase, aminophospholipid transporter (APLT), class I,
LOC702630
2.92
0.0030



type 8A, member 1


Mmu.3604.1.S1_s_at
synaptotagmin binding, cytoplasmic RNA interacting protein
LOC700732
2.92
0.0255


MmugDNA.35867.1.S1_at
fibronectin leucine rich transmembrane protein 3
FLRT3
2.92
0.0081


MmugDNA.27436.1.S1_at
—
—
2.92
0.0200


MmugDNA.9183.1.S1_at
Protein NipSnap3B (SNAP1)
NIPSNAP3B
2.91
0.0192


MmugDNA.39239.1.S1_at
TMEM9 domain family, member B /// hypothetical protein
LOC694700 ///
2.91
0.0009



LOC719509
LOC708447 ///




LOC719509


MmugDNA.9888.1.S1_at
Tetratricopeptide repeat protein 9 (TPR repeat protein 9)
LOC693495
2.91
0.0121


MmugDNA.29679.1.S1_at
—
—
2.91
0.0380


MmugDNA.36914.1.S1_at
—
—
2.90
0.0254


MmugDNA.38533.1.S1_at
—
—
2.90
0.0802


MmugDNA.6837.1.S1_at
sorting nexin 13
SNX13
2.89
0.0060


MmugDNA.3572.1.S1_at
—
—
2.89
0.0038


MmugDNA.27179.1.S1_at
synapse-associated protein 102
LOC697179
2.89
0.0797


MmugDNA.37780.1.S1_at
—
—
2.89
0.0748


MmugDNA.31668.1.S1_at
—
—
2.89
0.0279


MmuSTS.4659.1.S1_at
tumor necrosis factor, alpha-induced protein 3
TNFAIP3
2.89
0.0946


MmugDNA.25426.1.S1_at
—
—
2.89
0.0361


MmugDNA.24776.1.S1_at
protein phosphatase 1, regulatory subunit 7
LOC700574
2.89
0.0728


MmugDNA.5386.1.S1_at
zinc finger protein 354B
LOC712885
2.89
0.0369


MmugDNA.21944.1.S1_s_at
holocytochrome c synthase (cytochrome c heme-lyase)
HCCS
2.89
0.0331


MmugDNA.2867.1.S1_at
—
—
2.88
0.0624


MmugDNA.21421.1.S1_at
RAB3A interacting protein isoform alpha 2
LOC717215
2.88
0.0107


MmugDNA.3747.1.S1_at
Transmembrane protein 51
LOC693771
2.88
0.0127


MmugDNA.26393.1.S1_at
MOCO sulphurase C-terminal domain containing 2
LOC705543
2.88
0.0080


MmugDNA.22547.1.S1_at
transcriptional adaptor 2-like
TADA2L
2.87
0.0311


MmugDNA.7154.1.S1_at
kelch repeat and BTB (POZ) domain containing 2
KBTBD2
2.87
0.0286


MmugDNA.14782.1.S1_at
CG15120-PA
LOC715522
2.87
0.0118


MmuSTS.3706.1.S1_at
presenilin 2
PSEN2
2.87
0.0715


MmugDNA.15936.1.S1_s_at
—
—
2.87
0.0067


MmugDNA.39373.1.S1_at
putative aminopeptidase Fxna
LOC717415
2.87
0.0888


MmugDNA.34782.1.S1_at
Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8)
—
2.87
0.0613



(Keratin-8) (K8)


MmugDNA.8649.1.S1_at
p300/CBP-associated factor
LOC698283
2.87
0.0028


MmugDNA.29427.1.S1_at
hypothetical protein LOC702110
LOC702110
2.86
0.0045


MmugDNA.26314.1.S1_at
basigin isoform 1
LOC721068
2.86
0.0328


MmugDNA.2721.1.S1_s_at
—
—
2.86
0.0111


MmugDNA.27358.1.S1_at
—
—
2.86
0.0056


MmugDNA.15702.1.S1_at
—
—
2.86
0.0184


MmugDNA.43128.1.S1_at
choline kinase alpha isoform a
LOC710564
2.86
0.0726


MmuSTS.3669.1.S1_at
eyes absent 1 isoform b
LOC694364
2.86
0.0024


MmugDNA.31695.1.S1_at
Alpha-parvin (Calponin-like integrin-linked kinase-binding
LOC703481
2.85
0.0278



protein) (CH-ILKBP)


MmugDNA.6693.1.S1_at
CG3304-PA, isoform A
LOC708497
2.85
0.0432


Mmu.3814.1.S1_at
MGC15407-like
LOC677698
2.85
0.0073


MmugDNA.8146.1.S1_at
ELOVL family member 7, elongation of long chain fatty
LOC709866
2.85
0.0008



acids


MmugDNA.17821.1.S1_at
Protein KIAA1434
LOC719117
2.85
0.0623


MmugDNA.34061.1.S1_s_at
glycosyltransferase 28 domain containing 1
LOC706863
2.85
0.0030


MmugDNA.43525.1.S1_at
—
—
2.85
0.0870


MmugDNA.11817.1.S1_at
—
—
2.84
0.0015


MmugDNA.10536.1.S1_at
—
—
2.84
0.0255


MmugDNA.20224.1.S1_at
cullin 4B
CUL4B
2.84
0.0531


MmugDNA.21065.1.S1_at
—
—
2.84
0.0726


MmugDNA.11873.1.S1_s_at
NEDD4 family-interacting protein 2 (NEDD4 WW domain-
NDFIP2
2.84
0.0019



binding protein 5A) (Putative MAPK-activating protein



PM04/PM05/PM06/PM07) (Putative NF-kappa-B-activating



protein 413)


MmugDNA.30250.1.S1_at
multiple coiled-coil GABABR1-binding protein
LOC722750
2.84
0.0046


MmugDNA.3547.1.S1_at
nuclear receptor binding factor 2
LOC697756
2.84
0.0023


MmugDNA.39661.1.S1_at
heparan sulfate 2-O-sulfotransferase 1
HS2ST1
2.84
0.0407


MmugDNA.23891.1.S1_at
Derlin-3 (Degradation in endoplasmic reticulum protein 3)
DERL3
2.84
0.0321



(Der1-like protein 3) (DERtrin-3)


MmugDNA.35787.1.S1_at
—
—
2.83
0.0922


MmugDNA.15859.1.S1_at
hypothetical protein LOC709702
LOC709702
2.83
0.0784


MmugDNA.906.1.S1_at
tRNA nucleotidyl transferase, CCA-adding, 1
TRNT1
2.83
0.0724


MmugDNA.39895.1.S1_at
—
—
2.83
0.0492


MmugDNA.12342.1.S1_at
—
—
2.83
0.0679


MmugDNA.41431.1.S1_at
—
—
2.83
0.0252


MmugDNA.24761.1.S1_at
—
—
2.82
0.0013


MmugDNA.8211.1.S1_at
—
—
2.82
0.0781


MmugDNA.40614.1.S1_at
—
—
2.82
0.0136


MmugDNA.9573.1.S1_at
—
—
2.82
0.0541


MmugDNA.36144.1.S1_at
G-protein coupled receptor 113
LOC696215
2.82
0.0137


MmugDNA.5429.1.S1_at
RNA pseudouridylate synthase domain containing 4
LOC714162
2.82
0.0238


MmugDNA.390.1.S1_at
—
—
2.82
0.0224


MmuSTS.1860.1.S1_at
Homeobox protein CDX-1 (Caudal-type homeobox protein
CDX1
2.82
0.0302



1)


MmugDNA.15649.1.S1_at
—
—
2.81
0.0524


MmugDNA.41609.1.S1_at
golgi apparatus protein 1
LOC710037
2.81
0.0682


MmugDNA.39981.1.S1_at
microtubule associated monoxygenase, calponin and LIM
MICAL2
2.81
0.0354



domain containing 2


MmugDNA.41888.1.S1_at
UDP glycosyltransferase 8 (UDP-galactose ceramide
UGT8
2.81
0.0002



galactosyltransferase)


Mmu.1028.1.S1_at
Tetraspanin-8 (Tspan-8) (Transmembrane 4 superfamily
TSPAN8
2.80
0.0037



member 3) (Tumor-associated antigen CO-029)


MmugDNA.40411.1.S1_at
—
—
2.80
0.0431


MmugDNA.6270.1.S1_at
—
—
2.80
0.0207


MmugDNA.3465.1.S1_at
—
—
2.80
0.0758


MmugDNA.28869.1.S1_s_at
follicular lymphoma variant translocation 1
LOC700476
2.80
0.0299


MmugDNA.17877.1.S1_at
—
—
2.80
0.0198


MmugDNA.43133.1.S1_at
Nucleoside diphosphate kinase homolog 5 (NDK-H 5) (NDP
LOC713837
2.80
0.0119



kinase homolog 5) (nm23-H5) (Testis-specific nm23



homolog) (Inhibitor of p53-induced apoptosis-beta) (IPIA-



beta)


MmugDNA.38316.1.S1_at
family with sequence similarity 20, member A
LOC718937
2.80
0.0064


MmugDNA.28033.1.S1_at
SID1 transmembrane family, member 1
SIDT1
2.80
0.0014


MmugDNA.29959.1.S1_at
transducin-like enhancer protein 4
TLE4
2.80
0.0125


MmugDNA.11210.1.S1_s_at
protocadherin gamma subfamily A, 12 isoform 2 precursor
LOC702071
2.79
0.0187


MmuSTS.1312.1.S1_at
DnaJ (Hsp40) homolog, subfamily C, member 6
LOC698682
2.79
0.0716


MmugDNA.19131.1.S1_at
BTB (POZ) domain containing 4
BTBD4
2.79
0.0448


MmugDNA.26541.1.S1_at
fibronectin type III domain containing 4
LOC702098
2.79
0.0462


MmugDNA.11140.1.S1_at
notch homolog 5
LOC694004
2.79
0.0549


MmugDNA.20304.1.S1_at
modulator of apoptosis 1
LOC707922 ///
2.79
0.0003




LOC708231


MmugDNA.8309.1.S1_at
—
—
2.79
0.0744


MmugDNA.35571.1.S1_at
transposon-derived Buster3 transposase-like
LOC695905
2.79
0.0239


MmuSTS.3190.1.S1_at
—
—
2.78
0.0062


MmugDNA.31552.1.S1_at
CG18769-PB, isoform B
LOC698670
2.78
0.0044


MmugDNA.11968.1.S1_at
—
—
2.78
0.0831


MmugDNA.31850.1.S1_at
START domain containing 4, sterol regulated
LOC706654
2.78
0.0281


MmugDNA.26580.1.S1_at
TGF beta receptor associated protein -1
LOC713102
2.78
0.0062


MmugDNA.39053.1.S1_at
—
—
2.78
0.0250


MmugDNA.13898.1.S1_at
—
—
2.78
0.0892


Mmu.15592.2.S1_at
phosphatidylinositol glycan, class F isoform 1
LOC714844
2.78
0.0019


MmugDNA.29438.1.S1_at
—
—
2.78
0.0522


MmugDNA.13438.1.S1_at
CG11670-PA
LOC701685
2.77
0.0273


MmugDNA.33828.1.S1_at
hypothetical protein LOC693883
LOC693883
2.77
0.0613


MmugDNA.12035.1.S1_at
—
—
2.77
0.0187


MmugDNA.28591.1.S1_s_at
taspase 1
TASP1
2.77
0.0529


MmugDNA.29219.1.S1_at
—
—
2.77
0.0025


MmugDNA.17221.1.S1_at
hypothetical protein LOC719100
LOC719100
2.77
0.0461


Mmu.2523.1.S1_at
legumain
LGMN
2.76
0.0855


MmugDNA.14436.1.S1_at
—
—
2.76
0.0851


MmugDNA.12446.1.S1_at
—
—
2.76
0.0162


MmugDNA.24601.1.S1_at
—
—
2.76
0.0027


MmugDNA.7915.1.S1_at
—
—
2.76
0.0117


MmugDNA.35603.1.S1_at
Sortilin precursor (Neurotensin receptor 3) (NTR3) (NT3)
SORT1
2.75
0.0309



(Glycoprotein 95) (Gp95) (100 kDa NT receptor)


MmugDNA.36573.1.S1_at
CTCL tumor antigen se57-1
LOC694841
2.75
0.0207


MmuSTS.2972.1.S1_at
lipase A precursor
LOC695240
2.75
0.0071


MmuSTS.3122.1.S1_at
myosin VIIA and Rab interacting protein
LOC717173
2.74
0.0042


MmugDNA.26602.1.S1_at
nuclear factor of activated T-cells, cytosolic component 1
LOC698089
2.74
0.0049



isoform C


MmuSTS.1119.1.S1_at
secreted modular calcium-binding protein 2
LOC703155
2.74
0.0582


MmugDNA.38654.1.S1_at
—
—
2.74
0.0116


MmugDNA.24367.1.S1_at
islet cell autoantigen 1
LOC695889
2.74
0.0417


MmugDNA.7470.1.S1_at
—
—
2.74
0.0823


MmugDNA.21317.1.S1_at
spermatid perinuclear RNA-binding protein
LOC695402
2.74
0.0240


MmugDNA.36894.1.S1_at
dehydrogenase/reductase (SDR family) member 7
DHRS7
2.74
0.0004


MmuSTS.3892.1.S1_at
sphingomyelin phosphodiesterase 1, acid lysosomal
SMPD1
2.73
0.0291


MmuSTS.3004.1.S1_at
mutS homolog 3
MSH3
2.73
0.0912


MmugDNA.18199.1.S1_at
unc-13 homolog D
LOC704431
2.73
0.0133


MmugDNA.32264.1.S1_at
G protein-coupled receptor 126 alpha 2
LOC706017
2.73
0.0429


MmuSTS.2507.1.S1_at
GTP binding protein 1
GTPBP1
2.73
0.0496


MmugDNA.22747.1.S1_at
tripartite motif-containing 2
LOC696517
2.73
0.0162


MmuSTS.1188.1.S1_at
phospholipid scramblase 1
LOC713232
2.73
0.0006


MmugDNA.2003.1.S1_at
—
—
2.73
0.0904


MmugDNA.6213.1.S1_at
—
—
2.73
0.0031


MmugDNA.27564.1.S1_at
Guanine nucleotide-binding protein G(t), alpha-3 subunit
LOC708828
2.73
0.0162



(Gustducin alpha-3 chain)


MmugDNA.33552.1.S1_at
—
—
2.73
0.0364


MmuSTS.2414.1.S1_at
Guanine nucleotide-binding protein alpha-12 subunit (G
LOC699857
2.72
0.0319



alpha-12)


MmugDNA.37242.1.S1_at
serine/threonine kinase 32A
LOC708524
2.72
0.0499


MmuSTS.2307.1.S1_at
beta isoform of regulatory subunit B55, protein phosphatase 2
PPP2R2B
2.72
0.0797


MmugDNA.35445.1.S1_at
PHD finger protein 7 isoform 1
LOC697103
2.72
0.0380


MmugDNA.31310.1.S1_at
CG13902-PA
LOC699197
2.72
0.0796


Mmu.13628.1.S1_x_at
FGFR1 oncogene partner 2
LOC708905
2.72
0.0287


MmugDNA.34470.1.S1_s_at
hypothetical protein LOC708552
LOC708552
2.71
0.0083


MmugDNA.27420.1.S1_at
—
—
2.71
0.0567


MmugDNA.15282.1.S1_at
hypothetical protein LOC711477
LOC711477
2.71
0.0018


MmugDNA.12849.1.S1_at
Eukaryotic translation initiation factor 6 (eIF-6) (B4 integrin
ITGB4BP
2.71
0.0280



interactor) (CAB) (p27(BBP)) (B(2)GCN homolog)


MmugDNA.14244.1.S1_at
—
—
2.71
0.0049


MmugDNA.25223.1.S1_at
CG31803-PA
LOC701263
2.71
0.0197


MmugDNA.22504.1.S1_at
—
—
2.71
0.0906


MmuSTS.3220.1.S1_at
v-myb myeloblastosis viral oncogene homolog (avian)-like 1
MYBL1
2.71
0.0824


MmugDNA.13093.1.S1_at
hypothetical protein LOC708259
LOC708259
2.71
0.0701


MmugDNA.13057.1.S1_at
protease, serine, 36
LOC714626
2.70
0.0599


MmugDNA.9375.1.S1_at
—
—
2.70
0.0479


MmuSTS.1294.1.S1_at
RAP1, GTPase activating protein 1
RAP1GAP
2.70
0.0278


MmugDNA.11685.1.S1_at
poly (ADP-ribose) polymerase family, member 8
LOC702637
2.70
0.0995


Mmu.14396.1.S1_at
Glutathione S-transferase A1 (GTH1) (HA subunit 1) (GST-
—
2.70
0.0140



epsilon) (GSTA1-1) (GST class-alpha)


MmugDNA.20427.1.S1_at
inosine monophosphate dehydrogenase 1 isoform b
LOC701039
2.70
0.0686


MmugDNA.26008.1.S1_at
—
—
2.70
0.0015


MmugDNA.24890.1.S1_at
CG4341-PA
LOC698022
2.70
0.0249


MmuSTS.1767.1.S1_at
N-myc downstream regulated gene 3
LOC702452
2.70
0.0887


MmugDNA.28653.1.S1_at
—
—
2.70
0.0331


MmugDNA.11814.1.S1_at
zinc finger protein 322A
LOC701098
2.70
0.0466


MmugDNA.25299.1.S1_at
Small nuclear ribonucleoprotein Sm D1 (snRNP core protein
LOC698965
2.70
0.0816



D1) (Sm-D1) (Sm-D autoantigen)


MmugDNA.41883.1.S1_at
—
—
2.70
0.0762


MmugDNA.31230.1.S1_at
Fibronectin type-III domain-containing protein 3a
LOC705570
2.69
0.0370


MmugDNA.42805.1.S1_at
Kinesin-like protein KIF2
LOC696561
2.69
0.0624


MmugDNA.26243.1.S1_at
—
—
2.69
0.0404


MmugDNA.27058.1.S1_at
phosphoribosyl pyrophosphate amidotransferase proprotein
LOC694868
2.69
0.0094


MmugDNA.41943.1.S1_at
—
—
2.69
0.0346


MmugDNA.9762.1.S1_at
—
—
2.69
0.0721


MmugDNA.22290.1.S1_at
brefeldin A-inhibited guanine nucleotide-exchange protein 1
LOC704359
2.69
0.0717


MmugDNA.41355.1.S1_at
—
—
2.68
0.0676


MmugDNA.37885.1.S1_at
homer 1
HOMER1
2.68
0.0925


MmugDNA.38723.1.S1_at
a disintegrin and metalloprotease domain 28 isoform 1
LOC710953
2.68
0.0741


MmugDNA.12874.1.S1_at
—
—
2.68
0.0745


MmugDNA.38436.1.S1_at
hypothetical protein LOC695519
LOC695519
2.68
0.0060


MmugDNA.23725.1.S1_at
stress 70 protein chaperone, microsome-associated, 60 kDa
STCH
2.67
0.0479


MmugDNA.18237.1.S1_at
peroxisomal short-chain alcohol dehydrogenase
—
2.67
0.0492


Mmu.7752.1.S1_at
hypothetical protein LOC704532
LOC704532
2.67
0.0265


Mmu.7453.1.S1_at
rabaptin, RAB GTPase binding effector protein 1
LOC711646
2.67
0.0190


MmugDNA.13154.1.S1_at
—
—
2.67
0.0955


MmugDNA.12949.1.S1_at
—
—
2.67
0.0394


MmuSTS.2807.1.S1_at
solute carrier family 38, member 1
LOC702135
2.67
0.0217


MmugDNA.28465.1.S1_at
Transgelin-3 (Neuronal protein NP25) (Neuronal protein 22)
TAGLN3
2.67
0.0651



(NP22)


MmugDNA.29560.1.S1_at
hypothetical protein LOC710681
LOC710681
2.67
0.0154


MmugDNA.16975.1.S1_at
—
—
2.67
0.0968


MmugDNA.30208.1.S1_at
—
—
2.66
0.0462


MmugDNA.33379.1.S1_at
—
—
2.66
0.0063


MmugDNA.29425.1.S1_at
B0507.2
LOC704194
2.66
0.0105


MmugDNA.28288.1.S1_at
Dual specificity protein phosphatase 3 (Dual specificity
DUSP3
2.66
0.0224



protein phosphatase VHR)


MmugDNA.15303.1.S1_s_at
ninein isoform 5
LOC709532
2.65
0.0437


MmugDNA.29050.1.S1_at
—
—
2.65
0.0291


MmunewRS.265.1.S1_at
kin of IRRE like 3
LOC714534
2.65
0.0267


MmugDNA.24675.1.S1_at
—
—
2.65
0.0414


MmugDNA.8597.1.S1_at
—
—
2.65
0.0379


MmugDNA.10005.1.S1_at
pre-B-cell leukemia transcription factor interacting protein 1
LOC717036
2.65
0.0501


MmugDNA.951.1.S1_at
—
—
2.65
0.0297


MmugDNA.35108.1.S1_at
secretory carrier membrane protein 5
LOC710454
2.64
0.0103


MmugDNA.13757.1.S1_at
Placenta-specific gene 8 protein (C15 protein)
PLAC8
2.64
0.0186


MmugDNA.30027.1.S1_at
hypothetical protein LOC695033
LOC695033
2.64
0.0128


MmugDNA.7760.1.S1_at
—
—
2.64
0.0072


MmugDNA.21589.1.S1_at
protocadherin beta 4
PCDHB4
2.64
0.0703


Mmu.9306.1.S1_at
growth factor receptor-bound protein 2 isoform 2
LOC702041
2.63
0.0360


MmugDNA.11105.1.S1_at
centaurin, gamma 2 isoform 2
LOC693652
2.63
0.0244


MmugDNA.26258.1.S1_at
—
—
2.63
0.0637


Mmu.14771.1.S1_at
calcipressin 1 isoform c
LOC697108
2.63
0.0245


MmugDNA.30706.1.S1_at
—
—
2.63
0.0016


MmugDNA.37595.1.S1_s_at
mortality factor 4 like 1 isoform b
LOC711357
2.63
0.0734


MmugDNA.42160.1.S1_at
—
—
2.63
0.0710


MmugDNA.34056.1.S1_at
RAP1 interacting factor 1
LOC694817
2.63
0.0344


MmugDNA.40644.1.S1_at
solute carrier family 41 member 1
LOC696944
2.62
0.0135


MmugDNA.43211.1.S1_at
IBR domain containing 1
LOC716647
2.62
0.0077


MmugDNA.32694.1.S1_at
tumor necrosis factor, alpha-induced protein 8
LOC700778
2.62
0.0399


MmugDNA.22014.1.S1_at
golgi autoantigen, golgin subfamily a, 7
LOC709911
2.62
0.0044


MmugDNA.32609.1.S1_at
—
—
2.61
0.0756


MmugDNA.28006.1.S1_at
minichromosome maintenance protein domain containing 1
LOC714711
2.61
0.0293


MmugDNA.21156.1.S1_at
—
—
2.61
0.0666


MmuSTS.2808.1.S1_s_at
chromobox homolog 3
—
2.61
0.0714


MmugDNA.14756.1.S1_at
hypothetical protein LOC694136
LOC694136
2.61
0.0658


MmuSTS.4364.1.S1_at
sterol O-acyltransferase (acyl-Coenzyme A: cholesterol
SOAT1
2.61
0.0632



acyltransferase) 1


MmugDNA.34121.1.S1_at
pappalysin 2
PAPPA2
2.60
0.0655


MmugDNA.3334.1.S1_at
sidekick homolog 1
LOC719431
2.60
0.0565


MmugDNA.14892.1.S1_at
iduronate-2-sulfatase
IDS
2.60
0.0535


MmugDNA.39834.1.S1_s_at
—
—
2.60
0.0269


MmugDNA.16052.1.S1_at
SEC10 protein
EXOC5
2.60
0.0882


MmugDNA.10569.1.S1_at
Golgin subfamily A member 1 (Golgin-97)
LOC693285
2.60
0.0126


MmugDNA.10679.1.S1_at
vacuolar H+ ATPase G1
LOC699522
2.60
0.0027


MmugDNA.1854.1.S1_at
ankyrin repeat domain 20 family, member A2
LOC707318
2.60
0.0773


MmugDNA.23815.1.S1_at
—
—
2.59
0.0204


Mmu.7599.1.S1_at
smooth muscle cell associated protein 5
LOC706656
2.59
0.0065


MmugDNA.14931.1.S1_at
syntaxin 7
LOC701269
2.59
0.0544


MmugDNA.13732.1.S1_at
—
—
2.59
0.0529


MmugDNA.4660.1.S1_at
—
—
2.59
0.0470


MmugDNA.23822.1.S1_s_at
cell adhesion molecule 1
CADM1
2.59
0.0163


MmugDNA.37623.1.S1_at
protein tyrosine phosphatase, receptor type, G precursor
LOC703937
2.59
0.0246


MmugDNA.32519.1.S1_at
—
—
2.58
0.0279


MmugDNA.13687.1.S1_at
—
—
2.58
0.0779


MmuSTS.4721.1.S1_at
thyroid hormone receptor interactor 11
LOC697489
2.58
0.0012


MmugDNA.21480.1.S1_at
—
—
2.58
0.0742


MmugDNA.13466.1.S1_at
activating transcription factor 6
LOC720056
2.58
0.0029


MmuSTS.3905.1.S1_at
recoverin
LOC717807
2.57
0.0728


MmuSTS.1760.1.S1_at
alpha-N-acetylgalactosaminidase
NAGA
2.57
0.0040


MmugDNA.9095.1.S1_at
—
—
2.57
0.0102


MmugDNA.535.1.S1_at
—
—
2.57
0.0131


MmugDNA.22662.1.S1_at
—
—
2.57
0.0151


MmugDNA.42675.1.S1_at
transforming growth factor, beta 2
LOC707540
2.57
0.0522


MmugDNA.6958.1.S1_at
—
—
2.57
0.0725


MmugDNA.2631.1.S1_at
Tetraspanin-6 (Tspan-6) (Transmembrane 4 superfamily
LOC703166
2.57
0.0170



member 6) (T245 protein) (Tetraspanin TM4-D) (A15



homolog)


MmugDNA.13189.1.S1_at
CG10233-PA, isoform A
LOC706860
2.57
0.0238


Mmu.14100.1.S1_at
hypothetical protein LOC716612
LOC716612
2.56
0.0589


MmugDNA.37486.1.S1_at
—
—
2.56
0.0030


MmugDNA.6803.1.S1_at
—
—
2.56
0.0676


MmugDNA.20096.1.S1_at
tropomodulin 3 (ubiquitous)
TMOD3
2.56
0.0158


MmugDNA.4732.1.S1_at
—
—
2.56
0.0239


MmugDNA.3551.1.S1_at
Y73F8A.5
LOC697670
2.56
0.0018


MmugDNA.11777.1.S1_at
—
—
2.56
0.0022


MmugDNA.6129.1.S1_at
solute carrier family 25, member 35
LOC721965
2.56
0.0343


MmuSTS.1392.1.S1_at
—
—
2.55
0.0039


MmugDNA.33992.1.S1_at
PTPRF interacting protein alpha 1
PPFIA1
2.55
0.0925


MmuSTS.1581.1.S1_at
IQ motif containing GTPase activating protein 2
IQGAP2
2.55
0.0393


MmugDNA.32972.1.S1_at
—
—
2.55
0.0061


MmuSTS.1848.1.S1_at
resistance to inhibitors of cholinesterase 8B isoform 2
LOC703061
2.55
0.0576


MmugDNA.12186.1.S1_at
protein tyrosine phosphatase-like (proline instead of
—
2.55
0.0353



catalytic arginine), member b


MmugDNA.10635.1.S1_at
Hypothetical protein LOC717382
—
2.54
0.0303


MmugDNA.7743.1.S1_at
hypothetical protein LOC694489
LOC694489
2.54
0.0909


MmugDNA.22818.1.S1_at
LOC57821
LOC700803
2.54
0.0571


MmugDNA.28543.1.S1_at
ubiquitin specific protease 46
LOC698618
2.54
0.0001


MmugDNA.7920.1.S1_at
synaptosomal-associated protein 29
LOC696708
2.53
0.0316


MmugDNA.41817.1.S1_at
—
—
2.53
0.0047


MmugDNA.33998.1.S1_at
CG9240-PA /// hypothetical protein LOC718215
LOC696105 ///
2.53
0.0613




LOC718215


MmuSTS.4005.1.S1_at
thrombospondin 2 precursor
LOC708165
2.53
0.0700


MmugDNA.7442.1.S1_at
NAD(P) dependent steroid dehydrogenase-like
LOC714229
2.53
0.0286


MmugDNA.37241.1.S1_at
hypothetical protein LOC704834
LOC704834
2.53
0.0785


MmugDNA.18544.1.S1_at
MAPK/MAK/MRK overlapping kinase
RAGE
2.52
0.0619


MmugDNA.14567.1.S1_at
CGI-01 protein isoform 1
LOC704943
2.52
0.0722


MmugDNA.39392.1.S1_at
Tumor necrosis factor receptor superfamily member 19L
LOC718143
2.52
0.0339



precursor (Receptor expressed in lymphoid tissues)


MmugDNA.36135.1.S1_at
—
—
2.52
0.0009


MmugDNA.38008.1.S1_at
asparaginase-like 1 protein
LOC718871
2.52
0.0079


MmugDNA.894.1.S1_at
—
—
2.52
0.0553


MmugDNA.9940.1.S1_s_at
—
—
2.52
0.0117


MmugDNA.30902.1.S1_at
zinc finger protein 452
LOC708122
2.52
0.0174


MmunewRS.671.1.S1_at
—
—
2.51
0.0611


MmugDNA.29345.1.S1_at
Golgi-localized syntaphilin-related protein isoform C
LOC699436
2.51
0.0454


MmuSTS.1714.1.S1_s_at
muscle-type acylphosphatase 2
LOC716728
2.51
0.0007


MmugDNA.17463.1.S1_at
hypothetical protein LOC696917
LOC696917
2.51
0.0447


MmuSTS.4655.1.S1_at
2′,5′-oligoadenylate synthetase 1
OAS1
2.51
0.0103


MmugDNA.2445.1.S1_at
—
—
2.51
0.0229


MmuSTS.2654.1.S1_at
ATP-binding cassette, sub-family A member 3
LOC696496
2.51
0.0198


MmugDNA.10791.1.S1_at
Coiled-coil domain-containing protein 11
LOC700084
2.50
0.0645


MmugDNA.30349.1.S1_at
Transmembrane protein 33 (DB83 protein)
TMEM33
2.50
0.0047


MmugDNA.8272.1.S1_at
—
—
2.50
0.0928


MmuSTS.3815.1.S1_at
ATPase, H+ transporting, lysosomal accessory protein 1
ATP6AP1
2.50
0.0128


MmugDNA.16292.1.S1_at
transmembrane protein 56
LOC709729
2.50
0.0116


MmugDNA.33608.1.S1_at
jumonji domain containing 1B
LOC716648
2.50
0.0832


MmugDNA.20325.1.S1_s_at
Kruppel-like factor 3 (basic)
KLF3
2.50
0.0533


MmugDNA.36544.1.S1_at
—
—
2.50
0.0239


MmugDNA.18568.1.S1_s_at
coiled-coil domain containing 64
LOC698147
2.50
0.0156


MmuSTS.1282.1.S1_at
retinoic acid induced 2
LOC693329
2.50
0.0020


MmugDNA.16604.1.S1_at
—
—
2.50
0.0753


MmugDNA.2019.1.S1_at
—
—
2.50
0.0009


MmugDNA.15319.1.S1_at
EH-domain containing 3
LOC705316
2.49
0.0546


MmuSTS.3025.1.S1_at
—
—
2.49
0.0259


MmugDNA.4609.1.S1_at
sparc/osteonectin, cwcv and kazal-like domains
SPOCK1
2.49
0.0876



proteoglycan 1


MmugDNA.26967.1.S1_at
ROD1 regulator of differentiation 1
LOC711210
2.49
0.0050


MmugDNA.37971.1.S1_at
heat shock 70 kDa protein 4 isoform a
LOC709585
2.49
0.0242


MmuSTS.3404.1.S1_at
—
—
2.49
0.0276


MmugDNA.2456.1.S1_at
CG14185-PA
LOC698952
2.49
0.0639


Mmu.4703.1.S1_at
—
—
2.49
0.0143


MmugDNA.16581.1.S1_at
calponin 3
LOC709538
2.49
0.0128


MmugDNA.6.1.S1_at
secretogranin III
LOC694089
2.49
0.0059


MmuSTS.1273.1.S1_at
doublecortin and CaM kinase-like 1
LOC722071
2.49
0.0570


MmugDNA.39606.1.S1_at
DNAJ domain-containing
LOC700339
2.48
0.0702


MmugDNA.32745.1.S1_at
—
—
2.48
0.0016


MmugDNA.5221.1.S1_at
—
—
2.48
0.0528


MmugDNA.13152.1.S1_at
—
—
2.48
0.0168


MmugDNA.27246.1.S1_s_at
leucine rich repeat containing 16
LOC694909
2.48
0.0648


MmuSTS.3254.1.S1_at
semaphorin 3A
LOC708263
2.47
0.0730


MmugDNA.12122.1.S1_s_at
—
—
2.47
0.0389


MmugDNA.29872.1.S1_at
GTPase activating Rap/RanGAP domain-like 1 isoform 1
LOC695674
2.47
0.0024


MmugDNA.34800.1.S1_at
—
—
2.47
0.0944


MmugDNA.25958.1.S1_at
DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57
LOC713523
2.47
0.0649


MmugDNA.32735.1.S1_at
hypothetical protein LOC702345
LOC702345
2.47
0.0058


MmugDNA.17104.1.S1_at
—
—
2.47
0.0822


MmugDNA.15497.1.S1_at
Hypothetical protein LOC708044
—
2.47
0.0563


MmugDNA.13708.1.S1_at
—
—
2.47
0.0398


MmugDNA.35844.1.S1_at
Protein C10orf57 homolog
LOC701130
2.47
0.0547


MmugDNA.3000.1.S1_at
signal sequence receptor gamma subunit
LOC706518
2.47
0.0144


MmugDNA.18159.1.S1_at
bone morphogenetic protein receptor type II
BMPR2
2.47
0.0575


Mmu.10229.1.S1_at
CD46 molecule, complement regulatory protein
CD46
2.47
0.0654


MmugDNA.13343.1.S1_at
erythrocyte protein band 4.1-like 1 isoform L
LOC710697
2.47
0.0020


MmugDNA.32527.1.S1_at
mitogen-activated protein kinase kinase kinase 7 interacting
LOC696875
2.46
0.0710



protein 2


MmugDNA.8354.1.S1_at
HGFL protein
LOC716694
2.46
0.0605


MmugDNA.32803.1.S1_at
hypothetical protein LOC717255
LOC717255
2.46
0.0654


MmugDNA.25652.1.S1_at
netrin-G1 ligand
LOC698610
2.46
0.0244


MmugDNA.39872.1.S1_at
parathyroid hormone-responsive B1 isoform 2
LOC708412
2.46
0.0721


MmugDNA.13779.1.S1_at
protein kinase C and casein kinase substrate in neurons 3
LOC713919
2.46
0.0997


MmugDNA.11262.1.S1_at
—
—
2.46
0.0172


MmugDNA.11097.1.S1_at
Ribonuclease K6 precursor (RNase K6)
—
2.46
0.0658


MmugDNA.13830.1.S1_at
—
—
2.45
0.0381


MmugDNA.20861.1.S1_at
spermatogenesis associated 13
LOC721468
2.45
0.0640


MmuSTS.2607.1.S1_at
citrate synthase precursor, isoform a
—
2.45
0.0385


MmugDNA.15111.1.S1_at
—
—
2.45
0.0528


MmuSTS.2246.1.S1_at
phospholipase C, gamma 2 (phosphatidylinositol-specific)
PLCG2
2.45
0.0006


MmugDNA.17805.1.S1_at
solute carrier family 9 (sodium/hydrogen exchanger),
LOC712199
2.45
0.0407



isoform 2


MmugDNA.19536.1.S1_at
—
—
2.45
0.0378


MmugDNA.17107.1.S1_at
mitogen-activated protein kinase 1
MAPK1
2.44
0.0344


MmugDNA.24092.1.S1_at
hypothetical protein LOC708570
LOC708570
2.44
0.0745


MmugDNA.14738.1.S1_at
TRAF2 and NCK interacting kinase
TNIK
2.44
0.0358


MmugDNA.5147.1.S1_s_at
Kelch repeat and BTB domain-containing protein 4 (BTB
LOC711452
2.44
0.0121



and kelch domain-containing protein 4)


MmugDNA.6438.1.S1_at
nudix (nucleoside diphosphate linked moiety X)-type motif
LOC707828
2.44
0.0458



21


MmugDNA.17791.1.S1_at
—
—
2.44
0.0445


MmugDNA.19209.1.S1_s_at
Neutrophil gelatinase-associated lipocalin precursor (NGAL)
LOC697208
2.44
0.0703



(p25) (25 kDa alpha-2-microglobulin-related subunit of



MMP-9) (Lipocalin-2) (Oncogene 24p3)


MmugDNA.20574.1.S1_at
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
KIT
2.44
0.0258



homolog


MmugDNA.35313.1.S1_at
hypothetical protein LOC704554 /// adenylate cyclase 9
ADCY9 ///
2.44
0.0330




LOC704554


MmugDNA.20823.1.S1_at
—
—
2.43
0.0067


MmugDNA.42796.1.S1_at
inositol 1,3,4,5,6-pentakisphosphate 2-kinase
LOC705937
2.43
0.0129


MmugDNA.17764.1.S1_at
CG6678-PA
LOC715524
2.43
0.0114


MmugDNA.43422.1.S1_at
postsynaptic protein CRIPT
LOC714949
2.43
0.0240


MmugDNA.34136.1.S1_at
Normal mucosa of esophagus-specific gene 1 protein
LOC713440
2.43
0.0780


MmugDNA.30592.1.S1_at
transmembrane 9 superfamily member 2
TM9SF2
2.43
0.0017


MmugDNA.27400.1.S1_at
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
LOC708094
2.43
0.0393



acetylglucosaminyltransferase, isoenzyme A


MmuSTS.4839.1.S1_at
golgi phosphoprotein 2
LOC715029
2.43
0.0064


Mmu.8934.1.S1_at
Alpha- and gamma-adaptin-binding protein p34
LOC711436
2.43
0.0144


MmugDNA.2329.1.S1_at
—
—
2.43
0.0587


MmugDNA.17344.1.S1_at
neurotrophin 3
NTF3
2.42
0.0822


MmugDNA.36340.1.S1_at
—
—
2.42
0.0398


MmugDNA.21012.1.S1_at
rabphilin 3A-like (without C2 domains)
—
2.42
0.0932


MmugDNA.17438.1.S1_at
—
—
2.42
0.0767


MmuSTS.1305.1.S1_at
disrupted in renal carcinoma 2
LOC715135
2.42
0.0004


MmuSTS.664.1.S1_at
caspase 7 isoform delta
LOC697633
2.42
0.0130


MmugDNA.26043.1.S1_at
Ataxin-7-like protein 1
LOC698666
2.41
0.0286


MmugDNA.33509.1.S1_at
CG11178-PB, isoform B
LOC693868
2.41
0.0659


MmugDNA.6922.1.S1_at
—
—
2.41
0.0385


MmugDNA.31513.1.S1_at
ubiquitin specific protease 38
LOC700235
2.41
0.0544


MmuSTS.1706.1.S1_at
ATP binding cassette, sub-family A (ABC1), member 13
LOC695208
2.41
0.0215


MmuSTS.415.1.S1_at
—
—
2.41
0.0183


MmugDNA.5945.1.S1_at
CG6729-PA
LOC711172
2.41
0.0529


MmugDNA.16172.1.S1_at
transmembrane protein 5
TMEM5
2.41
0.0000


MmugDNA.7215.1.S1_at
uronyl-2-sulfotransferase
LOC697355
2.41
0.0823


MmugDNA.20155.1.S1_at
—
—
2.41
0.0172


MmugDNA.39588.1.S1_at
—
—
2.41
0.0526


MmugDNA.1883.1.S1_at
EGFR-coamplified and overexpressed protein
LOC716151
2.41
0.0004


MmugDNA.2888.1.S1_at
HMT1 hnRNP methyltransferase-like 1
PRMT2
2.41
0.0030


MmugDNA.36209.1.S1_at
—
—
2.40
0.0506


MmugDNA.5649.1.S1_at
autocrine motility factor receptor
LOC699972
2.40
0.0223


MmugDNA.33055.1.S1_at
hypothetical protein LOC696384
LOC696384
2.40
0.0752


MmuSTS.2026.1.S1_at
cAMP-dependent protein kinase inhibitor gamma
LOC712474
2.40
0.0094


MmugDNA.14045.1.S1_at
advillin
LOC712581
2.40
0.0001


MmugDNA.35277.1.S1_s_at
actin related protein 2/3 complex, subunit 5
LOC699657
2.40
0.0138


MmugDNA.30729.1.S1_s_at
golgi reassembly stacking protein 2
LOC694170
2.40
0.0106


MmugDNA.36130.1.S1_at
attractin
ATRN
2.40
0.0097


MmugDNA.7819.1.S1_at
mitogen-activated protein kinase 8 isoform 1
LOC711115
2.39
0.0438


MmugDNA.43615.1.S1_at
—
—
2.39
0.0695


MmugDNA.25611.1.S1_at
phosphodiesterase 6D, cGMP-specific, rod, delta
LOC712629
2.39
0.0100


MmugDNA.27560.1.S1_at
Hypothetical protein LOC709178
—
2.39
0.0044


MmugDNA.13637.1.S1_at
zinc finger protein 135 (clone pHZ-17)
LOC706617
2.39
0.0734


MmugDNA.103.1.S1_at
PDZ and LIM domain 7 isoform 2
LOC706581
2.39
0.0805


MmugDNA.41605.1.S1_s_at
casein kinase II, alpha 1 polypeptide
LOC714841
2.39
0.0647


MmuSTS.3945.1.S1_at
synaptotagmin I
SYT1
2.39
0.0424


MmugDNA.5481.1.S1_at
—
—
2.39
0.0011


MmugDNA.10940.1.S1_at
—
—
2.39
0.0516


MmugDNA.9600.1.S1_at
regulating synaptic membrane exocytosis 2 isoform 1
LOC694366
2.39
0.0629


MmuSTS.2040.1.S1_at
hypothetical protein LOC716045
LOC716045
2.38
0.0203


MmugDNA.5934.1.S1_at
—
—
2.38
0.0282


MmugDNA.7962.1.S1_at
syntaphilin
SNPH
2.38
0.0359


MmugDNA.13339.1.S1_at
G protein-coupled receptor 178
LOC705039
2.38
0.0053


MmuSTS.1208.1.S1_at
trimethyllysine hydroxylase, epsilon
TMLHE
2.38
0.0921


MmugDNA.31636.1.S1_at
HMT1 hnRNP methyltransferase-like 3
LOC701789
2.38
0.0213


MmugDNA.3222.1.S1_at
—
—
2.38
0.0317


MmugDNA.38925.1.S1_at
CG15021-PA
LOC699097
2.38
0.0200


MmugDNA.8848.1.S1_at
transmembrane protein 37
LOC695060
2.38
0.0843


MmuSTS.168.1.S1_x_at
isopentenyl-diphosphate delta isomerase
LOC710052
2.38
0.0011


MmugDNA.10165.1.S1_at
Hematological and neurological expressed 1
—
2.38
0.0381


MmugDNA.14296.1.S1_at
—
—
2.37
0.0118


MmugDNA.26530.1.S1_at
hypothetical protein LOC721032
LOC721032
2.37
0.0873


MmugDNA.42344.1.S1_at
ADP-ribosylarginine hydrolase
ADPRH
2.37
0.0911


MmugDNA.31196.1.S1_at
—
—
2.37
0.0106


MmugDNA.6107.1.S1_at
Juxtaposed with another zinc finger protein 1
LOC697973
2.37
0.0564


MmugDNA.12227.1.S1_at
—
—
2.37
0.0092


MmugDNA.6506.1.S1_at
—
—
2.37
0.0548


MmugDNA.33621.1.S1_at
zinc finger protein 528
LOC720193
2.37
0.0807


MmugDNA.5483.1.S1_at
cell death inducing protein
LOC705579
2.37
0.0183


MmugDNA.4206.1.S1_at
calcium-activated potassium channel beta 4 subunit
LOC717360
2.37
0.0762


MmugDNA.27722.1.S1_at
—
—
2.37
0.0449


MmugDNA.37306.1.S1_at
melanoma antigen family E, 1
LOC705379
2.36
0.0431


MmugDNA.38283.1.S1_at
NADPH cytochrome B5 oxidoreductase
LOC695553
2.36
0.0419


MmugDNA.9872.1.S1_at
lysosomal-associated membrane protein 1
LAMP1
2.36
0.0380


MmugDNA.39305.1.S1_at
Fc fragment of IgG binding protein
LOC700539
2.36
0.0153


MmugDNA.19557.1.S1_at
filamin-binding LIM protein-1 isoform a
LOC695727
2.36
0.0284


Mmu.4737.1.S1_at
riboflavin kinase
LOC704540
2.36
0.0146


MmugDNA.3346.1.S1_at
makorin, ring finger protein, 2
LOC697649
2.36
0.0193


MmuSTS.3988.1.S1_at
Cathepsin S precursor
LOC708080
2.36
0.0054


MmugDNA.38289.1.S1_at
WD repeat domain 27
LOC695097
2.36
0.0583


MmugDNA.684.1.S1_at
alpha 2 type IX collagen
LOC694248
2.36
0.0316


MmugDNA.41344.1.S1_at
solute carrier family 4 member 11
LOC718393
2.36
0.0120


MmugDNA.8324.1.S1_at
—
—
2.35
0.0096


MmugDNA.12588.1.S1_at
—
—
2.35
0.0199


MmugDNA.36202.1.S1_at
—
—
2.35
0.0482


MmugDNA.23185.1.S1_at
TATA element modulatory factor 1
LOC696619
2.35
0.0108


MmugDNA.12313.1.S1_at
CG2943-PA
LOC702573
2.35
0.0270


MmugDNA.15670.1.S1_s_at
insulysin
IDE
2.35
0.0735


MmugDNA.30396.1.S1_at
Corneodesmosin precursor (S protein)
LOC714553
2.35
0.0729


MmugDNA.12626.1.S1_s_at
SWI/SNF-related matrix-associated actin-dependent
SMARCA4
2.35
0.0853



regulator of chromatin a4


MmugDNA.20551.1.S1_at
discoidin, CUB and LCCL domain containing 1
DCBLD1
2.35
0.0001


MmugDNA.19751.1.S1_at
ADP-ribosylhydrolase like 1 isoform 1
LOC697842
2.34
0.0761


MmugDNA.5198.1.S1_at
uncharacterized protein family UPF0227 member
LOC717757
2.34
0.0500



RGD1359682


MmugDNA.28177.1.S1_s_at
hypothetical protein LOC712492
LOC712492
2.34
0.0330


MmugDNA.14571.1.S1_s_at
phosphatidylinositol glycan, class T precursor
LOC710556
2.34
0.0061


Mmu.15853.1.S1_x_at
ADP-ribosylation-like factor 6 interacting protein 5
LOC696360
2.34
0.0344


MmuSTS.255.1.S1_at
non-imprinted in Prader-Willi/Angelman syndrome 1
LOC710236
2.34
0.0619


MmugDNA.10012.1.S1_at
transmembrane protein 16D
LOC695973
2.34
0.0997


MmugDNA.19562.1.S1_at
zinc finger protein 406 isoform ZFAT-1
LOC698512
2.34
0.0839


MmugDNA.22652.1.S1_s_at
—
—
2.34
0.0641


MmugDNA.29515.1.S1_at
splicing factor, arginine/serine-rich 14
LOC719666
2.34
0.0382


MmugDNA.17884.1.S1_at
Nuclear respiratory factor 1 (NRF-1) (Alpha palindromic-
LOC701933
2.34
0.0353



binding protein) (Alpha-pal)


MmugDNA.32746.1.S1_at
—
—
2.34
0.0282


MmuSTS.1396.1.S1_s_at
zinc finger, MYND domain containing 11
ZMYND11
2.34
0.0128


MmugDNA.18506.1.S1_at
basic beta 1 syntrophin
LOC703245
2.33
0.0093


MmugDNA.26826.1.S1_s_at
solute carrier family 11 (proton-coupled divalent metal ion
SLC11A1
2.33
0.0675



transporters), member 1


MmugDNA.38731.1.S1_at
steroid 5 alpha-reductase 2-like
LOC696381
2.33
0.0646


MmugDNA.27590.1.S1_at
—
—
2.33
0.0789


MmugDNA.17575.1.S1_at
—
—
2.33
0.0623


MmugDNA.17935.1.S1_at
—
—
2.33
0.0075


MmugDNA.22419.1.S1_at
—
—
2.33
0.0972


MmugDNA.23057.1.S1_at
—
—
2.33
0.0060


MmugDNA.41434.1.S1_at
gamma-glutamyl hydrolase precursor
LOC700747
2.33
0.0384


MmugDNA.17895.1.S1_at
—
—
2.33
0.0135


MmugDNA.23827.1.S1_at
hypothetical protein LOC699699
LOC699699
2.33
0.0944


MmugDNA.10050.1.S1_at
—
—
2.33
0.0710


Mmu.2224.1.A1_at
—
—
2.32
0.0001


Mmu.12870.1.S1_at
thymic dendritic cell-derived factor 1
TMEM59
2.32
0.0246


MmugDNA.19523.1.S1_at
CD164 antigen, sialomucin
CD164
2.32
0.0019


MmugDNA.22579.1.S1_at
Growth-arrest-specific protein 7 (GAS-7)
LOC717827
2.32
0.0431


MmuSTS.2905.1.S1_at
Pre-B lymphocyte protein 3 precursor (VpreB3 protein)
VPREB3
2.32
0.0105



(N27C7-2)


MmugDNA.41669.1.S1_at
apolipoprotein B mRNA editing enzyme, catalytic
LOC714993
2.32
0.0081



polypeptide-like 4 (putative)


MmugDNA.11443.1.S1_at
—
—
2.32
0.0432


MmugDNA.18263.1.S1_at
zinc finger, DHHC domain containing 9
ZDHHC9
2.32
0.0271


MmuAffx.1008.1.S1_at
Glutathione peroxidase 3 precursor (GSHPx-3) (GPx-3)
LOC713057
2.32
0.0926



(Plasma glutathione peroxidase) (GSHPx-P) (Extracellular



glutathione peroxidase) (GPx-P)


MmugDNA.22975.1.S1_at
hydroxysteroid dehydrogenase like 1
LOC714962
2.31
0.0247


MmugDNA.35709.1.S1_at
calsyntenin 2
LOC715514
2.31
0.0056


MmugDNA.14527.1.S1_at
F-box only protein 2
LOC722738
2.31
0.0601


MmugDNA.35626.1.S1_s_at
Ras association (RalGDS/AF-6) domain family 6 isoform a
LOC704459
2.31
0.0137


MmuSTS.2492.1.S1_at
zinc finger protein 509
LOC712422
2.31
0.0239


MmuSTS.3145.1.S1_at
nodal modulator 2 isoform 2
LOC714226
2.31
0.0001


MmuSTS.3540.1.S1_at
p21-activated kinase 3
PAK3
2.31
0.0898


MmugDNA.15593.1.S1_at
lysosomal acid phosphatase 2
ACP2
2.31
0.0605


MmugDNA.18121.1.S1_at
—
—
2.31
0.0029


MmugDNA.39434.1.S1_at
—
—
2.31
0.0976


MmugDNA.25583.1.S1_at
PDZ domain containing 8
LOC709084
2.31
0.0851


MmugDNA.38757.1.S1_at
—
—
2.31
0.0970


MmugDNA.10667.1.S1_at
ribophorin II precursor
LOC708971
2.30
0.0244


MmugDNA.22894.1.S1_at
cellular modulator of immune recognition
LOC708030
2.30
0.0097


MmuSTS.4136.1.S1_at
enolase 2
ENO2
2.30
0.0000


MmunewRS.108.1.S1_at
RNA binding motif protein 18
LOC698457
2.30
0.0318


MmugDNA.13579.1.S1_at
—
—
2.30
0.0823


MmugDNA.13215.1.S1_at
myosin VB
MYO5B
2.30
0.0008


MmuSTS.3395.1.S1_at
T16G12.5
LOC704499
2.30
0.0158


MmugDNA.3907.1.S1_at
—
—
2.30
0.0862


MmugDNA.26180.1.S1_at
—
—
2.29
0.0769


MmugDNA.37638.1.S1_at
Hypothetical protein LOC721042
—
2.29
0.0189


MmuSTS.4204.1.S1_at
growth arrest-specific 8
GAS8
2.29
0.0119


MmuSTS.1320.1.S1_at
Calcipressin-2 (Thyroid hormone-responsive protein ZAKI-4)
DSCR1L1
2.29
0.0211



(Down syndrome candidate region 1-like 1) (Myocyte-



enriched calcineurin-interacting protein 2) (MCIP2)


MmuSTS.1142.1.S1_at
pleiomorphic adenoma gene-like 1 isoform 2
LOC699985
2.29
0.0086


MmuSTS.1514.1.S1_at
—
—
2.29
0.0218


MmuSTS.629.1.S1_at
insulin-like growth factor 2 receptor
IGF2R
2.29
0.0358


MmugDNA.34704.1.S1_at
pecanex homolog
LOC694094
2.29
0.0679


MmuSTS.2468.1.S1_at
DHHC1 protein
ZDHHC3
2.29
0.0010


MmugDNA.39065.1.S1_at
elongation factor Tu GTP binding domain containing 1
—
2.29
0.0258


MmugDNA.43592.1.S1_at
—
—
2.29
0.0291


MmugDNA.18594.1.S1_at
DNA-directed RNA polymerases I, II, and III 7.0 kDa
POLR2K
2.29
0.0182



polypeptide (ABC10-alpha) (RPB7.0) (RPB10alpha)



(RPABC4)


MmugDNA.22717.1.S1_at
—
—
2.29
0.0484


MmugDNA.11519.1.S1_at
breakpoint cluster region isoform 1
LOC709258
2.28
0.0734


MmugDNA.14224.1.S1_at
hypothetical protein LOC715184
LOC715184
2.28
0.0889


MmugDNA.2963.1.S1_at
KIAA1900
LOC709276
2.28
0.0527


MmugDNA.41313.1.S1_at
Oxytocin-neurophysin 1 precursor (OT-NPI)
OXT
2.28
0.0512


MmugDNA.23270.1.S1_at
archaemetzincins-2 isoform 1
LOC718462
2.28
0.0394


MmugDNA.7783.1.S1_at
solute carrier organic anion transporter family, member 3A1
SLCO3A1
2.28
0.0616


MmugDNA.40350.1.S1_s_at
glutamate dehydrogenase 1
GLUD1
2.28
0.0037


MmugDNA.9234.1.S1_at
tau tubulin kinase 2
LOC712249
2.27
0.0807


MmugDNA.21304.1.S1_s_at
MAX protein isoform c
LOC708228
2.27
0.0165


MmuSTS.3238.1.S1_at
raft-linking protein
RAFTLIN
2.27
0.0108


MmuSTS.1238.1.S1_at
serine/threonine protein phosphatase with EF-hand motifs 1
PPEF1
2.27
0.0956


MmugDNA.39116.1.S1_at
CDW92 antigen isoform 2
LOC715816
2.27
0.0566


Mmu.924.1.S1_at
anaphase promoting complex subunit 13
LOC717294
2.27
0.0128


MmugDNA.33266.1.S1_at
—
—
2.27
0.0418


MmuSTS.1309.1.S1_at
Doublesex- and mab-3-related transcription factor 2
DMRT2
2.27
0.0682



(Doublesex-like 2 protein) (DSXL-2)


MmugDNA.34994.1.S1_s_at
—
—
2.27
0.0940


MmugDNA.42427.1.S1_at
—
—
2.27
0.0034


MmugDNA.16606.1.S1_s_at
synapse-associated protein 97
DLG1
2.27
0.0636


MmugDNA.16402.1.S1_at
cyclin M4
LOC710164
2.27
0.0425


MmugDNA.42754.1.S1_at
—
—
2.27
0.0453


MmugDNA.29639.1.S1_at
—
—
2.27
0.0957


MmugDNA.4933.1.S1_at
—
—
2.27
0.0759


MmugDNA.30201.1.S1_at
Transcription factor Ovo-like 2 (hOvo2) (Zinc finger protein
LOC719066
2.27
0.0162



339)


MmugDNA.13664.1.S1_at
—
—
2.26
0.0969


MmugDNA.11714.1.S1_at
transmembrane 6 superfamily member 1
LOC700147
2.26
0.0935


MmuSTS.160.1.S1_at
cancer susceptibility candidate 1
LOC707753
2.26
0.0756


MmugDNA.32421.1.S1_at
Mediator complex subunit 4 (Mediator of RNA polymerase II
LOC704644
2.26
0.0005



transcription subunit 4) (Vitamin D3 receptor-interacting



protein complex 36 kDa component) (DRIP36) (Activator-



recruited cofactor 36 kDa component) (ARC36)



(TRAP/SMCC/PC2 subunit . . .


MmugDNA.617.1.S1_at
pleckstrin homology domain containing, family H (with
LOC713855
2.26
0.0144



MyTH4 domain) member 1


MmugDNA.29286.1.S1_at
hypothetical protein LOC708459
LOC708459
2.26
0.0585


MmugDNA.26513.1.S1_at
—
—
2.26
0.0079


MmugDNA.4207.1.S1_at
hypothetical protein LOC695219
LOC695219
2.25
0.0404


Mmu.11792.1.S1_at
syntaxin 12
LOC716455
2.25
0.0076


MmugDNA.3187.1.S1_at
midline 1
LOC713037
2.25
0.0123


MmuSTS.2358.1.S1_at
Reticulon-2 (Neuroendocrine-specific protein-like 1) (NSP-
RTN2
2.25
0.0554



like protein 1) (NSPLI)


MmugDNA.13865.1.S1_at
—
—
2.25
0.0808


MmuSTS.1169.1.S1_at
carbohydrate (chondroitin 4) sulfotransferase 12
CHST12
2.25
0.0631


MmugDNA.7568.1.S1_at
myotubularin related protein 6
MTMR6
2.25
0.0109


MmugDNA.42542.1.S1_at
—
—
2.25
0.0141


MmuSTS.2722.1.S1_at
homer 2
HOMER2
2.25
0.0035


MmugDNA.10742.1.S1_at
farnesyl-diphosphate farnesyltransferase 1
FDFT1
2.25
0.0008


MmugDNA.42437.1.S1_at
N-ethylmaleimide-sensitive factor attachment protein, alpha
LOC717355
2.25
0.0490


MmugDNA.23264.1.S1_at
—
—
2.25
0.0558


MmugDNA.33445.1.S1_at
ring finger protein 180
LOC698166
2.25
0.0840


MmugDNA.31781.1.S1_at
vacuolar protein sorting 37C
LOC694898
2.25
0.0416


MmugDNA.15898.1.S1_s_at
ATPase, H+ transporting, lysosomal 70 kD, V1 subunit A,
LOC696878 ///
2.25
0.0009



isoform 1
LOC709958


MmugDNA.29220.1.S1_at
mitogen-activated protein kinase kinase kinase 13
LOC701085
2.25
0.0665


MmugDNA.18194.1.S1_at
mitogen-activated protein kinase kinase 6
LOC693914
2.25
0.0209


Mmu.10240.1.S1_at
ubiquitin C-terminal hydrolase UCH37
LOC712473
2.25
0.0146


MmugDNA.2778.1.S1_at
WW, C2 and coiled-coil domain containing 1
LOC720812
2.25
0.0619


MmugDNA.14327.1.S1_at
lactamase, beta isoform a
LOC705365
2.24
0.0027


MmugDNA.6356.1.S1_at
CG14980-PB
LOC718128
2.24
0.0083


MmugDNA.41963.1.S1_s_at
calcium binding atopy-related autoantigen 1
LOC701131 ///
2.24
0.0120




LOC708654


MmuSTS.357.1.S1_s_at
malin
LOC704451
2.24
0.0520


MmugDNA.12984.1.S1_at
influenza virus NS1A binding protein isoform a
LOC714152
2.24
0.0122


MmugDNA.36042.1.S1_at
myotubularin-related protein 2
MTMR2
2.24
0.0122


MmugDNA.32344.1.S1_at
phosphatidylinositol glycan, class K
PIGK
2.24
0.0015


MmuSTS.1829.1.S1_at
shroom
LOC699613
2.24
0.0312


Mmu.14177.1.S1_at
unc-50 homolog
UNC50
2.24
0.0511


MmugDNA.17303.1.S1_at
—
—
2.24
0.0816


MmuSTS.4053.1.S1_at
diacylglycerol kinase, iota
DGKI
2.24
0.0540


MmugDNA.31861.1.S1_at
ADP-ribosylation factor interacting protein 1 isoform 2
LOC697533
2.24
0.0738


MmugDNA.32277.1.S1_at
DNA methyltransferase 2
DNMT2
2.24
0.0117


MmugDNA.7347.1.S1_at
—
—
2.23
0.0783


MmuSTS.242.1.S1_x_at
hypothetical protein LOC710534
LOC710534
2.23
0.0769


MmugDNA.29827.1.S1_at
—
—
2.23
0.0209


MmuSTS.2213.1.S1_at
T03G11.3
—
2.23
0.0690


MmugDNA.37378.1.S1_at
—
—
2.23
0.0285


MmuSTS.3577.1.S1_at
protocadherin beta 15
PCDHB15
2.23
0.0039


MmugDNA.39878.1.S1_at
CG15528-PA
LOC716271
2.23
0.0314


MmugDNA.21179.1.S1_at
SEC22 vesicle trafficking protein homolog C isoform b
LOC716351
2.23
0.0145


MmuSTS.3806.1.S1_at
ADP-ribosylation factor GTPase activating protein 3
LOC711160
2.23
0.0530


MmugDNA.31478.1.S1_at
Ras-related protein Rab-33A (Small GTP-binding protein
RAB33A
2.23
0.0714



S10)


MmugDNA.9384.1.S1_at
—
—
2.23
0.0215


MmuSTS.3704.1.S1_at
protein kinase, X-linked
PRKX
2.23
0.0502


MmugDNA.1624.1.S1_at
F-box only protein 3 isoform 2
LOC693281
2.22
0.0611


MmugDNA.732.1.S1_at
hexosaminidase B
HEXB
2.22
0.0224


MmugDNA.12951.1.S1_at
zinc finger protein 77
LOC712142
2.22
0.0290


MmugDNA.24637.1.S1_at
zinc finger protein HIT-39
LOC710861
2.22
0.0274


MmuSTS.1852.1.S1_at
cell division cycle 25A isoform a
LOC710858
2.22
0.0331


MmugDNA.34293.1.S1_at
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase 5
B4GALT5
2.22
0.0063


MmuSTS.4187.1.S1_at
NAD(P)H: quinone oxidoreductase type 3, polypeptide A2
LOC704519
2.22
0.0262


MmugDNA.42423.1.S1_at
—
—
2.22
0.0136


MmugDNA.34057.1.S1_at
Protein C9orf46
LOC693286
2.22
0.0134


MmugDNA.35491.1.S1_at
CG13624-PC, isoform C
LOC703459
2.22
0.0168


MmugDNA.22976.1.S1_s_at
CG2747-PB, isoform B
—
2.22
0.0105


MmuSTS.1422.1.S1_at
hypothetical protein LOC721211
LOC721211
2.22
0.0334


MmugDNA.22793.1.S1_at
tribbles homolog 2
LOC710966
2.22
0.0901


MmugDNA.40572.1.S1_at
fucosidase, alpha-L- 1, tissue
FUCA1
2.22
0.0228


MmugDNA.817.1.S1_at
proteasome (prosome, macropain) 26S subunit, ATPase 2
LOC722117
2.21
0.0637


MmugDNA.38292.1.S1_at
SORCS receptor 1 isoform b
LOC693969
2.21
0.0537


MmugDNA.35537.1.S1_at
cathepsin L
CTSL
2.21
0.0957


MmugDNA.8681.1.S1_at
CG14967-PA
LOC709307
2.21
0.0675


MmuSTS.3280.1.S1_at
calcium channel, voltage-dependent, alpha 2/delta subunit 2
LOC702429
2.21
0.0789



isoform b


MmugDNA.38348.1.S1_at
adducin 1 (alpha)
ADD1
2.21
0.0553


MmugDNA.8155.1.S1_at
—
—
2.21
0.0001


Mmu.394.1.S1_at
—
—
2.21
0.0019


Mmu.14589.1.A1_at
Secretory carrier membrane protein 1
—
2.21
0.0253


MmugDNA.15428.1.S1_at
acetoacetyl-CoA synthetase
LOC707015
2.21
0.0296


MmugDNA.2672.1.S1_at
—
—
2.21
0.0718


Mmu.7319.1.S1_at
hypothetical protein LOC698039
LOC698039
2.21
0.0978


Mmu.14167.1.S1_at
DNA topoisomerase I
LOC697300
2.21
0.0879


MmugDNA.26813.1.S1_at
—
—
2.20
0.0739


MmugDNA.18358.1.S1_at
jumonji domain containing 2B
JMJD2B
2.20
0.0264


MmugDNA.30037.1.S1_at
hypothetical protein LOC700951
LOC700951
2.20
0.0539


MmugDNA.40481.1.S1_at
dynamin binding protein
LOC709334
2.20
0.0109


MmugDNA.25680.1.S1_at
hypothetical protein LOC702485
LOC702485
2.20
0.0848


MmugDNA.20470.1.S1_at
—
—
2.20
0.0464


MmugDNA.7063.1.S1_at
—
—
2.20
0.0848


MmugDNA.37434.1.S1_at
karyopherin alpha 1
KPNA1
2.20
0.0119


MmuSTS.2333.1.S1_at
Peroxisome assembly factor 1 (PAF-1) (Peroxin-2)
LOC701636
2.20
0.0939



(Peroxisomal membrane protein 3) (35 kDa peroxisomal



membrane protein) (RING finger protein 72)


MmugDNA.17606.1.S1_at
BTB (POZ) domain containing 11 isoform 3 /// hypothetical
LOC704916 ///
2.20
0.0238



protein LOC705027
LOC705027


MmugDNA.32862.1.S1_at
zinc finger protein 174
ZNF174
2.20
0.0684


MmugDNA.2565.1.S1_at
—
—
2.20
0.0079


MmugDNA.35698.1.S1_at
—
—
2.20
0.0366


MmugDNA.23911.1.S1_at
—
—
2.19
0.0292


MmugDNA.21753.1.S1_at
—
—
2.19
0.0073


MmugDNA.8775.1.S1_at
—
—
2.19
0.0057


MmugDNA.22114.1.S1_at
5′-methylthioadenosine phosphorylase
MTAP
2.19
0.0179


MmuSTS.3163.1.S1_at
regulator of G-protein signalling 7
RGS7
2.19
0.0763


MmugDNA.10574.1.S1_at
amyloid beta A4 precursor protein-binding, family B,
LOC712585
2.19
0.0110



member 1 isoform delta E9


MmugDNA.11741.1.S1_at
hypothetical protein LOC694910
LOC694910
2.19
0.0055


MmugDNA.25725.1.S1_at
Potassium voltage-gated channel subfamily E member 1
KCNE1
2.19
0.0377



(IKs producing slow voltage-gated potassium channel beta



subunit Mink) (Minimal potassium channel) (Delayed



rectifier potassium channel subunit IsK)


MmugDNA.39110.1.S1_at
membrane component chromosome 11 surface marker 1
LOC717473
2.19
0.0812



isoform 1


MmugDNA.2250.1.S1_at
hypothetical protein LOC716978
LOC716978
2.19
0.0969


MmugDNA.17877.1.S1_s_at
—
—
2.19
0.0717


MmugDNA.24132.1.S1_at
F16A11.1
LOC703783
2.19
0.0504


MmugDNA.34793.1.S1_at
—
—
2.19
0.0542


MmugDNA.7971.1.S1_at
hypothetical protein LOC719652
LOC719652
2.19
0.0475


MmugDNA.96.1.S1_at
—
—
2.18
0.0813


MmuSTS.2238.1.S1_at
collapsin response mediator protein 1
CRMP1
2.18
0.0048


MmugDNA.17576.1.S1_at
p21-activated kinase 1
LOC698585
2.18
0.0691


MmugDNA.42599.1.S1_at
acyl-CoA synthetase long-chain family member 5 isoform a
LOC696404
2.18
0.0180


MmuSTS.4809.1.S1_at
fucosyltransferase 8
FUT8
2.18
0.0898


MmugDNA.33186.1.S1_at
kelch-like 20
LOC708546
2.18
0.0022


MmugDNA.39650.1.S1_at
multiple coagulation factor deficiency 2
LOC717900
2.18
0.0365


MmugDNA.12193.1.S1_at
beta chimerin
CHN2
2.18
0.0041


MmugDNA.35302.1.S1_at
sterol regulatory element-binding transcription factor 2
LOC712307
2.18
0.0113


MmugDNA.327.1.S1_at
—
—
2.18
0.0722


MmugDNA.38687.1.S1_at
hypothetical protein LOC698137
LOC698137
2.18
0.0558


MmugDNA.7208.1.S1_at
seizure related 6 homolog (mouse)-like 2 isoform 2
LOC707244
2.18
0.0767


MmugDNA.16529.1.S1_at
twisted gastrulation
LOC705804
2.18
0.0004


Mmu.1309.1.S1_at
BCL2-associated transcription factor 1
BCLAF1
2.18
0.0898


MmugDNA.42025.1.S1_at
—
—
2.17
0.0333


MmugDNA.20036.1.S1_at
—
—
2.17
0.0261


MmugDNA.36083.1.S1_at
—
—
2.17
0.0019


MmuSTS.4278.1.S1_at
secretagogin precursor
LOC694072
2.17
0.0504


MmuSTS.4293.1.S1_at
CEGP1 protein
LOC708152
2.17
0.0095


Mmu.12751.1.S1_at
Grancalcin
GCA
2.17
0.0079


MmuSTS.4137.1.S1_at
ectonucleoside triphosphate diphosphohydrolase 6
ENTPD6
2.17
0.0582


MmugDNA.36157.1.S1_at
—
—
2.17
0.0466


MmugDNA.40937.1.S1_at
hypothetical protein LOC699965
LOC699965
2.17
0.0264


MmugDNA.41687.1.S1_at
—
—
2.17
0.0243


MmugDNA.32233.1.S1_s_at
Transmembrane protein 50B (HCV p7-transregulated
TMEM50B
2.17
0.0009



protein 3)


MmugDNA.38432.1.S1_at
WD repeat and FYVE domain containing 3 isoform 1
LOC706535
2.17
0.0583


MmuSTS.2292.1.S1_at
protein phosphatase 1, regulatory (inhibitor) subunit 3F
LOC715950
2.17
0.0293


MmugDNA.28838.1.S1_at
tumor necrosis factor receptor superfamily, member 25
TNFRSF25
2.17
0.0954


MmugDNA.43442.1.S1_at
—
—
2.17
0.0092


MmugDNA.40985.1.S1_at
—
—
2.17
0.0995


MmugDNA.1900.1.S1_s_at
—
—
2.16
0.0135


Mmu.11367.1.S1_at
developmentally regulated protein TPO1
LOC710413
2.16
0.0661


MmugDNA.11644.1.S1_at
CG5022-PA
LOC711670
2.16
0.0671


MmugDNA.5070.1.S1_at
hypothetical protein LOC709015
LOC709015
2.16
0.0456


MmugDNA.34622.1.S1_at
B aggressive lymphoma gene
PARP9
2.16
0.0894


MmugDNA.28503.1.S1_at
—
—
2.16
0.0168


MmugDNA.14771.1.S1_s_at
—
—
2.16
0.0146


MmugDNA.4305.1.S1_at
—
—
2.16
0.0396


MmugDNA.42501.1.S1_at
Dmx-like 2
LOC693954
2.16
0.0536


Mmu.828.1.S1_at
leucine rich repeat containing 40
LOC702565
2.16
0.0103


MmugDNA.26452.1.S1_at
TRIO and F-actin-binding protein (Protein Tara) (Trio-
LOC701241
2.16
0.0659



associated repeat on actin)


MmugDNA.14006.1.S1_at
methyltransferase 5 domain containing 1
LOC698208
2.16
0.0220


MmugDNA.16489.1.S1_at
—
—
2.16
0.0929


MmugDNA.33403.1.S1_at
WD repeat and SOCS box-containing protein 2 (WSB-2)
LOC695359
2.16
0.0010



(CS box-containing WD protein)


MmuSTS.3848.1.S1_at
Surfeit locus protein 5
LOC714097
2.16
0.0346


MmugDNA.28161.1.S1_at
AMIGO protein
AMIGO1
2.16
0.0117


Mmu.1020.1.S1_s_at
cysteine-rich with EGF-like domains 1 isoform 2
LOC699345
2.15
0.0581


MmugDNA.23895.1.S1_at
—
—
2.15
0.0568


MmugDNA.34300.1.S1_at
—
—
2.15
0.0476


MmugDNA.25815.1.S1_at
—
—
2.15
0.0128


MmuSTS.2538.1.S1_at
Interleukin-13 receptor alpha-1 chain precursor (IL-13R-
LOC710986
2.15
0.0172



alpha-1) (IL-13RA-1) (CD213a1 antigen)


MmugDNA.31245.1.S1_at
butyrophilin, subfamily 2, member A2 isoform a
LOC699861
2.15
0.0979


MmugDNA.36602.1.S1_at
transducin-like enhancer protein 1
LOC707336
2.15
0.0343


MmugDNA.21781.1.S1_at
Testis-specific Y-encoded-like protein 3 (TSPY-like 3)
LOC712128
2.15
0.0723


Mmu.2576.1.S1_at
RING1 and YY1 binding protein
LOC694390
2.15
0.0893


MmugDNA.9098.1.S1_at
SWI/SNF related, matrix associated, actin dependent
SMARCA1
2.15
0.0737



regulator of chromatin, subfamily a, member 1


MmugDNA.14464.1.S1_at
ornithine decarboxylase antizyme inhibitor
LOC693581
2.15
0.0021


MmugDNA.6468.1.S1_at
WD repeat domain 48
LOC695026
2.15
0.0807


MmugDNA.12543.1.S1_at
R13A5.9
LOC710476
2.14
0.0209


MmugDNA.35647.1.S1_at
BTB and kelch domain containing 3
LOC706382
2.14
0.0185


MmugDNA.18973.1.S1_at
nucleobindin 1
LOC718380
2.14
0.0548


MmugDNA.7913.1.S1_at
—
—
2.14
0.0589


MmugDNA.9254.1.S1_at
solute carrier family 35, member C1
SLC35C1
2.14
0.0474


MmuSTS.702.1.S1_at
inhibin, beta B (activin AB beta polypeptide)
INHBB
2.14
0.0076


MmugDNA.1591.1.S1_at
—
—
2.14
0.0915


Mmu.8048.1.S1_at
protein phosphatase 3 (formerly 2B), catalytic subunit, alpha
PPP3CA
2.13
0.0704



isoform (calcineurin A alpha)


MmugDNA.19851.1.S1_at
—
—
2.13
0.0874


MmugDNA.5616.1.S1_at
serine/threonine kinase 38
STK38
2.13
0.0148


MmugDNA.4789.1.S1_at
TP53-regulating kinase (p53-related protein kinase) (Nori-2)
LOC716636
2.13
0.0179


MmugDNA.38238.1.S1_at
stearoyl-CoA desaturase (delta-9-desaturase)
LOC694079
2.13
0.0088


MmugDNA.14345.1.S1_s_at
—
—
2.13
0.0164


MmugDNA.17444.1.S1_at
nucleoplasmin 2
LOC715448
2.13
0.0571


MmuSTS.4377.1.S1_at
—
—
2.13
0.0948


MmugDNA.26500.1.S1_at
KIAA0564 protein
KIAA0564
2.13
0.0336


MmugDNA.4249.1.S1_at
—
—
2.13
0.0344


MmuSTS.935.1.S1_at
talin 2
LOC705008
2.13
0.0652


MmugDNA.33197.1.S1_at
—
—
2.13
0.0665


MmugDNA.39459.1.S1_at
Sec23 (S. cerevisiae) homolog B
LOC698440
2.13
0.0020


MmuSTS.3997.1.S1_at
—
—
2.12
0.0188


Mmu.9557.1.S1_at
OTU domain containing 4 protein isoform 1
LOC701837
2.12
0.0798


MmugDNA.14887.1.S1_at
Protein NipSnap1
LOC717745
2.12
0.0225


MmugDNA.25767.1.S1_at
like-glycosyltransferase
LOC717403
2.12
0.0858


MmugDNA.30227.1.S1_at
nitric oxide synthase trafficking isoform 1
LOC705063
2.12
0.0210


MmugDNA.29197.1.S1_at
hypothetical protein LOC698413
LOC698413
2.12
0.0069


MmugDNA.35367.1.S1_at
—
—
2.12
0.0045


MmuSTS.1000.1.S1_at
myoneurin
LOC698094
2.12
0.0044


MmugDNA.27645.1.S1_at
hypothetical protein LOC710801
LOC710801
2.12
0.0193


MmugDNA.32669.1.S1_at
Sur-8 CG5407-PA, isoform A
—
2.12
0.0319


MmugDNA.43367.1.S1_at
genetic suppressor element 1
LOC693298
2.12
0.0210


MmugDNA.41452.1.S1_at
sperm protein 17
LOC574157
2.12
0.0436


MmugDNA.37832.1.S1_at
—
—
2.12
0.0135


MmugDNA.33994.1.S1_at
unc-5 homolog B
LOC715786
2.12
0.0074


MmugDNA.31700.1.S1_at
stromal membrane-associated protein 1-like
LOC694502
2.12
0.0138


MmugDNA.12779.1.S1_at
remodeling and spacing factor 1
LOC699078
2.12
0.0480


MmugDNA.20356.1.S1_at
platelet-activating factor acetylhydrolase 2
LOC719750
2.11
0.0689


MmuSTS.1250.1.S1_at
cAMP responsive element binding protein-like 2
LOC696952
2.11
0.0786


MmugDNA.1301.1.S1_at
InaD-like protein isoform 1
LOC694408
2.11
0.0733


MmugDNA.38366.1.S1_at
Eukaryotic translation initiation factor 3 subunit 1 (eIF-3
LOC712295
2.11
0.0343



alpha)


MmugDNA.15094.1.S1_at
hypothetical protein LOC699533
LOC699533
2.11
0.0073


MmugDNA.24933.1.S1_at
hypothetical protein LOC701291
LOC701291
2.11
0.0405


MmugDNA.18451.1.S1_at
Peroxiredoxin-4 (Prx-IV) (Thioredoxin peroxidase AO372)
LOC697635
2.11
0.0133



(Thioredoxin-dependent peroxide reductase A0372)



(Antioxidant enzyme AOE372) (AOE37-2)


MmugDNA.30695.1.S1_at
—
—
2.11
0.0121


MmugDNA.21266.1.S1_s_at
sorcin isoform b
LOC705215
2.11
0.0255


MmugDNA.41706.1.S1_at
—
—
2.11
0.0059


MmuSTS.2300.1.S1_at
—
—
2.11
0.0732


MmuSTS.2136.1.S1_at
AXIN1 up-regulated 1
LOC694328
2.10
0.0010


MmugDNA.34250.1.S1_at
hypothetical protein LOC697587
LOC697587
2.10
0.0430


MmugDNA.30761.1.S1_at
abhydrolase domain containing 10
—
2.10
0.0313


MmugDNA.25568.1.S1_at
ligase III, DNA, ATP-dependent
LIG3
2.10
0.0203


MmugDNA.41814.1.S1_at
Meis1 homolog
MEIS1
2.10
0.0730


MmugDNA.23946.1.S1_at
—
—
2.10
0.0824


MmugDNA.15939.1.S1_at
—
—
2.10
0.0599


MmuSTS.3941.1.S1_at
cell cycle progression 1 isoform 2
LOC698918
2.09
0.0097


MmugDNA.31766.1.S1_at
—
—
2.09
0.0173


MmugDNA.34607.1.S1_at
THAP domain containing 7
LOC693821
2.09
0.0838


Mmu.10002.1.S1_at
methionine adenosyltransferase II, alpha
MAT2A
2.09
0.0100


MmugDNA.8056.1.S1_at
Uteroglobin precursor (Secretoglobin family 1A member 1)
LOC718857
2.09
0.0677



(Clara cell phospholipid-binding protein) (CCPBP) (Clara



cells 10 kDa secretory protein) (CC10) (Urinary protein 1)



(Urine protein 1) (UP1)


MmugDNA.8398.1.S1_at
odd Oz/ten-m homolog 3
LOC700867
2.09
0.0151


MmugDNA.41504.1.S1_at
SUMO1/sentrin/SMT3 specific protease 2
SENP2
2.09
0.0168


MmugDNA.25057.1.S1_s_at
WW domain containing E3 ubiquitin protein ligase 2
WWP2
2.09
0.0899


MmugDNA.30167.1.S1_at
tumor rejection antigen (gp96) 1
HSP90B1
2.09
0.0317


MmugDNA.23937.1.S1_at
—
—
2.09
0.0679


MmunewRS.900.1.S1_at
—
—
2.08
0.0913


Mmu.13707.1.S1_at
Transcribed locus, moderately XP_001163736.1
—
2.08
0.0995



prostaglandin-D synthase [Pan troglodytes]


MmugDNA.42106.1.S1_at
—
—
2.08
0.0031


MmugDNA.25377.1.S1_at
—
—
2.08
0.0867


MmugDNA.33263.1.S1_at
amine oxidase, copper containing 2 isoform b
LOC711900
2.08
0.0495


Mmu.10780.1.S1_at
ATP-binding cassette, sub-family D, member 3
ABCD3
2.08
0.0668


MmugDNA.23614.1.S1_at
DDHD domain containing 1
LOC694361
2.08
0.0695


MmugDNA.28356.1.S1_at
hypothetical protein LOC715793
LOC715793
2.08
0.0799


MmugDNA.39375.1.S1_at
oligonucleotide/oligosaccharide-binding fold containing 1
LOC714968
2.08
0.0397


MmugDNA.17230.1.S1_at
ets homologous factor
LOC717350
2.08
0.0092


MmugDNA.43483.1.S1_at
ubiquitin specific protease 47
USP47
2.07
0.0354


MmuSTS.4574.1.S1_at
Alpha-mannosidase IIx (Mannosyl-oligosaccharide 1,3-1,6-
MAN2A2
2.07
0.0066



alpha-mannosidase) (MAN IIx) (Mannosidase alpha class



2A member 2)


MmugDNA.42098.1.S1_at
AP-1 complex subunit sigma-2 (Adapter-related protein
LOC713244
2.07
0.0007



complex 1 sigma-1B subunit) (Sigma-adaptin 1B) (Adaptor



protein complex AP-1 sigma-1B subunit) (Golgi adaptor



HA1/AP1 adaptin sigma-1B subunit) (Clathrin assembly



protein complex 1 si . . .


MmugDNA.21632.1.S1_at
KIAA0368 protein
KIAA0368
2.07
0.0077


MmugDNA.8695.1.S1_at
—
—
2.07
0.0027


MmugDNA.3713.1.S1_at
CG14535-PA
LOC712374
2.07
0.0672


MmugDNA.32882.1.S1_at
Hypothetical protein LOC718964
—
2.07
0.0156


MmugDNA.39148.1.S1_at
—
—
2.07
0.0379


MmuSTS.2882.1.S1_at
TCDD-inducible poly(ADP-ribose) polymerase
LOC706180
2.07
0.0051


MmugDNA.6389.1.S1_at
—
—
2.07
0.0452


MmugDNA.25050.1.S1_at
restin
RSN
2.07
0.0543


MmugDNA.28737.1.S1_at
CG2843-PA
LOC695474
2.07
0.0871


MmugDNA.39973.1.S1_at
Jade1 protein long isoform
LOC693690
2.06
0.0012


Mmu.14041.1.S1_at
ubiquitin specific protease 15
USP15
2.06
0.0149


MmugDNA.30790.1.S1_at
chromobox homolog 7
CBX7
2.06
0.0331


MmugDNA.35116.1.S1_at
kelch-like 12
LOC694420 ///
2.06
0.0120




LOC694548 ///




LOC705991


MmugDNA.9677.1.S1_at
—
—
2.06
0.0871


MmugDNA.16866.1.S1_at
Rho guanine nucleotide exchange factor (GEF) 10-like
LOC701164
2.06
0.0444



isoform 2


MmugDNA.12243.1.S1_at
—
—
2.06
0.0214


MmuSTS.1567.1.S1_at
diphosphomevalonate decarboxylase
MVD
2.06
0.0860


MmuSTS.4422.1.S1_at
tripartite motif-containing 36
TRIM36
2.06
0.0017


MmuSTS.3089.1.S1_at
latrophilin 1
LPHN1
2.06
0.0754


MmugDNA.3623.1.S1_at
CG30497-PA, isoform A
LOC714457
2.06
0.0085


MmuSTS.633.1.S1_at
apical protein of Xenopus-like
APXL
2.06
0.0169


MmuSTS.3572.1.S1_at
coronin, actin binding protein, 2B
CORO2B
2.06
0.0096


MmugDNA.8806.1.S1_at
—
—
2.06
0.0017


MmugDNA.15578.1.S1_at
—
—
2.06
0.0364


MmugDNA.25084.1.S1_at
baculoviral IAP repeat-containing 6
BIRC6
2.05
0.0157


MmugDNA.1057.1.S1_at
DnaJ (Hsp40) homolog, subfamily A, member 1
DNAJA1
2.05
0.0253


MmugDNA.28429.1.S1_at
hypothetical protein LOC716268
LOC716268
2.05
0.0256


MmugDNA.25034.1.S1_at
regulator of G-protein signalling 11 isoform 1
LOC694588
2.05
0.0266


MmugDNA.42945.1.S1_at
—
—
2.05
0.0548


MmugDNA.26306.1.S1_at
—
—
2.05
0.0580


MmugDNA.17707.1.S1_at
—
—
2.05
0.0141


MmugDNA.1190.1.S1_at
dpy-19-like 1, like
LOC699789 ///
2.05
0.0511




LOC707898 ///




LOC709323


MmugDNA.32656.1.S1_at
axonemal dynein light chain 1
LOC697410
2.05
0.0635


MmugDNA.20986.1.S1_s_at
cytochrome P450, family 39, subfamily A, polypeptide 1
LOC704242
2.05
0.0860


MmugDNA.19048.1.S1_at
SDA1 domain containing 1
LOC700863
2.05
0.0742


MmugDNA.39253.1.S1_at
CDC42 effector protein 5
LOC718922
2.05
0.0045


MmugDNA.14544.1.S1_at
—
—
2.05
0.0125


MmugDNA.4740.1.S1_at
chromosome 2 open reading frame 7
LOC706052
2.04
0.0714


MmugDNA.5141.1.S1_at
hypothetical protein LOC715248
LOC715248
2.04
0.0755


MmugDNA.19626.1.S1_at
tripartite motif protein 32 (predicted)
LOC705563
2.04
0.0199


Mmu.2091.3.S1_x_at
HLA class I histocompatibility antigen, A-74 alpha chain
LOC699243 ///
2.04
0.0896



precursor (MHC class I antigen A*74) (Aw-74) (Aw-19) ///
LOC699987 ///



HLA class I histocompatibility antigen, B-38 alpha chain
LOC715737 ///



precursor (MHC class I antigen B*38) (Bw-4) /// major
LOC721022 ///



histocom
LOC723284 ///




LOC723552 ///




MAMU-A


MmugDNA.40849.1.S1_at
7-dehydrocholesterol reductase
DHCR7
2.04
0.0437


MmugDNA.2414.1.S1_at
plastin 1
PLS1
2.04
0.0023


MmugDNA.19830.1.S1_at
glycoprotein hormone alpha 2
LOC717261
2.04
0.0977


MmugDNA.27493.1.S1_at
Rho-guanine nucleotide exchange factor (Rho-interacting
LOC703897
2.04
0.0532



protein 2) (RhoGEF) (RIP2)


Mmu.1943.1.S1_at
Tax1 (human T-cell leukemia virus type I) binding protein 1
LOC698103
2.04
0.0133


MmunewRS.977.1.S1_s_at
hypothetical protein LOC719873
LOC719873
2.04
0.0805


MmugDNA.28230.1.S1_at
intersex-like
LOC698032
2.04
0.0031


MmugDNA.14009.1.S1_s_at
5T4 oncofetal trophoblast glycoprotein
LOC693944
2.04
0.0005


MmugDNA.3795.1.S1_at
dynactin 4 (p62)
DCTN4
2.04
0.0039


MmugDNA.24691.1.S1_at
selenoprotein I
SELI
2.04
0.0078


MmugDNA.5288.1.S1_at
pyridoxine 5′-phosphate oxidase
PNPO
2.04
0.0025


MmuSTS.2059.1.S1_at
phospholipase C beta 4 isoform a
LOC718418
2.04
0.0043


MmugDNA.10284.1.S1_at
MORC family CW-type zinc finger 2
MORC2
2.04
0.0531


MmugDNA.22142.1.S1_at
—
—
2.04
0.0858


MmuSTS.3730.1.S1_at
SLIT-ROBO Rho GTPase activating protein 2
SRGAP2
2.04
0.0146


MmugDNA.21501.1.S1_at
—
—
2.03
0.0030


MmuSTS.4228.1.S1_at
dehydrogenase/reductase (SDR family) member 8
DHRS8
2.03
0.0360


MmugDNA.14076.1.S1_s_at
tripartite motif-containing 59
LOC704829
2.03
0.0593


MmuSTS.4498.1.S1_at
LGP1 homolog
LOC709656
2.03
0.0795


MmugDNA.37577.1.S1_at
MAM domain containing glycosylphosphatidylinositol anchor 1
LOC719423
2.03
0.0884


MmugDNA.3734.1.S1_at
eukaryotic translation initiation factor 5A2
LOC695647
2.03
0.0565


MmugDNA.1893.1.S1_at
RNA guanylyltransferase and 5-phosphatase
LOC721442
2.03
0.0469


MmugDNA.2395.1.S1_at
—
—
2.03
0.0090


MmugDNA.8455.1.S1_at
tigger transposable element derived 2
LOC706461
2.03
0.0283


MmugDNA.20114.1.S1_at
translocating chain-associating membrane protein
TRAM1
2.03
0.0380


MmugDNA.442.1.S1_at
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase 4
B3GALT4
2.03
0.0668


MmugDNA.476.1.S1_s_at
programmed cell death 6 interacting protein
LOC706636
2.03
0.0387


MmugDNA.39070.1.S1_at
androgen-induced 1
LOC700988
2.03
0.0113


MmugDNA.38882.1.S1_at
hypothetical protein LOC712812
LOC712812
2.03
0.0123


Mmu.6318.1.S1_at
family with sequence similarity 18, member B /// Protein
FAM18B ///
2.03
0.0170



FAM18B
LOC719298 ///




LOC723697


Mmu.2050.1.S1_s_at
HIG1 domain family member 1A (Hypoxia-inducible gene 1
HIGD1A
2.03
0.0066



protein)


MmugDNA.8048.1.S1_at
calcium/calmodulin-dependent protein kinase II inhibitor 1
LOC705302
2.02
0.0005


MmugDNA.10177.1.S1_at
TNF receptor-associated factor 3
TRAF3
2.02
0.0434


MmuSTS.735.1.S1_at
—
—
2.02
0.0009


MmugDNA.1551.1.S1_s_at
chloride channel 3 isoform c
LOC694472
2.02
0.0414


Mmu.7639.1.S1_at
signal transducer and activator of transcription 1
STAT1
2.02
0.0894


MmuSTS.2418.1.S1_at
—
—
2.02
0.0452


MmuSTS.88.1.S1_at
—
—
2.02
0.0434


MmugDNA.29466.1.S1_at
phosphorylase kinase, beta
PHKB
2.02
0.0634


MmugDNA.21556.1.S1_at
DNA primase large subunit, 58 kDa
LOC712921
2.02
0.0187


Mmu.4348.1.S1_at
membrane interacting protein of RGS16
LOC694849
2.02
0.0243


MmugDNA.2374.1.S1_at
—
—
2.02
0.0321


MmugDNA.20015.1.S1_at
—
—
2.02
0.0683


MmuSTS.1350.1.S1_at
—
—
2.02
0.0712


MmugDNA.15232.1.S1_at
—
—
2.02
0.0376


MmugDNA.7589.1.S1_at
F-box only protein 24 isoform 1
LOC719216
2.02
0.0212


MmugDNA.12745.1.S1_at
integrin, alpha 8
ITGA8
2.02
0.0990


MmugDNA.20321.1.S1_at
HIR (histone cell cycle regulation defective, S. cerevisiae)
LOC719142
2.02
0.0441



homolog A


MmuSTS.2829.1.S1_at
—
—
2.02
0.0906


MmugDNA.12571.1.S1_at
Ras-associated protein Rap1
LOC694037
2.02
0.0243


MmugDNA.34707.1.S1_at
slit and trk like 6
LOC699338
2.02
0.0231


MmugDNA.19770.1.S1_at
tumor differentially expressed 2-like
SERINC2
2.01
0.0493


MmugDNA.18541.1.S1_at
RAB guanine nucleotide exchange factor (GEF) 1
LOC695887
2.01
0.0739


MmugDNA.8837.1.S1_at
karyopherin alpha 4
KPNA4
2.01
0.0619


MmugDNA.22626.1.S1_at
dihydrolipoamide S-acetyltransferase (E2 component of
—
2.01
0.0061



pyruvate dehydrogenase complex)


MmugDNA.6899.1.S1_at
—
—
2.01
0.0370


MmugDNA.40422.1.S1_at
—
—
2.01
0.0545


MmugDNA.12060.1.S1_at
UDP-glucose:glycoprotein glucosyltransferase 2
LOC697784
2.01
0.0461


MmugDNA.23452.1.S1_at
valosin containing protein (p97)/p47 complex interacting
LOC703582
2.01
0.0501



protein 1


MmugDNA.6995.1.S1_at
—
—
2.01
0.0671


MmugDNA.599.1.S1_at
dpy-19-like 3
LOC700921
2.01
0.0681


Mmu.2601.1.S1_at
transmembrane emp24 protein transport domain containing 4
LOC699105
2.01
0.0032


MmuSTS.4174.1.S1_at
Cathepsin F precursor (CATSF)
LOC713743
2.01
0.0025


MmugDNA.26527.1.S1_at
zinc finger protein 697
LOC715582
2.01
0.0171


MmunewRS.902.1.S1_at
embigin homolog
LOC702068
2.01
0.0964


MmugDNA.10114.1.S1_at
odd Oz/ten-m homolog 4
LOC701138
2.01
0.0938


MmugDNA.37121.1.S1_at
dishevelled-associated activator of morphogenesis 1
LOC701706
2.01
0.0282


MmugDNA.34099.1.S1_at
—
—
2.00
0.0953


MmugDNA.25664.1.S1_at
zinc finger protein 710
LOC701358
2.00
0.0791


MmugDNA.33143.1.S1_at
nuclear factor, interleukin 3 regulated
LOC704757
2.00
0.0359


MmugDNA.4085.1.S1_at
cyclin E1 isoform 1
LOC700589
2.00
0.0203


MmuSTS.749.1.S1_at
LysM, putative peptidoglycan-binding, domain containing 1
LOC709539
2.00
0.0752


MmugDNA.24820.1.S1_at
casein kinase 1, gamma 3
CSNK1G3
2.00
0.0461


MmugDNA.29470.1.S1_at
—
—
2.00
0.0098


MmugDNA.19512.1.S1_at
tenascin C (hexabrachion)
TNC
92.06
0.0005


MmugDNA.6877.1.S1_at
ankyrin repeat and sterile alpha motif domain containing 1B
LOC694033
37.28
0.0256


MmuSTS.2164.1.S1_s_at
BUB1 budding uninhibited by benzimidazoles 1 homolog
LOC696598
30.10
0.0998


MmuSTS.355.1.S1_at
podoplanin
PDPN
29.70
0.0578


MmugDNA.23448.1.S1_at
Keratin, type I cytoskeletal 14 (Cytokeratin-14) (CK-14)
LOC703932
26.57
0.0038



(Keratin-14) (K14)


MmugDNA.1670.1.S1_at
cysteine and tyrosine-rich 1 protein precursor
LOC708008
25.38
0.0325


MmuSTS.4685.1.S1_at
thymidylate synthetase
TYMS
24.58
0.0475


MmugDNA.2975.1.S1_at
DNA polymerase epsilon subunit 2
LOC707526
24.10
0.0653


MmugDNA.32729.1.S1_at
antigen identified by monoclonal antibody Ki-67
MKI67
22.59
0.0758


MmugDNA.33387.1.S1_at
T-LAK cell-originated protein kinase
PBK
19.75
0.0623


MmuSTS.3275.1.S1_at
Probable dimethyladenosine transferase (S-
—
19.29
0.0213



adenosylmethionine-6-N,N-adenosyl(rRNA)



dimethyltransferase) (18S rRNA dimethylase)


MmugDNA.13802.1.S1_at
decorin
DCN
17.00
0.0183


MmuSTS.4094.1.S1_at
endothelin receptor type B
EDNRB
16.58
0.0867


MmugDNA.17329.1.S1_at
cell division cycle associated 7
LOC696474
16.22
0.0389


MmugDNA.38956.1.S1_at
nucleolar and spindle associated protein 1
NUSAP1
15.82
0.0583


MmugDNA.24653.1.S1_at
hyaluronan-mediated motility receptor
HMMR
14.87
0.0507


MmugDNA.12273.1.S1_at
DNA topoisomerase II, alpha isozyme
TOP2A
14.45
0.0012


MmugDNA.17571.1.S1_at
Repetin
LOC712894
14.37
0.0893


MmugDNA.40742.1.S1_at
cyclin B2
LOC702184
14.17
0.0157


MmugDNA.36470.1.S1_at
kinetochore associated 2
LOC696232
13.85
0.0725


MmugDNA.19272.1.S1_s_at
sperm associated antigen 5
SPAG5
13.79
0.0181


MmuSTS.844.1.S1_at
lymphocyte-specific protein 1 isoform 1
LOC721048
13.75
0.0307


MmugDNA.25384.1.S1_at
Ubiquitin-conjugating enzyme E2 C (Ubiquitin-protein ligase
UBE2C
13.38
0.0002



C) (Ubiquitin carrier protein C) (UbcH10)


MmuSTS.2303.1.S1_s_at
discs large homolog 7
LOC696772
13.04
0.0536


MmuSTS.1203.1.S1_at
alpha 1 type XV collagen
COL15A1
12.52
0.0022


MmugDNA.11364.1.S1_at
forkhead box M1 isoform 3
LOC708805
12.31
0.0691


MmugDNA.18486.1.S1_s_at
serine protease inhibitor, Kazal type 2 (acrosin-trypsin
LOC693946
12.30
0.0374



inhibitor)


MmuSTS.2672.1.S1_at
centromere protein F (350/400 kD)
LOC709000
12.11
0.0860


MmugDNA.41909.1.S1_at
endomucin
LOC709580
12.02
0.0215


MmugDNA.24707.1.S1_at
Fibroblast growth factor 19 precursor (FGF-19)
FGF19
11.99
0.0680


MmugDNA.19464.1.S1_at
ubiquitin-like, containing PHD and RING finger domains, 1
LOC695531
11.73
0.0111


MmugDNA.28534.1.S1_at
interleukin 1 receptor, type II
IL1R2
11.11
0.0247


MmuSTS.3846.1.S1_at
sulfotransferase, estrogen-preferring
SULT1E1
11.06
0.0880


MmuSTS.1223.1.S1_at
periostin, osteoblast specific factor
POSTN
10.97
0.0077


MmugDNA.10977.1.S1_at
DAZ interacting protein 1 isoform 2
LOC695529
10.94
0.0839


MmugDNA.33823.1.S1_s_at
KIAA0101
KIAA0101
10.89
0.0363


MmugDNA.35172.1.S1_at
hypothetical protein LOC701037
LOC701037
10.86
0.0896


MmuSTS.1955.1.S1_at
baculoviral IAP repeat-containing protein 5 isoform 1
LOC709565
10.69
0.0838


MmugDNA.40509.1.S1_at
basonuclin 2
BNC2
10.50
0.0020


MmugDNA.33427.1.S1_at
—
—
10.41
0.0428


MmuSTS.3136.1.S1_at
Regulator of G-protein signaling 5
RGS5
10.29
0.0555


MmugDNA.4481.1.S1_at
EGF-containing fibulin-like extracellular matrix protein 1
LOC718984
10.22
0.0021



precursor


MmuSTS.2035.1.S1_at
platelet-derived growth factor receptor alpha
PDGFRA
10.01
0.0496


MmuSTS.3987.1.S1_at
—
SLC27A3
9.99
0.0105


MmugDNA.8100.1.S1_at
polymerase (DNA directed), epsilon
POLE
9.87
0.0244


MmugDNA.9037.1.S1_at
Nasopharyngeal carcinoma-associated antigen NPC-A-5
—
9.87
0.0936


MmugDNA.33356.1.S1_at
development and differentiation enhancing factor 1
LOC695681
9.84
0.0572


MmugDNA.33929.1.S1_at
trophinin associated protein (tastin)
LOC709931
9.71
0.0772


MmuSTS.4310.1.S1_at
histone 1, H2ai (predicted)
LOC695891
9.64
0.0566


MmuSTS.2700.1.S1_at
E2F transcription factor 7
LOC694423
9.61
0.0927


MmugDNA.9851.1.S1_at
arachidonate 15-lipoxygenase
ALOX15
9.59
0.0773


MmugDNA.4983.1.S1_at
collagen, type XXVII, alpha 1
LOC708451
9.38
0.0390


MmuSTS.2858.1.S1_at
SRY (sex determining region Y)-box 15
SOX15
9.38
0.0147


MmunewRS.17.1.S1_at
aurora kinase B
AURKB
9.35
0.0340


MmuSTS.1534.1.S1_at
—
KIF20A
9.26
0.0827


MmugDNA.34877.1.S1_at
melanoma-associated chondroitin sulfate proteoglycan 4
LOC713086
9.25
0.0703


MmuSTS.1125.1.S1_at
snail 2
SNAI2
9.21
0.0089


MmugDNA.37680.1.S1_at
WD repeat and HMG-box DNA binding protein 1
WDHD1
9.11
0.0234


MmugDNA.5089.1.S1_at
growth factor receptor-bound protein 10 isoform a
LOC694786
9.10
0.0634


MmugDNA.40702.1.S1_at
enolase superfamily member 1
ENOSF1
9.03
0.0552


Mmu.11047.2.S1_s_at
Ig gamma-1 chain C region
LOC711303
8.99
0.0572


MmuSTS.4834.1.S1_at
glioma-associated oncogene homolog 1
GLI1
8.98
0.0230


MmugDNA.32726.1.S1_at
Antigen KI-67
LOC705021
8.97
0.0000


MmugDNA.25678.1.S1_at
EGF-like-domain, multiple 9
LOC700106
8.94
0.0026


MmuSTS.3919.1.S1_s_at
regulator of G-protein signaling 10 isoform a
LOC703125
8.93
0.0254


MmugDNA.23023.1.S1_at
hypothetical protein LOC702839
LOC702839
8.93
0.0988


MmugDNA.13565.1.S1_at
kinesin family member 11
KIF11
8.83
0.0906


MmuSTS.1877.1.S1_at
collagen, type XVIII, alpha 1
COL18A1
8.81
0.0147


MmugDNA.34601.1.S1_at
Ribosomal protein S6
RPS6
8.79
0.0857


MmugDNA.33493.1.S1_at
tumor protein p73-like
LOC703997
8.70
0.0516


MmugDNA.13626.1.S1_at
prostaglandin I2 (prostacyclin) synthase /// prostaglandin I2
PTGIS
8.67
0.0049



(prostacyclin) synthase


MmugDNA.15250.1.S1_at
centromere protein A, 17 kDa
CENPA
8.66
0.0498


MmugDNA.32562.1.S1_s_at
Hemoglobin theta-1 subunit (Hemoglobin theta-1 chain)
HBQ1 ///
8.53
0.0646



(Theta-1-globin) /// alpha 2 globin
LOC701930


MmugDNA.31059.1.S1_at
Securin (Pituitary tumor-transforming protein 1) (Tumor
PTTG1
8.52
0.0329



transforming protein 1) (Esp1-associated protein) (hPTTG)


MmugDNA.24523.1.S1_at
cell division cycle associated 2
LOC711581
8.46
0.0921


MmugDNA.33436.1.S1_at
thymosin-like 8
LOC693501
8.40
0.0296


MmugDNA.978.1.S1_at
CDNA FLJ41452 fis, clone BRSTN2010363
—
8.22
0.0795


MmugDNA.21584.1.S1_s_at
—
—
8.21
0.0000


MmuSTS.2916.1.S1_at
iroquois homeobox protein 2
IRX2
8.18
0.0698


MmugDNA.7359.1.S1_s_at
TYRO protein tyrosine kinase binding protein
TYROBP
8.15
0.0468


MmugDNA.33098.1.S1_at
homeobox A3 isoform a
LOC699979
8.11
0.0577


MmugDNA.18373.1.S1_at
hypothetical protein LOC697150
LOC697150
8.11
0.0360


MmugDNA.8851.1.S1_at
E2F transcription factor 2
E2F2
8.10
0.0630


MmugDNA.21962.1.S1_at
inhibin beta A
INHBA
8.09
0.0493


MmuSTS.1592.1.S1_at
neuritin
LOC722968
8.08
0.0300


MmuSTS.4722.1.S1_at
thyroid hormone receptor interactor 13
LOC709328
7.99
0.0914


MmugDNA.16663.1.S1_at
alpha 1 type VII collagen
COL7A1
7.91
0.0603


MmugDNA.5836.1.S1_at
pregnancy-associated plasma protein A, pappalysin 1
PAPPA
7.58
0.0602


MmuSTS.2073.1.S1_at
peripheral myelin protein 22
LOC693527
7.57
0.0237


MmugDNA.29315.1.S1_at
DEP domain containing 1a
LOC701888
7.46
0.0609


MmuSTS.4833.1.S1_at
gap junction protein, beta 5 (connexin 31.1)
LOC711078
7.46
0.0501


MmugDNA.36119.1.S1_at
hypothetical protein FLJ10357
FLJ10357
7.46
0.0549


MmuSTS.4814.1.S1_at
gamma-aminobutyric acid (GABA) A receptor, epsilon
GABRE
7.35
0.0325


MmugDNA.29829.1.S1_at
hypothetical protein LOC718022
LOC718022
7.26
0.0181


MmugDNA.10011.1.S1_at
establishment of cohesion 1 homolog 2
LOC713186
7.23
0.0759


MmugDNA.15721.1.S1_at
DNA polymerase theta
POLQ
7.21
0.0495


MmugDNA.23132.1.S1_s_at
muscleblind-like 1
LOC708735
7.18
0.0870


MmugDNA.16746.1.S1_at
Transcribed locus
—
7.13
0.0397


MmugDNA.9813.1.S1_at
steroid-sensitive protein 1
LOC708504
7.09
0.0041


MmugDNA.42865.1.S1_at
cell division cycle 2 protein
CDC2
7.09
0.0944


MmuSTS.673.1.S1_s_at
chromatin assembly factor 1, subunit A (p150)
LOC721861
7.08
0.0407


MmugDNA.42327.1.S1_at
fibulin 1
FBLN1
7.05
0.0157


MmuSTS.3146.1.S1_s_at
minichromosome maintenance deficient protein 5
MCM5
7.02
0.0229


MmugDNA.9770.1.S1_at
G-2 and S-phase expressed 1
LOC714207
7.02
0.0673


MmuSTS.4144.1.S1_at
glutathione transferase A5
—
7.01
0.0016


MmugDNA.1499.1.S1_at
Pigment epithelium-derived factor precursor (PEDF) (EPC-
LOC721262
6.99
0.0750



1)


MmuSTS.1535.1.S1_at
kinesin family member 2C
KIF2C
6.86
0.0738


MmuSTS.3642.1.S1_at
fibroblast growth factor receptor 2
FGFR2
6.84
0.0157


MmugDNA.3959.1.S1_at
hypothetical protein LOC701440
LOC701440
6.74
0.0674


MmugDNA.22744.1.S1_s_at
—
—
6.73
0.0581


MmugDNA.10643.1.S1_s_at
Apolipoprotein D precursor (Apo-D) (ApoD)
LOC709223
6.71
0.0197


MmugDNA.41251.1.S1_at
hypothetical protein LOC712701
LOC712701
6.69
0.0805


MmugDNA.25121.1.S1_at
pancreatic ribonuclease
RNASE1
6.65
0.0350


MmugDNA.18755.1.S1_at
hypothetical protein LOC200030
LOC200030
6.64
0.0332


MmuSTS.644.1.S1_at
citron
LOC695846
6.63
0.0190


MmugDNA.35559.1.S1_at
Histone H1.2 (H1d)
LOC698238
6.62
0.0050


MmugDNA.37528.1.S1_at
—
—
6.57
0.0211


MmugDNA.41268.1.S1_at
cyclin B1
CCNB1
6.55
0.0927


MmugDNA.40366.1.S1_at
solute carrier family 24, member 5
SLC24A5
6.55
0.0000


Mmu.5727.1.S1_at
G1/S-specific cyclin-D2
CCND2
6.53
0.0003


MmugDNA.9497.1.S1_at
kinesin family member C1
KIFC1
6.44
0.0172


MmuSTS.1904.1.S1_at
dicer1
LOC702516
6.43
0.0387


MmugDNA.25436.1.S1_at
minichromosome maintenance protein 3
MCM3
6.40
0.0000


MmuSTS.1881.1.S1_at
alpha 3 type VI collagen isoform 5 precursor
LOC694701
6.38
0.0086


MmuSTS.4021.1.S1_at
cytochrome P450, family 4, subfamily B, polypeptide 1
LOC709290
6.35
0.0285


MmugDNA.35290.1.S1_at
hypothetical protein LOC696863
LOC696863
6.33
0.0371


MmugDNA.32826.1.S1_at
kallikrein 8 isoform 2
—
6.32
0.0948


MmugDNA.36260.1.S1_at
EGF, latrophilin and seven transmembrane domain
ELTD1
6.31
0.0018



containing 1


MmuSTS.4328.1.S1_at
plasminogen activator inhibitor type 1, member 2
SERPINE2
6.28
0.0044


MmugDNA.41228.1.S1_at
NADP-dependent leukotriene B4 12-hydroxydehydrogenase ///
LTB4DH
6.27
0.0527



NADP-dependent leukotriene B4 12-



hydroxydehydrogenase (15-oxoprostaglandin 13-reductase)


MmugDNA.31506.1.S1_at
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2
HMGCS2
6.25
0.0306



(mitochondrial)


MmuSTS.3741.1.S1_at
tyrosine phosphatase, receptor-type, Z polypeptide 1
PTPRZ1
6.23
0.0829


MmugDNA.20272.1.S1_at
cysteine-rich, angiogenic inducer, 61
CYR61
6.21
0.0552


MmugDNA.14075.1.S1_at
Restin
—
6.21
0.0576


MmugDNA.35622.1.S1_at
Kinesin family member 14
KIF14
6.21
0.0036


MmugDNA.19983.1.S1_s_at
testis derived transcript
CAV1
6.20
0.0330


MmuSTS.1023.1.S1_at
—
SCN4B
6.19
0.0994


MmugDNA.42793.1.S1_at
calcium/calmodulin-dependent protein kinase kinase 1,
CAMKK1
6.18
0.0467



alpha


MmugDNA.23406.1.S1_at
SH3 domain containing ring finger 2
SH3RF2
6.17
0.0135


MmugDNA.19771.1.S1_at
Transcribed locus
—
6.16
0.0821


MmuSTS.1779.1.S1_at
NIMA (never in mitosis gene a)-related kinase 2
NEK2
6.16
0.0886


MmugDNA.7491.1.S1_at
Biliverdin reductase A
—
6.13
0.0066


MmugDNA.30433.1.S1_at
SHC SH2-domain binding protein 1
LOC716009
6.05
0.0001


MmugDNA.13151.1.S1_at
Probable G-protein coupled receptor 92
GPR92
6.04
0.0268


MmugDNA.39863.1.S1_at
chromosome 18 open reading frame 24
C18orf24
5.99
0.0496


MmugDNA.34856.1.S1_at
RNA binding motif protein 6
RBM6
5.96
0.0446


Mmu.16175.1.S1_at
CK230007
—
5.95
0.0684


Mmu.11188.1.S1_at
caldesmon 1 isoform 4
LOC707050
5.93
0.0513


MmuSTS.2639.1.S1_at
FAT tumor suppressor 2 precursor
LOC713698
5.91
0.0047


MmugDNA.22443.1.S1_at
nuclear factor I/B
NFIB
5.88
0.0187


MmugDNA.19397.1.S1_at
Chromosome 2 open reading frame 17
C2orf17
5.88
0.0483


MmugDNA.26212.1.S1_at
ephrin-B1
EFNB1
5.88
0.0634


MmugDNA.27687.1.S1_s_at
guanine nucleotide binding protein gamma 11
LOC700606
5.87
0.0207


MmugDNA.42502.1.S1_at
Activity-dependent neuroprotector
ADNP
5.86
0.0016


MmugDNA.35031.1.S1_at
Transcription factor COE1 (OE-1) (O/E-1) (Early B-cell
LOC694086
5.82
0.0007



factor) (Olfactory neuronal transcription factor) (Olf-1)


Mmu.1262.1.A1_at
—
MEF2C
5.82
0.0164


MmuSTS.2987.1.S1_at
MADS box transcription enhancer factor 2, polypeptide C
LOC694992
5.77
0.0370



(myocyte enhancer factor 2C)


MmugDNA.24078.1.S1_at
hypothetical protein LOC699417
LOC699417
5.76
0.0711


MmugDNA.40153.1.S1_at
olfactomedin-like 2A
OLFML2A
5.74
0.0254


MmugDNA.37742.1.S1_at
oncostatin M receptor
LOC693569
5.74
0.0716


MmugDNA.8988.1.S1_at
hypothetical protein LOC143381
LOC143381
5.70
0.0738


MmugDNA.18189.1.S1_at
Insulin-like growth factor-binding protein 4 precursor
LOC700963
5.69
0.0440



(IGFBP-4) (IBP-4) (IGF-binding protein 4)


MmugDNA.8529.1.S1_at
Secretory granule proteoglycan core protein precursor
PRG1
5.63
0.0001



(Platelet proteoglycan core protein) (P.PG) (Hematopoetic



proteoglycan core protein) (Serglycin)


MmugDNA.23178.1.S1_at
Chromobox homolog 5 (HP1 alpha homolog, Drosophila)
CBX5
5.59
0.0958


MmugDNA.36354.1.S1_at
fibroblast growth factor receptor 3
FGFR3
5.59
0.0298


MmugDNA.39673.1.S1_at
SRY (sex determining region Y)-box 6
SOX6
5.57
0.0064


MmuSTS.4420.1.S1_at
TPX2, microtubule-associated protein homolog
TPX2
5.54
0.0556


MmugDNA.12787.1.S1_at
tensin /// tensin
TNS
5.54
0.0009


MmugDNA.35052.1.S1_at
Dermatopontin precursor (Tyrosine-rich acidic matrix
LOC700181
5.51
0.0038



protein) (TRAMP)


MmugDNA.27071.1.S1_at
retinoic acid receptor responder (tazarotene induced) 2
LOC704993
5.50
0.0557


MmugDNA.21100.1.S1_at
laminin alpha 3 subunit isoform 1
LOC701313
5.49
0.0087


MmugDNA.37305.1.S1_at
FRA10AC1 protein
LOC700389
5.48
0.0630


MmugDNA.17614.1.S1_at
T-box 5
TBX5
5.48
0.0963


MmugDNA.23701.1.S1_at
—
—
5.46
0.0105


MmugDNA.6672.1.S1_at
dystonin
DST
5.46
0.0844


MmugDNA.40463.1.S1_at
MRNA; cDNA DKFZp686B0610 (from clone
—
5.44
0.0808



DKFZp686B0610)


MmuSTS.2214.1.S1_at
six transmembrane epithelial antigen of the prostate
STEAP1
5.44
0.0063


MmuSTS.1928.1.S1_at
myeloblastosis proto-oncogene product isoform 2
LOC712321
5.41
0.0003


MmugDNA.35645.1.S1_s_at
Rho GTPase activating protein 9
ARHGAP9
5.40
0.0030


MmugDNA.14897.1.S1_at
AXL receptor tyrosine kinase isoform 2
LOC706123
5.35
0.0181


MmugDNA.1117.1.S1_at
Friend leukemia virus integration 1
FLI1
5.35
0.0975


MmuSTS.4424.1.S1_at
frizzled 7
LOC703064
5.31
0.0161


MmugDNA.25887.1.S1_s_at
filamin 1 (actin-binding protein-280)
FLNA
5.29
0.0256


MmugDNA.40242.1.S1_at
LOC441301
—
5.27
0.0914


MmugDNA.21548.1.S1_s_at
anthrax toxin receptor 2
LOC696513
5.26
0.0654


MmugDNA.36182.1.S1_at
aquaporin 1
AQP1
5.26
0.0435


MmugDNA.14767.1.S1_at
FRAS1 related extracellular matrix protein 2
FREM2
5.25
0.0835


MmugDNA.33751.1.S1_at
Dexamethasone-induced Ras-related protein 1 (Activator of
RASD1
5.25
0.0984



G-protein signaling 1)


MmugDNA.25691.1.S1_at
solute carrier family 16 (monocarboxylic acid transporters),
SLC16A6
5.25
0.0466



member 6


MmuSTS.1922.1.S1_at
v-ets erythroblastosis virus E26 oncogene homolog 1
ETS1
5.23
0.0322


MmugDNA.3558.1.S1_at
serine/threonine protein kinase 6
AURKA
5.22
0.0358


MmugDNA.4124.1.S1_at
cell division cycle associated 5
LOC721995
5.21
0.0575


MmugDNA.2333.1.S1_at
synaptopodin
SYNPO
5.21
0.0006


MmuSTS.2701.1.S1_at
epidermal growth factor-like protein 6 precursor
LOC711280
5.20
0.0491


MmugDNA.40392.1.S1_at
lumican
LUM
5.19
0.0120


MmugDNA.21491.1.S1_at
CDNA clone IMAGE: 6043059, partial cds
—
5.19
0.0980


MmugDNA.22192.1.S1_at
vitamin K-dependent protein S precursor
LOC694845
5.18
0.0750


MmugDNA.28039.1.S1_at
Chromosome 10 open reading frame 18
C10orf18
5.17
0.0535


MmugDNA.23945.1.S1_at
mitochondrial ribosomal protein L54
LOC713878
5.16
0.0885


MmugDNA.28350.1.S1_at
Heparin-binding growth factor 1 precursor (HBGF-1) (Acidic
FGF1
5.16
0.0183



fibroblast growth factor) (aFGF) (Beta-endothelial cell



growth factor) (ECGF-beta)


MmugDNA.4851.1.S1_at
angiotensin II receptor, type 1
LOC712773
5.15
0.0653


MmugDNA.34285.1.S1_at
nitric oxide synthase trafficking isoform 1
—
5.14
0.0724


MmugDNA.19357.1.S1_at
Transcribed locus, strongly similar to XP_496055.1 similar
—
5.13
0.0676



to p40 [Homo sapiens]


Mmu.14966.1.S1_at
EH domain binding protein 1
LOC693902
5.12
0.0757


MmugDNA.42808.1.S1_at
transcription factor 8 (represses interleukin 2 expression)
TCF8
5.11
0.0254


MmugDNA.30007.1.S1_at
coiled-coil domain containing 102A
LOC704988
5.10
0.0846


MmugDNA.5184.1.S1_s_at
beta globin
LOC715559
5.10
0.0122


MmuSTS.2069.1.S1_at
Rac GTPase activating protein 1
LOC711887
5.06
0.0587


MmugDNA.15651.1.S1_at
steroid sulfatase (microsomal), arylsulfatase C, isozyme S
STS
5.04
0.0307


MmugDNA.19465.1.S1_at
Transcribed locus, weakly similar to NP_060190.1 signal-
—
5.03
0.0125



transducing adaptor protein-2 [Homo sapiens]


MmugDNA.27239.1.S1_s_at
retinol-binding protein 4, plasma precursor
LOC701270
5.03
0.0423


MmugDNA.43409.1.S1_at
solute carrier family 27 member 3
LOC718424
5.02
0.0762


MmugDNA.13155.1.S1_at
chondroitin sulfate proteoglycan 2 (versican)
LOC712365
5.00
0.0576


MmugDNA.18099.1.S1_at
complement component 3
C3
4.97
0.0146


MmuSTS.2151.1.S1_at
branched chain aminotransferase 1, cytosolic
LOC707321
4.96
0.0031


MmunewRS.412.1.S1_s_at
solute carrier family 9 (sodiumhydrogen exchanger), isoform
SLC9A4
4.95
0.0130



4 (SLC9A4), mRNA


MmugDNA.9733.1.S1_at
Muscleblind-like (Drosophila)
MBNL1
4.95
0.0396


MmugDNA.20784.1.S1_at
quaking homolog, KH domain RNA binding (mouse)
QKI
4.95
0.0001


MmuSTS.2287.1.S1_at
peroxisome proliferator-activated receptor gamma 1-b
PPARGAMMA
4.93
0.0218


MmuSTS.1783.1.S1_at
nuclear factor I/A
LOC694022
4.92
0.0568


MmugDNA.5690.1.S1_at
septin 4 isoform 3
LOC714724
4.92
0.0427


MmugDNA.23105.1.S1_s_at
Ig lambda chain V-II region BUR /// Ig lambda chain V-II
LOC706778 ///
4.91
0.0034



region MGC /// Immunoglobulin lambda-like polypeptide 1
LOC707940 ///



precursor (Immunoglobulin-related protein 14.1)
LOC708547 ///



(Immunoglobulin omega polypeptide) (Ig lambda-5)
LOC720711



(CD179b antigen) /// Ig lambda chain V-II region NIG-84


MmugDNA.39956.1.S1_at
Hairless homolog (mouse)
HR
4.90
0.0242


MmuSTS.2029.1.S1_at
polo-like kinase
PLK1
4.88
0.0403


MmuSTS.154.1.S1_x_at
—
BTN3A2
4.87
0.0977


MmugDNA.35115.1.S1_at
heparan sulfate proteoglycan 2
HSPG2
4.85
0.0002


MmugDNA.964.1.S1_at
SH3-domain binding protein 1
SH3BP1
4.83
0.0803


MmugDNA.9449.1.S1_at
WD repeat domain 76
LOC711191
4.83
0.0376


MmuSTS.165.1.S1_at
inhibitor of DNA binding 3
LOC710290
4.82
0.0001


MmugDNA.43567.1.S1_at
Homo sapiens, Similar to hypothetical protein FLJ21936,
—
4.82
0.0615



clone IMAGE: 4044084, mRNA


MmugDNA.40816.1.S1_at
tumor necrosis factor, alpha-induced protein 9
TNFAIP9
4.82
0.0196


MmugDNA.23454.1.S1_at
15-hydroxyprostaglandin dehydrogenase [NAD+] (PGDH)
HPGD
4.82
0.0099



(Prostaglandin dehydrogenase 1)


MmugDNA.38346.1.S1_at
phosphoserine aminotransferase isoform 1
LOC706387
4.81
0.0646


MmugDNA.28728.1.S1_at
KIAA0485 protein
KIAA0485
4.80
0.0069


MmuSTS.4004.1.S1_at
thrombospondin 1 precursor
LOC705413
4.78
0.0185


MmugDNA.23996.1.S1_at
alpha 2 type I collagen
LOC700359
4.75
0.0161


MmugDNA.18235.1.S1_at
TGFB-induced factor 2 (TALE family homeobox)
TGIF2
4.72
0.0241


MmugDNA.30842.1.S1_s_at
Transgelin (Smooth muscle protein 22-alpha) (SM22-alpha)
TAGLN
4.71
0.0509



(WS3-10) (22 kDa actin-binding protein)


MmugDNA.822.1.S1_at
Transcribed locus, moderately similar to XP_517655.1
—
4.71
0.0218



similar to KIAA0825 protein [Pan troglodytes]


MmugDNA.19564.1.S1_s_at
melanoma cell adhesion molecule
LOC708449
4.71
0.0221


MmugDNA.26005.1.S1_at
thyroglobulin
TG
4.71
0.0150


MmugDNA.9817.1.S1_at
Likely ortholog of mouse TORC2-specific protein AVO3
AVO3
4.70
0.0316



(S. cerevisiae)


MmugDNA.12099.1.S1_at
transducer of ERBB2, 1
TOB1
4.70
0.0197


MmugDNA.20357.1.S1_at
interleukin 1 receptor, type I
IL1R1
4.69
0.0159


MmugDNA.38818.1.S1_at
adipocyte enhancer binding protein 1 precursor
LOC699977
4.67
0.0329


MmugDNA.34995.1.S1_s_at
collagen, type I, alpha 1
COL1A1
4.66
0.0032


MmugDNA.4218.1.S1_at
four and a half LIM domains 1
FHL1
4.65
0.0322


MmuSTS.869.1.S1_at
dysferlin
DYSF
4.64
0.0604


MmugDNA.31007.1.S1_s_at
fibronectin 1
FN1
4.63
0.0000


MmugDNA.21203.1.S1_x_at
amyloid beta (A4) precursor protein-binding, family B,
LOC707383
4.61
0.0921



member 1 interacting protein


MmugDNA.16224.1.S1_s_at
hypothetical protein LOC704308
LOC704308
4.60
0.0117


MmugDNA.22096.1.S1_at
Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-
LGALS1
4.59
0.0571



galactoside-binding lectin L-14-I) (Lactose-binding lectin 1)



(S-Lac lectin 1) (Galaptin) (14 kDa lectin) (HPL) (HBL)



(Putative MAPK-activating protein MP12)


MmugDNA.26778.1.S1_at
Hypothetical protein similar to KIAA0187 gene product
LOC96610
4.58
0.0395


MmugDNA.16831.1.S1_s_at
synuclein, gamma (breast cancer-specific protein 1)
LOC696535
4.58
0.0058


MmugDNA.35261.1.S1_at
Fc fragment of IgG, low affinity IIa, receptor (CD32)
FCGR2A
4.58
0.0713


MmugDNA.31316.1.S1_at
hypothetical protein LOC702054 /// hypothetical protein
LOC702054 ///
4.57
0.0204



LOC702584
LOC702584


MmugDNA.30287.1.S1_at
GTPase, IMAP family member 6 isoform 1
LOC713565
4.57
0.0897


MmugDNA.5299.1.S1_at
Rho-related BTB domain containing 1
RHOBTB1
4.56
0.0702


MmugDNA.30627.1.S1_s_at
jub, ajuba homolog isoform 1
LOC712865
4.55
0.0343


MmuSTS.220.1.S1_at
SCL/TAL1 interrupting locus
LOC710099
4.54
0.0619


MmugDNA.33541.1.S1_at
calpain small subunit 2
LOC698721
4.54
0.0190


MmugDNA.10511.1.S1_at
mucin 15
LOC700194
4.53
0.0419


MmuSTS.90.1.S1_at
high mobility group AT-hook 2
HMGA2
4.53
0.0315


MmugDNA.22320.1.S1_s_at
pregnancy specific beta-1-glycoprotein 4
PSG4
4.52
0.0011


MmugDNA.6347.1.S1_at
runt-related transcription factor 3
RUNX3
4.51
0.0494


MmugDNA.21974.1.S1_at
keratin 5
KRT3
4.50
0.0002


MmugDNA.21584.1.S1_at
—
—
4.49
0.0045


MmugDNA.19709.1.S1_x_at
growth hormone 1
GH1
4.48
0.0372


MmuSTS.4832.1.S1_at
connexin 31
LOC710834
4.48
0.0144


MmugDNA.24059.1.S1_at
Transcribed locus
—
4.47
0.0651


MmugDNA.32484.1.S1_s_at
tissue inhibitor of metalloproteinase 3 (Sorsby fundus
TIMP3
4.47
0.0150



dystrophy, pseudoinflammatory)


MmugDNA.35122.1.S1_at
Discoidin domain receptor family, member 2
DDR2
4.47
0.0050


MmugDNA.18271.1.S1_at
CDNA FLJ44429 fis, clone UTERU2015653
—
4.46
0.0001


MmuSTS.2362.1.S1_at
S100-B (S100 calcium-binding protein B) (S-100 protein
S100B
4.45
0.0185



beta subunit) (S-100 protein beta chain)


MmugDNA.41157.1.S1_at
matrix Gla protein
MGP
4.44
0.0252


MmuSTS.934.1.S1_at
four jointed box 1
LOC717833
4.44
0.0328


MmugDNA.30788.1.S1_at
COBL-like 1
LOC702934
4.41
0.0521


MmugDNA.1969.1.S1_at
hypothetical protein LOC714686
LOC714686
4.40
0.0385


MmuSTS.112.1.S1_at
Asporin precursor (Periodontal ligament-associated protein
LOC718125
4.40
0.0318



1) (PLAP-1)


MmugDNA.13768.1.S1_at
CDNA: FLJ22256 fis, clone HRC02860
—
4.39
0.0198


MmugDNA.28759.1.S1_at
—
—
4.39
0.0482


MmugDNA.15862.1.S1_at
CDC28 protein kinase 2
LOC697324
4.39
0.0028


MmugDNA.22453.1.S1_at
keratin 13 isoform b
LOC706830
4.38
0.0080


MmugDNA.34784.1.S1_at
CDNA FLJ12091 fis, clone HEMBB1002582
—
4.38
0.0522


MmugDNA.41887.1.S1_at
MYB-related protein B
MYBL2
4.36
0.0821


MmugDNA.17000.1.S1_at
Activating transcription factor 7
ATF7
4.36
0.0972


MmugDNA.29263.1.S1_at
Glycoprotein hormones alpha chain precursor (Anterior
LOC697859
4.34
0.0348



pituitary glycoprotein hormones common alpha subunit)



(Follitropin alpha chain) (Follicle-stimulating hormone alpha



chain) (FSH-alpha) (Lutropin alpha chain) (Luteinizing



hormone alph . . .


MmugDNA.21650.1.S1_at
Epidermal growth factor receptor (erythroblastic leukemia
EGFR
4.33
0.0164



viral (v-erb-b) oncogene homolog, avian)


MmugDNA.24420.1.S1_at
kidney predominant protein NCU-G1
LOC719468
4.33
0.0291


MmugDNA.26915.1.S1_at
follistatin
FST
4.32
0.0314


MmugDNA.35764.1.S1_s_at
High affinity immunoglobulin epsilon receptor gamma-
LOC720291
4.32
0.0456



subunit precursor (FceRI gamma) (IgE Fc receptor gamma-



subunit) (Fc-epsilon RI-gamma)


MmugDNA.23015.1.S1_at
Y43E12A.2
LOC702083
4.32
0.0536


MmuSTS.3532.1.S1_at
CD53 antigen
LOC702350
4.31
0.0013


MmuSTS.1975.1.S1_at
nuclear receptor subfamily 3, group C, member 1
NR3C1
4.31
0.0356


MmugDNA.30097.1.S1_at
coronin, actin binding protein, 1C
CORO1C
4.30
0.0925


MmugDNA.16359.1.S1_at
deleted in liver cancer 1
DLC1
4.30
0.0527


MmugDNA.23180.1.S1_at
cartilage associated protein
CRTAP
4.29
0.0637


MmugDNA.11572.1.S1_at
chemokine (C—X—C motif) ligand 12 (stromal cell-derived
CXCL12
4.28
0.0367



factor 1)


MmuSTS.3488.1.S1_at
CD48 antigen precursor (B-lymphocyte activation marker
CD48
4.28
0.0930



BLAST-1) (BCM1 surface antigen) (Leucocyte antigen



MEM-102) (TCT.1)


Mmu.9771.1.S1_at
osteomodulin
OMD
4.28
0.0946


MmugDNA.34344.1.S1_at
Neuron navigator 1
NAV1
4.27
0.0395


MmugDNA.37179.1.S1_at
CG10889-PA
LOC714837
4.27
0.0079


MmugDNA.985.1.S1_at
pyruvate dehydrogenase kinase 4
PDK4
4.25
0.0509


MmugDNA.19882.1.S1_at
potassium channel tetramerisation domain containing 15
LOC704761
4.25
0.0224


MmuSTS.3690.1.S1_at
collagen, type VI, alpha 1
COL6A1
4.23
0.0002


MmuSTS.3265.1.S1_at
RGM domain family, member A
LOC712949
4.23
0.0001


MmugDNA.7509.1.S1_at
hypothetical protein LOC710962
LOC710962
4.22
0.0691


MmugDNA.15267.1.S1_at
RNA binding protein with multiple splicing 2
LOC712536
4.22
0.0002


MmugDNA.15951.1.S1_at
reticulon 4
RTN4
4.21
0.0366


MmugDNA.13995.1.S1_at
—
—
4.21
0.0348


MmugDNA.19825.1.S1_s_at
phosducin-like 3
LOC696369
4.21
0.0667


MmugDNA.3461.1.S1_at
similar to RIKEN cDNA 1200014N16 gene
MGC14289
4.19
0.0308


MmugDNA.23968.1.S1_s_at
ubiquitin specific protease 32
LOC716857
4.19
0.0249


MmuSTS.3891.1.S1_at
smoothened
LOC701334
4.19
0.0433


MmuSTS.3429.1.S1_at
Collagen alpha-1(XII) chain precursor
LOC717820
4.19
0.0386


MmuSTS.1967.1.S1_at
FYN binding protein (FYB-120/130) isoform 1
LOC693951
4.18
0.0997


MmugDNA.27563.1.S1_at
hypothetical protein FLJ13910 /// hypothetical protein
FLJ13910 ///
4.16
0.0252



LOC285074
LOC285074


MmugDNA.15700.1.S1_s_at
phosphoglycerate dehydrogenase
PHGDH
4.15
0.0032


MmuSTS.3850.1.S1_at
ABI gene family, member 3 (NESH) binding protein
LOC701192
4.14
0.0817


MmugDNA.1158.1.S1_at
CD36 antigen (collagen type I receptor, thrombospondin
CD36
4.14
0.0397



receptor)


MmugDNA.34925.1.S1_at
secreted protein, acidic, cysteine-rich (osteonectin)
SPARC
4.09
0.0078


MmugDNA.31894.1.S1_at
thioredoxin interacting protein
LOC698683
4.09
0.0028


MmugDNA.18794.1.S1_at
cell division cycle 20
CDC20
4.09
0.0481


MmuSTS.1308.1.S1_at
dystrophin (muscular dystrophy, Duchenne and Becker
DMD
4.09
0.0098



types)


MmugDNA.27355.1.S1_at
low density lipoprotein-related protein 1
LRP1
4.08
0.0607


MmugDNA.7866.1.S1_at
DNA replication factor
LOC711530
4.07
0.0109


MmugDNA.31873.1.S1_at
Fatty acid-binding protein, adipocyte (AFABP) (Adipocyte
FABP4
4.07
0.0130



lipid-binding protein) (ALBP) (A-FABP)


MmugDNA.36912.1.S1_at
complement factor D preproprotein
LOC721138
4.07
0.0237


MmugDNA.10186.1.S1_at
AF15q14 protein
AF15Q14
4.06
0.0211


MmugDNA.6192.1.S1_at
Baculoviral IAP repeat-containing 6 (apollon)
BIRC6
4.06
0.0861


MmugDNA.26073.1.S1_at
RAB30, member RAS oncogene family
LOC701550
4.03
0.0735


MmugDNA.21516.1.S1_at
phospholipid transfer protein
PLTP
4.03
0.0251


MmugDNA.36883.1.S1_at
PDZ domain containing 3
PDZK3
4.02
0.0007


MmugDNA.16991.1.S1_at
integrin alpha 7 precursor
LOC707279
4.02
0.0319


MmugDNA.3447.1.S1_at
diacylglycerol O-acyltransferase homolog 2
LOC696549
4.02
0.0054


MmugDNA.17919.1.S1_at
arachidonate 15-lipoxygenase, second type
ALOX15B
4.01
0.0499


MmugDNA.35103.1.S1_at
actin, alpha 2, smooth muscle, aorta
ACTA2
4.01
0.0296


Mmu.16433.2.S1_at
collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV,
COL3A1
3.99
0.0332



autosomal dominant)


MmugDNA.24230.1.S1_s_at
chemokine-like factor superfamily 3 isoform a
LOC695592
3.99
0.0604


MmugDNA.16772.1.S1_at
immunoglobulin J chain
LOC706650
3.98
0.0350


MmugDNA.34863.1.S1_at
hypothetical protein LOC283445
LOC283445
3.98
0.0580


MmunewRS.431.1.S1_at
tyrosine phosphatase, receptor type, S
—
3.97
0.0140


MmuSTS.61.1.S1_at
helicase, lymphoid-specific
LOC701598
3.97
0.0034


MmugDNA.34155.1.S1_at
nidogen (enactin)
NID1
3.95
0.0965


MmugDNA.9153.1.S1_s_at
angiopoietin 1
ANGPT1
3.94
0.0482


MmugDNA.36429.1.S1_at
Phosphoglycerate dehydrogenase like 1
PHGDHL1
3.93
0.0965


MmugDNA.26560.1.S1_at
Transcribed locus
—
3.93
0.0251


MmugDNA.36525.1.S1_at
junctional adhesion molecule 2
JAM2
3.91
0.0727


MmugDNA.43116.1.S1_at
glycoprotein (transmembrane) nmb isoform b precursor
LOC704990
3.91
0.0020


MmugDNA.14973.1.S1_at
CDC45-like
LOC711800
3.90
0.0056


MmuSTS.1523.1.S1_at
mannose receptor C type 1
MRC1
3.90
0.0326


MmugDNA.39378.1.S1_at
ribonuclease HI, large subunit
RNASEH2A
3.90
0.0623


MmugDNA.27459.1.S1_at
Transcribed locus
—
3.89
0.0217


MmugDNA.17136.1.S1_at
Sorbin and SH3 domain containing 1
SORBS1
3.89
0.0146


MmugDNA.15966.1.S1_at
Bromodomain adjacent to zinc finger domain, 2A
BAZ2A
3.88
0.0740


MmugDNA.20219.1.S1_at
myc target 1
LOC711296
3.88
0.0363


MmugDNA.43499.1.S1_at
—
—
3.88
0.0557


MmugDNA.10801.1.S1_s_at
—
—
3.86
0.0121


Mmu.6201.1.S1_at
Glycogen phosphorylase, liver
PYGL
3.86
0.0383


MmuSTS.4157.1.S1_at
Mitotic spindle assembly checkpoint protein MAD2A (MAD2-
LOC708574
3.85
0.0975



like 1) (HsMAD2)


MmugDNA.37083.1.S1_at
pleckstrin homology-like domain, family B, member 2
LOC709353
3.84
0.0493


MmugDNA.2976.1.S1_at
hypothetical protein LOC718180
LOC718180
3.83
0.0297


MmugDNA.34946.1.S1_at
—
—
3.82
0.0871


MmugDNA.2272.1.S1_at
CDNA FLJ34664 fis, clone LIVER2000592
—
3.82
0.0256


MmugDNA.27284.1.S1_at
endothelial differentiation, lysophosphatidic acid G-protein-
LOC709208
3.81
0.0286



coupled receptor, 2


MmugDNA.29523.1.S1_at
hypothetical protein LOC700994
LOC700994
3.81
0.0180


MmugDNA.33148.1.S1_at
mitochondrial glycerol 3-phosphate acyltransferase
GPAM
3.79
0.0111


MmugDNA.12151.1.S1_at
chromosome 18 open reading frame 54
LOC694192
3.79
0.0342


MmugDNA.11637.1.S1_s_at
nestin
LOC718562
3.79
0.0391


Mmu.15601.1.S2_s_at
Intestinal alkaline phosphatase
—
3.79
0.0175


MmugDNA.27885.1.S1_at
excision repair cross-complementing rodent repair
LOC699138
3.78
0.0396



deficiency complementation group 6 - like


MmugDNA.33913.1.S1_at
Calmodulin-like 4
CALML4
3.77
0.0635


MmugDNA.42756.1.S1_at
—
—
3.77
0.0776


MmugDNA.33637.1.S1_s_at
melanoma antigen family D, 4 isoform 1
LOC697293
3.76
0.0236


MmugDNA.32538.1.S1_at
ecotropic viral integration site 2B
LOC712972
3.76
0.0866


MmugDNA.7512.1.S1_at
mediator of RNA polymerase II transcription, subunit 13
THRAP1
3.76
0.0009



homolog


MmuSTS.4815.1.S1_at
gamma-aminobutyric acid (GABA) A receptor, pi
GABRP
3.76
0.0213


MmugDNA.42949.1.S1_at
Kinectin 1 (kinesin receptor)
KTN1
3.75
0.0642


MmugDNA.9357.1.S1_at
Similar to ribosomal protein S12
—
3.75
0.0693


MmuSTS.1780.1.S1_at
hypothetical protein LOC710960
LOC710960
3.75
0.0391


MmugDNA.40177.1.S1_at
HRAS-like suppressor 5 (H-rev107-like protein 5)
LOC718317
3.75
0.0439


MmugDNA.41855.1.S1_at
chloride intracellular channel 4
CLIC4
3.75
0.0477


MmugDNA.39310.1.S1_at
homeo box C4
HOXC4
3.75
0.0753


MmugDNA.33364.1.S1_at
lysosomal-associated membrane protein 1
LAMP1
3.75
0.0891


MmuSTS.2956.1.S1_at
Lysosomal-associated multispanning membrane protein-5
LAPTM5
3.74
0.0769


MmugDNA.15666.1.S1_at
prostatic secretory protein (PSP-94)
MSMB
3.74
0.0536


MmugDNA.37771.1.S1_at
Ring finger protein 12
RNF12
3.73
0.0118


MmugDNA.25197.1.S1_at
asp (abnormal spindle)-like, microcephaly associated
LOC711153
3.73
0.0360


MmugDNA.35955.1.S1_at
Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog,
UBE2D3
3.73
0.0666



yeast)


MmugDNA.39545.1.S1_at
sialyltransferase 7
ST6GALNAC2
3.73
0.0048


MmugDNA.24940.1.S1_at
SERTA domain containing 4
SERTAD4
3.73
0.0064


MmuSTS.2245.1.S1_at
phospholipase C, delta 1
PLCD1
3.72
0.0012


MmugDNA.4054.1.S1_at
solute carrier family 25 (mitochondrial carrier; Graves
SLC25A16
3.72
0.0026



disease autoantigen), member 16


MmugDNA.38062.1.S1_at
Very hypothetical protein
—
3.71
0.0666


MmuSTS.1539.1.S1_at
lamin B1
LMNB1
3.70
0.0425


MmugDNA.29710.1.S1_at
mitogen-activated protein kinase kinase kinase 6
LOC715911
3.70
0.0525


MmugDNA.3079.1.S1_at
START domain containing 7
STARD7
3.70
0.0054


MmuSTS.3358.1.S1_at
Hematopoietic progenitor cell antigen CD34 precursor
LOC713858
3.70
0.0201


MmugDNA.23709.1.S1_at
Ras-related protein Rab-13
LOC695135
3.69
0.0042


MmugDNA.13640.1.S1_at
Plunc precursor (Palate lung and nasal epithelium clone
PLUNC
3.68
0.0341



protein) (Lung-specific protein X) (Nasopharyngeal



carcinoma-related protein) (Tracheal epithelium-enriched



protein) (Secretory protein in upper respiratory tracts) (Von



Ebn . . .


MmugDNA.19840.1.S1_at
Flavin containing monooxygenase 2
FMO2
3.67
0.0200


MmugDNA.12797.1.S1_at
early B-cell factor 3
LOC713536
3.67
0.0679


MmugDNA.43327.1.S1_at
Alpha crystallin B chain (Alpha(B)-crystallin) (Rosenthal fiber
CRYAB
3.66
0.0179



component) (Heat-shock protein beta-5) (HspB5) (NY-REN-



27 antigen)


MmugDNA.26357.1.S1_at
CG14299-PA, isoform A
LOC700766
3.65
0.0974


Mmu.16242.1.S1_at
Pallidin (Pallid protein homolog) (Syntaxin 13-interacting
PLDN
3.65
0.0676



protein)


MmugDNA.3343.1.S1_at
suppressor of cytokine signaling 3
SOCS3
3.65
0.0146


MmunewRS.372.1.S1_at
gi:39645656 Homo sapiens similar to Serinethreonine-
MGC75495
3.64
0.0005



protein kinase Nek1 (NimA-related protein kinase 1), mRNA



(cDNA clone MGC: 75495 IMAGE: 30383658), complete cds


MmugDNA.4113.1.S1_at
heat shock 22 kDa protein 8
HSPB8
3.64
0.0306


MmugDNA.42494.1.S1_at
Transcribed locus
—
3.64
0.0679


MmuSTS.4058.1.S1_at
sushi-repeat-containing protein, X-linked
SRPX
3.63
0.0619


MmugDNA.17872.1.S1_at
Putative serum amyloid A-3 protein
SAA3P
3.63
0.0242


MmugDNA.34659.1.S1_s_at
hypothetical protein LOC705662
LOC705662
3.63
0.0100


MmugDNA.34077.1.S1_at
WD repeat and FYVE domain containing 2
WDFY2
3.63
0.0201


MmugDNA.3557.1.S1_at
WD40 repeat protein Interacting with phosphoInositides of
WIPI49
3.62
0.0905



49 kDa


MmugDNA.5835.1.S1_at
hypothetical protein LOC700615
LOC700615
3.62
0.0021


MmunewRS.1055.1.S1_at
Myosin regulatory light chain 2, smooth muscle isoform
LOC709784
3.61
0.0184



(Myosin RLC) (LC20) (Myosin regulatory light chain 9)


MmuSTS.4533.1.S1_at
breast cancer 1, early onset isoform 1
LOC712634
3.61
0.0225


MmugDNA.37529.1.S1_at
pleckstrin homology domain containing, family H (with
LOC713488
3.61
0.0629



MyTH4 domain) member 2


MmugDNA.36745.1.S1_at
tubulin, beta 8
—
3.61
0.0229


MmugDNA.21536.1.S1_at
proline arginine-rich end leucine-rich repeat protein
PRELP
3.61
0.0589


MmugDNA.29432.1.S1_at
CDNA FLJ12246 fis, clone MAMMA1001343
—
3.61
0.0308


MmuSTS.911.1.S1_at
enhancer of zeste 2
EZH2
3.60
0.0107


MmugDNA.17513.1.S1_at
LIM and cysteine-rich domains 1
LMCD1
3.59
0.0642


MmunewRS.170.1.S1_at
gi:34535503 Homo sapiens cDNA FLJ46364 fis, clone
—
3.59
0.0005



TESTI4051015, weakly similar to Aquaporin 7


MmugDNA.37690.1.S1_at
zinc finger protein 208
ZNF208
3.59
0.0722


MmugDNA.14830.1.S1_at
thyroid hormone responsive (SPOT14 homolog, rat)
THRSP
3.58
0.0198


MmugDNA.38914.1.S1_at
Rap guanine nucleotide exchange factor (GEF)-like 1
LOC699843
3.57
0.0737


MmugDNA.15276.1.S1_at
sushi, von Willebrand factor type A, EGF and pentraxin
LOC709478
3.57
0.0542



domain containing 1


MmugDNA.9453.1.S1_at
lysyl oxidase preproprotein
LOC699997
3.57
0.0512


MmuSTS.417.1.S1_at
alpha-2A-adrenergic receptor
ADRA2A
3.56
0.0301


MmugDNA.328.1.S1_at
Nuclear protein 1 (Protein p8) (Candidate of metastasis 1)
P8
3.56
0.0178


MmugDNA.34766.1.S1_at
Corticoliberin precursor (Corticotropin-releasing factor)
LOC702877
3.55
0.0843



(CRF) (Corticotropin-releasing hormone)


MmugDNA.7723.1.S1_at
male-specific lethal 3-like 1 (Drosophila)
MSL3L1
3.55
0.0630


MmugDNA.25407.1.S1_at
carboxypeptidase M
CPM
3.54
0.0593


MmuSTS.1530.1.S1_at
Kv channel interacting protein 2 isoform 6
LOC712434
3.54
0.0273


MmugDNA.12610.1.S1_at
OX-2 membrane glycoprotein precursor (MRC OX-2
CD200
3.54
0.0915



antigen) (CD200 antigen)


MmuSTS.835.1.S1_at
downregulated in ovarian cancer 1 isoform 2
LOC699594
3.54
0.0876


MmugDNA.21403.1.S1_at
trigger of mitotic entry 1
LOC722088
3.53
0.0250


MmugDNA.2694.1.S1_at
ZW10 interactor (ZW10-interacting protein 1) (Zwint-1)
LOC702198
3.52
0.0095


MmugDNA.32957.1.S1_at
CG15105-PA, isoform A
LOC696852
3.51
0.0745


MmunewRS.730.1.S1_at
cadherin 13
CDH13
3.50
0.0291


MmugDNA.28367.1.S1_at
SPARC-like 1
SPARCL1
3.49
0.0017


MmugDNA.28270.1.S1_at
Early B-cell factor
EBF
3.48
0.0343


MmugDNA.30316.1.S1_at
Protein inhibitor of activated STAT, 1
PIAS1
3.48
0.0646


MmuSTS.1363.1.S1_at
annexin A8
ANXA8
3.48
0.0190


MmugDNA.6544.1.S1_at
Triosephosphate isomerase (TIM) (Triose-phosphate
TPI1
3.48
0.0290



isomerase)


MmugDNA.15422.1.S1_at
absent in melanoma 1
LOC697117
3.47
0.0217


MmugDNA.37873.1.S1_at
kinase related protein, telokin
MYLK
3.44
0.0740


MmugDNA.22106.1.S1_at
sterile alpha motif domain containing 4
SAMD4
3.44
0.0269


MmugDNA.25115.1.S1_at
delta-like 1 homolog isoform 1
LOC707595
3.43
0.0452


MmugDNA.25541.1.S1_at
hypothetical protein LOC705360
LOC705360
3.43
0.0002


MmuSTS.3320.1.S1_at
cyclin E2 isoform 1
LOC700382
3.43
0.0417


MmuSTS.4488.1.S1_at
spectrin, beta, non-erythrocytic 1
SPTBN1
3.43
0.0416


MmugDNA.13714.1.S1_at
kallikrein 11 isoform 2 precursor
—
3.43
0.0019


MmugDNA.14368.1.S1_at
lipidosin
LOC709676
3.41
0.0245


MmugDNA.7128.1.S1_at
triggering receptor expressed on myeloid cells 4
TREM4
3.41
0.0097


MmugDNA.15051.1.S1_at
A kinase (PRKA) anchor protein 2
AKAP2
3.41
0.0145


MmugDNA.39271.1.S1_at
Transcribed locus
—
3.41
0.0712


MmugDNA.38296.1.S1_at
KIAA1102 protein
KIAA1102
3.40
0.0636


MmugDNA.12755.1.S1_s_at
bone morphogenetic protein 1
BMP1
3.39
0.0254


MmugDNA.35196.1.S1_at
Transcribed locus
—
3.39
0.0878


MmugDNA.7507.1.S1_at
ATP-binding cassette, sub-family A, member 9
LOC693411
3.39
0.0736


Mmu.15849.1.S1_at
transcription elongation regulator 1 isoform 1
LOC707912
3.38
0.0370


MmugDNA.25155.1.S1_at
Nuclear ubiquitous casein and cyclin-dependent kinases
NUCKS1
3.38
0.0007



substrate (P1)


MmuSTS.2361.1.S1_at
S100-A2 (S100 calcium-binding protein A2) (Protein S-
LOC715264
3.37
0.0014



100L) (CAN19)


MmuAffx.23.12.S1_at
Transcribed locus, strongly XP_001153513.1 hypothetical
—
3.36
0.0459



protein [Pan troglodytes]


MmugDNA.13395.1.S1_at
interferon, gamma-inducible protein 16
LOC719253
3.34
0.0180


MmugDNA.34006.1.S1_at
leucine rich repeat and death domain containing protein
LOC700580
3.34
0.0246



isoform 1


MmugDNA.13401.1.S1_s_at
metastasis associated lung adenocarcinoma transcript 1
MALAT1
3.34
0.0765



(non-coding RNA)


MmuSTS.2405.1.S1_at
growth differentiation factor 11
GDF11
3.34
0.0680


MmugDNA.22100.1.S1_at
Baculoviral IAP repeat-containing protein 5 (Apoptosis
BIRC5
3.34
0.0120



inhibitor survivin) (Apoptosis inhibitor 4)


MmuSTS.2514.1.S1_at
hematopoietically expressed homeobox
LOC699012
3.33
0.0592


MmugDNA.29693.1.S1_at
hypothetical protein FLJ21742
FLJ21742
3.33
0.0066


MmuSTS.1347.1.S1_at
high-mobility group box 2
LOC697057
3.32
0.0266


MmuSTS.1397.1.S1_at
Complement C1q subcomponent subunit B precursor
LOC718307
3.31
0.0198


MmugDNA.42305.1.S1_at
A kinase (PRKA) anchor protein 13
AKAP13
3.31
0.0571


MmugDNA.19389.1.S1_at
Chromosome 21 open reading frame 34
C21orf34
3.30
0.0456


MmugDNA.12452.1.S1_at
hypothetical protein LOC699186
LOC699186
3.30
0.0179


MmugDNA.26596.1.S1_at
methyltransferase like 4
LOC696353
3.30
0.0082


MmuSTS.4306.1.S1_at
glycogenin 2
LOC703955
3.30
0.0119


MmuSTS.1398.1.S1_at
complement component 1, s subcomponent
C1S
3.29
0.0531


MmugDNA.37738.1.S1_at
GRAM domain containing 3
LOC697870
3.29
0.0849


MmugDNA.36423.1.S1_at
angiomotin like 1
LOC698211
3.29
0.0435


MmugDNA.38698.1.S1_at
complement component 1, q subcomponent, receptor 1
C1QR1
3.28
0.0036


MmugDNA.21696.1.S1_at
hypothetical protein BC007901
LOC91461
3.28
0.0816


MmugDNA.20213.1.S1_at
meningioma expressed antigens 5 (hyaluronidase)
MGEA5
3.27
0.0067


MmugDNA.19007.1.S1_at
catalase
CAT
3.26
0.0419


MmugDNA.20699.1.S1_at
hypothetical protein LOC694371
LOC694371
3.26
0.0587


MmugDNA.6381.1.S1_at
cystatin F
LOC704850
3.26
0.0825


MmugDNA.13610.1.S1_at
Full length insert cDNA clone YT94E02
—
3.25
0.0318


MmuSTS.159.1.S1_at
microfibrillar-associated protein 4
LOC709521
3.25
0.0567


MmugDNA.3114.1.S1_at
Wee1-like protein kinase (WEE1hu)
WEE1
3.25
0.0474


MmuSTS.2860.1.S1_at
Neuroligin 4
—
3.24
0.0013


MmuSTS.3636.1.S1_at
Ets2 repressor factor
ERF
3.24
0.0422


MmugDNA.24307.1.S1_s_at
Sarcospan (K-ras oncogene-associated protein) (Kirsten-
SSPN
3.24
0.0853



ras-associated protein)


MmugDNA.18122.1.S1_at
RAP2B, member of RAS oncogene family
RAP2B
3.24
0.0026


MmugDNA.13964.1.S1_at
trophoblast-derived noncoding RNA
TncRNA
3.23
0.0115


MmugDNA.7717.1.S1_at
MCM10 minichromosome maintenance deficient 10 (S. cerevisiae)
MCM10
3.23
0.0644


MmugDNA.10682.1.S1_at
aquaporin 7
AQP7
3.22
0.0409


MmugDNA.9561.1.S1_at
tissue inhibitor of matrix metalloproteinase-2
TIMP-2
3.22
0.0005


MmugDNA.9052.1.S1_at
MAM domain containing 2
LOC700333
3.21
0.0581


MmugDNA.23764.1.S1_at
cyclin A
CCNA2
3.21
0.0284


MmugDNA.962.1.S1_at
platelet-derived growth factor receptor beta /// hypothetical
LOC711667 ///
3.20
0.0641



protein LOC711667
PDGFRB


MmugDNA.30376.1.S1_at
minichromosome maintenance protein 7
MCM7
3.20
0.0000


MmugDNA.40338.1.S1_s_at
Collagen alpha-1(V) chain precursor
LOC722009
3.20
0.0018


MmugDNA.43126.1.S1_at
KIAA1909 protein
KIAA1909
3.19
0.0678


MmugDNA.12886.1.S1_at
hypothetical protein LOC283755 /// D15F37 (pseudogene) ///
LOC283755 ///
3.19
0.0143



MGC57820 protein
MN7 ///




MGC57820


MmugDNA.33174.1.S1_at
T-cell receptor beta chain V region C5 precursor
—
3.18
0.0008


MmugDNA.20801.1.S1_at
Transcribed locus, moderately similar to XP_515629.1
—
3.16
0.0121



similar to U5 snRNP-specific protein, 200 kDa; U5 snRNP-



specific protein, 200 kDa (DEXH RNA helicase family) [Pan



troglodytes]


MmuSTS.249.1.S1_at
integrin, beta 2
ITGB2
3.16
0.0580


MmugDNA.18032.1.S1_at
desmoglein 3 (pemphigus vulgaris antigen)
DSG3
3.16
0.0084


MmugDNA.32328.1.S1_at
lipoma HMGIC fusion partner
LOC696978
3.16
0.0243


MmugDNA.3768.1.S1_at
Kruppel-like factor 8
KLF8
3.16
0.0772


MmugDNA.34645.1.S1_s_at
hypothetical protein LOC714309
LOC714309
3.15
0.0439


MmugDNA.19768.1.S1_at
proliferation associated nuclear element 1 isoform a
LOC709006
3.15
0.0103


MmugDNA.19278.1.S1_at
phosphatase and actin regulator 2
PHACTR2
3.15
0.0524


MmugDNA.26562.1.S1_s_at
growth arrest-specific 5
GAS5
3.14
0.0006


MmugDNA.15046.1.S1_at
hemicentin 1
LOC714026
3.14
0.0142


MmugDNA.32563.1.S1_at
methionine sulfoxide reductase B3 isoform 2
LOC717617
3.13
0.0827


MmugDNA.3350.1.S1_at
L-3-hydroxyacyl-Coenzyme A dehydrogenase
HADHSC
3.13
0.0983


MmugDNA.27093.1.S1_at
alpha-2-macroglobulin
A2M
3.13
0.0027


MmugDNA.28905.1.S1_at
testis/prostate/placenta-expressed protein, isoform 2
LOC706183
3.12
0.0596



isoform 1


MmunewRS.723.1.S1_at
serine (or cysteine) proteinase inhibitor, clade H, member 1
SERPINH1
3.12
0.0967


MmugDNA.39240.1.S1_at
acyl-CoA synthetase long-chain family member 1
LOC694871
3.12
0.0034


MmugDNA.36848.1.S1_at
Tissue factor pathway inhibitor 2 precursor (TFPI-2)
TFPI2
3.11
0.0431



(Placental protein 5) (PP5)


MmugDNA.5658.1.S1_at
Bcl-2-related protein A1 (BFL-1 protein) (Hemopoietic-
BCL2A1
3.11
0.0888



specific early response protein) (GRS protein)


MmugDNA.25040.1.S1_at
clusterin
CLU
3.11
0.0568


MmugDNA.15918.1.S1_at
monocyte to macrophage differentiation-associated
LOC706723
3.10
0.0191



precursor


MmugDNA.5064.1.S1_at
transforming growth factor, beta-induced, 68 kDa
TGFBI
3.10
0.0079


MmuSTS.4112.1.S1_at
early growth response 1
EGR1
3.10
0.0015


MmugDNA.37314.1.S1_at
Zinc finger, CCHC domain containing 6
ZCCHC6
3.09
0.0274


MmugDNA.16942.1.S1_at
CDNA FLJ34374 fis, clone FEBRA2017502
—
3.09
0.0999


MmugDNA.24636.1.S1_at
RAB, member of RAS oncogene family-like 2B
RABL2B
3.09
0.0696


MmugDNA.24841.1.S1_at
hypothetical protein LOC709979
LOC709979
3.08
0.0018


MmuSTS.4753.1.S1_at
Wnt inhibitory factor 1
WIF1
3.08
0.0124


MmugDNA.30671.1.S1_at
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39
LOC718822
3.08
0.0898


MmugDNA.2069.1.S1_at
Isocitrate dehydrogenase 1 (NADP+), soluble
IDH1
3.08
0.0678


MmugDNA.37149.1.S1_at
oxysterol binding protein-like 6
OSBPL6
3.08
0.0801


MmugDNA.1095.1.S1_at
Mediator of RNA polymerase II transcription, subunit 28
MED28
3.07
0.0008



homolog (yeast)


MmugDNA.41794.1.S1_at
moesin
MSN
3.07
0.0208


MmugDNA.1253.1.S1_at
—
—
3.07
0.0105


MmugDNA.17781.1.S1_at
neuroepithelial cell transforming gene 1
NET1
3.07
0.0094


MmugDNA.18663.1.S1_at
Slit homolog 2 (Drosophila)
SLIT2
3.07
0.0607


MmugDNA.25811.1.S1_at
Transcribed locus
—
3.07
0.0033


MmugDNA.18485.1.S1_at
GC-rich sequence DNA-binding factor candidate
LOC700489
3.07
0.0819


MmugDNA.10654.1.S1_at
X-ray repair complementing defective repair in Chinese
XRCC5
3.06
0.0952



hamster cells 5 (double-strand-break rejoining; Ku



autoantigen, 80 kDa)


MmugDNA.42236.1.S1_at
Ribosomal protein L10a
RPL10A
3.05
0.0207


MmugDNA.35088.1.S1_at
Fibroblast growth factor receptor 1 (fms-related tyrosine
FGFR1
3.05
0.0419



kinase 2, Pfeiffer syndrome)


MmugDNA.18922.1.S1_at
Hypothetical protein AY099107
LOC152185
3.05
0.0748


MmugDNA.31239.1.S1_at
Forkhead box O3A
FOXO3A
3.03
0.0108


MmugDNA.5694.1.S1_at
ADAM metallopeptidase with thrombospondin type 1 motif, 5
ADAMTS5
3.03
0.0946


MmugDNA.39840.1.S1_at
coactosin-like 1
LOC715376
3.03
0.0023


MmuSTS.2604.1.S1_at
zinc finger homeobox 1b
ZFHX1B
3.02
0.0942


MmugDNA.21087.1.S1_at
integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
ITGA5
3.02
0.0160


MmuSTS.3523.1.S1_at
B-cell CLL/lymphoma 11B isoform 1
LOC705238
3.02
0.0082


Mmu.7842.1.S1_at
alpha 1 type IV collagen
COL4A1
3.02
0.0409


MmugDNA.8730.1.S1_at
Homo sapiens, clone IMAGE: 4778480, mRNA
—
3.02
0.0632


MmuSTS.4829.1.S1_at
growth hormone receptor
GHR
3.02
0.0012


MmugDNA.14593.1.S1_at
frizzled 4
LOC704754
3.01
0.0106


MmugDNA.42280.1.S1_at
—
—
3.01
0.0740


MmugDNA.34063.1.S1_at
lysophosphatidylglycerol acyltransferase 1
LPGAT1
3.01
0.0644


MmuSTS.124.1.S1_at
Homeobox protein Hox-A10 (Hox-1H) (Hox-1.8) (PL)
LOC704713
3.01
0.0416


MmuSTS.24.1.S1_at
Glycoprotein Xg precursor (Protein PBDX)
XG
3.01
0.0839


MmugDNA.10983.1.S1_at
septin 10
10-Sep
2.99
0.0257


MmugDNA.10337.1.S1_at
CG9047-PA, isoform A
LOC704595
2.99
0.0300


MmugDNA.15798.1.S1_s_at
HLA class II histocompatibility antigen, DQ(2) alpha chain
LOC717623
2.99
0.0862



precursor


MmugDNA.8592.1.S1_at
fatty acid binding protein 3, muscle and heart (mammary-
FABP3
2.99
0.0766



derived growth inhibitor)


MmugDNA.31542.1.S1_at
colon carcinoma related protein
LOC719328
2.98
0.0021


MmuSTS.1998.1.S1_at
estrogen receptor 1
ESR1
2.98
0.0868


MmugDNA.22982.1.S1_at
hypothetical protein LOC708514
LOC708514
2.98
0.0729


MmugDNA.25545.1.S1_at
Full length insert cDNA clone ZD69D05
—
2.98
0.0295


MmugDNA.8954.1.S1_at
glycerol-3-phosphate dehydrogenase 1 (soluble)
GPD1
2.97
0.0050


MmuSTS.1138.1.S1_at
Phospholipase A2, membrane associated precursor
PLA2G2A
2.97
0.0880



(Phosphatidylcholine 2-acylhydrolase) (Group IIA



phospholipase A2) (GIIC sPLA2) (Non-pancreatic secretory



phospholipase A2) (NPS-PLA2)


MmugDNA.10778.1.S1_at
cyclin-dependent kinase inhibitor 3
LOC694877
2.97
0.0442


MmugDNA.10040.1.S1_at
p53-regulated DDA3 isoform a
LOC698060
2.96
0.0854


Mmu.2305.1.S1_at
bluestreak CG6451-PA
—
2.96
0.0295


MmuSTS.2278.1.S1_at
peroxidasin
LOC721654
2.95
0.0127


MmugDNA.1496.1.S1_at
fatty acid desaturase 3
LOC722337
2.95
0.0442


MmugDNA.29758.1.S1_at
proline-rich cyclin A1-interacting protein
LOC709846
2.94
0.0143


MmuSTS.3401.1.S1_s_at
CCAAT/enhancer-binding protein alpha (C/EBP alpha)
LOC717153
2.94
0.0015


MmugDNA.2393.1.S1_at
perilipin
PLIN
2.93
0.0008


MmugDNA.393.1.S1_at
CDNA FLJ26120 fis, clone SYN00419
—
2.93
0.0092


MmugDNA.30771.1.S1_at
spermatogenesis associated factor SPAF
LOC708640
2.93
0.0712


MmugDNA.15387.1.S1_at
NEDD8 ultimate buster-1
NYREN18
2.92
0.0520


MmugDNA.5488.1.S1_at
dehydrogenase/reductase (SDR family) member 3
LOC715548
2.92
0.0258


MmugDNA.35654.1.S1_at
minichromosome maintenance protein 6
MCM6
2.92
0.0680


MmugDNA.30962.1.S1_at
advanced glycosylation end product-specific receptor
LOC717296
2.92
0.0097



isoform 1 precursor


MmugDNA.36279.1.S1_at
P3ECSL
LOC705660
2.91
0.0626


MmugDNA.30623.1.S1_at
ephrin receptor EphA1
EPHA1
2.91
0.0185


MmugDNA.42862.1.S1_s_at
Fasciculation and elongation protein zeta 2 (Zygin-2) (Zygin
LOC708288
2.91
0.0388



II) (Zygin-related protein types I/II)


MmuSTS.2298.1.S1_at
deafness, autosomal dominant 5 protein
DFNA5
2.91
0.0812


MmugDNA.18093.1.S1_at
FERM domain containing 6
LOC707266
2.91
0.0939


MmugDNA.34261.1.S1_at
PI-3-kinase-related kinase SMG-1
LOC693542
2.90
0.0022


MmugDNA.39398.1.S1_at
hypothetical protein LOC699173
LOC699173
2.89
0.0182


MmugDNA.6471.1.S1_at
Cerebellar degeneration-related antigen 1 (CDR34)
LOC698431
2.89
0.0015


MmugDNA.38313.1.S1_at
Serum amyloid A protein precursor (SAA) /// serum amyloid
LOC694944 ///
2.89
0.0137



A1 isoform 2
SAA1


MmugDNA.4080.1.S1_at
peptidylprolyl isomerase F (cyclophilin F)
PPIF
2.88
0.0024


MmugDNA.26182.1.S1_at
heterogeneous nuclear ribonucleoprotein A1
HNRPA1
2.87
0.0025


MmugDNA.27473.1.S1_at
CASP8 and FADD-like apoptosis regulator
CFLAR
2.87
0.0203


MmugDNA.35112.1.S1_at
kleisin beta isoform 2
LOC716120
2.87
0.0321


MmugDNA.22473.1.S1_at
PP2135 protein
PP2135
2.86
0.0928


MmugDNA.37882.1.S1_at
hypothetical protein LOC703464 /// hypothetical protein
LOC703464 ///
2.86
0.0211



LOC705990
LOC705990


MmuAffx.52.1.A1_at
chemokine (C-C motif) ligand 4
CCL4
2.84
0.0361


MmugDNA.31283.1.S1_at
hypothetical protein LOC693798
LOC693798
2.84
0.0659


MmuSTS.2520.1.S1_at
heterogeneous nuclear ribonucleoprotein H2
HNRPH2
2.84
0.0827


MmugDNA.28432.1.S1_at
adipocyte-specific adhesion molecule
LOC708098
2.84
0.0517


MmugDNA.13083.1.S1_at
activating transcription factor 7 interacting protein
LOC698815
2.84
0.0965


MmugDNA.8865.1.S1_at
Visinin-like protein 1 (VILIP) (Neural visinin-like protein 1)
LOC699459
2.83
0.0285



(NVL-1) (NVP-1) (21 kDa CABP)


MmuSTS.2601.1.S1_at
embryonal Fyn-associated substrate isoform 2
LOC713838
2.83
0.0000


MmugDNA.38045.1.S1_at
Transcribed locus
—
2.82
0.0094


MmugDNA.9654.1.S1_at
Heterogeneous nuclear ribonucleoprotein D (AU-rich
HNRPD
2.82
0.0440



element RNA binding protein 1, 37 kDa)


MmugDNA.38313.1.S1_s_at
serum amyloid A1 isoform 2
LOC694944
2.81
0.0253


MmugDNA.24597.1.S1_at
carbonyl reductase 3
LOC695769
2.81
0.0598


MmugDNA.36863.1.S1_at
vang-like 1
LOC709730
2.80
0.0744


MmugDNA.15427.1.S1_at
sterile alpha motif and leucine zipper containing kinase AZK
ZAK
2.80
0.0920


MmugDNA.19311.1.S1_at
laminin, beta 2
LAMB2
2.80
0.0012


MmugDNA.22113.1.S1_at
Transcribed locus, strongly similar to XP_510155.1 similar
—
2.80
0.0719



to PAPOLA protein [Pan troglodytes]


MmuSTS.3531.1.S1_s_at
—
CCL4L
2.80
0.0516


MmugDNA.21105.1.S1_at
DNA ligase I
LIG1
2.80
0.0904


MmugDNA.15362.1.S1_at
HEG homolog
HEG
2.77
0.0055


MmugDNA.6611.1.S1_at
hypothetical protein LOC701646
LOC701646
2.77
0.0623


MmugDNA.10320.1.S1_at
nicotinamide nucleotide adenylyltransferase 3
NMNAT3
2.77
0.0937


MmugDNA.5714.1.S1_at
timeless homolog
LOC712835
2.77
0.0737


MmugDNA.6879.1.S1_at
SNF1-like kinase 2
LOC711453
2.77
0.0878


MmugDNA.40900.1.S1_at
Host cell factor-binding transcription factor Zhangfei (HCF-
LOC702942
2.76
0.0186



binding transcription factor Zhangfei) (Tyrosine kinase-



associated leucine zipper protein LAZip)


MmugDNA.5326.1.S1_at
cyclin-dependent kinase 3
CDK3
2.76
0.0203


MmugDNA.42369.1.S1_s_at
Josephin domain containing 3
LOC696602
2.76
0.0792


MmuSTS.607.1.S1_at
Heat-shock protein beta-7 (HspB7) (Cardiovascular heat
LOC696704
2.75
0.0029



shock protein) (cvHsp)


MmugDNA.39315.1.S1_at
Leukemia inhibitory factor receptor
LIFR
2.75
0.0588


MmuSTS.631.1.S1_at
angiomotin like 2
LOC718868
2.74
0.0095


MmuSTS.2866.1.S1_at
Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18)
LOC719733
2.74
0.0870



(Op18) (Leukemia-associated phosphoprotein p18) (pp17)



(Prosolin) (Metablastin) (Protein Pr22)


MmugDNA.41518.1.S1_s_at
vimentin
VIM
2.74
0.0725


MmugDNA.5148.1.S1_at
Notchless gene homolog
NLE1
2.74
0.0939


MmugDNA.34796.1.S1_at
chromosome 10 open reading frame 99
C10orf99
2.73
0.0070


MmugDNA.27576.1.S1_at
—
—
2.73
0.0033


MmuSTS.2115.1.S1_at
—
ARHGEF6
2.72
0.0401


MmugDNA.27574.1.S1_at
membrane-spanning 4-domains, subfamily A, member 6A
LOC697689
2.72
0.0785



isoform 2


MmugDNA.12560.1.S1_at
enoyl Coenzyme A hydratase domain containing 3
LOC693583
2.72
0.0499


MmugDNA.35275.1.S1_at
transmembrane protease, serine 8 (intestinal)
LOC697965
2.72
0.0064


MmugDNA.43094.1.S1_at
procollagen C-endopeptidase enhancer 2
PCOLCE2
2.72
0.0769


Mmu.3054.2.S1_at
upstream of NRAS
CSDE1
2.72
0.0039


MmuSTS.2641.1.S1_at
ATP synthase, H+ transporting, mitochondrial F1 complex,
—
2.72
0.0461



alpha subunit


MmugDNA.18980.1.S1_at
neuromedin B
NMB
2.71
0.0546


MmugDNA.23958.1.S1_at
G protein-coupled receptor 37
GPR37
2.71
0.0888


MmugDNA.43305.1.S1_at
—
—
2.71
0.0499


MmugDNA.31834.1.S1_at
Fanconi anemia group A protein (Protein FACA)
LOC714932
2.71
0.0205


MmugDNA.36837.1.S1_at
poly(rC) binding protein 2 (predicted) /// poly(rC) binding
LOC694744 ///
2.70
0.0636



protein 2
LOC703175


MmugDNA.11099.1.S1_at
Catenin (cadherin-associated protein), beta 1, 88 kDa
CTNNB1
2.70
0.0381


MmugDNA.37576.1.S1_at
PHD finger protein 20-like 1 isoform 1
LOC701406
2.70
0.0015


MmuSTS.541.1.S1_at
oxysterol-binding protein-like protein 8 isoform a
LOC693338
2.69
0.0396


MmugDNA.16521.1.S1_at
hypothetical protein DKFZp761N09121
DKFZP761N09121
2.69
0.0319


MmugDNA.9406.1.S1_at
Ubiquitin-conjugating enzyme E2H (UBC8 homolog, yeast)
UBE2H
2.69
0.0368


MmuSTS.3625.1.S1_at
polycystin 2
LOC702179
2.68
0.0079


MmugDNA.41756.1.S1_at
membrane protein, palmitoylated 3 (MAGUK p55 subfamily
MPP3
2.68
0.0063



member 3)


MmugDNA.7204.1.S1_at
serum/glucocorticoid regulated kinase
LOC713082
2.67
0.0050


MmugDNA.19300.1.S1_at
Endothelial protein C receptor precursor (Endothelial cell
LOC706040
2.67
0.0858



protein C receptor) (Activated protein C receptor) (APC



receptor) (CD201 antigen)


MmugDNA.7974.1.S1_at
TRAF interacting protein
TRAIP
2.67
0.0891


MmugDNA.14150.1.S1_at
CG8745-PA
LOC702302
2.67
0.0453


MmugDNA.24498.1.S1_at
replication factor C (activator 1) 4, 37 kDa
RFC4
2.67
0.0043


MmugDNA.31559.1.S1_at
CTD small phosphatase-like protein (CTDSP-like) (Small C-
LOC697898
2.67
0.0039



terminal domain phosphatase 3) (Small CTD phosphatase



3) (SCP3) (Nuclear LIM interactor-interacting factor 1) (NLI-



interacting factor 1) (NIF-like protein) (RBSP3) (YA22



protein) (. . .


MmugDNA.27755.1.S1_at
Similar to KIAA0393 protein
MGC57820
2.67
0.0755


MmuSTS.825.1.S1_x_at
degenerative spermatocyte homolog 1, lipid desaturase
LOC702128
2.67
0.0943


MmugDNA.32190.1.S1_at
HRAS-like suppressor 3
HRASLS3
2.66
0.0205


MmugDNA.378.1.S1_at
Syntaxin 7
STX7
2.66
0.0271


MmugDNA.7129.1.S1_at
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
LOC701790
2.66
0.0855



acetylgalactosaminyltransferase-like 4


MmugDNA.37173.1.S1_at
methyltransferase like 7A
LOC693894
2.66
0.0812


MmugDNA.15924.1.S1_at
Eukaryotic translation initiation factor 4E member 2
EIF4E2
2.66
0.0777


MmugDNA.18344.1.S1_at
Jagged 1 (Alagille syndrome)
JAG1
2.66
0.0523


MmugDNA.18912.1.S1_at
inter-alpha trypsin inhibitor heavy chain precursor 5 isoform 2
LOC722614
2.65
0.0437


MmugDNA.38963.1.S1_at
inhibitor of DNA binding 1 isoform b
LOC713160
2.65
0.0167


MmugDNA.38359.1.S1_at
H2A histone family, member Y
H2AFY
2.65
0.0069


MmuSTS.1880.1.S1_at
collagen, type IV, alpha 2
COL4A2
2.65
0.0233


MmuSTS.999.1.S1_at
myc proto-oncogene protein
MYC
2.65
0.0644


MmugDNA.27587.1.S1_at
Homo sapiens, clone IMAGE: 5170410, mRNA
—
2.65
0.0784


MmugDNA.20660.1.S1_at
tripartite motif-containing 33 protein
TRIM33
2.64
0.0247


MmugDNA.7029.1.S1_at
Receptor activity-modifying protein 3 precursor (CRLR
LOC697349
2.64
0.0289



activity-modifying protein 3) (Calcitonin-receptor-like



receptor activity-modifying protein 3)


MmuSTS.3328.1.S1_at
origin recognition complex, subunit 1
LOC713271
2.63
0.0374


MmugDNA.38420.1.S1_s_at
Transmembrane BAX inhibitor motif-containing protein 4 (Z-
TMBIM4
2.63
0.0011



protein) (S1R protein)


MmugDNA.32616.1.S1_at
XIAP associated factor-1 isoform 1
LOC713425
2.63
0.0099


MmugDNA.2794.1.S1_at
Epithelial membrane protein 1 (EMP-1) (Tumor-associated
EMP1
2.63
0.0386



membrane protein) (CL-20) (B4B protein)


MmugDNA.28550.1.S1_at
heat shock protein, alpha-crystallin-related, B6
LOC710760
2.62
0.0083


MmugDNA.19535.1.S1_at
desmocollin 3
DSC3
2.62
0.0261


MmugDNA.14923.1.S1_at
Adenomatosis polyposis coli 2
APC2
2.62
0.0847


MmugDNA.10555.1.S1_at
CDNA FLJ36553 fis, clone TRACH2008478
—
2.61
0.0113


MmugDNA.35200.1.S1_at
hypothetical protein FLJ13305
FLJ13305
2.61
0.0709


MmugDNA.10323.1.S1_s_at
RNA binding motif protein 25
LOC695911
2.60
0.0340


MmugDNA.25448.1.S1_at
CG13745-PA
LOC699878
2.60
0.0499


MmugDNA.40326.1.S1_at
MRNA; cDNA DKFZp686F1318 (from clone
—
2.60
0.0643



DKFZp686F1318)


MmugDNA.11833.1.S1_at
Homo sapiens, clone IMAGE: 5278284, mRNA
—
2.60
0.0515


MmugDNA.31867.1.S1_at
golgi associated, gamma adaptin ear containing, ARF
GGA2
2.59
0.0586



binding protein 2


MmugDNA.33539.1.S1_at
Ankyrin 3, node of Ranvier (ankyrin G)
ANK3
2.59
0.0204


MmugDNA.37283.1.S1_at
Polypyrimidine tract binding protein 2
PTBP2
2.57
0.0946


MmugDNA.40388.1.S1_at
lactotransferrin
LOC713115
2.57
0.0012


MmunewRS.711.1.S1_at
corticotropin releasing hormone binding protein
LOC707589
2.56
0.0397


MmugDNA.20034.1.S1_at
Full length insert cDNA clone ZD69D05
—
2.55
0.0473


MmugDNA.40606.1.S1_at
Activin A receptor type II-like 1
ACVRL1
2.55
0.0529


MmugDNA.42565.1.S1_at
H+ transporting F1 ATP synthase epsilon subunit
—
2.55
0.0439


MmugDNA.16683.1.S1_at
solute carrier family 24 (sodium/potassium/calcium
SLC24A3
2.54
0.0562



exchanger), member 3


MmugDNA.864.1.S1_at
Chromosome 16 open reading frame 28
C16orf28
2.54
0.0225


MmugDNA.41780.1.S1_at
interleukin 6 signal transducer receptor
IL-6
2.53
0.0980


MmugDNA.37515.1.S1_at
Hypothetical protein FLJ13941
FLJ13941
2.53
0.0038


MmugDNA.25797.1.S1_at
Hypothetical protein MGC10067
MGC10067
2.53
0.0315


MmugDNA.27004.1.S1_at
follistatin-like 1
FSTL1
2.52
0.0172


MmugDNA.1644.1.S1_at
eukaryotic translation initiation factor 5B
EIF5B
2.52
0.0295


MmugDNA.23477.1.S1_at
RAS and EF hand domain containing
RASEF
2.52
0.0477


MmugDNA.40191.1.S1_at
Ubiquinol-cytochrome c reductase complex 14 kDa protein
UQCRB
2.52
0.0061



(Complex III subunit VI) (QP-C)


MmugDNA.5276.1.S1_at
two AAA domain containing protein
LOC704478
2.51
0.0788


MmugDNA.9275.1.S1_at
Acetyl-Coenzyme A synthetase 2 (ADP forming)
ACAS2
2.51
0.0312


MmugDNA.23637.1.S1_at
Rho GTPase activating protein 23
ARHGAP23
2.51
0.0377


MmugDNA.31862.1.S1_at
Transcribed locus, moderately similar to XP_524454.1
—
2.51
0.0338



LOC469069 [Pan troglodytes]


MmugDNA.39520.1.S1_at
Rho GDP-dissociation inhibitor 2 (Rho GDI 2) (Rho-GDI
ARHGDIB
2.50
0.0744



beta) (Ly-GDI)


MmugDNA.22495.1.S1_at
choline phosphotransferase 1
LOC696056
2.50
0.0276


MmugDNA.40534.1.S1_s_at
S-phase kinase-associated protein 2 isoform 1
LOC700617
2.49
0.0640


MmugDNA.25179.1.S1_s_at
hypothetical protein LOC707276 /// Acidic leucine-rich
ANP32B ///
2.49
0.0301



nuclear phosphoprotein 32 family member B (PHAPI2
LOC707276



protein) (Silver-stainable protein SSP29) (Acidic protein rich



in leucines)


MmugDNA.20756.1.S1_at
methionine aminopeptidase 1D
MAP1D
2.49
0.0157


MmugDNA.10451.1.S1_at
lipoprotein lipase
LPL
2.48
0.0793


MmugDNA.37784.1.S1_at
Microfibrillar-associated protein 5 precursor (MFAP-5)
MFAP5
2.48
0.0288



(Microfibril-associated glycoprotein 2) (MAGP-2) (MP25)


MmugDNA.11410.1.S1_at
WW domain-containing adapter with a coiled-coil region
LOC715828
2.48
0.0246



isoform 1


MmugDNA.16003.1.S1_at
hypothetical protein LOC713457
LOC713457
2.48
0.0832


MmugDNA.7480.1.S1_at
Glutaredoxin-1 (Thioltransferase-1) (TTase-1)
GLRX
2.48
0.0177


MmugDNA.41094.1.S1_at
cytochrome P450, family 2, subfamily E, polypeptide 2
LOC718303
2.47
0.0545



homolog


MmuSTS.2498.1.S1_at
zinc finger protein 8
ZNF8
2.47
0.0011


MmuSTS.3305.1.S1_at
Oxysterols receptor LXR-alpha (Liver X receptor alpha)
NR1H3
2.47
0.0882



(Nuclear orphan receptor LXR-alpha)


MmugDNA.22116.1.S1_at
Neurotensin/neuromedin N precursor
NTS
2.47
0.0663


MmuSTS.1525.1.S1_at
mitochondrial ribosomal protein L35
MRPL35
2.47
0.0431


MmugDNA.14539.1.S1_at
KIAA1450 protein
KIAA1450
2.46
0.0140


MmugDNA.2162.1.S1_at
C20orf111
LOC693890
2.46
0.0194


MmugDNA.14181.1.S1_at
CDNA: FLJ23006 fis, clone LNG00414
—
2.46
0.0527


MmugDNA.38899.1.S1_at
alpha 2 type VI collagen isoform 2C2 precursor
LOC709493
2.46
0.0950


MmugDNA.12419.1.S1_at
sno, strawberry notch homolog 1
LOC709260
2.46
0.0741


Mmu.13956.1.S1_at
mitochondrial aldehyde dehydrogenase 2
ALDH2
2.46
0.0559


MmugDNA.27955.1.S1_at
thrombospondin 3
THBS3
2.45
0.0003


Mmu.12740.1.S1_at
activating transcription factor 2
LOC699072
2.45
0.0690


MmugDNA.2942.1.S1_at
Ras-related protein Rab-15
LOC708330
2.44
0.0561


MmugDNA.42705.1.S1_at
SH3 multiple domains 1
LOC714868
2.44
0.0830


MmugDNA.2199.1.S1_at
hypothetical protein LOC706003
LOC706003
2.44
0.0707


MmugDNA.31469.1.S1_at
Mitochondrial 28S ribosomal protein S25 (S25mt) (MRP-
LOC703261
2.44
0.0413



S25)


MmugDNA.32362.1.S1_at
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
MAFB
2.43
0.0446



B (avian)


MmugDNA.37182.1.S1_at
C17G10.1
LOC700219
2.43
0.0349


MmugDNA.3948.1.S1_at
B-cell lymphoma 6 protein
LOC708736
2.43
0.0461


MmugDNA.29568.1.S1_at
Hypothetical gene supported by BX640700
—
2.43
0.0882


MmugDNA.22001.1.S1_at
mucin 7, salivary
LOC707153
2.43
0.0161


MmugDNA.24814.1.S1_at
RAS protein activator like 2
RASAL2
2.43
0.0553


MmugDNA.23518.1.S1_at
Muscleblind-like 2 (Drosophila)
MBNL2
2.42
0.0661


MmugDNA.10700.1.S1_at
opioid growth factor receptor-like 1
LOC715189
2.42
0.0889


MmugDNA.13067.1.S1_at
serine/threonine kinase 4
STK4
2.42
0.0978


MmugDNA.40225.1.S1_at
LIM domain containing preferred translocation partner in
LPP
2.42
0.0289



lipoma


MmugDNA.31182.1.S1_at
centrosome spindle pole associated protein
LOC704476
2.42
0.0587


MmugDNA.19553.1.S1_at
damage-specific DNA binding protein 2 (48 kD)
DDB2
2.41
0.0098


MmugDNA.2267.1.S1_at
Transcribed locus
—
2.41
0.0491


MmugDNA.2874.1.S1_at
DNA polymerase gamma subunit 2, mitochondrial precursor
LOC720356
2.41
0.0413



(Mitochondrial DNA polymerase accessory subunit) (PolG-



beta) (MtPolB) (DNA polymerase gamma accessory 55 kDa



subunit) (p55)


Mmu.11306.1.S1_at
MYC binding protein 2
MYCBP2
2.41
0.0484


MmugDNA.27252.1.S1_at
Transcribed locus
—
2.41
0.0826


MmugDNA.4547.1.S1_at
aarF domain containing kinase 5
ADCK5
2.41
0.0068


MmugDNA.29817.1.S1_at
Ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog,
UBE2E2
2.41
0.0791



yeast)


MmugDNA.22188.1.S1_at
Rho guanine nucleotide exchange factor (GEF) 10
ARHGEF10
2.40
0.0882


MmugDNA.3376.1.S1_at
caspase recruitment domain family, member 8
CARD8
2.40
0.0302


MmugDNA.43065.1.S1_at
pregnancy-induced growth inhibitor isoform 1
LOC714549
2.40
0.0211


MmugDNA.40500.1.S1_at
hypothetical protein LOC694075
LOC694075
2.40
0.0409


MmugDNA.11419.1.S1_at
molecule interacting with Rab13
MICAL-L1
2.39
0.0963


MmugDNA.1847.1.S1_at
tissue inhibitor of metalloproteinase 2
TIMP2
2.39
0.0030


MmugDNA.11882.1.S1_at
hypothetical protein LOC721782
LOC721782
2.39
0.0452


MmuSTS.1231.1.S1_at
copine II
LOC703557
2.39
0.0061


MmugDNA.22620.1.S1_at
Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1)
LGALS7
2.38
0.0861


Mmu.15973.14.S1_at
growth hormone variant /// growth hormone 1 isoform 1 ///
CSH-3 ///
2.38
0.0038



chorionic somatommamotropin hormone 3 /// growth
CSH-4 /// GH1 ///



hormone 1 /// chorionic somatommamotropin hormone 4
LOC700885 ///




LOC718116 ///




LOC718474


MmugDNA.40962.1.S1_at
Patched homolog (Drosophila)
PTCH
2.37
0.0228


MmugDNA.11810.1.S1_at
chromatin-specific transcription elongation factor large
LOC708066
2.37
0.0275



subunit


MmuSTS.2967.1.S1_at
alcohol dehydrogenase, iron containing, 1
LOC703118
2.37
0.0768


MmugDNA.3168.1.S1_at
CDNA clone IMAGE: 5294683, partial cds
—
2.37
0.0307


MmugDNA.4900.1.S1_s_at
amylase, alpha 2A; pancreatic
AMY2A
2.37
0.0873


MmuSTS.1626.1.S1_at
thyroid hormone receptor interactor 10
LOC703934
2.36
0.0148


MmuSTS.3226.1.S1_at
myosin IXA
LOC701520
2.36
0.0256


MmugDNA.23835.1.S1_at
RNA binding motif protein 5
RBM5
2.35
0.0695


MmuSTS.1925.1.S1_at
Tissue factor precursor (TF) (Coagulation factor III)
F3
2.35
0.0169



(Thromboplastin) (CD142 antigen)


MmugDNA.23256.1.S1_at
guanylate cyclase 1, soluble, alpha 3
LOC699365
2.35
0.0208


MmunewRS.334.1.S1_at
gi:42657654
—
2.35
0.0278


MmugDNA.524.1.S1_at
Full length insert cDNA clone YX74D05
—
2.34
0.0963


MmuSTS.891.1.S1_at
Microfibrillar-associated protein 2 precursor (MFAP-2)
MFAP2
2.34
0.0609



(Microfibril-associated glycoprotein) (MAGP) (MAGP-1)


MmuSTS.4399.1.S1_at
cell division cycle associated 8
LOC719808
2.34
0.0254


MmugDNA.36.1.S1_at
Sorting nexin-10
SNX10
2.33
0.0528


MmugDNA.24165.1.S1_at
ATP synthase lipid-binding protein, mitochondrial precursor
—
2.33
0.0024



(ATP synthase proteolipid P1) (ATPase protein 9) (ATPase



subunit C)


MmugDNA.38800.1.S1_at
connexin 43
GJA1
2.33
0.0658


MmugDNA.2930.1.S1_at
Full length insert cDNA clone ZE03F06
—
2.33
0.0266


MmugDNA.42198.1.S1_at
glycosyltransferase-like 1B
LOC714846
2.33
0.0727


MmugDNA.782.1.S1_s_at
adenine phosphoribosyltransferase isoform b
APRT
2.33
0.0978


MmugDNA.40585.1.S1_at
—
—
2.32
0.0884


Mmu.13676.1.S1_s_at
Transcribed locus
—
2.32
0.0702


MmugDNA.38278.1.S1_at
Solute carrier family 1 (glutamate/neutral amino acid
SLC1A4
2.32
0.0846



transporter), member 4


MmugDNA.37513.1.S1_at
Y-box-binding protein 2 (Germ cell-specific Y-box-binding
LOC714750
2.32
0.0853



protein) (FRGY2 homolog)


MmuSTS.699.1.S1_at
calcium activated chloride channel 2
LOC711959
2.32
0.0311


MmugDNA.35545.1.S1_at
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
DDX17
2.32
0.0193


MmuSTS.4279.1.S1_at
ephrin A4 isoform b
LOC717315
2.31
0.0921


MmuSTS.4415.1.S1_at
nuclear matrix protein p84
THOC1
2.31
0.0067


MmugDNA.20377.1.S1_at
growth arrest-specific 6
LOC716066
2.31
0.0374


MmugDNA.9919.1.S1_at
solute carrier family 25, member 36
LOC715375
2.30
0.0365


MmugDNA.41865.1.S1_at
procollagen C-endopeptidase enhancer
PCOLCE
2.30
0.0277


Mmu.2142.1.S1_at
tripartite motif-containing 22
TRIM22
2.30
0.0336


MmugDNA.21471.1.S1_at
butyrophilin-like 9
BTNL9
2.30
0.0203


MmugDNA.33142.1.S1_at
Thyroid hormone receptor associated protein 2
THRAP2
2.30
0.0902


MmugDNA.911.1.S1_at
tRNA splicing endonuclease 54 homolog (SEN54, S. cerevisiae)
LOC702604
2.29
0.0159


MmugDNA.462.1.S1_at
Chromobox homolog 3 (HP1 gamma homolog, Drosophila)
CBX3
2.29
0.0325


MmugDNA.16130.1.S1_at
hypothetical protein LOC90393
LOC90393
2.29
0.0237


MmugDNA.32185.1.S1_s_at
Troponin T, fast skeletal muscle (TnTf) (Fast skeletal
LOC704095
2.29
0.0954



muscle troponin T) (fTnT) (Beta TnTF)


MmuSTS.268.1.S1_at
U2-associated SR140 protein
LOC716408
2.29
0.0066


MmugDNA.39036.1.S1_at
Coatomer subunit zeta-2 (Zeta-2 coat protein) (Zeta-2 COP)
COPZ2
2.28
0.0507


MmugDNA.21025.1.S1_at
cold inducible RNA binding protein
LOC706175
2.28
0.0249


MmugDNA.40486.1.S1_s_at
Immortalization-up-regulated protein (Hepatocyte growth
LOC714854
2.28
0.0153



factor activator inhibitor type 2-related small pprotein) (HAI-



2-related small protein) (H2RSP)


MmugDNA.26396.1.S1_at
proline rich 6
LOC700414
2.28
0.0073


MmuSTS.2009.1.S1_at
protocadherin 18 precursor
LOC698420
2.27
0.0824


MmugDNA.9315.1.S1_at
kinesin light chain 3
LOC714331
2.27
0.0027


MmugDNA.31698.1.S1_at
chromosome 10 open reading frame 86
LOC705375
2.27
0.0652


MmugDNA.30174.1.S1_at
v-ets erythroblastosis virus E26 oncogene like
ERG
2.27
0.0267


MmuSTS.7.1.S1_at
GULP, engulfment adaptor PTB domain containing 1
LOC708601
2.27
0.0459


MmuSTS.4265.1.S1_at
glypican 4
LOC706665
2.26
0.0874


MmugDNA.14551.1.S1_at
cat eye syndrome critical region protein 1 isoform a
LOC709295
2.26
0.0215



precursor


MmugDNA.28933.1.S1_at
septin 11
11-Sep
2.26
0.0320


MmugDNA.24711.1.S1_at
rhomboid family 1
LOC693423
2.26
0.0985


MmugDNA.22992.1.S1_at
zinc finger protein (C2H2 type) 277
ZNF277
2.26
0.0065


MmugDNA.24410.1.S1_at
melanoma associated antigen (mutated) 1
MUM1
2.26
0.0947


MmugDNA.9906.1.S1_at
Histone H1.5 (Histone H1a)
LOC705100
2.26
0.0128


MmuSTS.3965.1.S1_at
colony stimulating factor 1 receptor precursor
LOC711512
2.26
0.0542


MmugDNA.1769.1.S1_at
CG4699-PA, isoform A
LOC713138
2.25
0.0713


MmugDNA.43306.1.S1_at
cyclin I
—
2.25
0.0498


MmugDNA.42603.1.S1_at
ankyrin repeat domain 28
LOC696592
2.25
0.0775


MmugDNA.37006.1.S1_at
B-cell translocation gene 1, anti-proliferative
LOC710112
2.25
0.0352


MmugDNA.7428.1.S1_at
Wolf-Hirschhorn syndrome candidate 1 protein isoform 1
LOC712618
2.25
0.0954


MmugDNA.37011.1.S1_at
CXXC finger 6
LOC694137
2.25
0.0304


MmugDNA.35449.1.S1_at
Sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-
SIAT7B
2.24
0.0030



galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-



sialyltransferase) B /// CDNA clone IMAGE: 3831740, partial



cds


MmuSTS.1106.1.S1_at
platelet/endothelial cell adhesion molecule (CD31 antigen)
LOC718302
2.24
0.0231


MmugDNA.12061.1.S1_at
—
—
2.24
0.0089


MmuSTS.4678.1.S1_at
three prime repair exonuclease 1 isoform d
LOC710035
2.24
0.0664


Mmu.4786.2.S1_at
pyrophosphatase 1
LOC716720
2.24
0.0781


MmugDNA.38317.1.S1_at
Transcribed locus
—
2.23
0.0610


MmugDNA.26830.1.S1_at
polymerase (DNA directed), eta
LOC700772
2.23
0.0463


MmugDNA.18586.1.S1_at
structural maintenance of chromosomes 2-like 1
SMC2L1
2.23
0.0554


MmugDNA.11249.1.S1_at
potassium channel tetramerisation domain containing 12
LOC695756
2.23
0.0517


MmugDNA.8879.1.S1_at
sestrin 3
SESN3
2.23
0.0195


MmugDNA.24687.1.S1_at
SLIT-ROBO Rho GTPase activating protein 1
SRGAP1
2.22
0.0821


MmugDNA.37739.1.S1_at
serine/threonine kinase 24 (STE20 homolog, yeast)
STK24
2.22
0.0258


MmuSTS.1280.1.S1_at
RAB39
LOC709951
2.21
0.0169


MmugDNA.24944.1.S1_at
Cytochrome P450, family 4, subfamily F, polypeptide 3
—
2.21
0.0677


MmunewRS.254.1.S1_at
putative ISG12(c) protein
IFI27
2.21
0.0683


MmugDNA.34004.1.S1_s_at
secretory carrier membrane protein 2
SCAMP2
2.21
0.0608


MmugDNA.12030.1.S1_at
SEC8 protein
—
2.20
0.0199


MmugDNA.21255.1.S1_at
neutrophil cytosolic factor 1
NCF1
2.20
0.0161


MmugDNA.43588.1.S1_at
hypothetical protein LOC712570
LOC712570
2.20
0.0824


MmugDNA.23296.1.S1_s_at
thyroid receptor-interacting protein 6
TRIP6
2.20
0.0513


MmugDNA.14929.1.S1_at
insulin-like growth factor 2 mRNA binding protein 2 isoform b
LOC701536
2.20
0.0109


MmugDNA.39168.1.S1_at
platelet-derived growth factor C precursor
LOC700236
2.19
0.0284


MmuSTS.1102.1.S1_at
poly(rC) binding protein 4 isoform b
PCBP4
2.19
0.0477


MmugDNA.41718.1.S1_at
CG12134-PA, isoform A
LOC706314
2.19
0.0509


MmugDNA.36456.1.S1_at
C1q and tumor necrosis factor related protein 2
LOC695783
2.18
0.0650


MmuSTS.4542.1.S1_at
Glycophorin C (PAS-2) (Glycoprotein beta) (GLPC)
LOC712092
2.18
0.0118



(Glycoconnectin) (Sialoglycoprotein D) (Glycophorin D)



(GPD) (CD236 antigen)


MmugDNA.10214.1.S1_at
KIAA0792 gene product
KIAA0792
2.18
0.0596


MmugDNA.7604.1.S1_at
THO complex 2
THOC2
2.18
0.0947


MmugDNA.4607.1.S1_at
zinc finger protein 326 isoform 2
LOC696575
2.18
0.0302


MmugDNA.26241.1.S1_at
cytochrome b5 reductase
LOC714058
2.18
0.0499


MmugDNA.24148.1.S1_at
trafficking protein, kinesin binding 2
LOC701779
2.17
0.0404


MmugDNA.15712.1.S1_x_at
Cathepsin B
CTSB
2.17
0.0099


MmugDNA.34134.1.S1_at
quaking homolog, KH domain RNA binding isoform HQK-5
LOC712600
2.17
0.0569


MmugDNA.20961.1.S1_at
abhydrolase domain containing 1 (predicted)
LOC711493
2.17
0.0641


MmugDNA.11400.1.S1_at
Homo sapiens, clone IMAGE: 6152133, mRNA
—
2.17
0.0985


MmugDNA.32260.1.S1_at
—
—
2.17
0.0854


MmugDNA.3224.1.S1_at
beta adrenergic receptor kinase 2
LOC714510
2.17
0.0824


MmuSTS.144.1.S1_at
minichromosome maintenance protein 2
LOC710888
2.16
0.0450


MmugDNA.8814.1.S1_at
TBC1 domain family, member 4
LOC696915
2.15
0.0771


MmugDNA.31838.1.S1_s_at
histamine N-methyltransferase
HNMT
2.15
0.0984


MmuSTS.224.1.S1_at
solute carrier family 25, member 27
SLC25A27
2.15
0.0161


MmugDNA.24609.1.S1_at
hypothetical protein LOC707415
LOC707415
2.14
0.0692


MmugDNA.9218.1.S1_at
RNA binding motif protein 30
RBM30
2.14
0.0450


MmugDNA.1986.1.S1_at
type 1 tumor necrosis factor receptor shedding
ARTS-1
2.14
0.0959



aminopeptidase regulator


MmugDNA.21483.1.S1_at
zinc finger protein 579
LOC701452
2.14
0.0953


MmugDNA.16054.1.S1_at
TWIST neighbor
LOC707781
2.14
0.0733


MmugDNA.7039.1.S1_at
—
—
2.14
0.0038


MmuSTS.3729.1.S1_at
fibromodulin precursor
LOC703048
2.14
0.0183


MmugDNA.10834.1.S1_at
allograft inflammatory factor 1
AIF1
2.14
0.0300


MmugDNA.32311.1.S1_at
hormone-sensitive lipase
LOC707997
2.14
0.0209


MmugDNA.12478.1.S1_at
pleckstrin homology domain containing, family C (with
LOC693958
2.14
0.0232



FERM domain) member 1


MmugDNA.37583.1.S1_at
Protein tyrosine phosphatase, receptor type, S
PTPRS
2.13
0.0946


MmugDNA.19987.1.S1_s_at
hypothetical protein LOC284454
LOC284454
2.13
0.0374


MmugDNA.7038.1.S1_at
Fc fragment of IgG, low affinity IIIb, receptor (CD16b)
FCGR3B
2.13
0.0550


MmugDNA.32358.1.S1_at
lamin A/C
LMNA
2.13
0.0347


MmugDNA.16962.1.S1_at
establishment of cohesion 1 homolog 1
LOC698845
2.13
0.0556


MmugDNA.23571.1.S1_at
Epithelial stromal interaction 1 (breast)
EPSTI1
2.13
0.0778


MmuSTS.2627.1.S1_at
exostoses (multiple)-like 1
EXTL1
2.13
0.0154


MmuSTS.1193.1.S1_at
phorbol-12-myristate-13-acetate-induced protein 1
LOC702789
2.13
0.0133


MmugDNA.20278.1.S1_at
Insulin-like growth factor-binding protein 7 precursor
LOC693564
2.12
0.0219



(IGFBP-7) (IBP-7) (IGF-binding protein 7) (MAC25 protein)



(Prostacyclin-stimulating factor) (PGI2-stimulating factor)



(IGFBP-rP1)


MmugDNA.22598.1.S1_at
poliovirus receptor-related 1 (herpesvirus entry mediator C;
PVRL1
2.12
0.0579



nectin)


MmugDNA.3092.1.S1_at
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP
HNRPA2B1
2.12
0.0077



A2/hnRNP B1)


MmuSTS.8.1.S1_at
Histone H2A.x (H2a/x)
LOC703073
2.12
0.0010


MmuSTS.2363.1.S1_at
squamous cell carcinoma antigen recognized by T cells 2
LOC716054
2.12
0.0083


MmuSTS.3798.1.S1_at
scavenger receptor class A, member 3 isoform 1
LOC718263
2.12
0.0501


MmugDNA.22785.1.S1_at
—
—
2.11
0.0320


MmugDNA.38565.1.S1_at
v-fos FBJ murine osteosarcoma viral oncogene homolog
FOS
2.11
0.0239


MmugDNA.20885.1.S1_at
chromosome 10 open reading frame 6
LOC710786
2.11
0.0526


MmugDNA.11836.1.S1_at
—
—
2.11
0.0069


MmugDNA.16849.1.S1_at
NAD-dependent deacetylase sirtuin-4 (SIR2-like protein 4)
LOC720498
2.11
0.0416


MmuSTS.4531.1.S1_at
ankyrin repeat and SOCS box-containing protein 1
ASB1
2.11
0.0647


MmugDNA.607.1.S1_at
ras-like protein TC10
LOC717769
2.11
0.0443


MmugDNA.33195.1.S1_at
hypothetical protein LOC704974 /// G-protein coupled
LOC704974 ///
2.11
0.0049



purinergic receptor P2Y5
LOC705081


MmugDNA.40999.1.S1_at
DAB2 interacting protein
DAB2IP
2.10
0.0008


MmugDNA.9833.1.S1_at
v-maf musculoaponeurotic fibrosarcoma oncogene homolog
MAF
2.10
0.0082



(avian)


MmugDNA.21011.1.S1_at
hypothetical protein FLJ90396
FLJ90396
2.10
0.0507


MmugDNA.2101.1.S1_at
stearoyl-CoA desaturase (delta-9-desaturase)
SCD
2.10
0.0023


MmuSTS.822.1.S1_at
drebrin 1
DBN1
2.10
0.0386


MmugDNA.41100.1.S1_at
GPI-anchored metastasis-associated protein homolog
LOC718197
2.10
0.0588


MmugDNA.38957.1.S1_at
Cleavage stimulation factor, 3′ pre-RNA, subunit 2, 64 kDa,
CSTF2T
2.10
0.0646



tau variant


MmugDNA.34474.1.S1_at
cysteine sulfinic acid decarboxylase-related protein 2
LOC701290
2.08
0.0698


MmugDNA.9802.1.S1_at
aldehyde dehydrogenase 3 family, member A1
ALDH3A1
2.08
0.0132


MmugDNA.43169.1.S1_at
CD109 antigen (Gov platelet alloantigens)
CD109
2.08
0.0492


MmuSTS.698.1.S1_at
CKLF-like MARVEL transmembrane domain-containing
CMTM6
2.08
0.0065



protein 6 (Chemokine-like factor superfamily member 6)


MmugDNA.34248.1.S1_at
splicing factor, arginine/serine-rich 15
LOC701931
2.08
0.0239


MmugDNA.33686.1.S1_s_at
hypothetical protein LOC722265
LOC722265
2.08
0.0776


MmugDNA.33032.1.S1_at
K06A9.1b
LOC710668
2.07
0.0082


MmugDNA.14765.1.S1_at
polymerase I and transcript release factor
PTRF
2.07
0.0288


MmugDNA.32283.1.S1_at
ladinin 1
LOC707971
2.07
0.0106


MmuSTS.2113.1.S1_at
—
ARHGEF19
2.07
0.0016


MmugDNA.11281.1.S1_at
proline-, glutamic acid-, leucine-rich protein 1
LOC709306
2.07
0.0128


MmugDNA.21716.1.S1_at
CDNA FLJ36544 fis, clone TRACH2006378
—
2.07
0.0908


MmugDNA.33042.1.S1_at
latent transforming growth factor beta binding protein 2
LOC699435
2.07
0.0762


MmugDNA.9373.1.S1_at
metastasis-associated protein 2
—
2.06
0.0100


Mmu.13445.1.S1_at
calumenin precursor
LOC699730
2.06
0.0342


MmuSTS.4590.1.S1_at
transglutaminase 2
TGM2
2.06
0.0817


MmugDNA.19480.1.S1_at
KIAA1219 protein
KIAA1219
2.06
0.0781


MmugDNA.10100.1.S1_at
hypothetical protein LOC722637
LOC722637
2.06
0.0099


MmugDNA.16322.1.S1_at
Transcribed locus, weakly similar to NP_055301.1 neuronal
—
2.06
0.0989



thread protein AD7c-NTP [Homo sapiens]


MmugDNA.4438.1.S1_at
transmembrane protein 39B
LOC706700
2.06
0.0916


MmugDNA.35973.1.S1_at
agrin
LOC693314
2.06
0.0197


MmugDNA.36549.1.S1_at
Hypothetical protein FLJ14888
FLJ14888
2.06
0.0846


MmugDNA.15963.1.S1_at
PABP1-dependent poly A-specific ribonuclease subunit
PAN3
2.05
0.0740



PAN3


MmugDNA.18234.1.S1_at
runt-related transcription factor 2 isoform b
LOC703331
2.05
0.0228


MmugDNA.32119.1.S1_at
cytosolic malic enzyme 1
ME1
2.05
0.0425


MmugDNA.18163.1.S1_at
gamma-aminobutyric acid (GABA) B receptor 1 isoform a
LOC708987
2.05
0.0129



precursor


MmugDNA.18569.1.S1_at
phospholipase A2, group IVB
LOC707262
2.04
0.0116


MmugDNA.23773.1.S1_at
alpha 1 type XVIII collagen isoform 1 precursor
LOC721919
2.04
0.0444


Mmu.16285.1.A1_at
—
ANP32A
2.04
0.0274


MmuSTS.2061.1.S1_at
phospholipase C gamma 1 isoform a
LOC697069
2.04
0.0259


MmugDNA.25737.1.S1_at
Abl-interactor 1
ABI1
2.04
0.0333


MmugDNA.37418.1.S1_at
NMD3 homolog
LOC701677
2.04
0.0354


MmugDNA.29644.1.S1_at
RAN binding protein 2-like 1
RANBP2L1
2.04
0.0405


MmugDNA.22841.1.S1_at
Karyopherin alpha 5 (importin alpha 6)
KPNA5
2.04
0.0159


MmugDNA.40840.1.S1_at
ring finger and KH domain containing 2
LOC719403
2.03
0.0970


MmugDNA.39873.1.S1_s_at
solute carrier family 38, member 2
LOC702253
2.03
0.0018


MmugDNA.29688.1.S1_at
G-protein coupled receptor 116
LOC704887
2.03
0.0715


MmugDNA.2555.1.S1_at
CDNA FLJ37816 fis, clone BRSSN2003093
—
2.03
0.0765


MmugDNA.27712.1.S1_at
golgi SNAP receptor complex member 1
GOSR1
2.03
0.0166


MmuSTS.3453.1.S1_at
PYD and CARD domain containing isoform b
LOC713563
2.03
0.0818


MmugDNA.38737.1.S1_s_at
transcription factor B1, mitochondrial
LOC701830
2.03
0.0574


MmugDNA.371.1.S1_at
—
—
2.03
0.0252


MmuSTS.2285.1.S1_at
POU domain, class 5, transcription factor 1
POU5F1
2.02
0.0989


MmugDNA.11375.1.S1_at
spartin
LOC693663
2.02
0.0884


MmuSTS.3541.1.S1_at
NOD2 protein
LOC695542
2.02
0.0867


MmunewRS.886.1.S1_at
gi:51465519
—
2.02
0.0891


MmugDNA.33688.1.S1_at
ribosomal protein L17
RPL17
2.02
0.0384


MmugDNA.31199.1.S1_at
ADP-ribosylation factor-like protein 4C (ADP-ribosylation
ARL4C
2.02
0.0154



factor-like 7)


MmugDNA.32540.1.S1_at
centaurin-alpha 2 protein
CENTA2
2.02
0.0939


MmugDNA.19746.1.S1_at
solute carrier family 2 (facilitated glucose transporter),
SLC2A3
2.02
0.0013



member 3


MmugDNA.30247.1.S1_at
RNA-binding region containing protein 2 isoform b
LOC704198
2.01
0.0297


MmugDNA.35944.1.S1_at
CDNA FLJ13136 fis, clone NT2RP3003139
—
2.01
0.0963


MmugDNA.29822.1.S1_at
carbonic anhydrase IV
CA4
2.01
0.0637


MmugDNA.15283.1.S1_at
Transcribed locus
—
2.01
0.0424


MmuSTS.1380.1.S1_at
basic helix-loop-helix domain containing, class B, 3
BHLHB3
2.01
0.0588


MmugDNA.19213.1.S1_at
unconventional myosin class XV CG2174-PA
LOC711013
2.01
0.0214


Mmu.2043.1.S1_at
axonal transport of synaptic vesicles
LOC722674
2.01
0.0295


MmugDNA.18297.1.S1_at
COP9 (constitutive photomorphogenic) homolog, subunit 2
LOC714814
2.00
0.0897


MmuSTS.263.1.S1_at
sprouty homolog 1, antagonist of FGF signaling
LOC708752
2.00
0.0535


MmuSTS.542.1.S1_at
osteopetrosis associated transmembrane protein 1
LOC701341
2.00
0.0249


MmugDNA.39776.1.S1_at
hypothetical protein LOC696417
LOC696417
2.00
0.0224


MmuSTS.4423.1.S1_at
frizzled homolog 2
FZD2
2.00
0.0679


MmugDNA.40363.1.S1_at
Hypothetical protein FLJ10948
FLJ10948
2.00
0.0540


Mmu.3412.1.A1_at
Transcribed locus
—
2.00
0.0909


MmugDNA.31062.1.S1_at
CDC42 binding protein kinase gamma (DMPK-like)
CDC42BPG
2.00
0.0044


MmugDNA.36785.1.S1_a_at
hypothetical protein MGC2780
MGC2780
107.99
0.2056


MmugDNA.11034.1.S1_at
MRNA full length insert cDNA clone EUROIMAGE 994183
—
66.61
0.0016


MmugDNA.15521.1.S1_at
helicase with zinc finger /// ovostatin 2 /// cDNA sequence
HELZ /// OVOS2 ///
38.75
0.0810



BC048546
LOC440080


MmugDNA.6868.1.S1_at
adenosine deaminase-like
ADAL
29.88
0.0860


MmugDNA.3759.1.S1_at
zinc finger protein 208
ZNF208
27.54
0.1523


MmugDNA.19225.1.S1_at
hemochromatosis type 2 (juvenile)
HFE2
27.11
0.1919


MmugDNA.19620.1.S1_at
Transcribed locus
—
26.88
0.0322


MmunewRS.411.1.S1_at
T-cell lymphoma breakpoint-associated target 1
TCBA1
23.70
0.0159


MmugDNA.5507.1.S1_at
—
—
23.68
0.0045


MmuSTS.2342.1.S1_at
receptor (calcitonin) activity modifying protein 2
RAMP2
22.81
0.0433


MmuSTS.4185.1.S1_at
nidogen 2
NID2
22.41
0.0046


Mmu.12045.1.S1_at
phosphatidylinositol glycan, class K
PIGK
21.51
0.0191


Mmu.2196.1.A1_at
APP-70 mRNA fragment for amyloid precursor protein
X15985
21.32
0.0840



protease inhibitor domain.


MmuSTS.1412.1.S1_at
potassium intermediate/small conductance calcium-activated
KCNN3
20.30
0.0082



chann, , subfamily N, member 3


MmugDNA.21052.1.S1_at
Transcribed locus
—
19.79
0.0089


MmugDNA.5232.1.S1_at
CDNA clone IMAGE: 4811759
—
16.97
0.0006


MmugDNA.13275.1.S1_at
solute carrier family 34 (sodium phosphate), member 2
LOC694217
16.22
0.1746


MmugDNA.33984.1.S1_at
CDNA clone IMAGE: 4814828
—
16.07
0.1046


MmugDNA.31271.1.S1_at
Replication protein A3, 14 kDa
RPA3
15.96
0.0083


MmugDNA.19644.1.S1_at
anterior pharynx defective 1 homolog B (C. elegans) ///
APH1B
15.89
0.0141



anterior pharynx defective 1 homolog B (C. elegans)


MmuSTS.4301.1.S1_at
sema domain, seven thrombospondin repeats (type 1 and type
SEMA5A
15.83
0.0613



1-lik, , transmembrane domain (TM) and short cytoplasmic



domain, (semaphorin) 5A


MmugDNA.39574.1.S1_at
RWD domain containing 2
RWDD2
15.13
0.0179


MmuSTS.4181.1.S1_at
cullin 2
CUL2
15.12
0.0079


MmugDNA.30525.1.S1_at
Transcribed locus, weakly XP_489263.1 RIKEN cDNA
230450_at
15.07
0.0170



9130004C02 gene [Mus musculus]


MmuSTS.2619.1.S1_at
erythroblast membrane-associated protein (Scianna blood
ERMAP
14.89
0.1814



group)


MmugDNA.18007.1.S1_s_at
family with sequence similarity 102, member B
FAM102B
14.49
0.1119


MmuSTS.4534.1.S1_at
Bruton agammaglobulinemia tyrosine kinase
BTK
13.98
0.0369


MmuSTS.898.1.S1_at
Engulfment and cell motility 1
ELMO1
13.94
0.0068


MmugDNA.1875.1.S1_at
aldehyde dehydrogenase 1 family, member B1
ALDH1B1
13.77
0.1752


MmugDNA.8764.1.S1_at
—
—
13.77
0.0751


MmuSTS.2829.1.S1_at
solute carrier family 7 (cationic amino acid transporter, y+ sys,
SLC7A6
13.70
0.0036



m), member 6


MmugDNA.12524.1.S1_at
response gene to complement 32
RGC32
13.37
0.0077


MmugDNA.24601.1.S1_at
Chromosome 18 open reading frame 17
C18orf17
13.37
0.0025


MmugDNA.9600.1.S1_at
regulating synaptic membrane exocytosis 2
RIMS2
13.30
0.0310


MmugDNA.14408.1.S1_at
chromosome 12 open reading frame 24
C12orf24
12.75
0.1070


MmugDNA.37885.1.S1_at
homer homolog 1 (Drosophila)
HOMER1
12.68
0.0144


MmugDNA.15936.1.S1_s_at
CDNA: FLJ21874 fis, clone HEP02488
—
12.38
0.0063


MmuSTS.3629.1.S1_at
EMI domain containing 1
EMID1
12.26
0.0380


MmugDNA.10412.1.S1_x_at
Hypothetical protein KIAA0187 gene product ///
LOC96610 ///
12.20
0.2034



Immunoglobulin lambda locus
IGL@


MmugDNA.21132.1.S1_at
hypothetical locus FLJ30594
FLJ30594
12.08
0.1018


MmugDNA.16717.1.S1_s_at
seizure related 6 homolog (mouse)-like 2 /// seizure related 6
SEZ6L2 ///
11.95
0.0313



homolog (mouse)-like 2 isoform 1
LOC652900


MmuSTS.721.1.S1_at
N-acetylneuraminate pyruvate lyase (dihydrodipicolinate
NPL
11.73
0.0624



synthase


MmugDNA.23998.1.S1_at
DKFZP434B0335 protein
DKFZP434B0335
11.67
0.0140


Mmu.10472.1.S1_at
acid sphingomyelinase-like phosphodiesterase 3A
LOC713696
11.58
0.0004


MmugDNA.34582.1.S1_at
limbic system-associated membrane protein
LSAMP
11.56
0.1465


MmugDNA.27799.1.S1_at
chromosome 8 open reading frame 47
C8orf47
11.54
0.0051


MmugDNA.35367.1.S1_at
transmembrane emp24 protein transport domain containing 8
TMED8
11.54
0.0000


MmuSTS.4580.1.S1_at
heparan sulfate (glucosamine) 3-O-sulfotransferase 5
HS3ST5
11.36
0.0340


MmugDNA.14099.1.S1_at
protein disulfide isomerase family A, member 5
PDIA5
11.07
0.0354


MmunewRS.286.1.S1_at
cDNA FLJ46082 fis, clone TESTI2005153.
gi:34536371
10.92
0.1933


MmugDNA.13637.1.S1_at
hypothetical protein LOC169834
LOC169834
10.91
0.0446


MmugDNA.21508.1.S1_at
CDNA FLJ37235 fis, clone BRAMY2002525
—
10.58
0.2144


MmugDNA.26503.1.S1_at
polyhomeotic-like 2 (Drosophila)
PHC2
10.50
0.0002


MmugDNA.9977.1.S1_at
ethanolamine kinase 1
ETNK1
10.43
0.0022


MmuSTS.629.1.S1_at
insulin-like growth factor 2 receptor
IGF2R
10.32
0.0115


MmugDNA.42459.1.S1_at
nucleotide binding protein 1 (MinD homolog, E. coli)
NUBP1
10.13
0.0076


MmugDNA.16304.1.S1_at
paraoxonase 2
PON2
10.03
0.2019


MmugDNA.27226.1.S1_at
chromosome 10 open reading frame 49
C10orf49
10.03
0.1874


MmugDNA.27601.1.S1_at
—
—
10.01
0.0801


MmugDNA.19069.1.S1_at
transient receptor potential cation channel, subfamily M,
TRPM7
9.84
0.0026



member 7


MmugDNA.12483.1.S1_at
HLA complex group 27
HCG27
9.82
0.1032


MmugDNA.15012.1.S1_at
Arylformamidase
AFMID
9.78
0.0546


MmugDNA.689.1.S1_at
hypothetical protein LOC707842
LOC707842
9.65
0.1426


MmugDNA.1511.1.S1_at
Transcribed locus
—
9.54
0.1466


MmugDNA.6078.1.S1_at
Sp2 transcription factor
SP2
9.47
0.1325


MmugDNA.34436.1.S1_at
Hypothetical protein LOC152485
LOC152485
9.36
0.0053


Mmu.15003.1.S1_x_at
activating signal cointegrator 1 complex subunit 3-like 1
LOC705184
9.28
0.0157


MmugDNA.24349.1.S1_at
Transcribed locus
—
9.26
0.0882


MmugDNA.21279.1.S1_at
Leucine-rich repeat protein SHOC-2 (Ras-binding protein Sur-
RP11-139H14.4
9.21
0.0670



8)


MmugDNA.13732.1.S1_at
PHD finger protein 20-like 1
PHF20L1
9.20
0.0626


MmugDNA.28092.1.S1_at
breakpoint cluster region isoform 1
LOC644165
9.11
0.2063


MmugDNA.4326.1.S1_at
Transcribed locus
—
8.93
0.0080


Mmu.15748.1.S1_s_at
Transcribed locus, weakly XP_933032.2 hypothetical protein
—
8.88
0.0874



[Homo sapiens]


MmugDNA.17676.1.S1_at
peroxisomal biogenesis factor 5-like
PEX5L
8.86
0.0737


MmugDNA.38590.1.S1_at
ligand-gated ion channel, zinc activated 1
LGICZ1
8.81
0.0142


MmugDNA.33781.1.S1_at
dynein, axonemal, heavy polypeptide 10
DNAH10
8.80
0.1157


MmugDNA.43623.1.S1_s_at
disabled homolog 2, mitogen-responsive phosphoprotein
DAB2
8.75
0.0103



(Drosophila)


MmugDNA.20593.1.S1_at
tripeptidyl peptidase II
TPP2
8.68
0.2180


MmugDNA.24454.1.S1_at
phosphatidic acid phosphatase type 2C
PPAP2C
8.68
0.1046


MmugDNA.4150.1.S1_at
hypothetical protein FLJ40298
FLJ40298
8.67
0.1356


MmugDNA.22927.1.S1_at
—
—
8.66
0.1089


MmugDNA.39321.1.S1_at
CDNA FLJ41751 fis, clone HSYRA2008154
—
8.65
0.0090


MmugDNA.38636.1.S1_at
hypothetical protein FLJ39653
FLJ39653
8.61
0.0384


MmugDNA.8681.1.S1_at
KIAA0100 /// hypothetical protein FLJ22349
KIAA0100 ///
8.61
0.0075




FLJ22349


MmugDNA.27488.1.S1_at
suppression of tumorigenicity 14 (colon carcinoma)
ST14
8.58
0.0576


MmugDNA.29768.1.S1_at
melanocortin 2 receptor accessory protein
MRAP
8.56
0.0423


MmugDNA.42270.1.S1_at
gremlin 1, cysteine knot superfamily, homolog (Xenopus
GREM1
8.53
0.1415



laevis)


MmugDNA.30894.1.S1_at
Transcribed locus, strongly NP_067647.1 leucine-rich repeat-
—
8.44
0.1092



containing G protein-coupled receptor 7 [Homo sapiens]


MmugDNA.37925.1.S1_at
plasma glutamate carboxypeptidase
PGCP
8.43
0.0055


MmugDNA.7703.1.S1_s_at
pyrroline-5-carboxylate reductase family, member 2
PYCR2
8.42
0.0481


MmugDNA.29962.1.S1_at
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
P4HA3
8.41
0.0311



hydroxylase), alpha polypeptide III


MmugDNA.29322.1.S1_at
chromosome 6 open reading frame 159
C6orf159
8.37
0.1465


MmugDNA.32728.1.S1_at
GLIS family zinc finger 2
LOC708454
8.33
0.0118


MmugDNA.39848.1.S1_at
DIP2 disco-interacting protein 2 homolog C (Drosophila)
DIP2C
8.32
0.0054


MmugDNA.9959.1.S1_at
—
—
8.31
0.2016


MmuSTS.2576.1.S1_at
DnaJ (Hsp40) homolog, subfamily B, member 12
DNAJB12
8.25
0.0207


MmugDNA.3860.1.S1_at
—
—
8.16
0.0618


Mmu.4703.1.S1_at
—
CO774986
8.16
0.0134


MmugDNA.33155.1.S1_at
likely ortholog of MEF2-activating SAP transcriptional regulator
FLJ36070
8.15
0.0863


MmugDNA.20631.1.S1_at
Transcribed locus, strongly XP_513258.1 LOC456687 [Pan
230613_at
8.08
0.2120



troglodytes]


MmugDNA.39834.1.S1_s_at
fragile histidine triad gene
FHIT
8.00
0.0019


MmugDNA.26008.1.S1_at
musashi homolog 2 (Drosophila)
MSI2
7.97
0.0002


MmugDNA.36272.1.S1_s_at
dCMP deaminase
DCTD
7.87
0.0027


MmugDNA.21159.1.S1_at
hypothetical protein FLJ31846
FLJ31846
7.84
0.1945


MmugDNA.7644.1.S1_at
amyloid beta (A4) precursor-like protein 2
APLP2
7.82
0.0540


MmugDNA.26889.1.S1_at
Transcribed locus
—
7.82
0.1703


MmugDNA.35633.1.S1_at
Transcribed locus, strongly NP_659486.1 hypothetical protein
—
7.80
0.0389



MGC10067 [Homo sapiens]


MmugDNA.11626.1.S1_at
dynein, cytoplasmic 2, heavy chain 1
DYNC2H1
7.80
0.0014


MmugDNA.18533.1.S1_at
phospholipase D family, member 5
PLD5
7.80
0.0512


MmugDNA.36604.1.S1_at
Transcribed locus
—
7.77
0.0005


MmugDNA.12098.1.S1_at
Transcribed locus
—
7.76
0.0954


MmugDNA.8791.1.S1_at
KIAA0586
KIAA0586
7.72
0.0606


MmugDNA.25037.1.S1_at
CDNA FLJ30090 fis, clone BNGH41000015
—
7.68
0.0828


MmugDNA.30003.1.S1_at
BTB (POZ) domain containing 16
BTBD16
7.66
0.0893


MmugDNA.29464.1.S1_at
inositol monophosphatase domain containing 1
IMPAD1
7.65
0.0204


MmugDNA.29130.1.S1_at
adenylate cyclase 1 (brain)
ADCY1
7.64
0.0222


MmugDNA.42065.1.S1_at
distal-less homeobox 6
DLX6
7.64
0.2136


MmugDNA.3371.1.S1_at
reticulon 1
RTN1
7.63
0.0730


MmugDNA.23995.1.S1_at
zinc finger protein 501
ZNF501
7.62
0.1374


MmugDNA.5842.1.S1_at
—
—
7.59
0.1545


MmugDNA.21402.1.S1_at
R3H domain and coiled-coil containing 1
R3HCC1
7.58
0.0122


MmugDNA.11091.1.S1_at
Nuclear factor I/A
NFIA
7.58
0.0395


MmuSTS.383.1.S1_at
lipase, gastric
LIPF
7.56
0.1613


MmugDNA.26814.1.S1_at
chromosome 3 open reading frame 19
C3orf19
7.55
0.0189


MmugDNA.38434.1.S1_at
WD repeat domain 5B
WDR5B
7.50
0.1039


MmugDNA.5186.1.S1_at
RNA binding motif protein 23
RBM23
7.45
0.0136


MmugDNA.22050.1.S1_at
EID-2-like inhibitor of differentiation-3
EID-3
7.45
0.0340


MmugDNA.40688.1.S1_at
zinc finger protein 235
ZNF235
7.43
0.0135


MmugDNA.30778.1.S1_at
growth factor, augmenter of liver regeneration (ERV1
GFER
7.42
0.0002



homolog, S. cerevisiae)


MmuSTS.2673.1.S1_at
calmegin
CLGN
7.41
0.0581


MmugDNA.9553.1.S1_at
Mannosidase, alpha, class 1A, member 1
MAN1A1
7.38
0.0114


MmugDNA.16242.1.S1_at
—
—
7.37
0.0006


MmugDNA.23074.1.S1_at
plexin A2
PLXNA2
7.36
0.0096


MmugDNA.31786.1.S1_at
hypothetical protein LOC158402
LOC158402
7.36
0.0327


MmugDNA.9822.1.S1_at
immunoglobulin superfamily containing leucine-rich repeat 2
ISLR2
7.34
0.1736


MmugDNA.5439.1.S1_at
catechol-O-methyltransferase
COMT
7.32
0.0094


MmugDNA.23942.1.S1_at
—
—
7.26
0.0768


MmugDNA.37455.1.S1_at
Transcribed locus
—
7.25
0.0155


MmugDNA.34284.1.S1_at
sodium channel, voltage-gated, type III, beta
SCN3B
7.25
0.0578


MmugDNA.19576.1.S1_at
zinc finger protein 547
ZNF547
7.24
0.0782


MmugDNA.34395.1.S1_at
zinc finger protein 230
ZNF230
7.23
0.0152


MmugDNA.6131.1.S1_at
chromosome 16 open reading frame 35
C16orf35
7.20
0.1537


MmugDNA.6727.1.S1_at
—
—
7.20
0.0804


MmugDNA.24272.1.S1_at
KIAA1922 protein
KIAA1922
7.19
0.1247


MmugDNA.6286.1.S1_at
zinc finger protein 599
ZNF599
7.14
0.0790


MmuSTS.3570.1.S1_at
collagen, type IV, alpha 4
COL4A4
7.14
0.0006


MmugDNA.39056.1.S1_at
chromodomain helicase DNA binding protein 4
CHD4
7.13
0.0047


MmugDNA.34250.1.S1_at
hypothetical protein LOC645644
FLJ42627
7.13
0.0043


MmuSTS.1813.1.S1_at
sterol O-acyltransferase 2
SOAT2
7.11
0.0279


MmugDNA.24694.1.S1_at
Retinoblastoma binding protein 4
RBBP4
7.10
0.0185


MmugDNA.24480.1.S1_at
splicing factor proline/glutamine-rich (polypyrimidine tract
SFPQ
7.09
0.0095



binding protein associated)


MmugDNA.33264.1.S1_at
TIP41, TOR signalling pathway regulator-like (S. cerevisiae)
TIPRL
7.08
0.1207


MmugDNA.31611.1.S1_at
PRotein Associated with Tlr4
MGC40499
7.01
0.0583


MmugDNA.26071.1.S1_s_at
RAB30, member RAS oncogene family
RAB30
6.97
0.0043


MmugDNA.11685.1.S1_at
poly (ADP-ribose) polymerase family, member 8
PARP8
6.94
0.0303


MmugDNA.38371.1.S1_at
hexosaminidase A (alpha polypeptide)
HEXA
6.94
0.0512


MmugDNA.5558.1.S1_at
tRNA phosphotransferase 1
TRPT1
6.93
0.0013


MmugDNA.34597.1.S1_at
tetraspanin 1
TSPAN1
6.86
0.0007


MmugDNA.18788.1.S1_at
Capping protein (actin filament) muscle Z-line, alpha 2
CAPZA2
6.85
0.0915


MmugDNA.28272.1.S1_at
molybdenum cofactor synthesis 1
MOCS1
6.83
0.0681


MmugDNA.14078.1.S1_at
EBNA1 binding protein 2
EBNA1BP2
6.82
0.0463


MmuSTS.2123.1.S1_at
retinal outer segment membrane protein 1
ROM1
6.81
0.0210


MmugDNA.9513.1.S1_at
exostoses (multiple)-like 2
EXTL2
6.79
0.0112


Mmu.7528.1.S1_at
Zygin 1
ZYG1
6.76
0.0713


MmugDNA.12416.1.S1_at
coiled-coil domain containing 51
CCDC51
6.76
0.0052


MmuSTS.3946.1.S1_at
T-cell activation kelch repeat protein
TA-KRP
6.76
0.0172


MmugDNA.12522.1.S1_at
Pyrophosphatase (inorganic) 2
PPA2
6.74
0.0061


MmugDNA.39796.1.S1_at
DIRAS family, GTP-binding RAS-like 3
DIRAS3
6.72
0.0734


MmugDNA.1685.1.S1_at
zinc finger protein 682
ZNF682
6.72
0.0142


MmuSTS.2157.1.S1_at
Scm-like with four mbt domains 1
SFMBT1
6.71
0.0051


MmugDNA.2165.1.S1_at
small nuclear ribonucleoprotein polypeptide E
SNRPE
6.70
0.0389


MmugDNA.2643.1.S1_at
chromosome 11 open reading frame 59
C11orf59
6.69
0.0306


MmugDNA.13192.1.S1_s_at
peptidylprolyl isomerase E (cyclophilin E)
PPIE
6.67
0.0336


MmugDNA.13901.1.S1_at
KIAA0194 protein
KIAA0194
6.65
0.0029


MmugDNA.9677.1.S1_at
hypothetical protein MGC39606 /// hypothetical protein
MGC39606 ///
6.64
0.0636



LOC644596
LOC644596


MmugDNA.21296.1.S1_at
CDNA FLJ14188 fis, clone NT2RP2005980
—
6.64
0.0539


MmugDNA.36977.1.S1_at
transmembrane protein 107
TMEM107
6.62
0.0537


MmuSTS.3859.1.S1_at
solute carrier family 26, member 9
SLC26A9
6.62
0.0483


MmuSTS.514.1.S1_at
ATPase, Class VI, type 11C
ATP11C
6.62
0.0004


MmugDNA.18137.1.S1_at
—
—
6.60
0.0451


MmugDNA.36662.1.S1_at
STAM binding protein-like 1
STAMBPL1
6.60
0.0041


MmugDNA.13357.1.S1_at
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein
KDELR1
6.58
0.0618



retention receptor 1


MmugDNA.34884.1.S1_at
CUB and zona pellucida-like domains 1
CUZD1
6.58
0.0561


MmugDNA.10426.1.S1_at
neuron navigator 3
NAV3
6.56
0.0493










MmunewRS.777.1.S1_at
This record was removed as a result of standard genome annotation
6.54
0.0904



processing.











MmugDNA.32277.1.S1_at
DNA (cytosine-5-)-methyltransferase 2
DNMT2
6.51
0.0001


MmunewRS.654.1.S1_at
taste receptor, type 2, member 44
TAS2R44
6.51
0.1568


MmuSTS.3981.1.S1_at
SH3-domain GRB2-like 2
SH3GL2
6.48
0.0289


MmugDNA.23979.1.S1_at
tetratricopeptide repeat domain 8
TTC8
6.47
0.0227


MmugDNA.9202.1.S1_at
PRO0633
—
6.45
0.0369


MmugDNA.19839.1.S1_at
metallothionein 1G
MT1G
6.44
0.0115


MmugDNA.11505.1.S1_at
RNA (guanine-9-) methyltransferase domain containing 3
RG9MTD3
6.44
0.0224


MmugDNA.37839.1.S1_s_at
Full length insert cDNA clone ZD82B02
—
6.41
0.0024


MmugDNA.26070.1.S1_at
putatative 28 kDa protein
LOC56902
6.39
0.0219


MmugDNA.4320.1.S1_at
chromosome 14 open reading frame 93
C14orf93
6.39
0.0814


MmugDNA.42430.1.S1_at
chromosome 5 open reading frame 28
C5orf28
6.39
0.0427


MmugDNA.13752.1.S1_at
spermatogenesis associated 7
SPATA7
6.37
0.0117


MmugDNA.39646.1.S1_s_at
chromosome 19 open reading frame 10
C19orf10
6.36
0.1162


MmugDNA.4241.1.S1_at
FRAS1 related extracellular matrix 3
FREM3
6.34
0.0744


MmugDNA.5102.1.S1_at
—
—
6.33
0.0111


MmugDNA.23567.1.S1_at
protein arginine methyltransferase 6
PRMT6
6.33
0.0382


MmugDNA.42806.1.S1_at
—
—
6.33
0.0980


MmugDNA.35790.1.S1_at
solute carrier family 7 (cationic amino acid transporter, y+
SLC7A3
6.31
0.1159



system), member 3


MmugDNA.11215.1.S1_at
—
—
6.30
0.0526


MmugDNA.9057.1.S1_at
transmembrane protein 107 /// transmembrane protein 107
TMEM107
6.28
0.0390


MmugDNA.37336.1.S1_at
stathmin-like 2
STMN2
6.27
0.1549


MmugDNA.117.1.S1_at
DPH5 homolog (S. cerevisiae)
DPH5
6.27
0.0417


Mmu.15115.1.S1_at
Ribonuclease UK114 (14.5 kDa translational inhibitor
LOC705533
6.25
0.0280



protein) (p14.5) (UK114 antigen homolog)


MmugDNA.21121.1.S1_at
Insulin-like growth factor 1 receptor
IGF1R
6.25
0.0700


MmugDNA.13304.1.S1_at
Fukuyama type congenital muscular dystrophy (fukutin)
FCMD
6.24
0.0342


MmugDNA.40836.1.S1_at
chromosome 6 open reading frame 168
C6orf168
6.23
0.0000


MmugDNA.23421.1.S1_at
FLJ16124 protein
ELJ16124
6.23
0.1070


MmugDNA.29466.1.S1_at
Transcribed locus
—
6.22
0.0243


MmugDNA.41017.1.S1_at
CDNA clone IMAGE: 4791585
—
6.20
0.0430


MmugDNA.18662.1.S1_at
parathyroid hormone receptor 2
PTHR2
6.19
0.1555


MmugDNA.27914.1.S1_at
family with sequence similarity 55, member D
FAM55D
6.19
0.1240


MmugDNA.39981.1.S1_at
microtubule associated monoxygenase, calponin and LIM
MICAL2
6.17
0.0214



domain containing 2


MmugDNA.33630.1.S1_at
apolipoprotein B mRNA editing enzyme, catalytic
APOBEC3G
6.13
0.0918



polypeptide-like 3G


MmugDNA.41272.1.S1_at
KIAA0174
KIAA0174
6.12
0.0498


MmugDNA.4554.1.S1_at
membrane-associated ring finger (C3HC4) 9
9-Mar
6.12
0.0006


MmuSTS.4598.1.S1_at
hypoxia up-regulated 1
HYOU1
6.11
0.0224


MmugDNA.40815.1.S1_at
Family with sequence similarity 77, member D
FAM77D
6.11
0.0370


MmugDNA.10816.1.S1_at
CDNA FLJ90571 fis, clone OVARC1001725, highly Homo
—
6.09
0.0585



sapiens patched related protein TRC8 (TRC8) gene


Mmu.15827.1.S1_at
tafazzin
TAZ
6.09
0.0279


MmugDNA.18337.1.S1_at
neurofilament, heavy polypeptide 200 kDa
NEFH
6.08
0.0788


MmuSTS.3411.1.S1_at
phosphoribosyl pyrophosphate synthetase 1
PRPS1
6.08
0.0271


MmugDNA.4215.1.S1_at
matrix-remodelling associated 8
MXRA8
6.07
0.0277


MmugDNA.2493.1.S1_at
Full-length cDNA clone CS0DI054YK19 of Placenta Cot 25-
—
6.07
0.0954



normalized of Homo sapiens (human)


MmugDNA.29221.1.S1_at
mannosidase, alpha, class 2A, member 1
MAN2A1
6.06
0.0356


MmuSTS.2268.1.S1_at
polymerase (RNA) II (DNA directed) polypeptide C, 33 kDa
POLR2C
6.06
0.0054


MmugDNA.16039.1.S1_at
Transcribed locus
—
6.05
0.1426


MmugDNA.23370.1.S1_at
SH3 and PX domains 2A
SH3PXD2A
6.02
0.1440


Mmu.5073.1.S1_at
histone deacetylase 1
LOC708441
6.01
0.0636


MmugDNA.18754.1.S1_at
hypothetical protein LOC134466
LOC134466
6.00
0.0506


MmugDNA.34454.1.S1_at
—
—
5.97
0.0048


MmugDNA.23057.1.S1_at
hypothetical gene supported by AK125122
FLJ13137
5.97
0.0012


MmugDNA.27855.1.S1_at
—
—
5.97
0.0167


MmuSTS.3142.1.S1_at
methyl-CpG binding domain protein 5
MBD5
5.95
0.0115


MmugDNA.23903.1.S1_at
Protein inhibitor of activated STAT, 2
PIAS2
5.94
0.0193


MmugDNA.7631.1.S1_at
CDNA FLJ11682 fis, clone HEMBA1004880
—
5.94
0.1697


MmugDNA.20356.1.S1_at
platelet-activating factor acetylhydrolase 2, 40 kDa
PAFAH2
5.94
0.0009


MmugDNA.2708.1.S1_at
Son of sevenless homolog 1 (Drosophila)
SOS1
5.91
0.0461


MmugDNA.10905.1.S1_at
tectonic
FLJ21127
5.89
0.0025


MmugDNA.28625.1.S1_at
without children CG5965-PA
LOC707028
5.89
0.0638


MmugDNA.11493.1.S1_at
eukaryotic translation initiation factor 4A, isoform 2
EIF4A2
5.87
0.0421


MmugDNA.23572.1.S1_s_at
glutamate-cysteine ligase, modifier subunit
GCLM
5.86
0.0027


MmuSTS.2280.1.S1_at
Dapper, antagonist of beta-catenin, homolog 1 (Xenopus
DACT1
5.86
0.0752



laevis)


MmugDNA.25697.1.S1_at
Ubiguitin-conjugating enzyme E2W (putative)
UBE2W
5.85
0.0579


MmugDNA.24422.1.S1_at
glucosidase, beta, acid 3 (cytosolic)
GBA3
5.84
0.1210


MmugDNA.26055.1.S1_at
THAP domain containing 5
THAP5
5.82
0.1799


MmuSTS.1960.1.S1_at
forkhead box D1
FOXD1
5.81
0.0736


MmugDNA.35294.1.S1_at
protein tyrosine phosphatase-like A domain containing 1
PTPLAD1
5.80
0.0213


MmugDNA.15150.1.S1_at
histone deacetylase 8
HDAC8
5.77
0.0384


MmugDNA.32612.1.S1_s_at
prostaglandin D2 synthase 21 kDa (brain) /// prostaglandin
PTGDS
5.77
0.1930



D2 synthase 21 kDa (brain)


MmuSTS.1829.1.S1_at
Shroom-related protein
ShrmL
5.77
0.0060


MmuSTS.3849.1.S1_at
Spectrin repeat containing, nuclear envelope 2
SYNE2
5.74
0.0000


Mmu.13961.1.S1_at
Protein NipSnap3A (NipSnap4) (Target for Salmonella
LOC716188
5.72
0.0252



secreted protein C) (TassC)


MmugDNA.29451.1.S1_at
Transcribed locus
241668_s_at
5.71
0.1366


MmugDNA.39448.1.S1_at
Interferon regulatory factor 2
IRF2
5.71
0.0394


MmugDNA.13520.1.S1_at
cytoplasmic linker associated protein 2
CLASP2
5.70
0.0457


MmugDNA.35274.1.S1_at
Hypothetical protein FLJ30707
FLJ30707
5.69
0.0422


MmugDNA.1285.1.S1_at
zinc finger protein-like 1
ZFPL1
5.67
0.1329


MmugDNA.31491.1.S1_at
KIAA1333
KIAA1333
5.66
0.1185


MmuSTS.1032.1.S1_at
nucleoporin 133 kDa
NUP133
5.65
0.1949


MmugDNA.28191.1.S1_at
Pleiotropic regulator 1 (PRL1homolog, Arabidopsis)
PLRG1
5.64
0.0702


MmugDNA.42978.1.S1_at
Transcribed locus, weakly XP_530800.1 PREDICTED:
—
5.64
0.0280



hypothetical protein XP_530800 [Pan troglodytes]


MmugDNA.11439.1.S1_at
5′-nucleotidase domain containing 1
NT5DC1
5.64
0.0577


MmuSTS.706.1.S1_at
interleukin-1 receptor-associated kinase 4
IRAK4
5.64
0.0778


MmugDNA.37826.1.S1_at
Hypothetical protein LOC285346
LOC285346
5.63
0.0874


MmuSTS.4259.1.S1_at
dual specificity phosphatase 4
DUSP4
5.63
0.1028


MmunewRS.954.1.S1_at
zinc finger protein 484 isoform a
ZNF484
5.63
0.1344


MmugDNA.24846.1.S1_at
vacuolar protein sorting 26 homolog B (S. cerevisiae)
VPS26B
5.61
0.0039


MmugDNA.36142.1.S1_at
chromosome 9 open reading frame 117
C9orf117
5.58
0.0052


MmugDNA.3197.1.S1_at
RNA binding motif protein 25
RBM25
5.58
0.2066


MmugDNA.30489.1.S1_at
neurolysin (metallopeptidase M3 family)
NLN
5.56
0.0281


MmugDNA.15190.1.S1_at
chromosome 1 open reading frame 151
C1orf151
5.55
0.0874


MmugDNA.21034.1.S1_at
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
GALNT1
5.54
0.0402



acetylgalactosaminyltransferase 1 (GalNAc-T1)


MmugDNA.14671.1.S1_at
dynein, cytoplasmic 2, light intermediate chain 1
DYNC2LI1
5.52
0.0052


MmugDNA.21379.1.S1_at
SNF1-like kinase 2
SNF1LK2
5.52
0.0281


MmugDNA.5564.1.S1_at
zinc finger protein 3
ZNF3
5.51
0.0061


MmugDNA.30983.1.S1_at
Metallophosphoesterase 1
MPPE1
5.50
0.0158


MmuSTS.2242.1.S1_at
TH1-like (Drosophila)
TH1L
5.49
0.0001


MmugDNA.7470.1.S1_at
hypothetical LOC400523
LOC400523
5.49
0.0366


MmugDNA.34874.1.S1_at
casein kinase 2, alpha prime polypeptide
CSNK2A2
5.47
0.0014


MmugDNA.43133.1.S1_at
non-metastatic cells 5, protein expressed in (nucleoside-
NME5
5.45
0.0009



diphosphate kinase)


MmuSTS.3223.1.S1_at
phospholipase D3, phophatidylcholine-specific
PLD3
5.44
0.0358


Mmu.10002.1.S1_s_at
methionine adenosyltransferase II, alpha
MAT2A
5.44
0.0000


MmugDNA.32811.1.S1_at
Transcribed locus
—
5.44
0.0954


MmugDNA.284.1.S1_at
hypothetical LOC149643
LOC149643
5.43
0.0564


MmuSTS.2289.1.S1_at
protein phosphatase 1, regulatory subunit 10
PPP1R10
5.43
0.0004


MmugDNA.7541.1.S1_at
coiled-coil domain containing 88
CCDC88
5.41
0.0296


MmugDNA.1662.1.S1_at
PRP38 pre-mRNA processing factor 38 (yeast) domain
PRPF38A
5.39
0.0054



containing A


MmuSTS.4599.1.S1_at
huntingtin interacting protein B
HYPB
5.38
0.0000


MmugDNA.5606.1.S1_at
5′-nucleotidase, cytosolic III-like
NT5C3L
5.38
0.0235


MmugDNA.12250.1.S1_at
CDNA clone IMAGE: 3928921
—
5.37
0.0135


MmugDNA.25740.1.S1_at
coenzyme Q9 homolog (S. cerevisiae)
COQ9
5.37
0.0000


MmugDNA.34111.1.S1_s_at
heat shock 105 kDa/110 kDa protein 1
HSPH1
5.37
0.0000


MmugDNA.21848.1.S1_at
TSPY-like 1
TSPYL1
5.37
0.0105


MmugDNA.9756.1.S1_at
HERPUD family member 2
HERPUD2
5.36
0.0453


Mmu.3466.1.S1_at
—
CN648872
5.36
0.0770


MmugDNA.23725.1.S1_at
stress 70 protein chaperone, microsome-associated, 60 kDa
STCH
5.34
0.0144


MmugDNA.38793.1.S1_at
cholecystokinin
CCK
5.33
0.2072


MmugDNA.41164.1.S1_at
phosphonoformate immuno-associated protein 5
PFAAP5
5.32
0.0567


MmugDNA.35343.1.S1_s_at
CDNA FLJ41946 fis, clone PLACE6019701
—
5.31
0.0490


MmugDNA.26593.1.S1_at
armadillo repeat containing, X-linked 5
ARMCX5
5.31
0.0081


MmugDNA.14053.1.S1_at
—
—
5.29
0.0696


MmugDNA.9095.1.S1_at
zinc finger protein 396
ZNF396
5.27
0.0141


MmugDNA.25958.1.S1_at
DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57
DHX57
5.27
0.0389


MmugDNA.21062.1.S1_at
suppression of tumorigenicity 7
ST7
5.27
0.0326


MmugDNA.12969.1.S1_at
ribonuclease H2, subunit C
RNASEH2C
5.27
0.0527


MmugDNA.39661.1.S1_at
heparan sulfate 2-O-sulfotransferase 1
HS2ST1
5.26
0.0062


MmugDNA.26250.1.S1_at
zinc finger protein 111
LOC388565
5.25
0.0232


MmugDNA.39242.1.S1_at
melanoma inhibitory activity family, member 3
MIA3
5.25
0.0014


MmugDNA.35720.1.S1_at
zinc finger protein 306 /// zinc finger protein 306
ZNF306
5.25
0.0552


MmuSTS.4680.1.S1_at
thymic stromal lymphopoietin
TSLP
5.25
0.0113


MmugDNA.35830.1.S1_at
—
—
5.24
0.0523


MmuSTS.2253.1.S1_at
polymerase (DNA directed), iota
POLI
5.23
0.0000


MmugDNA.41690.1.S1_at
Fibronectin type III domain containing 3
FNDC3
5.23
0.0908


MmugDNA.16026.1.S1_at
—
—
5.22
0.0871


MmugDNA.12860.1.S1_at
hypothetical protein 284297
FLJ35258
5.21
0.0605


Mmu.6352.1.S1_at
F16A11.1
LOC703783
5.21
0.0698


MmugDNA.28831.1.S1_at
G protein-regulated inducer of neurite outgrowth 1
KIAA1893
5.21
0.0138


MmuSTS.4601.1.S1_at
interleukin 19
IL19
5.20
0.0401


MmugDNA.25269.1.S1_at
chitinase domain containing 1
CHID1
5.20
0.0280


MmuAffx.956.1.S1_at
dolichyl-diphosphooligosaccharide-protein
—
5.20
0.0203



glycosyltransferase


MmugDNA.10359.1.S1_at
DEAH (Asp-Glu-Ala-His) box polypeptide 30
DHX30
5.20
0.0654


MmugDNA.32727.1.S1_at
—
—
5.19
0.0109


MmugDNA.37069.1.S1_at
dihydropyrimidinase
DPYS
5.19
0.0266


MmugDNA.30075.1.S1_at
chromosome 6 open reading frame 162
C6orf162
5.18
0.0316


MmugDNA.9073.1.S1_at
—
—
5.18
0.0376


MmugDNA.12316.1.S1_at
KIAA0090
KIAA0090
5.18
0.0905


MmugDNA.39259.1.S1_at
MRNA; cDNA DKFZp564E202 (from clone DKFZp564E202) ///
—
5.17
0.0284



CDNA FLJ44257 fis, clone TKIDN2015263


MmugDNA.38606.1.S1_at
chromosome 9 open reading frame 89
C9orf89
5.16
0.0215


MmugDNA.3686.1.S1_at
intraflagellar transport 57 homolog (Chlamydomonas)
IFT57
5.14
0.0000


MmugDNA.29286.1.S1_at
zinc finger protein 320 /// hypothetical protein FLJ38482
ZNF320 ///
5.14
0.0252




FLJ38482


MmugDNA.31720.1.S1_at
CUE domain containing 1
CUEDC1
5.14
0.0362


MmugDNA.22403.1.S1_at
receptor accessory protein 5
REEP5
5.14
0.0303


MmugDNA.1116.1.S1_at
Transcribed locus
—
5.12
0.0056


MmugDNA.8918.1.S1_at
WNT1 inducible signaling pathway protein 2
WISP2
5.12
0.1048


MmugDNA.17764.1.S1_at
RCC1 domain containing 1
RCCD1
5.11
0.0040


MmugDNA.31260.1.S1_at
chromosome 11 open reading frame 63
C11orf63
5.11
0.0246


Mmu.6716.1.S1_at
Cathepsin S precursor
LOC708080
5.09
0.0754


MmuSTS.299.1.S1_at
potassium intermediate/small conductance calcium-
KCNN2
5.09
0.0055



activated chann, , subfamily N, member 2


MmugDNA.31161.1.S1_at
Homo sapiens, clone IMAGE: 4095671, mRNA
—
5.09
0.0722


MmugDNA.34930.1.S1_at
—
—
5.08
0.1327


MmugDNA.19331.1.S1_at
Full-length cDNA clone CS0DK012YA15 of HeLa cells Cot
—
5.07
0.0161



25-normalized of Homo sapiens (human)


MmugDNA.36727.1.S1_at
zinc finger, MYM-type 4
ZMYM4
5.07
0.0456


MmugDNA.42518.1.S1_at
nudE nuclear distribution gene E homolog like 1 (A. nidulans)
NDEL1
5.05
0.0746


MmugDNA.14355.1.S1_at
chromosome 21 open reading frame 6
C21orf6
5.05
0.0047


MmugDNA.4328.1.S1_at
zinc finger protein 480
ZNF480
5.03
0.0101


MmuSTS.2927.1.S1_at
potassium voltage-gated channel, subfamily H (eag-
KCNH3
5.00
0.0509



related), memb, 3


MmuSTS.4230.1.S1_at
discs, large (Drosophila) homolog-associated protein 4
DLGAP 4
5.00
0.0584


MmugDNA.27648.1.S1_at
—
—
4.98
0.0573


MmugDNA.41452.1.S1_at
sperm autoantigenic protein 17
SPA17
4.98
0.0031


MmuSTS.3254.1.S1_at
sema domain, immunoglobulin domain (Ig), short basic
SEMA3A
4.98
0.0854



domain, sec ted, (semaphorin) 3A


MmugDNA.3708.1.S1_at
Full length insert cDNA clone YX81F03
—
4.97
0.0024


MmugDNA.3643.1.S1_at
hypothetical protein LOC643749
LOC643749
4.97
0.0165


MmugDNA.7067.1.S1_at
RNA binding motif protein 18
LOC698457
4.97
0.0025


MmugDNA.10033.1.S1_at
poliovirus receptor
PVR
4.96
0.0778


MmugDNA.16402.1.S1_at
cyclin M4
CNNM4
4.96
0.0001


MmugDNA.42450.1.S1_at
—
—
4.96
0.1236


MmugDNA.7713.1.S1_at
chromosome 4 open reading frame 17
C4orf17
4.96
0.0059


MmugDNA.11708.1.S1_at
chloride channel CLIC-like 1
CLCC1
4.95
0.0038


MmugDNA.19659.1.S1_at
Interleukin 17 receptor D
IL17RD
4.95
0.0034


MmugDNA.11406.1.S1_at
protein tyrosine phosphatase, receptor type, G
PTPRG
4.95
0.0002


MmugDNA.3737.1.S1_at
chromosome 13 open reading frame 23
C13orf23
4.95
0.0133


MmugDNA.1748.1.S1_at
transmembrane protein 27
TMEM27
4.94
0.0726


MmugDNA.30715.1.S1_at
armadillo repeat containing 8
ARMC8
4.94
0.0096


MmugDNA.31956.1.S1_at
Transcribed locus
—
4.94
0.0633


MmugDNA.2511.1.S1_at
CDNA FLJ40061 fis, clone TESOP2000083
—
4.94
0.1619


MmugDNA.20090.1.S1_at
TDP-glucose 4, 6-dehydratase
TGDS
4.93
0.0336


MmugDNA.17318.1.S1_at
Transcribed locus
—
4.91
0.1084


MmugDNA.22124.1.S1_at
transmembrane protein 138
TMEM138
4.90
0.1081


Mmu.6994.1.S1_at
basic fibroblast growth factor mRNA, partial cds.
AF251270
4.89
0.0539


MmugDNA.25717.1.S1_s_at
retinoblastoma-like 2 (p130)
RBL2
4.89
0.1029


MmugDNA.32584.1.S1_at
zinc finger protein 571
ZNF571
4.88
0.0004


MmuSTS.32.1.S1_at
zinc finger protein 32
ZNF32
4.87
0.0000


MmugDNA.30643.1.S1_at
B9 protein
EPPB9
4.86
0.1011


MmugDNA.14909.1.S1_at
N-acetyltransferase 1 (arylamine N-acetyltransferase)
NAT1
4.86
0.0099


MmuSTS.2239.1.S1_at
testis expressed sequence 264
TEX264
4.85
0.0109


MmugDNA.28738.1.S1_at
zinc finger protein 354C
LOC713468
4.85
0.0244


MmuSTS.773.1.S1_at
core 1 UDP-galactose:N-acetylgalactosamine-alpha-R beta
C1GALT2
4.85
0.0022



1,3-gala, osyltransferase 2


MmugDNA.7405.1.S1_at
multiple substrate lipid kinase
MULK
4.84
0.0000


MmugDNA.8329.1.S1_at
chromosome 10 open reading frame 72
C10orf72
4.83
0.1341


MmugDNA.33312.1.S1_at
zinc finger, CCHC domain containing 9
ZCCHC9
4.83
0.0024


Mmu.11141.1.S1_at
catenin (cadherin-associated protein), alpha 1, 102 kDa
CTNNA1
4.83
0.0647


MmugDNA.3844.1.S1_at
—
—
4.82
0.0000


MmuSTS.1873.1.S1_at
cornichon homolog
CNIH
4.82
0.0001


Mmu.1020.1.S1_s_at
cysteine-rich with EGF-like domains 1 isoform 2
LOC699345
4.82
0.0586


MmugDNA.24075.1.S1_at
CG15828-PA
244889_at
4.81
0.0948


MmugDNA.30042.1.S1_at
chromosome X open reading frame 6
CXorf6
4.81
0.0517


MmuSTS.351.1.S1_at
synaptophysin
SYP
4.81
0.0485


MmugDNA.38488.1.S1_s_at
LSM10, U7 small nuclear RNA associated
LSM10
4.80
0.0004


MmugDNA.1625.1.S1_at
protein kinase, AMP-activated, alpha 1 catalytic subunit
PRKAA1
4.80
0.0425


MmugDNA.25564.1.S1_at
MRNA; cDNA DKFZp564G1162 (from clone
—
4.79
0.0079



DKFZp564G1162)


MmugDNA.29139.1.S1_at
chromosome 14 open reading frame 50
C14orf50
4.79
0.1206


MmuSTS.1491.1.S1_at
zinc finger protein 281
ZNF281
4.78
0.0190


MmugDNA.5201.1.S1_at
chromosome 14 open reading frame 130
C14orf130
4.78
0.0074


MmunewRS.875.1.S1_at
neuroligin 4, Y-linked
NLGN4Y
4.78
0.0000


MmugDNA.6389.1.S1_at
zinc finger, CCHC domain containing 12
ZCCHC12
4.76
0.0124


MmugDNA.12224.1.S1_at
CDNA clone IMAGE: 4821804
—
4.76
0.0779


MmunewRS.335.1.S1_at
full length insert cDNA clone YZ18B05.
gi:3483412
4.75
0.0715


MmugDNA.21758.1.S1_at
DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae)
DCLRE1C
4.75
0.1520


MmugDNA.4778.1.S1_at
KIAA1505 protein
KIAA1505
4.75
0.1070


MmugDNA.133.1.S1_at
zinc finger protein 223
LOC711740
4.74
0.1432


MmugDNA.7270.1.S1_at
zinc finger protein 641
ZNF641
4.74
0.0002


MmugDNA.20328.1.S1_s_at
N-acetylglucosamine-1-phosphate transferase, gamma
GNPTG
4.74
0.0000



subunit


MmugDNA.40786.1.S1_at
arylsulfatase family, member K
ARSK
4.74
0.0631


Mmu.11997.1.S1_at
calmodulin 1
LOC698552
4.73
0.0030


MmugDNA.1667.1.S1_at
immunoglobulin superfamily, member 4D
IGSF4D
4.73
0.1791


MmugDNA.20342.1.S1_at
spindlin family, member 2 /// spindlin family, member 2 ///
SPIN2 /// SPIN-2
4.72
0.0223



spindlin-like protein 2 /// spindlin-like protein 2


MmugDNA.3891.1.S1_at
chromosome 2 open reading frame 15
C2orf15
4.72
0.0163


MmugDNA.32461.1.S1_at
—
—
4.72
0.0094


MmugDNA.14567.1.S1_at
KIAA0859
KIAA0859
4.72
0.1058


MmugDNA.43246.1.S1_at
neutral sphingomyelinase (N-SMase) activation associated
NSMAF
4.72
0.0053



factor


MmugDNA.2324.1.S1_at
KIAA0895 protein
KIAA0895
4.71
0.0648


MmugDNA.1640.1.S1_at
Transcribed locus
—
4.71
0.1101


MmugDNA.42549.1.S1_at
galanin
GAL
4.71
0.0951


MmugDNA.3017.1.S1_at
LQK1 hypothetical protein short isoform
LQK1
4.70
0.0226


MmugDNA.28661.1.S1_at
coiled-coil domain containing 28B
CCDC28B
4.69
0.1325


MmuSTS.4364.1.S1_at
sterol O-acyltransferase 1
SOAT1
4.69
0.0729


MmugDNA.2668.1.S1_at
mannose receptor-like
LOC709768
4.69
0.0118


MmugDNA.8460.1.S1_at
LAG1 longevity assurance homolog 6 (S. cerevisiae)
LASS6
4.68
0.0041


MmugDNA.30211.1.S1_at
ATPase, Ca++ transporting, type 2C, member 1
ATP2C1
4.67
0.0624


MmugDNA.22541.1.S1_at
chromosome 1 open reading frame 89 /// chromosome 1
C1orf89
4.66
0.0231



open reading frame 89


MmugDNA.23541.1.S1_at
coiled-coil domain containing 50
CCDC50
4.65
0.0487


MmugDNA.38008.1.S1_at
asparaginase-like 1 protein
LOC718871
4.65
0.0005


MmugDNA.34690.1.S1_at
MAWD binding protein
MAWBP
4.65
0.0787


MmugDNA.31478.1.S1_at
RAB33A, member RAS oncogene family
RAB33A
4.64
0.0430


MmugDNA.28356.1.S1_at
hypothetical protein LOC715793
LOC715793
4.64
0.1301


MmugDNA.35760.1.S1_at
receptor transporter protein 4
RTP4
4.63
0.1847


MmugDNA.1257.1.S1_at
peptidylprolyl isomerase (cyclophilin)-like 1
PPIL1
4.63
0.0032


MmugDNA.38638.1.S1_at
inhibitor of kappa light polypeptide gene enhancer in B-
IKBKB /// NCSTN
4.61
0.0019



cells, kinase beta /// nicastrin


MmugDNA.31887.1.S1_at
hypothetical LOC402617
LOC402617
4.60
0.1114


MmugDNA.18767.1.S1_at
MRNA full length insert cDNA clone EUROIMAGE 110216
—
4.57
0.1233


MmugDNA.40451.1.S1_at
polycomb group ring finger 1
PCGF1
4.56
0.0175


MmugDNA.18456.1.S1_at
CDNA FLJ33400 fis, clone BRACE2009828
—
4.55
0.1261


MmugDNA.31245.1.S1_at
butyrophilin, subfamily 2, member A2
BTN2A2
4.55
0.0552


MmugDNA.43078.1.S1_at
KIAA1838
KIAA1838
4.55
0.0050


MmugDNA.39763.1.S1_at
ubiquitin specific peptidase 36
USP36
4.54
0.0836


MmugDNA.12921.1.S1_at
hypothetical protein FLJ36208
FLJ36208
4.54
0.1669


MmugDNA.3000.1.S1_at
signal sequence receptor, gamma (translocon-associated
SSR3
4.54
0.0185



protein gamma)


MmugDNA.31177.1.S1_at
zinc finger protein 582
ZNF582
4.54
0.0129


MmuSTS.2548.1.S1_at
thioredoxin domain containing 12 (endoplasmic reticulum)
TXNDC12
4.54
0.0231


MmugDNA.32746.1.S1_at
inositol 1,4,5-triphosphate receptor, type 2
ITPR2
4.54
0.0394


MmugDNA.14882.1.S1_s_at
Huntingtin interacting protein K
HYPK
4.53
0.0411


MmugDNA.2875.1.S1_at
protein-O-mannosyltransferase 1
POMT1
4.53
0.0018


MmugDNA.13007.1.S1_at
hypothetical protein LOC284669
LOC284669
4.52
0.0142


Mmu.3693.1.S1_at
splicing factor p54
LOC702698
4.52
0.0572


MmugDNA.20453.1.S1_at
heterogeneous nuclear ribonucleoprotein L
HNRPL
4.51
0.0000


MmugDNA.14296.1.S1_at
hypothetical protein FLJ37201
FLJ37201
4.51
0.0035


MmugDNA.9174.1.S1_at
coiled-coil domain containing 129
CCDC129
4.51
0.0743


MmugDNA.17031.1.S1_at
DTW domain containing 1
DTWD1
4.50
0.0000


MmugDNA.10168.1.S1_at
trafficking protein particle complex 4
TRAPPC4
4.50
0.0069


MmugDNA.33621.1.S1_at
zinc finger-like
LOC400713
4.49
0.0368


MmugDNA.28329.1.S1_at
Zinc finger protein 250
ZNF250
4.49
0.0001


MmugDNA.3693.1.S1_at
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
DDX17
4.49
0.0217


MmugDNA.5788.1.S1_s_at
transmembrane 4 L six family member 5
TM4SF5
4.48
0.1028


MmugDNA.3666.1.S1_at
glucose 6 phosphatase, catalytic, 3
G6PC3
4.47
0.0353


MmugDNA.4300.1.S1_at
CDNA clone IMAGE: 4812643
—
4.47
0.0315


MmugDNA.13717.1.S1_at
Type 1 tumor necrosis factor receptor shedding
ARTS-1
4.46
0.0839



aminopeptidase regulator


MmugDNA.31311.1.S1_at
methyltransferase like 5
METTL5
4.46
0.0001


MmugDNA.19122.1.S1_at
N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2
NDST2
4.46
0.1122


MmugDNA.17470.1.S1_at
translocase of inner mitochondrial membrane 9 homolog
TIMM9
4.45
0.0749



(yeast)


MmugDNA.36689.1.S1_at
dihydroxyacetone kinase 2 homolog (S. cerevisiae)
DAK
4.45
0.2128


MmugDNA.32341.1.S1_at
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
GALNT5
4.45
0.0515



acetylgalactosaminyltransferase 5 (GalNAc-T5)


MmugDNA.29495.1.S1_at
ankyrin and armadillo repeat containing
ANKAR
4.45
0.0616


MmugDNA.9999.1.S1_at
cytochrome b5 domain containing 2
CYB5D2
4.45
0.0104


MmugDNA.28421.1.S1_at
Discs, large (Drosophila) homolog-associated protein 1
DLGAP1
4.45
0.0793


MmugDNA.38681.1.S1_at
—
—
4.44
0.1501


MmugDNA.28495.1.S1_at
integrin beta 1 binding protein 1
ITGB1BP1
4.44
0.0060


MmugDNA.42735.1.S1_at
hypothetical protein LOC144874
LOC144874
4.44
0.1195


MmugDNA.6818.1.S1_at
armadillo repeat containing 2
ARMC2
4.43
0.0802


MmugDNA.40576.1.S1_at
—
—
4.43
0.1762


MmugDNA.8518.1.S1_at
Hypothetical protein LOC645323
LOC645323
4.42
0.1298


MmugDNA.16049.1.S1_at
Ubiquitin specific peptidase 30
USP30
4.42
0.0000


MmuSTS.4469.1.S1_s_at
vasodilator-stimulated phosphoprotein
VASP
4.42
0.0468


MmugDNA.38086.1.S1_at
chromosome 10 open reading frame 137
C10orf137
4.41
0.0223


MmugDNA.31273.1.S1_at
bobby sox homolog (Drosophila)
BBX
4.41
0.0269


MmugDNA.39436.1.S1_at
Transcribed locus
—
4.41
0.0107


MmuSTS.2675.1.S1_s_at
ATP-binding cassette, sub-family B (MDR/TAP), member 10
ABCB10
4.41
0.0156


Mmu.2243.1.S1_at
eukaryotic translation initiation factor 3, subunit 2 beta,
EIF3S2
4.40
0.0204



36 kDa


MmugDNA.14154.1.S1_at
ceroid-lipofuscinosis, neuronal 5
CLN5
4.40
0.0271


MmugDNA.8714.1.S1_s_at
inosine triphosphatase (nucleoside triphosphate
ITPA
4.40
0.0380



pyrophosphatase)


Mmu.15592.2.S1_at
phosphatidylinositol glycan, class F isoform 1
LOC714844
4.39
0.0098


MmugDNA.19980.1.S1_at
tripartite motif-containing 5
TRIM5
4.39
0.1642


MmugDNA.3645.1.S1_at
serine/threonine kinase receptor associated protein
STRAP
4.39
0.0135


MmugDNA.29562.1.S1_at
prohibitin
PHB
4.37
0.0035


MmugDNA.2122.1.S1_at
stomatin
STOM
4.37
0.0263


MmugDNA.20601.1.S1_s_at
prolyl endopeptidase-like
PREPL
4.37
0.0512


MmugDNA.26227.1.S1_at
RFT1 homolog (S. cerevisiae)
RFT1
4.37
0.1974


MmugDNA.119.1.S1_at
zinc finger protein 542
ZNF542
4.36
0.1250


MmugDNA.38257.1.S1_at
chromosome 3 open reading frame 18
C3orf18
4.36
0.0391


MmugDNA.38303.1.S1_at
TAF4b RNA polymerase II, TATA box binding protein
TAF4B
4.35
0.0954



(TBP)-associated factor, 105 kDa


Mmu.13799.1.S1_at
hypothetical protein LOC696762
LOC696762
4.35
0.0294


MmugDNA.24015.1.S1_at
LanC lantibiotic synthetase component C-like 2 (bacterial)
LANCL2
4.35
0.0403


MmugDNA.38882.1.S1_at
zinc finger protein 775
ZNF775
4.35
0.0238


MmugDNA.11471.1.S1_at
ATPase family, AAA domain containing 1
ATAD1
4.35
0.0077


MmugDNA.6735.1.S1_at
zinc finger protein 642
ZNF642
4.33
0.0727


MmugDNA.18469.1.S1_at
zinc finger protein 588
ZNF588
4.33
0.1354


MmugDNA.11216.1.S1_at
cancer susceptibility candidate 4
CASC4
4.33
0.0008


MmugDNA.28842.1.S1_at
CKLF-like MARVEL transmembrane domain containing 7
CMTM7
4.32
0.0168


MmugDNA.19883.1.S1_at
SECIS binding protein 2
SECISBP2
4.32
0.0191


MmugDNA.18544.1.S1_at
renal tumor antigen
RAGE
4.32
0.0365


MmugDNA.31414.1.S1_at
SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)
SUMO1
4.32
0.0298


MmugDNA.30985.1.S1_at
glucosidase, beta (bile acid) 2
GBA2
4.32
0.0080


MmugDNA.33696.1.S1_at
hyaluronan binding protein 4
HABP4
4.32
0.0433


MmugDNA.24247.1.S1_at
chromosome 10 open reading frame 11
C10orf11
4.31
0.1241


Mmu.11729.1.S1_s_at
Translocon-associated protein beta subunit precursor
LOC719383
4.31
0.0536



(TRAP-beta) (Signal sequence receptor beta subunit) (SSR-



beta)


MmugDNA.33158.1.S1_at
coiled-coil domain containing 22
CCDC22
4.30
0.0689


MmugDNA.10111.1.S1_at
chromosome 1 open reading frame 131
C1orf131
4.29
0.0196


MmugDNA.43034.1.S1_at
HLA-B associated transcript 5
BAT5
4.29
0.0313


MmugDNA.10771.1.S1_at
ligase IV, DNA, ATP-dependent
LIG4
4.29
0.0048


MmugDNA.39663.1.S1_at
Bernardinelli-Seip congenital lipodystrophy 2 (seipin) ///
BSCL2 ///
4.28
0.0093



heterogeneous nuclear ribonucleoprotein U-like 2
HNRPUL2


MmugDNA.36927.1.S1_at
DNA (cytosine-5-)-methyltransferase 3 alpha
DNMT3A
4.28
0.0096


MmugDNA.24861.1.S1_s_at
neuroguidin, EIF4E binding protein
NGDN
4.27
0.0007


MmugDNA.24533.1.S1_at
cathepsin S
CTSS
4.27
0.0031


MmuSTS.1546.1.S1_at
musashi homolog 2
MSI2
4.27
0.0014


MmugDNA.831.1.S1_at
Chromosome 14 open reading frame 161
C14orf161
4.26
0.0165


MmugDNA.10644.1.S1_at
Muscleblind-like 2 (Drosophila)
MBNL2
4.25
0.0000


MmugDNA.33695.1.S1_at
zinc finger protein 34
ZNF34
4.25
0.0030


MmugDNA.23792.1.S1_at
thrombospondin, type I, domain containing 3
THSD3
4.24
0.1178


MmugDNA.12396.1.S1_at
chromosome 3 open reading frame 41
C3orf41
4.24
0.0202


MmugDNA.21184.1.S1_at
hypoxia inducible factor 3, alpha subunit
HIF3A
4.24
0.1766


MmugDNA.6866.1.S1_at
STEAP family member 3
STEAP3
4.24
0.1494


MmugDNA.15710.1.S1_at
vacuolar protein sorting 39 (yeast)
VPS39
4.23
0.0007


Mmu.586.1.S1_at
Protein KIAA0143
LOC696036
4.23
0.0432


MmuSTS.2503.1.S1_at
zinc finger, SWIM domain containing 5
ZSWIM5
4.23
0.0370


MmugDNA.21399.1.S1_at
Transcribed locus
—
4.22
0.0664


MmuSTS.2401.1.S1_s_at
replication protein A1, 70 kDa
RPA1
4.22
0.0162


Mmu.5491.1.S1_at
prosaposin
LOC709510
4.22
0.1033


MmugDNA.15874.1.S1_at
Mitochondrial fission regulator 1
MTFR1
4.21
0.0570


MmugDNA.32637.1.S1_at
nucleosomal binding protein 1
NSBP1
4.21
0.0038


MmugDNA.10551.1.S1_at
mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-
MGAT2
4.21
0.0530



acetylglucosaminyltransferase /// mannosyl (alpha-1,6-)-



glycoprotein beta-1,2-N-acetylglucosaminyltransferase


MmugDNA.41398.1.S1_at
chromosome 3 open reading frame 31
C3orf31
4.21
0.0943


MmugDNA.17617.1.S1_s_at
trophinin /// trophinin
TRO
4.21
0.0108


MmugDNA.39122.1.S1_at
chromosome 3 open reading frame 1
C3orf1
4.21
0.0262


MmugDNA.18454.1.S1_at
Transcribed locus
—
4.20
0.0989


MmugDNA.39611.1.S1_at
Dedicator of cytokinesis 2
DOCK2
4.19
0.1153


MmuSTS.2075.1.S1_at
POU domain, class 2, transcription factor 3
POU2F3
4.19
0.0002


MmugDNA.28348.1.S1_s_at
chaperonin containing TCP1, subunit 2 (beta)
CCT2
4.18
0.0291


MmugDNA.26826.1.S1_s_at
solute carrier family 11 (proton-coupled divalent metal ion
SLC11A1
4.17
0.0308



transporters), member 1


Mmu.9862.2.S1_at
F-box only protein 4 isoform 2
LOC697007
4.17
0.2109


Mmu.303.1.S1_at
crystallin, zeta
LOC704403
4.17
0.0292


MmugDNA.19380.1.S1_at
chromosome 1 open reading frame 19
C1orf19
4.16
0.0000


MmugDNA.11030.1.S1_s_at
chromosome 3 open reading frame 15
C3orf15
4.16
0.0146


MmugDNA.732.1.S1_at
hexosaminidase B (beta polypeptide)
HEXB
4.16
0.0013


MmugDNA.43014.1.S1_at
hypothetical LOC389172
LOC389172
4.16
0.0052


MmugDNA.14429.1.S1_at
chromosome X open reading frame 58
CXorf58
4.15
0.0672


MmugDNA.33820.1.S1_at
KIAA0100
KIAA0100
4.15
0.0184


MmugDNA.1154.1.S1_at
SNF1-like kinase /// SNF1-like kinase
SNF1LK
4.15
0.0142


MmugDNA.9493.1.S1_at
phosphodiesterase 4D, cAMP-specific (phosphodiesterase
PDE4D
4.15
0.0016



E3 dunce homolog, Drosophila)


MmugDNA.38138.1.S1_at
zinc finger protein 267
ZNF267
4.14
0.0014


MmugDNA.37212.1.S1_at
zinc finger, ZZ-type containing 3
ZZZ3
4.14
0.0098


MmugDNA.41461.1.S1_at
zinc finger protein 333
ZNF333
4.14
0.1972


MmugDNA.19606.1.S1_at
pseudouridylate synthase 7 homolog (S. cerevisiae)-like ///



pseudouridylate synthase 7 homolog (S. cerevisiae)-like
PUS7L
4.13
0.0653


MmugDNA.11456.1.S1_at
ligatin
LGTN
4.13
0.0557


MmugDNA.36143.1.S1_s_at
choline dehydrogenase
CHDH
4.13
0.2015


MmugDNA.7248.1.S1_s_at
CCR4-NOT transcription complex, subunit 2
CNOT2
4.13
0.0005


MmugDNA.5833.1.S1_at
phosphoinositide-3-kinase, regulatory subunit 4, p150
PIK3R4
4.13
0.0029


MmugDNA.39422.1.S1_at
UDP-GlcNAc:betaGal beta-1,3-N-
B3GNT1
4.12
0.0370



acetylglucosaminyltransferase 1


MmugDNA.1591.1.S1_at
Homo sapiens, clone IMAGE: 3352913, mRNA
—
4.12
0.0569


MmugDNA.34328.1.S1_at
dyslexia susceptibility 1 candidate 1
DYX1C1
4.12
0.0834


MmugDNA.111.1.S1_at
zinc finger protein 180
ZNF180
4.11
0.1267


MmugDNA.5762.1.S1_at
vacuolar protein sorting 25 homolog (S. cerevisiae)
VPS25
4.10
0.0377


MmugDNA.16868.1.S1_at
hypothetical protein FLJ36665
FLJ36665
4.09
0.1171


MmugDNA.6114.1.S1_s_at
DEAD (Asp-Glu-Ala-Asp) box polypeptide 18
DDX18
4.09
0.0159


MmugDNA.33106.1.S1_at
—
—
4.09
0.0272


MmugDNA.24857.1.S1_at
RAP2A, member of RAS oncogene family /// RAP2B,
RAP2A /// RAP2B
4.07
0.1231



member of RAS oncogene family


MmunewRS.1035.1.S1_s_at
cDNA FLJ31653 fis, clone NT2RI2004190.
gi:16551556
4.06
0.0241


MmugDNA.6270.1.S1_at
synaptogyrin 1
SYNGR1
4.06
0.0066


MmugDNA.42267.1.S1_at
Transcribed locus
—
4.06
0.1725


MmugDNA.1721.1.S1_at
zinc finger protein 442 /// zinc finger protein 442
ZNF442
4.06
0.0870


MmugDNA.1190.1.S1_at
dpy-19-like 2 (C. elegans)
DPY19L2
4.06
0.0340


MmugDNA.10350.1.S1_at
DEAH (Asp-Glu-Ala-His) box polypeptide 16
DHX16
4.05
0.0105


MmuSTS.2597.1.S1_at
eukaryotic translation elongation factor 1 epsilon 1
EEF1E1
4.05
0.0005


MmugDNA.13760.1.S1_at
AHA1, activator of heat shock 90 kDa protein ATPase
AHSA1
4.05
0.0000



homolog 1 (yeast)


MmugDNA.27617.1.S1_at
tektin 2 (testicular)
TEKT2
4.04
0.0469


MmugDNA.29808.1.S1_at
mannosidase, alpha, class 2C, member 1
MAN2C1
4.04
0.0015


MmugDNA.29621.1.S1_at
bone morphogenetic protein 6
BMP6
4.04
0.0815


MmugDNA.26069.1.S1_at
—
—
4.04
0.0531


MmuSTS.3237.1.S1_at
RAD54 homolog B (S. cerevisiae)
RAD54B
4.04
0.0748


Mmu.9266.1.S1_x_at
alpha-defensin 4 precursor, mRNA, complete cds.
AY859406
4.02
0.0972


MmugDNA.35254.1.S1_at
nudix (nucleoside diphosphate linked moiety X)-type motif
NUDT16P
4.01
0.1650



16 pseudogene


MmugDNA.40333.1.S1_at
low density lipoprotein receptor-related protein associated
LRPAP1
4.01
0.0177



protein 1


Mmu.4677.1.S1_s_at
rabconnectin-3 beta isoform 2
LOC695302
4.01
0.0167


MmugDNA.15059.1.S1_at
zinc finger protein 780B
ZNF780B
4.01
0.1768


MmugDNA.2321.1.S1_at
ELL associated factor 2
EAF2
4.00
0.0663


Mmu.14167.1.S1_at
DNA topoisomerase I
LOC697300
4.00
0.1952


MmugDNA.3213.1.S1_at
single stranded DNA binding protein 4
SSBP4
4.00
0.0429


MmugDNA.42484.1.S1_at
ARP6 actin-related protein 6 homolog (yeast)
ACTR6
4.00
0.0252


MmugDNA.7865.1.S1_at
PPAR binding protein
PPARBP
4.00
0.0589


MmugDNA.18301.1.S1_at
chromosome 18 open reading frame 10
C18orf10
4.00
0.0013


MmugDNA.40541.1.S1_at
zinc finger protein 555
ZNF555
4.00
0.0028


MmugDNA.6772.1.S1_at
ER degradation enhancer, mannosidase alpha-like 2
EDEM2
3.99
0.0411


MmugDNA.24353.1.S1_at
retinoic acid receptor responder (tazarotene induced) 1
RARRES1
3.99
0.1529


MmugDNA.34452.1.S1_s_at
—
—
3.98
0.0067


MmugDNA.9814.1.S1_at
Transcribed locus
—
3.98
0.0111


MmugDNA.27740.1.S1_at
U2-associated SR140 protein
SR140
3.98
0.0286


MmuSTS.3952.1.S1_at
SEC22 vesicle trafficking protein homolog C (S. cerevisiae)
SEC22C
3.98
0.0001


MmugDNA.36936.1.S1_at
deoxyguanosine kinase
DGUOK
3.97
0.0061


MmugDNA.16551.1.S1_at
hypothetical protein FLJ25770
FLJ25770
3.97
0.0789


MmugDNA.32988.1.S1_at
ring finger protein 123
RNF123
3.97
0.0078


MmugDNA.40932.1.S1_at
zinc finger protein 691
ZNF691
3.97
0.0191


MmugDNA.42528.1.S1_at
cytochrome P450, family 4, subfamily F, polypeptide 2
CYP4F2
3.96
0.1843


MmugDNA.38754.1.S1_at
Galactokinase 2
GALK2
3.96
0.0572


MmuSTS.2536.1.S1_at
Interferon tau-1
IFNT1
3.96
0.1884


MmugDNA.21837.1.S1_at
CDNA FLJ40810 fis, clone TRACH2009743
—
3.95
0.0554


Mmu.10030.1.S1_at
syntenin isoform 3
LOC698381
3.95
0.0001


Mmu.5329.1.S1_at
Phospholipid hydroperoxide glutathione peroxidase,
GPX4
3.95
0.1220



mitochondrial precursor (PHGPx) (GPX-4)


MmugDNA.36752.1.S1_at
lymphocyte antigen 6 complex, locus G5C
LY6G5C
3.93
0.1998


MmuSTS.897.1.S1_at
sema domain, seven thrombospondin repeats (type 1 and
SEMA5B
3.93
0.0637



type 1-lik, , transmembrane domain (TM) and short



cytoplasmic domain, (semaphorin) 5B


MmugDNA.40072.1.S1_at
hypothetical protein DKFZp313A2432
DKFZp313A2432
3.93
0.1059


MmugDNA.19577.1.S1_at
phosphatidylinositol glycan anchor biosynthesis, class M
PIGM
3.93
0.2113


MmugDNA.11968.1.S1_at
UBX domain containing 7
UBXD7
3.93
0.0163


MmugDNA.19665.1.S1_at
hypothetical protein LOC196394
LOC196394
3.93
0.0165


MmugDNA.23833.1.S1_at
chromosome 21 open reading frame 58
C21orf58
3.93
0.1718


MmugDNA.27456.1.S1_at
polymerase (RNA) I polypeptide D, 16 kDa
POLR1D
3.92
0.0000


MmugDNA.30349.1.S1_at
Transcribed locus
—
3.92
0.0066


MmugDNA.7253.1.S1_at
—
—
3.92
0.1111


MmugDNA.14931.1.S1_at
t-SNARE domain containing 1
TSNARE1
3.91
0.0947


MmugDNA.30795.1.S1_at
chromosome 10 open reading frame 81
C10orf81
3.91
0.0955


MmugDNA.17018.1.S1_s_at
butyrophilin, subfamily 2, member A1
BTN2A1
3.91
0.0004


MmugDNA.26488.1.S1_at
nischarin
NISCH
3.90
0.0435


MmugDNA.1076.1.S1_at
WD repeat domain 61
WDR61
3.89
0.0001


MmugDNA.19511.1.S1_at
death inducer-obliterator 1
DIDO1
3.89
0.0638


MmugDNA.5147.1.S1_s_at
kelch repeat and BTB (POZ) domain containing 4
KBTBD4
3.89
0.0043


MmugDNA.26429.1.S1_at
AP2 associated kinase 1
AAK1
3.89
0.1855


MmugDNA.36463.1.S1_s_at
tyrosine kinase, non-receptor, 1
TNK1
3.89
0.0001


MmuSTS.1060.1.S1_at
Solute carrier family 25, member 29
SLC25A29
3.89
0.0804


MmugDNA.12692.1.S1_at
quinolinate phosphoribosyltransferase (nicotinate-
QPRT
3.88
0.0444



nucleotide pyrophosphorylase (carboxylating))


MmugDNA.19435.1.S1_s_at
DnaJ (Hsp40) homolog, subfamily A, member 1
DNAJA1
3.88
0.0014


MmugDNA.1963.1.S1_at
CDNA clone IMAGE: 5278089
—
3.88
0.1079


MmugDNA.40985.1.S1_at
CDNA clone IMAGE: 4825288
—
3.88
0.0338


MmuSTS.3495.1.S1_at
A kinase (PRKA) anchor protein 3
AKAP3
3.87
0.0508


MmuSTS.3737.1.S1_at
protein tyrosine phosphatase, receptor type, C
PTPRC
3.87
0.0186


MmugDNA.31476.1.S1_at
RAB28, member RAS oncogene family
RAB28
3.87
0.0939


MmugDNA.30719.1.S1_at
dom-3 homolog Z (C. elegans)
DOM3Z
3.87
0.0007


MmugDNA.3113.1.S1_at
transient receptor potential cation channel, subfamily C,
TRPC2
3.87
0.0121



member 2


MmuSTS.4117.1.S1_at
transmembrane protein 15
TMEM15
3.87
0.0145


MmugDNA.41463.1.S1_at
Vac14 homolog (S. cerevisiae)
VAC14
3.86
0.0546


MmugDNA.26499.1.S1_at
leupaxin
LPXN
3.86
0.0090


MmugDNA.37595.1.S1_at
mortality factor 4 like 1
MORF4L1
3.85
0.0059


MmugDNA.22504.1.S1_at
—
—
3.84
0.0508


MmugDNA.20249.1.S1_at
RNA binding motif protein 26
RBM26
3.84
0.0198


MmugDNA.13483.1.S1_at
—
—
3.84
0.0604


MmugDNA.16424.1.S1_at
gelsolin (amyloidosis, Finnish type)
GSN
3.84
0.0118


MmugDNA.16896.1.S1_at
stromal antigen 3
STAG3
3.82
0.0959


MmuSTS.2334.1.S1_at
peroxisomal membrane protein 4, 24 kDa
PXMP4
3.81
0.0013


MmugDNA.28442.1.S1_s_at
chromosome 20 open reading frame 74
C20orf74
3.81
0.0043


MmugDNA.6811.1.S1_at
smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans)
SMU1
3.80
0.0001


MmugDNA.13860.1.S1_at
—
—
3.79
0.0387


MmugDNA.13463.1.S1_at
COP9 constitutive photomorphogenic homolog subunit 6
COPS6
3.79
0.0192



(Arabidopsis)


MmugDNA.4402.1.S1_s_at
mago-nashi homolog
FLJ10292
3.78
0.0492


MmugDNA.18844.1.S1_at
cholinergic receptor, nicotinic, alpha 1 (muscle)
CHRNA1
3.77
0.1879


MmugDNA.40143.1.S1_at
transmembrane protein 67
TMEM67
3.77
0.0848


MmuSTS.2481.1.S1_at
zinc finger protein 294
ZNF294
3.77
0.0304


MmugDNA.30140.1.S1_at
thioredoxin-like 4B
TXNL4B
3.77
0.0239


MmugDNA.38654.1.S1_at
MORN repeat containing 2
MORN2
3.77
0.0047


MmuSTS.2773.1.S1_at
solute carrier family 1 (neutral amino acid transporter),
SLC1A5
3.76
0.0113



member


MmugDNA.31203.1.S1_at
THAP domain containing, apoptosis associated protein 2
THAP2
3.76
0.0136


MmugDNA.13298.1.S1_at
zinc finger protein 473
ZNF473
3.76
0.0210


MmugDNA.19431.1.S1_at
ZXD family zinc finger C
ZXDC
3.76
0.1070


MmugDNA.33573.1.S1_s_at
serine/threonine kinase 16
STK16
3.76
0.0507


MmugDNA.24286.1.S1_at
coagulation factor II (thrombin) receptor-like 1
F2RL1
3.76
0.0055


MmugDNA.41306.1.S1_at
zinc finger protein 650
ZNF650
3.76
0.0002


MmugDNA.8919.1.S1_at
Transcribed locus
—
3.75
0.0786


MmugDNA.4185.1.S1_at
nicolin 1
NICN1
3.75
0.1272


MmugDNA.21236.1.S1_at
arginine/serine-rich coiled-coil 1
LOC704232
3.75
0.0445


MmugDNA.32661.1.S1_at
dihydropyrimidine dehydrogenase
DPYD
3.75
0.0062


MmugDNA.20872.1.S1_at
docking protein 1, 62 kDa (downstream of tyrosine kinase 1)
DOK1
3.75
0.0846


MmugDNA.34300.1.S1_at
nicotinamide nucleotide adenylyltransferase 1
NMNAT1
3.75
0.0851


MmuSTS.3697.1.S1_at
COP9 constitutive photomorphogenic homolog subunit 4
COPS4
3.74
0.0000


MmuSTS.3649.1.S1_at
chloride channel 4
CLCN4
3.74
0.1113


MmugDNA.40690.1.S1_at
zinc finger protein 197
ZNF197
3.74
0.0025


MmugDNA.41072.1.S1_at
chromosome X and Y open reading frame 10
CXYorf10
3.73
0.0146


MmugDNA.26793.1.S1_at
hypothetical protein MGC40579
MGC40579
3.73
0.0030


MmugDNA.7453.1.S1_at
integrator complex subunit 9
RC74
3.73
0.0020


MmugDNA.41810.1.S1_at
KIAA1429
KIAA1429
3.72
0.0204


MmugDNA.42873.1.S1_at
nuclear transcription factor, X-box binding 1
NFX1
3.72
0.1160


MmugDNA.13884.1.S1_at
TNFAIP3 interacting protein 2
TNIP2
3.72
0.0166


MmugDNA.6002.1.S1_at
apolipoprotein A-I binding protein
APOA1BP
3.72
0.0046


MmugDNA.28839.1.S1_at
Hypothetical protein LOC150384
LOC150384
3.72
0.0243


MmugDNA.11009.1.S1_at
elongation factor Tu GTP binding domain containing 1
EFTUD1
3.72
0.0006


MmuSTS.2811.1.S1_s_at
solute carrier family 39 (zinc transporter), member 7
SLC39A7
3.72
0.1074


MmugDNA.11298.1.S1_at
RNA binding motif protein 12B
RBM12B
3.72
0.1376


MmugDNA.38831.1.S1_at
transient receptor potential cation channel, subfamily C,
TRPC4AP
3.71
0.0751



member 4 associated protein


MmuSTS.1121.1.S1_at
single-strand-selective monofunctional uracil-DNA
SMUG1
3.71
0.1049



glycosylase 1


MmugDNA.23627.1.S1_at
caspase 2, apoptosis-related cysteine peptidase (neural
CASP2
3.71
0.1012



precursor cell expressed, developmentally down-regulated



2)


Mmu.14962.1.S1_at
glycosyltransferase 8 domain containing 1
LOC695999
3.71
0.0060


MmugDNA.13631.1.S1_s_at
CD320 molecule
CD320
3.71
0.0663


MmugDNA.23982.1.S1_at
phosphoprotein associated with glycosphingolipid
PAG1 ///
3.71
0.0018



microdomains 1 /// phosphoprotein associated with
LOC653745



glycosphingolipid microdomains 1


MmuSTS.2557.1.S1_at
tumor necrosis factor (ligand) superfamily, member 19
TNFSF4
3.70
0.0375


MmugDNA.9215.1.S1_s_at
REX2, RNA exonuclease 2 homolog (S. cerevisiae)
REXO2
3.70
0.0235


MmugDNA.14634.1.S1_at
alcohol dehydrogenase IB (class I), beta polypeptide
ADH1B
3.70
0.2072


MmuSTS.2989.1.S1_at
met proto-oncogene
MET
3.69
0.0006


MmugDNA.6796.1.S1_at
F-box and WD-40 domain protein 8
FBXW8
3.69
0.0022


MmugDNA.35611.1.S1_at
—
—
3.69
0.0476


MmunewRS.1092.1.S1_at
F-box and WD-40 domain protein 12
FBXW12
3.69
0.1972


MmugDNA.37110.1.S1_at
chromosome 1 open reading frame 34
C1orf34
3.69
0.0005


MmugDNA.8905.1.S1_at
Transcribed locus, strongly XP_376888.2 PREDICTED:
—
3.69
0.0321



Laminin receptor 1 [Homo sapiens]


MmugDNA.24188.1.S1_s_at
deleted in a mouse model of primary ciliary dyskinesia
RP11-529I10.4
3.68
0.0323


MmugDNA.36794.1.S1_at
zinc finger protein 593
ZNF593
3.68
0.0540


MmuSTS.4394.1.S1_at
DENN/MADD domain containing 4A
DENND4A
3.67
0.0345


MmugDNA.4893.1.S1_at
hypothetical protein MGC16385
MGC16385
3.67
0.0054


MmunewRS.474.1.S1_at
ras homolog gene family, member C
RHOC
3.67
0.1242


MmugDNA.29861.1.S1_at
carbonic anhydrase XI
CA11
3.67
0.0227


MmugDNA.3791.1.S1_at
sphingosine-1-phosphate phosphatase 1
SGPP1
3.67
0.0007


MmugDNA.10595.1.S1_at
—
—
3.67
0.1276


MmugDNA.34611.1.S1_at
Hypothetical protein LOC643011
LOC643011
3.67
0.0005


MmugDNA.38962.1.S1_at
acid phosphatase 6, lysophosphatidic
ACP6
3.66
0.0113


MmugDNA.3351.1.S1_at
DNA segment on chromosome 4 (unique) 234 expressed
D4S234E
3.66
0.0658



sequence


MmugDNA.2806.1.S1_s_at
mitogen-activated protein kinase kinase kinase kinase 1
MAP4K1
3.66
0.0540


MmugDNA.1419.1.S1_at
CDNA: FLJ23065 fis, clone LNG04894
—
3.65
0.1255


MmugDNA.24776.1.S1_at
protein phosphatase 1, regulatory subunit 7
PPP1R7
3.65
0.0367


MmugDNA.35069.1.S1_at
RAB6B, member RAS oncogene family
RAB6B
3.65
0.0351


MmugDNA.29893.1.S1_at
ankyrin repeat domain 28
ANKRD28
3.64
0.0027


MmugDNA.2018.1.S1_at
RNA binding protein S1, serine-rich domain /// RNA binding
RNPS1
3.64
0.0026



protein S1, serine-rich domain


MmugDNA.31080.1.S1_at
phosphatidylinositol glycan anchor biosynthesis, class O
PIGO
3.64
0.0464


MmugDNA.24890.1.S1_at
transmembrane and tetratricopeptide repeat containing 2
TMTC2
3.64
0.0230


MmugDNA.5735.1.S1_at
—
—
3.64
0.0557


MmugDNA.26841.1.S1_at
estrogen-related receptor alpha
ESRRA
3.63
0.0274


MmugDNA.27441.1.S1_at
protein phosphatase 2 (formerly 2A), regulatory subunit A
PPP2R1B
3.63
0.0345



(PR 65), beta isoform


MmuSTS.1040.1.S1_at
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5
ST8SIA5
3.63
0.0623


MmugDNA.7493.1.S1_at
intraflagellar transport 122 homolog (Chlamydomonas)
IFT122
3.63
0.0020


MmuSTS.3957.1.S1_at
splicing factor, arginine/serine-rich 6
SFRS6
3.62
0.0000


MmugDNA.29820.1.S1_at
calcium and integrin binding 1 (calmyrin)
CIB1
3.62
0.0323


MmugDNA.16149.1.S1_at
Full-length cDNA clone CS0DC025YP03 of Neuroblastoma
—
3.62
0.0491



Cot 25-normalized of Homo sapiens (human)


MmugDNA.6842.1.S1_at
proteasome maturation protein
POMP
3.62
0.0204


MmuSTS.1527.1.S1_at
mitochondrial ribosomal protein L49
MRPL49
3.62
0.0034


MmugDNA.19557.1.S1_at
filamin binding LIM protein 1
FBLIM1
3.61
0.0016


MmugDNA.32221.1.S1_at
family with sequence similarity 3, member C
FAM3C
3.61
0.0022


MmuSTS.1501.1.S1_at
membrane cofactor protein
MCP
3.60
0.0015


MmugDNA.38325.1.S1_s_at
chromosome 15 open reading frame 17
C15orf17
3.60
0.0580


MmugDNA.3200.1.S1_at
Homo sapiens, clone IMAGE: 5768746, mRNA
—
3.60
0.1685


MmugDNA.2659.1.S1_at
coiled-coil domain containing 32
CCDC32
3.60
0.0505


MmugDNA.19268.1.S1_at
mitochondrial ribosomal protein L2
MRPL2
3.60
0.0018


MmugDNA.24173.1.S1_at
Mastermind-like 2 (Drosophila)
MAML2
3.59
0.0493


MmugDNA.24843.1.S1_at
zinc finger protein 226
ZNF226
3.59
0.0000


MmugDNA.35062.1.S1_s_at
aconitase 2, mitochondrial
ACO2
3.59
0.0031


MmugDNA.17481.1.S1_at
tripartite motif-containing 36
TRIM36
3.58
0.0010


MmugDNA.3106.1.S1_at
protective protein for beta-galactosidase (galactosialidosis)
PPGB
3.58
0.0000


MmugDNA.38210.1.S1_at
Full-length cDNA clone CS0DF025YA01 of Fetal brain of
—
3.58
0.0127



Homo sapiens (human)


MmugDNA.15726.1.S1_at
corin, serine peptidase
CORIN
3.58
0.2106


MmugDNA.24500.1.S1_at
CGI-09 protein
CGI-09
3.57
0.0000


MmugDNA.16131.1.S1_at
penta-EF-hand domain containing 1
PEF1
3.57
0.0794


MmugDNA.9872.1.S1_at
lysosomal-associated membrane protein 1
LAMP1
3.56
0.0236


Mmu.4348.1.S1_at
membrane interacting protein of RGS16
LOC694849
3.56
0.0006


MmugDNA.5941.1.S1_at
BTB (POZ) domain containing 9
BTBD9
3.56
0.1375


MmugDNA.10425.1.S1_at
chondroitin polymerizing factor
CHPF
3.56
0.0133


MmugDNA.845.1.S1_at
aspartylglucosaminidase
AGA
3.56
0.0019


MmugDNA.3137.1.S1_at
protein phosphatase 1G (formerly 2C), magnesium-
PPM1G
3.56
0.0107



dependent, gamma isoform


MmugDNA.35064.1.S1_at
acyl-Coenzyme A oxidase 2, branched chain
ACOX2
3.55
0.0374


MmugDNA.33241.1.S1_at
Impact homolog (mouse)
IMPACT
3.55
0.0052


MmugDNA.18757.1.S1_at
chromosome 3 open reading frame 39
C3orf39
3.55
0.0763


MmugDNA.4130.1.S1_at
mitochondrial ribosomal protein L14
MRPL14
3.55
0.0210


MmugDNA.7996.1.S1_at
zinc finger protein 536
ZNF536
3.55
0.1304


MmugDNA.34470.1.S1_s_at
Hypothetical protein FLJ20309
FLJ20309
3.55
0.0078


MmugDNA.722.1.S1_at
—
—
3.54
0.0027


MmugDNA.26101.1.S1_at
chromosome 10 open reading frame 25
C10orf25
3.54
0.1140


MmugDNA.10676.1.S1_s_at
Dmx-like 1
DMXL1
3.54
0.0303


MmugDNA.16755.1.S1_at
ureidopropionase, beta
UPB1
3.54
0.1655


MmugDNA.22341.1.S1_at
CDNA FLJ31513 fis, clone NT2RI1000127
—
3.54
0.0101


MmuSTS.4756.1.S1_at
Fanconi anemia, complementation group A
FANCA
3.54
0.0421


MmuSTS.149.1.S1_at
MAM domain containing glycosylphosphatidylinositol
MDGA1
3.54
0.0991



anchor 1


Mmu.9020.1.S1_at
—
CN802973
3.53
0.0706


MmugDNA.14464.1.S1_at
antizyme inhibitor 1
AZIN1
3.53
0.0000


MmugDNA.3591.1.S1_at
hematopoietic signal peptide-containing
LOC284361
3.52
0.0013


MmugDNA.2520.1.S1_at
gamma-aminobutyric acid (GABA) A receptor, beta 3
GABRB3
3.52
0.1177


MmugDNA.9838.1.S1_x_at
protein disulfide isomerase family A, member 4 /// protein
PDIA4
3.52
0.0436



disulfide isomerase family A, member 4


MmugDNA.961.1.S1_at
hypothetical protein BC009862
LOC90113
3.52
0.0115


MmugDNA.11411.1.S1_at
—
—
3.52
0.0264


MmuSTS.3925.1.S1_at
sal-like 2 (Drosophila)
SALL2
3.51
0.0042


MmugDNA.32205.1.S1_s_at
cytochrome b5 type A (microsomal)
CYB5A
3.51
0.0112


MmugDNA.32647.1.S1_at
KIAA0409
KIAA0409
3.51
0.0080


MmugDNA.11293.1.S1_at
F-box protein 4
FBXO4
3.51
0.0376


MmugDNA.4391.1.S1_at
secernin 2
SCRN2
3.51
0.0570


MmugDNA.15005.1.S1_at
glutaminase
GLS
3.50
0.1533


MmugDNA.28947.1.S1_at
lactamase, beta 2
LACTB2
3.50
0.0364


MmugDNA.16632.1.S1_at
Coenzyme Q10 homolog B (S. cerevisiae)
COQ10B
3.50
0.0485


MmugDNA.8992.1.S1_at
cytoplasmic beta-actin
LOC709469
3.50
0.1131


MmugDNA.36746.1.S1_at
FYVE, RhoGEF and PH domain containing 6
FGD6
3.50
0.0657


MmugDNA.24282.1.S1_at
RIKEN cDNA 4921524J17
LOC388272
3.50
0.0156


MmugDNA.6398.1.S1_at
1-acylglycerol-3-phosphate O-acyltransferase 7
AGPAT7
3.50
0.0454



(lysophosphatidic acid acyltransferase, eta)


MmugDNA.8757.1.S1_at
chromosome 21 open reading frame 108
C21orf108
3.49
0.0797


MmugDNA.26500.1.S1_at
KIAA0564 protein
RP11-125A7.3
3.49
0.0000


MmugDNA.34273.1.S1_at
Mitochondrial transcription termination factor
MTERF
3.49
0.0856


MmuSTS.2708.1.S1_at
a disintegrin and metalloproteinase domain 10
ADAM10
3.49
0.0131


MmugDNA.41055.1.S1_at
chromosome 3 open reading frame 62
C3orf62
3.49
0.0726


MmugDNA.29251.1.S1_at
guanine nucleotide binding protein (G protein), alpha
GNAT2
3.49
0.0400



transducing activity polypeptide 2


MmugDNA.26180.1.S1_at
Chromosome 9 open reading frame 42
C9orf42
3.49
0.0292


MmuSTS.1660.1.S1_at
leucyl-tRNA synthetase 2, mitochondrial
LARS2
3.49
0.0460


MmugDNA.43332.1.S1_at
Transcribed locus
—
3.49
0.0334


MmugDNA.20126.1.S1_at
5,10-methenyltetrahydrofolate synthetase (5-
MTHFS
3.48
0.0071



formyltetrahydrofolate cyclo-ligase)


MmuSTS.1987.1.S1_at
death-associated protein
DAP
3.48
0.0005


MmugDNA.40683.1.S1_at
heterogeneous nuclear ribonucleoprotein K
HNRPK
3.48
0.0301


MmugDNA.22114.1.S1_at
methylthioadenosine phosphorylase
MTAP
3.47
0.0264


MmugDNA.40281.1.S1_at
Transcribed locus
237420_at
3.47
0.0200


MmugDNA.9668.1.S1_at
PWP1 homolog (S. cerevisiae)
PWP1
3.47
0.0124


MmugDNA.3432.1.S1_at
plexin C1
PLXNC1
3.47
0.0162


MmugDNA.11221.1.S1_s_at
catenin (cadherin-associated protein), beta 1, 88 kDa
CTNNB1
3.47
0.0447


MmugDNA.32959.1.S1_at
CDNA FLJ38419 fis, clone FEBRA2009846
—
3.47
0.1735


MmugDNA.19660.1.S1_s_at
epoxide hydrolase 1, microsomal (xenobiotic)
EPHX1
3.46
0.0000


MmuSTS.4149.1.S1_at
lipoic acid synthetase
LIAS
3.45
0.0166


MmugDNA.27400.1.S1_at
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
MGAT4A
3.45
0.0004



acetylglucosaminyltransferase, isozyme A


MmugDNA.3969.1.S1_at
Transcribed locus, strongly XP_372416.1 PREDICTED:
—
3.45
0.1619



leucine rich repeat containing 10 [Homo sapiens]


MmunewRS.977.1.S1_s_at
chromosome 10 open reading frame 125
C10orf125
3.45
0.0268


MmugDNA.336.1.S1_s_at
SH3 and multiple ankyrin repeat domains 2
SHANK2
3.44
0.0424


MmugDNA.10656.1.S1_at
GPI-anchored membrane protein 1
GPIAP1
3.44
0.0012


MmugDNA.38403.1.S1_at
—
—
3.44
0.0927


MmugDNA.28792.1.S1_at
metallo-beta-lactamase superfamily protein
LOC153364
3.43
0.0467


MmugDNA.15913.1.S1_at
NudC domain containing 2
NUDCD2
3.43
0.0000


MmugDNA.10398.1.S1_s_at
G protein-coupled receptor 172A
GPR172A
3.43
0.0559


MmugDNA.15.1.S1_at
Hypothetical protein FLJ30655
FLJ30655
3.43
0.0037


MmugDNA.39070.1.S1_at
androgen-induced 1
AIG1
3.43
0.0025


MmugDNA.2721.1.S1_s_at
Transcribed locus, weakly XP_864747.1 PREDICTED:
—
3.43
0.0094



hypothetical protein XP_859654 [Canis familiaris]


Mmu.12027.3.S1_at
heterogeneous nuclear ribonucleoprotein K isoform a
LOC709112
3.43
0.0681


MmugDNA.38984.1.S1_at
uracil-DNA glycosylase 2
UNG2
3.43
0.0995


MmuSTS.4179.1.S1_at
cathepsin O
CTSO
3.43
0.0144


MmugDNA.26924.1.S1_at
hypothetical protein LOC720691
LOC720691
3.42
0.1571


Mmu.1137.1.S1_at
clone 2.32 T-cell receptor gamma chain mRNA, complete
AY190025
3.42
0.0301



cds.


MmuSTS.3149.1.S1_at
nuclear receptor subfamily 2, group F, member 6
NR2F6
3.42
0.0585


MmugDNA.3922.1.S1_at
CDNA clone IMAGE: 5266242
—
3.42
0.0051


MmugDNA.8473.1.S1_at
KIAA1875
KIAA1875
3.42
0.0943


MmugDNA.38687.1.S1_at
family with sequence similarity 121B /// NODAL modulator 3
FAM121B ///
3.42
0.1139




NOMO3


MmugDNA.21376.1.S1_s_at
SMAD, mothers against DPP homolog 3 (Drosophila) ///
SMAD3 /// UROD
3.42
0.0101



uroporphyrinogen decarboxylase


MmugDNA.17400.1.S1_at
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
GALNT7
3.42
0.0000



acetylgalactosaminyltransferase 7 (GalNAc-T7)


Mmu.4958.1.S1_at
Rhesus monkey apolipoprotein(a) mRNA, 3 end.
J04635
3.42
0.0785


MmugDNA.9546.1.S1_s_at
succinate dehydrogenase complex, subunit B, iron sulfur
SDHB
3.41
0.0242



(Ip)


MmugDNA.8291.1.S1_at
spectrin, beta, erythrocytic (includes spherocytosis, clinical
SPTB ///
3.41
0.1210



type I) /// spectrin, beta, erythrocytic (includes
LOC653716



spherocytosis, clinical type I)


MmugDNA.5881.1.S1_at
IQ motif containing C
IQCC
3.40
0.0207


MmugDNA.2675.1.S1_at
trimethyllysine hydroxylase, epsilon
TMLHE
3.40
0.1204


MmugDNA.36751.1.S1_at
ret finger protein 2
RFP2
3.40
0.0005


MmugDNA.32977.1.S1_at
osmosis responsive factor
OSRF
3.40
0.0100


MmugDNA.20463.1.S1_at
EST from clone 27306, 5′ end
—
3.40
0.0005


MmugDNA.14340.1.S1_s_at
SEH1-like (S. cerevisiae)
SEH1L
3.39
0.0258


MmugDNA.34005.1.S1_at
CG8580-PA, isoform A
LOC718520
3.39
0.0005


MmugDNA.767.1.S1_at
hypothetical protein BC015395
LOC130940
3.39
0.1357


MmugDNA.10620.1.S1_at
Rho GTPase activating protein 18
ARHGAP18
3.39
0.0000


Mmu.11667.1.S1_at
Calcyclin-binding protein (CacyBP) (hCacyBP) (Siah-
CACYBP ///
3.39
0.0000



interacting protein) (S100A6-binding protein)
LOC709343


MmugDNA.8892.1.S1_at
hypothetical protein LOC646482
LOC646482
3.38
0.1081


MmugDNA.26367.1.S1_at
acyl-CoA synthetase short-chain family member 1
ACSS1
3.38
0.0380


MmugDNA.2176.1.S1_at
interferon stimulated exonuclease gene 20 kDa
ISG20
3.38
0.0000


MmugDNA.29483.1.S1_at
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
GALNT13
3.38
0.0534



acetylgalactosaminyltransferase 13 (GalNAc-T13)


MmuSTS.3944.1.S1_at
succinate-CoA ligase, GDP-forming, beta subunit
SUCLG2
3.37
0.0043


MmugDNA.2878.1.S1_at
IQ motif containing E
IQCE
3.37
0.0575


MmugDNA.24079.1.S1_s_at
coiled-coil domain containing 115
CCDC115
3.37
0.0018


MmugDNA.646.1.S1_at
zinc finger protein 420
ZNF420
3.37
0.0215


MmuSTS.2567.1.S1_s_at
Ubiquitin-like 4
UBL4
3.37
0.0006


MmunewRS.414.1.S1_at
transcription elongation factor A (SII)-like 1
TCEAL1
3.37
0.0002


MmugDNA.18382.1.S1_at
potassium channel tetramerisation domain containing 18
KCTD18
3.37
0.0036


MmugDNA.36367.1.S1_at
replication factor C (activator 1) 1, 145 kDa
RFC1
3.36
0.0093


MmuSTS.2408.1.S1_s_at
splicing factor, arginine/serine-rich 15
SFRS15
3.36
0.0084


MmugDNA.38549.1.S1_at
elongation protein 4 homolog (S. cerevisiae)
ELP4
3.36
0.0279


MmugDNA.27232.1.S1_at
RNA binding motif and ELMO/CED-12 domain 1
RBED1
3.36
0.0628


MmugDNA.30570.1.S1_at
flightless I homolog (Drosophila)
FLII
3.36
0.0522


MmugDNA.22711.1.S1_at
arginyl-tRNA synthetase-like
RARSL
3.36
0.0078


MmugDNA.40118.1.S1_at
vitelliform macular dystrophy 2-like 2
VMD2L2
3.35
0.0953


MmuSTS.3727.1.S1_at
protein tyrosine phosphatase, non-receptor type substrate 1
PTPNS1
3.35
0.0115


MmugDNA.16151.1.S1_at
zinc finger protein 567
ZNF567
3.35
0.0104


MmugDNA.34207.1.S1_at
Transcribed locus
—
3.35
0.1488


MmugDNA.3005.1.S1_at
polymerase (RNA) II (DNA directed) polypeptide B, 140 kDa
POLR2B
3.34
0.0033


MmugDNA.26951.1.S1_at
zinc finger protein 174
ZNF174
3.34
0.0446


MmugDNA.25836.1.S1_at
SWI/SNF related, matrix associated, actin dependent
SMARCA4
3.34
0.0394



regulator of chromatin, subfamily a, member 4


MmugDNA.40790.1.S1_at
matrin 3
MATR3
3.34
0.0880


MmugDNA.15859.1.S1_s_at
FAST kinase domains 2
FASTKD2
3.33
0.0003


MmugDNA.26707.1.S1_at
aarF domain containing kinase 4
ADCK4
3.33
0.0000


MmuSTS.1553.1.S1_at
Mitogen-activated protein kinase kinase kinase 7 interacting
MAP3K7IP1
3.33
0.0067



protein 1


MmugDNA.27387.1.S1_s_at
mannosidase, alpha, class 2B, member 1
MAN2B1
3.32
0.0175


MmugDNA.23626.1.S1_at
—
—
3.32
0.0842


MmugDNA.27590.1.S1_at
—
—
3.32
0.1370


MmugDNA.13842.1.S1_at
ADP-ribosylation-like factor 6 interacting protein 4
ARL6IP4
3.31
0.0687


MmugDNA.36711.1.S1_at
bolA-like 1 (E. coli)
BOLA1
3.31
0.0000


MmugDNA.35351.1.S1_at
round spermatid basic protein 1
RSBN1
3.31
0.0414


MmunewRS.884.1.S1_at
zinc finger protein 29
MGC75360
3.31
0.1372


MmugDNA.21146.1.S1_at
STT3, subunit of the oligosaccharyltransferase complex,
STT3A
3.29
0.0106



homolog A (S. cerevisiae)


MmugDNA.14126.1.S1_at
chromosome 1 open reading frame 176
C1orf176
3.29
0.0492


MmugDNA.3522.1.S1_at
KRIT1, ankyrin repeat containing
KRIT1
3.29
0.0900


MmugDNA.1835.1.S1_at
zinc finger protein 786
ZNF786
3.29
0.0065


MmugDNA.30488.1.S1_at
isocitrate dehydrogenase 2 (NADP+), mitochondrial
IDH2
3.29
0.0771


MmugDNA.35876.1.S1_at
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2
ST8SIA2
3.28
0.0593


MmugDNA.29769.1.S1_at
Proteasome (prosome, macropain) subunit, beta type, 7
PSMB7
3.28
0.1130


MmuSTS.3141.1.S1_at
methionine adenosyltransferase I, alpha
MAT1A
3.28
0.0685


MmugDNA.28691.1.S1_at
chromosome 4 open reading frame 30
C4orf30
3.28
0.0289


MmugDNA.27041.1.S1_at
solute carrier family 25 (mitochondrial carrier; phosphate
SLC25A23
3.27
0.0245



carrier), member 23


MmugDNA.1453.1.S1_at
dysbindin (dystrobrevin binding protein 1) domain
DBNDD2
3.27
0.0046



containing 2


MmuSTS.2928.1.S1_at
potassium voltage-gated channel, subfamily H (eag-
KCNH7
3.27
0.1254



related), memb, 7


Mmu.1184.1.S1_at
endomembrane protein emp70 precursor isolog
TM9SF3
3.27
0.1019


MmugDNA.17590.1.S1_at
hypothetical gene supported by BC036588
LOC400657
3.27
0.0882


MmugDNA.4941.1.S1_at
ring finger protein 14
RNF14
3.27
0.1095


MmugDNA.15613.1.S1_at
glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID)
GNS
3.27
0.0730


MmugDNA.15594.1.S1_at
gonadotropin-releasing hormone 2
GNRH2
3.27
0.0389


MmuSTS.1234.1.S1_at
carnitine palmitoyltransferase II
CPT2
3.26
0.0017


MmugDNA.1780.1.S1_at
—
—
3.26
0.0226


MmugDNA.36001.1.S1_at
septin 3
3-Sep
3.26
0.1383


MmugDNA.18459.1.S1_at
protease, serine, 15
PRSS15
3.26
0.1011


MmugDNA.31437.1.S1_at
Glycosylphosphatidylinositol specific phospholipase D1
GPLD1
3.26
0.0097


MmugDNA.736.1.S1_at
Full-length cDNA clone CS0DJ002YF02 of T cells (Jurkat
—
3.25
0.0015



cell line) Cot 10-normalized of Homo sapiens (human)


MmugDNA.27420.1.S1_at
—
—
3.25
0.0258


MmugDNA.16170.1.S1_s_at
transmembrane protein 4
TMEM4
3.25
0.0005


MmugDNA.37197.1.S1_at
cytochrome b5 domain containing 1
CYB5D1
3.25
0.0905


MmugDNA.3346.1.S1_at
makorin, ring finger protein, 2
MKRN2
3.25
0.0000


MmugDNA.8231.1.S1_at
triple functional domain (PTPRF interacting)
TRIO
3.25
0.2126


MmugDNA.32917.1.S1_at
G protein-coupled receptor 56
GPR56
3.24
0.0001


MmugDNA.34839.1.S1_at
unc-5 homolog A (C. elegans)
UNC5A
3.24
0.0215


MmugDNA.35448.1.S1_at
phosphohistidine phosphatase 1
PHPT1
3.24
0.0749


MmugDNA.8574.1.S1_at
tetraspanin 32
TSPAN32
3.24
0.0871


MmugDNA.33908.1.S1_at
KIAA0141
KIAA0141
3.24
0.0050


MmuSTS.4810.1.S1_at
follicular lymphoma variant translocation 1
FVT1
3.23
0.0006


MmugDNA.17221.1.S1_at
chromosome 11 open reading frame 11
C11orf11
3.23
0.0529


MmugDNA.15445.1.S1_at
chromosome 14 open reading frame 132
C14orf132
3.23
0.0629


MmugDNA.37901.1.S1_at
COX4 neighbor
COX4NB
3.23
0.0005


MmugDNA.9762.1.S1_at
Hypothetical protein LOC643382
LOC643382
3.23
0.0376


MmuSTS.2544.1.S1_at
translocase of inner mitochondrial membrane 23 homolog
TIMM23
3.22
0.0000



(yeast)


MmuSTS.3926.1.S1_at
tetraspanin 31
TSPAN31
3.22
0.0303


MmugDNA.23914.1.S1_at
hypothetical gene supported by AF064843; AK025716 ///
LOC439994 ///
3.21
0.1319



hypothetical protein LOC642361 /// hypothetical protein
LOC642361 ///



LOC646509
LOC646509


MmugDNA.25504.1.S1_at
tubulin, gamma complex associated protein 5
TUBGCP5
3.21
0.0027


MmugDNA.19562.1.S1_at
zinc finger protein 406 /// Zinc finger protein 406
ZNF406 ///
3.21
0.0468




LOC654252


MmugDNA.11799.1.S1_at
CAS1 domain containing 1
CASD1
3.21
0.0679


MmugDNA.22745.1.S1_at
oxidoreductase NAD-binding domain containing 1
OXNAD1
3.21
0.0025


MmugDNA.29698.1.S1_at
transmembrane protein 128
TMEM128
3.21
0.0063


MmugDNA.21404.1.S1_at
high-mobility group 20B
HMG20B
3.20
0.0295


MmugDNA.37311.1.S1_at
F-box and leucine-rich repeat protein 20
FBXL20
3.20
0.1599


MmugDNA.26098.1.S1_at
Yip1 domain family, member 4
YIPF4
3.20
0.0937


MmunewRS.416.1.S1_at
ATPase, H+ transporting, lysosomal 5658 kDa, V1 subunit
gi:39645818
3.20
0.0716



B, isoform 1 (Renal tubular acidosis with deafness), mRNA



(cDNA clone MGC: 74733 IMAGE: 5208385), complete cds.



/GEN = ATP6V1B1 /PROD = ATPase, H+ transporting,



lysosomal 5658 kD, V1subunit B, isoform 1


MmugDNA.24420.1.S1_s_at
Chromosome 1 open reading frame 85
C1orf85
3.19
0.0399


MmugDNA.1438.1.S1_at
mitochondrial ribosomal protein 63
MRP63
3.19
0.0838


MmugDNA.25245.1.S1_at
cSH-PTP2
LOC441868
3.18
0.0771


MmugDNA.20570.1.S1_at
WW domain binding protein 1
WBP1
3.18
0.0001


MmugDNA.37020.1.S1_at
dedicator of cytokinesis 1
DOCK1
3.18
0.0728


MmuSTS.1407.1.S1_at
potassium channel, subfamily K, member 3
KCNK3
3.18
0.0806


MmugDNA.11054.1.S1_at
transmembrane protein 53
TMEM53
3.18
0.1004


MmugDNA.25885.1.S1_at
ATP/GTP binding protein-like 3
AGBL3
3.18
0.0755


MmugDNA.38701.1.S1_at
glucosidase, alpha; acid (Pompe disease, glycogen storage
GAA
3.18
0.0184



disease type II)


MmugDNA.43423.1.S1_s_at
Nuclear respiratory factor 1
NRF1
3.18
0.0933


MmugDNA.3251.1.S1_at
KIAA1183 protein
KIAA1183
3.18
0.2092


MmugDNA.30199.1.S1_at
transmembrane protein 70
TMEM70
3.18
0.0021


MmugDNA.15760.1.S1_at
peroxiredoxin 5
PRDX5
3.17
0.1334


MmugDNA.30636.1.S1_at
eukaryotic translation initiation factor 2-alpha kinase 3
EIF2AK3
3.17
0.0171


MmugDNA.36645.1.S1_at
isochorismatase domain containing 1
ISOC1
3.17
0.0099


Mmu.3814.1.S1_at
MGC15407-like
LOC677698
3.17
0.0744


MmugDNA.16486.1.S1_at
coiled-coil domain containing 66
CCDC66
3.16
0.0054


MmugDNA.12087.1.S1_at
peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae)
PTRH1
3.16
0.0024


MmugDNA.33464.1.S1_at
PHD finger protein 6 /// PHD finger protein 6
PHF6
3.16
0.0667


MmuSTS.238.1.S1_at
3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase
HMGCL
3.16
0.0027



(hydroxymethyl, utaricaciduria)


MmunewRS.64.1.S1_at
mitochondrial ribosomal protein L13
MRPL13
3.16
0.0003


MmugDNA.15050.1.S1_x_at
chromosome 5 open reading frame 31
C5orf31
3.16
0.0390


Mmu.3280.1.S1_at
retinoblastoma-associated protein 140
LOC722528
3.16
0.0136


MmugDNA.28942.1.S1_at
—
—
3.16
0.0067


MmugDNA.43211.1.S1_at
IBR domain containing 1
IBRDC1
3.15
0.0006


MmuSTS.1528.1.S1_at
mitochondrial ribosomal protein L50
MRPL50
3.15
0.0206


MmuSTS.3308.1.S1_at
SATB family member 1
SATB1
3.15
0.0007


MmugDNA.8392.1.S1_s_at
SWI/SNF related, matrix associated, actin dependent
SMARCA5
3.15
0.0053



regulator of chromatin, subfamily a, member 5


MmugDNA.11966.1.S1_at
ribonuclease T2
RNASET2
3.15
0.0025


MmugDNA.19079.1.S1_s_at
karyopherin alpha 1 (importin alpha 5)
KPNA1
3.14
0.0136


MmuSTS.2957.1.S1_at
LIM domain binding 1
LDB1
3.14
0.0697


MmuSTS.1291.1.S1_at
de-etiolated 1
DET1
3.14
0.0395


MmugDNA.9689.1.S1_at
chromosome 20 open reading frame 82
C20orf82
3.14
0.0503


MmugDNA.4538.1.S1_at
dynein, light chain, roadblock-type 2
DYNLRB2
3.14
0.0037


MmugDNA.10006.1.S1_at
activating signal cointegrator 1 complex subunit 3-like 1 ///
ASCC3L1
3.14
0.0043



activating signal cointegrator 1 complex subunit 3-like 1


MmugDNA.35020.1.S1_at
PHD finger protein 20
PHF20
3.14
0.0000


MmugDNA.18760.1.S1_at
integrin alpha FG-GAP repeat containing 3
ITFG3
3.14
0.0000


MmuSTS.4243.1.S1_s_at
protein phosphatase 1F (PP2C domain containing)
PPM1F
3.14
0.0303


MmugDNA.21710.1.S1_at
CDNA FLJ38498 fis, clone FELNG2000241
—
3.14
0.0038


MmugDNA.18438.1.S1_at
Rho guanine nucleotide exchange factor (GEF) 12
ARHGEF12
3.13
0.1368


MmugDNA.27794.1.S1_at
Transcribed locus, strongly NP_079090.1 Cas-Br-M
—
3.13
0.0004



(murine) ecotropic retroviral transforming sequence-like 1;



E-cadherin binding protein E7 [Homo sapiens]


MmugDNA.36386.1.S1_at
hypothetical protein LOC283680
LOC283680
3.13
0.0048


MmugDNA.13015.1.S1_at
echinoderm microtubule associated protein like 4
EML4
3.13
0.0093


MmugDNA.7282.1.S1_at
hypothetical protein MGC5242
MGC5242
3.13
0.0008


MmugDNA.36432.1.S1_at
smoothelin
SMTN
3.13
0.0273


MmugDNA.21419.1.S1_at
hypothetical protein LOC644096
LOC644096
3.13
0.0006


Mmu.2231.1.S1_at
F-actin capping protein alpha-1 subunit
CAPZA1
3.13
0.1124


MmugDNA.30086.1.S1_at
CG13876-PA
LOC693668
3.13
0.0672


MmugDNA.8672.1.S1_at
syndecan 3 (N-syndecan)
SDC3
3.13
0.0201


MmugDNA.1837.1.S1_at
radial spokehead-like 1 /// radial spokehead-like 1
RSHL1
3.13
0.2159


MmugDNA.40109.1.S1_at
ubiquitin-like 7 (bone marrow stromal cell-derived)
UBL7
3.13
0.0040


MmuSTS.3145.1.S1_at
NODAL modulator 1
NOMO1
3.12
0.0003


MmugDNA.1608.1.S1_at
F-box and leucine-rich repeat protein 2
FBXL2
3.12
0.0301


MmugDNA.7343.1.S1_at
CDNA clone IMAGE: 4797878
—
3.12
0.1962


MmugDNA.20535.1.S1_at
chromosome 1 open reading frame 50
C1orf50
3.12
0.0081


MmuSTS.2562.1.S1_s_at
tumor suppressing subtransferable candidate 1
TSSC1
3.12
0.0010


MmugDNA.19650.1.S1_at
deoxyhypusine hydroxylase/monooxygenase ///
DOHH
3.12
0.0831



deoxyhypusine hydroxylase/monooxygenase


MmugDNA.3700.1.S1_at
transmembrane protein 39A
TMEM39A
3.12
0.0384


MmugDNA.41216.1.S1_at
AF034176 Human mRNA (Tripodis and Ragoussis) Homo
—
3.11
0.1344



sapiens cDNA clone ntcon5 contig


MmugDNA.24685.1.S1_at
retinitis pigmentosa 2 (X-linked recessive)
RP2
3.11
0.0605


MmuSTS.507.1.S1_s_at
N-acylsphingosine amidohydrolase 3-like
ASAH3L
3.11
0.0119


MmugDNA.988.1.S1_at
3-phosphoinositide dependent protein kinase-1
PDPK1
3.11
0.0509


MmugDNA.3400.1.S1_at
Doublecortin domain-containing protein 2
LOC642926
3.11
0.0189


MmugDNA.15806.1.S1_at
CDNA clone IMAGE: 4813920
—
3.11
0.1892


MmugDNA.41923.1.S1_at
eukaryotic translation initiation factor 2 alpha kinase 4
EIF2AK4
3.11
0.0696


MmugDNA.7995.1.S1_at
cysteine-rich PAK1inhibitor
CRIPAK
3.11
0.1785


MmugDNA.5163.1.S1_at
Transcribed locus
—
3.10
0.0566


MmugDNA.23909.1.S1_at
acyl-Coenzyme A dehydrogenase family, member 8
ACAD8
3.10
0.1817


MmugDNA.28412.1.S1_at
KIAA1370
KIAA1370
3.10
0.0000


MmugDNA.11861.1.S1_at
salvador homolog 1 (Drosophila)
SAV1
3.10
0.0059


MmugDNA.7288.1.S1_s_at
KIAA0280
KIAA0280
3.09
0.0105


MmugDNA.15715.1.S1_at
HCLS1 associated protein X-1
HAX1
3.09
0.0106


MmugDNA.38581.1.S1_at
excision repair cross-complementing rodent repair
ERCC1
3.09
0.0102



deficiency, complementation group 1 (includes overlapping



antisense sequence)


MmugDNA.9603.1.S1_at
KIAA0753
KIAA0753
3.09
0.0595


MmugDNA.22362.1.S1_at
proteasome (prosome, macropain) subunit, beta type, 1
PSMB1
3.09
0.0108


MmugDNA.6764.1.S1_at
ATPase type 13A1
ATP13A1
3.08
0.0244


MmunewRS.184.1.S1_at
hypothetical protein LOC701867
LOC701867
3.08
0.1983


MmugDNA.23270.1.S1_at
hypothetical protein FLJ32065
FLJ32065
3.08
0.0304


MmugDNA.41792.1.S1_at
keratinocyte associated protein 3
KRTCAP3
3.08
0.0277


MmugDNA.28683.1.S1_at
chromosome 9 open reading frame 39
C9orf39
3.08
0.0154


MmuSTS.4748.1.S1_at
ubiquitin specific protease 18
USP18
3.08
0.1155


MmugDNA.13548.1.S1_at
cytochrome c oxidase subunit Va
COX5A
3.07
0.0790


MmugDNA.30189.1.S1_at
hypothetical protein LOC283481
LOC283481
3.07
0.2062


MmugDNA.35491.1.S1_at
adult retina protein
LOC153222
3.07
0.0001


MmugDNA.37253.1.S1_s_at
heterogeneous nuclear ribonucleoprotein D-like
HNRPDL
3.07
0.0577


MmugDNA.31553.1.S1_at
cofactor of BRCA1
COBRA1
3.07
0.0232


MmugDNA.25401.1.S1_at
abhydrolase domain containing 14B
ABHD14B
3.07
0.0170


MmuSTS.4318.1.S1_at
solute carrier family 36 (proton/amino acid symporter),
SLC36A4
3.07
0.1274



member 4


MmuSTS.4037.1.S1_at
solute carrier family 41, member 2
SLC41A2
3.07
0.1483


MmugDNA.41507.1.S1_at
ATP-binding cassette, sub-family B (MDR/TAP), member 6
ABCB6
3.06
0.0126


MmugDNA.14233.1.S1_at
sperm specific antigen 2
SSFA2
3.06
0.0120


MmugDNA.34695.1.S1_at
Leucine rich repeat neuronal 6C
LRRN6C
3.06
0.1945


MmugDNA.39744.1.S1_at
zinc finger protein 609
ZNF609
3.06
0.0160


MmugDNA.4156.1.S1_at
ATPase, H+ transporting V0 subunit E2-like (rat)
ATP6V0E2L
3.06
0.0340


MmugDNA.29456.1.S1_at
Breakpoint cluster region protein, uterine leiomyoma, 2
WDR22
3.06
0.0131


MmugDNA.4944.1.S1_at
tau tubulin kinase 1
TTBK1
3.05
0.0548


MmugDNA.22968.1.S1_at
—
—
3.05
0.0531


MmugDNA.42434.1.S1_at
N-acetylglucosaminidase, alpha- (Sanfilippo disease IIIB)
NAGLU
3.05
0.0982


MmugDNA.42291.1.S1_at
G protein-coupled receptor kinase 6
GRK6
3.05
0.0293


MmugDNA.121.1.S1_at
golgi SNAP receptor complex member 2
GOSR2
3.05
0.0435


MmugDNA.17630.1.S1_at
cell division cycle 40 homolog (S. cerevisiae)
CDC40
3.05
0.0398


MmugDNA.30084.1.S1_at
—
—
3.05
0.0012


MmugDNA.33923.1.S1_at
chromosome 1 open reading frame 79
C1orf79
3.05
0.0664


MmugDNA.37503.1.S1_at
ets variant gene 7 (TEL2 oncogene)
ETV7
3.05
0.0228


MmugDNA.15871.1.S1_at
BSD domain containing 1
BSDC1
3.04
0.0107


MmugDNA.32390.1.S1_at
dipeptidyl-peptidase 7
DPP7
3.04
0.1328


MmugDNA.41073.1.S1_at
Transcribed locus
—
3.04
0.0000


MmuSTS.2834.1.S1_at
solute carrier family 8 (sodium/calcium exchanger), member 3
SLC8A3
3.04
0.0879


MmugDNA.20734.1.S1_at
zinc finger and BTB domain containing 11
ZBTB11
3.04
0.0326


MmuSTS.247.1.S1_at
inositol polyphosphate-1-phosphatase
INPP1
3.04
0.0049


MmugDNA.22134.1.S1_at
SIN3 homolog A, transcription regulator (yeast)
SIN3A
3.04
0.0000


MmugDNA.17708.1.S1_at
torsin A interacting protein 1
TOR1AIP1
3.03
0.0001


MmugDNA.42050.1.S1_at
—
—
3.03
0.0980


MmugDNA.30213.1.S1_at
zinc finger, MYM-type 5
ZMYM5
3.03
0.0036


MmugDNA.43311.1.S1_at
LDLR-FUT fusion protein (LDLR-FUT)
—
3.02
0.1029


MmugDNA.26409.1.S1_at
hypothetical protein LOC644242 /// hypothetical protein
LOC644242 ///
3.02
0.0510



LOC650429 /// hypothetical protein LOC650446
LOC650429 ///




LOC650446


MmuSTS.59.1.S1_at
histone deacetylase 5
HDAC5
3.02
0.0063


MmugDNA.34663.1.S1_at
flavin containing monooxygenase 3
FMO3
3.02
0.1292


MmugDNA.40441.1.S1_at
CDNA clone IMAGE: 5270500
—
3.02
0.1493


MmuSTS.1202.1.S1_at
component of oligomeric golgi complex 7
COG7
3.01
0.0056


MmugDNA.33076.1.S1_at
Transcribed locus
—
3.01
0.0492


MmuSTS.658.1.S1_at
putative T1/ST2 receptor binding protein
IL1RL1LG
3.01
0.0153


MmugDNA.26960.1.S1_at
WD repeats and SOF1 domain containing
WDSOF1
3.01
0.0000


MmugDNA.24887.1.S1_at
tripartite motif-containing 2
TRIM2
3.01
0.0073


MmugDNA.26072.1.S1_at
active BCR-related gene
ABR
3.01
0.0038


MmugDNA.28188.1.S1_at
hypothetical gene supported by AK124342
FLJ42351
3.01
0.0975


MmugDNA.40888.1.S1_at
taurine upregulated gene 1
TUG1
3.00
0.0221


MmugDNA.39101.1.S1_at
—
—
3.00
0.1428


MmuSTS.4591.1.S1_at
thyroid hormone receptor, alpha
THRA
3.00
0.0270


MmugDNA.16168.1.S1_s_at
structural maintenance of chromosomes 3
SMC3
3.00
0.0000


MmugDNA.40670.1.S1_at
3′(2′), 5′-bisphosphate nucleotidase 1
BPNT1
3.00
0.0221


MmuSTS.1100.1.S1_at
PAX transcription activation domain interacting protein 1 like
PAXIP1L
3.00
0.0160


MmugDNA.4318.1.S1_at
FLJ12716 protein
FLJ12716
3.00
0.0565


MmugDNA.28833.1.S1_at
CDNA FLJ41690 fis, clone HCASM2009405
—
2.99
0.0293


MmugDNA.28320.1.S1_at
CDNA clone IMAGE: 5259419
—
2.99
0.2149


MmugDNA.19977.1.S1_at
KIAA1217
KIAA1217
2.99
0.0595


MmunewRS.283.1.S1_at
NAD(P) dependent steroid dehydrogenase-like
HSPC105
2.99
0.1709


MmuSTS.4337.1.S1_at
F-box only protein 25
FBXO25
2.99
0.0969


MmugDNA.42396.1.S1_at
germ cell-less
LOC701545
2.99
0.0783


MmugDNA.23292.1.S1_at
Ras suppressor protein 1
RSU1
2.99
0.0016


MmugDNA.17188.1.S1_at
acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain
ACADS
2.99
0.0453


MmugDNA.8639.1.S1_at
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21
DDX21
2.99
0.0027


MmugDNA.6559.1.S1_at
chromosome 9 open reading frame 119
C9orf119
2.99
0.0393


MmugDNA.41506.1.S1_at
ankyrin repeat and SOCS box-containing 6
ASB6
2.99
0.0077


MmugDNA.13579.1.S1_at
KIAA1712
KIAA1712
2.99
0.0879


MmugDNA.19830.1.S1_at
glycoprotein hormone alpha 2
GPHA2
2.99
0.0280


Mmu.3556.1.S1_s_at
family with sequence similarity 96, member A isoform a
LOC714217
2.98
0.0000


MmugDNA.10102.1.S1_s_at
heat shock 70 kDa protein 8
HSPA8
2.98
0.0043


MmugDNA.4343.1.S1_at
hypothetical protein FLJ10241
FLJ10241
2.98
0.0015


MmugDNA.6426.1.S1_at
CD151 molecule (Raph blood group)
CD151
2.98
0.0338


MmugDNA.27731.1.S1_at
MRNA from chromosome 5q21-22, clone: 843Ex
—
2.98
0.0000


MmugDNA.33252.1.S1_at
protease, serine, 16 (thymus)
PRSS16
2.98
0.0020


MmugDNA.20450.1.S1_at
chromosome 19 open reading frame 2
C19orf2
2.97
0.0001


MmuSTS.3421.1.S1_at
claudin 3
CLDN3
2.97
0.0204


MmugDNA.26818.1.S1_at
methyltransferase like 4
METTL4
2.97
0.0076


MmugDNA.33099.1.S1_at
KIAA0423
KIAA0423
2.97
0.0005


MmuAffx.1252.1.A1_at
protocadherin alpha (PCDH) mRNA, 3 prime UTR.
AY598414
2.96
0.1373


MmugDNA.9975.1.S1_at
zinc finger protein 331
ZNF331
2.95
0.0596


MmugDNA.41468.1.S1_at
necdin-like 2
NDNL2
2.95
0.0006


MmugDNA.17362.1.S1_at
PTD016 protein
LOC51136
2.95
0.0267


MmugDNA.43033.1.S1_at
HemK methyltransferase family member 2
HEMK2
2.95
0.1934


MmugDNA.29141.1.S1_at
UDP-glucose ceramide glucosyltransferase-like 1
UGCGL1
2.95
0.0396


MmugDNA.13178.1.S1_at
CDC14 cell division cycle 14 homolog B (S. cerevisiae)
CDC14B
2.95
0.0382


MmugDNA.26142.1.S1_at
coiled-coil domain containing 95
CCDC95
2.95
0.0654


MmugDNA.2882.1.S1_at
zinc finger CCCH-type containing 7B
ZC3H7B
2.95
0.0351


MmugDNA.22445.1.S1_at
Ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)
UBE2I
2.95
0.0079


MmugDNA.5279.1.S1_at
transmembrane protein 33
TMEM33
2.95
0.0097


Mmu.1276.1.S1_at
serine protease inhibitor, Kunitz type, 2
LOC714755
2.94
0.0663


MmugDNA.43012.1.S1_at
chromosome 17 open reading frame 28
C17orf28
2.94
0.0440


MmuSTS.1982.1.S1_at
CD14 antigen
CD14
2.94
0.0049


MmugDNA.41964.1.S1_at
hypothetical protein LOC646870
LOC646870
2.94
0.0728


MmugDNA.37306.1.S1_at
melanoma antigen family E, 1
MAGEE1
2.94
0.0035


MmugDNA.36805.1.S1_at
CDNA clone IMAGE: 5265020
—
2.93
0.0047


MmugDNA.23752.1.S1_at
Hypothetical gene supported by AK126569
230404_at
2.93
0.0014


MmugDNA.7176.1.S1_at
zinc finger protein 508
ZNF508
2.93
0.1404


MmugDNA.15639.1.S1_s_at
nuclear distribution gene C homolog (A. nidulans)
NUDC
2.93
0.1171


MmugDNA.23645.1.S1_at
kinase insert domain receptor (a type III receptor tyrosine
KDR
2.93
0.0526



kinase)


MmugDNA.28242.1.S1_at
G protein-coupled receptor 82
GPR82
2.92
0.0520


MmugDNA.26896.1.S1_at
hypothetical protein LOC285847
LOC285847
2.92
0.1348


MmugDNA.33291.1.S1_at
E74-like factor 2 (ets domain transcription factor)
ELF2
2.92
0.0090


MmugDNA.1352.1.S1_at
3-hydroxyisobutyryl-Coenzyme A hydrolase
HIBCH
2.92
0.0317


Mmu.14583.1.S1_at
Transcribed locus
—
2.92
0.0000


MmugDNA.23757.1.S1_at
high-mobility group protein 2-like 1
HMG2L1
2.92
0.0821


MmugDNA.3973.1.S1_at
TBP-interacting protein
TIP120A
2.92
0.0295


MmugDNA.20292.1.S1_at
breast cancer metastasis suppressor 1
BRMS1
2.92
0.0411


MmugDNA.28666.1.S1_at
palmdelphin
PALMD
2.91
0.0451


MmuSTS.2571.1.S1_at
ubiquitin specific peptidase 20
USP20
2.91
0.0475


MmugDNA.26331.1.S1_at
Mitogen-activated protein kinase kinase kinase 13
MAP3K13
2.91
0.0470


MmugDNA.10238.1.S1_at
testis expressed sequence 9
TEX9
2.91
0.1328


MmunewRS.102.1.S1_at
mRNA for KIAA1979 protein.
gi:18916872
2.90
0.1195


MmuSTS.3241.1.S1_at
BCL2/adenovirus E1B 19 kDa interacting protein 1
BNIP1
2.90
0.0091


MmugDNA.1167.1.S1_at
pyrophosphatase (inorganic) 2 /// ring finger protein 36
PPA2 /// RNF36
2.90
0.0008


MmugDNA.2679.1.S1_at
small nuclear ribonucleoprotein polypeptide A′
SNRPA1
2.90
0.0215


MmugDNA.29871.1.S1_at
NADH dehydrogenase (ubiquinone) Fe—S protein 2, 49 kDa
NDUFS2
2.89
0.0192



(NADH-coenzyme Q reductase)


Mmu.4717.1.S1_at
ankyrin repeat and BTB (POZ) domain containing 1 isoform 2
LOC710603
2.89
0.0439


MmugDNA.20718.1.S1_at
heterogeneous nuclear ribonucleoprotein A3 pseudogene 1 ///
HNRPA3P1 ///
2.89
0.0013



heterogeneous nuclear ribonucleoprotein A3
HNRPA3


MmugDNA.28284.1.S1_at
GA binding protein transcription factor, alpha subunit 60 kDa
GABPA
2.89
0.0000


MmuSTS.4752.1.S1_at
vacuolar protein sorting 45 homolog (S. cerevisiae)
VPS45
2.89
0.0020


MmugDNA.7814.1.S1_at
family with sequence similarity 120A
FAM120A
2.89
0.0377


MmugDNA.43320.1.S1_at
UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase,
B3GALT4
2.89
0.0379



polypeptide 4


MmugDNA.38533.1.S1_at
CDNA FLJ11692 fis, clone HEMBA1004983
—
2.89
0.1672


MmugDNA.37108.1.S1_at
Ribosomal protein L7-like 1
RPL7L1
2.89
0.0294


MmugDNA.43087.1.S1_at
choroideremia (Rab escort protein 1) /// hypothetical protein
CHM ///
2.89
0.0003



LOC642090
LOC642090


MmugDNA.37619.1.S1_at
serine/threonine/tyrosine interacting protein ///
STYX ///
2.89
0.0039



serine/threonine/tyrosine interacting protein
LOC653890


MmugDNA.6995.1.S1_at
Heterogeneous nuclear ribonucleoprotein A0
HNRPA0
2.89
0.0419


MmugDNA.33286.1.S1_at
centrosomal protein 57 kDa
CEP57
2.88
0.0039


MmugDNA.7613.1.S1_at
vitelliform macular dystrophy 2 (Best disease, bestrophin)
VMD2
2.88
0.0211


MmugDNA.41643.1.S1_at
TPTE and PTEN homologous inositol lipid phosphatase
LOC374491 ///
2.88
0.1625



pseudogene /// TPTE and PTEN homologous inositol lipid
LOC642904 ///



phosphatase isoform gamma /// TPTE and PTEN
LOC649370



homologous inositol lipid phosphatase isoform gamma


MmugDNA.17851.1.S1_at
NADH dehydrogenase (ubiquinone) 1, alpha/beta
NDUFAB1
2.88
0.0718



subcomplex, 1, 8 kDa


MmugDNA.35659.1.S1_at
chromosome 9 open reading frame 84
C9orf84
2.88
0.1866


MmuSTS.1608.1.S1_at
kelch-like 7 (Drosophila)
KLHL7
2.88
0.0008


MmugDNA.20882.1.S1_at
hypothetical protein MGC61571
MGC61571
2.88
0.0025


MmugDNA.7201.1.S1_at
carboxypeptidase D
CPD
2.87
0.0239


MmugDNA.22156.1.S1_at
LOC166075
LOC401097
2.87
0.0185


MmugDNA.18427.1.S1_at
Keratin associated protein 5-11
KRTAP5-11
2.87
0.0621


MmugDNA.10502.1.S1_at
dehydrogenase/reductase (SDR family) member 13
DHRS13
2.87
0.0613


MmuSTS.2492.1.S1_at
zinc finger protein 509
ZNF509
2.87
0.0312


MmugDNA.33371.1.S1_at
chymotrypsin-like
CTRL
2.87
0.0277


MmugDNA.24978.1.S1_at
neuronal PAS domain protein 1
NPAS1
2.87
0.1278


MmugDNA.37408.1.S1_at
tyrosyl-tRNA synthetase 2 (mitochondrial)
YARS2
2.86
0.0023


MmugDNA.27947.1.S1_at
FLJ45244 protein
FLJ45244
2.86
0.2182


MmugDNA.38426.1.S1_at
KIAA0892
KIAA0892
2.86
0.0020


Mmu.12307.1.S1_at
KIAA1008
KIAA1008
2.86
0.1271


MmuSTS.534.1.S1_at
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
B4GALT2
2.86
0.1428



polypeptide


MmugDNA.21102.1.S1_at
hypothetical protein LOC651803
LOC651803
2.86
0.0893


MmugDNA.25674.1.S1_at
potassium channel tetramerisation domain containing 14
KCTD14
2.86
0.0286


MmugDNA.11321.1.S1_at
FUN14 domain containing 1
FUNDC1
2.86
0.0497


MmugDNA.27909.1.S1_at
hypothetical protein FLJ20125
FLJ20125
2.86
0.0288


MmugDNA.41621.1.S1_at
tetratricopeptide repeat domain 30B
TTC30B
2.85
0.0837


MmugDNA.22964.1 S1_at
Transcribed locus
—
2.85
0.1242


MmugDNA.32172.1.S1_at
haloacid dehalogenase-like hydrolase domain containing 2
HDHD2
2.85
0.0025


MmugDNA.33685.1.S1_at
chromosome X open reading frame 26
CXorf26
2.85
0.0000


MmuSTS.2187.1.S1_at
solute carrier family 41, member 3
SLC41A3
2.85
0.0794


MmuSTS.3436.1.S1_at
alpha-methylacyl-CoA racemase
AMACR
2.85
0.0891


MmuSTS.1512.1.S1_at
isoprenylcysteine carboxyl methyltransferase
ICMT
2.84
0.0002


MmuSTS.234.1.S1_at
chromosome 15 open reading frame 40
C15orf40
2.84
0.0002


MmunewRS.872.1.S1_at
otopetrin 1
OTOP1
2.84
0.0322


MmugDNA.28434.1.S1_at
TROVE domain family, member 2
TROVE2
2.84
0.0136


MmugDNA.18405.1.S1_s_at
Suppression of tumorigenicity 7 like
ST7L
2.84
0.0768


MmugDNA.32265.1.S1_at
chromosome 19 open reading frame 52
C19orf52
2.84
0.0659


MmugDNA.11590.1.S1_at
chromosome 1 open reading frame 165
C1orf165
2.83
0.0087


MmugDNA.12017.1.S1_at
fibronectin type III and ankyrin repeat domains 1
FANK1
2.82
0.0001


MmugDNA.8492.1.S1_at
chromosome 6 open reading frame 153
C6orf153
2.82
0.0193


MmugDNA.22105.1.S1_at
dynein, axonemal, light intermediate polypeptide 1
DNALI1
2.82
0.0264


Mmu.16365.1.S1_at
PRP4 pre-mRNA processing factor 4 homolog B (yeast)
LOC709497 ///
2.82
0.0238



(predicted)
LOC710193


MmugDNA.42362.1.S1_at
ornithine decarboxylase antizyme 2
OAZ2
2.82
0.0858


MmugDNA.2230.1.S1_at
phosphatidylinositol 4-kinase, catalytic, alpha polypeptide
PIK4CA
2.82
0.0002


MmugDNA.23113.1.S1_at
Midline 2
MID2
2.81
0.0018


MmugDNA.9055.1.S1_at
multiple C2 domains, transmembrane 2
MCTP2
2.81
0.1229


MmugDNA.28806.1.S1_at
Zinc finger protein 284
ZNF284
2.81
0.0754


MmugDNA.6963.1.S1_at
tweety homolog 2 (Drosophila)
TTYH2
2.81
0.0997


MmugDNA.24592.1.S1_at
CTD (carboxy-terminal domain, RNA polymerase II,
CTDSP2
2.81
0.1065



polypeptide A) small phosphatase 2


MmugDNA.18857.1.S1_at
KIAA0467
KIAA0467
2.81
0.0008


MmugDNA.40098.1.S1_at
hypothetical protein LOC144363
LOC144363
2.81
0.1331


MmugDNA.23612.1.S1_at
Transcribed locus
—
2.81
0.0728


MmuSTS.1461.1.S1_at
mitogen-activated protein kinase kinase kinase kinase 3
MAP4K3
2.81
0.0000


MmuSTS.2022.1.S1_at
prostaglandin D2 synthase, hematopoietic
PGDS
2.80
0.1324


MmugDNA.21008.1.S1_at
ubiquitin specific peptidase 14 (tRNA-guanine
USP14
2.80
0.0026



transglycosylase)


MmugDNA.5481.1.S1_at
Full-length cDNA clone CS0DF012YD09 of Fetal brain of
—
2.80
0.0074



Homo sapiens (human)


MmuSTS.4011.1.S1_at
solute carrier family 35, member B3
SLC35B3
2.80
0.0186


MmugDNA.12978.1.S1_at
phosphoinositide-3-kinase, class 2, alpha polypeptide
PIK3C2A
2.80
0.0138


MmugDNA.25990.1.S1_at
coiled-coil domain containing 123
CCDC123
2.79
0.1079


MmugDNA.21323.1.S1_at
CDNA FLJ14181 fis, clone NT2RP2004300
—
2.79
0.1179


MmugDNA.34194.1.S1_at
chromosome 6 open reading frame 120
C6orf120
2.79
0.1196


MmugDNA.1311.1.S1_at
hypothetical protein MGC26733
MGC26733
2.79
0.0076


MmugDNA.10629.1.S1_at
translocase of inner mitochondrial membrane 17 homolog A
TIMM17A
2.79
0.0004



(yeast)


MmugDNA.33991.1.S1_at
CDNA: FLJ22539 fis, clone HRC13227
—
2.78
0.0066


MmugDNA.20536.1.S1_at
transmembrane and tetratricopeptide repeat containing 3
TMTC3
2.78
0.0230


MmugDNA.6356.1.S1_at
chromosome 7 open reading frame 28A /// chromosome 7
C7orf28A ///
2.78
0.0024



open reading frame 28B
C7orf28B


MmugDNA.6519.1.S1_at
WD repeat domain 39
WDR39
2.78
0.0098


MmugDNA.36685.1.S1_at
SET domain, bifurcated 2
SETDB2
2.78
0.0199


MmugDNA.22793.1.S1_s_at
tribbles homolog 2 (Drosophila)
TRIB2
2.78
0.1659


MmugDNA.2623.1.S1_at
prefoldin subunit 4
PFDN4
2.77
0.0015


MmuSTS.421.1.S1_at
ORM1-like 3 (S. cerevisiae)
ORMDL3
2.77
0.0697


MmugDNA.36435.1 S1_s_at
histidyl-tRNA synthetase
HARS
2.77
0.0220


MmugDNA.39696.1.S1_at
UTP15, U3 small nucleolar ribonucleoprotein, homolog
UTP15
2.77
0.1158



(S. cerevisiae)


MmugDNA.13739.1.S1_at
sorting nexin 14
SNX14
2.77
0.0059


MmuSTS.1965.1.S1_at
frequently rearranged in advanced T-cell lymphomas 2
FRAT2
2.77
0.0258


MmugDNA.18514.1.S1_at
RNA (guanine-9-) methyltransferase domain containing 2
RG9MTD2
2.77
0.0616


MmugDNA.26813.1.S1_at
MRNA; cDNA DKFZp762M127 (from clone
—
2.77
0.0023



DKFZp762M127)


MmunewRS.1000.1.S1_s_at
zinc finger protein 432
ZNF432
2.76
0.1958


MmugDNA.22282.1.S1_at
WD repeat and FYVE domain containing 1
WDFY1
2.76
0.1120


MmuSTS.4631.1.S1_at
vascular endothelial growth factor B
VEGFB
2.76
0.0010


MmugDNA.14574.1.S1_at
dedicator of cytokinesis 5
DOCK5
2.76
0.0832


MmugDNA.32208.1.S1_at
katanin p80 (WD repeat containing) subunit B 1
KATNB1
2.76
0.0202


MmugDNA.7187.1.S1_at
splicing factor, arginine/serine-rich 4
SFRS4
2.76
0.0061


MmuSTS.1088.1.S1_at
Solute carrier family 43, member 2
SLC43A1
2.76
0.0585


MmugDNA.4698.1.S1_at
calcium binding and coiled-coil domain 2
CALCOCO2
2.76
0.0099


MmugDNA.11372.1.S1_at
Cysteine rich BMP regulator 2 (chordin-like)
CRIM2
2.76
0.1851


MmugDNA.18070.1.S1_at
Kruppel-like factor 9
KLF9
2.76
0.0804


MmugDNA.14499.1.S1_at
zinc finger protein 596
ZNF596
2.76
0.0833


MmugDNA.40758.1.S1_at
galactokinase 2 /// retinoblastoma binding protein 8
GALK2 /// RBBP8
2.76
0.0046


MmugDNA.33141.1.S1_at
nitrilase 1
NIT1
2.75
0.0000


MmugDNA.42186.1.S1_at
hippocampus abundant transcript 1
HIAT1
2.75
0.0086


MmugDNA.4834.1.S1_at
aarF domain containing kinase 2
ADCK2
2.75
0.0220


MmugDNA.26458.1.S1_at
Activating transcription factor 6
ATF6
2.74
0.0017


MmugDNA.2646.1 S1_at
atrophin 1
ATN1
2.74
0.0001


MmugDNA.40233.1.S1_at
X-ray repair complementing defective repair in Chinese
XRCC1
2.74
0.1076



hamster cells 1


MmugDNA.20861.1.S1_at
spermatogenesis associated 13
LOC721468
2.74
0.0177


MmugDNA.12752.1.S1_s_at
spastic paraplegia 20, spartin (Troyer syndrome)
SPG20
2.74
0.0000


MmugDNA.41135.1.S1_at
Colorectal cancer-related mRNA sequence
—
2.74
0.1356


MmuSTS.4719.1.S1_at
tripartite motif-containing 6
TRIM6
2.74
0.0029


MmugDNA.4017.1.S1_at
—
—
2.74
0.1313


MmugDNA.27784.1.S1_at
—
—
2.74
0.1942


MmuSTS.4614.1.S1_at
tripartite motif-containing 4
TRIM4
2.74
0.0305


MmugDNA.8727.1.S1_at
t-complex 1
TCP1
2.74
0.0457


MmugDNA.638.1.S1_at
cytoskeleton associated protein 1
CKAP1
2.74
0.1205


MmugDNA.6338.1.S1_at
hypothetical protein FLJ20152
FLJ20152
2.73
0.0006


MmuSTS.2636.1.S1_at
family with sequence similarity 3, member A
FAM3A
2.73
0.0019


MmugDNA.33300.1.S1_at
WWC family member 3
WWC3
2.73
0.1279


MmugDNA.18996.1.S1_at
elongation factor Tu GTP binding domain containing 2
EFTUD2
2.73
0.0230


MmugDNA.24045.1.S1_s_at
zinc finger protein 292
ZNF292
2.73
0.1182


MmugDNA.1299.1.S1_at
CLPTM1-like
CLPTM1L
2.73
0.0121


MmugDNA.22429.1.S1_at
family with sequence similarity 120B
FAM120B
2.73
0.0002


MmugDNA.13037.1.S1_at
chromosome 21 open reading frame 119
C21orf119
2.72
0.0357


MmugDNA.20321.1.S1_at
HIR histone cell cycle regulation defective homolog A (S. cerevisiae)
HIRA
2.72
0.0018


MmugDNA.42547.1.S1_at
histidyl-tRNA synthetase-like
HARSL
2.72
0.0116


MmugDNA.1760.1.S1_s_at
COP9 constitutive photomorphogenic homolog subunit 8
COPS8
2.72
0.0761



(Arabidopsis)


MmugDNA.13758.1.S1_at
COMM domain containing 3
COMMD3
2.72
0.0140


MmuSTS.304.1.S1_at
single stranded DNA binding protein 3
SSBP3
2.71
0.0862


MmuSTS.2591.1.S1_at
Xenotropic and polytropic retrovirus receptor
XPR1
2.71
0.0029


MmugDNA.33009.1.S1_at
zinc finger protein 700
ZNF700
2.71
0.0451


MmugDNA.1463.1.S1_s_at
proline rich 14
PRR14
2.71
0.0339


MmugDNA.35741.1.S1_at
coiled-coil-helix-coiled-coil-helix domain containing 6 ///
CHCHD6
2.71
0.0482



coiled-coil-helix-coiled-coil-helix domain containing 6


MmugDNA.4692.1.S1_at
zinc finger RNA binding protein
ZFR
2.71
0.0332


MmugDNA.36934.1.S1_at
zinc finger protein 643
ZNF643
2.71
0.1950


MmugDNA.16923.1.S1_at
tumor necrosis factor receptor superfamily, member 13B
TNFRSF13B
2.71
0.1291


MmugDNA.15223.1.S1_at
hypothetical protein FLJ39061
FLJ39061
2.70
0.0031


MmuSTS.350.1.S1_at
spectrin repeat containing, nuclear envelope 1
SYNE1
2.70
0.1061


MmuSTS.246.1.S1_at
leucine rich repeat containing 42
LRRC42
2.70
0.0007


MmuSTS.2186.1.S1_at
zinc finger protein 354B
ZNF354B
2.70
0.0677


Mmu.12802.2.S1_at
chaperonin containing TCP1, subunit 2
LOC717182
2.70
0.1220


MmugDNA.6418.1.S1_at
zinc finger protein 83
ZNF83
2.70
0.0013


MmuSTS.528.1.S1_at
ATPase, Cu++ transporting, beta polypeptide (Wilson
ATP7B
2.70
0.0280



disease)


MmuSTS.727.1.S1_at
cyclin M2
CNNM2
2.70
0.1167


MmugDNA.15549.1.S1_s_at
GDP-mannose 4,6-dehydratase
GMDS
2.70
0.0006


MmugDNA.8210.1.S1_at
PR domain containing 16
PRDM16
2.70
0.1783


MmuSTS.3743.1.S1_at
RAB26, member RAS onocogene family
RAB26
2.69
0.0289


MmugDNA.6865.1.S1_at
Transcribed locus, moderately NP_689672.2 hypothetical
—
2.69
0.0231



protein MGC45438 [Homo sapiens]


MmuSTS.2292.1.S1_at
protein phosphatase 1, regulatory (inhibitor) subunit 3F
PPP1R3F
2.69
0.0001


MmugDNA.34280.1.S1_at
KIAA0683 gene product
KIAA0683
2.69
0.0352


MmugDNA.13838.1.S1_at
zinc finger protein 502
ZNF502
2.69
0.0750


MmuSTS.1404.1.S1_at
potassium inwardly-rectifying channel, subfamily J, member 6
KCNJ6
2.69
0.1718


MmugDNA.19168.1.S1_at
enhancer of mRNA decapping 4
EDC4
2.69
0.0220


MmugDNA.34757.1.S1_s_at
dynactin 6
DCTN6
2.69
0.0000


MmugDNA.8435.1.S1_at
proline synthetase co-transcribed homolog (bacterial)
PROSC
2.69
0.0000


MmugDNA.6197.1.S1_at
chromosome 4 open reading frame 24
C4orf24
2.69
0.2130


MmugDNA.3702.1.S1_at
CDNA FLJ46881 fis, clone UTERU3015647, moderately
—
2.69
0.0653



Embigin precursor


MmugDNA.12591.1.S1_s_at
dendritic cell-derived ubiquitin-like protein
DC-UbP
2.68
0.0503


MmugDNA.11985.1.S1_at
asparagine-linked glycosylation 2 homolog (S. cerevisiae,
ALG2
2.68
0.0105



alpha-1,3-mannosyltransferase)


MmugDNA.25835.1.S1_at
Homo sapiens, clone IMAGE: 4133122, mRNA
—
2.68
0.0342


MmuSTS.3979.1.S1_at
serum/glucocorticoid regulated kinase family, member 3
SGK3
2.68
0.0238


MmugDNA.9043.1.S1_at
ADP-ribosylation factor-like 6 interacting protein 2
ARL6IP2
2.68
0.0814


Mmu.7150.1.S1_at
Heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP
HNRPA2B1
2.68
0.0223



A2/hnRNP B1)


MmugDNA.33865.1.S1_s_at
chromosome 20 open reading frame 7 /// chromosome 20
C20orf7 ///
2.67
0.0426



open reading frame 7 /// transmembrane protein 14B ///
TMEM14B



transmembrane protein 14B


MmugDNA.3820.1.S1_at
clathrin, light polypeptide (Lcb)
CLTB
2.67
0.2188


MmugDNA.30567.1.S1_at
hypothetical protein BC014011
LOC116349
2.67
0.0466


MmugDNA.40707.1.S1_at
zinc finger, X-linked, duplicated B
ZXDB
2.66
0.0300


MmugDNA.43058.1.S1_at
kinesin family member 13A
KIF13A
2.66
0.1629


MmuSTS.4168.1.S1_at
M-phase phosphoprotein 6
MPHOSPH9
2.66
0.0283


MmugDNA.3585.1.S1_at
—
—
2.66
0.1649


MmugDNA.37285.1.S1_at
mitochondrial GTPase 1 homolog (S. cerevisiae)
MTG1
2.66
0.0492


MmugDNA.25292.1.S1_at
jagunal homolog 1 (Drosophila)
JAGN1
2.66
0.0199


MmugDNA.9421.1.S1_at
mannose-6-phosphate receptor (cation dependent)
M6PR
2.66
0.0305


MmugDNA.18308.1.S1_at
poliovirus receptor-related 2 (herpesvirus entry mediator B)
PVRL2
2.65
0.1122


MmugDNA.20905.1.S1_at
Chromosome 13 open reading frame 10
C13orf10
2.65
0.0168


MmugDNA.34704.1.S1_at
pecanex homolog (Drosophila)
PCNX
2.65
0.1063


MmugDNA.12760.1.S1_at
Fibroblast growth factor 14
FGF14
2.65
0.0872


MmugDNA.43498.1.S1_at
NmrA-like family domain containing 1
NMRAL1
2.65
0.0479


MmugDNA.21653.1.S1_at
hypothetical protein FLJ30596
FLJ30596
2.65
0.0681


MmugDNA.14752.1.S1_at
MRNA; cDNA DKFZp547E193 (from clone DKFZp547E193)
—
2.65
0.1773


MmuSTS.4276.1.S1_at
SREBF chaperone
SCAP
2.64
0.0005


MmugDNA.8363.1.S1_at
tyrosyl-DNA phosphodiesterase 1
TDP1
2.64
0.1058


MmugDNA.34065.1.S1_at
uncharacterized hematopoietic stem/progenitor cells protein
MDS032
2.64
0.0254



MDS032


MmunewRS.641.1.S1_at
selenoprotein S
SELS
2.64
0.0693


MmugDNA.7596.1.S1_at
—
—
2.64
0.2105


MmugDNA.3465.1.S1_at
Full-length cDNA clone CS0DI027YJ20 of Placenta Cot 25-
—
2.64
0.1052



normalized of Homo sapiens (human)


MmugDNA.13992.1.S1_at
Leo1, Paf1/RNA polymerase II complex component,
LEO1
2.64
0.0000



homolog (S. cerevisiae)


MmugDNA.14603.1.S1_at
bicaudal D homolog 1 (Drosophila)
BICD1
2.64
0.0314


Mmu.2724.1.S1_at
glutamate dehydrogenase 1
GLUD1
2.63
0.0345


MmugDNA.26006.1.S1_at
hypothetical protein MGC16169
MGC16169
2.63
0.1844


MmugDNA.34293.1.S1_at
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase,
B4GALT5
2.63
0.0018



polypeptide 5


MmugDNA.5213.1.S1_at
Spleen tyrosine kinase
SYK
2.63
0.0169


MmugDNA.26186.1.S1_at
ankyrin repeat and IBR domain containing 1
ANKIB1
2.63
0.0499


MmugDNA.30722.1.S1_at
tetratricopeptide repeat domain 12
TTC12
2.63
0.1383


MmugDNA.20572.1.S1_at
trafficking protein particle complex 6A
TRAPPC6A
2.63
0.1754


MmuSTS.645.1.S1_at
Charcot-Marie-Tooth neuropathy 4B2 (autosomal recessive,
CMT4B2
2.63
0.0754



with my, in outfolding)


MmugDNA.12020.1.S1_at
YTH domain family, member 3
YTHDF3
2.63
0.1578


MmugDNA.23364.1.S1_at
Transcribed locus, strongly XP_515572.1 PREDICTED:
—
2.63
0.1417



hypothetical protein XP_515572 [Pan troglodytes]


MmugDNA.3150.1.S1_s_at
Cdc42 guanine nucleotide exchange factor (GEF) 9
ARHGEF9
2.63
0.0380


MmugDNA.26131.1.S1_at
Nuclear transcription factor, X-box binding-like 1
NFXL1
2.62
0.0005


MmugDNA.23082.1.S1_at
nudix (nucleoside diphosphate linked moiety X)-type motif
NUDT14
2.62
0.0487



14


MmugDNA.33074.1.S1_at
Transcribed locus, strongly XP_068632.2 PREDICTED:
—
2.62
0.0003



hypothetical protein XP_068632 [Homo sapiens]


MmugDNA.30447.1.S1_at
Hermansky-Pudlak syndrome 6
HPS6
2.62
0.0431


MmugDNA.37520.1.S1_at
chromosome 1 open reading frame 66
C1orf66
2.62
0.0280


MmuSTS.4696.1.S1_at
alanyl-tRNA synthetase
AARS
2.62
0.0110


Mmu.1900.1.S1_s_at
H3 histone, family 3B
LOC693887 ///
2.62
0.0092




LOC693939 ///




LOC694152 ///




LOC695663 ///




LOC699443 ///




LOC702881 ///




LOC707040 ///




LOC708847 ///




LOC708899 ///




LOC709296 ///




LOC710748 ///




LOC718673


MmugDNA.3450.1.S1_at
signal recognition particle receptor (‘docking protein’)
SRPR
2.62
0.0000


MmugDNA.20613.1.S1_at
CSL-type zinc finger-containing protein 2 (DelGEF-
ZCSL2
2.61
0.0000



interacting protein 1) (DelGIP1)


MmugDNA.26173.1.S1_at
LOC440133
LOC440133
2.61
0.1688


MmugDNA.15693.1.S1_at
acyl-Coenzyme A dehydrogenase family, member 11
ACAD11
2.61
0.1017


Mmu.14509.2.S1_at
cytosolic malate dehydrogenase
MDH1
2.61
0.0408


Mmu.967.1.S1_s_at
N-acetylated alpha-linked acidic dipeptidase 2
—
2.61
0.0338


MmugDNA.33096.1.S1_s_at
coiled-coil domain containing 47
CCDC47
2.61
0.0002


MmugDNA.43345.1.S1_at
Family with sequence similarity 98, member B
FAM98B
2.61
0.0000


MmugDNA.20494.1.S1_at
Ewing sarcoma breakpoint region 1
EWSR1
2.61
0.0040


MmugDNA.901.1.S1_at
—
—
2.61
0.1627


MmugDNA.18015.1.S1_at
major histocompatibility complex, class II, DM beta /// major
HLA-DMB
2.61
0.1120



histocompatibility complex, class II, DM beta


MmugDNA.18688.1.S1_at
FLJ32363 protein
FLJ32363
2.61
0.1221


MmugDNA.40426.1.S1_at
chromosome 20 open reading frame 42
C20orf42
2.61
0.0017


MmugDNA.17109.1.S1_at
zinc finger protein 570
ZNF570
2.61
0.0031


MmuSTS.448.1.S1_at
piggyBac transposable element derived 2
PGBD2
2.60
0.0847


MmuSTS.2213.1.S1_at
lysosomal trafficking regulator
LYST
2.60
0.0532


MmugDNA.41077.1.S1_at
chromosome 11 open reading frame 10
C11orf10
2.60
0.0723


MmugDNA.7760.1.S1_at
Transcribed locus, strongly XP_498525.1 PREDICTED:
—
2.60
0.0044



hypothetical protein XP_498525 [Homo sapiens]


MmuDNA.14575.1.S1_at
hypothetical protein FLJ32810
FLJ32810
2.60
0.0347

## Claims

1. A composition consisting of (i) a purified primate taste cell population, wherein the purified taste cells co-express KIT, T1R1 and T1R3 and (ii) a probe that provides for the specific detection of nucleic acids encoding KIT nucleic acid or KIT polypeptides.

2. The composition containing purified taste cell population of claim 1, wherein the probe comprises at least one nucleic acid which hybridizes to KIT.

3. The composition containing purified taste cell population of claim 1, wherein the probe comprises at least antibody which specifically binds to KIT polypeptides.

4. The composition containing purified taste cell population of claim 1, wherein the purified taste cells further express TRPM5.

5. The composition containing purified taste cell population of claim 1, wherein the purified taste cells are macaque taste cells.

6. The composition containing purified taste cell population of claim 1, wherein the purified taste cells are human taste cells.

7. A method of isolating taste cells that express KIT, comprising: (i) contacting an impure population of cells containing taste cells with a probe that specifically detects taste cells which express KIT; (ii) separating the detected KIT-expressing taste cells from the impure cell population and (iii) identifying in the resultant KIT-expressing taste cells those taste cells which further co-express T1R1 and T1R3.

8. The method of claim 7, wherein the probe comprises at least one nucleic acid which hybridizes to KIT.

9. The method of claim 7, wherein the probe comprises at least antibody which specifically binds to KIT polypeptides.

10. The method of claim 7, further comprising separating those KIT expressing cells which are detected to further express T1R1 and T1R3.

11. The method of claim 7, wherein the KIT-expressing taste cells and/or KIT/T1R1 and/or T1R3 co-expressing cells taste cells are separated by FACS or magnetic bead cell separation.

12. The method of claim 7, wherein the purified taste cells are macaque taste cells.

13. The method of claim 7, wherein the purified taste cells are human taste cells.